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Colorectal cancer is one of the commonest cancers affecting individuals across 
the world. An improvement in survival has been attributed to multidisciplinary 
management, better diagnostics, improved surgical options for the primary and 
metastatic disease and advances in adjuvant therapy. In this book, international 
experts share their experience and knowledge on these different aspects in the 
management of colorectal cancer. An in depth analysis of screening for colorectal 
cancer, detailed evaluation of diagnostic modalities in staging colorectal cancer, recent 
advances in adjuvant therapy and principles and trends in the surgical management 
of colorectal cancer is provided. This will certainly prove to be an interesting and 
informative read for any clinician involved in the management of patients with 
colorectal cancer.
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Colorectal cancer is one of the commonest cancers affecting both men and women in the
western world. Surgery has been the mainstay of treatment with 5 years survival rates be‐
tween 80-90% for stage I and II and dropping to 40% for advanced disease. The last decade
has seen significant developments in the diagnosis and management of colorectal cancer.
Better survival and improved patient outcomes have been reported across the globe due to
advances in technology, better diagnostics and improvements in adjuvant therapy.
It’s extremely important for any clinician dealing with colorectal cancer patients to stay up
to date with their knowledge of the disease, its behavior, management options and response
to therapy. This book provides state of the art papers on some very important topics in the
field of management of colorectal cancer. The chapter on screening critically analyses the
different screening tests and also gives a comprehensive review of different screening mo‐
dalities used in different countries. An update on MRI, PET and Ultrasound imaging for col‐
orectal cancer is provided. Advances in surgical technology including laparoscopic surgery,
single port surgery and robotic surgery are discussed in detail and the data from published
literature & authors experiences are presented in a simple and comprehensible way for the
readers. Section on adjuvant therapy covers the role of chemotherapy and radiotherapy very
well, with particular emphasis on newer biological agents and targeted therapy. Genomics
in colorectal cancer have been the focus of some significant research and this area has been
covered very well by expert authors sharing their experience and providing useful insights
into the topic.
This book will be an interesting read for any clinician dealing with colorectal cancer in their
practice. This will also prove a useful update manual for any trainees in colorectal surgery,
gastroenterology and radiology. I am grateful to all the authors for sharing their experience
and valuable work and also would like to thank Sandra Bakic for her unreserved support in
editing this work. Last but not least I am very grateful to my wife, Sadaf for providing me
with the inspiration and help all the way along, enabling me to complete this task.
Jim Khan
Consultant Colorectal & Minimal Access Surgeon
Portsmouth Hospitals NHS Trust
Portsmouth, UK
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1. Introduction
It has become an acknowledged fact that Colorectal Cancer (CRC) is a worldwide problem,
with an annual incidence of approximately 1 million cases and an annual mortality of more
than 500,000. Furthermore, the absolute number of cases will increase over the next two
decades as a result of the aging and expansion of populations in both the developed and
developing countries.
Apparently, CRC is the second most common cause of cancer related mortality among men
and women in the world; so, most CRCs arise from sporadic adenomas, and a few from genetic
polyposis syndromes or inflammatory bowel disease (IBD). The term “polyp” refers to a
discrete mass that protrudes into the intestinal lumen. Therefore, the reported prevalence of
adenomatous polyps, on the basis of screening colonoscopy data, is in the range of 18–36%.
The fact is that the risk for CRC varies from country to country and even within countries; the
risk also varies among individual people based on diet, lifestyle, and hereditary factors. The
most common neoplastic outcome of colorectal cancer screening is the adenoma. After having
removed, patients need to be placed in a follow-up surveillance programme, very much similar
to the patients with identified and treated cancer.
In the western world, we are very much aware that colorectal cancer has become an important
health problem as each year, over 380,000 persons are diagnosed with colorectal cancer; bout
half of these, patients die of the disease making colorectal cancer the second leading cause of
cancer deaths in Europe. An estimated figure reveals that almost one million people suffering
from colorectal cancer are going through cost – intensive treatments putting a huge burden on
the healthcare system.
Screening is defined as population based testing in an asymptomatic individual to identify
particular disease. The aim of screening is to lower the burden of cancer in the population by
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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discovering latent disease in its early stages and treating it more effectively than diagnosed
later when symptoms have appeared. As such, screening is a commendable method to reduce
the burden of the disease. However, population screening targets a predominantly healthy
population, and should therefore only be conducted after a careful consideration of both harms
and benefits.
In 1968 the World Health Organization [1] (WHO) defined the first set of principles of
population screening (Wilson &Junger 1968). These principles are still valid today.
The desirable features for community screening program for any disease are:
1. The disease should be an important health problem
2. Natural history of the disease must be known
3. The disease should be detectable at an early stage
4. Benefits of early detection should be there
5. Simple test should be available at early stage
6. The test should have high sensitivity and specificity and should be safe, effective,
acceptable, inexpensive, and repeatable after an interval
7. Services should be in place to treat the early disease
8. Benefits of decrease mortality and morbidity should be there
Recommendation for action- general:
• Develop and disseminate structured educational programme for members of the public,
providers, health-care systems, and policy-makers/political leaders. Effective educational
programmes should be directed to each of the important participants in an acceptable
manner.
• Develop evidence-based standards for quality throughout the screening process.
• Develop and disseminate inexpensive, easy-to-use clinical management systems.
• Advocate screening through national and local venues.
• Promote colorectal cancer screening as a part of comprehensive clinical preventive care.
Recommendation for action –Programme design:
Planning the screening programme:
• A target population should identify-asymptomatic men and women, age, risk factors (e.g.,
familial)
• The decision to implement colorectal cancer screening should be based on the relative
burden of the colorectal cancer in the population to be screened.
• The screening strategy (test, interval, age range) should be based on medical evidence
(guidelines), availability of resources, level of risk, and cultural acceptance by population.
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• Support by influential professional and patient advocacy groups and from the media is
essential.
• Evaluate the feasibility of the proposed programme. Address the development and
allocation of the resources (financial, personnel, facilities).
• Evaluate the specific cultural and language needs of the population.
Implementation of screening programme:
• Identify the target unit for implementation, and ensure communication (training and
education) with providers (general practitioners and others) and the target population.
• Develop and disseminate guidelines on screening, diagnosis, treatment, and surveillance in
a patient friendly and culture sensitive manner.
• Develop methods for initial patient enrollment and follow-up.
Monitoring the Screening program:
• Careful, timely monitoring of following rates: screening uptake, re-screening, and follow-
up of the positive test.
• Compliance with surveillance recommendations.
• Measurement of the programme quality should be in place, and evaluated regularly.
• Outcomes, including detection rates, cancer stage distribution, adenoma detection, compli‐
cations, and finally, the effect on the population incidence and mortality.
2. Colorectal cancer risk assessment tools and referral system in different
countries in the world
It is believed that colorectal cancer risk varies regionally according to geographical distribution
of the population. As we will see in following sections, colorectal screening is yet to be
implemented fully in general population of developed countries of the world. So in different
regions, colorectal cancer risk assessment tools has been introduced to identify the high risk
patients needs to be screened in general population of the society. Usually these risk assess‐
ment tools are for GPs and primary care units to identify the high risk patients to be screened.
2.1. Hamilton risk assessment tool for colorectal cancer
The risk assessment tool was based on work done by Professor Willie Hamilton in the CAPER
studies (Cancer Prediction in Exeter), a series of case control studies which identified symp‐
toms of common cancers that were presented to primary care and quantified the risk of cancer
associated with them. The tool acts as reminder to GPs to consider the likelihood of an
individual patient aged 40 or over having lung or bowel cancer given the symptom or
combination of symptoms they present with. It is presented as three tables (colorectal cancer,
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lung cancer for non smokers and lung cancer for smokers) containing the risk values for each
symptom in isolation or combination and is available as mouse mat or a desk easel so as to be
easy to hand.
The parameter used in Hamilton risk assessment tool are: constipation, diarrhoea, rectal
bleeding, loss of weight, abdominal pain, abdominal tenderness, abnormal rectal examination
and haemoglobin <10g/dl.
2.2. USA National Cancer Institute (NCI USA TOOL)
A recent online tool for calculating colorectal cancer risk in men and women age 50 or older
was launched, based on a new risk assessment model developed by researchers at the National
Cancer Institute (NCI), part of the National Institute of Health. This new tool may help health
care providers and their patients in making informed choices about when and how to screen
for colorectal cancers and can be used in designing colorectal cancer screening and prevention
trials.
So, by using easily obtainable information (e.g., personal and family medical history, lifestyle
behaviours, and age), the tool provides an estimate of an individual`s risk of developing
colorectal cancer over certain time periods (within five years, ten years, and over the course
of lifetime). This risk-assessment model is first to provide an absolute risk estimate for
colorectal cancer (i.e., the probability of developing colorectal cancer over a given period of
time) for general non –Hispanic white population age 50 or older in United States.
In order to develop the risk assessment model, the researcher used data from two large- based
case control studies. Several factors that have been previously associated with colorectal risk
were shown to be predicted of a colorectal cancer diagnosis in those two studies including age;
family history of colorectal cancer; consumption of vegetables; body mass index; cigarette
smoking; use of aspirin or other non-steroidal anti inflammatory drugs; physical activity; use
of hormone replacement therapy; previous history of sigmoidoscopy and/or colonoscopy; and
history of polyps. Estimates of relative risk (comparisons of risk in one group to another) from
the case-control studies were combined with population based data on colorectal cancer
incidence from NCI`sSEER (Surveillance, Epidemiology and End Results) cancer registries to
make the model broadly applicable in United States. [2]
“This colorectal cancer risk model should provide physicians and their patients a new tool to
help in making informed decisions about cancer screening and other cancer prevention
strategies. It may also assist policy makers in evaluating the usefulness of current and future
population colorectal cancer screening approaches” said Andrew Freedman,Ph.D., lead author
of the paper that describes the development of the risk-assessment model.
It has been observed that the majority of participants in the two case-control studies used
to develop the model  were non-Hispanic  whites  aged 50 or  older,  the researchers  were
unable to estimate relative risks for other age and racial/ethnic groups. However, there are
plans to expand the tool to include these populations in the future. In addition, the tool is
not  applicable  to  individuals  with  certain  gastrointestinal  disorders  (such  as  ulcerative
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colitis or Crohn`s disease), certain inherited genetic conditions, such as familial adenoma‐
tous  polyposis  or  hereditary  nonpolyposis  colorectal  cancers)  or  a  personal  history  of
colorectal cancer. These conditions are known to carry a high risk of colorectal cancer.
2.3. Asia-Pacific Colorectal Screening (APCS) score
From a development set of 860 asymptomatic subjects undergoing screening colonoscopy,
multiple logistic regression was applied to identify significant risk factors advanced colorectal
neoplasia defined as invasive carcinoma or advance adenoma. Odd Ratios for significant risk
factors were utilised to develop risk score ranging from 0 to 7 (Asia- pacific Colorectal
Screening (APCS score). Three tiers of risk were arbitrarily defined:0-1 ̀ average risk` (AR); 2-3
`moderate risk` (MR); 4-7 `high risk` (HR). In this study performance of the APCS score in
predicting risk of advanced neoplasia was evaluated
3. Current tests for colorectal screening and emerging screening tools
The following screening methods are currently used globally:
Guaiac-Based faecal occult bleeding test (gFOBT) is at present the most frequently used method
in screening programme throughout the world. It detects the peroxidase reaction of Hemo‐
globin, which causes the detection paper impregnated with guaiac resin to turn blue. As it can
react with animal haemoglobin, dietetic restrictions are necessary to exclude the false- positive
results. A number of studies showed limited sensitivity of this test for both, advanced
adenomas (11%) and carcinomas (13%). With gFOBT, a decrease in mortality for colorectal
cancer by 15 to 33% has been proved.
Immunological faecal occult bleeding test (iFOBT) reacts exclusively to human haemoglo‐
bin, so no dietetic restrictions are seen as necessary.Taking and assessing the stool samples
are  easier  than the  case  with  gFOBTs,  which may explain  a  higher  participation in  the
target  population.  A wide range of  qualitative and quantitative tests  are available,  with
varying  levels  of  sensitivity  and  specificity.  The  advantage  of  quantitative  tests  is  the
possibility to set cut-off  limits;  the most frequently used values are 75 or 10 ng/ml.  The
disadvantage of iFOBT is its cost. It is, no doubt, an expensive test as compared to gFOBT.
But, presently, the price is approaching that of gFOBT for qualitative tests. As this test has
higher sensitivity and specificity as compared to gFOBT, iFOBT is being increasingly used
in screening programmes.
New screening methods include tests which examine the stool for the presence of abnormal
DNA. Generally, these tests have higher sensitivity but lower specificity than gFOBT. They
are expensive tests and a major obstacle in their implementation is their price. [3]
Flexible  sigmoidoscopy  is  an  endoscopic  examination  with  maximum  reach  to  splenic
flexure. On the basis of emerging evidence---this is a promising screening test. A number
of  studies  are  under  progress  to  accumulate  enough  evidence  for  usage  of  flexible
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sigmoidoscopy as a screening test based on WHO guidelines. Recommended interval varies
from 3 to 5 years. A recent pilot study carried out in Darby UK* [36]. In the UK flexible
sigmoidoscopy trial, 90% of all CRC detected at screening was found in the distal colon.
According to one report by Sophie White et al from university of Sheffield, more than 60%
adenomas are detected in left side of colon at screening age of the population and more
than 70% CRC detected by flexible sigmoidoscopy at the screening age of the population.
Colonoscopy is another screening tool used in diagnostic and therapeutic endoscopic proce‐
dure which also detects lesion in proximal colon. It is more sensitive in detecting both
adenomas and carcinomas. This is an established screening procedure for synchronous and
metachronous tumours and surveillance of polyposis and non polyposis hereditary colorectal
cancers. This is also a primary surveillance tool for multiple polyps according to guidelines.
The risk of serious adverse events is higher than any other screening test with one in five
hundred colonic perforation rate in expert hands. In spite of being gold standard, colonoscopy
will not establish itself as an ideal population screening test due to its cost and adverse events
and a lack of wide spread skills available.
Computed tomographic colonography (virtual colonoscopy) can detect lesions in the colon
and rectum by reconstructing two-and three-dimentional images. To date, there is no evidence
of reduction in incidence and mortality of colorectal cancer by this method in comparison with
other screening tools. In cases, where caecum is not reached during colonoscopy due to patient
related factors, CT colonography is the preferable screening tool to complete the examination.
According to current NICE guidelines, the evidence of meta-analysis of data of 14 studies with
a total of 1324 patients concluded that for CT colonography, the pooled per-patient sensitivity
for polyps 10mm or larger was 88%, for polyps 6-9mm it was 84% and for polyps 5mm or
smaller it was 65%. The pooled per-polyp sensitivity for polyps 10mm or larger was 81%, for
polyps 6-9mm it was 62% and for polyp 5mm or smaller it was 43%. The overall specificity for
the detection of polyps 10mm or larger was 95%. No significant complications were reported
in the studies
Double contrast barium enema shows entire colon and rectum, although with significantly
lower sensitivity and specificity than colonoscopy. The percentage of undetected carcinomas
is upto 22%. This test is no longer widespread and in clinical practice due to its low sensitivity
and specificity and availability of other better screening tools. Despite the fact, it still has a role
in the areas in the world where colonoscopy and flexible sigmoidoscopy resources are severely
limited.
It is quite obvious that Colorectal Screening is a complex process which in order to function
requires the coexistence of number of factors such as a functioning invitation-reminder system,
media campaigns targeted at the general public, the development of recommendations for
general practitioners, patients compliance, sufficient funding, stratification of risks, and last
but not least the election of the most suitable screening test. Among all available screening
tests, only Fecal Occult Blood Test meets the WHO criteria.
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4. Current global colorectal cancer screening pathways
4.1. Europe
Until 2007 Colorectal Cancer Screening was running or being established in 19 of 27 European
countries [4] The target group contains approximately 136 million individuals suitable for
colorectal screening ( aged 50 to 74 years). Of this number, 43% individual come from 12
countries where colorectal population screening is performed or being prepared on either
national or regional level; 34% come from the five countries where national population
screening has been implemented (Finland, France, Italy, Poland and United Kingdom).
In 2007,gFOBT (which in 2003 was the only test recommended by the council of the European
union) was used as the only screening method in twelve countries (Bulgaria, Czech republic,
Finland, France, Hungary, Latvia, Portgal, Romania, Slovena, Spain, Sweedon, and United
Kingdom). Colonoscopy was the only screening method used in Poland. In six countries, two
types of the tests were used: i FOBT and flexible sigmoidoscopy in Italy, and g FOBT and
colonoscopy in Austria, Cyprus, Germany, Greece, and Slovak republic. In the remaining 8
states, (Belgium, Denmark, Estonia, Ireland, Lithuania, Luxembourg, Malta, and the Nether‐
lands), colorectal cancer screening has not been implemented yet. The age limit for target
population varies across EU countries.
After 2007 Report, EU countries progressed toward the implementation of population
screening programme. Recently, new EU guidelines for screening of colorectal cancers have
been introduced.
In United Kingdom, a screening programme was announced in 2004 and initiated in 2006, with
prospects of national coverage in 2009. It has been designed in two stages: with gFOBT tests
at two yearly intervals with colonoscopy for positive tests. In 2007, the compliance was 52%.
The program is carried out through regional centres falling under one of the five national hubs.
The role of general practitioners is less significant here. [5]
The NHS Bowel Cancer Screening has achieved nation-wide coverage by 2010. The programme
hubs operate a national call and recall system to send out FOBT kits, analyse samples and
dispatch results. Consequently, each hub is responsible for coordinating the programme in
their area and works up-to 20 local screening centres. The screening centres provide endoscopy
services and specialist screening nurse clinics for people receiving abnormal results. Screening
centres are also responsible for referring those requiring treatment to local hospital multidis‐
ciplinary team (MDT).
In Ireland, colorectal screening programme was launched in 2009 after National Screening
Board Report which was published in December 2008 [6] A summary of the screening
programme highlights:
• An immunochemical faecal occult blood test (iFOBT) is the primary screening tool for
population-based colorectal screening programme.
• A target population for screening of all men and women aged 55 and 74 years with a
screening interval of two years.
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• Colonoscopy to be offered to those individuals who test positive with iFOBT
In France, Screening program was initiated in 2003, based on gFOBT tests at 2 years intervals
with colonoscopy for positive result [7]. The role of general practitioners as coordinators is of
crucial importance. The major advantage of French program is its good organization, with a
call-recall system comprising central management at national level and individual steps taken
by centres in individual departments. Asymptomatic individuals aged from 50-70yrs are
mailed gFOBT tests, with the reminder at three monthly intervals for nonparticipants.
Compliance in referred districts achieved 42%, and overall positive test rate was 2.7%. The
screening programme has been generalised to the whole French territory since 2008.
In Italy, a nation-wide campaign was initiated in 2005; the implementation was entrusted
entirely to 21 regional centres, including choice of the testing method. In Piedmont region,
flexible sigmoidoscopy is the method of choice, in other regions iFOBT, with colonoscopy for
positive tests. [8]
In Spain, the main obstacle to its implementation was the highly heterogeneous healthcare
system, in terms of organization and insurance coverage in individual self governing units.
That is why they are behind in implementation of screening program as compared to the UK,
Germany, France, Italy and Finland.
In Finland, a structured screening programme was initiated in 2004. The target population,
aged from 60 to 69 years (106000 individuals), was randomised into two groups. Individuals
in the screening group were mailed a gFOBT test at intervals of 2 years. The finish program
shows a high level compliance of the target population (70.8%), particularly for females [9]
Poland is the only state at the moment using colonoscopy as the only screening method,
without the alternative of of FOBTs. An opportunistic screening programme was initiated in
2000, and by 2005, this had grown to 57 centres across Poland. The program is financed by
ministry of health, independent of the overall healthcare system. The target population
(Asymptomatic individuals aged 55-66 years) is recruited through general practitioners. High
emphasis is placed on the quality control of the colonoscopies, with complications reported
for 0.1% of the procedures, and no patient mortality. The advantage of the programme is
through monitoring and evaluation, including monitoring of interval cancers. [10]
Germany was the first country to introduce a population screening program (in 1976) based
on annual gFOBT for individuals more than 44 year of age. Since 2002, it has been offering
participants a choice between colonoscopy at 55 year of age and FOBT at annual intervals
between 50 and 55 year of age. After 55 year of age, examinations are carried out at 2 year, if
the test results are positive colonoscopy is indicated. Those who undergo a screening colono‐
scopy with no neoplasia detected at initial examination are recommended re-examination at
10 years time if the first colonoscopy was carried out before they were 65. The positive feature
of screening and data gathering is the emphasis on staging the disease at the time of its
diagnosis. [11]
In the Czech Republic, CRC screening has many years of tradition. The country was the second
in the world to start screening nation-wide, in 2000. In the initial years, gFOBT was offered to
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asymptomatic individuals more than 50 years of age by their general practitioners at preven‐
tative medical checks, followed by colonoscopies if tests were positive. Now both gFOBT and
iFOBT are being offered. The implementation of the newly designed programme is supported
by intense media campaign. [12,13]
Recently, the following EU guidelines for Colorectal Screening are published:
4.2. Australia
According to a recent survey, one in 12 Australians are likely to develop the colorectal cancers
in their lifetime. [14] In Australia, CRC is second most common cause of cancer-related
mortality. [15] survival from colorectal cancer is stage-dependent, yet fewer than 40% of
individuals are diagnosed at a localised stage. [16]
In Australia, clinical practice guidelines for the prevention, early detection and management
of colorectal cancer (the national guidelines) recommend that asymptomatic people classified
as “at or slightly above risk” receive FOBT screening biennially, commencing at 50 years of
age, with sigmoidoscopy (preferable flexible) consider every 5 yrs. [17]. Colonoscopy screening
is endorsed only for asymptomatic people who are considered to be at “moderately increased
risk” or “potentially high risk”due to risk features including personal or family history of CRC,
adenoma and chronic ulcerative colitis. The recently re-funded National Bowel Cancer
Screening Programme (NBCSP) offers one-off Immunochemical FOBT screening to people
turning 50, 55 or 65 years of age.
Implementation of biennial CRC screening in Australia for all those aged 50-74 years could
prevent up to 500 deaths per year, [18] with cost effectiveness comparable to breast and cervical
cancer screening Programs. [19]
4.3. United States
In USA, men and women who are 50 to 75 year old should be screened for colorectal cancer
in one of the following three ways; [20]
• A high-sensitivity faecal occult blood test (FOBT) every year.
• Sigmoidoscopy every five years and a high-sensitivity FOBT every three years.
• A colonoscopy every10 year.
Colorectal screening rates rose for both men and women. The rate for women increased slightly
faster, so that the rates for men and women were about the same in 2010 [58.5% for men and
50.8%for women.The colorectal cancer screening was 58.6%, below the target of 70.5%.
4.4. Asia
In Asia colorectal screening percentage is at its lowest level and research revealed that
colorectal cancer burden rapidly increasing in Asian countries [21]. A study to evaluate the
cost-effectiveness of FOBT, flexible sigmoidoscopy and colonoscopy in Asian countries
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indicated that FOBT is cost-effective compared to flexible sigmoidoscopy or colonoscopy for
colorectal screening in average risk population. [22]
The Increasing rate of colorectal cancer in Asia means that we need to take action immediately
to prevent colorectal cancer and to diagnose the disease at early stages. The cost-effectiveness
of screening programmes must be assessed in each individual country and research should be
done to elucidate the epidemiology, genetic and environmental factors in development of
colorectal cancer. [21]
5. Management of screening detected polyps
It is now widely accepted that the majority of colonic cancers arise from pre-existing adenom‐
atous polyps (adenoma-carcinoma sequence).The supporting evidence being as follows: [23]
1. The prevalence of adenomas correlates well with that of carcinomas, average age of
adenoma patients being around 5 years younger than patients with carcinomas.
2. Adenomatous tissue often accompanies cancer, and it is unusual to find small cancers
with no contagious adenomatous tissue.
3. Sporadic adenomas are identical histologically to the adenomas of familial adenomatous
polyposis (FAP), and this condition is unequivocal premalignant.
4. Large adenomas are more likely to display cellular atypia and genetic abnormalities than
small lesions.
5. Distribution of adenomas throughout the colon is similar to that of carcinomas.
6. Adenomas are found up to one-third of all surgical specimens resected for colorectal
cancers
7. The incidence of colorectal cancer has been shown to fall with long-term screening
programme involving colonoscopy and polypectomy.
The patients who have undergone colonoscopy and had adenomas removed are at increased
risk of developing colorectal cancer (CRC) in future, and therefore might benefit from
colonoscopic surveillance. [24]
Surveillance Guidelines about colorectal adenomas are established by British Society of
Gastroentrology. According to these guidelines surveillance of the colorectal adenomas
depends upon ; number of polys, size of polyps and grade of dysplasia present in histology.
Risk of colorectal cancer and adenomas with advanced pathology (>1cm or severely dysplastic)
is greater. Risk can be stratified according to the findings at baseline and refined at each
subsequent surveillance examination.
A Summary of surveillance guidelines [25] is:
• Low risk Patients with only 1-2 small <1cm) adenomas. No follow up or five yearly until
one negative examination.
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• Intermediate risk; Patients with 3-4 small adenomas or at least one >1cm.Three yearly
colonoscopy until two consecutive negative examinations.
• High risk; Patients with >5 adenomas or > 3 adenomas at least one of which >1cm. An extra
examination should be undertaken at 12 months before returning to three yearly surveil‐
lance.
The cut off age for stopping surveillance is usually 75 years but should also depends upon
patients wishes and comorbidity.
Patients with incomplete examinations due to failed colonoscopies, for whatever reasons,
should undergo repeat colonoscopy or alternative complete colonic examination (ct colonog‐
raphy). These guidelines are based on accurate detection of adenomas; otherwise risk status
will be under estimated.
Large sessile adenomas removed piecemeal should be re-examined every three months. Small
areas of residual polyp can be retreated endoscopically, for further check for complete
eradications in three months. If extensive residual polyp is seen, open surgical resection needs
to be considered. If there is complete healing of polypectomy site, then there should be
sigmoidoscopy or colonoscopy at one year before returning to three yearly Surveillance. India
ink tattooing aids recognition of the polypectomy site at follow up.
Stopping Surveillance.
The cut-off age for stopping surveillance is usually quoted as 75 years as the remaining life
expectancy is likely to be less than the average time required for new adenomas to become
malignant. After this age, it is unlikely that the benefits of surveillance will outweigh the
potential risk of the procedure. However, this should not preclude further surveillance in a fit
and motivated person who has a tendency to produce multiple or advanced adenomas at
follow up.
The risk and benefit of adenoma surveillance needs to be balanced at all ages, particularly in
patients who have significant co morbidity.
The decision to undertake each colonoscopy examination at follow up should depend not only
on the number and type of adenomas, but also on the patient’s age and wishes, and the presence
of significant co morbidity. The Patient status should be established prior to attendance for
each examination possibly by questionnaires.
6. Importance of audit in screening and screening relating colonoscopies
In any screening programme, as with any other medical service programme, adequate steps
must be taken to ensure that the original objectives are being met and that methodology meets
appropriate standard. The importance of maintaining the quality of screening programmes
should never be under estimated. Evaluation, audit and quality control should be an integral
part of any screening programme to ensure that it is achieving what it meant to be.
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Colonoscopy is gold standard in important ultimate diagnostic tool in population screening
programmes. Skilful colonoscopy with more then 95% caecal intubation rate is requirement
for effective colorectal screening.
In the UK, before rolling out of the National Bowel Cancer Screening Programme, a large-scale
study of colonoscopy practice was carried out. [26] The study demonstrated disappointing
results with poor caecal intubation rates (76.95) and higher than expected complication rates.
Since then there has been significant investment in endoscopic training, a quality assurance
framework for endoscopic units has been implemented and National Bowel Screening
Programme (NBSP) has been rolled out.
A nationwide audit of colonoscopy practice was conducted over a 2-weeks periods from 28
February 2011 until 11 March 2011. [27]. The study was performed prospectively, with the data
entry occurring electronically through the purpose built website. All units performing >100
colonoscopies annually on NHS patients were included. Data on 20085 colonoscopies and 2681
colonoscopists were collected from 301units. Results showed 95.8% adjusted caecal intubation,
32.1% polyp detection rate, 92.3% resected polyps were retrieved and 90.2% o procedures
achieved acceptable level of comfort. A total of 8 perforations and 52 significant haemorrhages
were reported. Eight patients underwent surgery as a consequence of a complication.
The audit confirms that there has been significant improvement in performance of colonoscopy
in UK since the last study reported 7 Years ago (caecal intubation rate 76.9%) and the per‐
formance is above the required national standard. But there is continuous need for assessment
and audit of screening tools to keep the required national standard.
7. Colonoscopy capacity, training and accreditation
Most colon cancers are assumed to have adenomatous polyp phase. Therefore, colonoscopic
detection and polypectomy provides the opportunity for cancer prevention [25]. So, colono‐
scopy is gold standard in high risk patients and patients with FOBT positive in population
screening program. As we have discussed in previous sections, effective colorectal screening
depends on available colonoscopy expertise in different part of the world
The aim of colonoscopy is to visualize whole of the colonic mucosa in order to identify
pathology. A systemic review [28] of back-to-back studies has shown polyp miss rate at
colonoscopy of 22% even in expert hands, especially polyps less than 1cm. Available data about
polyp miss rates have shown a variation in performance between endoscopists, but this can
be wider in very expert endoscopists. This shows that there is link between individual technical
skill and polyps detection rate [29]. The single most important factor in the technique is
withdrawal time after caecal intubation. The current recommendation is that colonoscopists
should spend 6-10 minutes during withdrawal inspecting the colonic mucosa [30].
Skills in colonoscopy technique and coecal intubation rates are directly proportional to
adenoma detection rate. In a standard endoscopy unit, single adenoma detection rate should
Colorectal Cancer - Surgery, Diagnostics and Treatment14
not be less than 20%. Inadequate skills in colonoscopy can also lead to higher percentage of
the procedure related complications.
In 2004, the largest prospective study of colonoscopic practice in UK revealed poor outcome
in terms of completion and perforation rate, as well as deficiencies in all aspect of training. The
guidelines on training have been published both in UK and the USA. [30-31]
Colonoscopy training and its accreditation is a challenging task. Structured colonoscopy
training is lacking in most of the countries. The NHS Bowel Cancer Screening Programme
(NHS BCSP) commenced in July 2006 and recruited expert colonoscopists to carry out
colonoscopies in the programme. Owing to the known variability in colonoscopy skills, strict
criteria have been developed for the accreditation of screening endoscopists to minimize the
risk of the complications and inaccurate and incomplete examinations.
The Joint Advisory Group of GI Endoscopy (JAG) was established under the Academy of
Medical Royal Colleges and now has a number of colleges and societies with an interest in
endoscopy as members who are responsible for agreeing and setting policy and strategy and
advising its constituent bodies and organizations (such as GMC and NHS )on standard and
in endoscopy. The Jag office manages the administrative functions of the screening Assessor
Accreditation System process on behalf of the NHS BCSP which is a web-based application
process.
There are several advantages of this accreditation process, to both the unit and the individual
endoscopists involved. Accreditation is an essential part of preparation for the implementation
of local screening programme in UK. It also provides opportunities to demonstrate high level
colonoscopic skills and improve the local endoscopy service. In addition it helps clinicians who
wish to teach colonoscopy locally or on courses. The accreditation process leads to the Joint
Advisory Group on GI Endoscopy (JAG) certificate of competency to perform screening
derived colonoscopy.
8. Hereditary risk cancer and colorectal cancer screening protocol
Inherited bowel cancer comprises of 5% of the total colorectal cancers. Based on risk of
Inherited bowel cancer population can be divided into three groups: Low risk group, Moderate
risk group and High risk group based on family history. Approach for screening surveillance
is different in three groups:
8.1. Low risk group
It includes the individuals with:
1. No personal history of bowel cancer: no confirmed family history of bowel cancer; or
2. No first degree relative (i.e. parent sibling or child ) with bowel cancer; or
3. One first degree relative with bowel cancer at or above the age of 40 years.
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In this group, the risk of bowel cancer may be twice the average risk [31] and there is no
evidence to support invasive surveillance in his group [24]. These individuals should be
explained that they are atonly marginally increased risk of developing colorectal cancer, and
that this risk is not sufficient to outweigh the disadvantages of colonoscopy. They should be
educated regarding symptoms of colorectal cancer, and importance of reporting if further
members of the family develop cancers. And they should be encouraged to take part in the
population screening for colorectal cancer.
8.2. Moderate risk group
Individuals are included in this category if there is:
1. One first-degree relative with colorectal cancer below the age of 45 without any feature
of high risk group.
2. Two first-degree relatives with bowel cancer diagnosed at any age without any of the
feature of high risk group.
In this group there is three to six fold relative risk of colorectal cancer. [31]. There is only
marginal benefit from invasive surveillance (colonoscopy). Current recommendations are that
individuals should be offered colonoscopy at 35-40 year of age (or at presentation if they are
older), and again at the age of 55 years. [24]. Coecal intubation is mandatory, as neoplasms in
individuals with a strong family history are often proximal; if the caecum is not reached, virtual
colonoscopy should be performed.
8.3. High risk group
In this group, hereditary non-polyposis colorectal cancer (HNPCC) and various polyposis
syndromes are included. Criteria for inclusion in this group includes:
1. Family member of familial adenomatous polyposis (FAP) or other polyposis syndrome;
or
2. Member of family with known lynch syndrome; or
3. Pedigree suggestive of autosomal dominantly inherited colorectal (or other lynch
syndrome associated) cancers.
In this group the individuals have one upto a 1 in 2 chance of inheriting a lifetime risk and
more than 50 % chances of developing colorectal cancers. They must be referred to a clinical
genetics service.
According to World Gastroenterology Organisation, the low risk group and population
without obvious inherited colorectal cancer history are labelled as average risk population,
while moderate rick and high risk groups are considered as one group with increased risk of
colorectal cancer. Global screening guidelines cascades are established in 2007 based on these
risk groups.
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8.4. Lynch syndrome or Hereditary Non Polyposis Colorectal Cancers (HNPCC)
Lynch syndrome is inherited as an autosomal dominant fashion. It comprises of 2% of the
colorectal cancers and is commonest of inherited bowel cancers. It is associated with endome‐
trial carcinoma (30-70%), gastric carcinoma (5-10%), ovarian carcinoma in females (5-10%),
urothelial carcinoma (5%) and others (small bowel pancreas and brain)< %5
Predictive genetic testing should be offered. These individuals should have first colonoscopy
at the age of 25 years or five years before earliest colonoscopy in the family and gastroscopy
at the age of 50 or five years before earliest gastric cancer in family. [24]. Colonoscopy and
gastroscopy should be done two yearly.
Screening for extracoloic cancers in Lynch syndrome is available. There is little evidence of
benefit. Recommendation varies from centre to centre, but surveillance is advised if there is
family history of particular cancer. Recommended options for extracolonic surveillance [32]
are;
• Annual transvaginal ultrasound, colour flow Doppler imaging and endometrial sampling.
• Annual CA125 level and clinical examination (pelvic and abdominal).
• Upper gastrointestinal endoscopy every two years.
• Annual urinalysis /cytology.
• Annual abdominal ultrasound of renal tracts, pelvis, and pancreas.
• Annual liver function tests,CA19-9,CEA
Familial adenomatous polyposis (FAP)
It is less common than Lynch syndrome. In FAP risk of colorectal cancer is 100%.
FAP is characterised by:
• Hundred of colorectal adenomatous polyps at a young age (second or third decade of life);
• Duodenal adenomatous polyps;
• extra-intestinal manifestation;
• Mutation in the APC gene at chromosome5q
If family mutation is known, at risk family member should be offered predictive genetic testing
in their early teens. If this is not possible, then clinical surveillance is required. Usually, polys
develop in teenage. Colonoscopy should only be performed in symptomatic children before
teenage years. Otherwise annual flexible sigmoidoscopy starting at 13-15 years of age is
recommended. If no polyps are detected, 5 yearly colonoscopy at the age of 20 years with
annual flexible sigmoidoscopy in the intervening years. [24]. Flexible sigmoidoscopy should
be performed carefully to avoid false negative results. Chromo-endoscopy is an option in
doubtful cases.
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9. Future research for improvement of screening programme
Although most of the screening programme based on research has shown improved survival
in patients whose tumours are detected by screening, all population screening studies are
prone to biases.
Selection bias arises from the tendency of people who accept screening to be particularly
health conscious and therefore atypical of population as a whole.
Length bias indicates the tendency for screening to detect a disproportionate number of
cancers which are slow growing, which thereby has good prognosis.
Lead-time bias results from the time between the date detection of cancer by screening and
date when it would have been diagnosed had the subject not been screened. As survival is
measured from time of diagnosis, screening advances the date at which diagnosis is made,
thus lengthening the survival time without necessarily altering the date of death.
Because of these biases effectiveness of any screening can be assessed only by well designed
randomized trials comparing disease –specific mortality in a population offered screening with
that in an identical population not offered screening.
Initially three large randomized trials, using FOBT (Minnesota, Nottingham, in Funen
Denmark) [33,34,35] showed reduction in mortality. These trials provided solid ground to
initiate colorectal screening programme in western countries and US.
Randomized controlled trials are expensive and difficult to manage and may be ethically
questionable in situations where control group is denied treatment for the condition in
question. Despite this, UK National Screening Committee will only recommend the introduc‐
tion of any new programme after assessing the findings of a properly conducted randomized
controlled trial. The committee also keeps all screening programmes under regular review to
ensure that they continue to perform in the way intended and continue to be effective.
9.1. Bowel cancer screening programme research committee
The research committee considers the feasibility and scientific value of research projects that
arises from the screening programme in UK. It encourages collaboration between researchers
and tries to prevent duplication.
The committee, chaired by Professor John Scholefield, meets quarterly and has considered over
60 research applications. The area of research considered by the committee included uptake/
acceptability of screening test, epidemiology/histopathology and screening technologies. Here
we will mention some important research project in relation with screening.
9.2. False positive research study
A research project to investigate the causes of false positive results on Foecal Occult Blood
(FOB) testing is now under way. The five year project, funded by cancer research UK is a
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collaboration between university of Oxford and newly formed NHS cancer screening pro‐
grammes` Research unit, which is based in the university` cancer epidemiology unit.
The pilot studies started early in 2008 and the study will eventually involve over 200,000
screening programme participants, including about 2,500people with a positive FOB test result
who are categorized as normal following a colonoscopy.
9.3. UK flexible sigmoidoscopy screening trial
This trial looked at bowel cancer incidence and mortality reduction 11 years after a single
screening examination with flexible sigmoidoscopy [36]
It examined the efficacy and duration of effect of ;
• A once only flexible sigmoidoscopy screen between ages 55 and 64 years.
• Removal of small polyps (<10m) during screening
• Colonoscopy only for high risk adenomas.
170,000 people were entered into the trial. Cumulative incidence, including prevalent cancers
detected at screening, was reduced by 50% for the cancers in the rectum and sigmoid colon,
and 33 percent for bowel cancer overall. Bowel cancer mortality was reduced by 43 percent.
The trial concluded that flexible sigmoidoscopy screening-with removal of small polyps at the
examination is safe and, when offered only once between the ages 55 and 64, confers a
substantial and long lasting benefit.
9.4. HTA: Frequency of follow-up for patients with intermediate grade colorectal adenomas
Beginning in September 2006, this study examined the effort of extending intervals between
follow-up colonoscopies in people found to have intermediate adenomas, as defined by the
British Society of Gastroentrology guidelines. It is using data from hospitals ad from bowel
cancer screening initiatives to identify groups of patients with intermediate adenomas. The
risk of cancer and severe adenomas will be assessed according to the interval between
examinations and the number, size and features of adenomas detected.
Firstly, the study will identify whether all patients with intermediate adenomas require
surveillance; secondly, whether the intervals are of the appropriate length; thirdly, it should
also demonstrate how many follow-up examinations are needed. Finally, it will determine
whether informing patients they need to have colonoscopy distresses them or whether they
feel reassured as a result. A health economist will analyze the cost to individual patients and
to the NHS and compare these with any potential benefit.
9.5. NHS bowel cancer screening programme evaluation group
The NHS Bowel Cancer Screening Programme Evaluation Group reviews and develops
criteria used for evaluation and monitoring the progress of the Bowel Cancer Screening
Programme.
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9. Future research for improvement of screening programme
Although most of the screening programme based on research has shown improved survival
in patients whose tumours are detected by screening, all population screening studies are
prone to biases.
Selection bias arises from the tendency of people who accept screening to be particularly
health conscious and therefore atypical of population as a whole.
Length bias indicates the tendency for screening to detect a disproportionate number of
cancers which are slow growing, which thereby has good prognosis.
Lead-time bias results from the time between the date detection of cancer by screening and
date when it would have been diagnosed had the subject not been screened. As survival is
measured from time of diagnosis, screening advances the date at which diagnosis is made,
thus lengthening the survival time without necessarily altering the date of death.
Because of these biases effectiveness of any screening can be assessed only by well designed
randomized trials comparing disease –specific mortality in a population offered screening with
that in an identical population not offered screening.
Initially three large randomized trials, using FOBT (Minnesota, Nottingham, in Funen
Denmark) [33,34,35] showed reduction in mortality. These trials provided solid ground to
initiate colorectal screening programme in western countries and US.
Randomized controlled trials are expensive and difficult to manage and may be ethically
questionable in situations where control group is denied treatment for the condition in
question. Despite this, UK National Screening Committee will only recommend the introduc‐
tion of any new programme after assessing the findings of a properly conducted randomized
controlled trial. The committee also keeps all screening programmes under regular review to
ensure that they continue to perform in the way intended and continue to be effective.
9.1. Bowel cancer screening programme research committee
The research committee considers the feasibility and scientific value of research projects that
arises from the screening programme in UK. It encourages collaboration between researchers
and tries to prevent duplication.
The committee, chaired by Professor John Scholefield, meets quarterly and has considered over
60 research applications. The area of research considered by the committee included uptake/
acceptability of screening test, epidemiology/histopathology and screening technologies. Here
we will mention some important research project in relation with screening.
9.2. False positive research study
A research project to investigate the causes of false positive results on Foecal Occult Blood
(FOB) testing is now under way. The five year project, funded by cancer research UK is a
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collaboration between university of Oxford and newly formed NHS cancer screening pro‐
grammes` Research unit, which is based in the university` cancer epidemiology unit.
The pilot studies started early in 2008 and the study will eventually involve over 200,000
screening programme participants, including about 2,500people with a positive FOB test result
who are categorized as normal following a colonoscopy.
9.3. UK flexible sigmoidoscopy screening trial
This trial looked at bowel cancer incidence and mortality reduction 11 years after a single
screening examination with flexible sigmoidoscopy [36]
It examined the efficacy and duration of effect of ;
• A once only flexible sigmoidoscopy screen between ages 55 and 64 years.
• Removal of small polyps (<10m) during screening
• Colonoscopy only for high risk adenomas.
170,000 people were entered into the trial. Cumulative incidence, including prevalent cancers
detected at screening, was reduced by 50% for the cancers in the rectum and sigmoid colon,
and 33 percent for bowel cancer overall. Bowel cancer mortality was reduced by 43 percent.
The trial concluded that flexible sigmoidoscopy screening-with removal of small polyps at the
examination is safe and, when offered only once between the ages 55 and 64, confers a
substantial and long lasting benefit.
9.4. HTA: Frequency of follow-up for patients with intermediate grade colorectal adenomas
Beginning in September 2006, this study examined the effort of extending intervals between
follow-up colonoscopies in people found to have intermediate adenomas, as defined by the
British Society of Gastroentrology guidelines. It is using data from hospitals ad from bowel
cancer screening initiatives to identify groups of patients with intermediate adenomas. The
risk of cancer and severe adenomas will be assessed according to the interval between
examinations and the number, size and features of adenomas detected.
Firstly, the study will identify whether all patients with intermediate adenomas require
surveillance; secondly, whether the intervals are of the appropriate length; thirdly, it should
also demonstrate how many follow-up examinations are needed. Finally, it will determine
whether informing patients they need to have colonoscopy distresses them or whether they
feel reassured as a result. A health economist will analyze the cost to individual patients and
to the NHS and compare these with any potential benefit.
9.5. NHS bowel cancer screening programme evaluation group
The NHS Bowel Cancer Screening Programme Evaluation Group reviews and develops
criteria used for evaluation and monitoring the progress of the Bowel Cancer Screening
Programme.
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It Includes representatives from all the professional groups in the programme as from the
Cancer Screening Evaluation Unit, the Health and Social Care Information Centre and Bowel
Screening Wales.
10. Current screening percentage of at risk world population and future of
colorectal screening
World Gastroenterology Organization (WGO), in affiliation with International Digetive
Cancer Alliance (IDCA), launched guidelines for international colorectal screening pro‐
grammes after indicating the low percentage of screening programme in place in different
coutries of the world. In these guidelines, they emphasise the need of some kind of screening
programme in place based on locally available screening facilities
As mentioned earlier, the risk for colorectal cancers varies from country to country and even
within countries. The risk also varies among individual people based on diet, lifestyle, and
hereditary factors. Colorectal cancer screening is particularly challenging, as reflected in
current low screening rates in most countries where there is high risk for colorectal cancer.
Colorectal cancer screening is complex as there are multiple options, it requires considerable
patient effort (Fecal Occult Blood Slides, Colonoscopy Preparation etc.), and it requires
sedation and health-care partner for some tests (colonoscopy). [37]
It is an acknowledged fact that the lowest screening percentage of on risk population for
colorectal cancer is in Asia and Africa. In most Asian and African countries, National Health
Care systems and Health Insurance cover only a minority of people. So, access to healthcare
facilities is limited in many rural areas and communities of low socio-economic status. In Asian
countries, there is little health authority support for colorectal cancer screening and very low
public awareness for this emerging epidemic in Asia. [38]
For the screening programme to be successful, multiple steps need to be taken correctly,
beginning from awareness and recommendation from the primary-care physician, patient
acceptance, financial coverage, risk stratification, screening test, timely diagnosis, timely
treatment and appropriate follow-up. If any one of these steps is left faulty or not of high
quality, the screening programme will certainly fail. (WGO)
10.1. International colorectal screening cascade
According to WGO guidelines, colorectal screening cascade consist of set of recommendations
based on availability of resources in different countries of the world beginning with 1 (highest
resources available) and ending with 6 (minimal resources available. [37]
10.1.1. Cascade Level 1
This is a set of recommendations for countries where high level of resources (Financial,
professional, facilities) available.
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For average- risk 10 yearly colonoscopies starting at 50 years.
For increased- risk patients more frequently two yearly or five yearly colonoscopies starting
at 40 yrs of age.
10.1.2. Cascade Level 2
Recommendations are same as cascade level 1 but they apply when colonoscopy resources are
more limited.
For average- risk once in life time colonoscopy at the age of 50.
For increased risk recommendations are same as cascade1.
10.1.3. Cascade Level 3
Recommendation are same as cascade level 1 but apply when colonoscopy resources are more
limited but flexible sigmoidoscopy resources are available.
For average- risk flexible colonoscopy 5 yearly starting from 50 years of age with diagnostic
workup with full colonoscopy in case of positive flexible sigmoidoscopy.
Recommendations for increased- risk are same as level 1 cascade.
10.1.4. Cascade Level 4
Recommendations are same as level 3 but they apply when flexible sigmoidoscopy and
colonoscopy resources are more limited.
For average-risk screening flexible sigmoidoscopy once in life time at the age of 50 years.
Diagnostic colonoscopy workup for positive flexible sigmoidoscopy or neoplasia depending
on availability of resources.
Recommendations for increased risk are same as level 1 cascade.
10.1.5. Cascade level 5
Recommendations are same as resource level 4 but they apply when diagnostic colonoscopy
is severely limited.
For average- risk population flexible sigmoidoscopy is recommended once in a life time at the
age of 50 years. Diagnostic colonoscopy only when advanced neoplasia is detected.
Recommendations for screening increased-risk patients depend on colonoscopy resources
available.
10.1.6. Cascade Level 6
Recommendations are same as for level 1 but they apply when flexible sigmoidoscopy and
colonoscopy resources are severely limited.
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within countries. The risk also varies among individual people based on diet, lifestyle, and
hereditary factors. Colorectal cancer screening is particularly challenging, as reflected in
current low screening rates in most countries where there is high risk for colorectal cancer.
Colorectal cancer screening is complex as there are multiple options, it requires considerable
patient effort (Fecal Occult Blood Slides, Colonoscopy Preparation etc.), and it requires
sedation and health-care partner for some tests (colonoscopy). [37]
It is an acknowledged fact that the lowest screening percentage of on risk population for
colorectal cancer is in Asia and Africa. In most Asian and African countries, National Health
Care systems and Health Insurance cover only a minority of people. So, access to healthcare
facilities is limited in many rural areas and communities of low socio-economic status. In Asian
countries, there is little health authority support for colorectal cancer screening and very low
public awareness for this emerging epidemic in Asia. [38]
For the screening programme to be successful, multiple steps need to be taken correctly,
beginning from awareness and recommendation from the primary-care physician, patient
acceptance, financial coverage, risk stratification, screening test, timely diagnosis, timely
treatment and appropriate follow-up. If any one of these steps is left faulty or not of high
quality, the screening programme will certainly fail. (WGO)
10.1. International colorectal screening cascade
According to WGO guidelines, colorectal screening cascade consist of set of recommendations
based on availability of resources in different countries of the world beginning with 1 (highest
resources available) and ending with 6 (minimal resources available. [37]
10.1.1. Cascade Level 1
This is a set of recommendations for countries where high level of resources (Financial,
professional, facilities) available.
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For average- risk 10 yearly colonoscopies starting at 50 years.
For increased- risk patients more frequently two yearly or five yearly colonoscopies starting
at 40 yrs of age.
10.1.2. Cascade Level 2
Recommendations are same as cascade level 1 but they apply when colonoscopy resources are
more limited.
For average- risk once in life time colonoscopy at the age of 50.
For increased risk recommendations are same as cascade1.
10.1.3. Cascade Level 3
Recommendation are same as cascade level 1 but apply when colonoscopy resources are more
limited but flexible sigmoidoscopy resources are available.
For average- risk flexible colonoscopy 5 yearly starting from 50 years of age with diagnostic
workup with full colonoscopy in case of positive flexible sigmoidoscopy.
Recommendations for increased- risk are same as level 1 cascade.
10.1.4. Cascade Level 4
Recommendations are same as level 3 but they apply when flexible sigmoidoscopy and
colonoscopy resources are more limited.
For average-risk screening flexible sigmoidoscopy once in life time at the age of 50 years.
Diagnostic colonoscopy workup for positive flexible sigmoidoscopy or neoplasia depending
on availability of resources.
Recommendations for increased risk are same as level 1 cascade.
10.1.5. Cascade level 5
Recommendations are same as resource level 4 but they apply when diagnostic colonoscopy
is severely limited.
For average- risk population flexible sigmoidoscopy is recommended once in a life time at the
age of 50 years. Diagnostic colonoscopy only when advanced neoplasia is detected.
Recommendations for screening increased-risk patients depend on colonoscopy resources
available.
10.1.6. Cascade Level 6
Recommendations are same as for level 1 but they apply when flexible sigmoidoscopy and
colonoscopy resources are severely limited.
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For average -risk population, Faecal Occult Blood Testing (FOBT) should be done every year
starting at the age of 50 years. The type of test used depends upon colonoscopy resources
available and dietary habits of the population. The diagnostic work-up can be done either with
colonoscopy, if available or barium enema, if colonoscopy is not readily available.
Therefore, recommendations for increased risk individuals are to identify them separately for
special screening (level 1) and the decision depends on available colonoscopy resources. If not
available, these people can be screened with average-risk individuals.
These guidelines are established considering a lack of resources in poor socioeconomically
countries and can provide a base for the structured global screening programme. We hope the
world will take measures to implement population screening programmes to save mankind
from the cruel hands of colorectal cancer.
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1. Introduction
Colorectal cancer (CRC) is the third most diagnosed cancer in men, next to prostate and lung
cancer. In women it is the second most diagnosed cancer, next to breast cancer. In a time of
limited resources in health care, there has been considerable debate which imaging modality
offers the best non-invasive examination of colorectal cancer, offering both detection and
characterization. The use of multiple diagnostic modalities is both costly and time-consuming.
Clinical evidence amassed over the last several decades indicates that routine colorectal cancer
(CRC) screening, compared to no screening, detects CRC at an earlier stage, reduces the
incidence of CRC or the progression early CRC through polypectomy, and reduces CRC
mortality.
2. Endoscopy
The first complete examination of the colon using a flexible fiber optic endoscope is reported
by Wolff and Shinya in 1971 [42]. Nowadays colonoscopy is the gold standard for evaluation
of the entire colonic mucosa with therapeutic capability of resecting detected malignancies.
In the last years the colonoscopy is the modality of choice to detect and correct the adenomatous
polyps and colorectal cancer. The diagnosis CRC can be confirmed after biopsy in a known
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malignant pathology and by obtaining more tissue sampling and/or a second opinion from a
consulting pathologist in none diagnostic, highly suspected colon lesion. Besides the role as a
diagnostic tool in CRC, colonoscopy identifies subsequent lesions at the time of surgery, which
is called preoperative endoscopic marking. It is performed through metallic clip placement
and endoscopic tattooing.
The colonoscopic equipment consists of camera and four-way tip controls [43]. The camera
can produce images of high-definition quality. The four way tip controls include (1) exami‐
nation of a found patch to confirm an abnormal growth; (2) insufflating air to dilate the lumen
for mucosal inspection and relieving air after examination, (3) irrigating a suspected region;
(4) suctioning to avoid missing lesions under fluid, and (5) inserting biopsy devices.
The patient must undergo bowel preparation - taking clear liquid diet and ingesting laxative
solutions for colon cleansing the day before examination. Sedation is needed to relieve the
discomfort during the procedure, but it increases the costs. The complication of sedation are
different cardiac disturbances such as hypotension, arrhythmias,oxygen desaturation, and
others. The preparation with purgatives may cause abdominal discomfort, nausea, and other
symptoms. The colonoscopy continues from 30 minutes to an hour. The risk during colono‐
scopy consists in colonic perforation in 0,1 % of cases. Colonoscopy fails to visualize the entire
colon in 10–15% and it may miss up to 10–20% of polyps fewer than 10 mm.
Colonoscopy is golden standard for diagnosing of CRC but there are more symptoms which
could be evaluated and appreciated by endoscopic examination, for example- abdominal pain,
unexplained gastrointestinal bleeding, diarrhea of unexplained origin, chronic inflammatory
bowel disease, etc. It is also the most common interventional modality for polypectomy,
hemostasis, balloon dilation, foreign body removal, palliative treatment of neoplasms, etc.
Colonoscopy could be the best screening option for all none specific underdiagnosed gastro‐
intestinal symptoms.
Colonoscopy removes all detected polyps, regardless of histology type- adenomatous or
hyperplastic. Not all of them must undergo resection. The polyps vary in size and polyps under
5 mm are not detected endoscopic. For detection of polyps smaller than 5 mm the virtual
colonospcopy is the alternative to the conventional colonoscopy.
3. Virtual colonoscopy
Virtual Colonoscopy uses computed tomography (CT) imaging virtual- reality technology for
the purpose of screening the entire colon which is reconstructed from abdominal CT images.
The technique starts after cleansing of the colon with oral laxatives with inflation of air or CO2
introduced through rectal tube [71]. Then abdominal CT images are taken during a single
breath holding with sub mm resolution in axial and transverse directions. The volume model
of the colon is constructed from the spiral CT images. Image segmentation is necessary for the
reconstruction of an accurate colon model [72]. Computer graphics navigate inside the 3D
colon model, the navigation is called fly through model. For validating the detection in the 3D
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colon model, interpretation of the 2D image slices at transverse, sagital and coronal directions
is often included in the procedure.
The virtual colonoscopy achieves higher sensitivity and specificity rates compared to conven‐
tional colonoscopy for detecting polyps, which are 8 mm and larger by the same bowel
preparation, and for polyps larger than 10 mm they have a comparable performance. CTC can
be a potential screening tool to supplement OC for colorectal cancer. CTC is refused to be
included in Medicare coverage because of its radiation risk- in about 50 mAs or 2 rads.
Reducing the radiation could be achieved by decreasing of the mAs level optimization of kVp
value, X-ray flux beam collimation, filtering, etc. The low-mAs strategy will lead to higher
noise in the acquired data which results in steak artifacts. The significant amount of X-ray
radiation exposure and the data noise cannot be disregarded and allowed to the CTC to be a
preferred screening modality.
An alternative method to minimize the radiation is to use magnetic resonance imaging (MRI),
i.e., MR colonography (MRC). However, this MRC has several limitation compared to CTC-
high costs, sensitiveness to motion and other artifacts, and has lower spatial resolution.
Modern CT can reach sub-millimeter spatial resolution and acquire a volumetric image of the
abdomen, detecting polyps which are smaller than 5mm.
There are other reasons responsibe for missing small polyps.
The main reason is due to the partial colon cleansing and air/CO2 inflation and this will not
generate a good interface between the colon wall and the lumen. Others include loss of image
information in post-imaging processing, different anatomical characteristics in the bowel
mucosa, residual fluid or stool covering the polyps. The solution could be virtual or electronic
colon cleansing (ECC) - special type of software programming for virtually cleansing of the
colon. It consists of three main components - (1) fecal tagging, (2) image segmentation for
classifying the tagged image voxels, and (3) post-segmentation operation for cleansing the
colon. ECC works virtually on the residual faecal materials with or without adequate bowel
preparation with purgatives (the so called cathartic-free CTC). The ECC must handle with the
partial volume (PV) effect and with the non-uniformly altered image intensity distribution.
Partial volume (PV) effect is the interface between the colon wall and the fecal materials with
heterogeneously enhanced image intensities. The PV effect blurs the interface over several
image voxels, causing the loss of details about the interface what results in the misdetection
of small polyps. A dual energy scans of a modern CT device or a dual X-ray source scanner is
a new challenging imagining modality. Two volumetric images can be acquired simultane‐
ously at two energy levels. It is expected that the polyps would have different image contrasts
in the two scans and if the contrasts are insufficient for segmenting the image voxels, oral
contrast media may be utilized to increase the density of the polyps. The ECC role in this dual
energy strategy is to segment the colonic materials from multi-spectral CT images. After ECC-
cleansing the colon lumen could be easily inspected for abnormalities and polyps along the
long colon during the fly-through navigation.
Variation among readers with different experience has been noticed. Computer-aided
detection (CAD) can minimize the variation among readers’ assessments. CAD system’s
Diagnostic Modalities in Colorectal Cancer –Endoscopy, Ct and Pet Scanning, Magnetic Resonance...
http://dx.doi.org/10.5772/57508
31
malignant pathology and by obtaining more tissue sampling and/or a second opinion from a
consulting pathologist in none diagnostic, highly suspected colon lesion. Besides the role as a
diagnostic tool in CRC, colonoscopy identifies subsequent lesions at the time of surgery, which
is called preoperative endoscopic marking. It is performed through metallic clip placement
and endoscopic tattooing.
The colonoscopic equipment consists of camera and four-way tip controls [43]. The camera
can produce images of high-definition quality. The four way tip controls include (1) exami‐
nation of a found patch to confirm an abnormal growth; (2) insufflating air to dilate the lumen
for mucosal inspection and relieving air after examination, (3) irrigating a suspected region;
(4) suctioning to avoid missing lesions under fluid, and (5) inserting biopsy devices.
The patient must undergo bowel preparation - taking clear liquid diet and ingesting laxative
solutions for colon cleansing the day before examination. Sedation is needed to relieve the
discomfort during the procedure, but it increases the costs. The complication of sedation are
different cardiac disturbances such as hypotension, arrhythmias,oxygen desaturation, and
others. The preparation with purgatives may cause abdominal discomfort, nausea, and other
symptoms. The colonoscopy continues from 30 minutes to an hour. The risk during colono‐
scopy consists in colonic perforation in 0,1 % of cases. Colonoscopy fails to visualize the entire
colon in 10–15% and it may miss up to 10–20% of polyps fewer than 10 mm.
Colonoscopy is golden standard for diagnosing of CRC but there are more symptoms which
could be evaluated and appreciated by endoscopic examination, for example- abdominal pain,
unexplained gastrointestinal bleeding, diarrhea of unexplained origin, chronic inflammatory
bowel disease, etc. It is also the most common interventional modality for polypectomy,
hemostasis, balloon dilation, foreign body removal, palliative treatment of neoplasms, etc.
Colonoscopy could be the best screening option for all none specific underdiagnosed gastro‐
intestinal symptoms.
Colonoscopy removes all detected polyps, regardless of histology type- adenomatous or
hyperplastic. Not all of them must undergo resection. The polyps vary in size and polyps under
5 mm are not detected endoscopic. For detection of polyps smaller than 5 mm the virtual
colonospcopy is the alternative to the conventional colonoscopy.
3. Virtual colonoscopy
Virtual Colonoscopy uses computed tomography (CT) imaging virtual- reality technology for
the purpose of screening the entire colon which is reconstructed from abdominal CT images.
The technique starts after cleansing of the colon with oral laxatives with inflation of air or CO2
introduced through rectal tube [71]. Then abdominal CT images are taken during a single
breath holding with sub mm resolution in axial and transverse directions. The volume model
of the colon is constructed from the spiral CT images. Image segmentation is necessary for the
reconstruction of an accurate colon model [72]. Computer graphics navigate inside the 3D
colon model, the navigation is called fly through model. For validating the detection in the 3D
Colorectal Cancer - Surgery, Diagnostics and Treatment30
colon model, interpretation of the 2D image slices at transverse, sagital and coronal directions
is often included in the procedure.
The virtual colonoscopy achieves higher sensitivity and specificity rates compared to conven‐
tional colonoscopy for detecting polyps, which are 8 mm and larger by the same bowel
preparation, and for polyps larger than 10 mm they have a comparable performance. CTC can
be a potential screening tool to supplement OC for colorectal cancer. CTC is refused to be
included in Medicare coverage because of its radiation risk- in about 50 mAs or 2 rads.
Reducing the radiation could be achieved by decreasing of the mAs level optimization of kVp
value, X-ray flux beam collimation, filtering, etc. The low-mAs strategy will lead to higher
noise in the acquired data which results in steak artifacts. The significant amount of X-ray
radiation exposure and the data noise cannot be disregarded and allowed to the CTC to be a
preferred screening modality.
An alternative method to minimize the radiation is to use magnetic resonance imaging (MRI),
i.e., MR colonography (MRC). However, this MRC has several limitation compared to CTC-
high costs, sensitiveness to motion and other artifacts, and has lower spatial resolution.
Modern CT can reach sub-millimeter spatial resolution and acquire a volumetric image of the
abdomen, detecting polyps which are smaller than 5mm.
There are other reasons responsibe for missing small polyps.
The main reason is due to the partial colon cleansing and air/CO2 inflation and this will not
generate a good interface between the colon wall and the lumen. Others include loss of image
information in post-imaging processing, different anatomical characteristics in the bowel
mucosa, residual fluid or stool covering the polyps. The solution could be virtual or electronic
colon cleansing (ECC) - special type of software programming for virtually cleansing of the
colon. It consists of three main components - (1) fecal tagging, (2) image segmentation for
classifying the tagged image voxels, and (3) post-segmentation operation for cleansing the
colon. ECC works virtually on the residual faecal materials with or without adequate bowel
preparation with purgatives (the so called cathartic-free CTC). The ECC must handle with the
partial volume (PV) effect and with the non-uniformly altered image intensity distribution.
Partial volume (PV) effect is the interface between the colon wall and the fecal materials with
heterogeneously enhanced image intensities. The PV effect blurs the interface over several
image voxels, causing the loss of details about the interface what results in the misdetection
of small polyps. A dual energy scans of a modern CT device or a dual X-ray source scanner is
a new challenging imagining modality. Two volumetric images can be acquired simultane‐
ously at two energy levels. It is expected that the polyps would have different image contrasts
in the two scans and if the contrasts are insufficient for segmenting the image voxels, oral
contrast media may be utilized to increase the density of the polyps. The ECC role in this dual
energy strategy is to segment the colonic materials from multi-spectral CT images. After ECC-
cleansing the colon lumen could be easily inspected for abnormalities and polyps along the
long colon during the fly-through navigation.
Variation among readers with different experience has been noticed. Computer-aided
detection (CAD) can minimize the variation among readers’ assessments. CAD system’s
Diagnostic Modalities in Colorectal Cancer –Endoscopy, Ct and Pet Scanning, Magnetic Resonance...
http://dx.doi.org/10.5772/57508
31
disadvantages are many false positives (FPs), such as partial bowel cleansing, image noise,
motion artifacts, colon fold structures, etc. High sensitivity CAD with minimal number of FPs
and development of various texture features and virtual biopsy features remains an innovative
research goal.
Figure 1. Endoscopic view of corectal tumor – conventional endoscopy
Figure 2. Virtual colonoscopy – a view of pediculaneted polypus and a small carcinoma - CT images.
Figure 3. Virtual colonoscopy – a view of pediculaneted polypus and a small carcinoma - a 3-D reconstruction after
software rendering.
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4. Imaging diagnostics in rectal cancer
Staging of rectal cancer is of great importance before the surgical treatment, because staging
predicts the management, prognosis, recurrence and/or metastatic disease risk (13). Staging is
divided into local and distant staging. Local staging points at wall invasion, resection margin
involvement and the nodal status for metastasis and distant staging refers to presence or
absence of metastatic disease. Rectal examination using proctoscopy may be considered as an
important tool for newly diagnosed rectal cancers. Proctoscopy may determine better visual‐
ization, localization and fixity of the tumor, including taking biopsy, which may affects
positively the staging of the rectal cancer.
Nowadays several imaging modalities or combination of these are available for evaluating
preoperative staging of colorectal cancer- computed tomography (CT), magnetic resonance
imaging (MRI), and/or endorectal ultrasonography (EUS). EUS and MRI of the pelvis are used
to appreciate the local dissemination while CT defines systemic dissemination. PET is indi‐
cated when there is clinical, biochemical or radiological suspicion of local recurrence or
systemic disease. Functional imaging such as diffusion weighted MRI imaging (DWI) and CT/
PET are used to distinguish fibrosis from tumor [33].
The T staging accuracy in more advanced cancer is achieved by using MR imaging modality
because MRI can distinguish between mesorectum and mesorectal fascia. The N staging
accuracy is also provided by MRI particularly using superparamagnetic iron oxide particles.
4.1. Endorectal ultrasound
The advancing of imaging technologies has made endoscopic ultrasound a modality of choice
in gastrointestinal diseases, regarding diagnosis, staging and prognosis stratification. These
novel techniques assign excellent to rectal tumors.
Endorectal ultrasound (EUS) is useful in evaluating early rectal cancers (T1 and T2 lesions)
and post transanal surgery. EUS can visualize the rectal wall without distinguishing of
mesorectal fascia, peritumor inflammation, or faeces collections. The accuracy of the T stage
evaluation varies from 60%-90% [45].
In comparison to MRI EUS was found to be highly accurate in early lesions ( for T1 and T2 the
accuracy can reach to 100%), as well as for nodal metastases. For evaluation of metastatic
disease neither MRI nor EUS enable reliable diagnosis.
Besides the misleading lymph node assessment, EUS has its disadvantages in detecting T3
lesions (advanced, stenotic, bulky lesions) or tumors after neoadjuvant therapy, and the
technique is operator dependent.
Hypoechoic appearance, size > 5 mm, round shape, peritumoral location are characteristics
suggestive of malignant involvement of lymph nodes [45,46,51-53]. EUS-guided fine-needle
aspiration can be carried out from the lesion or suspiciously looking lymph nodes.
An newer technique is the three-dimensional ERUS (3D-ERUS). It consists of transverse,
coronal and sagittal scan and has been found to be more reliable in staging colon cancer to
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two-dimensional EUS and CT. The accuracy of 3D-ERUS for assessing the depth of cancer
infiltration and for nodal involvement is with 10% more than the other imaging modalities.
3D images have proved a better visualization of the mesorectal margins. With 3D-ERUS the
surgeon can perform endoscopic mucosal resections of early tumors. A reliable predictor for
response after chemoradiation therapy are the accurate volumetric measurements achieved
by 3D-ERUS. Using Doppler signal enhancers tumor perfusion can be determine, coming to
better results in neoadjuvant therapy and antiangiogenesis treatment.
3D-ERUS, elastography, and contrast enhancement might bring additional information,
increasing diagnostic accuracy of ERUS and amplifying its roles in the complex management
in rectal cancer.
Figure 4. Endorectal ultrasonography – a view of T-3 carcinoma - 3-D reconstruction after real-time software render‐
ing.
T and LN staging
In colon cancer patients it is essential to correctly determine the TNM stage. The modalities of
choice are CT, MRI and, as mentioned above, the novel technique ERUS.
ERUS shows high sensitivity and specificity in T-staging and is prior to CT and MRI for staging
superficial rectal tumors, with accuracy in evaluating rectal wall invasion to 97% [23,24]. For
T1, T2, T3 and T4 staging accuracy of ERUS is more than 80%. One common finding is a lower
accuracy for T2 tumors, because the impossibility in distinguishing those tumors that have
deep invasion into the muscularis propria from those with microscopic invasion into the
perirectal fat.
Transanal endoscopic microsurgery (TEM) and endoscopic submucosal dissections are novel
important strategies which directs the mode of surgery because of the ability to visualize the
submucosa. This can lead to down- or upstaging of the detected rectal cancer. Besides ERUS
can detect recurrence at the anastomosis site and to differentiate between postoperative scars
and local recurrences. Unfortunately assessment for nodal metastases is less accurate than that
for tumor depth and reaches 75%. For rectal cancer in particular, over half of the metastatic
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nodes are less than 5 mm and are located within 3 cm of the primary tumor [31]. Metastatic
disease was shown to predict local recurrence.
The sensitivity of ERUS in detecting LN metastasis ranges from 50% to 83%, because small
lymph node (less than 5mm) is not observed with ERUS and it has limited field of view. Factors
for malignancy in lymph node besides node size, echogenicity, shape, border, include:
hypoechogenicity, short axis ≥ 5 mm, long axis length greater than 9 mm.
Detecting of iliac adenopathy is crucial because it goes after total mesorectal excision. This is
possible through flexible not rigid probes. In general, ERUS is better at detecting lymph nodes
in the distal and middle thirds of the rectum [21,33]. The reactive swollen lymph nodes, small
blood vessels, urethra, and seminal vesicle often are mistaken for malignant lymph nodes and
these results in over staging of the disease. On the other hand, the major reason for nodal status
under staging is misdetecting of very small involved nodes (less than 2 mm) and nodes outside
the perirectal tissue [21,33].
Preoperative chemoradiation is a limiting factor affecting accurate staging of rectal cancer.
There are associated reactive and inflammatory changes in the rectum wall after radiotherapy.
However, radiotherapy affects the wall thickness but does not change the five-layered image.
The 3D reconstruction allows improved T and N staging through direct visualization of subtle
protrusions of tumors infiltrating into adjacent tissues and organs.
Limitations of ERUS are several. Firstly it is operator’s experience dependent; it varies after
partial excision or neoadjuvant chemoradiation. It has poor patient acceptability and it has
limited depth of penetration; Another disadvantages are those that it cannot be performed in
obstructive tumors [16,21]; it is unable to visualize tumors located higher with a rigid probe.
It is insufficient in detecting lymph nodes outside the range of the transducer, or visualize
mesorectal fascia because of its limited field of view. In addition, accuracy is affected by villous
or pedunculated tumors, inflammation, hemorrhage [22,31].
MRI
MRI obtain image identification of the distance of the CRM to the tumor, the relation to pelvic
floor and anal sphincter complex, differentiation between mucinous and none mucinous
neoplasia. T staging accuracy of MRI is 52% when compared to histology, because of the
interface between muscularis propria, perirectal fat and mesorectal fascia. MRI cannot
distinguish between T1 and T2 lesions, as well as between T2 and T3 cancer.
T staging
The depth of invasion through the muscle wall is one important element seen on MRI that can
help guide clinical decision making for patients with rectal cancer. Not only does the inci‐
dence of nodal involvement increase with increasing tumor penetration [19,20], but clinical
studies have shown that patients with stage Ⅰ (T1-2 N0) rectal cancer do not benefit from neo-
adjuvant radiotherapy [21] and may be amenable to a less than radical surgical treatment [22].
Patients with clinically staged T3-4 tumors typically require preoperative CRT since it re‐
duces the rates of local recurrence more effectively than either postoperative CRT or preopera‐
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There are associated reactive and inflammatory changes in the rectum wall after radiotherapy.
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protrusions of tumors infiltrating into adjacent tissues and organs.
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limited depth of penetration; Another disadvantages are those that it cannot be performed in
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It is insufficient in detecting lymph nodes outside the range of the transducer, or visualize
mesorectal fascia because of its limited field of view. In addition, accuracy is affected by villous
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floor and anal sphincter complex, differentiation between mucinous and none mucinous
neoplasia. T staging accuracy of MRI is 52% when compared to histology, because of the
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The depth of invasion through the muscle wall is one important element seen on MRI that can
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tive radiotherapy alone [23-25]. However, some problems remain with T stage determination
on MR imaging. Overall, the agreement between MRI and histology for T staging has ranged
from 66%-94% [18,26-28]. One of the main problems of T staging on MRI is the distinction
between T2 and T3 tumors. In fact, investigators have shown that the negative predictive value
for invasion beyond the muscularis propria varied from 93% (expert reading) to 76% (general
radiologist reading) [26]. This difficulty is attributed to the presence of desmoplastic reac‐
tions around the tumor. This reaction makes it difficult to distinguish between spiculation in
the perirectal fat caused by fibrosis alone from that caused by fibrous tissue that contains tumor
cells [26]. In contrast, MRI has been shown to be more accurate in imaging the more advanced
tumors (T4) [27,29]. According to a metaanalysis, MRI for T4 lesions has a specificity of 96% [30].
CRM
The CRM (lateral, radial) is defined as the surgical cut surface of the connective tissues (i.e.
lymphovascular, fatty and neural tissue) that circumferentially encase the rectum. It equates
to the mesorectal fascia that forms the plane of dissection in rectal cancer surgery. It is assessed
Figure 5. Endorectal ultrasonography – a real time 3-D reconstruction with different options for endorectal evaluation
of the tumor process.
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by marking the outer surface (i.e. the CRM) with ink, taking serial cuts through the specimen
and examining the macroscopic and microscopic relations between the tumor and the inked
margin. The CRM gives significant information not only about the quality of the performed
operation but also prognosis of the disease. Indeed, in a recent study based on the data from
a randomized clinical trial, Nagtegaal et al [31] demonstrated in a multivariate model that the
CRM is more important than the T stage for the prognosis of rectal cancer. The definition of a
positive CRM remains a matter of debate. A review of the literature in 2006 showed that the
majority of studies that dealt with CRM status used the ≤ 1 mm definition for positive CRM
(91.1%; 7373 of 8094 patients) [32].
Six distinct types of CRM involvement have been described; direct tumor spread which occurs
in 18% to 29% of cases; discontinuous tumor spread in 14% to 67% of cases; lymph node
metastases in 12% to 14% of cases; venous invasion in 14% to 57% of cases; lymphatic invasion
in 9% of cases; and perineural tumor spread in 7% to 14% of cases [32]. In approximately 30%
of patients, there is more than one type of margin involvement. In contrast to direct tumor
spread, the involvement of the CRM by lymph node metastases is not associated with local
recurrence [32]. MRI is highly accurate and reliable for prediction of the CRM [33,34]. In their
most recent study of 98 rectal cancer patients, Brown et al [27] reported a 92% agreement
between MRI images and histologic findings for prediction of CRM involvement. In another
study assessing the tumor relationship to the mesorectal fascia, two observers independently
scored the tumor stage and the distance to the mesorectal fascia on MRI and compared these
observations with the final histological findings [26]. For twelve tumors with involved
mesorectal fascia, and thus, a CRM of 0 mm, the accuracy in predicting the CRM was 100% for
both readers. In 29 patients with a wide CRM (10 mm), the accuracy for predicting the negative
margin was 97% (27 of 28) for one reader and 93% (26 of 28) for the other [26]. It is relevant to
point out that 5 mm of mesorectal tissue surrounding the lateral tumor edge on MRI was shown
to equal a CRM of 2 mm in the surgical specimen [26]. In the report by Nagtegaal et al [35], a
linear regression curve showed that the crucial distance of at least 2 mm could be predicted
with 97% confidence when the distance on MRI is at least 6 mm. Therefore, the safe rule to
predict CRM involvement on MRI is considered to be an MRI measurement minus 4 mm due
to shrinkage of the specimen with fixation [6]. Of note, the CRM becomes more difficult to
identify in low, anterior tumors and in patients with a limited amount of perirectal fat [36]. In
a recent study by Frasson et al [37], the 5-year local recurrence rates for patients with a
preoperative CRM of < 2 mm on MRI or EUS who did not receive preoperative chemoradiation
was 19.4% compared to 5.4% for patients with a non-threatened margin. It is important to
realize that a short course of preoperative radiotherapy has limited ability to control positive
CRM. An analysis of more than 17 500 pathologic specimens by Nagtegaal et al [32] revealed
that the chance of local recurrence was higher for patients with a positive CRM after neoad‐
juvant treatment (both radiotherapy and radiochemotherapy) than those with a positive CRM
following immediate surgery (Hazard ratio 6.3 vs 2.0, respectively). Similar results have been
reported following postoperative treatment [38]. In the MRC CR-07 trial, patients with positive
radial margins who were selected to receive postoperative chemoradiation had a 21% local
recurrence rate [39]. Thus, in cases where the tumors are close (< 2 mm) or through the
mesorectal margin on preoperative MRI, a more aggressive treatment regimen is required with
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linear regression curve showed that the crucial distance of at least 2 mm could be predicted
with 97% confidence when the distance on MRI is at least 6 mm. Therefore, the safe rule to
predict CRM involvement on MRI is considered to be an MRI measurement minus 4 mm due
to shrinkage of the specimen with fixation [6]. Of note, the CRM becomes more difficult to
identify in low, anterior tumors and in patients with a limited amount of perirectal fat [36]. In
a recent study by Frasson et al [37], the 5-year local recurrence rates for patients with a
preoperative CRM of < 2 mm on MRI or EUS who did not receive preoperative chemoradiation
was 19.4% compared to 5.4% for patients with a non-threatened margin. It is important to
realize that a short course of preoperative radiotherapy has limited ability to control positive
CRM. An analysis of more than 17 500 pathologic specimens by Nagtegaal et al [32] revealed
that the chance of local recurrence was higher for patients with a positive CRM after neoad‐
juvant treatment (both radiotherapy and radiochemotherapy) than those with a positive CRM
following immediate surgery (Hazard ratio 6.3 vs 2.0, respectively). Similar results have been
reported following postoperative treatment [38]. In the MRC CR-07 trial, patients with positive
radial margins who were selected to receive postoperative chemoradiation had a 21% local
recurrence rate [39]. Thus, in cases where the tumors are close (< 2 mm) or through the
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neoadjuvant CRT or an upfront regimen of chemotherapy before chemoradiation prior to
operation. In contrast, patients with a free margin > 2 mm from mesorectal fascia may undergo
surgery [total mesorectal excision (TME)] alone, avoiding preoperative chemoradiation.
Interestingly, MRI-based therapy for CRM positive tumors was able to reduce the frequency
of neoadjuvant therapy for rectal carcinoma by 35% without the risk of worsening the
oncological results [40]. However, omitting preoperative chemoradiation for all CRM-negative
tumors on MRI needs to be further investigated in prospective clinical trials before it is adopted
as standard therapy.
N staging
The presence of involved lymph nodes is an indicator for the likelihood of systemic disease
and local recurrence [41]. Therefore node-positive disease is generally an indication for
preoperative chemoradiation. However, radiological evaluation of lymph node metastatic
involvement remains a challenge. Results of anatomic studies show that over half of the
metastatic nodes from rectal cancer are within 3 cm of the primary tumor and are smaller than
5 mm in size [42]. With a standard TME, the perirectal nodes are removed with the primary
tumor, but the internal iliac and obturator nodes are left in place. Moriya et al [43] reported
that as many as 28% of lymph node-positive distal rectal cancers have involvement of lateral
nodes and in 6% of cases, these were the only nodes involved. This means that in 6% of patients,
the disease was incorrectly staged postoperatively as node-negative at TME. For pre-operative
lymph node imaging, MRI at present is only moderately accurate, although this could change
with advances in new MR techniques. Currently, the reported accuracy rate of MRI for nodal
staging ranges from 71% to 91% [42]. On MRI, lymph nodes typically have lower signal
intensity than the perirectal fat but higher signal intensity than arteries and veins. In patients
with mucinous carcinoma, metastatic lymph nodes are visualized as hyperintense nodules
alone or as hyperintense areas within hypointense nodules. A node is considered enlarged if
the major axis length is more than 5 mm (mesorectal), 7 mm (internal iliac), 10 mm (external
iliac), or 9 mm (common iliac) [44]. However, the morphological features or signal intensity of
the nodes on MRI may more accurately determine metastatic involvement rather than
measurement of size. Brown et al [45] demonstrated that an irregular border or mixed signal
intensity of lymph nodes on MRI improved the specificity of predicting nodal status from 68%
(based on size alone) to 97%. One of the more promising advances of MRI may be the use of
new lymphographic agents that help assess tumor spread to lymph nodes. In a recent study,
gadofosveset-enhanced MRI improved the specificity of nodal staging from 82% achieved with
standard MRI to 97% [46]. Fusion of diffusion-weighted MR with T2-weighted images
improves identification of pelvic lymph nodes compared with T2-weighted images alone.
Using fusion images, 29% additional nodes were detected compared with T2-weighted images
alone [47]. The improved nodal identification may aid in treatment planning.
For the vast majority of rectal carcinomas, MRI is currently the most accurate modality on
which to base treatment decisions for patients with rectal cancer. Traditionally, the decision
to apply preoperative treatment for rectal cancer patients has been based on the T- and N-
stage. Lately, other MRI findings such as the radial distance of the tumor to the CRM and
extramural vascular invasion score have been identified as important risk factors for local
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failure and survival. Every center that treats patients with rectal cancer should develop a
multidisciplinary team featuring a description of the MRI findings and their implementation
in the treatment strategy with the aim of increasing resectability, reducing the local recurrence
and treatment morbidity, and improving the quality of life.
Figure 6. MRI – a view of T-3 carcinoma - 3-D reconstruction after real-time software rendering.
CT, MRI and intraoperative ultrasound for evaluation of the systematic progression in
colorectal cancer
The morbidity rate for patients with cancer depends on the early detection of liver metastases.
The presence of liver metastases makes of the primary tumour non-resectable for oncologic
reasons, except for tumour palliative treatment (for example resection for obstruction of the
gastrointestinal tract). For a few malignancies, as in colorectal carcinoma, resection of liver
metastases has been shown to improve the survival of the patients. The hepatic metastases are
divided into synchronous (i.e. occurring at the time of diagnosis of the primary tumour) and
metachronous (occurring after diagnosis of the primary tumour). The surgical resection of the
metastases depends on the division, number, size, regional distribution and all clinical
parameters of the patient, which makes resectable only 30% of all colorectal patients with
metastases. The 5-year survival rate of these patients is more than 30% in comparison to a
survival of less than 5% of patients with liver metastases not amenable to liver surgery [1–4].
The goal of imaging modalities is to assess the presence or absence of liver metastases in
surgical candidates. Different studies indicate ferumoxide-enhanced magnetic resonance (MR)
imaging as more sensitive and specific than contrast-enhanced computed tomography (CT) in
detection of hepatic metastases. The different MR pulse sequences and MR contrast media
agents makes MRI the modality of choice for non-invasive lesion characterization.
Preoperative assessment of surgical candidates
Preoperative assessment of metastatic liver involvement should be performed for all surgery
candidates. This preoperative staging is conceivable by contrast-enhanced CT and/or MRI in
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that as many as 28% of lymph node-positive distal rectal cancers have involvement of lateral
nodes and in 6% of cases, these were the only nodes involved. This means that in 6% of patients,
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iliac), or 9 mm (common iliac) [44]. However, the morphological features or signal intensity of
the nodes on MRI may more accurately determine metastatic involvement rather than
measurement of size. Brown et al [45] demonstrated that an irregular border or mixed signal
intensity of lymph nodes on MRI improved the specificity of predicting nodal status from 68%
(based on size alone) to 97%. One of the more promising advances of MRI may be the use of
new lymphographic agents that help assess tumor spread to lymph nodes. In a recent study,
gadofosveset-enhanced MRI improved the specificity of nodal staging from 82% achieved with
standard MRI to 97% [46]. Fusion of diffusion-weighted MR with T2-weighted images
improves identification of pelvic lymph nodes compared with T2-weighted images alone.
Using fusion images, 29% additional nodes were detected compared with T2-weighted images
alone [47]. The improved nodal identification may aid in treatment planning.
For the vast majority of rectal carcinomas, MRI is currently the most accurate modality on
which to base treatment decisions for patients with rectal cancer. Traditionally, the decision
to apply preoperative treatment for rectal cancer patients has been based on the T- and N-
stage. Lately, other MRI findings such as the radial distance of the tumor to the CRM and
extramural vascular invasion score have been identified as important risk factors for local
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failure and survival. Every center that treats patients with rectal cancer should develop a
multidisciplinary team featuring a description of the MRI findings and their implementation
in the treatment strategy with the aim of increasing resectability, reducing the local recurrence
and treatment morbidity, and improving the quality of life.
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CT, MRI and intraoperative ultrasound for evaluation of the systematic progression in
colorectal cancer
The morbidity rate for patients with cancer depends on the early detection of liver metastases.
The presence of liver metastases makes of the primary tumour non-resectable for oncologic
reasons, except for tumour palliative treatment (for example resection for obstruction of the
gastrointestinal tract). For a few malignancies, as in colorectal carcinoma, resection of liver
metastases has been shown to improve the survival of the patients. The hepatic metastases are
divided into synchronous (i.e. occurring at the time of diagnosis of the primary tumour) and
metachronous (occurring after diagnosis of the primary tumour). The surgical resection of the
metastases depends on the division, number, size, regional distribution and all clinical
parameters of the patient, which makes resectable only 30% of all colorectal patients with
metastases. The 5-year survival rate of these patients is more than 30% in comparison to a
survival of less than 5% of patients with liver metastases not amenable to liver surgery [1–4].
The goal of imaging modalities is to assess the presence or absence of liver metastases in
surgical candidates. Different studies indicate ferumoxide-enhanced magnetic resonance (MR)
imaging as more sensitive and specific than contrast-enhanced computed tomography (CT) in
detection of hepatic metastases. The different MR pulse sequences and MR contrast media
agents makes MRI the modality of choice for non-invasive lesion characterization.
Preoperative assessment of surgical candidates
Preoperative assessment of metastatic liver involvement should be performed for all surgery
candidates. This preoperative staging is conceivable by contrast-enhanced CT and/or MRI in
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most oncologic centers. All imaging modalities present different false-positive or false-
negative diagnoses- for helical CT- in 42%, intraoperative US- in 22.8%, mangafodipir-
enhanced MRI- in 10%, ferumoxide-enhanced MRI technique is accurate as CT during
arterioportography (CTAP)- in 19%. Another study found that FDG-PET CT is the most
sensitive method for detection of metastases. There is no firm statement which is the best
imaging modality, further more the choice depends on local equipment, availability, and
operator expertise. MDCT is preferred as a screening method for hepatic lesions because of its
ability to reduce respiration-related artifacts, to shorten scan time, to perform multiphase
scanning. The disadvantage is the high radiation exposure.
Clinical Role of Intraoperative US
Intraoperative US provide more diagnostic and staging information to the surgeon during
hepatic resection. Intraoperative US supplies 35% more information about the lesion type,
localization and expansion to adjacent tissues, relation to vascular structures, providing more
specificity in the evaluation of liver lesions. In addition intraoperative US represent 25% more
lesions than did preoperative US, CT, or angiography. This results in correction in disease
staging, which affects the surgical management and postoperative treatment. The intraoper‐
ative US has a positive effect on patient care, surgical planning, and clinical outcome.
Magnetic resonance imaging
The standard phased array MRI produces good quality images with good contrast resolution
and a relatively large field of view, so it is the modality of choice for preoperative staging of
rectal primary tumor. MRI is reliable for assessment of the tumor and its locoregional exten‐
sion, for identifying recurrence and for planning radiation therapy. The disadvantage of MRI
is impossibility in evaluation nodal metastases.
Figure 7. Intraoperative ultrasound of the liver
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Deciding in management of rectal cancer is the differentiation of the mesorectal fascia-
circumstance, which is possible using phased-array coils (confirmed from the multicentre
European MERCURY study)(21,23).
MRI may not be the examination of choice for every patient. Patients with contraindications
to MRI (e.g. implantable pacemakers), or unable to tolerate MRI (e.g. due to claustrophobia)
would preferably undergo preoperative imaging with CT. Motion related imaging artifacts
that can severely dampen the diagnostic quality of MRI will occur in patients who are unable
to breath hold for longer than 20 seconds.
FDG PET in the Initial Staging of CRC
FDG PET is not a routine investigation for primary cancer due to its limited spatial resolution.
PET cannot define the T-category of the primary tumor, but PET is superior to other imaging
modalities in detecting of lymph node and distant metastases- an important prognostic factor.
After PET-CT investigation the patient could be upstaged in 17% because of identifying
unsuspected systemic and lymph node metastases. But the specificity of PET in nodal staging
does not be higher than multi-detector CT scan (MDCT).
The  principle  of  positron  emission  tomography (PET)  (and Fluoro-deoxy-glucose  (FDG)
used as tracer or enhancer) is based on the differential metabolic profile of tumors - higher
metabolic activity, change in the tumor biology. FDG/PET is mainly useful in the assess‐
ment of local recurrence and metastases.  Besides in neoplastic cells FDG accumulates in
areas of inflammation, infection,  in organs of increased metabolic activity such as brain,
myocardium, liver or kidneys leading to false positive results. Interpretation of PET without
anatomic correlation is difficult which results in necessity of fusing PET with CT images-
PET-CT fusion scans are invented. This offers a detailed anatomical and functional imaging.
The combination provides additional value to localize the hot spots. The false positive rates
are  due  to  other  diseases  and physiological  processes.  PET scans  improve  the  manage‐
ment plan for rectal cancer. The addition of FDG-PET changes patient management in up
to  30%  of  patients  with  potentially  resectable  liver  metastases,  mainly  by  detecting
previously unknown extrahepatic disease. Furthermore, FDG-PET is useful in the follow-
up  of  patients  who  underwent  surgical  procedures  of  the  liver,  since  it  is  sensitive  in
detecting residual or relapse malignancy in scarred liver tissue following both resection and
local ablative techniques. For follow-up during systemic therapy, early FDG-PET appears
predictive  for  response  to  therapy.  FDG-PET,  computerized  tomography  and  magnetic
resonance imaging are complementary techniques in staging and restaging patients with
advanced colorectal  cancer.  A combination of  FDG-PET and CT scanning characteristics
seems promising, and integrated PET/ CT is becoming more widely available, although the
exact clinical value and efficacy is not yet fully established. In addition, assessment of these
modalities in joint reading sessions with radiologist, nuclear medicine physician, medical
and  surgical  oncologists  significantly  impacts  upon  patient  management.  This  review
evaluates the potential of FDG-PET and combined PET/CT in patients with colorectal liver
metastases and discusses potential future possibilities.
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Suggested investigations for tumor staging of rectal cancer
CT scanning is still the current standard for distant staging, but not to stage the local neoplasm.
The combination of CT and PET offers both anatomical and functional imaging, so it is
sufficient for recurrent rectal cancers. MRI and EUS should be considered as the initial
modalities to stage the local tumor. For T1-T2 lesions EUS is more appropriate, whereas MRI
is used in advanced rectal cancer. MRI has been shown to be highly accurate in predicting a
clear circumferential resection margin in patients undergoing TME.
Suggested investigation for nodal staging of rectal cancer
Significant malignant lymph nodes (more than 1cm in diameter), in conjunction with size,
shape and morphology, are identified through MRI, CT and EUS studies. The enlarged lymph
node can be as a result of the inflammatory process but normal size nodes can have microme‐
tastases. Moreover the halves of nodes less than 5 mm are proved to be malignant. One novel
technique involves use of a contrast media containing superparamagnetic iron oxide particles
SPIO which accumulates in normal lymph nodes, but not in malignant nodes due to poor
uptake. Then, using T2 weighted imaging, these nodes can be identified. Initial studies are
promising but further research is needed [35].
Figure 8. Positron emission tomography of the liver – an observation of metastasis from colorectal origin
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Figure 9. Positron emission tomography of the body – an observation of perirectal lymphadenopathy
5. Conclusion
Optical colonoscopy (OC) and virtual colonoscopy (VC) (i.e. CT colonoscopy and MR colono‐
scopy) are constantly developing and adapting to the new clinical needs. The optical colono‐
scopy has the advantage of being both diagnostic and therapeutic procedure for patients with
positive findings on screening tests. The virtual colonoscopy is much less invasive method and
can be used for mass screening because of the high prevalence of the colorectal cancer. As a
screening test the VC has advantages over OC and other options such as FOBT, FIT, stool DNA
testing, and DCBE. These methods can make a good combination of VC screening with OC
follow-up on the positive findings. The current imaging modalities for VC are CT and MRI
and in the future other modalities might be available.
The imaging standard for accurate diagnostics for colorectal cancer includes ultrasound (US),
CT and MRI. The nuclear medicine has its role in finding extra-regional localization of the main
disease by FDG-PET and FDG-PET/CT. The protocol for liver metastases includes CT as a first
choice, which is followed by US. Lung-metastases are evaluated by X-ray or chest CT. The
extrahepatic metastases are assessed by CT. The present guidelines could be adjusted by
conducting comparative studies on different strategies for colon and rectal cancer, such as CT
liver/abdomen vs. MRI liver/abdomen for liver and extrahepatic metastases, X-ray chest and
CT chest for lung metastases.
The screening of asymptomatic patients is justified due to the high prevalence of colon
carcinoma and the mortality can be effectively reduced by removing adenomatous polyps.
Although effective, this method consumes large resources if applied to the whole target
population. The currently available screening options have limitations. The VC has the option
to identify patients with adenomatous polyps. The combination of VC screening and OC
follow-up might prove as a cost-effective measure against colorectal cancer.
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Suggested investigations for tumor staging of rectal cancer
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modalities to stage the local tumor. For T1-T2 lesions EUS is more appropriate, whereas MRI
is used in advanced rectal cancer. MRI has been shown to be highly accurate in predicting a
clear circumferential resection margin in patients undergoing TME.
Suggested investigation for nodal staging of rectal cancer
Significant malignant lymph nodes (more than 1cm in diameter), in conjunction with size,
shape and morphology, are identified through MRI, CT and EUS studies. The enlarged lymph
node can be as a result of the inflammatory process but normal size nodes can have microme‐
tastases. Moreover the halves of nodes less than 5 mm are proved to be malignant. One novel
technique involves use of a contrast media containing superparamagnetic iron oxide particles
SPIO which accumulates in normal lymph nodes, but not in malignant nodes due to poor
uptake. Then, using T2 weighted imaging, these nodes can be identified. Initial studies are
promising but further research is needed [35].
Figure 8. Positron emission tomography of the liver – an observation of metastasis from colorectal origin
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Figure 9. Positron emission tomography of the body – an observation of perirectal lymphadenopathy
5. Conclusion
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testing, and DCBE. These methods can make a good combination of VC screening with OC
follow-up on the positive findings. The current imaging modalities for VC are CT and MRI
and in the future other modalities might be available.
The imaging standard for accurate diagnostics for colorectal cancer includes ultrasound (US),
CT and MRI. The nuclear medicine has its role in finding extra-regional localization of the main
disease by FDG-PET and FDG-PET/CT. The protocol for liver metastases includes CT as a first
choice, which is followed by US. Lung-metastases are evaluated by X-ray or chest CT. The
extrahepatic metastases are assessed by CT. The present guidelines could be adjusted by
conducting comparative studies on different strategies for colon and rectal cancer, such as CT
liver/abdomen vs. MRI liver/abdomen for liver and extrahepatic metastases, X-ray chest and
CT chest for lung metastases.
The screening of asymptomatic patients is justified due to the high prevalence of colon
carcinoma and the mortality can be effectively reduced by removing adenomatous polyps.
Although effective, this method consumes large resources if applied to the whole target
population. The currently available screening options have limitations. The VC has the option
to identify patients with adenomatous polyps. The combination of VC screening and OC
follow-up might prove as a cost-effective measure against colorectal cancer.
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The challenges of VC are the associated radiation and the differentiation of the colonic
materials from the colon wall. The MRI-based VC has no radiation and has better potential in
differentiation of colonic materials from the colonic wall, but it has lower spatial resolution
and is prone to motion artifacts. CT and MRI VC require sophisticated software processing to
construct the colon model and real-time fly-through inside the lumen. More sophisticated
image processing is important for the differentiation of adenomatous from hyperplastic ones.
The extraction of the colon wall can be performed by the new method of electronic colon
cleansing and analysis of texture features from image intensity of the wall. These processing
methods are step toward computer-aided detection and diagnosis. Despite recent advances in
chemotherapeutic agents, the prognosis for metastatic colon cancer remains poor. Over the
past two decades, hepatic metastasectomy has emerged as a promising technique for improv‐
ing survival in patients with metastatic colon cancer and in some cases providing long-term
cure. To maximize safety and efficacy of metastasectomy, appropriate pre-operative imaging
is needed. Advancements in computed tomography (CT), magnetic resonance imaging (MRI)
and positron emission tomography (PET) have led to improved detection of occult lesions and
better definition of surgical anatomy. While CT, PET and MRI have a comparable sensitivity
for detection of large liver metastases, MRI excels at detection of subcentimeter liver metastases
compared to CT and FDG-PET, especially with the combination of diffusion weighted imaging
(DWI) and hepatocyte-specific contrast agents. CT may be useful as a screening modality or
in preoperative planning such as volumetric estimation of the remnant liver size or in defining
preoperative arterial anatomy for hepatic artery infusion pump placement. While technologic
advancements have led to unprecedented image quality and clarity, this does not replace the
need for a dedicated, competent radiologist with experience in hepatic imaging.
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1. Introduction
This chapter will give an overview of the magnetic resonance imaging (MRI) modalities used
in locally advanced rectal cancer (LARC) staging with an emphasis on the role of MRI and its
significance for planning an effective therapeutic strategy for the individual patient.
Specifically, the aim of this chapter is to present a brief review about:
1. Methodologies of Magnetic Resonance Imaging in LARC staging
a. Morphologic MRI
b. Functional MRI
i. Dynamic Contrast Enhanced MRI (DCE-MRI)
ii. Diffusion Weighted MRI (DW-MRI)
2. The role of MRI in diagnosis, staging, evaluation of response of neoadjuvant treatment,
follow-up post surgery.
This chapter will be organised in the following sections. First, in order to better define the role
of MRI in LARC management, we will briefly describe the epidemiological scenario and
therapeutic options, with an emphasis on issues in which MRI is relevant. Second, we will
describe morphologic and functional MRI including DCE-MRI and DW-MRI. Finally, a
systematic review of the literature concerning MRI, CT and PET for LARC management will
be presented.
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2. Epidemiology
Colorectal cancer is the third most common cancer worldwide [1], which includes cancers of
the colon, rectum, rectosigmoid junction and anus. Specifically, in men it represents the third
commonest neoplasm after prostate and lung cancers while in women it is the second major
cause of morbidity and mortality, following breast cancer.
In recent years, mortality rates have decreased due to several factors, including less exposure
risk factors, more possibility of prevention and “early diagnosis” followed by an effective
management of the disease. In particular, major changes in therapeutic management are given
by the standardization of operative procedures and the introduction of adjuvant and neoad‐
juvant therapy [2-7], able to reduce recurrence risk and tumor size.
Cancers are characterized by profound spatial and temporal heterogeneity in their biologic
characteristics. Most invasive cancers typically have alterations in cell physiology that promote
malignant growth [2-7]. Rectal cancer is the result of a complex interaction between genetic
and environmental factors and it is defined as a tumor whose aboral margin measured with
the rigid rectoscope is 16 cm or less from the anocutaneous line. This distance serves to classify
rectal cancer into tumours of the upper third (12–16 cm), the middle third (6–12 cm), and the
lower third (<6 cm) [26] according to the Union for International Cancer Control (UICC).
The mesorectal fascia is an important anatomic landmark for the diagnostic evaluation of local
tumor extent [26]. It is a connective tissue sheath that surrounds the rectum and the perirectal
fatty tissue and acts as a natural barrier for tumor spread.
A locally advanced tumor often describes a tumor extending beyond the rectal wall with
infiltration to surrounding organs or structures, and/or perforation of the visceral peritoneum.
It includes bulky T3 tumors with threatened circumferential margins or T4 tumors, tumors
with growth onto the peritoneal surface. A radiological T4 tumor is considered when detected
growing outside the mesorectal fascia, while a T3 tumor refers to a tumor invading through
muscularis propria [26].
These tumors have traditionally been looked upon as “unresectable”, although previous
staging, due to the wide tumor extension. However, when it is possible, these tumors cannot
be resected without leaving microscopic or gross residual disease at the local site because of
tumor adherence or fixation to that site.
3. Therapeutic options
In LARC accurate and detailed anatomic information in tumor extent is essential not only for
the selection of the patients for neoadjuvant chemotherapy and radiation therapy to achieve
tumor shrinkage but also for the optimal surgical procedure planning. Moreover, the treatment
for patients with locally advanced and recurrent rectal cancer differs significantly from patients
with rectal cancer restricted to the mesorectum.
Colorectal Cancer - Surgery, Diagnostics and Treatment54
Adequate preoperative imaging of the pelvis is therefore important to identify those patients
who are candidates for multimodality treatment, including preoperative chemoradiation
protocols, intraoperative radiotherapy, and extended surgical resections. Much effort should
be made to select patients with these advanced tumors for treatment in specialized referral
centers. This has been shown to reduce morbidity and mortality and improve long-term
survival rates.
Two main therapeutic options can be considered according to different pathological stages
presented [13-35]:
1. Total mesorectal excision (TME): using this surgical technique, the rectum is resected
together with all surrounding lymphatic pathways, lymph nodes, mesorectal fatty tissue,
and the mesorectal fascia while the parietal pelvis fascia and the pelvic splanchnic nerves
are spared. This surgical technique minimizes the chance of tumor being left inside;
2. Adjuvant/neoadjuvant therapy: the aims of adjuvant or neoadjuvant therapy are to enable
or facilitate total tumor resection even in advanced disease, to prevent local tumor
recurrence, and to minimize the risk of distant metastases.
The majority of patients with primary rectal cancer have a tumor located within the mesorectal
fascia, which is generally treated with total mesorectal excision (TME). Results of TME surgery
are excellent with a significant reduction in local recurrences when preoperative short-term
radiotherapy (5 x 5 Gy) is delivered one week prior to surgery [27]. In ≈10% of all rectal cancer
patients the tumor extends into or beyond the enveloping fascia of the mesorectal compart‐
ment.
Often these tumors infiltrate adjacent structures and therefore have a higher risk to develop a
local recurrence [28].
Patients with these primary locally advanced or recurrent rectal cancer are difficult to treat
with surgery alone, but outcome has significantly improved using multimodality treatment.
Although preoperative and adjuvant therapy is important in these patients, the mainstay of
treatment in rectal cancer is complete surgical removal of the tumor. In both locally advanced
and recurrent rectal cancers, this involves not only the removal of the total mesorectum, but
en bloc resection of involved structures is often needed.
Although postoperative chemoradiotherapy (CRT) has long been recommended for locally
advanced and node positive rectal cancer patients, preoperative treatment is now widely used
worldwide. In many European centers, radiotherapy only was used as neoadjuvant treatment
for locally advanced rectal cancer, but the addition of chemotherapy has recently demonstrated
to improve local control in two large randomized trials [30,31]. Addition of 5-FU and leuco‐
vorin to preoperative radiation slightly increased the amount of acute toxicity in T3 to T4
resectable rectal cancer patients [32]. However, it increased the number of complete responses
and decreased the local recurrence rate after 5 years.
Not only new chemotherapeutic drugs, but also a vascular endothelial cell growth factor-
(VEGF-) specific monoclonal antibody in combination with chemoradiation was recently
reported by Willet et al [32] to lead to considerable downstaging of the tumor. Other modalities
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growing outside the mesorectal fascia, while a T3 tumor refers to a tumor invading through
muscularis propria [26].
These tumors have traditionally been looked upon as “unresectable”, although previous
staging, due to the wide tumor extension. However, when it is possible, these tumors cannot
be resected without leaving microscopic or gross residual disease at the local site because of
tumor adherence or fixation to that site.
3. Therapeutic options
In LARC accurate and detailed anatomic information in tumor extent is essential not only for
the selection of the patients for neoadjuvant chemotherapy and radiation therapy to achieve
tumor shrinkage but also for the optimal surgical procedure planning. Moreover, the treatment
for patients with locally advanced and recurrent rectal cancer differs significantly from patients
with rectal cancer restricted to the mesorectum.
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Adequate preoperative imaging of the pelvis is therefore important to identify those patients
who are candidates for multimodality treatment, including preoperative chemoradiation
protocols, intraoperative radiotherapy, and extended surgical resections. Much effort should
be made to select patients with these advanced tumors for treatment in specialized referral
centers. This has been shown to reduce morbidity and mortality and improve long-term
survival rates.
Two main therapeutic options can be considered according to different pathological stages
presented [13-35]:
1. Total mesorectal excision (TME): using this surgical technique, the rectum is resected
together with all surrounding lymphatic pathways, lymph nodes, mesorectal fatty tissue,
and the mesorectal fascia while the parietal pelvis fascia and the pelvic splanchnic nerves
are spared. This surgical technique minimizes the chance of tumor being left inside;
2. Adjuvant/neoadjuvant therapy: the aims of adjuvant or neoadjuvant therapy are to enable
or facilitate total tumor resection even in advanced disease, to prevent local tumor
recurrence, and to minimize the risk of distant metastases.
The majority of patients with primary rectal cancer have a tumor located within the mesorectal
fascia, which is generally treated with total mesorectal excision (TME). Results of TME surgery
are excellent with a significant reduction in local recurrences when preoperative short-term
radiotherapy (5 x 5 Gy) is delivered one week prior to surgery [27]. In ≈10% of all rectal cancer
patients the tumor extends into or beyond the enveloping fascia of the mesorectal compart‐
ment.
Often these tumors infiltrate adjacent structures and therefore have a higher risk to develop a
local recurrence [28].
Patients with these primary locally advanced or recurrent rectal cancer are difficult to treat
with surgery alone, but outcome has significantly improved using multimodality treatment.
Although preoperative and adjuvant therapy is important in these patients, the mainstay of
treatment in rectal cancer is complete surgical removal of the tumor. In both locally advanced
and recurrent rectal cancers, this involves not only the removal of the total mesorectum, but
en bloc resection of involved structures is often needed.
Although postoperative chemoradiotherapy (CRT) has long been recommended for locally
advanced and node positive rectal cancer patients, preoperative treatment is now widely used
worldwide. In many European centers, radiotherapy only was used as neoadjuvant treatment
for locally advanced rectal cancer, but the addition of chemotherapy has recently demonstrated
to improve local control in two large randomized trials [30,31]. Addition of 5-FU and leuco‐
vorin to preoperative radiation slightly increased the amount of acute toxicity in T3 to T4
resectable rectal cancer patients [32]. However, it increased the number of complete responses
and decreased the local recurrence rate after 5 years.
Not only new chemotherapeutic drugs, but also a vascular endothelial cell growth factor-
(VEGF-) specific monoclonal antibody in combination with chemoradiation was recently
reported by Willet et al [32] to lead to considerable downstaging of the tumor. Other modalities
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such as the use of intensity-modulated radiotherapy (IMRT), which has the potential of more
accurate delivery of higher radiotherapy dosages, thus avoiding the damage of critical
structures surrounding the tumor, are being tested in rectal cancer.
Total pelvic exenteration (TPE) is a widely used technique for resection of locally advanced or
recurrent rectal tumors invading the bladder and/or prostate. Longterm survival with excellent
local control is possible after TPE for primary locally advanced rectal cancer [33-35]. The
majority of resections in primary cancer are without microscopic or macroscopic residual
tumor mass, which clearly justifies the use of TPE in selected patients with primary disease.
Although current guidelines for colorectal cancer surgery advocate TPE, only one third of the
patients in a recent study based on SEER (survival, epidemiology and end results) data
underwent the appropriate surgical resection.
These patients had a clinically significant overall survival benefit with no increase in short-
term mortality compared with similar patients who did not receive a multi-visceral resection.
Local control in rectal cancer patients is related to the dose of irradiation, but because of toxicity
to radiosensitive organs (such as small bowels), the external radiation dose should not exceed
60 Gy. A combination of external radiation and intraoperative radiation therapy (IORT) allows
the safe delivery of higher effective doses of irradiation than can be delivered with external-
beam only techniques. IORT is used when resection margins are narrow or involved with
tumor cells and can be applied very specifically to an area at risk, under direct visual control,
and with the ability to shield the surrounding structures from radiation. The biological
effectiveness of single-dose IORT is considered to be as effective as 2 to 3 times the equivalent
dose of fractionated radiotherapy.
3. Role of MRI vs other modalities
3.1. Generalities
Imaging techniques play a pivotal role in the strategies for management of locally advanced
rectal cancer patients. The role of diagnostic imaging is to perform a loco-regional staging as
accurate as possible in both evaluation of infiltration and extension degrees of disease. Image
features also enable preoperative assessment of important prognostic outlines, which may
guide patient selection for neoadjuvant therapies. Moreover, imaging plays an important role
in therapeutic assessment, surveillance after surgery, and evaluation of suspected disease fall-
out. To date, imaging innovations have led to improvements in spatial and contrast resolution,
increased data acquisition speeds, and enabled complex image to achieve excellence in
anatomic resolution.
There are many different imaging modalities suitable for rectal cancer staging, tumour location
and restaging but not all of them have the same accuracy for each indication. An optimal
visualization of tumor volume and of its surrounding anatomical structures is necessary for
any local cancer treatment. This issue is particularly important for radiotherapy treatment
planning in order that a geographical miss can be avoided and the tumor adequately treated.
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Among the imaging methods available Magnetic Resonance Imaging (MRI) is currently the
modality of choice because of its capacity to perform local staging, since it enables evaluation
of anatomic aspects and prognostic factors that are key to choosing the appropriate surgical
approach and determining the need for neoadjuvant treatment.
3.2. MRI physical basics
MRI is an imaging technique based on the different magnetic properties of tissues in the body.
The exposure to a high intensity magnetic field determines the alignment of the hydrogen
nuclei (protons) along the magnetic field axis itself. The emission of radio frequency pulses
causes a shift from this alignment, which tends to reconstitute as soon as the impulse is
interrupted. This phenomenon leads to a variation in energy level of the charges, which can
be translated into a signal whose decoding is the basis of the generation of magnetic resonance
images. All this is based on specific parameters that describe these steps of energy levels
(including the so-called "relaxation times T1 and T2"), as well as on the concentration of protons
within a given tissue.
Pulses sequences are used to obtain the different MR images, sequences consisting of radio
frequency pulses with different characteristics in terms of duration, frequency and type of
sampling of the resulting signal.
In the various biological tissues, the characteristics of the magnetic resonance signal are
influenced mainly by the content of hydrogen atoms (whose nuclei are composed of only one
proton). Since water is the most abundant molecule in the body and contains hydrogen atoms,
it can be reasonably stated that the increase or the decrease of water in a given tissue is almost
always at the basis of changes in signal intensity when using sequences of magnetic resonance
imaging.
Where tissue contrast depends primarily on electron density, the tissue contrast obtained by
MRI can be extensively varied by imaging the intrinsic tissue properties, as spin-lattice and
spin-spin relaxation times, protons density, magnetization transfer, separately or in combina‐
tion, using a number of pulse sequences, which in turn can be altered by an essentially infinite
number of different experimental conditions. These MR parameters can be exploited and
tailored to facilitate optimal tumor visualization and evaluation. Another feature of MRI is
that cortical bone does not give rise to an MR signal and therefore appears hypointense. This
is because cortical bone contains calcium and there are few hydrogen protons to provide an
MR signal. Furthermore, MRI can obtain detailed anatomical images in any desired plane, also
acquiring 3D or volumetric image sets. Therefore, the superior soft tissue definition provided
by MRI, together with its unrestricted multiplanar, volumetric, vascular and functional
information has benefits for 3D treatment planning.
3.3. Comparison of MRI and CT
Computed Tomography (CT) scanning is an imaging technique able to reproduce a 3D image
of internal organs by irradiating X-ray. In LARC treatment CT shows the effective tumor size
and its possible dissemination to internal organs. Although CT imaging provides excellent
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such as the use of intensity-modulated radiotherapy (IMRT), which has the potential of more
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recurrent rectal tumors invading the bladder and/or prostate. Longterm survival with excellent
local control is possible after TPE for primary locally advanced rectal cancer [33-35]. The
majority of resections in primary cancer are without microscopic or macroscopic residual
tumor mass, which clearly justifies the use of TPE in selected patients with primary disease.
Although current guidelines for colorectal cancer surgery advocate TPE, only one third of the
patients in a recent study based on SEER (survival, epidemiology and end results) data
underwent the appropriate surgical resection.
These patients had a clinically significant overall survival benefit with no increase in short-
term mortality compared with similar patients who did not receive a multi-visceral resection.
Local control in rectal cancer patients is related to the dose of irradiation, but because of toxicity
to radiosensitive organs (such as small bowels), the external radiation dose should not exceed
60 Gy. A combination of external radiation and intraoperative radiation therapy (IORT) allows
the safe delivery of higher effective doses of irradiation than can be delivered with external-
beam only techniques. IORT is used when resection margins are narrow or involved with
tumor cells and can be applied very specifically to an area at risk, under direct visual control,
and with the ability to shield the surrounding structures from radiation. The biological
effectiveness of single-dose IORT is considered to be as effective as 2 to 3 times the equivalent
dose of fractionated radiotherapy.
3. Role of MRI vs other modalities
3.1. Generalities
Imaging techniques play a pivotal role in the strategies for management of locally advanced
rectal cancer patients. The role of diagnostic imaging is to perform a loco-regional staging as
accurate as possible in both evaluation of infiltration and extension degrees of disease. Image
features also enable preoperative assessment of important prognostic outlines, which may
guide patient selection for neoadjuvant therapies. Moreover, imaging plays an important role
in therapeutic assessment, surveillance after surgery, and evaluation of suspected disease fall-
out. To date, imaging innovations have led to improvements in spatial and contrast resolution,
increased data acquisition speeds, and enabled complex image to achieve excellence in
anatomic resolution.
There are many different imaging modalities suitable for rectal cancer staging, tumour location
and restaging but not all of them have the same accuracy for each indication. An optimal
visualization of tumor volume and of its surrounding anatomical structures is necessary for
any local cancer treatment. This issue is particularly important for radiotherapy treatment
planning in order that a geographical miss can be avoided and the tumor adequately treated.
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Among the imaging methods available Magnetic Resonance Imaging (MRI) is currently the
modality of choice because of its capacity to perform local staging, since it enables evaluation
of anatomic aspects and prognostic factors that are key to choosing the appropriate surgical
approach and determining the need for neoadjuvant treatment.
3.2. MRI physical basics
MRI is an imaging technique based on the different magnetic properties of tissues in the body.
The exposure to a high intensity magnetic field determines the alignment of the hydrogen
nuclei (protons) along the magnetic field axis itself. The emission of radio frequency pulses
causes a shift from this alignment, which tends to reconstitute as soon as the impulse is
interrupted. This phenomenon leads to a variation in energy level of the charges, which can
be translated into a signal whose decoding is the basis of the generation of magnetic resonance
images. All this is based on specific parameters that describe these steps of energy levels
(including the so-called "relaxation times T1 and T2"), as well as on the concentration of protons
within a given tissue.
Pulses sequences are used to obtain the different MR images, sequences consisting of radio
frequency pulses with different characteristics in terms of duration, frequency and type of
sampling of the resulting signal.
In the various biological tissues, the characteristics of the magnetic resonance signal are
influenced mainly by the content of hydrogen atoms (whose nuclei are composed of only one
proton). Since water is the most abundant molecule in the body and contains hydrogen atoms,
it can be reasonably stated that the increase or the decrease of water in a given tissue is almost
always at the basis of changes in signal intensity when using sequences of magnetic resonance
imaging.
Where tissue contrast depends primarily on electron density, the tissue contrast obtained by
MRI can be extensively varied by imaging the intrinsic tissue properties, as spin-lattice and
spin-spin relaxation times, protons density, magnetization transfer, separately or in combina‐
tion, using a number of pulse sequences, which in turn can be altered by an essentially infinite
number of different experimental conditions. These MR parameters can be exploited and
tailored to facilitate optimal tumor visualization and evaluation. Another feature of MRI is
that cortical bone does not give rise to an MR signal and therefore appears hypointense. This
is because cortical bone contains calcium and there are few hydrogen protons to provide an
MR signal. Furthermore, MRI can obtain detailed anatomical images in any desired plane, also
acquiring 3D or volumetric image sets. Therefore, the superior soft tissue definition provided
by MRI, together with its unrestricted multiplanar, volumetric, vascular and functional
information has benefits for 3D treatment planning.
3.3. Comparison of MRI and CT
Computed Tomography (CT) scanning is an imaging technique able to reproduce a 3D image
of internal organs by irradiating X-ray. In LARC treatment CT shows the effective tumor size
and its possible dissemination to internal organs. Although CT imaging provides excellent
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definition between structures with different electron density or X-ray attenuation character‐
istics, it distinguishes poorly between structures with similar electron density such as different
soft tissue structures, including tumors, unless there is an obvious fat or air interface [60]. The
major advantage of MRI compared with CT is in its superior ability to demonstrate and
characterize soft tissues that have similar electron densities. In this manner, MRI may provide
better delineation not only of the tumor extent, but also of the adjacent critical soft tissue organs.
This will allow conformal planning to enhance its therapeutic ratio by more accurately
targeting the tumor, avoiding the organs at risk and subsequently improving local control.
3.4. Comparison of MRI and PET/CT
In LARC patient management detection of tumor sites throughout the body is needed with
high sensitivity and specificity in order to have accurate information about the local extent. As
discussed in the previous section, an accurate tumour visualization can be performing using
MRI techniques. An additional value should be given to consider the combination of Positron
Emission Tomography (PET) and CT [61]. PET/CT is a diagnostic procedure that allows to
obtain morphological images of the human body provided by CT and images of the tissue
metabolic processes provided by PET by means of a co-registration system.
Tissues appear differently on PET and on CT images. CT displays anatomy with high spatial
resolution, but with low contrast resolution for soft tissues, while PET visualizes pathological
sites with high contrast resolution but a limited spatial resolution and surrounding normal
anatomical structures are hardly visualized. The combination of metabolic activity with anatomic
localization achievable with PET/CT improve accuracy over that of PET or CT alone [62].
4. Role of MRI in LARC
In the recent years MRI has undergone significant transformations resulting from technolog‐
ical innovation that have taken place as the introduction of high-field magnets, powerful
gradients, multi-channel phased array coils and endorectal coils improvement. These techno‐
logical developments have certainly allowed the executing of high quality diagnostic studies
due to the high spatial resolution and contrast obtained, to the possibility of identification and
distinction of rectal wall layers, and to the possibility of assessing perirectal and sphinteric
structures. Mainly, superficial endorectal coils are currently able to identify various layers of
lower rectum wall. MRI is thus the ideal technique for rectal cancer staging, combining the
capabilities of an accurate loco-regional staging to the outlook and multi-planar properties.
In conclusion, MRI can currently stage with high accuracy the T parameter (related to the
degree of tumor infiltration) due to the possibility offered by the endorectal coil to recognize
the wall layers, resulting also extremely useful in planning surgery and in prognostic stratifi‐
cation, owing to the ability to accurately identify mesorectum and the distance between
mesorectal fascia and neoplasia. Furthermore the high temporal resolution of last generation
devices allows to perform perfusion and dynamic studies after gadolinium administration that
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allow to detection of the residual tumor after neoadjuvant therapy and to diagnose recurrences,
distinguishing them from fibrosis.
4.1. Morphological MRI
As regards the topographic relationship of the tumor with the mesorectal fascia can be
adequately established with morphologic MRI [26]. The advent of powerful gradient systems
and, above all, the development of high-resolution phased array surface coil systems in recent
years brought the breakthrough in the staging of rectal cancer by MRI. The use of these phased-
array surface coils combines a very high spatial resolution with a large FOV that allows not
only detailed evaluation of the intestinal wall but also depicts surrounding anatomy including
the mesorectal fascia.
A standard phased-array morphologic MRI protocol for LARC staging (including T-N stage
and CRM evaluation) consists of T2-weighted coronal, transversal and sagittal turbospin-echo
MR sequences with high spatial resolution (Fig. 1) [26].
Figure 1. (a) A heterogeneous irregular thickening along the entire rectal wall is well shown on T2w axial pre-pCRT
scan (arrowheads). (b) After pCRT, a hypo-intense spiculated area with thin digitations into peri-rectal fat is visible on
T2w axial scan (arrowheads). (c) In the same patient, multiple irregular rectal wall thickening are shown on T2w sagit‐
tal pre-pCRT scan (arrowheads). (d) A single hypo-intense area, showed also in (b) is pointed by arrowheads, suspect‐
ing for a residual post-pCRT tumor focus (arrowheads).
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definition between structures with different electron density or X-ray attenuation character‐
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characterize soft tissues that have similar electron densities. In this manner, MRI may provide
better delineation not only of the tumor extent, but also of the adjacent critical soft tissue organs.
This will allow conformal planning to enhance its therapeutic ratio by more accurately
targeting the tumor, avoiding the organs at risk and subsequently improving local control.
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MRI techniques. An additional value should be given to consider the combination of Positron
Emission Tomography (PET) and CT [61]. PET/CT is a diagnostic procedure that allows to
obtain morphological images of the human body provided by CT and images of the tissue
metabolic processes provided by PET by means of a co-registration system.
Tissues appear differently on PET and on CT images. CT displays anatomy with high spatial
resolution, but with low contrast resolution for soft tissues, while PET visualizes pathological
sites with high contrast resolution but a limited spatial resolution and surrounding normal
anatomical structures are hardly visualized. The combination of metabolic activity with anatomic
localization achievable with PET/CT improve accuracy over that of PET or CT alone [62].
4. Role of MRI in LARC
In the recent years MRI has undergone significant transformations resulting from technolog‐
ical innovation that have taken place as the introduction of high-field magnets, powerful
gradients, multi-channel phased array coils and endorectal coils improvement. These techno‐
logical developments have certainly allowed the executing of high quality diagnostic studies
due to the high spatial resolution and contrast obtained, to the possibility of identification and
distinction of rectal wall layers, and to the possibility of assessing perirectal and sphinteric
structures. Mainly, superficial endorectal coils are currently able to identify various layers of
lower rectum wall. MRI is thus the ideal technique for rectal cancer staging, combining the
capabilities of an accurate loco-regional staging to the outlook and multi-planar properties.
In conclusion, MRI can currently stage with high accuracy the T parameter (related to the
degree of tumor infiltration) due to the possibility offered by the endorectal coil to recognize
the wall layers, resulting also extremely useful in planning surgery and in prognostic stratifi‐
cation, owing to the ability to accurately identify mesorectum and the distance between
mesorectal fascia and neoplasia. Furthermore the high temporal resolution of last generation
devices allows to perform perfusion and dynamic studies after gadolinium administration that
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allow to detection of the residual tumor after neoadjuvant therapy and to diagnose recurrences,
distinguishing them from fibrosis.
4.1. Morphological MRI
As regards the topographic relationship of the tumor with the mesorectal fascia can be
adequately established with morphologic MRI [26]. The advent of powerful gradient systems
and, above all, the development of high-resolution phased array surface coil systems in recent
years brought the breakthrough in the staging of rectal cancer by MRI. The use of these phased-
array surface coils combines a very high spatial resolution with a large FOV that allows not
only detailed evaluation of the intestinal wall but also depicts surrounding anatomy including
the mesorectal fascia.
A standard phased-array morphologic MRI protocol for LARC staging (including T-N stage
and CRM evaluation) consists of T2-weighted coronal, transversal and sagittal turbospin-echo
MR sequences with high spatial resolution (Fig. 1) [26].
Figure 1. (a) A heterogeneous irregular thickening along the entire rectal wall is well shown on T2w axial pre-pCRT
scan (arrowheads). (b) After pCRT, a hypo-intense spiculated area with thin digitations into peri-rectal fat is visible on
T2w axial scan (arrowheads). (c) In the same patient, multiple irregular rectal wall thickening are shown on T2w sagit‐
tal pre-pCRT scan (arrowheads). (d) A single hypo-intense area, showed also in (b) is pointed by arrowheads, suspect‐
ing for a residual post-pCRT tumor focus (arrowheads).
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An adequate, state-of-the-art MRI staging classification is capable to predict whether a tumor-
free CRM is likely to be achieved or not [26]. In this way one would be able to differentiate
patients with minimal mesorectal infiltration in whom neoadjuvant therapy is not mandatory
from patients who would definitely benefit from neoadjuvant therapy because the mesorectal
fascia is infiltrated or at risk.
The common use of total mesorectal excision (TME) and the shift from a postoperative to a
preoperative chemo-radiotherapy (pre-CRT) approach have substantially reduced the risk of
local recurrences, increasing curative resection and the rate of anal sphincter preservation and
improving local control and overall survival rates [13-18].
4.2. Functional MRI
Although morphological tumour assessment performed by MRI has been repeatedly shown
to be the most accurate modality in evaluating the presence of a positive circumferential
resection margin (CRM), MRI is considered not to be conclusive in pre-CRT tumor response
evaluation since histopathological downstage is not always associated with tumour effective
reduction [17]. The main difficulty regarding post-chemoradiation MRI includes discrimina‐
tion of active tumour and post-treatment fibrosis, particularly when differentiating stage T2
and stage T3 carcinomas, according to different recurrence and overall survival rates between
Low Risk (T1/T2N0) and Intermediate Risk (T3/N0) as reported by Gunderson et al. [23-24].
Several studies have shown the potential of functional [diffusion- or perfusion] weighted
imaging to predict the response to adjuvant or neoadjuvant therapy [5–7,19].
In fact, it has long been known that the pathophysiology and aggressiveness of a tumor are
determined not only by the macroscopic tumor extent but also by other factors such as tumor
microcirculation and angiogenesis.
4.2.1. DCE-MRI
Previous considerations support a Dynamic Contrast Enhanced-Magnetic Resonance Imaging
(DCE-MRI) approach that could gain a renewed role to MRI adding functional data to the
morphological examination. DCE-MRI has been reported by many authors as a tool potentially
able to permit an evaluation of pre-CRT effectiveness basing on the strict relationship between
tumor growth and angiogenesis [6-7,24-25].
DCE-MRI is gaining a large consensus as a technique for diagnosis, staging and assessment of
therapy response for different types of tumours, due to its capability to detect highly active
angiogenesis. It is well known that angiogenesis is a key factor in the growth and dissemination
of cancer; characterization of the angiogenic status of the tumour on an individual patient basis
could allow for a more targeted approach to treatment of rectal cancer [24].
More specifically, in the case of rectal cancer, previous trials have provided the proof of
principle that inhibition of angiogenesis has the potential to enhance the effectiveness of the
treatment for this disease. In vivo imaging techniques capable to assess tumour perfusion have
Colorectal Cancer - Surgery, Diagnostics and Treatment60
the potential to improve the management of treatment for patients with rectal cancer
[6-7,24-25].
Angiogenesis is a key factor for the growth and dissemination of solid tumors and is a
prognostic marker in CRC. Neovascularization arises early in the adenoma–carcinoma
sequence via upregulation of vascular endothelial growth factor. Tumor angiogenesis is
characterized by structurally abnormal blood vessels that are thin, fragile, tortuous, and
hyperpermeable. They have a chaotic, heterogeneous intratumoral distribution. Abnormal
vascularity often extends beyond the tumor boundaries into surrounding tissues.
DCE-MRI techniques inform on tissue perfusion and vascular leakage (Fig. 2). T1- or relaxivity-
based MR sequences are sensitive to the presence of dilute contrast medium in the extrava‐
scular– extracellular space. In most tumors, low-molecular-weight contrast media readily
diffuse from the blood into the extravascular– extracellular space at a rate determined by
perfusion and the capillary permeability and surface area.
The most commonly used model for analyzing DCE-MRI data uses two compartments where
the contrast agent resides (blood plasma and extravascular– extracellular space). Ktrans (volume
transfer constant between the blood plasma and the extravascular–extracellular space, the
washin rate, measured in minutes−1) and kep (rate constant between the extravascular–
extracellular space back to the blood plasma, the washout rate, measured in minutes−1)
determine the transport between these two compartments.
Physiologically, Ktrans indicates a variable combination of the flow and permeability properties.
For blood vessels where leakage is rapid (that is, when the extraction fraction during the first
pass of the contrast agent is high, as typically is found in tumors), perfusion will determine
contrast agent distribution and Ktrans approximates to tissue blood flow per unit volume. There
are circumstances in which transport out of the vasculature does not significantly deplete
intravascular contrast medium concentration (that is, tissues with lower first-pass extraction
fraction). This is typically found after treatment with chemotherapy or late after radiotherapy
and in fibrotic lesions, and in these situations, Ktrans approximates to the product of permea‐
bility and the surface area (permeability surface area product).
4.2.2. Diffusion-weighted imaging DWI-MRI
At present, the use of diffusion-weighted imaging (DWI) incorporated into a standard MR
protocol is gradually increasing because of its proven benefit not only for tumor detection/
characterization  but  also  for  monitoring  treatment  response  (8–12).  Diffusion-weighted
imaging measures water diffusion characteristics, which are dependent on multiple factors
such as cell density, vascularity, viscosity of extracellular fluid, and cell membrane integri‐
ty  (12).  By  quantifying  these  properties  and  expressing  them  as  an  apparent  diffusion
coefficient (ADC), DWI could potentially be used as an imaging biomarker to better select
patients with poor prognosis who will truly benefit from a more aggressive neoadjuvant
treatment  (8-12).  In  literature  it  was  demonstrated  that  ADC  values  of  rectal  cancers
significantly correlate with prognostic factors including the MRF status, the nodal stage and
the histological differentiation grade.
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Previous considerations support a Dynamic Contrast Enhanced-Magnetic Resonance Imaging
(DCE-MRI) approach that could gain a renewed role to MRI adding functional data to the
morphological examination. DCE-MRI has been reported by many authors as a tool potentially
able to permit an evaluation of pre-CRT effectiveness basing on the strict relationship between
tumor growth and angiogenesis [6-7,24-25].
DCE-MRI is gaining a large consensus as a technique for diagnosis, staging and assessment of
therapy response for different types of tumours, due to its capability to detect highly active
angiogenesis. It is well known that angiogenesis is a key factor in the growth and dissemination
of cancer; characterization of the angiogenic status of the tumour on an individual patient basis
could allow for a more targeted approach to treatment of rectal cancer [24].
More specifically, in the case of rectal cancer, previous trials have provided the proof of
principle that inhibition of angiogenesis has the potential to enhance the effectiveness of the
treatment for this disease. In vivo imaging techniques capable to assess tumour perfusion have
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determine the transport between these two compartments.
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For blood vessels where leakage is rapid (that is, when the extraction fraction during the first
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The movement of water molecules in biologic tissues is restricted because their motion is
modified and limited by interactions with cell membranes and macromolecules. Water-
molecule motion in tissues can be assessed by applying diffusion- weighting gradients to T2-
weighted sequences. This process entails the application of two balanced gradients placed
symmetrically about a focusing 180° pulse. Water molecules that have not moved during the
time taken to apply the first gradient will have acquired phase shifts that are exactly cancelled
out by the proceeding second gradient; thus, there is no net additional signal loss induced by
the application of the paired diffusion gradients. For water molecules that have moved during
the application of the first gradient, however, the acquired phase shifts will not be cancelled
out by the second gradient; residual phase incoherence will result in net losses of signal. Hence,
the motion of water molecules is detected as attenuation of the measured signal intensity on
DWI (Fig. 3).
The sensitivity of the DWI sequence to water motion can be varied by changing the parameter
known as the b value (measured in s/mm2), which is proportional to the gradient amplitude,
duration of the applied gradient, and time interval between the paired gradients. DWI can be
Figure 2. T1w post-contrast scan obtained on the same patient in fig. 8, before (a)-(b) and after (c)-(d) pre-CRT. The
analysis of TIC calculated on a ROI, drawn outside the rectal wall where on T2w scans (fig. 8) tumor clearly spreads into
peri-rectal fat pad, confirm this suspect showing a rapid CA intake and a fast discharge (b). After pre-CRT, on the same
areas showed on T2w scans (fig. 8) no pathological CA uptake is present confirming that hypo-intense tissue visible on
T2w scans are tumor nests but only residual inflammation due to pre-CRT. This patient was considered as a Responder.
Histopathology showed a TRG 1.
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exploited in clinical practice to provide indirect assessments of tissue properties such as
cellularity, gland formation, perfusion, and cell death. In general, the greater the cell density
per high power field, the more impeded will be tissue water diffusion. Diffusion-weighted
signal is derived from the motion of water molecules within the extravascular–extracellular
space and intravascular space with some component from intracellular space water. The
relative contribution of each space to the derived signal varies from tissue to tissue. In highly
vascular tumors, intravascular water diffusion will account for a significant proportion of the
diffusion-weighted signal. In highly glandular tissues, such as the pancreas and salivary
glands, significant signal contributions arise from glandular water.
By performing DWI using different b values, quantitative analysis is possible with the
calculation of the apparent diffusion coefficient (ADC, measured in μm/s). Areas of restricted
diffusion show low ADC values. ADC values are inversely correlated with tumor cellularity
and reductions in ADC correlate with response to cytotoxic therapy.
Areas retaining high signal intensity on high-b-value images usually (but not always) indicate
highly  cellular  tissues  such  as  tumors.  Normal  tissues  including  lymph  nodes,  spleen,
nervous  tissues,  adrenal  glands,  bowel  mucosa,  and  endometrium may show the  same
findings. Lower-signal-intensity regions are seen in most organized normal tissues, cystic
spaces, and vessels. However, high signal intensities on high-b-value images are not always
reliable  indicators  of  increased  cellularity  on  their  own.  Occasionally,  fluid,  edema,  or
mucinous materials remain of high signal intensity because of high proton density. This
observation  is  called  T2-shine  through,  but  this  effect  can  be  detected  easily  by  noting
corresponding high signal on ADC maps.
There is growing interest in the application of DWI for the evaluation of CRC. DWI aids in
detection of lesions, particularly when lesions are small. High-b-value DWI may be a useful
tool for detecting and defining tumor extent.
DWI has been shown to be feasible as an early marker of treatment response because cell death
and vascular alterations typically occur before size changes. Increases in ADC values with
Figure 3. (a) Axial diffusion weigthed imaging b=0, (b) Axial diffusion weigthed imaging b=800. Hyperintensity diffu‐
sion weigthed imaging is consistent with the diagnosis of tumor.
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treatment reflect decreases in cellularity and thus provide indirect assessment of chemothera‐
py induced cell death. It has been reported that transient decreases in ADC may occur early in
treatment related to cellular swelling, reduction in blood flow, or reduction in the extravascu‐
lar– extracellular space due to dehydration. However, early decreases in ADC values are not
consistently seen, and it has recently been reported that increases in ADC value with therapy
response occur within 3–7 days in responding CRC patients treated with chemotherapy.
Responders had a lower ADC at presentation than non responders. Higher pretreatment ADC
values in nonresponders may reflect necrotic tumors that are more resistant to therapy because
of concomitant hypoxia. Similarly, for CRC liver metastases, a higher pretreatment ADC is
also predictive of poor response.
5. A systematic review
5.1. Methodologies
A systematic literature search was performed to identify English-language studies and articles
concerning different diagnostic imaging methodologies available in locally advanced rectal
cancer disease after radiation therapy. Data were identified using PubMed database with the
following keywords: “locally advanced rectal cancer, magnetic resonance imaging, CT
planning, PET imaging”. This yielded 309 titles. Articles, reviews and studies that did not
present data about specificity and sensibility of tests treated were excluded. Due to the small
number of studies for each imaging modality, there was not set a minimum number of patients
as an inclusion criteria. For this reason, a total number of 12 titles were considered as studies
included in the research.
Details regarding the number of patients, imaging modality investigated, the accuracy values
and parameters examined of the studies were recorded. Cascini et al. [41] evaluated 18F-FDG
PET to assess the effect of chemoradiation therapy in thirty-three patients with LARC proved
disease. They correlate the change in tumor 18F-FDG standardized uptake value (SUV) during
and after preoperative radiotherapy with the pathologic response achieved.
The accuracy of CT and MRI in restaging rectal cancer after preoperative chemoradiation in
order to plan optimal therapy was performed in Martellucci et al. [42] study, in which thirty-
seven consecutive patients undergoing neoadjuvant therapy were evaluated. Considering the
depth of invasion after treatment only in neoplasia with stage T3 they found CT agree with
histopathology in 19 cases and MRI in 10/12 cases.
Denecke et al. [46] compare CT, MRI and FDG-PET examining a total of twenty-three patients
with T3/4 rectal cancer. Response criteria were a change in T category and tumour volume for
CT and MRI and a change in glucose uptake for FDG-PET. Their results in sensitivity and
specificity suggest that PET is superior to CT and MRI in predicting response to preoperative
multimodal treatment of LARC.
A prospective analysis to evaluate tumor response with 18F-FDG PET in twenty-seven patients
with biopsy-proven rectal adenocarcinoma was conducted by Leibold et al. [47]. They found
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of the total 27 patients, 11 (41%) had pathologic complete response; 16 (59%) had suboptimal
response. They evaluate the ability of change in 4 specific PET parameters to predict pathologic
response: the maximum SUV in the region of interest, SUVmax; the average SUV throughout
the entire region of interest, SUVavg; the summed metabolic rate of the tumor, TLG; the virtual
graded global assessment of response, VRS.
Chien-Chih Chen et al. [37] evaluated the correlation between pathological verified tumor
stage and clinical stage predicted by MRI. The overall predictive accuracy in T stage was 52%,
whereas overstaging and understaging occurred in 38% and 10% of patients, respectively.
Another study regard the MRI accuracy was conducted by Dresen et al. [45] using T2- weighted
MR images obtained before and after radiation therapy and correlating findings with histo‐
pathology results.
Kristiansen et al. [39] investigated the possibility of using PET/CT to predict the histopatho‐
logic response in 30 patients with LARC treated with a combination of radiotherapy and
concurrent Uftoral® and leucovorine. PET/CT correctly identified six of eight patients,
specificity 75%, with complete pathologic response.
To evaluate the correlation between the change of SUVmax and of apparent diffusion coefficient
(ADC) before and after neoadjuvant therapy, thirty patients with locally advanced rectal
cancer were recruited in Ippolito et al. [40] analysis, in which all the patients underwent a
whole body 18F-FDG PET/CT scan and a pelvic MR examination including DW imaging for
staging therapy.
Table 1 summarizes the main characteristics of the examined methodologies in locally
advanced rectal cancer studies.
Study Modality No.Patients Parameters
C. C. Chen et al. [37]
T. Denecke et al. [46]
G. L. Cascini et al. [41]
C. Capirci et al. [38]
C. Kristiansen et al. [39]
R. Rosenberg et al. [44]
A. Suppiah et al. [36]
R. C. Dresen et al. [45]
T. Leibold et al. [47]
D. Ippolito et al. [40]
J. Martellucci et al. [42]
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5.2. Summary ROC curves and Forest Plots
In order to assess individual methodology in LARC treatment, Summary Receiver Operating
Characteristic (SROC) curves have been realized, Fig. 4. ROC curves is a statistic technique for
displaying, organizing and selecting classifiers based on their performance.
Figure 4. Estimated Summary ROC curves and original data points for four imaging techniques. MRI= magnetic reso‐
nance imaging, CT= computed tomography, PET= Positron emission tomography, PET/CT= positron emission tomog‐
raphy and computed tomography.
ROC analysis was performed through the study of the function that links the probability to
obtain a true-positive result in the disease like class, i.e. the sensitivity, to the probability to
obtain a false-positive result in the non-diseased class, linked to the specificity. In this way a
graphical 2D representation that shows the false-positive proportion in x-axis and true-positive
proportion in y-axis, relatively to values obtained from each test applied.
For each modality, a model was obtained that was adjusted for significant variables that were
set to 1, indicating the ideal design versus 0, as appropriate, Fig. 4. The position of the summary
ROC curve indicates the difference in diagnostic performance among the imaging modalities.
A summary ROC curve located near the upper left corner indicate rte better diagnostic
Colorectal Cancer - Surgery, Diagnostics and Treatment66
modality, while a summary ROC curve for a worthless modality is represented by the bisector,
also named change line.
Another additional graphical representation realized is the Forest Plot, Fig. 5, which shows
the sensitivity and specificity estimates of the results for each study. It is composed of a plot
of the measure of effect for each of these studies incorporating confidence intervals represented
by horizontal bars. The confidence interval expresses the precision level associated with the
parameter estimation: the more is small, the more indicates that the prediction is accurate. In
this analysis confidence intervals are computed with a probability of containing the true effect
size equal to 95%. The blue square represents the point estimate, i.e. the sensitivity or specif‐
icity.
Figure 5. Forest Plot of MRI, CT, PET and PET/CT sensitivity and specificity estimates and their confidence intervals
(95%).
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The objective of this statistical analysis was to evaluate the diverse methodologies (MRI, PET,
PET/CT, CT) in LARC management. In particular, in our analysis we considered the accuracy
in assessing the therapy response.
Although, the ROC curves analysis showed that PET has the best accuracy in term of sensitivity
and specificity it should be noticed that only three studies have been retrieved from the
literature.
However, in agreement with the intuitive considerations MRI and PET/ CT showed a high
diagnostic accuracy and their results are also more reliable than PET because the statistical
analysis has been carried out on a larger number of studies (6 studies for MRI with a total of
239 patients and 5 studies for PET/CT with a total of 176 patients).
The number of studies for CT is very small to draw detailed conclusions.
In conclusion we could state that a greater number of studies should be performed in the future
for each modalities to improve the reliability of any conclusion.
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1. Introduction
1.1. Immunodiagnostics of Colorectal cancer — CEA and CA 19-9
Colorectal cancer is the second most common cancer in terms of incidence in men and women.
Another concern is the high rate of morbidity and mortality in patients with this cancer.
Therefore, researchers are constantly searching for new diagnostic methods that would enable
the early detection of recurrent, clinically asymptomatic periods. The development of clinical
immunodiagnostics has enriched oncology with the possibility of determining the quantity of
glycoproteins and glycolipids in the blood of patients with cancer. These are called neoplastic
markers. The usefulness of a neoplastic marker assay has been confirmed in diagnosing
alimentary tract neoplasms, mainly in the early post-operative detection of a recurrence of
neoplastic disease and in the evaluation of the efficacy of surgery.
According to an account published by The European Group on Tumor Markers (EGTM) of
2003, CEA is the main marker that is used in detecting colorectal cancer. It is important to point
out, however, that approximately 10-15 % of patients do not produce CEA at all or that it is
secreted in only minimal amounts. In such cases, the normal level of CEA concentration does
not exclude the existence of a neoplasm even at an advanced stage. Therefore, the use of CA
19-9 as a tumor marker in diagnostics has been proposed.
1.1.1. Characteristic of CEA tumour marker
Carcinoembryonic antigen is a glycoprotein that contains about 60% carbohydrates. CEAs have
epitopes  that  are  specific  to  the  neoplasm and epitopes  that  connect  antibodies  against
nonspecific cross-reacting antigens (NCA, NCA2, BGP). Its upper normal range is 3 ng/ml [1, 2]
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1.1.2. Characteristic of CA 19-9 tumour marker
The CA 19-9 Antigen is associated with gastrointestinal cancers. It occurs in the sialyated Lewis
A blood group antigen that is produced in a small amount in the salivary and bronchial glands
as well as in the pancreatic and bile ducts. This marker is very useful in the diagnosis of
gastrointestinal cancers such as gastric, pancreatic, bile duct cancers and pancreatitis. Its upper
normal range is 37 U/ml, but in approximately 1% of healthy people, concentrations reaching
120 U/ml have been detected [1, 2].
1.2. Aim of the study
The purpose of the study was to estimate the usefulness of selected neoplastic markers –
conditioned by their location in the pre-operative and post-operative histological evaluations
of patients with gastrointestinal cancers.
1.3. Material and methods
256 patients, both won men and women, aged 19-86, in whom colorectal cancer was diagnosed
and histopathology was confirmed, were included into the research that was performed
between 1991-1998.
Patients were divided into two groups according to the progression of the disease on the TMN
scale and patients with a proctologic neoplasm on the Dukes and TMN scales. Neoplasm
markers were marked in serum using commercial kits (blood samples were collected from the
cubital vein and stored at -20°C after centrifugation). CEA and CA 19-9 were detected using
the MEIA method using an Abbott’s kit (USA). The upper normal range in healthy subjects is
3 ng/ml for CEA and 37 U/ml for CA 19-9.
The detection of neoplastic markers was performed in the Independent Laboratory of Clinical
Immunodiagnostics at State Hospital No. 5 in Sosnowiec, Poland. Blood samples were
collected preoperatively, in the first, second and third months after surgery and next after
every 3 months for 2-5 years.
1.4. Results
The detection of neoplastic markers was extended about lab tests, abdominal ultrasonography;
CT was performed in certain cases. Results were worked out using the t-Student test, the
Cochran-Cox test, variance analysis (ANOVA) and the Shapiro-Wilk test for hardly large test.
Table I describes the results of the division of patients according to the stage of the disease on
the TNM scale. The pre-operative CEA and CA 19-9 concentrations is presented in Figure 1
and Figure 2.
A pre-operative elevation of the CEA concentration in serum was found in 182 patients (71%).
CEA did not exceed the normal range in the Dukes A group. CA 19-9 was increased in 83 (32%)
patients in the Dukes C and D groups. The mean concentration of CEA and CA 19-9 changed
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according to the stage of the disease and were: Dukes A group – CEA (x̄=1.82 ng/ml, CA 19-9
x̄=12.45 U/ml, Dukes B group – CEA x̄=5.97 ng/ml, CA 19-9 x̄=15.37 U/ml, Dukes C group –
CEA x̄=7.42 ng/ml, CA 19-9 x̄=55.73 U/ml, Dukes D group – CEA x̄=17.97 ng/ml, CA 19-9 70.42
U/ml. In the post-operative follow-up, in which the Dukes D group was excluded, a recurrence
was found in 53 patients, an elevation of CEA was found in 47 patients (88.6%) and CA 19-9
was found in 36 patients (67.9%). The recurrence was detected in 100% of the patients when
an elevation of CEA CA 19-9 was accepted as a criterion. The results are shown in Figure 3.
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Figure 2. Mean concentration of CA 19-9 markers in pre-operative patients.
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Figure 3. Percentage of CEA and CA 19-9 concentration in patients with a recurrence.
1.5. Discussion
Although the dreams of Bates et al. [3] to find an ideal marker for an active neoplastic process,
i.e. that they have a different effect depending on the location of an organ and are absent in
healthy people, were frustrated, neoplastic markers are now widely used in clinical diagnos‐
tics, usually for patients who have undergone surgery to remove cancerous tissue. Studies that
lasted several years revealed that in order to estimate the efficacy of surgery, to detect a
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recurrence of a neoplastic process in the asymptomatic phase and to estimate the effectiveness
of supplementary therapy, a determination of markers in the serum of patients plays a crucial
role [1, 2, 4, 5, 6, 7, 8, 9].
Gold and Freedman [10] isolated carcinoembryonic antigen in colon cancer in 1966. They
thought that it  was specific to colorectal adenocarcinomas. The process of a quantitative
determination of CEA in systemic fluids was described shortly thereafter, which indicat‐
ed that more cancers produce CEA than had been previously thought. Moreover, it  was
found that its serum concentration may be higher than the normal range in non-neoplas‐
tic diseases such as pneumonia, bronchitis, tuberculosis, infections of the urinary tract and
also in 30% of smokers [1, 10].
CEA is increased in non-neoplastic diseases of the intestines like colitis ulcerosa and Crohn’s
disease [1, 4, 11]. This information appeared to reduce the clinical value of a CEA assay;
however, the development of monoclonal antibodies against CEA improved the specificity of
the assays. This antigen is not present in the serum of all patients, even in a case of a recurrence,
which was shown in studies that lasted for several years. Therefore, it is important to enhance
clinical immunodiagnostics through the use of other markers (epitopes), which can use the
information provided by the assay of CEA. The studies included 256 patients divided accord‐
ing to the stage of the cancer on the Dukes and TNM scales. Two neoplastic cancers CEA and
CA 19-9 were determined in all 256 patients. Increased CEA was found in 182 patients (71%)
and CA 19-9 was found in 83 patients (32%).
An analysis of the results revealed that in addition to CEA, CA 19-9 is an especially helpful
marker. This agrees with the reports of Dienst et al. [12], who found increased concentrations
of CEA in 49-58.5% of patients and increased concentrations of CA 19-9 in 21-67% of patients.
However, Filela et al. [5] observed increased concentrations of CEA in 61% of patients and
increased concentrations of CA 19-9 in 35% of patients. The concentration of both markers
changed depending on the stage of the disease. CEA and CA 19-9 concentrations were within
normal limits in the Dukes A group; the mean concentration of CEA was above the normal
limits, 5.97 ng/ml, and CA 19-9 was within the normal limits in the Dukes B group. In the Dukes
C group, the mean concentration of CEA was 7.42 ng/ml and the mean concentration of CA
19-9 was 55.73 U/ml. Similar results can be found in literature. Szymendera [2], Nowacki [7]
and Lindmark et al. [13] revealed that in the advanced stages of colon cancer, a percentage of
patients have elevated CEA and CEA concentrations. However, about 10-15% of patients do
not secrete CEA.
The literature reveals that about 11-13% of patients with histopathologically confirmed
colorectal cancer do not “produce” CEA and that an assay of these markers can lead to false
negative results [2, 4, 9]. In these cases, the presence of advanced cancer is not excluded by a
CEA concentration within the normal limits. CA 19-9 is the marker of first choice in this group
of patients. The addition of CA 19-9 to an assay of CEA increased the sensitivity from 71% to
83.6% in our studies; however, 12.5% of patients with CEA within the normal limits had
elevated CA 19-9. A positive correlation of CEA, CA 19-9 and the Dukes scale was revealed.
Similar results were obtained by other authors. Fillela et al. [5] revealed that multifactoral
analysis indicates the prognostic significance of CA 19-9 independent of the Dukes scale. New
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information about the CA 19-9 antigen has been revealed in recent years. CA 19-9 is sialofu‐
cololactotetraosyl and is included in the group of E-selectines. E-selectines enable a rise of
remote metastases that is caused by the adhesion of neoplastic cells to epithelial cells in
macrocirculation vessels. A pre-operative statistical analysis showed that the probability of
recurrence is higher in cases where there is a higher CEA concentration before a treatment.
However, Filela et al. [5] revealed that the risk of recurrence is 2.95 times greater in pre-
operative patients with an increased concentration of CA 19-9 than in patients with a normal
concentration of CA 19-9. 170 of 256 the patients who underwent surgery were tested in the
follow-up phase. Patients in the Dukes D group were not tested. A recurrence was observed
in 53 of the 170 patients (31%). The mean concentration of CEA was 20.71 ng/ml in the Dukes
B group and 20.55 ng/ml in the Dukes C group. The mean concentration of CA 19-9 was 61.61
U/ml and 197.18 U/ml, respectively. A recurrence was detected in 100% of the patients when
an increased concentration of CEA or CA 19-9 was used as a criterion. A recurrence was
detected in 88.6% of patients when only CEA was estimated and 67.9% of patients when only
CA 19-9 was estimated. The differentiation of a local neoplasm and remote metastases is
difficult. Szymendera [2] reported that a concentration of CEA that is greater than 20 indicates
metastases in the liver, while a small concentration of CEA or CA 19-9 might indicate meta‐
stases in the bones or lymph nodes.
1.6. Conclusions
1. Simultaneous detection of CEA and CA 19-9 should be the first immunodiagnostic test in
patients suspected of having colorectal cancer.
2. The use of carcinoembryonic antigen is advisable in order to monitor the course of the
disease in the case of an increased serum concentration of CEA and CA 19-9.
3. An increased concentration of CA 19-9 along with a normal lack of CEA in the serum of
patients with colorectal adenocarcinomas is unfavorable prognostically.
The continuous development of immunodiagnostic methods and the production of monoclo‐
nal antibodies can bring new neoplastic markers into diagnostics. One of these is the TPS
(Tissue Polipeptide Specific Antigen). Its structure is similar to the TPA (Tissue Polipeptide
Antigen). Reports in the last 2-3 years suggest the great value of the determination of TPS in
the serum of patients, including patients with gastrointestinal cancers, especially for the early
detection of release and estimation of therapy effectiveness. TPS is a marker of cell proliferation
and an increase in its concentration in serum often precedes the markers of a tumor
2. Scientific literature indicates interest of a cellular proliferation marker
— TPS
A review of medical reports from recent years shows an increasing interest in estimating TPS
levels mainly in oncologic diagnostics. Estimating TPS- concentration (which is a marker
connected with the proliferation of neoplastic cells) is very important for monitoring patients
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who have undergone cancer surgery (esp. of the digestive tract, but also for breast and ovarian
cancer) proceeding the clinical symptoms of metastasis for 2-7 months.
2.1. Characteristic of tissue polypeptide specific antigen (TPS) — Soluble fragments of
cytokeratine 18
TPS (tissue polypeptide specific antigen) is a new marker of cellular proliferation. The antibody
directed against TPS enables the determination of the concentration of the soluble fragments
of cytokeratin 18 [14]. TPS was introduced into oncological immunodiagnostics by Bjorklund.
It has one of the two active epitopes of TPA (tissue polypeptide antigen) that are detectable by
the monoclonal antibody M3. TPS is a singular conjugated polypeptide chain that is created
in the S and G2 phases of the cellular cycle and is released immediately after mitosis. It has 33
antigen determiners, two of which are connected with the activity of a tumor. TPS is strictly
connected with the proliferation of neoplastic cells and is a function of the velocity of cell
divisions [15].
2.2. Clinical results of serum concentration of TPS in patients with colorectal cancer
2.2.1. Aim of the study
1. To estimate pre-operative CEA and TPS concentrations in the blood serum of patients
with colorectal cancer and rectal carcinomas depending on the advancement of their
disease.
2. To attempt to determine whether TPS provides additional information that cannot be
obtained from CEA tests only.
2.2.2. Material and methods
178 patients (101 men and 77 women) aged 22-86 years who had been diagnosed with colorectal
cancer and had undergone surgery in the years 1991-2002 were included in the study. The
patients were being treated at the Department of General Surgery and Coloproctology of the
Medical University of Silesia in Sosnowiec. The CEA concentration was determined in the
patients’ blood serum using the MEIA method and commercial sets from Abbott (USA). TPS
was determined using the enzyme-immunological method (EIA) and sets from BEKI (Sweden).
The normal concentration of CEA was determined as 3 ng/ml and in the case of TPS – 90 U/l.
The  criteria  for  choosing  patients  for  the  research:  178  patients  whose  pre-operative
diagnostics confirmed the existence of a colon or rectal adenocarcinoma in a histopatholog‐
ical examination.
The criteria for excluding patients from the research. The research excluded patients who were
diagnosed with:
• an inflammation of the large intestine (colitis ulcerosa, Leśniowski-Crohn disease),
• chronic kidney diseases,
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information about the CA 19-9 antigen has been revealed in recent years. CA 19-9 is sialofu‐
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• chronic liver diseases,
• an inflammation of the rheumatoid joints,




The largest number of patients in the research was in the Dukes C group – 89 patients (50%).
The fewest number of patients was in the Dukes A group – 8 patients (10.11%)(Table II)











Table 2. The degree of the clinical advancement of colon and rectal carcinomas according to Dukes.
2.2.2.1. Statistical methods
All results were statistically measured using the Statistica 6.0 program from StatSoft Inc.
2.2.3. Results
No increased abnormal CEA concentration was found in any patient in the Dukes A subgroup.
An increased amount of CEA was found in 37 cases (59.7%) in the Dukes B subgroup, in 75
patients (83.9%) in the Dukes C subgroup and in 17 cases (89.57%) in the Dukes D subgroup.
Another profile was observed when determining TPS. An increased concentration was found
in 3 patients (37.5%) in the Dukes A subgroup. An increased concentration was found in 48
cases (77.4%) in the Dukes B subgroup, in 59 cases (65.5%) in the Dukes C subgroup and in 6
cases (31.6%) in the Dukes D subgroup. (Table III)





Table 3. The percentage of patients with an increased abnormal concentration of CEA and TPS in relation to the
Dukes scale.
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In cases where the division according to the degree of advancement in the whole group of 178
patients was not taken into account, the sensitivity for pre-operative CEA concentration was
72.5% and for TPS – 65.2%. When only cases with increased levels of CEA and TPS concen‐
trations were taken into account, the sensitivity of the test increased to 82.6%.
The concentration of CEA was: 2.34 ng/ml in the Dukes A subgroup, 5.71 ng/ml in the Dukes









Standard error -95% CI +95% CI
A 8 2,34 0,362284 0,128087 2,03462 2,64038
B 62 5,71 4,385849 0,557003 4,59636 6,82396
C 89 8,66 7,035047 0,745713 7,17906 10,14296
D 19 19,97 9,826148 2,254273 15,23553 24,70763
Table 4. CEA concentration in patients before surgery in relation to the degree of the advancement of the cancer
according to Dukes.
Another characteristic was observed in the case of the determination of TPS concentration. The
highest average pre-operative TPS concentration was found in the Dukes C subgroup – 226.7
U/l. It was 107.4 U/l in the Dukes A subgroup and 181.2 U/l in the Dukes B subgroup. However,
the average amount measured in the Dukes D subgroup was 167.37 U/l, which may be








Standard error -95% CI +95% CI
A 8 107,41 60,0221 21,22102 57,2328 157,5922
B 62 181,20 75,9138 9,64106 161,9283 200,4853
C 89 226,71 126,6201 13,42170 200,0392 253,3848
D 19 167,37 145,3267 33,34024 97,3295 237,4200
Table 5. TPS concentration in patients before operation in relation to the degree of the advancement of the cancer
according to Dukes.
A recurrence of the disease was detected in 47 patients (Dukes B and C). When the concentra‐
tion of CEA was used, recurrence was detected in 89.4% of patients and when the concentration
of TPS was used, recurrence was detected in 80.85% of patients. If the criterion was an elevated
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Table 5. TPS concentration in patients before operation in relation to the degree of the advancement of the cancer
according to Dukes.
A recurrence of the disease was detected in 47 patients (Dukes B and C). When the concentra‐
tion of CEA was used, recurrence was detected in 89.4% of patients and when the concentration
of TPS was used, recurrence was detected in 80.85% of patients. If the criterion was an elevated
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concentration of CEA or TPS, recurrence was detected in of 100% patients. The concentration
of CEA in patients with a recurrence was x̄=12.82 ± 4.73 ng/ml in the Dukes B group and x̄=13.5
± 7.69 ng/ml in the Dukes C group. The concentration of TPS was x̄=282.95 ± 56.08 U/l in the
Dukes B group and C x̄= 313.77 ± 116.62 U/l in the Dukes C group.
2.2.4. Discussion
In diagnosing carcinomas of the digestive system, particularly in the case of colon and rectal
carcinomas, the carcinoembryonic antigen (CEA) still remains the “gold standard” [16, 17,
18]. However, great expectations are connected with the introduction of the soluble fragments
of cytokeratin 18 (TPS) into the immunodiagnostics of colorectal cancer because TPS reflects
the velocity of cell divisions [19].
Our results of pre-operative CEA concentrations are similar to those that have been reported
by other researchers. Treska et al. obtained the highest sensitivity of CEA assessment from 45%
to 80% depending on the degree of the progression of cancer [20]. Similar results were reported
by Turoldo et al. and Marchena et al. [21, 22].
The main aim of the presented research was to estimate the usefulness of determining TPS
concentration. The TPS sensitivity was 65.17% in our own clinical research. The highest pre-
operative sensitivity equaling 70% was reported by Plebani et al. [23].
We also observed that the sensitivity of the test increased when the results of the determination
of TPS and CEA were combined. An abnormal pre-operative CEA concentration was recorded
in 129 patients (72.47%). When determining TPS concentration, 116 patients were found to
have increased abnormal levels (65.17%). When the established criterion was an increased level
of TPS or CEA, then the sensitivity of the test increased to 82.31%. Lindmark et al. using the
CEA, CA 19-9, CA 50 and TPS tests proved their correlation with one another; however, only
the TPS concentration test had the highest diagnostic sensitivity [18].
It is important to stress that adding TPS determination to the standard tests used for detecting
and monitoring colon and rectal carcinomas has recently been approved by the European
Group of Tumor Markers. According to the EGTM tests, adding TPS determination to the list
of “mass tumor” markers enables an increase in sensitivity, particularly in the earlier stages
of colorectal cancer [24].
2.2.5. Conclusions
1. The profile of the activity of pre-operative TPS concentration in the blood serum of patients
with colorectal cancer in relation to the degree of the advancement of the cancer is different
from that observed for CEA.
2. Determination of TPS concentration in patients with colorectal cancer provides essential
information necessary to confirm the cancer, particularly at the earliest stages of its
advancement.
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3. Apoptosis and proliferation – Bcl-2
The mechanism of malignancy is considered to be an imbalance between apoptosis and the
processes of proliferation. A phenotype that is resistant to apoptosis is one of the major features
of cancer cells. Recently, attention has been drawn to the function of a number of proteins that
inhibit the process of apoptosis within a tumor. To date, only a few works connected with the
assessment of apoptosis proteins serum concentrations have been published. Most of the works
about apoptosis concern immunohistochemistry studies.
This study attempts to find an answer to the question of whether the serum concentration of
antiapoptotic the Bcl-2 protein provides additional information for the post-operative moni‐
toring of patients with colorectal cancer.
3.1. Material and methods
The research was conducted on 46 patients (21 with a B Astler-Coller’s stage cancer and 25
with a C Astler-Coller’s stage cancer) was it colon cancer, who underwent surgery (resection
RO). Their ages ranged from 47 to 85 (average age 67); sex (19 women, 27 men). The patients
were divided into 2 groups: I –patients with a recurrence of cancer and II – patients without a
recurrence of cancer. The control group consisted of 20 healthy people, mainly medical staff.
The average CEA concentration in this group was 1.6 ng/ml+/- 0.43; TPS: 48.67U/l+/- 9.1; Bcl2:
0.31ng/ml+/- 0.13. The period of the observation of the patients and conducting the research
was 1-5 years. The recurrence of the disease or the lack of a recurrence was confirmed using a
physical examination and additional examinations during the oncological follow-up. Ten ml
of venous shunt blood was collected from each patient. The serum was frozen at -20°C after
centrifuging-. The blood for testing was collected one day before the surgery and 1, 3, 6 and
12 months after the surgery. CEA was measured using MEIA method and a commercial set
from ABBOT (USA). The standard concentration for a healthy person was adopted as 3ng/ml.
TPS was measured using the EIA method and sets from Beki Diagnostic Bromma (Sweden).
The standard for a healthy person does not exceed 90 U/I. Bcl-2 concentration was labeled
using the ELISA method using SORIN-BIOMEDICA tests (Italy). A standard for healthy
people is 0.5 ng/ml. The results obtained were analyzed statistically. Calculations were done
using Microsoft Excel 2003. The Ethical Committee at the Silesian Medical University approved
the studies.
3.2. Results
Of the 46 patients who underwent surgery, a recurrence was detected in 14 patients including
6 with an initial stage of a tumor – B according to the Dukes classification as modified by Astler-
Coller and 8 – degree C. The detection time of the recurrence was from 6 to 23 months. Most
of the recurrences were distant metastases: 9 in the liver and 2 in the lungs. A local recurrence
was observed in the intestinal stapling or retroperitoneal space in 3 patients. (Table VI) and
(Figures 4, 5 and 6)
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It was established that the Bcl-2 concentration was statistically significantly higher in the
recurrence group than in the non-recurrence group when examined 1, 3, 6 and 12 months after
the surgery. The TPS concentration was statistically significantly higher in the recurrence
group than in the non-recurrence group when examined before and 3, 6 and 12 months after
the surgery. The concentration of the antigen, i.e. CEA, was statistically significantly higher in
the recurrence group in relation to the non-recurrence group, as was TPS in the pre-operative
determinations and 3, 6 and 12 months after the surgery. Bcl-2, TPS and CEA serum concen‐
trations were unrelated to the Astler-Coller stage of colorectal cancer. However, insignificantly
higher concentrations of CEA at degree C than at degree B were observed. There was also no
dependence related to the sex, the age of a patient, the original location of the tumor and the
recurrence. Correlations between the concentrations of the determined parameters in all
patients (with a recurrence and without a recurrence) were also noticed. A strong correlation




Average SD Min. Max. Average SD Min. Max.
Bcl2_0 8,09 6,82 0,41 24,39 10,39 6,78 0,57 23,02
Bcl2_1 7,34 6,07 1,74 28,41 8,87 3,17 4,09 14,61
Bcl2_3 7,40 6,58 0,50 29,79 12,15 8,14 0,55 30,00
Bcl2_6 6,97 6,99 0,41 26,40 17,50 7,98 1,98 29,74
Bcl2_12 8,38 7,67 1,47 25,09 20,52 7,03 12,14 29,81
CEA_0 5,26 7,22 1,70 42,60 5,75 2,60 2,30 11,90
CEA_1 2,61 1,00 1,10 6,30 2,46 0,53 1,70 3,00
CEA_3 1,87 0,90 0,40 3,70 4,94 3,88 1,20 17,40
CEA_6 2,21 2,19 0,30 11,90 10,72 5,74 3,70 20,30
CEA_12 2,57 2,97 0,40 14,60 14,86 13,92 1,30 41,00
TPS_0 98,9 19,1 60,4 160,3 118,1 31,1 60,7 168,9
TPS_1 92,8 16,8 64,6 143,7 101,6 17,7 80,3 144,1
TPS_3 95,9 27,0 64,7 188,3 125,2 31,0 90,7 193,7
TPS_6 96,8 35,7 70,3 197,6 152,0 49,0 80,4 279,1
TPS_12 96,6 37,9 70,4 207,4 152,4 34,2 100,0 190,4
Age 66,2 10,9 47,0 85,0 70,4 4,0 64,0 77,0
Table 6. Values of the basic description parameters (0 – preoperative results and 1-, 3-, 6-, and 12 months after the
surgery.
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Figure 4. Results of the evaluation of post-operative CEA levels                 
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and the control group. 
 
 
Figure 5. Results of the evaluation of post-operative Bcl-2 levels              
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Figure 5. Results of the evaluation of post-operative Bcl-2 levels in the group without recurrence, the recurrence and
the control group.
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It was established that the Bcl-2 concentration was statistically significantly higher in the
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trations were unrelated to the Astler-Coller stage of colorectal cancer. However, insignificantly
higher concentrations of CEA at degree C than at degree B were observed. There was also no
dependence related to the sex, the age of a patient, the original location of the tumor and the
recurrence. Correlations between the concentrations of the determined parameters in all
patients (with a recurrence and without a recurrence) were also noticed. A strong correlation




Average SD Min. Max. Average SD Min. Max.
Bcl2_0 8,09 6,82 0,41 24,39 10,39 6,78 0,57 23,02
Bcl2_1 7,34 6,07 1,74 28,41 8,87 3,17 4,09 14,61
Bcl2_3 7,40 6,58 0,50 29,79 12,15 8,14 0,55 30,00
Bcl2_6 6,97 6,99 0,41 26,40 17,50 7,98 1,98 29,74
Bcl2_12 8,38 7,67 1,47 25,09 20,52 7,03 12,14 29,81
CEA_0 5,26 7,22 1,70 42,60 5,75 2,60 2,30 11,90
CEA_1 2,61 1,00 1,10 6,30 2,46 0,53 1,70 3,00
CEA_3 1,87 0,90 0,40 3,70 4,94 3,88 1,20 17,40
CEA_6 2,21 2,19 0,30 11,90 10,72 5,74 3,70 20,30
CEA_12 2,57 2,97 0,40 14,60 14,86 13,92 1,30 41,00
TPS_0 98,9 19,1 60,4 160,3 118,1 31,1 60,7 168,9
TPS_1 92,8 16,8 64,6 143,7 101,6 17,7 80,3 144,1
TPS_3 95,9 27,0 64,7 188,3 125,2 31,0 90,7 193,7
TPS_6 96,8 35,7 70,3 197,6 152,0 49,0 80,4 279,1
TPS_12 96,6 37,9 70,4 207,4 152,4 34,2 100,0 190,4
Age 66,2 10,9 47,0 85,0 70,4 4,0 64,0 77,0
Table 6. Values of the basic description parameters (0 – preoperative results and 1-, 3-, 6-, and 12 months after the
surgery.
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group. 
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when examined 1, 3, 6 and 12 months after the surgery. The TPS concentration 
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in the non-recurrence group when examined before and 3, 6 and 12 months after               
the surgery. The concentration of the antigen, i.e. CEA, was statistically 
significantly higher in the recurrence group in relation to the non-recurrence 
group, as was TPS in the pre-operative determinations and 3, 6 and 12 months 
after the surgery. Bcl-2, TPS and CEA serum concentrations were unrelated       
to the Astler-Coller stage of colorectal cancer. However, insignificantly higher 
concentrations of CEA at degree C than at degree B were observed.              
There was also no dependence related to the sex, the age of a patient,                
the original location of the tumor and the recurrence. Correlations between       
the concentrations of the determined parameters in all patients                    
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3.3. Discussion
The European Tumor Markers Association recommended CEA as a useful clinical marker in
the diagnosis and monitoring of patients with colorectal cancer in 2003. To date, many scientific
researchers have been shown that the addition of tumor markers in the diagnosis of patients
with colorectal cancer is necessary. Colorectal cancer, like breast and lung cancer, reveals a
high expression of the antiapoptotic p oteins: Bcl-2, Bcl-XL, PED, Il-4, which are secr ted by
tumor cells, strengthens that expression and protects neoplastic cells by environmental death
signals.
A low expression of BAX expression correlates with disease recurrence of the disease in
preoperatively irradiated rectal carcinomas and is connected with a worse response. A
decrease in the expression of BAX indicates the worst response to chemotherapy and reduces
the life expectancy of patients [25, 26, 27].
Our results show that an increase of Bcl-2 in the ser m of patients with colorectal cancer is bad
prognostically. A high concentration (x̄=14.46 ng/ml) was observed in the group with a
recurrence of the disease. The concentration of the Bcl-2 protein has been correlated with TPS
– a marker of cell proliferation. A high correlation in 12th month after surgery may confirm
that the suppression of the apoptosis of cancer cells increases their proliferation.
At the present time the apoptotic process and the process of cell proliferation are the targets
of many researchers in different areas of specialization.
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3.4. Conclusions
1. A statistically significant excess of Bcl-2 in patients who have a recurrence of colorectal
cancer makes information saying about the suppression of cancer cells apoptosis.
2. A statistically significant increase of the concentration of TPS in the group with a recur‐
rence seems to indicate that the suppression of apoptosis is conductive to an excessive
proliferation of cancer cells.
3. The findings obtained can mean that the evaluation of Bcl-2 and TPS may be complemen‐
tary to CEA determinations in the post-operative follow-up of patients with colorectal
cancer.
4. Angiogenesis – VEGF
The process of angiogenesis, which is the creation of new blood vessels, plays an important
role in the development and metastasis of cancer. It can be initiated by tumor cell hypoxia,
tumor suppressor gene mutations and oncogenes. As a result of the accumulation of these
processes, tumor cells activate the angiogenic factors. The main factor involved in angiogenesis
is VEGF-A. Blocking angiogenesis is one of the ways of preventing the development and
metastasis of cancer and is the future of cancer therapy.
4.1. Aim of the study
1. An assessment of the concentration of VEGF-A in the blood serum of patients with
colorectal cancer.
2. An attempt to answer the question of whether the determination of VEGF-A provides
clinically meaningful information in the post-operative monitoring of patients.
4.2. Material and methods
117 patients underwent surgery for colorectal cancer in the years 2004-2009. Patients were
divided according to the Dukes and TNM classifications. The control group consisted of 20
healthy volunteers. A recurrence was detected in 35 patients in the period of 623 months after
the surgery, including 11 patients in the Dukes B group and 24 patients in the Dukes C group.
Patients with a recurrence were grouped together, while the remaining 71 patients made up
the group without a recurrence.
The concentration of CEA and VEGF-A was determined in all of the patients before the surgery
and 1, 3, 6 and 12 months after the surgery. CEA was determined by MEIA using Abbott kits
(USA); the standard concentration in healthy people is 3 ng/ml. VEGF-A was determined by
ELISA using BIOMEDICA Sorin kits (Italy); the standard concentration in healthy people is
350 pg/ml.
The results were analyzed statistically. ROC curves were marked for the diagnostic parameters
studied.
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The pre-operative mean CEA concentrations differed significantly in all three degrees of the
severity of the disease (p<0.01). In the post-operative control, patients demonstrated statisti‐
cally significant differences in CEA concentrations 3, 6 and 12 months after surgery with the
largest concentration at the month follow-up (p<0,001). (Figure 7).
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of patients with and without a recurrence of a tumor in the subsequent stages          
of observation. 
 
Most recurrences were detected during this period. The average 
concentrations of CEA in patients without a recurrence was 2.18 ng/ml            
and in patients with a recurrence 7.58 ng/ml. The ROC curves analysis showed   
a concentration of CEA of 3.1 ng/ml as early as 3 months after the surgery, 







































































Figure 7. Evaluation of the concentrati n of CEA in the control group and in the groups f atients with and without
a recurrence of a tumor in the subsequent stages of observation.
Most recurrences were detected during this period. The average concentrations of CEA in
patients without a recurrence was 2.18 ng/ml and in patients with a recurrence 7.58 ng/ml. The
ROC curves analysis showed a concentration of CEA of 3.1 ng/ml as early as 3 months after
the surgery, which confirms the recurrence of the cancer (Figure 8).
Pre-operatively, a high concentration of VEGF-A was found in each stage of the disease;
however, it showed no difference in levels of statistical significance. Throughout the period of
post-operativ  observation, patients d monstrated a very high statistical sig ificance bet en
the group without a recurrence and those with a recurrence of the neoplastic process (p<0,001).
(Figure 9)
The average concentration in patients without a recurrence was 294.24 pg/ml, while in patients
with a recurrence it was 501.89 pg/ml. ROC curves showed the usefulness of VEGF-A in
detecting a recurrence a month after surgery and a concentration of 412 pg/ml, it is confirmed
(Figure 10).
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In addition, a high, statistically significant correlation between VEGF-A and CEA was












Figure 8. ROC curve for the concentration of CEA determined at the 3-month follow-up. 
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Figure 8. ROC curve for the concentration of CEA determined at the 3-month follow-up.
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Figure 9. Evaluation of the concentrati  of VEGF-A in the control group and in the group of p tients with and with‐
out a recurrence of a tumor in the subsequent stages of observation.
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Figure 10. ROC curve for the concentration of CEA determined at a one-month follow-up. 
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Figure 12. Correlation between the concentrations of CEA and VEGF-A in patients           
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Our results are similar to the results shown by Bombardieri [28], Treska [29], Kokocińska [30]
and many others. CEA was discussed in the first part of this chapter. VEGF-A was examined
in the blood of patients after the surgery.
We did not find any statistically significant differences between the Dukes classification. In
contrast, Fujisaki et al. [31] and Fuhrmann-Benzakein et al. [32] observed such a correlation.
The highest concentration of VEGF was observed in patients with a liver metastasis.
Chung et al. [33] and Ohta et al. [34] reported that VEGF may be considered as a proliferation
and prognostic factor. A high expression or concentration of VEGF indicates the possibility of
the recurrence of a disease in a relatively short time.
Afify et al. [35] also indicated that the concentration of VEGF is very useful in detecting a
recurrence of the disease and a metastasis to the liver.
However, Werther et al. and Karatzas et al. [36] reported that A high pre-operative concen‐
tration of VEGF suggests liver metastasis in the post-surgery period. Our results confirm those
of Afify, Werther and Chung.
The results of our researches show a statistically significantly correlation between VEGF-A
and CEA. It is possible that VEGF-A may stimulate the proliferation of tumor cells. To date,
only Chung et al. and Ohta et al. have confirmed a connection of VEGF with the proliferation
of tumor cells and with the development of cancer [33, 34].
All researches suggest that VEGF-A be added to the immunodiagnostics of CEA in patients
with colorectal cancer.
5. Conclusions
1. A statistically significant increase in VEGF-A in patients with a recurrence of a tumor in
the early post-operative period supports the usefulness of the inclusion of this marker for
monitoring patients, especially in planning their antiangiogenic therapy.
2. The high correlation between CEA and VEGF-A seems to indicate that the concentration
of VEGF-A has a close relationship with the proliferation of cells and the development of
cancer.
6. Summary
A review of the scientific literature on colorectal diseases over the last 20 years indicates the
continued development of Clinical Immunodiagnostics and the “gold standard”, which is
CEA, but also showed the usefulness and necessity of adding new markers: TPS, Bcl-2, VEGF
and their receptors.
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In the future, proteins, gene products, phenotyping of patients (determining the phenotype of
patients) and molecular cytology should also be added.
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1. Introduction
Since the introduction of laparoscopic surgery, minimally invasive techniques have been
widely used for benign and malignant diseases. [1, 2] Although many surgeons perform
laparoscopic colectomy for benign diseases, its application for colorectal malignancy had slow
progress because of oncological considerations. [3] Over time, many randomized controlled
trials have been published comparing open to laparoscopic surgery for colorectal cancer, which
show that in experienced hands, competent oncology resections can be performed the results
are equivalent to open surgery [4-7]. However, the results of the minimally invasive surgery
for rectal cancer have not been thoroughly investigated and large multicenter randomized
trials are underway.
Large number of randomized controlled trials comparing laparoscopic to open surgery for
colon cancer have established better short-term results - less pain, shorter length of stay, faster
return of bowel function and equivalent oncological outcomes [2-5]. Laparoscopic rectal
surgery is still developing with promising short-term benefit, although depending on the skills
and techniques of the surgeon [6]. Surgery of rectal cancer requires more technical skills (total
mesorectal excision, low pelvic anastomosis), many fear that the oncological principles could
be compromised during laparoscopic resection. In addition to oncological concerns, the
widespread of laparoscopic surgery for colorectal cancer is impeded by the significant learning
curve.
Hand-assisted techniques introduced in the 1990s were an attempt to overcome some of these
limitations and provide an overlap between open and laparoscopic techniques and the
transition from open to minimally invasive surgery for many surgeons [1, 8]. Acceptance of
minimally invasive procedures by patients and surgeons led to the developent of new
technologies to ease the laparoscopic approach. The introduction of single incision laparo‐
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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scopic surgery (SILS) devices has allowed fewer cuts. [9] The clinical application of endoscopic
natural orifice transluminal surgery (NOTES) in colorectal disease is not yet fully accepted,
but it was possible great advances in instrumentation and improving techniques for specimen
extraction after laparoscopic colectomy [12].
2. Systemic benefits
Basic science studies have demonstrated the better preservation of oncological and immuno‐
logical functions after laparoscopic surgery before trials on humans [7-9], thus giving hope for
better long-term oncologic outcome. Tumor cells are found in systemic blood circulation and
in the peritoneal fluid immediately after surgery and if they survive may avoid the immuno‐
logical defense of the organism. The surgical trauma causes immunological alterations and the
organism might be vulnerable during the postoperative period [7-9]. Laparoscopic surgery
causes lesser trauma and therefore less effect on the immune system, decreases the prolifera‐
tion stimuli for cancer cells and neoangiogenesis [7-9, 11]. The changes can last shortly after
the operation, but some are observed after months or longer [11]. These potential advantages
do not provide better long-term outcomes in human trials, although some report better
oncological results after laparoscopic surgery in terms of longer cancer-related survival and
less tumor recurrences [10-14].
The rate of conversion to open surgery is still very high, as demonstrated by three multicenter
prospective trials - the NCI Clinical Outcomes of Surgical Therapies (COST; 21%), Colon
Cancer Laparoscopic or Open Resection (COLOR; 17%), and the Conventional versus Lapa‐
roscopic-Assisted Surgery in Colorectal Cancer (CLASICC; 29%) [15, 16]. This could be due to
more precautious behavior of the surgeons and their inexperience.
A meta-analysis from 2006 demonstrated intriguing results. It includes 1134 patients after
colectomy in two periods – 1996-2000 and 2000-2004. Laparoscopic colectomy was introduced
as an option only in the second period. The authors found that 3-year overall survival
decreased in the latter, while the overall survival of patients after open colectomy remained
the same over the two periods. [17]
Intracorporeal anastomosis for right laparoscopic colectomy improved patient outcome
compared with patients who underwent extracorporeal anastomosis. There is found faster
recovery of nutrition, faster recovery of intestinal function, and shorter hospitalization.
However, there was no difference in average surgery time between the two groups.
According to the differences in age, gender, BMI, ASA class, or abdominal surgical history, in
laparoscopic colectomy with extracorporeal anastomosis (laparoscopic-assisted colectomy),
the bowel is externalized through a lateral mini-incision. With this approach, bowel mobili‐
zation and ligation of vessels is usually laparoscopic, whereas resection of the specimen and
creation of the anastomosis is extracorporeal. On the other hand, in laparoscopic right
colectomy with intracorporeal anastomosis (totally laparoscopic colectomy), bowel mobiliza‐
tion, ligation of vessels, resection of the specimen, and creation of the anastomosis are totally
intracorporeal.
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Regarding oncological radicality, there are significant differences in the number of lymph
nodes removed. An average of 19 lymph nodes from the intracorporeal group and 14 lymph
nodes from the extracorporeal group are reported to be removed. In the literature, some
authors have reported no differences in safety, whereas others noted that the only advantage
was a smaller incision. On the other hand, other studies affirmed the safety of intracorporeal
anastomosis, with the same complication rate as for extracorporeal anastomosis. Because
intracorporeal anastomosis is considered more difficult, only a few surgeons have used this
kind of technique; however less mobilization is required, and less tension is applied to the
bowel and mesentery because the bowel does not need to reach the anterior abdominal wall
for externalization. [11] Furthermore, the excessive tension on the mesentery during the
mobilization is associated with an increased risk of mesenteric or portal vein thrombosis.
Concerning surgical times, there is not a significant difference in surgical time between the
two groups. Patients in the intracorporeal group had a shorter hospitalization duration. In
some cases, the hospitalization duration was longer possibly because of age (43.2% of patients
in the intracorporeal group and 33.4% in the extracorporeal group were over 80 years old).
Our results showed a significantly shorter average hospitalization stay in the intracorporeal
group. These data agree with a recent Spanish study, although this difference was not
significant (P = 0.5424) because hospitalization duration is influenced by many patient factors.
On the other hand, we found that 71.4% of patients in the intracorporeal group went home
within 7 d, and 54.7% of patients in the extracorporeal group went home within this period.
[20, 21] Patients in the intracorporeal group and extracorporeal group went home within 7 d.
Concerning the recovery of intestinal function, our results found significantly shorter average
times for resumption of gas evacuation after 3 d in the intracorporeal group compared to after
3.8 d in the extracorporeal group. Bowel movements occurred after an average of 4.9 d in the
intracorporeal group. In the intracorporeal group, the nasogastric tube was removed after 1.8
d, whereas it was removed after 3 d in the extracorporeal group. This difference can be
explained by an increased percentage of paralytic ileus in the second group, which is due to
the traction of the right colon and terminal ileum through the mini-incision on the pancreas
and duodenum. This approach allowed a more rapid recovery of liquid and solid nutrition
consumption. [25-27] There are met some major complications, which included severe anemia,
occlusion, anastomotic dehisces, and enterocutaneous fistulae. There were no significant
differences between the two groups.
In conclusion, our study clearly shows that laparoscopic right colectomy with intracorporeal
anastomosis improves patient outcome. Intracorporeal anastomosis resulted in faster recovery
of nutrition consumption, faster recovery of intestinal function, and shorter hospitalization
duration. The higher number of lymph nodes removed seems to be related to vascular division
as the first surgical step as a rule. This confirms that a mini invasive approach improves patient
outcome.
3. Port site metastasis
The early trials of laparoscopic colectomy have established high rate of tumor recurrence near
the port wounds, which was considered a serious drawback of the new approach. The etiology
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duration. The higher number of lymph nodes removed seems to be related to vascular division
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3. Port site metastasis
The early trials of laparoscopic colectomy have established high rate of tumor recurrence near
the port wounds, which was considered a serious drawback of the new approach. The etiology
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is unclear, although some authors suggest poor surgical technique and tumor biology as a
probable cause. The reported rate in the early trials reached 21%. Recent trials (Hughes et al.,
1603 patients, [15] found the rate to be 0.68%. Fleshman et al. [5] reported results based on the
NCI COST trial, which demonstrated comparable rates for open and laparoscopic surgery after
5- and 8-year follow up (0.5% and 0.9%, respectively). The Barcelona trials had similar outcome
after a median follow-up of 95 months [7]. The European randomized controlled study, the
Colon Cancer Laparoscopic or Open Resection (COLOR) trial (2009) established after 53-month
median follow-up that the port site metastasis rate was 0.4% after open (n=542) and 1.3% after
laparoscopic colectomy (n=534). [19] The location of the recurrences was near the extraction
port (n=2) and near the trocar sites (n=5) [5]. Recent studies do not report such high recurrence
rates.
Proper training and the use of safe oncologic techniques are essential in the prevention of port
site metastases. Such safe techniques are the routing use of wound protectors, less instrument
exchange, avoidance of direct trauma to the tumor, avoidance of inadvertent desufflation.
4. Enhanced recovery after surgery
The approach employs a multimodal perioperative care pathway with the aim of attenuating
the stress response to surgery and accelerating recovery [21]. Implementation of enhanced
recovery protocols has led to improved outcomes across a range of different specialties
including reductions in postoperative morbidity and hospital stay [61-65]. The fundamental
premise of ERAS is the incorporation of evidence-based practice. It would seem to follow
therefore that the evolution of enhanced recovery guidelines should be dynamic, allowing
modifications of certain aspects of the program as new data becomes available. Some authors
have advocated a rigid adherence to the ERAS protocol, citing study data that demonstrates
a proportional relationship between deviation from the protocol and increased morbidity [61].
However, as evidence for components of the ERAS protocol change, it may be that a more
flexible and individualised approach should be considered.
5. Perioperative fluid administration
Traditionally, patients undergoing major colorectal surgery have received liberal volumes of
intravenous fluids [49]. Excess intravenous fluid during and after surgery has been associated
with delayed gut function and increased complication rates [50, 51]. Fluid restriction has been
proposed as a possible method of improving recovery and reducing postoperative complica‐
tions. Brandstrup et al [58] found that randomising patients undergoing elective colorectal
surgery resection to a restricted fluid protocol reduced cardiopulmonary and wound morbid‐
ity. MacKay et al [59] found no difference in recovery of gastrointestinal function or time to
discharge with postoperative fluid restriction while using a conservative intra-operative
protocol. Goal directed fluid therapy via oesophageal Doppler (OD) monitoring offers an
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opportunity to individualise peri-operative fluid administration. OD provides a real time
representation of haemodynamic function, and has been shown to be comparable with other
methods for estimating cardiac output such as LIDCO. A number of studies have shown that
goal-directed fluids reduce morbidity, critical care admissions, and hospital stay [62]. It is not
clear however whether these benefits are still significant within an enhanced recovery protocol.
Other goal-directed techniques employ central venous oxygen saturation (ScvO2) as a surro‐
gate for mixed venous oxygen saturation. ScvO2 is related to tissue oxygenation and so can be
used to titrate oxygen and fluid therapy, particularly in the immediate postoperative period.
This approach requires central venous access which is not always available as some groups
have developed a less invasive approach to monitoring. While a number of different fluid
protocols have been proposed, the optimal approach is still unclear.
6. Evolving postoperative analgesia
Epidural analgesia was considered central to early ERAS protocols, since it reduces the
endocrine-mediated stress response [53, 54], and improves postoperative intestinal function
[55]. Epidural analgesia also provides superior pain control to systemic opiates, particularly
in the first 24-36 h after surgery [56]. Data on the effect of epidural analgesia come predomi‐
nantly from studies in open surgery while the benefits in laparoscopic surgery are less clear.
Levy et al [65, 66] performed a meta-analysis to address this question but concluded that there
was a paucity of quality data. The authors subsequently performed a study in which patients
were randomised to receive epidural, spinal or patient-controlled opiate analgesia following
elective laparoscopic colorectal resection. They demonstrated a significantly longer hospital
stay, time to return of bowel function and duration of nausea in the epidural group. Intra-
thecal morphine has been proposed as an alternative [67]. A meta-analysis provides encour‐
aging results in patients undergoing abdominal surgery; reduced post-operative pain in the
first 48 h and significantly reduced opiate consumption compared with systemic opiates [68].
Transversus abdominus plane blocks have also been gaining in popularity although compa‐
rative data is still lacking [69]. Epidurals can cause vasodilatation and hypotension [70],
resulting in excess fluid challenges, third space shift and fluid overload. As studies emerge
demonstrating benefits of alternative analgesic techniques, it does raise the question: Should
epidural analgesia be the standard technique for all colorectal resections? Perhaps a more
individualised approach dependent on the procedure, use of laparoscopy and placement of
incisions should be considered. In this way more patients may be able to avoid potential
complications while maintaining adequate analgesia and facilitating early mobilisation.
7. Laparoscopic and open surgery in enhanced recovery
The adoption of laparoscopic techniques within colorectal surgery came at a similar time to
the introduction of "fast-track" surgery. Early studies examining the effect of laparoscopic
surgery showed clear superiority in short term outcomes when compared with open surgery
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is unclear, although some authors suggest poor surgical technique and tumor biology as a
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The approach employs a multimodal perioperative care pathway with the aim of attenuating
the stress response to surgery and accelerating recovery [21]. Implementation of enhanced
recovery protocols has led to improved outcomes across a range of different specialties
including reductions in postoperative morbidity and hospital stay [61-65]. The fundamental
premise of ERAS is the incorporation of evidence-based practice. It would seem to follow
therefore that the evolution of enhanced recovery guidelines should be dynamic, allowing
modifications of certain aspects of the program as new data becomes available. Some authors
have advocated a rigid adherence to the ERAS protocol, citing study data that demonstrates
a proportional relationship between deviation from the protocol and increased morbidity [61].
However, as evidence for components of the ERAS protocol change, it may be that a more
flexible and individualised approach should be considered.
5. Perioperative fluid administration
Traditionally, patients undergoing major colorectal surgery have received liberal volumes of
intravenous fluids [49]. Excess intravenous fluid during and after surgery has been associated
with delayed gut function and increased complication rates [50, 51]. Fluid restriction has been
proposed as a possible method of improving recovery and reducing postoperative complica‐
tions. Brandstrup et al [58] found that randomising patients undergoing elective colorectal
surgery resection to a restricted fluid protocol reduced cardiopulmonary and wound morbid‐
ity. MacKay et al [59] found no difference in recovery of gastrointestinal function or time to
discharge with postoperative fluid restriction while using a conservative intra-operative
protocol. Goal directed fluid therapy via oesophageal Doppler (OD) monitoring offers an
Colorectal Cancer - Surgery, Diagnostics and Treatment104
opportunity to individualise peri-operative fluid administration. OD provides a real time
representation of haemodynamic function, and has been shown to be comparable with other
methods for estimating cardiac output such as LIDCO. A number of studies have shown that
goal-directed fluids reduce morbidity, critical care admissions, and hospital stay [62]. It is not
clear however whether these benefits are still significant within an enhanced recovery protocol.
Other goal-directed techniques employ central venous oxygen saturation (ScvO2) as a surro‐
gate for mixed venous oxygen saturation. ScvO2 is related to tissue oxygenation and so can be
used to titrate oxygen and fluid therapy, particularly in the immediate postoperative period.
This approach requires central venous access which is not always available as some groups
have developed a less invasive approach to monitoring. While a number of different fluid
protocols have been proposed, the optimal approach is still unclear.
6. Evolving postoperative analgesia
Epidural analgesia was considered central to early ERAS protocols, since it reduces the
endocrine-mediated stress response [53, 54], and improves postoperative intestinal function
[55]. Epidural analgesia also provides superior pain control to systemic opiates, particularly
in the first 24-36 h after surgery [56]. Data on the effect of epidural analgesia come predomi‐
nantly from studies in open surgery while the benefits in laparoscopic surgery are less clear.
Levy et al [65, 66] performed a meta-analysis to address this question but concluded that there
was a paucity of quality data. The authors subsequently performed a study in which patients
were randomised to receive epidural, spinal or patient-controlled opiate analgesia following
elective laparoscopic colorectal resection. They demonstrated a significantly longer hospital
stay, time to return of bowel function and duration of nausea in the epidural group. Intra-
thecal morphine has been proposed as an alternative [67]. A meta-analysis provides encour‐
aging results in patients undergoing abdominal surgery; reduced post-operative pain in the
first 48 h and significantly reduced opiate consumption compared with systemic opiates [68].
Transversus abdominus plane blocks have also been gaining in popularity although compa‐
rative data is still lacking [69]. Epidurals can cause vasodilatation and hypotension [70],
resulting in excess fluid challenges, third space shift and fluid overload. As studies emerge
demonstrating benefits of alternative analgesic techniques, it does raise the question: Should
epidural analgesia be the standard technique for all colorectal resections? Perhaps a more
individualised approach dependent on the procedure, use of laparoscopy and placement of
incisions should be considered. In this way more patients may be able to avoid potential
complications while maintaining adequate analgesia and facilitating early mobilisation.
7. Laparoscopic and open surgery in enhanced recovery
The adoption of laparoscopic techniques within colorectal surgery came at a similar time to
the introduction of "fast-track" surgery. Early studies examining the effect of laparoscopic
surgery showed clear superiority in short term outcomes when compared with open surgery
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using traditional recovery technique [63, 64]. Patients undergoing laparoscopic surgery have
reduced in-patient stays, less morbidity and improved postoperative pain [65, 66]. What is less
clear is how much of the benefit is attributable to laparoscopy and how much is an effect of
differing perioperative care pathways. Since these early trials there have been a number of
small trials comparing laparoscopic and open colorectal surgery within an enhanced recovery
setting with conflicting results [55-61]. Most recently a four-armed randomised study of
patients undergoing either open or laparoscopic surgery, in an enhanced recovery or standard
recovery programme was performed. They demonstrated a significantly faster recovery time
following colonic surgery in those patients undergoing laparoscopic procedures within an
ERAS programme. What is clear is that there are still a number of areas within the enhanced
recovery protocol where the evidence-base continues to change. The relative contributions of
different facets of the protocol also remain to be determined. While this is the case we should
accept a flexible approach to facilitate the adoption of techniques supported by randomised
data. There may also be scope for a degree of individualisation to reflect the wide range of
patients and procedures to which enhanced recovery is now being applied. [70]
8. Laparoscopic colectomy
After the initial description in 1991, several reports of laparoscopic colectomy (LC) for
colorectal cancer were described. Significant concerns regarding this approach surfaced when
minimally invasive techniques applied to colorectal malignancy lead to increased surgical
complications and worse cancer outcomes compared to conventional open approaches. An
early report, using minimally invasive techniques for benign colorectal disease, showed a
significantly high rate of serious complications (18%), including inadvertent enterotomies,
intraoperative hemorrhage, anastomotic leaks, and pelvic abscesses. When LC was used to
treat colorectal cancer, several papers noted early wound or trocar site recurrences, including
one case series documenting a 21% rate. With a less than 1 percent wound implantation rate
for open surgery, serious concerns were raised as to the possibility that poor oncologic results
were due to a combination of poor technique and abnormal distribution of malignant cells
secondary to pneumoperitoneum. Further concerns that laparoscopic techniques may be
problematic to cancer patients arose when some studies demonstrated statistically significant
worse cancer-specific survival in patients who had conversion from laparoscopic to open
surgery. Moloo et al. described decreased survival at 2 years of 76% from 87% for all stages
(P = 0.02) of colorectal cancer collected from a prospective database of 377 consecutive
laparoscopic patients. In the same cohort, at 5 year followup, there was a trend toward
decreased overall survival in converted patients (61.9% versus 69.7%, P = 0.077). Chan et al.
showed an increased local recurrence rate at 3 year followup of 9.8% in the laparoscopically
converted group as compared to 2.8% in open patients (P = 0.03). The oncological concerns
raised in early reports provided a compelling argument to study the question of oncologic
equivalence between the open and laparoscopic approach to colorectal cancer in a controlled
fashion.
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In the early 1990s, several multicenter prospective randomized controlled trials comparing
laparoscopic and open surgery for colorectal cancer were initiated. Ultimately, seven large-
scale trials compared laparoscopic and open colectomy for colon carcinoma and examined
short-term and long-term outcomes. These trials included the Clinical Outcomes of Surgical
Therapies (COST) trial funded by the National Cancer Institute in the United States, the
Conventional versus Laparoscopic-Assisted Surgery in Colorectal Cancer (CLASICC) trial in
the United Kingdom, the Colon Cancer Laparoscopic or Open Resection (COLOR), a multi‐
center European trial, the Barcelona trial, and several others [20–26]. The main focus of these
trials was oncologic outcomes, but short-term outcomes, quality of life, and safety were also
evaluated. The CLASICC trial was the only large trial that also evaluated MIS in rectal cancer.
Though modest in early studies, the short-term patient-related advantages of laparoscopic
surgery have now been confirmed and are significant over the open approach. The Minimally
Invasive Colorectal Resection Outcomes (MICRO) review identified 22 randomized controlled
trials and 66 cohort series for benign and malignant colorectal disease [27]. Laparoscopic
colectomy results in significantly lower pain scores and analgesia requirements, estimated
blood loss, return of bowel function, and length of stay. Numerous other trials, including the
COST, COLOR, and CLASICC trials, examining short-term outcomes following laparoscopic
colectomy for colorectal cancer have confirmed these findings [20–26, 28]. Several studies have
also identified a decreased rate of postoperative morbidity including fewer wound infections
[21, 23, 27, 29]; this was recently reinforced by a large trial from the National Surgical Quality
Improvement Program (NSQIP) database of over 10, 000 patients identifying decreased
incidence of wound infection following laparoscopic colectomy (9.5% versus 16.1%, P < 0.001)
[30]. Quality of life has been assessed in several trials and results varied from no difference to
favoring improved quality of life in laparoscopic colectomy [31].
The initially cited oncologic concerns of laparoscopic colectomy for colorectal cancer were later
dispelled when surgeons trained in appropriate laparoscopic oncologic resection performed
operations in the trial setting. Major trials, including the COST, CLASICC, and COLOR trials,
examined tumor specimens and reported long-term data on recurrence and survival. The
surgical specimens were evaluated, and parameters such as lymph node yield, circumferential
resection margins, and longitudinal margins were quantified. No trial identified statistically
significant differences in lymph node yield [20–26] or resection margins [20, 22, 26]. This initial
evidence allayed some concerns regarding oncologic resections, but the long-term measures
for recurrence and survival were still unknown. Trial data matured, and more evidence
accumulated confirming similar recurrence patterns and rates between laparoscopic and open
colectomy. Local recurrence, distant recurrence, and wound or port site metastases were the
same between groups [4, 5, 7, 24, 32–34]. Disease-free and overall survival in long-term follow-
up (up to 7 years) is equivalent [4, 5, 7, 32–34]. The concern that conversion from laparoscopic
to open surgery in patients with colon cancer may lead to worse oncologic outcomes was not
seen when 5-year COST trial data showed no statistical difference in these two groups.
Despite evidence demonstrating improved short-term outcomes of laparoscopic colectomy
and oncologic equivalence, widespread implementation of this technique was slow. The lack
of formalized training, outside single-day laparoscopic training courses, and the significant
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using traditional recovery technique [63, 64]. Patients undergoing laparoscopic surgery have
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differing perioperative care pathways. Since these early trials there have been a number of
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setting with conflicting results [55-61]. Most recently a four-armed randomised study of
patients undergoing either open or laparoscopic surgery, in an enhanced recovery or standard
recovery programme was performed. They demonstrated a significantly faster recovery time
following colonic surgery in those patients undergoing laparoscopic procedures within an
ERAS programme. What is clear is that there are still a number of areas within the enhanced
recovery protocol where the evidence-base continues to change. The relative contributions of
different facets of the protocol also remain to be determined. While this is the case we should
accept a flexible approach to facilitate the adoption of techniques supported by randomised
data. There may also be scope for a degree of individualisation to reflect the wide range of
patients and procedures to which enhanced recovery is now being applied. [70]
8. Laparoscopic colectomy
After the initial description in 1991, several reports of laparoscopic colectomy (LC) for
colorectal cancer were described. Significant concerns regarding this approach surfaced when
minimally invasive techniques applied to colorectal malignancy lead to increased surgical
complications and worse cancer outcomes compared to conventional open approaches. An
early report, using minimally invasive techniques for benign colorectal disease, showed a
significantly high rate of serious complications (18%), including inadvertent enterotomies,
intraoperative hemorrhage, anastomotic leaks, and pelvic abscesses. When LC was used to
treat colorectal cancer, several papers noted early wound or trocar site recurrences, including
one case series documenting a 21% rate. With a less than 1 percent wound implantation rate
for open surgery, serious concerns were raised as to the possibility that poor oncologic results
were due to a combination of poor technique and abnormal distribution of malignant cells
secondary to pneumoperitoneum. Further concerns that laparoscopic techniques may be
problematic to cancer patients arose when some studies demonstrated statistically significant
worse cancer-specific survival in patients who had conversion from laparoscopic to open
surgery. Moloo et al. described decreased survival at 2 years of 76% from 87% for all stages
(P = 0.02) of colorectal cancer collected from a prospective database of 377 consecutive
laparoscopic patients. In the same cohort, at 5 year followup, there was a trend toward
decreased overall survival in converted patients (61.9% versus 69.7%, P = 0.077). Chan et al.
showed an increased local recurrence rate at 3 year followup of 9.8% in the laparoscopically
converted group as compared to 2.8% in open patients (P = 0.03). The oncological concerns
raised in early reports provided a compelling argument to study the question of oncologic
equivalence between the open and laparoscopic approach to colorectal cancer in a controlled
fashion.
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In the early 1990s, several multicenter prospective randomized controlled trials comparing
laparoscopic and open surgery for colorectal cancer were initiated. Ultimately, seven large-
scale trials compared laparoscopic and open colectomy for colon carcinoma and examined
short-term and long-term outcomes. These trials included the Clinical Outcomes of Surgical
Therapies (COST) trial funded by the National Cancer Institute in the United States, the
Conventional versus Laparoscopic-Assisted Surgery in Colorectal Cancer (CLASICC) trial in
the United Kingdom, the Colon Cancer Laparoscopic or Open Resection (COLOR), a multi‐
center European trial, the Barcelona trial, and several others [20–26]. The main focus of these
trials was oncologic outcomes, but short-term outcomes, quality of life, and safety were also
evaluated. The CLASICC trial was the only large trial that also evaluated MIS in rectal cancer.
Though modest in early studies, the short-term patient-related advantages of laparoscopic
surgery have now been confirmed and are significant over the open approach. The Minimally
Invasive Colorectal Resection Outcomes (MICRO) review identified 22 randomized controlled
trials and 66 cohort series for benign and malignant colorectal disease [27]. Laparoscopic
colectomy results in significantly lower pain scores and analgesia requirements, estimated
blood loss, return of bowel function, and length of stay. Numerous other trials, including the
COST, COLOR, and CLASICC trials, examining short-term outcomes following laparoscopic
colectomy for colorectal cancer have confirmed these findings [20–26, 28]. Several studies have
also identified a decreased rate of postoperative morbidity including fewer wound infections
[21, 23, 27, 29]; this was recently reinforced by a large trial from the National Surgical Quality
Improvement Program (NSQIP) database of over 10, 000 patients identifying decreased
incidence of wound infection following laparoscopic colectomy (9.5% versus 16.1%, P < 0.001)
[30]. Quality of life has been assessed in several trials and results varied from no difference to
favoring improved quality of life in laparoscopic colectomy [31].
The initially cited oncologic concerns of laparoscopic colectomy for colorectal cancer were later
dispelled when surgeons trained in appropriate laparoscopic oncologic resection performed
operations in the trial setting. Major trials, including the COST, CLASICC, and COLOR trials,
examined tumor specimens and reported long-term data on recurrence and survival. The
surgical specimens were evaluated, and parameters such as lymph node yield, circumferential
resection margins, and longitudinal margins were quantified. No trial identified statistically
significant differences in lymph node yield [20–26] or resection margins [20, 22, 26]. This initial
evidence allayed some concerns regarding oncologic resections, but the long-term measures
for recurrence and survival were still unknown. Trial data matured, and more evidence
accumulated confirming similar recurrence patterns and rates between laparoscopic and open
colectomy. Local recurrence, distant recurrence, and wound or port site metastases were the
same between groups [4, 5, 7, 24, 32–34]. Disease-free and overall survival in long-term follow-
up (up to 7 years) is equivalent [4, 5, 7, 32–34]. The concern that conversion from laparoscopic
to open surgery in patients with colon cancer may lead to worse oncologic outcomes was not
seen when 5-year COST trial data showed no statistical difference in these two groups.
Despite evidence demonstrating improved short-term outcomes of laparoscopic colectomy
and oncologic equivalence, widespread implementation of this technique was slow. The lack
of formalized training, outside single-day laparoscopic training courses, and the significant
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learning curve for straight laparoscopic techniques likely represented significant barriers to
adoption. As hand-assisted laparoscopic surgery grew in popularity, a more widespread
adaptation with fewer conversions to open surgery occurred in part due to a shorter learning
curve with this technique. Three randomized controlled trials have been performed to compare
a hand-assisted technique to a laparoscopic technique including patients with both benign and
malignant disease, all demonstrating decreased rates of conversion to open surgery [35–37].
A recent meta-analysis compiling 13 studies demonstrated decreased operative times and
decreased open conversion rates with a hand-assisted approach [38]. There were no differences
in short-term clinical outcomes or oncologic resection results. A recent study by the Mayo
Clinic prospectively analyzed the use of hand-assisted surgery in a minimally invasive
colorectal practice and found that when applied to a center performing large volumes of
laparoscopic surgery, hand-assisted techniques were responsible for more complex proce‐
dures to be done laparoscopically [39]. This technique is a minimally invasive approach that
has been helpful for surgeons to transition from open to laparoscopic colectomy, especially if
they have had little previous laparoscopic experience. Moreover, this technique has allowed
a MIS approach in patients otherwise not previously considered candidates (obese, adhesions).
As surgeon experience increased and as more studies demonstrated that laparoscopic colec‐
tomy for benign and malignant disease is an acceptable alternative to open surgery, the overall
ratio of laparoscopic to open colectomies in the United States has increased. A recent analysis
from 2000 through 2004 demonstrated an increasing incidence of laparoscopic colectomy from
3% to 6.5% nationally with increased rates of laparoscopic approaches in urban centers and
teaching hospitals [40]. A separate study and database of patients from 2004 through 2006
identified over 32, 000 patients, of which 34% underwent laparoscopic colectomy [41]. This
trend toward increased laparoscopy has also been influenced by public knowledge and patient
demand for this approach, as well as improved and formalized laparoscopic training in
residency programs.
The short-term advantages of laparoscopic surgery over the open approach are confirmed. The
minimally invasive approach is characterized by lower pain score and analgesia requirement,
estimated blood loss; earlier return of bowel function and shorter length of stay (Minimally
Invasive Colorectal Resection Outcomes (MICRO), [20]. The postoperative recovery of
pulmonary function is quicker after laparoscopic colectomy. None of the randomized trials
have observed significant increase in the anastomotic leakage rate [2-5]. Several studies
demonstrated the decreased rate of postoperative morbidity and less wound infections [2-7].
Quality of life after laparoscopic surgery has been evaluated in several trials and the results
varied from similar to better QoL than after open surgery [21].
In 2008 Lacy et al. reported the long-term outcomes of Barcelona trial (median follow-up 95
months). The overall survival rate was higher in the laparoscopic (64%) group when compared
with the open group (51%) with no statistically significant difference (p<0.07). Laparoscopic
group demonstrated higher cancer-related survival and lower cancer recurrence in (p<0.07 for
both). The differences in survival and recurrences between the open and laparoscopic groups
were observed for III stage tumors, with significantly better results in terms of overall-survival,
cancer-related survival and chances of being free of recurrence. Results for stage I and II did
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not show any statistical difference. The conclusion is that in a dedicated laparoscopic center,
LAC may result in a long-term survival benefit compared with OC, particularly in advanced
cases”. This oncological advantage can be explained by a preserved cellular immunity,
attenuated stress and inflammatory response. [7]
These results seem encouraging and lead the way for laparoscopic surgery, although in a 2007
study by Fleshman (5-year follow-up, COST trial) the data did not demonstrate significant
difference in the 5-year overall survival, 5-year disease-free survival, and recurrence rates
between the two groups. The pattern of recurrence is also similar. [5] In 2007 Bonjer et al.
reported meta-analysis, based on 3-year follow-up data from Barcelona, COST, COLOR and
CLASSIC trials. No significant difference in 3-year survival, 3-year disease free survival or
tumor recurrence rates between study groups was observed. Analysis by stages did not show
any statistical difference in survival between both groups [16].
The hand-assisted laparoscopic surgery is a potential way to decrease operative time and
maintain the benefits of the minimally invasive approach. The type of laparoscopic surgery
allows introducing a hand through special device in the abdominal cavity, while preserving
pneumoperitoneum. This provides proprioception and tactile feedback and ability to perform
manual dissection and retraction. A study by Marcell [8] reported the results after multicenter
randomized trial. The hand assisted sigmoidectomy group had significantly shorter operative
time by 30-minutes when compared with straight laparoscopic group. Both groups had similar
short-term outcomes. There were no differences in time to bowel function, pain scores, narcotic
use, or time to bowel function. Conversion to open surgery was also significantly less for the
hand-assisted group. Incision length was significantly longer for the hand-assisted group, but
the difference was small. The authors concluded that hand-assisted surgery results in signifi‐
cantly shorter operative time, while maintaining similar outcomes as straight laparoscopic
surgery [17]. Hand-assisted surgery allows to perform more complex procedures and to
operate on patients with adhesion or obesity.
9. Laparoscopy for rectal cancer
The use of laparoscopic approach in the treatment of rectal cancer has led to increase of surgical
complications and worse cancer outcomes in comparison to the open surgery [6] strong
statement to make, may be phrase it differently. Several papers reported increased rate of port-
site recurrences, reaching up to 21% [3]. The same parameter for the open approach is 1%.
Those results might be explained by poor surgical technique and abnormal distribution of
cancer cell due to the pneumoperitoneum [7]. The cancer-specific survival was significantly
lower after conversion to open surgery [8, 9].
Based on the data of a prospective trial, including 377 laparoscopic patients [22] the survival
decreased from 87% to 76% at 2 years for all stages of colorectal cancer. After a 5-year follow-
up the overall survival decreased in converted patients. The local recurrence also proved to
be higher: 9.8% and 2.8% for the laparoscopic and open groups, respectively. Several large
trials were initiated in the 1990 (Clinical Outcomes of Surgical Therapies (COST) [21]in the
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learning curve for straight laparoscopic techniques likely represented significant barriers to
adoption. As hand-assisted laparoscopic surgery grew in popularity, a more widespread
adaptation with fewer conversions to open surgery occurred in part due to a shorter learning
curve with this technique. Three randomized controlled trials have been performed to compare
a hand-assisted technique to a laparoscopic technique including patients with both benign and
malignant disease, all demonstrating decreased rates of conversion to open surgery [35–37].
A recent meta-analysis compiling 13 studies demonstrated decreased operative times and
decreased open conversion rates with a hand-assisted approach [38]. There were no differences
in short-term clinical outcomes or oncologic resection results. A recent study by the Mayo
Clinic prospectively analyzed the use of hand-assisted surgery in a minimally invasive
colorectal practice and found that when applied to a center performing large volumes of
laparoscopic surgery, hand-assisted techniques were responsible for more complex proce‐
dures to be done laparoscopically [39]. This technique is a minimally invasive approach that
has been helpful for surgeons to transition from open to laparoscopic colectomy, especially if
they have had little previous laparoscopic experience. Moreover, this technique has allowed
a MIS approach in patients otherwise not previously considered candidates (obese, adhesions).
As surgeon experience increased and as more studies demonstrated that laparoscopic colec‐
tomy for benign and malignant disease is an acceptable alternative to open surgery, the overall
ratio of laparoscopic to open colectomies in the United States has increased. A recent analysis
from 2000 through 2004 demonstrated an increasing incidence of laparoscopic colectomy from
3% to 6.5% nationally with increased rates of laparoscopic approaches in urban centers and
teaching hospitals [40]. A separate study and database of patients from 2004 through 2006
identified over 32, 000 patients, of which 34% underwent laparoscopic colectomy [41]. This
trend toward increased laparoscopy has also been influenced by public knowledge and patient
demand for this approach, as well as improved and formalized laparoscopic training in
residency programs.
The short-term advantages of laparoscopic surgery over the open approach are confirmed. The
minimally invasive approach is characterized by lower pain score and analgesia requirement,
estimated blood loss; earlier return of bowel function and shorter length of stay (Minimally
Invasive Colorectal Resection Outcomes (MICRO), [20]. The postoperative recovery of
pulmonary function is quicker after laparoscopic colectomy. None of the randomized trials
have observed significant increase in the anastomotic leakage rate [2-5]. Several studies
demonstrated the decreased rate of postoperative morbidity and less wound infections [2-7].
Quality of life after laparoscopic surgery has been evaluated in several trials and the results
varied from similar to better QoL than after open surgery [21].
In 2008 Lacy et al. reported the long-term outcomes of Barcelona trial (median follow-up 95
months). The overall survival rate was higher in the laparoscopic (64%) group when compared
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not show any statistical difference. The conclusion is that in a dedicated laparoscopic center,
LAC may result in a long-term survival benefit compared with OC, particularly in advanced
cases”. This oncological advantage can be explained by a preserved cellular immunity,
attenuated stress and inflammatory response. [7]
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reported meta-analysis, based on 3-year follow-up data from Barcelona, COST, COLOR and
CLASSIC trials. No significant difference in 3-year survival, 3-year disease free survival or
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trials were initiated in the 1990 (Clinical Outcomes of Surgical Therapies (COST) [21]in the
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USA, the Conventional versus Laparoscopic-Assisted Surgery in Colorectal Cancer (CLA‐
SICC) [6] in the United Kingdom, Colon Cancer Laparoscopic or Open Resection (COLOR) in
Europe and the Barcelona trial) [15]. Those trials evaluated laparoscopic and open colectomy
for colon carcinoma and examined short-term and long-term outcomes, as well as short-term
outcomes, quality of life and safety. Only the CLASSIC trials evaluated minimally invasive
surgery for rectal cancer.
The potential benefits of laparoscopic rectal surgery are known and were proven by meta-
analysis of studies of non-randomized trials – shorter time of bowel function restoration,
shorter length of stay [22]. A characteristic advantage of the laparoscopic surgery is that it
provides unobstructed view to the entire surgical team and magnified view of the operating
field, thus allowing more accurate dissection. The pneumoperitoneum helps to open the planes
of dissection of the mesorectum. The limitations of the laparoscopic rectal surgery are the
unsure data on oncological safety [2-5], the concerns about inadequate oncological distant
dissection, anastomotic leakage, technical challenges [23, 24].
Significant difficulty poses the obtaining of adequate exposure of the rectum. The narrow
pelvis in some patients may cause clashing of the instruments and poor dissection. An
experience assistant is required in such cases. The CLASSIC trial reported increased rate of
positive circumferential margin after laparoscopic rectal surgery (12%) in comparison to the
open group (6%). The distant margin of the tumor is difficult to be identified, as it cannot be
palpated. This may cause inadequate distal resection.
Figure 1. Laparoscopic resection of rectal cancer –anterior mobilization of the rectum
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The use of laparoscopic stapler requires multiple firings to complete distal rectal resection. In
the case of low rectal anastomoses, this increases the anastomotic leakage rate (17% below
12cm from the anal verge [11], 20% below 15cm [23]. The leakage rate after open total meso‐
rectal dissection varies from 4% to 11% [25, 26]. Future improvement of the stapler technology
is required.
Figure 2. Lymph node dissection in laparoscopic rectal cancer resection
The proven benefits of laparoscopy noted in colon cancer surgery including decreased
intraoperative blood loss, smaller length of incision, less postoperative pain, faster recovery
of intestinal function, and shorter length of hospital stay likely also apply to rectal cancer
surgery [37]. In RCTs the mean operative time for open surgical resection of rectal cancer
ranged from 106 to 284 min compared to 120 to 245 min for laparoscopic resection. As expected,
duration of operation was significantly longer in the laparoscopic group compared to the open
group in 6 of the 8 RCTs [7, 22, 31, 38-40]. Similar results were reported in RCTs of open vs
laparoscopic resection for colon cancer. Zhou et al [24] reported both shorter open and
laparoscopic operative times compared to other trials with no significant difference between
the two operative approaches (120 min vs 106 min for laparoscopic vs open resection respec‐
tively, P= 0.051). However, no details were provided on tumor stage, conversion rate, or
whether the analysis was performed on an intent-to-treat basis. Araujo et al [25] was the only
RCT to demonstrate significantly shorter operative times with laparoscopic compared to open
resection (228 min vs 284 min respectively, P = 0.04). However, they attributed these results to
fact that the surgical team performing laparoscopic APR was the same whereas open APR was
often performed by different surgical teams. In addition, extraction of the specimen from the
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perineum likely decreased operative time because there was not an abdominal incision to close.
Two meta-analyses included operative time as an outcome of interest. Aziz et al [17] included
22 studies comparing laparoscopic vs open rectal cancer resection in 2071 patients and found
that operative time was significantly increased with the laparoscopic group as compared to
the open group with a weighted mean difference (WMD) of 40.18 (95% CI, 26.46-56.13). Gao
et al [26] performed a meta-analysis of short-term outcomes after laparoscopic resection for
rectal cancer based on 11 studies and included 643 patients which reported no difference in
operating time between open and laparoscopic approaches with a WMD of 1.59 [1.2-1.98].
Intraoperative blood loss was significantly less for the laparoscopic group compared to the
open group in 4 of 6 RCTs and ranged from 20 mL to 321.7 mL and from 92 mL to 555.6 mL in
the laparoscopic and open groups respectively [31, 35, 38, 40]. Araujo et al [25] did not
specifically report on the amount of intraoperative blood loss but there was no statistically
significant difference in the need for blood transfusions between the two groups which was
attributed to the fact that in an APR the majority of blood loss occurs during the perineal
portion of the case which is the same regardless of surgical access.
A recent Cochrane review by Breukink et al [41] evaluating the safety and efficacy of elective
laparoscopic TME for the resection of rectal cancer found that in the majority of studies blood
loss was reduced with the laparoscopic approach although this did not translate to fewer blood
transfusions. Length of incision was measured in 3 of 8 RCTs and ranged from an average of
5 cm to 10 cm with the laparoscopic approach compared to an average of 19.1 cm to 22 cm with
the open approach [7, 38, 40]. Seven of the 8 trials reported a conversion rate which ranged
from 0%-34% [7, 38-40]. Conversion to the open approach was commonly defined as length of
incision greater than the size needed for tumor extraction or premature abdominal incision to
allow improved mobilization. In the majority of studies conversion to open surgery was
required because of local tumor invasion or difficult dissection in a narrow pelvis although
bulky tumor, dilated small bowel, dense adhesions, bleeding, rectal perforation, difficulty
mobilizing the splenic flexure, failure to identify or injury to the ureter, ischemia of the
descending colon, and anastomotic failure were also cited. Breukink et al [41] reported that 36
of 48 studies assessed conversion and showed a highly variable rate ranging from 0% to 33%.
However, they report that the lack of consensus in the definition made results difficult to
interpret. In addition, surgeon experience and patient selection criteria were often not
mentioned. Two trials reported particularly high rates of conversion. Ng et al [37] had a
conversion rate of 30.3% but they did not routinely perform preoperative staging with
computed tomography scans and therefore frequently converted after diagnostic laparoscopy.
Twelve of the 23 patients randomized to laparoscopic surgery were converted to open due to
local tumor invasion, bulky tumor, or dilated small bowel which may have been recognized
by preoperative imaging. In the CLASICC trial the conversion rate for laparoscopic resection
of rectal cancer was reported at 34% and attributed to excessive tumor fixation and uncertainty
of tumor clearance [6]. Surgeon learning curve may account for this high rate of conversion as
evidenced by the fact that the overall rate of conversion dropped by year of study from 38%
in year one to 16% in year six. However, consistent with several non-randomized reports, in
the CLASICC trial patients converted to open resection had a higher operative mortality
compared to patients in the laparoscopic or open groups (9% vs 1% vs 5% respectively) [6].
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Conversion was also associated with worse oncologic outcomes in nonrandomized compara‐
tive and descriptive studies [46].
Figure 3. Total mesorectal excision after laparoscopic rectal resection
10. Short-term oncologic outcomes
While the number of lymph nodes retrieved can vary based on age, gender, tumor site, use of
pre-operative radiation, and tumor grade, the extent and quality of surgical resection can also
have an impact on the number of nodes collected and is therefore often considered a surrogate
marker of the oncologic completeness of the resection [37]. The American Joint Committee on
Cancer recommends that at least 12 lymph nodes be examined in patients with rectal cancer
to confirm the absence of nodal involvement by the tumor [34]. In addition, a number of studies
have reported that the number of lymph nodes examined may be associated with patient
outcome [25, 26]. Six of the 8 RCTs reported the mean number of lymph nodes retrieved with
a range of 5.5 to 17 nodes in the laparoscopic group compared to 11.6 to 18 nodes in the open
group [22, 31, 34]. In 4 of the 6 trials the number of lymph nodes isolated was not significantly
different based on surgical approach. Araujo et al [25] reported a significantly lower yield of
lymph nodes with laparoscopic rectal resection compared to open resection (5.5 vs 11.9
respectively, P = 0.04). They suggested that laparoscopy offered better dissection and accuracy
due to better visualization and exposure of structures with less manipulation of the mesorec‐
Laparoscopy in the Management of Colorectal Cancer
http://dx.doi.org/10.5772/56913
113
perineum likely decreased operative time because there was not an abdominal incision to close.
Two meta-analyses included operative time as an outcome of interest. Aziz et al [17] included
22 studies comparing laparoscopic vs open rectal cancer resection in 2071 patients and found
that operative time was significantly increased with the laparoscopic group as compared to
the open group with a weighted mean difference (WMD) of 40.18 (95% CI, 26.46-56.13). Gao
et al [26] performed a meta-analysis of short-term outcomes after laparoscopic resection for
rectal cancer based on 11 studies and included 643 patients which reported no difference in
operating time between open and laparoscopic approaches with a WMD of 1.59 [1.2-1.98].
Intraoperative blood loss was significantly less for the laparoscopic group compared to the
open group in 4 of 6 RCTs and ranged from 20 mL to 321.7 mL and from 92 mL to 555.6 mL in
the laparoscopic and open groups respectively [31, 35, 38, 40]. Araujo et al [25] did not
specifically report on the amount of intraoperative blood loss but there was no statistically
significant difference in the need for blood transfusions between the two groups which was
attributed to the fact that in an APR the majority of blood loss occurs during the perineal
portion of the case which is the same regardless of surgical access.
A recent Cochrane review by Breukink et al [41] evaluating the safety and efficacy of elective
laparoscopic TME for the resection of rectal cancer found that in the majority of studies blood
loss was reduced with the laparoscopic approach although this did not translate to fewer blood
transfusions. Length of incision was measured in 3 of 8 RCTs and ranged from an average of
5 cm to 10 cm with the laparoscopic approach compared to an average of 19.1 cm to 22 cm with
the open approach [7, 38, 40]. Seven of the 8 trials reported a conversion rate which ranged
from 0%-34% [7, 38-40]. Conversion to the open approach was commonly defined as length of
incision greater than the size needed for tumor extraction or premature abdominal incision to
allow improved mobilization. In the majority of studies conversion to open surgery was
required because of local tumor invasion or difficult dissection in a narrow pelvis although
bulky tumor, dilated small bowel, dense adhesions, bleeding, rectal perforation, difficulty
mobilizing the splenic flexure, failure to identify or injury to the ureter, ischemia of the
descending colon, and anastomotic failure were also cited. Breukink et al [41] reported that 36
of 48 studies assessed conversion and showed a highly variable rate ranging from 0% to 33%.
However, they report that the lack of consensus in the definition made results difficult to
interpret. In addition, surgeon experience and patient selection criteria were often not
mentioned. Two trials reported particularly high rates of conversion. Ng et al [37] had a
conversion rate of 30.3% but they did not routinely perform preoperative staging with
computed tomography scans and therefore frequently converted after diagnostic laparoscopy.
Twelve of the 23 patients randomized to laparoscopic surgery were converted to open due to
local tumor invasion, bulky tumor, or dilated small bowel which may have been recognized
by preoperative imaging. In the CLASICC trial the conversion rate for laparoscopic resection
of rectal cancer was reported at 34% and attributed to excessive tumor fixation and uncertainty
of tumor clearance [6]. Surgeon learning curve may account for this high rate of conversion as
evidenced by the fact that the overall rate of conversion dropped by year of study from 38%
in year one to 16% in year six. However, consistent with several non-randomized reports, in
the CLASICC trial patients converted to open resection had a higher operative mortality
compared to patients in the laparoscopic or open groups (9% vs 1% vs 5% respectively) [6].
Colorectal Cancer - Surgery, Diagnostics and Treatment112
Conversion was also associated with worse oncologic outcomes in nonrandomized compara‐
tive and descriptive studies [46].
Figure 3. Total mesorectal excision after laparoscopic rectal resection
10. Short-term oncologic outcomes
While the number of lymph nodes retrieved can vary based on age, gender, tumor site, use of
pre-operative radiation, and tumor grade, the extent and quality of surgical resection can also
have an impact on the number of nodes collected and is therefore often considered a surrogate
marker of the oncologic completeness of the resection [37]. The American Joint Committee on
Cancer recommends that at least 12 lymph nodes be examined in patients with rectal cancer
to confirm the absence of nodal involvement by the tumor [34]. In addition, a number of studies
have reported that the number of lymph nodes examined may be associated with patient
outcome [25, 26]. Six of the 8 RCTs reported the mean number of lymph nodes retrieved with
a range of 5.5 to 17 nodes in the laparoscopic group compared to 11.6 to 18 nodes in the open
group [22, 31, 34]. In 4 of the 6 trials the number of lymph nodes isolated was not significantly
different based on surgical approach. Araujo et al [25] reported a significantly lower yield of
lymph nodes with laparoscopic rectal resection compared to open resection (5.5 vs 11.9
respectively, P = 0.04). They suggested that laparoscopy offered better dissection and accuracy
due to better visualization and exposure of structures with less manipulation of the mesorec‐
Laparoscopy in the Management of Colorectal Cancer
http://dx.doi.org/10.5772/56913
113
tum especially in a narrow pelvis. Four of the 8 RCTs reported the use of pre-operative
chemoradiation. In these trials, the mean number of lymph nodes retrieved ranged from 5.5
to 17 nodes in the laparoscopic group and from 11.6 to 18 nodes in the open group [31, 34, 38,
40]. Some authors [37] found that in the 17 trials that reported the number of lymph nodes
retrieved, the mean number of nodes was 10 for the laparoscopic group and 12 for the open
group (P = 0.001) with the majority of trials reporting a median of 11 or fewer nodes obtained.
In 9 of these 17 trials, both groups were treated with preoperative radiation therapy and
reported a mean of 10 lymph nodes harvested in the laparoscopic group and 11 in the open
group. One of the greatest concerns of laparoscopic TME is that obtaining a complete oncologic
resection will be more difficult. Involvement of the circumferential or distal margin is one of
the most important prognostic factors in rectal resection with TME and can lead to an increase
in local recurrence and a reduction in survival. Radial margins of less than 2 mm are associated
with a local recurrence rate of 16% compared to a significantly reduced local recurrence rate
of 6% with margins greater than 2 mm [27]. Six of the 8 RCTs reported the involvement of the
CRM and no difference was found by surgical approach [7, 31, 38-40, 45]. In the majority of
trials the rate of CRM involvement was less than 5%. Patients with positive radial margins
often had tumor invading the pelvic side wall or adjacent structure and were frequently
converted from a laparoscopic to an open procedure [39]. In the CLASICC study, the only
multicenter trial, a positive CRM was identified in 14 of 97 (14%) patients with open surgery
and in 30 of 193 (16%) patients with laparoscopic rectal resection [6]. Of patients undergoing
anterior resection, the CRM was positive in 16 of 129 (12%) individuals in the laparoscopic
group and in 4 of 64 (6%) individuals in the open group. While there is a non-significant higher
positivity of the CRM in the laparoscopic anterior resection group, this is once again likely due
to the fact that the learning curve was not completed before the start of this study. Two RCTs
reported on distal margin status and the incidence of distal margin positivity was not signif‐
icantly different between the two surgical approaches and in fact was 0% [3, 31]. All 3 meta-
analyses and the Cochrane review by Breukink et al [41] found no difference in positive margins
based on surgical access.
11. Postoperative course
Less postoperative pain, faster recovery of intestinal function, and shorter length of stay are
important benefits of laparoscopic colorectal surgery. Only 3 of 8 RCTs compared the exact
amount of post-operative pain medication and 2 of these studies reported a significant
reduction in analgesic use in the laparoscopic group [39, 40, 45]. Zhou et al [24] did not quantify
the exact usage of pain medication, but found no significant difference in the number of days
parental analgesics were necessary (4.1 vs 3.9 in the open and laparoscopic groups respective‐
ly). Resumption of bowel function was usually reported on post-operative days 3 to 5 and
ability to tolerate a solid food diet was reported on post-operative days 3 to 6 [7, 31, 35, 39, 40,
45]. In the majority of RCTs earlier bowel movements and diet advancement was reported with
the laparoscopic approach. The return of bowel function and reduction in wound pain was
thought to contribute to earlier discharge after laparoscopic surgery. While in a majority of
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trials, the length of stay was not significantly different between surgical approaches, there was
a trend toward decreased length of stay with laparoscopic rectal surgery. Breukink et al [41]
found that laparoscopic TME resulted in earlier return of normal diet, less pain, less narcotic
use and a shorter hospital stay.
12. Complications
Rectal cancer surgery is associated with a high rate of morbidity and mortality. Post-operative
mortality in RCTs ranged from 1%-4% and demonstrated no statistically significant difference
based on surgical approach. The rate of post-operative complications ranged from 6% to 69%
and with the exception of Zhou et al [24] did not differ significantly between laparoscopic and
open groups. Wound infection and urinary tract infection accounted for the majority of
perioperative complications in both groups. There was a higher incidence of wound infection
with the open approach however this did not reach statistical significance. Breukink et al [41]
found no difference in morbidity between the laparoscopic and open groups although there
was a trend toward lower morbidity with laparoscopic TME. Aziz et al [17] found no difference
in perioperative morbidity between the 2 groups while Gao et al [26] found that the overall
morbidity rate of the laparoscopic group was significantly lower than that of the open group.
Anastomotic leak is the most serious complication after sphincter sparing rectal cancer
resection especially with neoadjuvant chemoradiation. In addition, development of an
anastomotic leak is reported to be associated with decreased long-term survival and higher
rates of local recurrence after curative resection for colorectal cancer [39-43]. Operative
expertise and selective diversion in high risk patients has resulted in a anastomotic leak rate
of 1%-17% in most published series studying laparoscopic resection for rectal cancer [29, 30].
Consistent with reports from non-randomized comparative trials, RCTs demonstrated no
significant difference in the incidence of anastomotic leak between the laparoscopic and open
technique for the resection of rectal cancer. While the incidence of perioperative morbidity was
not different based on surgical access, fewer patients had long-term complications with
laparoscopic rectal cancer resection compared to the open approach. Adhesion related bowel
obstruction was the most common longterm morbidity. With a median follow-up of greater
than 9 years, Ng et al [37] found that adhesion-related obstruction requiring hospitalization
(18.9% vs 2.7%) and reoperation (6.8% vs 0%) was higher in the open group. They report a
cumulative probability of adhesion-related bowel obstruction at 10 years of 20.5% in the open
group and 3.9% in the laparoscopic group. [45] Data on long-term complications was not
separated by site of disease but the overall occurrence of incisional hernia (7.9% vs 10.9%, P =
0.32) and reoperation for adhesions (1.1% vs 2.5%, P = 0.30) was not statistically difference
between laparoscopic and open resection. Long-term studies need to be done to determine if
laparoscopy decreases the incidence of intra-abdominal adhesion formation by reduced
surgical trauma, less tissue handling, and smaller incisions.
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The initial reports of the long-term outcomes after laparoscopic surgery for rectal cancer were
discouraging. Several randomized trials report of the rate of positive circumferential radial
margin in the laparoscopic group in comparison to the open group (12-5.9% and 6-4.2%,
respectively). The 3-year follow-up did not establish higher local recurrence rate – 7.0% and
7.8%, respectively. The local recurrence rate after laparoscopic and open abdomino-perineal
resection were 15.1% and 21.1%, respectively. The overall disease-free survival rate was also
similar after laparoscopic and open anterior resection 70.9% and 70.4% and APR – 49.8% and
46.9%. Other data demonstrated 5-year disease survival reaching 83.7% for laparoscopic and
80.4% for open surgery. According to a meta-analysis of 20 laparoscopic rectal cancer studies
between 1993 and 2004, including over 2000 patients, there is no significant difference in the
number of harvested lymph nodes [22]. Despite the encouraging results, the laparoscopic rectal
surgery could be fully evaluated only after long-term results are available. The ongoing studies
are the American College of Surgeons Oncology Group (ACOSOG) Z6051 trial from the U.S.;
the COLOR II trial from Europe, Canada, and Asia; and the Japanese Japan Clinical Oncology
Group (JCOG) 0040 trial.
A number of the clinical trials were performed to determine the safety and feasibility of the
laparoscopic approach for rectal adenocarcinoma and therefore the data we have for long-term
outcomes is limited [5]. Braga et al [48] found no difference in local recurrence (4.0% in the
laparoscopic group vs 5.2% in the open group, P= 0.97), overall five-year survival, or disease
free five-year survival based on surgical approach. With a median follow-up of 87.2 mo in the
laparoscopic group and 90.1 mo in the open group, Ng et al [45] demonstrated that after
curative resection, the probability of five-year survival was 75.2% vs 76.5% for laparoscopic
vs open APR respectively (P = 0.20). In addition, stage-by-stage comparison for the two groups
showed no statistical difference. There were no port site recurrences and overall recurrence
rates were not significantly different between the two groups (laparoscopic 20% vs open 25%,
P = 0.60). Despite the higher rate of circumferential margin positivity in patients undergoing
laparoscopic anterior resection in the CLASICC trial, there was no difference in local recur‐
rence, three- year overall or three-year disease free survival between the two approaches (open
OS 66.7% and laparoscopic OS 74.6%, P = 0.17; open DFS 70.4% and laparoscopic DFS 70.9%,
P = 0.72; open LR 7.0% and laparoscopic LR 7.98%, P = 0.70) [6]. In addition, there was no
significant difference in the rates of local recurrence, three-year overall survival, or three-year
disease-free survival in patients undergoing laparoscopic vs open APR [12]. However, the
sample size is small and therefore larger studies are needed for conclusive results. Ng et al [37]
published results of a randomized trial of laparoscopic vs open anterior resection for upper
rectal cancer with a median follow-up of 9 years. No difference in local recurrence, overall
survival, or disease-free survival was reported. Although these studies suggest comparative
oncologic outcomes between laparoscopic and open rectal cancer resection, they include small
sample sizes and are almost all are single institution studies, highlighting the need for large,
multi-center RCTs to provide confirmatory data. With a mean follow-up of 35 mo for both
groups, overall local recurrence was not statistically different between the 2 groups (laparo‐
scopic 7% vs open 8%, P = NS). Eleven studies provided sufficient data to compare overall
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survival. Overall survival was 72% for patients undergoing laparoscopic rectal cancer resection
and 65% for open resection at an average of 4.4 years (P = 0.5). Subset analysis by [36] dem‐
onstrated no significant difference between laparoscopic and open rectal cancer resection in
terms of local recurrence (laparoscopic 7.2% vs open 7.8%, P = 0.46), development of distant
metastases (laparoscopic 13.5% vs open 9.1%, P = 0.60), or cancer-related mortality (laparo‐
scopic 9% vs open 10%, P = 0.16). While, this data is encouraging, it is no conclusive.
14. Hybrid and hand-assisted laparoscopic rectal surgery
Some authors have introduced a new method of hybrid rectal surgery, aiming to combine the
benefits of open and laparoscopic approach. The colonic mobilization is performed laparos‐
copically, while the rectal dissection is performed through a Pfannenstiel incision. A retro‐
spective review established significantly longer hospital stay after hybrid procedures than
after open procedures [27].
Another method is the hand-assisted laparoscopic surgery. A special access device for the hand
is introduced in the abdomen. Compared with fully open techniques this method provides
shorter operative time. High ligation of vessels, splenic flexure takedown, and lateral mobili‐
zation may be accomplished in a shorter period time with a hand-assisted technique. In hand-
assisted laparoscopic surgery, rectal exposure and dissection can be either performed directly
through the incision using the open techniques or laparoscopically with manual assistance
[28]. This method combines the excellent laparoscopic view and the dissection techniques in
open surgery and provides tactile sensation.
By performing distal rectal division directly through the incision using the open surgical
staplers, hand-assisted laparoscopic rectal surgery may result in a lower anastomotic leakage
rate.
15. Summary
After rigorous evaluation the laparoscopic surgery for colon cancer has become the gold
standard. Laparoscopic colon resection for cancer, in experienced hands, can be performed safely
and reliably with many short-term benefits to the patients while resulting in at least equiva‐
lent long-term outcomes as open surgery, which is supported by level 1 data. In conclusion,
RCTs have demonstrated that laparoscopy does not adversely affect cancer related survival in
patients with adenocarcinoma of the colon. Concerns about the technical difficulty of TME may
have contributed to the exclusion of rectal cancer patients from most of these large multicen‐
ter RCTs resulting in little data on oncologic outcomes with laparoscopic rectal cancer resec‐
tion. Laparoscopic rectal dissection is technically more demanding than open and constraints
of a narrow pelvis may result in difficulty assessing and obtaining adequate surgical margins.
However, there are several proposed benefits of laparoscopic rectal resection. A clear and
magnified view of the pelvis provided by the improved optics of laparoscopy may aid sharp
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lent long-term outcomes as open surgery, which is supported by level 1 data. In conclusion,
RCTs have demonstrated that laparoscopy does not adversely affect cancer related survival in
patients with adenocarcinoma of the colon. Concerns about the technical difficulty of TME may
have contributed to the exclusion of rectal cancer patients from most of these large multicen‐
ter RCTs resulting in little data on oncologic outcomes with laparoscopic rectal cancer resec‐
tion. Laparoscopic rectal dissection is technically more demanding than open and constraints
of a narrow pelvis may result in difficulty assessing and obtaining adequate surgical margins.
However, there are several proposed benefits of laparoscopic rectal resection. A clear and
magnified view of the pelvis provided by the improved optics of laparoscopy may aid sharp
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dissection for TME and assist in identification of vital pelvic structures including the ureters and
autonomic nerves. In addition, pneumoperitoneum may separate the parietal and visceral fascia
of the mesorectum facilitating dissection in this plane. Laparoscopic rectal cancer resection has
a steep learning curve but increased experience with both open and laparoscopic TME will lead
to shorter operating times and decreased morbidity. Current data suggests that laparoscopic
rectal cancer resection may benefit patients because of reduced blood loss, earlier return of bowel
function, and shorter hospital length of stay. Concerns that laparoscopic rectal cancer surgery
may compromise short-term oncologic outcomes including number of lymph nodes harvest‐
ed and CRM positivity do not appear to be supported by the available literature. However, there
is a paucity of data concerning long-term oncologic outcomes and complications with laparo‐
scopic rectal cancer surgery. There are two large, multicenter RCTs that are currently being
conducted: the COLOR II trial in Europe and the ACOSOG-Z6051 trial in the United States. Both
of these studies are comparing the laparoscopic and open approach for treatment of resectable
rectal cancer. Results from these trials will provide information on the long-term outcomes of
laparoscopic rectal cancer resection and are eagerly awaited. In view of the lack of level one data
on oncologic outcomes, laparoscopic TME for locally advanced, curable rectal cancer should
only be performed within the confines of a RCT.
Other potential, but less conclusively demonstrated benefits include better preservation of cell-
mediated immune function and reduced tumor cell proliferation. Although a similar level of
evidence does not yet exist for the laparoscopic rectal surgery for cancer, the evidence to date
suggests that it is likely that the ongoing large randomized trials will demonstrate clinical
benefits of laparoscopic rectal cancer surgery. New devices for minimizing of the abdominal
trauma are being developed. The steep learning curve, cost and difficult training are still
hindrance to the wide use of laparoscopic colon surgery.
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1. Introduction
The laparoscopic technique has been enthusiastically applied to the resection of colorectal
cancer for more than 15 years [1]. There is evidence that laparoscopy for colorectal cancer offers
the opportunity for a meticulous dissection of the mesocolon and mesorectum under direct
vision while facilitating a true no-touch technique [2]. Additional benefits, such as less
postoperative pain, reduced need for postoperative analgesia, less ileus, shorter hospital stay,
less blood loss, and better cosmesis are also well documented [3,4].
During recent years, great effort has been made to minimize parietal trauma for cosmetic
reasons and to further reduce surgery-related pain and morbidity. New techniques, such as
natural orifice transluminal endoscopic surgery (NOTES) [5] have been developed in order to
reach the goal of “scarless” surgery. Although NOTES actually allows for no scarring of the
body surface, it has several disadvantages and limitations with the currently available
instruments, including limited access, less familiar working angles and operative approaches.
Furthermore, it is associated with possible complications caused by opening of the stomach,
colon or vagina, and may not be fully suitable or safe for advanced procedures, such as
colectomies [6].
Single incision laparoscopic surgery (SILS) is currently regarded as the next major advance in
minimally invasive surgical approaches to colorectal disease that is more feasible for general‐
ized use [7-10]. SILS reduces the invasiveness of laparoscopic conventional surgery (LCS) by
decreasing the number of incisions and ports through the abdominal wall. This theoretically
could provide important clinical advantages, including less postoperative pain, reduction of
port-site associated morbidity (such as wound infection, bleeding, visceral injury and port site
herniation), quicker recovery and shorter hospital stay. The small incision through the
abdominal wall allows for “scarless” surgery as the wound is usually hidden within the
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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umbilicus, thus providing potentially better cosmesis. Moreover, SILS permits surgeons to use
familiar standard laparoscopic instruments but also perform complex procedures, such as
colorectal operations, which require extraction of large surgical specimens or intestinal
anastomosis.
2. Technical aspects of SILS
SILS was first reported in 1992 by gynecologists who performed single-incision hysterectomy
[11]. The performance of the first transumbilical cholecystectomy was published in 1999 [12]
and the first single-incision appendectomy was reported in 1998 [13]. The use of SILS in
colorectal surgery was first reported in 2008 by Remzi and co-workers [8] and Bucher and
colleagues [14].
Since these first reports, it has been evident that SILS raises a number of specific new challenges
compared with LCS. The skills required for SILS are different from those needed in conven‐
tional multiport laparoscopy, even for experienced laparoscopic surgeons [15]. The handling
of straight instruments in parallel with the laparoscope through a small single incision
decreases the freedom of movement for the surgeon, and complicates the holding of the
laparoscope for the assistant and instruments for the surgeon. The most outstanding technical
challenges involved in SILS are the following:
1. Loss of triangulation with straight instruments: the loss of this dogmatic principle of
laparoscopic surgery often imposes the need to operate with crossed hands and does not
allow an ergonomically favorable position for the surgeon and assistants. The inherent
technical challenge is that the visual axis becomes more axial or in-line, so a movement of
the camera often results in a inadvertent movement of an adjacent instrument, thus
increasing the difficulty of performing even relatively simple tasks.
2. Restricted number of working instruments and thus difficulty of achieving correct
exposure and the necessary traction to tissues.
3. Restricted external working space: the multiple instruments and laparoscopes required
for a procedure are competing for the same space at the fulcrum of the entry port, causing
external hand collisions and difficulty with instrument tip manipulation internally.
4. Difficulty in maintaining pneumoperitoneum.
5. Requirement of training and adjustment.
New operative hardware is being developed to facilitate the technique [16]. Many of the big
healthcare manufacturers have developed multilumen access devices to allow for the insertion
of several instruments through a single large fascial incision (Figure 1).
Initially, these devices offered three openings with limited gas inflow and outflow, but we
are  now  seeing  revision  of  the  devices,  incorporating  more  access  ports  so  standard
laparoscopic  dissection  techniques  can  be  utilized.  Newly  designed  equipment,  such  as
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articulating or curved instruments and flexible scopes,  have been introduced to recreate
triangulation (Figure 2).
Figure 2. Articulating and curved instruments for SILS: (a) SILS Hand Instrument (Covidien, Norwalk, Connecticut,
USA); (b) The Cuschieri Coaxial Deviating Instruments (Karl Storz, Tuttlingen, Germany); (c) Cambridge Endo Instru‐
ments (Cambridge Endoscopic Devices, Framingham, Massachusetts, USA).
Figure 1. Single port systems: (a) Uni-x (Pnavel Systems, Morganville, New Jersey, USA); (b) X-Cone (Karl Storz, Tuttlin‐
gen, Germany); (c) Endo-Cone (Karl Storz, Tuttlingen, Germany); (d) SILS Port (Covidien, Norwalk, Connecticut, USA);
(e) Olympus TriPort + (Advanced Surgical Concepts, Bray, Ireland.
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New operative hardware is being developed to facilitate the technique [16]. Many of the big
healthcare manufacturers have developed multilumen access devices to allow for the insertion
of several instruments through a single large fascial incision (Figure 1).
Initially, these devices offered three openings with limited gas inflow and outflow, but we
are  now  seeing  revision  of  the  devices,  incorporating  more  access  ports  so  standard
laparoscopic  dissection  techniques  can  be  utilized.  Newly  designed  equipment,  such  as
Colorectal Cancer - Surgery, Diagnostics and Treatment126
articulating or curved instruments and flexible scopes,  have been introduced to recreate
triangulation (Figure 2).
Figure 2. Articulating and curved instruments for SILS: (a) SILS Hand Instrument (Covidien, Norwalk, Connecticut,
USA); (b) The Cuschieri Coaxial Deviating Instruments (Karl Storz, Tuttlingen, Germany); (c) Cambridge Endo Instru‐
ments (Cambridge Endoscopic Devices, Framingham, Massachusetts, USA).
Figure 1. Single port systems: (a) Uni-x (Pnavel Systems, Morganville, New Jersey, USA); (b) X-Cone (Karl Storz, Tuttlin‐
gen, Germany); (c) Endo-Cone (Karl Storz, Tuttlingen, Germany); (d) SILS Port (Covidien, Norwalk, Connecticut, USA);
(e) Olympus TriPort + (Advanced Surgical Concepts, Bray, Ireland.
Single-Incision Laparoscopic Colectomy: A New Era in the Treatment of Colorectal Cancer?
http://dx.doi.org/10.5772/56871
127
Moreover, the introduction of an extra-long, 5 mm laparoscope allows placement of the camera
on a different plane from the other instruments and help in moving the operator’s hand further
apart to avoid handle collision (Figure 3) [17]. All these devices have made single site surgery
easier and more efficient.
Figure 3. Extra-long, 5 mm, 30° laparoscope (Karl Storz, Tuttlingen, Germany).
3. Feasibility and safety of single-incision colectomy
All the challenges encountered with single-port surgery are magnified with colorectal
procedures. Unlike laparoscopic cholecystectomy or appendicectomy, which involve surgery
in only one abdominal quadrant, single-incision laparoscopic colectomy often requires
operating in different abdominal quadrants. In addition, the need for adequate oncological
margins and the creation of a tension-free anastomosis are essential. Although the use of this
new approach for complex colorectal procedures might understandingly be viewed as difficult
to implement, over the past few years there has been significant interest in SILS for colonic
resections in both benign and malignant conditions. In fact, between 2008 and 2012, a nearly
7-fold increase occurred in the number of articles related to single-port colorectal surgery
[18-20]. Unfortunately, the currently available literature relating to the technique includes
mostly case reports or small case series describing the feasibility, safety and technical difficul‐
ties of different operations [21-42]. There are very few studies comparing SILS to LCS and there
is a need for randomized controlled trials to definitively establish that SILS is no different from
standard laparoscopic surgery in terms of completion rates, complications and oncological
adequacy but with the advantage of being more cosmetic with subsequently reduced mor‐
bidities including pain [43]. The studies published to date have a number of other flaws limiting
their impact. These include low sample size, selection bias and difficulty in blinding the
patients enrolled. The vast majority of studies involve a very carefully selected SILS cohort of
uncomplicated cases, which significantly limits their generalization.
The most significant datum emerging from the literature is that colonic SILS has been offered
to date to a highly selected group of patients [18,19]. This selection is based on two main
parameters: body mass index (BMI) that is an indirect measure of visceral fat, and tumor site,
that is directly linked to the type of surgical procedure.
It is well known that visceral fat is one the most critical factors in the identification of the correct
surgical plane in laparoscopic surgery [44]. This concept is obviously amplified in SILS and
visceral obesity is reported as the primary cause of conversion to multiport laparoscopy in
most studies [45]. Therefore it is understandable that most patients who are candidates for this
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type of surgery had a low BMI. Makino et al. [18] have reviewed 23 studies with a total of 378
patients undergoing single-port colectomy. The mean value of BMI was 25.5 kg/m2 in these
patients. Similar results have been found by Fung et al. [19] in their recent review. These
authors have analyzed 38 colonic SILS articles containing 565 patients and the median BMI
was 25.8 kg/m2. On the basis of these findings, some studies have suggested the use of
preoperative abdominal computed tomography to predict accurately the pattern of visceral
fat, allowing better selection of patients for SILS colectomy and reducing the number of
conversions [44].
The other factor that has markedly influenced the currently available data on SILS for colorectal
cancer is the type of surgical procedure. Makino et al. [18] have reported that 279 (73.8%) of
the 378 procedures analyzed in their review were right hemicolectomy, followed by sigmoi‐
dectomy (n = 27), performed essentially for diverticular disease, and anterior resection of the
rectum (n = 20). Moreover, a high number of published studies have specifically limited the
analysis of safety, feasibility and short-term results to only single-port right hemicolectomy
[14,25,32-38,42,45-48], thus demonstrating that this type of procedure is the least complex to
perform with the single-port technique at the beginning of the experience. Actually, right
hemicolectomy involves surgery only in one/two quadrants while left procedures require
operating in a multitude of different and opposite abdominal quadrants, from the hypochon‐
drium for splenic flexure mobilization to the pelvis for a total mesorectal excision (TME).
Moreover, in right hemicolectomy the surgeon has the possibility of creating an extracorporeal
intestinal anastomosis through umbilical access while in left colectomies and anterior resection
of the rectum the anastomosis is intracorporeal, thus augmenting the complexity of the
procedure.
These considerations clearly show that there is an inevitable case-selection bias in assessing
the outcomes of colo-rectal SILS from published studies. Although randomized controlled
trials comparing single-port and multi-port right hemicolectomy have not been reported yet,
the most significant data available to date relate to this type of procedure. In 2012, the two
largest experiences with single-port right hemicolectomies in a single institution have been
reported. Waters et al. [49] analyzed the short-term outcomes with single-incision right
hemicolectomy in 100 patients. Operative indications were oncological in 92 patients, 57 for
adenocarcinoma and 35 for polyps not suitable for endoscopic removal. Morbidity (13%) and
mortality (1%) rates were acceptable as well as operative time (median value, 105 minutes)
and conversion rate to multiport or open procedures (2% and 4%, respectively). Most impor‐
tantly, there was no compromise of oncological adequacy with no positive tumor margins and
a mean number of 18 lymph nodes retrieved and examined in the surgical specimens.
Interestingly, patients with a wide range of BMI measurements were offered single-incision
right hemicolectomy, with the largest approaching superobesity at a BMI of 46 kg/m2 and a
mean patient BMI of 28. Unfortunately, no results regarding postoperative pain, cosmetic
results or direct comparison with the multi-port laparoscopic approach were reported.
Chew et al. [50] have reported the short outcomes of single-incision laparoscopic hemicolec‐
tomy in 40 consecutive patients. These results were compared with those of 104 conventional
laparoscopic hemicolectomies. Indications for surgery were oncological in the majority of
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rectum (n = 20). Moreover, a high number of published studies have specifically limited the
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hemicolectomy involves surgery only in one/two quadrants while left procedures require
operating in a multitude of different and opposite abdominal quadrants, from the hypochon‐
drium for splenic flexure mobilization to the pelvis for a total mesorectal excision (TME).
Moreover, in right hemicolectomy the surgeon has the possibility of creating an extracorporeal
intestinal anastomosis through umbilical access while in left colectomies and anterior resection
of the rectum the anastomosis is intracorporeal, thus augmenting the complexity of the
procedure.
These considerations clearly show that there is an inevitable case-selection bias in assessing
the outcomes of colo-rectal SILS from published studies. Although randomized controlled
trials comparing single-port and multi-port right hemicolectomy have not been reported yet,
the most significant data available to date relate to this type of procedure. In 2012, the two
largest experiences with single-port right hemicolectomies in a single institution have been
reported. Waters et al. [49] analyzed the short-term outcomes with single-incision right
hemicolectomy in 100 patients. Operative indications were oncological in 92 patients, 57 for
adenocarcinoma and 35 for polyps not suitable for endoscopic removal. Morbidity (13%) and
mortality (1%) rates were acceptable as well as operative time (median value, 105 minutes)
and conversion rate to multiport or open procedures (2% and 4%, respectively). Most impor‐
tantly, there was no compromise of oncological adequacy with no positive tumor margins and
a mean number of 18 lymph nodes retrieved and examined in the surgical specimens.
Interestingly, patients with a wide range of BMI measurements were offered single-incision
right hemicolectomy, with the largest approaching superobesity at a BMI of 46 kg/m2 and a
mean patient BMI of 28. Unfortunately, no results regarding postoperative pain, cosmetic
results or direct comparison with the multi-port laparoscopic approach were reported.
Chew et al. [50] have reported the short outcomes of single-incision laparoscopic hemicolec‐
tomy in 40 consecutive patients. These results were compared with those of 104 conventional
laparoscopic hemicolectomies. Indications for surgery were oncological in the majority of
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patients in the two groups. The authors found that single-incision right hemicolectomy is a
feasible and safe procedure with equivalent outcomes in terms of operative time, oncological
adequacy, postoperative morbidity, and conversions when compared with conventional
laparoscopic right hemicolectomy. In particular, there were no differences in lymph node
retrieval (median value of 18 and 19 lymph nodes for multi-port and single-port surgery,
respectively) and resection margin clearance.
The data regarding left sided procedures, in particular anterior resection of the rectum for
cancer, are much more limited. This is mainly due to the complexity of these procedures, in
particular some surgical steps such as mobilizing the splenic flexure and dissection of the
mesorectum. The fairly great distance of the spleen and the deep pelvis from the umbilicus
amplify the difficulty of creating instrument triangulation, especially when standard, straight
laparoscopic instruments are used. Even adequate traction of the rectum and stapling proce‐
dures have been associated with technical difficulties and adjunctive methods of traction and
suspension such as transparietal suture, are frequently needed to achieve adequate surgical
exposure [51-56]. Bulut et al. [57] have recently reported their early experience in single-
incision surgery for rectal cancer treatment. This study was conducted on 10, highly selected
patients: the mean tumor diameter was very small (3.2 cm), BMI was ≤25 in all patients and 8
of them were females, thus providing the advantages of a wide pelvis and relative lack of
visceral fat. Although the authors stated that single-incision surgery for rectal cancer can be
performed safely in this kind of patient, the overall mean operation time was quite long (240
min) and 6 patients received stomas (4 had diverting ileostomy after anterior resection of the
rectum and 2 had colostomy after Hartmann procedure and abdominoperineal resection).
Moreover, mesorectum excision was classified as nearly complete in 4 patients and the median
number of examined lymph nodes was quite low, namely 14.
One of the most challenging maneuvers in single-incision rectal surgery is maintaining an
adequate operative field during TME. Uematsu et al. [54] have proposed a new rectum-
suspending system composed of a suspending bar and a bowel clamp with an extracorporeal
magnetic tool. This apparatus, along with single access through the right iliac fossa instead of
the umbilicus, allowed the authors to perform TME and transect the rectum by ensuring a
proper tension. Nevertheless, the proposed new technique is actually complex and, as the
authors stated, is not recommended for males with narrow pelvis or obese individuals or when
mobilization of the splenic flexure is required because of the distance between the spleen and
the single access through the right iliac fossa. Altogether, these data clearly show that some
unresolved issues still remain in performing SILS for the treatment of rectal cancer.
There are more data, which are somewhat more reliable regarding other less complex left-
sided procedures, such as left hemicolectomy or sigmoidectomy [52,58-60]. In fact, sigmoi‐
dectomy is the most frequent procedure performed for benign left-side pathology,
predominantly diverticular disease or large colonic polyps not suitable for endoscopic
removal. Recently, Vestweber et al. [61] have reported the largest series of patients undergoing
single-incision colorectal surgery in a single institution. One hundred and fifty out of 244
procedures were sigmoidectmy (n = 145) with left hemicolectomies (n = 4) and high anterior
resection of the rectum (n = 1). Most of these patients were operated on for diverticular disease
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(n = 142) followed by colonic polyps (n = 4) and colonic cancer (n = 4). The mean operative time
for left-sided procedures was 146 ± 48 min and in all cases standard straight, non-articulating
laparoscopic instruments along with ultrasonic or radiofrequency dissector/sealer were used.
It seems that the authors did not experience any particular technical problems in performing
these types of procedures that do not actually need wide splenic flexure mobilization or
mesorectal dissection. The fairly higher incidence of early postoperative complications (12.6%)
than rates stated in the literature, was imputed to the high rate of severe, complicated diver‐
ticular disease rather than to the complexity of single-incision procedure.
The literature concerning subtotal colectomy or proctocolectomy (with or without ileoanal
anastomosis), at this time consists only of case reports and a few small case series [62-68]. The
predominant indication for this type of operation has been ulcerative colitis followed by
polyposis coli [64,65,67]. Overall, 36 single-incision total colectomies have been reported in the
literature: these studies have demonstrated the feasibility and safety of single-incision
technique even in these more complex colonic procedures but cannot provide any comparative
results with traditional laparoscopy. It is likely that cosmetic results will be magnified by
single-incision total colectomy since patients suffering from ulcerative colitis or polyposis coli
are usually young and may prefer a small incision hidden in the umbilicus. If an ileostomy is
scheduled, the single incision is usually performed in the right lower quadrant of the abdomen
and the terminal ileum is brought out through this port-site, thus minimizing the traumatic
and cosmetic impact of the procedure.
4. Comparison between single-incision and conventional laparoscopic
colectomy
As all these data indicate, there are still several limitations to an analysis of the adequacy of
single-incision technique in the treatment of colorectal cancer. The most important limiting
factor in the interpretation of reported outcomes is the careful selection of patients, with an
almost 3-fold predominance of right-sided pathology, a low to average BMI and non-bulky
colonic disease. If this case-selection bias is taken into account and the oncological adequacy
of a single-incision procedure is hypothetically accepted, this innovation would be justified
only in the presence of clear short-term benefits over conventional laparoscopic colonic
surgery. These benefits should comprise a lower complication rate, reduced postoperative
pain, faster recovery and better cosmesis.
To date, only two randomized trials have compared short-term outcomes after single-incision
and conventional laparoscopic colectomies for colon cancer. In 2011, Huscher et al. [69]
reported the results of a study conducted on 32 patients, with 16 in the single-incision and 16
in the conventional laparoscopic group. Although the authors confirmed the safety and
technical feasibility of single-incision colectomy, they did not show any superiority of the
procedure over conventional laparoscopy in terms of postoperative morbidity, resumption of
oral liquid/solid food intake and length of hospital stay.
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laparoscopic instruments are used. Even adequate traction of the rectum and stapling proce‐
dures have been associated with technical difficulties and adjunctive methods of traction and
suspension such as transparietal suture, are frequently needed to achieve adequate surgical
exposure [51-56]. Bulut et al. [57] have recently reported their early experience in single-
incision surgery for rectal cancer treatment. This study was conducted on 10, highly selected
patients: the mean tumor diameter was very small (3.2 cm), BMI was ≤25 in all patients and 8
of them were females, thus providing the advantages of a wide pelvis and relative lack of
visceral fat. Although the authors stated that single-incision surgery for rectal cancer can be
performed safely in this kind of patient, the overall mean operation time was quite long (240
min) and 6 patients received stomas (4 had diverting ileostomy after anterior resection of the
rectum and 2 had colostomy after Hartmann procedure and abdominoperineal resection).
Moreover, mesorectum excision was classified as nearly complete in 4 patients and the median
number of examined lymph nodes was quite low, namely 14.
One of the most challenging maneuvers in single-incision rectal surgery is maintaining an
adequate operative field during TME. Uematsu et al. [54] have proposed a new rectum-
suspending system composed of a suspending bar and a bowel clamp with an extracorporeal
magnetic tool. This apparatus, along with single access through the right iliac fossa instead of
the umbilicus, allowed the authors to perform TME and transect the rectum by ensuring a
proper tension. Nevertheless, the proposed new technique is actually complex and, as the
authors stated, is not recommended for males with narrow pelvis or obese individuals or when
mobilization of the splenic flexure is required because of the distance between the spleen and
the single access through the right iliac fossa. Altogether, these data clearly show that some
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sided procedures, such as left hemicolectomy or sigmoidectomy [52,58-60]. In fact, sigmoi‐
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To date, only two randomized trials have compared short-term outcomes after single-incision
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More recently, Poon et al. [70] reported findings from a randomized controlled trial, which
enrolled 50 patients, 25 in each study group. As expected, the patients were carefully selected
in regard to BMI (median value, 23.2 kg/m2) and tumor size (< 4 cm). On the contrary, there
was a predominance of left-sided procedures, with 14 anterior resections, 1 sigmoidectomy, 2
left hemicolectomies and only 8 right hemicolectomies in the single-incision group. The
authors did not find any statistically significant difference in operative outcome and oncolog‐
ical adequacy between the single-incision and the conventional laparoscopic group. Interest‐
ingly, they found a lower postoperative pain score and shorter median hospital stay in the
single-incision group. Although these findings emerge from a randomized controlled trial,
they cannot be considered definitive due the low number of patients involved in the study.
Two recent meta-analyses have addressed the issue of comparison between SILS and LCS for
both benign and malignant colorectal diseases [71,72]. Both studies have been published in
2012 and thus have included all the comparative studies published to date with the exception
of the above mentioned randomized trial by Poon et al. Notwithstanding the heterogeneity of
the analyzed studies (14 by Zhou et al. and 15 by Yang et al) in terms of type of procedures
performed, indication for surgery, different patient inclusion and exclusion criteria, neither
meta-analysis found any significant difference in the incidence of postoperative complications
or operative time between single-incision and conventional laparoscopic colectomy. Impor‐
tantly, they show that patients undergoing single-incision colectomy had a significantly
shorter length of hospital stay, significantly shorter incision length, significantly less estimated
blood loss, and significantly more lymph nodes harvested during oncological resections.
Unfortunately, the two pooled analyses were not able to compare the pain score due to lack
of data, the differences in scoring methods and in postoperative care and pain management
in the available reported data. However, at least three studies [48,73,74] show a significant
decrease in pain scores for patients undergoing single-incision colectomy compared to
conventional laparoscopy. The decreased pain score is likely due to less surgical trauma as a
consequence of eliminating the additional ports at separate sites on the abdominal wall. There
is no meta-analysis regarding cosmetic results due to absence of adequate information on this
interesting outcome in the individual studies. Only one study reported cosmetic score results
with an advantage for SILS over LCS [23]. However, it is logical to assume that a shorter final
incision length in single-incision surgery results in improved cosmetic satisfaction for the
majority of the patients.
Another important issue emerging from the literature data is that experienced laparoscopic
surgeons have performed almost all single-incision colectomies. This implies that SILS is
offered not only to a select group of patients but is also performed by a select group of surgeons.
It might appear premature to propose a complex and technically challenging evolution of
conventional laparoscopy colectomy when this has yet to be fully accepted as a gold standard
in the treatment of colorectal cancer [75]. It must be considered that in 2010, only about 20%
of colorectal resections in England and in other countries were performed laparoscopically
[76]. Therefore, although the principles of SILS are highly attractive, they might not, at this
moment, be transferable and proposed to the general community of surgeons.
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The last but not least important concern about single-incision colectomy regards the costs. It
is logical to expect an initial increase in costs associated with SILC over conventional laparo‐
scopic surgery since the additional equipment such as single-incision access ports or flexible/
articulating instruments are still relatively new. In their analysis of single-incision right-
hemicolectomy, Waters et al. [46] found a marginal increase in direct operative cost of US $310
to $410 per case. If patients have a shorter length of hospital stay, and consequently, a quicker
return to work and normal activity after single-incision surgery, it is likely there will be an
improvement in the cost-effectiveness of SILS in the future.
5. Conclusion
Most of the current studies on single-incision colectomy for cancer are observational and lack
statistical power due to the relatively low number of patients studied. Although meta-analyses
can increase the statistical power by pooling results of all available trials, only randomized,
controlled studies can provide high levels of evidence. To date, only two randomized control‐
led studies have compared short-term results between single-incision and conventional
laparoscopic surgery and, unfortunately, even these studies have enrolled a very low number
of patients. Bearing in mind these limitations, we can still glean several important factors from
these published series:
1. Colonic SILS is technically demanding but the introduction of new specialized equipment
including multilumen ports, angled scopes, articulated instruments and instruments of
variable length, will eventually reduce this difficulty.
2. Principles of colonic SILS are attractive and applicable in carefully selected groups of
patients, namely with right-sided pathology, low BMI and non-bulky tumors.
3. In the hands of experienced laparoscopic surgeons, colonic SILS in the above mentioned
patients has been demonstrated to be safe and feasible with rates of surgery-related
complications and mortality, operative time and oncological adequacy comparable with
those of conventional laparoscopy.
4. Two meta-analyses and one randomized controlled study provide evidence in support of
some advantages of SILS over conventional laparoscopy, namely, shorter length of
hospital stay, significantly shorter incision length and significantly less estimated blood
loss; other hypothesized benefits, such as reduction in postoperative pain and improve‐
ment of cosmesis remain unproven.
Further high-powered randomized studies comparing SILS and LCS by using standardized
outcome assessment tools are needed to confirm or not the above-mentioned results. But one
thing is certain: we will not see the same dramatic clinical advantages with the passage from
LCS to SILS as we saw with the advent of laparoscopic technique over open surgery.
Furthermore, the more complex the procedure performed by single-incision surgery, the more
likely are there to be advantages in comparison with conventional laparoscopic procedures.
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In this prospective, a possible field of investigation might be the assessment of systemic stress
response of single-incision versus conventional laparoscopy in colorectal surgery. The reduced
parietal trauma and manipulation of the peritoneum could decrease the postoperative
inflammatory response to surgical stress and as a consequence, more efficient immunocom‐
petency against tumor cells might be maintained since the earliest postoperative days [77,78].
All these factors might influence the long-term oncological results of SILS with a potential
improvement in survival rates of patients operated on for colorectal cancer.
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1. Introduction
A robot is a mechanical or virtual agent, usually an electro-mechanical machine that is guided
by a computer program or electronic circuitry. Robots have been linked with the future and
modern civilization but have been around for more than 2000 years since ancient Greek
automata. Their real surgical application has been in the last 20 years [1, 2].
Robots were first used in medicine to help people with disabilities to aid in their rehabilitation
process. The Edinburgh Modular Arm System [3] was one of the first bionic arm which was
engineered by Dr. David Gow in the early eighties.
The National Aeronautics and Space Administration (NASA) developed the first telemanipu‐
lator robot in 1985 at the behest of the Defense Department of the United States of America
with the aim to decrease war casualties using telerobotic surgery [4].
It was believed that robots could have prevented more than a third of the soldiers from dying
during the Vietnam War secondary to haemorrhage [5].
Robotic colorectal operations have gained considerable interest after successful implementa‐
tion in the field of urology and gynaecology. The advantages of a stable platform, better vision
and better access has made this an attractive tool in many specialities. [6] Pelvic and rectal
resections are best suited for robotic operations [6].
2. The Da Vinci surgical robotic system
The Federal Drug and Administration approved the use of the da Vinci robotic system for
surgical treatment in 2000 and it was first used at the Ohio State University Hospital for
oesophageal and pancreatic surgery [22].
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At present it is extensively used throughout the world and has sold over 2000 units worldwide
in 2013. It is estimated then more than 200,000 operations have been performed in 2012 [23, 24].
The initial model of da Vinci was released in the year 1999, later this was updated to “S” in
2007 and in 2009 Si was released with improved functions and better performance. The author
uses the da Vinci “Si” robotic system for his colorectal operations.
The da Vinci system consists of a surgeon’s console and four interactive robotic arms attached
to the robotic cart controlled by the surgeon from the console. One of the arms carries an
endoscopic camera via a 12mm port. The camera has two lenses, which gives a 3D image with
stereoscopic vision when the surgeon looks through the eyepiece in the console. The three
other arms are used to hold tools and tissues i.e. scissors, bovies, electrocautery. The arms are
maneuvered using two-foot pedals and two hand controllers.
Year Milestones
1985 • PUMA 560 was used under computerised tomography guidance to orient a needle for brain biopsy [7]
1992 • PROBOT - developed at Imperial College, London and was used to perform prostatic surgery at Guy's and St
Thomas' Hospital, London [8]
• The ROBODOC developed by Integrated Surgical Systems was used to curve out accurate fittings in the
femur for hip replacement [8]
1998 • Zeus robotic surgical system – used for reconstruction of the Fallopian tube performed at the Ohio State
University Medical Center [9]
1999 • Robotics assisted closed chest bypass on a beating heart was performed at the London Health Sciences
Centre [10]
2000 • FDA approval of da Vinci robotic system[11]
2002 • Robotic cholecystectomy [12]
• Robotic Right Hemicolectomy [13]
• Robotic bowel resections [14]
2006 • Unassisted robotic surgery using artificial intelligence to correct atrial fibrillation at a hospital in Milan [15]
2007 • Denervation of spermatic cord for testicular pain using robotic assisted microsurgery performed at Winter
Haven Hospital and University of Florida [16]
2008 • Magnetic Resonance guided neurosurgical procedure performed at University of Calgary [17]
• Microsurge developed by German Aerospace Center [18]
2010 • Sophie Surgical System developed by Eindhoven University of Technology [19]
• Femoral reconstruction [20]
• World’s first all robotic operation i.e. prostatectomy using the da Vinci robot along with McSleepy robot
used for anaesthesia at McGill University Hospital, Canada [21]
Table 1. Development of Robotics to aid in Surgical Procedures.
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Unlike laparoscopy the da Vinci system allows the surgeon to perform operation seated at the
console, with the hands and eyes positioned in line with the instruments. The operating
surgeon is able to control the movements of the camera using the foot pedal rather than relying
on an assistant. The system is able to filter and decipher surgeon’s hand movements into steady
and precise micro movements.
Figure 1. [25]: showing the robotic stack/cart and the monitor used by the assistant to follow the operation
Figure 2. [26] : showing robotic and vision carts and the surgeon’s console with an additional teaching console
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3. Evidence of robotics in colorectal surgery
Robotic colorectal surgery is gaining widespread interest worldwide and in the continent. Data
collected in 2012 suggests that most of the reported or published data shows that majority of
the robotic colorectal operations have been performed in the United States (32%) followed by
South Korea (20%), Italy (15%), Canada, Germany and Netherlands accounted for 5% and the
rest of the world less than 2% [13].
The first colorectal surgical publication was published by Weber et al in 2002 [27] and since
then there has been a tenfold rise in publication in colorectal surgery [13]. The important
landmark studies are summarized in table 2.
Laparoscopic colorectal operations have many advantages over conventional open operations.
The benefits in terms of short term outcomes are well established and include shorter hospital
stay, faster return to work, better cosmesis, less post operative pain, less risk of bleeding and
ileus. Long term outcomes including cancer specific and disease free survival have been subject
of many well-designed trials.
The COLOR (COlon cancer Laparoscopic or Open resection) trial (330 stated that laparoscopic
colectomy was associated with less significant blood loss, earlier recovery of bowel function,
use of fewer analgesics and with a shorter hospital stay when compared with open colectomy.
It however took half an hour longer than open operations and had 19% chances of converting
to open operation. The reasons for conversion were mainly attributed to tumour size of more
than 6cms and in patients who had involvement of adjacent structures.
There were concerns regarding tumour recurrence associated with laparoscopic colectomy.
The meta-analysis of four randomized control trials (CLASICC trial, COST trial, Barcelona trial
and COLOR trial) where patients with colonic cancers were randomised to either open or
laparoscopically assisted colectomy concluded that the positive margins were found in
specimens after open operations were 2.1% as compared to 1.3% after laparoscopic operation.
The overall disease free survival at three years was 83.5% for open operations and 82.2% for
laparoscopic operations [34]. Hence, the evidence shows that laparoscopic colonic operation
is oncologically safe and viable with comparable outcomes to open surgery [34, 35].
The safety and viability for rectal cancers is still less clear especially with the higher circum‐
ferential margin (CRM) involvement with laparoscopic rectal operations when compared to
open rectal operations as mentioned in the CLASSIC trial [34]. There was however, no
difference in local recurrence at three years [36]. There was a higher conversion rate in the
laparoscopic rectal subgroup (34%) in comparison to laparoscopic colonic group (25%).
Conversions to open operations led to higher mortality and morbidity [34, 37]. Conversions
were mainly attributed to bulky tumours [33] and increased technical difficulty [37]. The robot
promises to abolish some of these technical problems faced during dissection of rectal tumours
using laparoscopy and the ROLARR (RObotic versus LAparoscopic Resection for Rectal
cancer) trial results are awaited. It is an international, multicentre, prospective, randomised,
and controlled, unblinded, parallel-group trial of robotic-assisted versus laparoscopic surgery
for the curative treatment of rectal cancer [37].
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Year Reference Country Study type Number of
patients
2002 Weber et al. USA Case series 2,
3,
Hashizume et al. Japan 18
Talamini et al. USA
2003 Vibert et al. France Case series 3,
Giulianotti et al. Italy 16
2004 Hubens et al. Belgium Case series, 8,
Anvari et al. Canada Prospective Comparative 10,
D'Annibale Italy Comparative 53
2005 Woeste et al. Germany Comparative, 6,
Bonder et al. Austria Case series, 14,
Ruurda et al. Holland Case series 23
2007 Heemskerk et al. Netherlands Comparative 19
2008 Baik et al. Korea, Randomized trial, 18,
Spinoglio Italy, Comparative, 50,
Huettner et al. USA, Comparative, 70,
Soravia et al. Switzerland Case series 40
2009 Baik et al. Korea Comparative, 56,
DeHoog et al. Netherlands Case control 20
2010 Tsoraides et al. USA, Retrospective, 102,
Kim and kang Korea, Comparative, 100,
Bianchi et al. Italy, Comparative, 56,
Pernazza and Morpurgo Italy, Case series, 50,
DeSouza et al. USA, Case control, 40,
Zimmern et al. USA, Case series, 131,
Popescu et al. Romania Comparative 122
2011 Kang and kim Korea Retrospective 204
2012 Antoniou SA et al [28] Germany Case series 39
2013 Casillas MA Jr et al [29] USA Case series 344
Germain A et al [30] France Case Series 77
Barrie J et al [31] UK Comparative 34
Wormer BA et al [32] USA Comparative 1809
Table 2. [13]
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3. Evidence of robotics in colorectal surgery
Robotic colorectal surgery is gaining widespread interest worldwide and in the continent. Data
collected in 2012 suggests that most of the reported or published data shows that majority of
the robotic colorectal operations have been performed in the United States (32%) followed by
South Korea (20%), Italy (15%), Canada, Germany and Netherlands accounted for 5% and the
rest of the world less than 2% [13].
The first colorectal surgical publication was published by Weber et al in 2002 [27] and since
then there has been a tenfold rise in publication in colorectal surgery [13]. The important
landmark studies are summarized in table 2.
Laparoscopic colorectal operations have many advantages over conventional open operations.
The benefits in terms of short term outcomes are well established and include shorter hospital
stay, faster return to work, better cosmesis, less post operative pain, less risk of bleeding and
ileus. Long term outcomes including cancer specific and disease free survival have been subject
of many well-designed trials.
The COLOR (COlon cancer Laparoscopic or Open resection) trial (330 stated that laparoscopic
colectomy was associated with less significant blood loss, earlier recovery of bowel function,
use of fewer analgesics and with a shorter hospital stay when compared with open colectomy.
It however took half an hour longer than open operations and had 19% chances of converting
to open operation. The reasons for conversion were mainly attributed to tumour size of more
than 6cms and in patients who had involvement of adjacent structures.
There were concerns regarding tumour recurrence associated with laparoscopic colectomy.
The meta-analysis of four randomized control trials (CLASICC trial, COST trial, Barcelona trial
and COLOR trial) where patients with colonic cancers were randomised to either open or
laparoscopically assisted colectomy concluded that the positive margins were found in
specimens after open operations were 2.1% as compared to 1.3% after laparoscopic operation.
The overall disease free survival at three years was 83.5% for open operations and 82.2% for
laparoscopic operations [34]. Hence, the evidence shows that laparoscopic colonic operation
is oncologically safe and viable with comparable outcomes to open surgery [34, 35].
The safety and viability for rectal cancers is still less clear especially with the higher circum‐
ferential margin (CRM) involvement with laparoscopic rectal operations when compared to
open rectal operations as mentioned in the CLASSIC trial [34]. There was however, no
difference in local recurrence at three years [36]. There was a higher conversion rate in the
laparoscopic rectal subgroup (34%) in comparison to laparoscopic colonic group (25%).
Conversions to open operations led to higher mortality and morbidity [34, 37]. Conversions
were mainly attributed to bulky tumours [33] and increased technical difficulty [37]. The robot
promises to abolish some of these technical problems faced during dissection of rectal tumours
using laparoscopy and the ROLARR (RObotic versus LAparoscopic Resection for Rectal
cancer) trial results are awaited. It is an international, multicentre, prospective, randomised,
and controlled, unblinded, parallel-group trial of robotic-assisted versus laparoscopic surgery
for the curative treatment of rectal cancer [37].
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Year Reference Country Study type Number of
patients
2002 Weber et al. USA Case series 2,
3,
Hashizume et al. Japan 18
Talamini et al. USA
2003 Vibert et al. France Case series 3,
Giulianotti et al. Italy 16
2004 Hubens et al. Belgium Case series, 8,
Anvari et al. Canada Prospective Comparative 10,
D'Annibale Italy Comparative 53
2005 Woeste et al. Germany Comparative, 6,
Bonder et al. Austria Case series, 14,
Ruurda et al. Holland Case series 23
2007 Heemskerk et al. Netherlands Comparative 19
2008 Baik et al. Korea, Randomized trial, 18,
Spinoglio Italy, Comparative, 50,
Huettner et al. USA, Comparative, 70,
Soravia et al. Switzerland Case series 40
2009 Baik et al. Korea Comparative, 56,
DeHoog et al. Netherlands Case control 20
2010 Tsoraides et al. USA, Retrospective, 102,
Kim and kang Korea, Comparative, 100,
Bianchi et al. Italy, Comparative, 56,
Pernazza and Morpurgo Italy, Case series, 50,
DeSouza et al. USA, Case control, 40,
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The skills required for laparoscopic operations are different to open operations.
Limitations of laparoscopic surgery include loss of depth perception, reduced tactile feedback
and a declined range of motion [33]. The author believes that limited space in the pelvis, with
two-dimensional visions and a bulky specimen can make laparoscopic operations very
difficult.
Laparoscopic TME rectal resections have a steep learning curve [38], requiring precise pelvic
dissection with preservation of autonomic nerves. There is higher incidence of male sexual
dysfunction due to inadvertent injury to the nerves following TME resections [39]. It is
estimated that 50% of colorectal surgeons perform laparoscopic colorectal operations in the
UK and only a quarter of them perform laparoscopic TME resections [40]. Approximately 50-70
cases are needed to surmount the laparoscopic colorectal learning curve [35, 38, 41].
The COREAN trail [42] trial compared open surgery with laparoscopic surgery for mid or low
rectal cancer after neoadjuvant chemoradiotherapy. There was a conversion rate of 1.2% in the
COREAN trial as compared to 34% in the CLASSIC trial. The low conversion rate in the
COREAN trial was attributed to greater experience of the surgeons who has performed an
average of seventy laparoscopic operations as compared to twenty per average surgeon in the
CLASSIC trial [43].
The learning curve for performing robotic colorectal operations is shorter and is achieved after
15-20 cases [37, 38]. There are three phases that has been identified in the learning curve for
robotic colorectal operations [44, 45, 46]
• Phase 1 – initial learning (1-15 cases)
• Phase 2 – increased competence (15-25 cases)
• Phase 3 – period of highest skill (>25 cases)
The other advantages of robotic colorectal resections are that
• It is superior in narrow areas like the pelvis and it’s safe and feasible [47] with good three
dimensional view and zoom magnification [37]
• It has 7 degrees of freedom of movement [37]
• It is associated with lower conversion rates to open operation [48]
• It has better pathologic and functional outcomes. It is associated with less complication rates,
shorter duration of hospital stay, time to recover to normal bowel function or first flatus and
time to start diet. It also causes less postoperative pain [49].
• Hospitals who perform high-volume robotic colorectal operations have significantly lower
rates of postoperative bleeding and ileus [50]
• the double console that comes with the robotic cart allow trainees to take part actively at the
surgical procedure and learn from it [51]
• simulators are available than can be attached to the console which provides a platform for
surgical trainees to practice their skills before actually performing the procedures
Colorectal Cancer - Surgery, Diagnostics and Treatment146
There are however some limitations of the da Vinci system. In particular
• there is a definite learning curve for this technique
• loss of tactile feedback although partly compensated by better vision, still can have its effects
on the performance and outcomes
• Hospitals that perform less robotic colorectal operations had more complications with
longer length of hospital stay causing higher cost for the hospital. [19]
• High cost of purchasing as well as maintaining the robotic system [22]
LNs (mean N) Distal margin(mean, cm) Positive CRM (%)
ROB LAP p ROB LAP p ROB LAP p
Park et al, 2010 17.3 14.2 0.06 2.1 2.3 ns 4.9 3.7 0.5
Kim et al, 2010 14.7 16.6 ns 2.7 2.6 0.09 3 2 ns
Kwak et al, 2011 20 21 0.7 2.2 2.0 0.8 1.7 0 >0.9
Baek et al, 2011 13 16 0.07 3.6 3.8 0.6 2.4 4.9 1
Bianchi et al, 2010 18 17 0.7 2 2 1.0 0 4 0.9
Baik et al, 2009 18.4 18.7 0.8 4 3.6 0.4 7 8 0.7
Patriti et al, 2009 10.3 11.2 >0.05 2.1 4.5 >0.05 0 0 ns
(LNs: lymph nodes, CRM: circumferential resection margin, ns: not significant, ROB: robotic procedure, LAP: laparo‐
scopic procedure.)
Table 3. Oncologic results of robotic and laparoscopic surgery for rectal cancer [52].
LNs (mean) Distal margin (mean, cm) Positive CRM (%)
ROB OPEN p ROB OPEN p ROB OPEN p
De Souza et al], 2011 15 16.8 0.26 na na 0 3 0.25
Kim et al, 2012 20 19.6 0.7 2.7 1.9 0.001 1 1 1
Park et al, 2011 19.4 18.5 0.06 2.8 2.3 0.002 1 2 0.9
(LN: lymph nodes, CRM: circumferential resection margin, na: not assessed, ROB: robotic procedure, OPEN: laparoscop‐
ic procedure.)
Table 4. Oncologic results of open and robotic surgery for rectal cancer [52].
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Patient selection is the key especially in the early stages of the learning curve. The author would
recommend choosing patients with
• ASA grade 1-3
• BMI <30
• Age <75 years
• No previous pelvic or intra-abdominal surgery
• T1/T2 tumours
• Tumors that are at or just above the peritoneal reflection of the rectum
• Avoid patients who received neo-adjuvant chemo-radiotherapy and
• Avoid patients who for medical reasons will not be able to tolerate Trendelenburg position
5. Patient preparation
• Bowel preparation – phosphate enema for left sided operations. Bowel preparation not
necessary for right sided colonic operations.
Bowel preparation is controversial in colorectal surgery. Surgeons differ in their approach.
Mechanical bowel preparation results in a colon that is clear of feces. However, it can leave
liquid stool in the bowel that is more likely to contaminate the operative field and the pelvis
in the event of an anastomotic leak. In our experience, bowel preparation also results in small
bowel distension that can make operations more difficult. The authors do not use bowel
preparation for right-sided colonic resections. Two-phosphate enemas are used for left sided
colorectal resections.
• low residue diet 3-4 days before operation
• 4 high calorie drinks to be taken the night before operation
• Eating and drinking normally up to 6 hours before operation
• 2 high calorie drinks to be taken up to 2 hours before operation
• Intra-operative fluids are restricted to 500 mL per hour as tolerated by the patient. This
minimizes the risk of edema of the face and neck that can occur due to the steep Trende‐
lenburg position and excessive fluids. Goal directed therapy is the standard approach using
esophageal Doppler.
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6. Operating room configuration
Figure 3. [53]: showing operating room set up during colectomy
7. Positioning
• Patient is positioned supine in a modified lithotomy position with legs wrapped around
adjustable stirrups
• Legs are abducted and slightly flexed at the knees
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6. Operating room configuration
Figure 3. [53]: showing operating room set up during colectomy
7. Positioning
• Patient is positioned supine in a modified lithotomy position with legs wrapped around
adjustable stirrups
• Legs are abducted and slightly flexed at the knees
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• Patient's arms are wrapped alongside the body to reduce possibility of shoulder injury and
additional shoulder harness can be placed to support Trendelburg’s position
• Pressure points and bony prominences are padded and the body position is secured with
vacuum-mattress device, especially lateral on the right side.
• Secure the patient to the table to avoid any shifting with the Trendelenburg position.
• Patient is tilted right side down and adjust the angle during initial exposure
• A body warmer (bear hugger) is applied to prevent patient hypothermia.
• Sequential compression devices (Flowtrons) are applied to the legs for DVT prophylaxis.
• After positioning, padding, securing and preparing the patient in the supine position, the
table is then placed in a Trendelenburg position, whereby the steepness should be adjusted
as per exposure needs during the initial exposure step.
Image 1. Showing positioning of patient
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8. Right-sided operations
Right-sided operations: 
Image 2: showing marking for Right Colonic resections. Insufflation via Veress needle at 
LUQ.
PORT PLACEMENTS: 
Preparing for Port Placement: 
 Port placement is the key for a successful robotic procedure. Narrow space 
between the ports will result in clashing of the arms and poor ergonomics. We 
recommend marking of the abdomen for port placement after CO2 insufflation.  
 The initial pneumopertioneum can be established with a Veress needle or Hassan’s 
technique at LUQ or at camera port site. 
 Initial assessment of entire anatomy of the abdomen focusing on adhesions, 
peritoneal seedlings and liver metastasis is carried out once the camera port is 
inserted. Place remaining ports under endoscopic vision avoiding injury to the 





I age 2. Showing marking for Right Colonic resections. Insufflation via Veress needle at LUQ.
9. Port placements
9.1. Preparing for port placement
• Port placement is the key for a successful robotic procedure. Narrow space between the
ports will result in clashing of the arms and poor ergono ics. We recommend arking of
the abdomen for port placement after CO2 insufflation.
• The initial pneumopertioneum can be established with a Veress needle or Hassan’s techni‐
que at LUQ or at camera port site.
• Initial assessment of entire anatomy of the abdomen focusing on adhesions, peritoneal
seedlings and liver metastasis is carried out once the camera port is inserted. Place remaining
ports under endoscopic vision avoiding injury to the inferior epigastric vessels.
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9.2. Instrument port placements for left sided colorectal operations [54]
Diagram 1 Showing post placements for left sided colorectal operations
• Robotic camera port, 12 mm (Blue): Place the port 3-4 cm right and 3-4 cm above umbilicus.
Distance to symphysis pubis should be ~22-24 cm.
• Robotic instrument arm port, 8 mm (Yellow): Place the port a minimum of 8 cm from the
camera port, on the right spinoumbilical line (SUL) at the crossing of the mid-clavicular line
(MCL). Distance to symphysis pubis should be ~14-16 cm. Linear stapler can be used from
this port.
• Robotic instrument arm port, 8 mm (Green): Place the port a minimum of 8 cm from the
camera port, on the left spinoumbilical line (SUL) at the crossing of the mid-clavicular line
(MCL). The distance to the symphysis pubis should be ~14-16 cm.
• Robotic instrument arm port, 8 mm (Red): Place the port ~ 3 cm sub-xyphoid and ~ 2 cm
medial to the right MCL
• Robotic instrument arm port, 8 mm (Green-Red): Place the port 7-8 cm below the left costal
margin, slightly medial to the left MCL. Place the port a minimum of 8 cm from the other
instrument ports and the camera port.
• Assistant port, 5 mm (White): Place the port 8-10 cm cephalad to the instrument arm port
and ~ 4 cm lateral to the right MCL (a minimum of 8 cm from the camera port). This port is
used for suction/irrigation, ligation and retraction.
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Image 3. Showing port placements for left sided colorectal operations
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9.3. Port placement for right sided colonic resections
Image 4. [74]: showing port placements for right sided colonic resections
9.4. Instrument port placements for right sided colorectal operations
• Camera port 12mm, at left spinoumbilical line (SUL)
• Robotic arm port 1, 8mm, at left mid-clavicular line (MCL) 8cms below costal margin
• Robotic arm port 2, 8mm, is placed in at right SUL 2cms lateral to right MCL
• Robotic arm port 3, 8mm, is placed in midline 3 cms from pubic symphysis
• Assistant port, 5mm, place at LIF lateral to left MCL
9.5. Operative steps for left sided colorectal operations
• Initial exposure is acquired by cephalad retraction of the omentum to expose the transverse
colon and by moving the small bowel out of the pelvis. Loops of small bowel can be stacked
in the right upper quadrant to expose the Inferior Mesenteric Vein (IMV). A small swab
placed against the small bowel loops can sometimes help by preventing the bowel from
slipping into the operative area.
• Primary vascular control is achieved by ligating the Inferior Mesenteric Artery (IMA) and
IMV earlier in the operation. Disposable locking clips are used to secure these vessels before
division.
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• Medial to lateral mobilization of sigmoid and descending colon is carried out towards the
left sidewall and superiorly towards the spleen. The plane between mesocolon and Gerota’s
fascia is developed. Left ureter and gonadal vesssels should be identified at this stage.
• Splenic flexure mobilization (SFM) is not mandatory. However, if the anastomosis is likely
to be at tension, SFM is strongly recommended. If SFM is needed, IMV is divided high and
the plane above the pancreas is developed which can lead the surgeon into the lesser sac.
Gastrocolic omental division from above can complete this step safely.
• Rectal dissection and division – Total Mesorectal Excision (TME) is carried out to the pelvic
floor for a mid to low rectal cancer or to the peritoneal reflection for an upper rectal cancer.
Great care is taken to avoid injury to the parasympathetic nerves.
• Anastomosis - Rectal division and anastomosis is performed using surgical staplers. Care
should be taken not to damage the pelvic floor at this stage. For rectal division, stapler can
be inserted through the assistant port or the R1 can be disabled and undocked and the port
changed to a 12 mm port to allow the stapler to pass through. In patients with a very narrow
pelvis, a supra-pubic port can be used to divide the rectum anteroposteriorly. We perform
a routine flexible sigmoidoscopy to check for anastomotic bleeding, viability of the colon
and rectum and at the same time perform a leak test to check for anastomotic leak.
9.6. Operative steps for right sided colonic resections
• The patient is positioned in modified Lloyd –Davis position with slight Trendelenberg tilt.
The ileocolic and Superior Mesenteric Artery (SMA) pedicles are exposed by retraction of
the small bowel and appropriate traction and counter traction on the mesentry. Dissection
along the Superior Mesenteric Vein (SMV) will expose the ileocolic vein and artery that are
then divided after clipping. Duodenum is identified early and dissection carried out towards
the liver to enter the lesser sac.
• Lateral to medial mobilization allows the right colon to be freed up. Sub ileal dissection
completes this dissection allowing the whole specimen to come to the midline. Gastrocolic
omental division results in complete mobilization of the heaptic flexure.
• Ileocolic anastomosis can be performed intra or extra corporeally depending upon the
surgeons preference. Specimen is extracted either through a midline or suprapubic incision.
9.7. Post-operative management — (Enhanced Recovery Programme [55])
Day of operation:
• Pain management with epidural followed by PCA and then oral/IV/IM analgesia
• Post-operatively the patients are transferred to Surgical High Care for close monitoring
• All patients should have DVT (unless contraindicated) and antibiotic prophylaxis
• Patients encouraged to sit out of bed and encouraged to drink straight after the operation
including 2 protein drinks
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9.3. Port placement for right sided colonic resections
Image 4. [74]: showing port placements for right sided colonic resections
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in the right upper quadrant to expose the Inferior Mesenteric Vein (IMV). A small swab
placed against the small bowel loops can sometimes help by preventing the bowel from
slipping into the operative area.
• Primary vascular control is achieved by ligating the Inferior Mesenteric Artery (IMA) and
IMV earlier in the operation. Disposable locking clips are used to secure these vessels before
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• Medial to lateral mobilization of sigmoid and descending colon is carried out towards the
left sidewall and superiorly towards the spleen. The plane between mesocolon and Gerota’s
fascia is developed. Left ureter and gonadal vesssels should be identified at this stage.
• Splenic flexure mobilization (SFM) is not mandatory. However, if the anastomosis is likely
to be at tension, SFM is strongly recommended. If SFM is needed, IMV is divided high and
the plane above the pancreas is developed which can lead the surgeon into the lesser sac.
Gastrocolic omental division from above can complete this step safely.
• Rectal dissection and division – Total Mesorectal Excision (TME) is carried out to the pelvic
floor for a mid to low rectal cancer or to the peritoneal reflection for an upper rectal cancer.
Great care is taken to avoid injury to the parasympathetic nerves.
• Anastomosis - Rectal division and anastomosis is performed using surgical staplers. Care
should be taken not to damage the pelvic floor at this stage. For rectal division, stapler can
be inserted through the assistant port or the R1 can be disabled and undocked and the port
changed to a 12 mm port to allow the stapler to pass through. In patients with a very narrow
pelvis, a supra-pubic port can be used to divide the rectum anteroposteriorly. We perform
a routine flexible sigmoidoscopy to check for anastomotic bleeding, viability of the colon
and rectum and at the same time perform a leak test to check for anastomotic leak.
9.6. Operative steps for right sided colonic resections
• The patient is positioned in modified Lloyd –Davis position with slight Trendelenberg tilt.
The ileocolic and Superior Mesenteric Artery (SMA) pedicles are exposed by retraction of
the small bowel and appropriate traction and counter traction on the mesentry. Dissection
along the Superior Mesenteric Vein (SMV) will expose the ileocolic vein and artery that are
then divided after clipping. Duodenum is identified early and dissection carried out towards
the liver to enter the lesser sac.
• Lateral to medial mobilization allows the right colon to be freed up. Sub ileal dissection
completes this dissection allowing the whole specimen to come to the midline. Gastrocolic
omental division results in complete mobilization of the heaptic flexure.
• Ileocolic anastomosis can be performed intra or extra corporeally depending upon the
surgeons preference. Specimen is extracted either through a midline or suprapubic incision.
9.7. Post-operative management — (Enhanced Recovery Programme [55])
Day of operation:
• Pain management with epidural followed by PCA and then oral/IV/IM analgesia
• Post-operatively the patients are transferred to Surgical High Care for close monitoring
• All patients should have DVT (unless contraindicated) and antibiotic prophylaxis
• Patients encouraged to sit out of bed and encouraged to drink straight after the operation
including 2 protein drinks




• The patient will have an epidural and urinary catheter
• Will be encouraged to drink 2 litres of fluid and drink 4 high protein drinks
• Will be encouraged to eat normal food
• Will be encouraged out of bed for 8 hours and take 3 walks of 50 meters each with help from
the physiotherapists
Second post-operative day:
• Epidural and urinary catheter removed. Pain management using PCA.
• Will be encouraged to drink 2 litres of fluid and drink 4 high protein drinks
• Will be encouraged to eat normal food
• Will be encouraged out of bed for 8 hours and take 3 walks of 50 meters each with help from
the physiotherapists
Post-operative days 3-5:
• The patient is discharged from the hospital if stable in three to five days i.e. passed flatus
and or opening bowels
• Pain controlled with oral medications
• Able to mobilize and physiotherapists happy with progress
Outpatient follow-up:
• Follow up at OPD 2-3 weeks post-operatively
• All Cancer patients are discussed at Multidisciplinary Team Meeting, regarding additional
therapy or adjuvant radiation with or without chemotherapy as indicated.
10. Future developments
10.1. Role of ICG in bowel anastomosis and lymph node mapping using da Vinci robot
Indocyanine green (ICG) is a cyanine fluorescent dye that absorbs near infrared wavelengths
of light. It binds to plasma proteins and travels in the vascular system [56]. ICG emits an
infrared signal when excited by laser light in situ, which can be detected with near-infrared
fluorescence camera system (NIRF) [57].
The image from NIRF gives visual assessment of blood vessels, blood flow, and tissue
perfusion. ICG has been widely used by the ophthalmologists to visualise retinal blood vessels
[58] and the technique has been amalgamated into the da Vinci Si robotic system.
Water soluble ICG can be given intravenously during surgical procedure. The surgeon is able
switch into fluorescence imaging modes from normal white light mode by pressing pedals in
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the console and is able to view infrared images of blood flow in the microvasculature as well
as tissue perfusion in real time. This is particularly useful during bowel anastomosis and
improving patient outcomes [59].
Lymph nodes harvesting can be a difficult procedure to perform in cancer surgery.
The use of ICG is an attractive method to facilitate visualisation of lymphatic vessels, sentinel
nodes, and metastatic lymph nodes. It was first introduced by Lim and Soter [60].
ICG has been used in the recent past to harvest lymphnodes for cutaneous rectal carcinoma
metastasis [61] and cutaneous Kaposi's sarcoma [62] with successful outcome.
It has also been used in transcutaneous Sentinel Lymph Node detection in vulvar cancer
patients [63] and for identification of lymphatic pathway involved in the spreading of prostate
cancer [64].
10.2. Robotic Single Incision Laparoscopic Surgery (SILS) or Colectomy (SILC)
Single incision laparoscopic colectomy (SILC) is well established. SILC is associated with
shorter post-operative length of hospital stay and smaller skin incision. There is no difference
in operating time or in conversion rate when compared to multiport laparoscopic colorectal
operations [65]. The main drawback with SILC is exposure, conflict of instruments, ease of
instrumentation, camera operation and ergonomics [66].
Robotic single incision laparoscopic surgery may be the answer to some of the problems
associated with SILC. The author believes that robotic single incision colectomy will result in
less abdominal wall trauma, less pain, needing fewer analgesics, early mobilisation and
decreased length of hospital stay. It will have better cosmetic result due to fewer numbers of
incisions. There is good evidence to suggest that multiple laparoscopic port incisions can cause
port site hernias even with 5mm ports [67, 68].
Early experience with robotic SILC performing right hemicolectomy is safe and feasible [69].
We need more studies to validate robotic SILC for left sided operations.
Other surgical specialties where robotic SILS is gaining interest are listed below:
• Spinioglio G et al mentioned that it took them less time to perform robotic single port
laparoscopic cholecystecomies than laparoscopic SILS [70].
• Robotic single-port trans-umbilical total hysterectomy is technically feasible in selected
patients with gynaecological disease [71].
• Hahn Tran et al have successfully performed robotic single-port inguinal hernia repair
without any complications [72].
• The authors believe that robots will also play a role in natural orifice endoscopic surgery
and specimen retrieval via the natural orifice in the near future
The perfect robotic platform should have a low external profile,  which can be deployed
through a single access site. It should be able to restore intra-abdominal triangulation while
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maintaining  the  maximum degree  of  freedom for  accurate  maneuvers  and  strength  for
reliable traction. Several purpose-built robotic prototypes for single-port surgery are being
tested [73].
The author believes that robots will also play a role in natural orifice endoscopic surgery and
specimen retrieval via the natural orifice in the near future.
11. Summary
In summary the developments of surgical robotics over the last decade has been very exciting.
The technology is improving rapidly. Robots certainly allow the surgeons to perform better
operations with improved safety. In colorectal surgery robotics will find its place in pelvic and
rectal cancer surgery. The cost of instruments and the system are the biggest barrier to the
widespread uptake of robotic surgery by the surgical community. The future applications of
this technology may result in further benefits that will offset the cost issue.
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1. Introduction
Colorectal carcinoma is one of the more common types of cancer around the world. For patients
in UICC stage I (i.e., those who have pT1/2 tumors and do not have any lymph node metasta‐
ses), the probability of surviving 5 years is 90% [2]. The prognosis of patients in stages II (pT3/4
tumors without lymph node metastases) and III (tumors with lymph node metastases) has
improved steadily in recent years. At present, the 5-year survival in these two groups is 80%
and 60% [1].
Approximately, 1.2 million cases of CRC occur yearly worldwide, with 412, 900 new cases
diagnosed in Western Europe alone and 150, 000 in the United States. [1, 2] Resection of
colorectal liver metastases (CRLM) is the only treatment offering the possibility of cure and
has been shown to provide clear survival benefits. [3] Unfortunately, only 10% to 20% of
patients with CRLM are eligible for this procedure upfront. On the other hand, during the last
10 years, major advances in the management of CRLM have taken place involving principally
three different fields: oncology (new and more effective chemotherapeutic agents), interven‐
tional radiology (portal embolization and radiofrequency), and surgery (better instruments
and newer techniques). These advances as part of a multidisciplinary team approach have
gradually but effectively increased the resectability rate to 20%-30% of cases with a 5-year
survival of 35%-50%. [3]
Nonetheless, distant metastases eventually arise in about 20% of patients who are stage II or
III at the time of diagnosis [3]. About 35% of all patients already have distant metastases when
the diagnosis is made. Patients with untreated hepatic metastases have a very poor prognosis.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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In a prospective, observational study carried out on 484 patients from 1980 to 1990, the median
time to death was 6.9 months [4]. Adson and colleagues, in the 1970’s, were the first to show
that patients could be cured by the resection of hepatic metastases [5]. Since then, resection
has become established as a standard treatment. For this review, we selectively searched the
literature for articles containing the words “colorectal liver metastases, ” “chemotherapy, ”
and “surgery, ” paying special attention to studies carried out on larger groups of patients and
to randomized clinical trials. [6]
Most favorable outcomes were observed in patients with pedicle lymph node involvement (5-
year survival rate 25% vs 0% for patients with celiac and/ or para-aortic lymph node metasta‐
ses), and in patients younger than 40 years (5-year survival rate 45% vs 10% for older patients).
[7, 8] In relation to our results and those reported by others, we recommend combining
hepatectomy with lymphadenectomy only for young CLM patients presenting with pedicle
lymph node involvement, in the absence of disease progression after preoperative chemo‐
therapy. On the other hand, patients presenting with celiac or para-aortic lymph node
involvement should not be subjected to this oncosurgical treatment strategy. Even concomitant
pulmonary metastases should not be considered a contraindication to surgery. Patients with
only pulmonary metastases as a site of extrahepatic disease have a particularly good outcome
after complete metastasectomy of both liver and lung disease. Five-year survival rates ranged
from 22% to 50% in patients with metastases limited to the lungs. [8] Also, selected patients
with complex multiorgan metastases have been associated with prolonged survival after a
multimodality treatment. Patients with simultaneous hepatic and extrahepatic disease (EHD)
do, however, need to be selected for surgery. Elias et al stated that EHD, when resectable, is
no longer a contraindication to hepatectomy. [18] More importantly, the total number of
metastases, whatever their location, has a strong prognostic effect than the site of the meta‐
stases. In addition, a study conducted at our centre demonstrated that patients with concom‐
itant EHD who were resected experienced a lower 5-year survival than those without EHD
(28% vs 55%, P<.001). Five poor prognostic factors were identified with multivariate analysis:
EHD location other than lung metastases, EHD concomitant to colorectal liver metastases
recurrence, CEA-level>10 ng/ml, >6 colorectal liver metastases and right colon cancer. The five-
year survival ranged from 64% (0 factors) to 0% (>3factors). [19]
We aim to report the new trends in strategies about surgical treatment of colorectal liver
metastases and our experience according to surgical and oncological outcome in patients,
operated for IV stage colorectal cancer.
2. Criteria for resectability
Currently available data have led to a change in the indications for resecting hepatic metastases
of colorectal carcinoma. Previously, the indication was based on tumor-biological and clinical
characteristics. The new criterion is the feasibility of complete resection of both intra- and
extrahepatic disease. R0-resectable hepatic metastases, in patients without any extrahepatic
metastases, should be resected. [12] As the determination of resectability is becoming ever
more complex, all patients with hepatic metastases of colorectal carcinoma should be presented
to an experienced hepatobiliary surgeon before the beginning of treatment. Postoperative
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hepatic function can be predicted more precisely with the aid of CT volumetry. This technique
enables prediction of the remaining volume of hepatic tissue after surgery to within 10% of
the actual value. [9, 11]
Metastases are considered resectable when the following criteria are met:
• exclusion of a non-resectable extrahepatic tumor manifestation,
• parenchymal involvement <75%,
• <3 hepatic veins and <7 hepatic segments involved,
• no hepatic insufficiency, no Child B or C cirrhosis,
• no severe accompanying diseases.
Metastases are considered non-resectable or marginally resectable when an R0 resection is not
possible. Metastases are also considered marginally resectable in the setting of, for example,
extra-hepatic tumor manifestations, technical impediments to surgery, or inadequate expected
residual liver mass. For these patients, intensified preoperative chemotherapy can be consid‐
ered. The feasibility of secondary resection should be evaluated at each re-staging under
chemotherapy. [15]
3. New treatment strategies
Today, patients with metastatic CRC should be treated by multidisciplinary teams including
surgeons, oncologists and radiologists. Evidence of the benefit of perioperative chemotherapy
over surgery alone [22] and the potential benefit of adjuvant chemotherapy (after liver
resection) [23] caused a rethink among the experts particularly in terms of the timing of the
administration of chemotherapy for CRC patients with initially resectable liver and lung
metastases. Poor prognostic factors for patients with liver metastases are multiple metastases,
>5 cm in diameter, synchronous presentation, lymph node-positive primary and high tumor
marker levels. [17] Thus, even when the metastases are technically resectable (in terms of
number, location and size), when facing a patient with more than one of the poor prognostic
factors listed above, the current trend is to refer patients for neoadjuvant chemotherapy before
surgery. The data from the EORTC study showed quite clearly that nearly all patients were
able to tolerate neo-adjuvant chemotherapy. Also, analysis of the PFS curves from the EORTC–
EPOC trial shows that the main difference comes after the first 2 months when the curves drop
down and then move out in parallel, suggesting that the benefit conferred by perioperative
chemotherapy might be a consequence of a reduction in the occurrence of early cancer relapse
as a consequence of preoperative chemotherapy. [16] An exception to preoperative chemo‐
therapy is, however, those patients with a single resectable metachronous metastasis who
could be directly referred to surgery, [14] with the recognition that this accounts for <10% of
patients seen in routine clinical practice. All other patients with resectable metastases should
be treated up front with chemotherapy, with the caveats that the patient is able to receive
chemotherapy and the position of the lesion is not going to be lost. On the other hand, it has
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also become a standard strategy to give postoperative adjuvant chemotherapy to all resected
patients (if possible) based on the data for the resected patients in the EORTC–EPOC trial. [22]
For patients who are non-responders, there are two treatment strategies available: 1) change
to a new chemotherapy protocol or 2) liver resection before the metastatic disease becomes
unresectable. At this point it is important to mention that, the decision to perform either
treatment strategy should always be decided by a multidisciplinary. Currently, it has become
mandatory to select the systemic therapy regimen based on biological predictive factors, such
as KRAS mutation status. This strategy has had a double impact: first of all, it has helped to
optimize the choice of first-line treatment, in turn decreasing the risk of immediate disease
progression; secondly, it has also helped to better select the second-line ‘rescue’ treatment
strategies with the possibility of resection. [27] However, considering that surgery is still the
only treatment that has curative potential per se, in some situations this can be the treatment
of choice, even if resistance to medical treatment generally means that the patient has a
unfavorable tumor biology. The situation is much simpler for patients whose metastases are
initially unresectable, where systemic therapy is administered until an adequate response has
been achieved. [24]
4. Primarily resectable hepatic metastases
For operable hepatic metastases, hepatic resection is the treatment of choice. The reported 5-
year-survival rates that have been achieved after the resection of isolated hepatic metastases
with curative intent range from 25% to 50% [1–4, 6–8]. Hepatic metastases, however, are
primarily resectable in only about 20% of patients [4]. For the remaining 80%, resection is
contraindicated by the presence of diffuse hepatic metastases, non-resectable extra-hepatic
disease, or impaired liver function. It is now generally accepted that the contraindications for
hepatic resection that were defined in the 1980’s are no longer applicable. At that time, the
presence of 4 or more tumor nodules, metastases exceeding 5 cm in size, extra-hepatic disease,
or a tumor-free resection margin of less than 1 cm [9] was held to contraindicate hepatic
resection. Many subsequent studies have confirmed that these are, indeed, relevant prognostic
factors for survival after the resection of hepatic metastases of colorectal carcinoma, yet long-
term survival is still possible when hepatic resection is performed despite the presence of these
supposed contraindications. There have also been technical improvements in the treatment of
hepatic metastases of colorectal carcinoma. Diagnostic assessment has become markedly more
sensitive through the use of modern types of CT and MRI scanners and the introduction of
PET-CT (5, 10–14]. Furthermore, surgical dissecting techniques and the development of potent
systemic chemotherapy protocols have been optimized [15–18]. As a result, 5-year survival
rates after the resection of hepatic metastases of colorectal carcinoma have improved markedly.
[6] Today, even patients with more than three metastases or with metastases larger than 5 cm
in diameter can be cured with appropriate surgical treatment, as found in a recent analysis [7].
One hundred and two patients were tumor-free 10 years after the resection of hepatic meta‐
stases of colorectal carcinoma, and only one patient among them developed a recurrent tumor
thereafter.
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Hepatic resections can now be performed safely and effectively. The mortality of hepatic
resection was about 5% as late as 1990, while recent articles on the subject generally document
figures between 1% and 2%. This reduction of mortality has been achieved even though the
resections themselves have become ever more extensive. [3]
6. Long-term results after hepatic resection
More than 40% of appropriately selected patients with colorectal carcinoma who undergo the
resection of hepatic metastases survive for at least 5 years thereafter [5, 6, 8, 9]. This is partic‐
ularly true of patients whose surgery was performed more recently. As many as two-thirds of
patients later develop a recurrent tumor, and half of them have a recurrent tumor in the liver
[23]. In one of the largest studies performed to date, which included 1001 patients, showed
that the benefit of surgery extends not just to patients who have undergone an R0 resection (5-
year survival: 37%), but also to those who have undergone an R1 resection, i.e., a resection
with positive margins, up to 20% of whom are still alive 5 years after surgery. [31]
7. Prognostic parameters
Many different prognostic scores are used to predict the patient’s risk of recurrence and
chances of long-term survival on the basis of preoperatively measured parameters. The three
most commonly used scoring systems in hepatic surgery are those of Nordlinger, Fong, and
Iwatsuki [2, 9, 24]. Although these scoring systems differ with respect to certain individual
parameters, they share the common feature that a low score (i.e., the presence of no more than
a few risk factors) is correlated with a low risk of recurrence, while the chance of long-term
survival is less than 10% when all risk factors are present. No preoperatively measurable
prognostic parameter can identify with any certainty the patients who will not benefit from
surgical treatment. The most important prognostic factor, according to all studies, is a tumor-
free resection margin [10, 11, 25, 26].
8. Expanded application of resection for CRLM
Liver resection is the current preferred treatment for CRLM patients and should be undertaken
whenever feasible and potentially curative (R0), regardless of prognostic factors and presence
of extra hepatic metastases. The main limiting factors to perform curative resection of CRLM
are: presence of bilobar or bulky disease and presence of extra hepatic disease. Resection in
patients with multiple or bulky lesions may result in insufficient residual hepatic tissue (i.e.,
less than 30% functional parenchyma). [19]
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9. Neoadjuvant chemotherapy in patients with resectable CRLM
Despite major survival improvements achieved with successful primary hepatectomy for
CRLM, [7-13, 20] many of these patients experience disease recurrence. Data indicate that pre
or post-operative chemotherapy may provide a meaningful benefit, although controlled trials
are needed. Tanaka et al [21] reported a retrospective analysis of patients with multiple CRLMs,
wherein use of neoadjuvant chemotherapy was an independent predictor of survival by
multivariate analysis. In 71 patients undergoing hepatectomy for more than five bilobar liver
tumors, 3- and 5-year survival rates were superior (P<.05, log-rank) in the neoadjuvant
chemotherapy group (n=48; 67.0% and 38.9%) than in the hepatectomy-alone group (n=23;
51.8% and 20.7%). Furthermore, neoadjuvant treatment reduced the need for extended (>4
segments) hepatectomies (39 of 48 neoadjuvant vs 23 of 23 control patients). Data from the
LiverMetSurvey [5] also indicate a survival improvement with neoadjuvant treatment. In 207
patients with more than five metastases resected, 5-year survival was better with neoadjuvant
treatment, although not significantly (20% vs 15%) and among 1, 045 patients who had only
one liver metastasis resected, 5-year survival rates were 49% and 57% with and without
neoadjuvant chemotherapy, respectively. Similar results were reported in a metanalysis by
Mitry et al, [22] which showed a strong trend toward better diseasefree survival with adjuvant
5-FU treatment (HR 0.76, P=5.8), and a trend toward favorable overall survival (HR 0.76, P=9.8).
In addition, a phase III randomized study (The EORTC Intergroup) examined perioperative
FOLFOX4 (5-fluorouracil (5-FU), leucovorin, oxaliplatin) chemotherapy for patients with
potentially resectable CRLM.23 A total of 364 patients with up to four CRLM were randomized
between perioperative FOLFOX4 (oxaliplatin 85 mg/mІ and LV5FU2), six cycles before and
six cycles after surgery (CT), vs surgery alone (S). Eleven of 182 patients were ineligible in each
arm, mostly due to more advanced disease; 31 and 30 patients in the CT and S arms, respec‐
tively, could not undergo resection. At a median follow-up of 3.9 years, progression-free
survival (PFS) was significantly better with CT in the group of resected patients, although the
trial was formally not positive in the intentionto- treat (ITT) analysis (HR 0.79, P=.058). In terms
of postoperative chemotherapy in resectable patients with CRLM data from United States and
Europe show better survival in patients receiving adjuvant chemotherapy after resection of
CRC liver metastases. [24] Use of adjuvant or neoadjuvant systemic treatment is widely
recognized as standard of care in cases of liver resection, and was the focus of single-center
studies with XELOX/FOLFOX25 and XELOX plus bevacizumab.26 So far, only one study has
as yet shown a clear benefit. [27] In this randomized trial, 109 patients (75 assessable) with one
to three hepatic lesions received hepatic arterial floxuridine plus intravenous 5-FU (n=30) or
no further therapy (n=45) after hepatectomy. The 4-year recurrence-free rates (46% vs 25%)
and 4-year liver recurrence-free rates (67% vs 43%) were significantly better in the adjuvant
therapy group. Median survival differences were not statistically significant (64% vs 49%),
however, the trial was insufficiently powered to evaluate overall survival. [33]
10. Strategies for improving resectability
At present, only 10% to 20% of patients with hepatic metastases of colorectal carcinoma can
be considered candidates for resective surgery. Opportunities for resection are often limited
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by an unfavorable anatomical site of the metastasis (-es), poor function of the remaining hepatic
parenchyma, and/or the patient’s poor general condition. Multiple strategies have been
developed in order to increase the percentage of patients whose metastases are resectable.
Liver surgery has progressed in parallel to the improvements in chemotherapy and interven‐
tional radiology. Bad-located tumors (situated deeply or close to critical vascular or biliary
structures)  can now be safely  resected thanks to  the  availability  of  sophisticated instru‐
ments such as the ultrasonic dissector, argon gas diathermy and new techniques such as the
one of low-central venous pressure anaesthesia that allows an almost bloodless field. With
the routine use of intraoperative ultrasound examination precise localization of liver lesions
and planning of the resection is done aiming at removing all possible lesions with a clear
margin and at the same time preserve the maximum of liver parenchyma. This improve‐
ment in surgical planning and techniques has been directly responsible for the low hospital
mortality. The risk of liver resection for CRLM has decreased in specialized hepatobiliary
centres probably below the figures observed after colorectal surgery. The mortality of elective
liver resection on non-cirrhotic livers is estimated to be around 1% [35, 36] at a time when
patients’ age and disease complexity are increasing, in addition to the associated changes of
SOS and CASH often present in chemotherapy patients undergoing surgery. The experi‐
ence of the centre has a major impact on outcome: the mortality and morbidity of liver
resections decreased inversely to the number of cases performed in the institution. [37] It has
been shown in US that patients resected at high volume centres (>25 cases/year) for liver
cancer have not only a better perioperative outcome, but also a better long-term survival, [38]
and similar results concerning the correlation between high volume surgery and specializa‐
tion and outcome were observed in Europe. [39]
11. Preoperative chemotherapy (“down-staging”)
When hepatic metastases of colorectal carcinoma are unresectable, systemic chemotherapy is
indicated. About 20% of metastases respond to treatment with 5-fluorouracil (5-FU) and folic
acid [4]. When these are used in combination with newer drugs, such as oxaliplatin or
irinotecan (CPT-11), the response rate rises as high as 60% [29]. Folprecht et al. reviewed the
available studies on the “down-staging” of hepatic metastases of colorectal carcinoma and
found that resectionrates are correlated with response rates [4]. The first major clinical series
of this type was published in 1996 by Bismuth et al. [13] and updated in the years thereafter
[14, 30]. The 5-year-survival was 40% (95% confidence interval: 33% to 68%) and was thus
comparable to that of patients with primarily resectable hepatic metastases. A major bias in
the studies of neoadjuvant chemotherapy published to date arises from patient selection. In
the available prospective studies of patients with “isolated” hepatic metastases (i.e., no
extrahepatic metastases), the criteria for nonresectability differ from one study to another and
are often poorly defined. The hepatotoxicity of all currently used chemotherapeutic drugs
argues against their use as neoadjuvant treatment for patients with primarily resectable hepatic
metastases. Oxaliplatin can cause sinusoidal obstruction (“blue liver”), while irinotecan can
induce fatty liver or steatohepatitis [31–34]. These changes are associated with significantly
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more frequent perioperative complications. Vauthey et al. found that steatohepatitis after
irinotecan use is associated with a significantly higher 90-day mortality [15].
12. Systemic chemotherapy in patients with non-resectable CRLM
Systemic chemotherapy is currently the main treatment approach for non-resectable CRLM.
Incorporation of drugs such as oxaliplatin and irinotecan have led to an improvement of
median survival as well as response rates compared with those achieved previously with 5-
fluoracil (5-FU)/leucovorin-based regimens. Development of oral fluoropyrimidines has also
improved treatment options in these patients. Median survival duration after systemic
chemotherapy alone is approximately 20 months, [28, 29] however, only 1% to 2% of such
patients remain alive at 5 years. [3, 30] On the other hand, the improved efficacy of newer
regimens in down staging tumors is rendering more patients resectable. [14]
13. Accompanying chemotherapy
There is no longer any doubt that patients benefit from hepatic resections that are performed
with curative intent. The current discussion concerns the question whether they also benefit
from accompanying adjuvant or neo-adjuvant chemotherapy. The first encouraging data on
adjuvant chemotherapy after hepatic resection were published by Kemeny et al., who com‐
pared local intra-arterial therapy combined with systemic 5-FU chemotherapy to adjuvant
treatment with 5-FU alone. A trend was found toward improved progression-free survival in
the group that additionally received regional therapy (37.4 versus 17.2 months, p = 0.06) [20,
44]. Nonetheless, the overall survival was no better in this group. This finding could not be
replicated in a German study of intraarterial chemotherapy administered in the hepatic artery
[21]. There are currently two further options for systemic chemotherapy: neo-adjuvant and
adjuvant postoperative chemotherapy. For adjuvant chemotherapy, data are only available on
5-FU based treatment. Portier et al., in the AURC 9002 trial, describe an improved 5-year tumor-
free survival of 33.5% among patients receiving adjuvant 5-FU bolus therapy, compared to
26.7% treated with resection alone [22]. These 5-FU patients’ overall survival was no better
than that of their counterparts without 5-FU, but the study size was, in any case, inadequate
to detect a moderate benefit. An unplanned subgroup analysis revealed that patients with a
greater tumor burden (diameter >5cm, or 3 or more tumor nodules) survived longer if they
received adjuvant chemotherapy. Likewise, a pooled analysis of a number of studies, including
the FFCD study, found a trend toward a benefit from adjuvant 5-FU treatment, in terms of
both progression-free survival and overall survival [23]. These data appear promising,
especially because there have been further improvements in chemotherapeutic regimens since
they were published. Further evidence that adjuvant 5-FU treatment confers a survival benefit
after the resection of hepatic metastases of colorectal carcinoma comes from a cohort study of
792 patients by Parks et al. [24]: The median survival time was 47 months, compared with 36
months without 5-FU. This year (2010), Nordlinger et al. have published the results of the
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EORTC 40 983 trial, in which neoadjuvant therapy with FOLFOX (folic acid, 5-FU, and
oxaliplatin) before and after hepatic resection was compared with resection alone. There were
182 patients in each of the study’s two groups (with and without neoadjuvant therapy). The
declared study endpoint of a significantly improved progression-free 3-year survival was not
met in the intent-to-treat analysis. Tumor-free survival was 28.1% after surgery alone and
35.4% in the FOLFOX group [25]. The study did, however, show a significantly improved
tumor-free 3-year survival when all patients whose data could be completely evaluated were
taken into account (as opposed to the intent-to-treat analysis). Data on overall survival are
currently unavailable. It should also be mentioned that the chemotherapy group had a higher
rate of postoperative complications, but their postoperative mortality was no higher. Thus, in
our view, preoperative chemotherapy should remain reserved, at least for now, to patients
whose hepatic metastases are marginally resectable. This group includes patients whose tumor
burden is high because of multiple hepatic metastases and extrahepatic tumor manifestations.
Our view is founded on the documented survival benefit that can be achieved in patients who
have a large burden of initially unresectable hepatic metastases by down-staging their tumors
with chemotherapy, in order to render them resectable. [29]
14. Portal-vein embolization
In some cases, the resection of one or more hepatic metastases is technically feasible, yet cannot
be performed because the amount of liver tissue remaining after resection would be too small.
To minimize the risk of postoperative hepatic insufficiency, ipsilateral hepatic atrophy and
contralateral hepatic hypertrophy can be induced preoperatively by selective embolization of
the hepatic portal vein, or else by ligation of the branch of the portal vein that leads to the
hepatic lobe containing the metastasis.
14.1. Definitions
Future liver remnant (FLR) is the liver that will be left in place after surgery and that was not
targeted by embolization. The FLR must hypertrophy after portal vein embolization (PVE).
Most teams wait 4 weeks before surgery. FLR hypertrophy must be measured by way of
computed axial tomography (CAT) examination after injection of iodine with volumetric
measurements of the FLR segments, with the results compared with the measurements
performed before PVE using the same technique. Hypertrophy can be quantified as FLR
hypertrophy, which is defined as the difference between FLR after a waiting period from 3 to
6 weeks after PVE minus FLR before PVE divided by FLR before PVE. The waiting period must
be long enough to allow hypertrophy and as short as possible to avoid tumor growth, which
precludes surgery. Hypertrophy can also be quantified by increased FLR ratio. The FLR ratio
is defined as (FLR volume—tumor in the FLR)/ (total liver volume—total tumor volume) [8].
Technical success of PVE is defined by a complete occlusion of portal branches feeding the
future resected liver segments. Branches of the FLR must be patent with hepatopetal flow. In
the late phase of control portography, parenchymography must be visible only in the FLR.
Clinical success is considered to occur when the patient reaches the volumetric criteria for liver
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resection. Patients with Tumors that Developed in Normal Underlying Liver Parenchyma PVE
is recommended when the FRL-to-total liver ratio is 25 to 30 [7, 10, 11]. The indication of PVE
can be extended to a 40% FLR ratio in patients having received chemotherapy or showing
abnormal indocyanine green test results (or other abnormal liver function tests) [10, 12, 13].
Portal-vein embolization should always be considered when the residual hepatic volume
without it would be less than 30% of the normal size of the liver, and when at least two
contiguous hepatic segments are free of metastases. For technical surgical reasons, the left
lateral segments 2 and 3 are particularly suitable for this approach. As long as the liver is not
cirrhotic, portal-vein embolization results in a 40% to 60% hypertrophy of the contralateral
hepatic lobe. It remains unclear at present whether the stimulus to hypertrophy that portal-
vein embolization provides might also accelerate the growth of tumor nodules [16, 35]. In any
case, the data regarding morbidity, mortality, and long-term survival are comparable to those
of standard hepatic resections [16, 36–39].
Patients with Tumors that Develop in Chronic Liver Disease and Cirrhosis States
In such cases, the decision is based either on liver volume or on liver volume plus estimation
of overall liver function by indocyanin green retention rate at 15 min. An FRLR of 40% is
recommended when the ICCG 15 is between 10% and 20%. When the ICCG 15 is[20%, an FRLR
of 50% is recommended [12–14].
Patients with Tumors Invading the Biliary Tree Associated with Cholestasis
Because biliary obstruction has impaired liver regeneration and hypertrophy, the biliary tree
of the FRL must be drained first, and PVE can be performed secondarily. The indication is an
FRLR\40% [15].
Contraindication for PVE [11]
PVE is contraindicated in the following types of patients:
1. Tumors invading the portal vein
2. Portal hypertension (blocked to free hepatic veinpressure gradient[12 mmHg)
3. Coagulation disorders (PT\60%, platelet count\50 G/l)
4. Even if previous transarterial chemoembolization (TACE) may improve PVE results [16],
a minimum of 3-week delay between TACE and PVE is recommended.
Patients should be informed that this procedure is not an antitumoral treatment but a treatment
made to increase safety or to enable a surgical procedure. Minor complications are encountered
in 20% to 25% of cases and are mainly associated with slight fever and abdominal discomfort
and pain. Major complications are infrequent and mainly include infection and subcapsular
hematoma, hemobilia, and portal vein thrombosis 9\2% of cases). Mortality due to PVE has
not been reported. When tumors (usually small nodules) are present in the nonembolized lobe,
it must be explained to the patient that those lesions might increase in size more quickly due
to PVE [17]. Patients must also be told that the efficacy of the procedure can be estimated
approximately 4 weeks after
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tumor-free 3-year survival when all patients whose data could be completely evaluated were
taken into account (as opposed to the intent-to-treat analysis). Data on overall survival are
currently unavailable. It should also be mentioned that the chemotherapy group had a higher
rate of postoperative complications, but their postoperative mortality was no higher. Thus, in
our view, preoperative chemotherapy should remain reserved, at least for now, to patients
whose hepatic metastases are marginally resectable. This group includes patients whose tumor
burden is high because of multiple hepatic metastases and extrahepatic tumor manifestations.
Our view is founded on the documented survival benefit that can be achieved in patients who
have a large burden of initially unresectable hepatic metastases by down-staging their tumors
with chemotherapy, in order to render them resectable. [29]
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be performed because the amount of liver tissue remaining after resection would be too small.
To minimize the risk of postoperative hepatic insufficiency, ipsilateral hepatic atrophy and
contralateral hepatic hypertrophy can be induced preoperatively by selective embolization of
the hepatic portal vein, or else by ligation of the branch of the portal vein that leads to the
hepatic lobe containing the metastasis.
14.1. Definitions
Future liver remnant (FLR) is the liver that will be left in place after surgery and that was not
targeted by embolization. The FLR must hypertrophy after portal vein embolization (PVE).
Most teams wait 4 weeks before surgery. FLR hypertrophy must be measured by way of
computed axial tomography (CAT) examination after injection of iodine with volumetric
measurements of the FLR segments, with the results compared with the measurements
performed before PVE using the same technique. Hypertrophy can be quantified as FLR
hypertrophy, which is defined as the difference between FLR after a waiting period from 3 to
6 weeks after PVE minus FLR before PVE divided by FLR before PVE. The waiting period must
be long enough to allow hypertrophy and as short as possible to avoid tumor growth, which
precludes surgery. Hypertrophy can also be quantified by increased FLR ratio. The FLR ratio
is defined as (FLR volume—tumor in the FLR)/ (total liver volume—total tumor volume) [8].
Technical success of PVE is defined by a complete occlusion of portal branches feeding the
future resected liver segments. Branches of the FLR must be patent with hepatopetal flow. In
the late phase of control portography, parenchymography must be visible only in the FLR.
Clinical success is considered to occur when the patient reaches the volumetric criteria for liver
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resection. Patients with Tumors that Developed in Normal Underlying Liver Parenchyma PVE
is recommended when the FRL-to-total liver ratio is 25 to 30 [7, 10, 11]. The indication of PVE
can be extended to a 40% FLR ratio in patients having received chemotherapy or showing
abnormal indocyanine green test results (or other abnormal liver function tests) [10, 12, 13].
Portal-vein embolization should always be considered when the residual hepatic volume
without it would be less than 30% of the normal size of the liver, and when at least two
contiguous hepatic segments are free of metastases. For technical surgical reasons, the left
lateral segments 2 and 3 are particularly suitable for this approach. As long as the liver is not
cirrhotic, portal-vein embolization results in a 40% to 60% hypertrophy of the contralateral
hepatic lobe. It remains unclear at present whether the stimulus to hypertrophy that portal-
vein embolization provides might also accelerate the growth of tumor nodules [16, 35]. In any
case, the data regarding morbidity, mortality, and long-term survival are comparable to those
of standard hepatic resections [16, 36–39].
Patients with Tumors that Develop in Chronic Liver Disease and Cirrhosis States
In such cases, the decision is based either on liver volume or on liver volume plus estimation
of overall liver function by indocyanin green retention rate at 15 min. An FRLR of 40% is
recommended when the ICCG 15 is between 10% and 20%. When the ICCG 15 is[20%, an FRLR
of 50% is recommended [12–14].
Patients with Tumors Invading the Biliary Tree Associated with Cholestasis
Because biliary obstruction has impaired liver regeneration and hypertrophy, the biliary tree
of the FRL must be drained first, and PVE can be performed secondarily. The indication is an
FRLR\40% [15].
Contraindication for PVE [11]
PVE is contraindicated in the following types of patients:
1. Tumors invading the portal vein
2. Portal hypertension (blocked to free hepatic veinpressure gradient[12 mmHg)
3. Coagulation disorders (PT\60%, platelet count\50 G/l)
4. Even if previous transarterial chemoembolization (TACE) may improve PVE results [16],
a minimum of 3-week delay between TACE and PVE is recommended.
Patients should be informed that this procedure is not an antitumoral treatment but a treatment
made to increase safety or to enable a surgical procedure. Minor complications are encountered
in 20% to 25% of cases and are mainly associated with slight fever and abdominal discomfort
and pain. Major complications are infrequent and mainly include infection and subcapsular
hematoma, hemobilia, and portal vein thrombosis 9\2% of cases). Mortality due to PVE has
not been reported. When tumors (usually small nodules) are present in the nonembolized lobe,
it must be explained to the patient that those lesions might increase in size more quickly due
to PVE [17]. Patients must also be told that the efficacy of the procedure can be estimated
approximately 4 weeks after
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PVE by way of CAT with injection of contrast media and liver volumetry.
14.2. Embolization method
Access to the portal system should be done under ultrasound guidance to puncture a periph‐
eral branch [8]. Access can be obtained by way of controlateral approach (i.e., puncture of the
left portal branch and embolization of theright portal branches) or ispsilateral approach
(puncture of the right portal branch to embolize right portal branches. The advantage of the
controlateral approach is easier catheterization, but there is a risk of damage to the FLR. Five-
French materials (catheter or introductory sheath) are usually recommended. The catheter
should be placed at the splenomesenteric confluence to perform a portography to visualize
portal anatomy, including its variations, and to localize segment IV branches. Measurement
of portal pressure is not routinely performed in patients with normal liver. In cirrhotic patients,
measuring the portal and central venous pressures is useful to determine whether the patient
has a portostemic gradient[12 mmHg in, which case the patient is at major risk of perisurgical
complications [18, 19]. These patients are not eligible for PVE. The aim of embolization is
complete obstruction of the targeted branches and redistribution of flow to the FLR branches
only. Final portography is mandatory to verify this objective. A final pressure measurement
should be obtained at the end of the procedure in patients with chronic liver disease to
document portal pressure increase, which is usually approximately 3 mmHg. Embolization of
segment IV branches is recommended in patients with tumors who are undergoing extended
right hepatectomy. However, if embolization of that segment causes risk of reflux into the
portal branch of the FRL, such embolization must not be performed because any major reflux
into FRL portal branches might preclude surgery.
15. Two-stage hepatic resection
A further way of enabling curative resection of patients with extensive bilobar hepatic
metastases of colorectal carcinoma is so-called two-stage hepatic resection [17]. This technique
is suitable for patients with bilateral hepatic metastases who can undergo neither complete
tumor resection, nor tumor resection combined with a local ablative procedure, because of the
risk of postoperative hepatic insufficiency. Most, but not all, of the tumor burden is resected
in a first operation, and then the remaining tumor nodules are resected in a second one, after
liver tissue has regenerated. The decision whether to operate in one or two stages depends on
the quantity and quality of the extratumoral hepatic tissue. The second operation is usually
performed three to four weeks after the first, to allow time for the residual liver tissue to become
adequately hypertrophic. [40]
16. Extreme liver surgery
Involvement of major vascular structures (vena cava or hepatic veins) by liver metastases has
been considered as a contraindication to surgery for colorectal liver metastases. However, at
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the present time this clinical situation is no longer considered as contraindication due to the
experience gained with total vascular exclusion (TVE) of the liver combined with vascular
reconstruction. These techniques have made the surgery possible even for this group of
patients, without exposing them to the risk of massive intraoperative blood loss and gas
embolism. TVE consists on hepatic inflow and outflow occlusion. [46-48] This can be achieved
by clamping the portal vein/ hepatic artery as well as the supra and infra hepatic vena cava.
Alternatively, the hepatic veins are isolated and clamped in addition to the vascular portal
structures. The latter technique is more advantageous as it can preserve the caval flow,
however, in cases of caval infiltration by metastatic lesion/s this technique is not feasible. On
the other hand, if hemodynamic instability is encountered while the vena cava is clamped, a
veno-venous bypass should be installed to overcome this complication. Although, it is believed
that the hepatic blood flow can be interrupted safely up to 60 minutes, when vascular resection/
reconstruction is necessary, a 60 minute duration of ischemia may be not sufficient. [47] Hence,
hypothermic perfusion of the liver should be instituted. The combination of TVE with in situ
hypothermic perfusion was evaluated in our center. [68] It is found that this combination was
(a) Portal hypertension (blocked to free hepatic veinpressure gradient[12 mmHg) 
2. Coagulation disorders (PT\60%, platelet count\50 G/l) 
(a) Even if previous transarterial chemoembolization (TACE) may improve PVE results (16), a minimum of 3-week delay between TACE and PVE is recommended. 
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postoperative hepatic insufficiency. Most, but not all, of the tumor burden is resected in a first operation, and then the remaining tumor nodules are resected in a second one, after liver tissue 
has regenerated. The decision whether to operate in one or two stages depends on the quantity and quality of the extratumoral hepatic tissue. The second operation is usually performed three to 
four weeks after the first, to allow time for the residual liver tissue to become adequately hypertrophic.(40)  
CT-scan of the liver in the same day after portal vein embolsiation with Lipiodol.
The same patient – hypertrophy of the left liver, 8 weeks later 
Figure 2. Portal vein embolization and liver hypertrophy.
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PVE by way of CAT with injection of contrast media and liver volumetry.
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eral branch [8]. Access can be obtained by way of controlateral approach (i.e., puncture of the
left portal branch and embolization of theright portal branches) or ispsilateral approach
(puncture of the right portal branch to embolize right portal branches. The advantage of the
controlateral approach is easier catheterization, but there is a risk of damage to the FLR. Five-
French materials (catheter or introductory sheath) are usually recommended. The catheter
should be placed at the splenomesenteric confluence to perform a portography to visualize
portal anatomy, including its variations, and to localize segment IV branches. Measurement
of portal pressure is not routinely performed in patients with normal liver. In cirrhotic patients,
measuring the portal and central venous pressures is useful to determine whether the patient
has a portostemic gradient[12 mmHg in, which case the patient is at major risk of perisurgical
complications [18, 19]. These patients are not eligible for PVE. The aim of embolization is
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risk of postoperative hepatic insufficiency. Most, but not all, of the tumor burden is resected
in a first operation, and then the remaining tumor nodules are resected in a second one, after
liver tissue has regenerated. The decision whether to operate in one or two stages depends on
the quantity and quality of the extratumoral hepatic tissue. The second operation is usually
performed three to four weeks after the first, to allow time for the residual liver tissue to become
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Preoperative imaging – bilateral 7 liver mets (A)
Preoperative imaging – bilateral 7 liver mets (D) 
Preoperative imaging – bilateral 7 liver mets (B) 
Preoperative imaging – bilateral 7 liver mets (C)
Preoperative imaging – bilateral 7 liver mets (E) First stage liver resection 
Second stage liver resection Postoperative imaging 
Figure 3. Two stage hepatectomy.
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associated with a better liver tolerance to ischemia, a better liver function, and a significantly
lower rate of complications compared to standard TVE >60 min. In some cases, a combined
liver and vascular resection may be required. An experience with such cases (combined liver
and vena cava resection) has shown that a 5-year survival of 38.3% can be obtained even for
this group of patients. [49] In conclusion, using TVE and vascular reconstruction techniques,
surgery in cases with involvement of the vena cava or hepatic veins is not necessarily contra‐
indicated. However, a very careful evaluation and selection of the cases should be done,
making sure that the risks involved do not counterbalance the desired benefits. [42]
17. Timing of surgery
Optimal duration chemotherapy and timing of liver surgery in responding patients have not
been definitively established. For patients not considered resectable, in the clinical setting,
most surgeons perform liver resection as soon as metastases become operable. Similarly, there
is still debate, whether chemotherapy should precede resection when metastases are synchro‐
nous, particularly when the primary tumor is in place and the surgery involves the resection
of the primary tumor as well as a simultaneous major liver resection. At the present, many
surgeons believe that the chemotherapy is a better choice for patients with synchronous liver
metastases, although these conclusions come from retrospective or surgical series from a single
center. Capussotti and colleagues have published several papers on this topic. [40-43] There is
only one randomized study [23] which has evaluated the results of preoperative chemotherapy
and demonstrating an absolute difference in favor of chemotherapy. However, this study has
a drawback as it was not possible to separate the benefits of preoperative chemotherapy from
those of adjuvant postoperative chemotherapy. Another issue is the impact which the disease
progression while on chemotherapy has on the timing of surgery. Disease progression during
neoadjuvant chemotherapy indicates a poor prognosis. In a cohort of 131 patients undergoing
rescue hepatectomy, 5-year survival rates were 8% if disease progressed during preoperative
chemotherapy, 30% if disease was stable, and 37% in responders. [14] These findings suggest
that hepatectomy for CRC metastases should be undertaken as soon as technically feasible and
underscore the importance of collaboration between medical oncologists and surgeons in
achieving that goal. Medical oncologists should be referring patients for surgery before tumor
progression, and surgeons need to consider tumor evolution in addition to resectability. Thus,
patients with biologically aggressive tumors unlikely to benefit from resection may be spared
surgery upfront and can instead consult with the medical oncologist for a better regimen likely
to induce tumor response or stabilization. [44]
18. Local tumor destruction and hybrid techniques
In recent years, local ablative methods such as cryotherapy and radiofrequency ablation (RFA)
have come into more common use for the in situ destruction of hepatic metastases. Among
these methods, RFA has been studied the best. It can be performed percutaneously, laparos‐
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associated with a better liver tolerance to ischemia, a better liver function, and a significantly
lower rate of complications compared to standard TVE >60 min. In some cases, a combined
liver and vascular resection may be required. An experience with such cases (combined liver
and vena cava resection) has shown that a 5-year survival of 38.3% can be obtained even for
this group of patients. [49] In conclusion, using TVE and vascular reconstruction techniques,
surgery in cases with involvement of the vena cava or hepatic veins is not necessarily contra‐
indicated. However, a very careful evaluation and selection of the cases should be done,
making sure that the risks involved do not counterbalance the desired benefits. [42]
17. Timing of surgery
Optimal duration chemotherapy and timing of liver surgery in responding patients have not
been definitively established. For patients not considered resectable, in the clinical setting,
most surgeons perform liver resection as soon as metastases become operable. Similarly, there
is still debate, whether chemotherapy should precede resection when metastases are synchro‐
nous, particularly when the primary tumor is in place and the surgery involves the resection
of the primary tumor as well as a simultaneous major liver resection. At the present, many
surgeons believe that the chemotherapy is a better choice for patients with synchronous liver
metastases, although these conclusions come from retrospective or surgical series from a single
center. Capussotti and colleagues have published several papers on this topic. [40-43] There is
only one randomized study [23] which has evaluated the results of preoperative chemotherapy
and demonstrating an absolute difference in favor of chemotherapy. However, this study has
a drawback as it was not possible to separate the benefits of preoperative chemotherapy from
those of adjuvant postoperative chemotherapy. Another issue is the impact which the disease
progression while on chemotherapy has on the timing of surgery. Disease progression during
neoadjuvant chemotherapy indicates a poor prognosis. In a cohort of 131 patients undergoing
rescue hepatectomy, 5-year survival rates were 8% if disease progressed during preoperative
chemotherapy, 30% if disease was stable, and 37% in responders. [14] These findings suggest
that hepatectomy for CRC metastases should be undertaken as soon as technically feasible and
underscore the importance of collaboration between medical oncologists and surgeons in
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18. Local tumor destruction and hybrid techniques
In recent years, local ablative methods such as cryotherapy and radiofrequency ablation (RFA)
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these methods, RFA has been studied the best. It can be performed percutaneously, laparos‐
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copically, or at open surgery and is currently used for tumors up to 5 cm in diameter. Lencioni
et al. recently reported a multicenter study of 423 patients with a total of 615 metachronous
metas - tases of colorectal carcinoma who were treated with RFA. The average tumor size was
2.7 cm [18]. In this patient group, 25% had local tumor progression, and the 1-, 3-, and 5-year
survival rates were 86%, 47%, and 24%. These figures correspond to those of Abdalla et al.,
who found that tumor progression is more probable after RFA than after surgical resection [19,
43]. In general, RFA is associated with low morbidity and mortality. As no prospective data
are yet available for a comparison of local ablative techniques to hepatic resection with curative
intent, the procedure cannot be recommended as an alternative to hepatic resection, though it
does play a role as an additional, complementary method of achieving complete tumor
destruction in patients whose lesions are not otherwise R0-resectable.
19. Radiofrequency thermal ablation (RFA)
RFA is the most widely used technique for local destruction of CRLM and has gained popu‐
larity because of its relative easy usage, and its effectiveness as an adjuvant treatment.48 For
the treatment of CRLM, RFA can be used as: 1) a definitive treatment per se; 2) a complemen‐
tary procedure to surgery, or 3) in the treatment of recurrent metastatic disease after surgery.
Results so far show that RFA must be restricted to cases in which the size of the dominant
lesion is less than 3 cm or when a maximum of three tumours are present.49 In a study on
percutaneous RFA for CRLM, local control was achieved in 78% of tumours <2.6 cm, but only
in 47% of tumours 2.6-4.0 cm and 32% of tumours >4.0 cm.42 The anatomic location of a
metastasis is an additional limitation of RFA. In the vicinity of a large hepatic vessel, the heat
sink effect significantly increases the risk of incomplete ablation. Also, the risk of thermal injury
is increased when nodules are close to main biliary structures or to extrahepatic organs. In
these cases, new RFA techniques or additional procedures, such as hepatic inflow occlusion
or intraductal cooling, have to be considered. [50, 51] Because of the high local recurrence rates,
and of the anatomical limitations described above, there is still no place for RFA in patients
with resectable colorectal metastases. Surgical RFA for small resectable CRLM could only be
acceptable in a randomized trial comparing resection with surgical RFA, [52] and it was shown
that hepatic resection is still the treatment of choice for CRLM and that RFA alone provides
survival only slightly superior to non-surgical treatment. [53] This is the case also for patients
with solitary liver metastases who are treated with RFA (higher LR rate and shorter recurrence
free and overall survival). [54] Radiofrequency ablation has been proposed to treat a limited
number of small metastases, simultaneously with right PVE. [46, 47] Although this strategy is
theoretically appealing because it limits the number of surgical operations, its effectiveness
compared to two-step hepatectomies is doubtful. The place of RFA in the treatment of CRM
is limited: it is most useful for early recurrences detected as small lesions after resection,
because it is not mandatory to stop the chemotherapy, except for the use of bevacizumab, and
because RFA allows a ‘‘test of time’’ that helps to select out patients with very aggressive/
disseminated disease that would not benefit from repeated surgery.
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19.1. Frequency of complications
19.1.1. Mortality
A total of 21 deaths were reported in 11 series, [41] with overall mortality varying from 0% to
5.2%. Four deaths were related to cirrhosis. Eleven occurred in patients undergoing resections,
eight of which were major hepatectomies. Eight deaths were related to liver failure, four of
which were subsequent to major hepatectomy with IRFA on the remnant liver for bilobar
disease. Five deaths were caused by myocardial infarct; one of these related to a carcinoid crisis
and another to a haemorrhage. Four deaths resulted from portal thrombosis, three of which
occurred in cirrhotic patients. One of these patients had been treated by IRFA alone. Four
deaths were related to septic complications; two of these referred to pulmonary infections, one
to infection of the ascites and one to multiple deep abscesses. Lastly, three deaths were reported
after postoperative haemorrhaging; one was caused by liver failure after an intrahepatic
haematoma in a cirrhotic setting, one resulted from myocardial infarction following a hae‐
morrhage in a large metastasis treated by IRFA, and one patient was treated by major hepa‐
tectomy and two IRFA sessions and died of cardiac arrest after postoperative bleeding.31
19.1.2. Infections
Abdominal infections were reported in 49 patients in 21 series. [41] Diagnosis of infection was
delayed by up to 5 months. Seventeen liver abscesses were reported, of which one was fatal
and were related to IRFA. Only one case of biliary digestive anastomosis was observed. Ten
cases of perihepatic abscesses at resection sites were reported. Twelve were following digestive
system-associated procedures. These abscesses were treated by percutaneous drainage and
antibiotics. One patient needed re-operation and died from septic shock. Seven cases of wound
infection were reported; two were re-operated. Lastly, one case of peritonitis after infection of
the ascites was reported and was fatal.
19.1.3. Biliary complications
Twenty-five  early  (30  postoperative  days)  and 14  delayed (sometimes  for  >4  months18)
biliary complications [42] were reported in 10 series. Twelve biliary leakages occurred, 10
of which were early. Six occurred in resection combined with IRFA. One early leakage was
caused by a prophylactic cholecystectomy, but two delayed leakages were associated with
a biliary stenosis. Fifteen intrahepatic bile collections were described, one of which induced
duodenal compression. One article gave details of the treatment of eight biliomas: all eight
were drained percutaneously and two recurred after drain clamping. Two were related to
biliary  stenoses  and were  treated by intrahepatic  stenting;  the  other  six  patients  under‐
went  endoscopic  sphincterotomy.  Eleven  biliary  stenoses  associated  with  jaundice  and
biliary  dilatation  were  reported,  of  which  five  were  early.  These  were  complicated  by
biliomas, biliary leakage and cholangitis. In their prospective study, some authors [43] did
not observe a correlation between central or peripheric localization of the tumour and the
frequency of biliary complications.
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Liver failure was reported in 24 patients in 11 articles [41] and was fatal in eight patients.
Fourteen liver failures occurred after IRFA combined with major resection. Six liver failures
occurred in cirrhotic patients; three of these failures occurred after IRFA alone. Two liver
failures were subsequent to portal thrombosis.
19.1.5. Vascular complications
Different types of vascular complication were described in in a total of 22 patients. Associated
procedures such as cholecystectomy or colectomy induced six haemorrhages, two of which
were fatal and one required re-operation after prophylactic cholecystectomy. Three haemor‐
rhages from the needle track were treated during surgery by compression. In three cirrhotic
patients, haemorrhage occurred in the necrosis induced by the IRFA; one patient died as a
result. [25]
Treatment of two juxta-portal lesions induced haemorrhages from arterial injuries. 25, 26 In
one patient, an arterio-portal fistula appeared in an area of necrosis 6 weeks later and was
treated by a transfemoral embolization. [18] Similarly, a false aneurysm occurred in one patient
6 months after IRFA and led to a haemorrhage. Five portal thromboses were reported, [19, 25,
34] four of which were complete and fatal. Three of these occurred in cirrhotic patients treated
with Pringle vascular occlusion.
19.1.6. Skin burns
Eight dispersive pad skin burns were reported in four articles. Skin burns occurred when RFA
ran for >30 min on high power and within large and multiple skin pads. One skin burn occurred
in a patient with bilateral hip prostheses.30 One third-degree skin burn required surgical
treatment. [38]
19.1.7. Visceral damage
Two instances of thermal gastric damage [41] and one of acute cholecystitis near the gallblad‐
der were observed after IRFA during surgery and were treated immediately.
19.1.8. Comparison with hepatectomy
The morbidity of hepatectomy depends on the extent and complexity of the hepatic resection.
Intraoperative RFA as a standalone treatment is indicated for unresectable tumours in patients
in whom major hepatectomy would leave a low level of functional hepatic reserve. Mortality
and morbidity rates in major hepatic resection are 0–5% and 20–50%, respectively. [45] Rates
of liver failure after major hepatectomy preceded by portal embolization are 4–10% vs.2.6%
after IRFA [46, 47] combined with hepatic resection. There is reported mortality of 2.3% and
morbidity of 19.8% in patients treated by resection and combined IRFA, and estimates their
results to be comparable with those of resection alone. [31] Morbidity rates after major hepatic
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resection and IRFA combined with hepatic resection are comparable, even if IRFA is indicated
in tumours unresectable by hepatectomy alone. [48]
The past 10 years have represented a period of learning for surgeons who deal with liverme‐
tastases with the aim of treating more patients by combining IRFA with resection. The benefit:
risk ratio is now well known and surgeons have access to the knowledge they need to make
more informed choices about whether to resect, ablate or renounce treatment on a lesion-by-
lesion basis. Surgeons who are skilled in intraoperative ultrasound diagnosis and guidance
are now not only able to choose whether or not to perform surgery, but are also able to perform
IRFA and do not need to involve a radiologist. Specific complications related to IRFA are rare,
especially if the lesion is <35 mm in diameter and is located far from a main biliary duct and
no additional septic procedures are used. The surgeon can decide to ablate a lesion in a more
difficult situation, but this carries greater risk. Combining resection with IRFA leads to higher
morbidity, especially in difficult patients with numerous bilateral lesions, but this may be
necessary to achieve R0 (microscopically negative) resection margins.
20. Hepatic re-resection in case of recurrent tumor
The resection of hepatic metastases of colorectal carcinoma is followed by tumor recurrence
in up to two thirds of cases, and about half of these recurrences are found in the liver [12, 23,
27, 28]. In general, whenever there is a chance of a curative resection, resection should be
considered for recurrent tumors as well. The operative morbidity and mortality of hepatic
reresection in experienced centers are no greater than those of primary resection. In a study
on second operations in 94 patients with recurrent hepatic metastases of colorectal carcinoma,
38% of the patients were alive 5 years after surgery [12]. Thus, whenever complete resection
of the tumor is possible, surgery is indicated even for patients with recurrent hepatic meta‐
stases.
21. Conclusion
The results of surgical treatment of metastatic colorectal carcinoma have improved markedly
in recent years. The reasons for this include developments in medical imaging, in perioperative
and surgical treatment, and in chemotherapy, with the introduction of potent new protocols.
Clinicopathological factors such as tumor size, number of tumor nodules, and extrahepatic
tumor manifestations no longer contraindicate hepatic resection. The main consideration at
present is the need to achieve a complete R0 resection. Accompanying chemotherapy should
be considered, especially for patients with an unfavorable risk profile. Neoadjuvant chemo‐
therapy is reserved for patients with marginally resectable metastases. The resectability or
nonresectability of hepatic metastases is a matter that must be evaluated by a surgeon who is
experienced in the treatment of hepatic metastases. Hepatic resection of colorectal liver
metastases after downsizing by chemotherapy provides the only chance of long term survival
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for patients with initially unresectable colorectal liver metastases. Additional surgical techni‐
ques can be combined to chemotherapy to further improve resectability. The only absolute
contraindication for resection is the inability to completely resect all metastases, avoiding
postoperative liver failure by leaving enough functional liver parenchyma. The presence of
poor prognostic factors no longer limits the indications for resection. Neoadjuvant treatment
with chemotherapeutic agents such as irinotecan and oxaliplatin, hepatic artery infusion
combined with systemic therapy and biologic agents (bevacizumab, cetuximab) play an
important role in increasing the number of patients eligible to secondary resection. However,
with the progressive use of neoadjuvant chemotherapy further studies are necessary to answer
questions such as the risk: benefit ratio in maximizing response rates versus vascular changes
in the liver (current opinion still divided concerning their importance). These questions remain
challenging and should not be underestimated. The perfecting of surgical techniques together
with safer procedures, as well as the improvement in chemotherapy regimens have allowed
doctors to offer patients with liver metastasis the possibility of curative treatment or longterm
survival. Factors that were previously considered contraindications for the surgery, such as
number of metastases, synchronous metastases and even the presence of extrahepatic disease,
must be considered only as prognostic factors and must not prevent the patient from having
the opportunity of being treated.
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1. Introduction
Colorectal cancer is one of the most frequent malignant tumors and a leading cause of cancer-
related death. One third of the patients develop a metastasis during the course of the disease.
Because of that, it is very important to know about the evolution of the illness, how to make a
quick diagnosis and how to provide an appropriate treatment depending on the tumor and
the location of the metastases.
Management of patients with colorectal metastases without the intervention of a multidisci‐
plinary team specialized in the liver can lead to patients being denied potentially curative
treatments.
1.1. Metastatic disease
It´s necessary to have a protocol before the treatment of metastatic disease:
• Physical examination
• Laboratory test: The serum carcinoembryonic antigen (CEA) level is a valuable marker in
patients with recurrent colorectal cancer. It must be remembered that about 25% of tumors
do not secrete CEA.
• Imaging: Radiologic imaging is a critical component of the preoperative research on a
patient with colorectal liver metastasis. In fact, it is often used to determine whether the
patient should be further considered for resection.
• Surgical indications: the patient must be in acceptable health to tolerate the physiologic
consequences of the surgery. Next, the primary colorectal cancer must be resected and the
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presence of other extrahepatic disease must be ruled out. Preoperative workup should
include a recent colonoscopy, chest X-ray and chest CT.
• Complications: Successful outcome in hepatic surgery depends largely upon minimizing
intraoperative blood loss. Excessive blood loss is not only associated with increased
perioperative morbidity but also with a shorter time to recurrence and decreased survival
rates after resection of colorectal liver metastases.
• Survival
2. Non hepatic disease in colorectal cancer
2.1. Lung metastases
2.1.1. Lung metastases in CRC
Colon cancer is a systemic disease in 19% of the patients, and the liver and lungs are the most
common locations for a metastasis. Colorectal adenocarcinoma is the most common cancer
leading to pulmonary metastasectomy
2.1.1.1. Symptoms
Most pulmonary metastases are asymptomatic and they are detected incidentally during the
initial diagnostic staging study for a primary tumor or in the monitoring imaging studies
afterwards, generally during a thoracic CT scan. Symptoms such as coughing, pain or
hemoptysis mainly appear in patients with hilar involvement.
2.1.1.2. Preoperative evaluation
A solitary pulmonary nodule in a patient with a previous cancer can be bening or malignant
(primary or secondary); although in most cases will be malignant (Mery et al. 2004). When
there are multiple nodules, the probability of metastatic disease increases significantly.
There are no pathognomonic radiological features that distinguish the metastasis of primary
tumors, even though metastasis is generally well circumscribed, spherical with smooth
margins and are mainly subpleurales or periferics. However, primary lung cancers are single
lesions, with irregular edges, asociated linear densities and are often more central.
Although the background and radiographic features of a lesion can provide clues as to whether
an individual lesion is bening or malignant, it is not posible to distinguish reliably a metastasis
from a primary lung cancer. The resection of the nodule is the most reliable method to establish
the diagnosis.
The presence of pulmonary metastasis makes it necessary to carry out a complete staging. The
extent of the required pulmonary resection will guide the preoperative evaluation of the
patients: patients who require a pneumonectomy will need a higher level of cardiopulmonary
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reserve compared with patients who only require wedge resections (Villeneuve and Sundar‐
esan 2009). The key for a successful surgical resection of pulmonary metastases is an adequate
selection of the patient through a preoperative evaluation and a precise surgical planning. To
do so, we can use the following diagnostic tests:
High-resolution helical CAT scan is a basic tool which detects approximately 20-25% more
nodes that standard CT, and the detection is reliable in nodes of 2-3 mm (Remy-Jardin et al.
1993; Collie et al. 1994).
PET – An examination with Positron Emission Tomography (PET-FDG) is recommended to
optimize the selection of patients who are candidates for pulmonary metastasectomy. How‐
ever, we have to take into account the fact that PET has a limited sensitivity for lesions <1 cm
in size (Reinhardt et al. 2006). It is very useful to assess the intra-thoracic node involvement
(hilar or mediastinal), local hidden recurrence of the primary tumor or in other locations such
as the abdomen or the pelvis (Villeneuve and Sundaresan 2009).
The main value of PET is its high sensitivity to detect an extra-thoracic disease. In general
terms, metastasectomy must not be performed unless all the deposits or foci of the disease are
treatable (except when the patient is included in a specific protocol such as a clinical trial for
a vaccine or symptomatic lesions that cannot be treated otherwise). In any case, a positive extra-
thoracic result in a PET examination is not enough evidence to rule a patient out from surgery
for pulmonary metastases. All suspicious extra-thoracic FDG-highlighted areas must be
biopsied before surgery.
Preoperative biopsy – In patients with highly suspicious lesions in imaging tests, the final
diagnosis is often achieved after the surgical removal of the metastases. However, in many
cases, a preoperative biopsy with CT-guided fine needle aspiration is a useful and less invasive
method to obtain a pathological diagnosis, particularly if the diagnosis of the metastatic disease
is not clear, if the patient is not a good candidate for surgery or if the patient has a primary
tumor (such as testicular germ-cell cancer or lymphoma) for which surgery may not be
required.
Bronchoscopy (with or without endobronchial ultrasound) is indicated as part of the evalua‐
tion in cases of lesions that are centrally located in the CT scan, patients with symptoms of
involvement of the respiratory tract and some types of tumors prone to endobronchial
involvement, such as breast cancer, colon cancer and renal cell carcinoma [36]. Bronchoscopy
is performed before surgery, when a positive result may contraindicate an operation.
The presence of pathological mediastinal adenopathies requires a biopsy with a mediastino‐
scopy or ultrasound-guided endobronchial needle aspiration cytology. Most authors consider
mediastinal node involvement (N2) as a contraindication for resection.
2.1.1.3.Treatment
Management of patients with pulmonary metastases, according to the guidelines of the
National Comprehensive Cancer Network (NCCN) will depend on the form of presentation
along time and on whether the metastases can be resected or not. Synchronous resectable
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metastases are treated with chemotherapy with or without later resection; and if they cannot
be resected, then chemotherapy is indicated. Metachronous resectable metastases can be
resected with or without neoadjuvant chemotherapy, and chemotherapy is indicated when
they cannot be resected. The evaluation of patients in treatment with chemotherapy that can
be transferred to surgery is carried out every 2 months in the selected cases (2013).
Although the quality of the currently available evidence on pulmonary metastasectomy in
cases of colorectal cancer is not enough to draw conclusions on the effectiveness of this kind
of surgery (Pfannschmidt et al. 2007; Fiorentino et al. 2010; Pfannschmidt et al. 2010; Salah et
al. 2012; Gonzalez et al. 2013), pulmonary metastasectomy in cases of selected patients with
metastatic colorectal cancer is a general practice and it is included in the clinical guidelines
(Poston et al. 2011). The objective is to limit surgery only for patients who have the highest
chances to benefit from it, either with longer survival rates or symptom relief, and to optimize
the time of the operation.
The resectability criteria admitted by the main groups are the following (Ehrenhaft et al.
1958; Martini and McCormack 1998; Greelish and Friedberg 2000; Jaklitsch et al. 2001;
Pfannschmidt et al. 2003; Kondo et al. 2005):
• Complete anatomical resection maintaining an adequate pulmonary function (McAfee et al.
1992; Regnard et al. 1998; Inoue et al. 2000; Sakamoto et al. 2001)
• Removal of the primary tumor without persistence of residual disease (R0)
• The existence of resectable extra-pulmonary metastases does not contraindicate pulmonary
resection (Yano et al. 1993; Ambiru et al. 1998; Irshad et al. 2001; Rena et al. 2002); in this
case, the metastases must be treatable with surgery or other therapeutic approach.
• Resectable metastases can be treated with a synchronous resection or a sequential approach.
The resection of one or more pulmonary lesions may also be indicated in a patient with a known
malignant tumor when:
• A new primary lung cancer cannot be ruled out
• There are symptomatic metastases (such as bronchial obstruction with distal suppuration)
that cannot be treated in any other way
• Tissue is required for a new therapeutic strategy (such as an autologous vaccine), preferably
in the framework of a clinical trial.
The approach depends on the number, size, location and estability during the time in TC. In
general, Video-assisted thoracoscopic surgery (VATS) is ideal for peripheral metastases single
or few, stable and smaller than 3 cm. The central lesions are likely to require a segmentectomy
or lobectomy and is best addressed by open thoracotomy.
Video-assisted thoracoscopic surgery has the advantage that it is less painful, postoperative
recovery is faster, hospitalization is shorter and lower long-term morbidity, especially
intrathoracic recurrences (Saisho et al. 2009). Recurrence rates appear to be similar to the
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approach using thoracotomy (Saisho et al. 2009). There are no randomised trials comparing
results between open resections and thoracoscopic surgery, although retrospectively patients
treated by VATS have similar results to patients treated by conventional open thoracotomy
(Carballo et al. 2009)
Concerning the number of metastasis, it is clear that technically the fewer there is, the better.
Although there is no general consensus, ideally from technical and oncologic point of view, it
would be less than five (Hellman and Weichselbaum 1995; Weichselbaum and Hellman 2011)
however it is true that in the majority of cases, unique pulmonary metastasectomies are
conducted and in these patients there is a greater survival advantage (Fiorentino et al. 2010).
Metastases in both lungs are not a contraindication for surgery.
For some patients with metastatic CRC, repeated pulmonary metastasectomy offers an
excellent opportunity for long-term survival, and it is associated with a low operative mortality
rate. Patients with more than 2 metastatic nodes and a maximum diameter of the metastatic
pulmonary node of more than 3 cm present a significantly lower survival rate (Hendriks et al.
2001; Salah et al. 2013).
In  the  case  of  patients  who  do  not  meet  the  criteria  for  a  metastasectomy,  there  are
alternative ablative techniques to locally control the lesion, such as stereotactic radiothera‐
py  and  radiofrequency  ablation  or  cryoablation.  The  experience  with  these  ablation
techniques is limited, but the initial results look promising (Pennathur, Abbas et al. 2009).
The role of chemotherapy  is not yet defined for pulmonary metastases with a colorectal
origin,  because  traditionally,  these  lesions  do  not  show  a  good  response  to  adjuvant
treatments. Currently, chemotherapy has shown very good responses in primary CRC with
regimens such as FOLFOX (fluorouracil, leucovorin and oxaliplatin) and FOLFIRI (fluorour‐
acil, leucovorin and irinotecan), with or without the addition of biological agents such as
bevacizumab (anti-vascular  endothelial  growth factor,  VEGF),  cetuximab and panitumu‐
mab (anti-epidermal growth factor, EGFR). These therapies have not yet been systematical‐
ly studied, and they may become the most effective treatment for pulmonary metastases.
As  a  last  resort,  patients  whose  functional  state  is  poor  are  candidates  for  palliative
treatment only (Villeneuve & Sundaresan 2009).
External radiotherapy can be an option in very specific cases or in clinical trials, provided that
the tumors are not potentially resectable.
2.1.2. Prognostic factors
There are many factors that have an influence on survival after a metastasectomy. The presence
of one or more factors for poor prognosis does not represent an absolute contraindication for
a metastasectomy (Quiros and Scott 2008). Unfavourable prognostic factors include number
and size of the metastasis, inability to completely resect the entire metastatic disease, a short
disease-free interval after treatment for the primary tumor and thoracic node involvement. For
its part, the histology of the tumor also influences the results.
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Figure 1. Comparison of chest scanning during shallow breathing (A) and chest scanning with additional low-dose CT
during maximal inspiration (B). (A) Lung metastasis from colorectal cancer is only barely visible during shallow breath‐
ing (arrow). Also note blurred lung vessels and congested lung parenchyma in this image. (B) Metastasis can be clearly
detected by low-dose CT during maximal inspiration (arrow). Additionally, lung parenchyma is well inflated, and lung
vessels are displayed sharply. http://jnm.snmjournals.org/content/48/1_suppl/45S/F2.expansion.html
(a) (b) 
Figure 2. Multiple metastases Multiple pulmonary metastases from colorectal carcinoma. http://radiopaedia.org/arti‐
cles/pulmonary-metastases, TC/PET metastases from colorectal cancer
3. Node metastases
3.1. Definition and physiopathology
Node metastases are, like with other cancers, the most important dissemination route for
colorectal cancers. This makes lymph node involvement the most important factor in the
prognosis and therapeutic approach for colorectal cancer.
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The first metastases usually appear in the paracolic nodes closest to the primary tumor they
are draining, and frequently only one or two nodes close to the tumor are involved. However,
as the disease evolves, node propagation is larger and affects a variable amount of nodes
located further away, on the arteriovenous system that depends on the intestinal segment
involved. As the neoplasm moves forward, nodes from the main colic vessels that drain the
intestinal neoplastic area are invaded, and the process gradually spreads upwards through
the node chain that accompanies the vessels until it finally reaches the nodes that depend on
the large mesenteric vessels (and, in the case of the rectum, the nodes that depend on the iliac
vessels through the hemorrhoidal venous system). In short, it is known that here is a correlation
between each segment of the colon and its venous and lymphatic drainage which, although
there may be individual alterations, essentially depends on the superior mesenteric venous
system up to the splenic flexure of the colon and, from there, up to the superior rectal vein
which depends on the inferior mesenteric vein. Both are affluent to the portal vein and the
structure of the lymph drainage system is essentially the same. In the area of the rectum, it has
been traditionally accepted that the superior rectal venous system depends on the inferior
mesenteric system, that the middle rectal system depends on the inferior mesenteric system
(a) 
(b) (c) 
Figure 3. Patient with rectal carcinoma and mildly FDG avid metastases to lung. (a) There is a suspicious right upper
lobe lung nodule (arrow) on CT in a patient with prior history of rectal carcinoma. (b) The lesion is only mildly FDG avid
(arrow) on fused PET-CT. Based on these images the lesion is not definitively malignant. This may be due to the limited
resolution of PET and the small lesion size or reduced cellularity. (c) Lung biopsy was subsequently performed confirm‐
ing that the lesion (arrow) represented a metastatic deposit from rectal carcinoma. http://www.hindawi.com/jour‐
nals/ijso/2011/846512/fig7/
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and the internal iliac system, and that the inferior rectal system depends on the internal and
external iliac system.
On the other hand, there are evidences that show that there are factors of the tumor cells which
increase angiogenesis and lymphomagenesis, and which lead to an increased rate of node
metastasis and a worse prognosis. Specifically, vascular endothelial growth factor C (VEGF-
C) and cyclooxygenase-2 (COX-2) (Coexpression of VEGF-C and Cox-2 in Human Colorectal
Cancer and its Association With Lymph Node Metastasis Soumaoro et al. Dis Colon Rectum,
March 2006 392-398).
Node involvement plays a fundamental role in the correct definition of the extent of tumor
spread, together with the depth of the involvement through the wall of the colon or the rectum,
the size of the tumor or the presence of metastases. The number of involved nodes and their
distance to the tumor is the basis of some classic classifications, such as Dukes, Astler and
Coller and the more modern TNM, whose description is already analyzed elsewhere. All
decisions on the treatment must be adopted with reference to the TNM classification, instead
of the old Dukes system or the modified Astler-Coller staging system (Colon and rectum. In:
Edge SB, Byrd DR, Compton CC, et al., eds.: AJCC Cancer Staging Manual. 7th ed. New York,
NY: Springer, 2010, pp 143-64).
Given the importance of the whole number of involved nodes in a proper staging and in order
to obtain a reliable and comparable prognosis, it is necessary to establish a set of minimum
quality criteria for lymphadenectomy. Otherwise, the scenario might be undervalued. Patients
in stage I or II (that is, without node involvement) show five-year survival rates of 75%; in
contrast to survival rates with N1, which are only 45-60%. Also, the higher the number of nodes
studied by the pathologist (and indirectly, resected by the surgeon), the higher the staging
accuracy; if that number is low, there is an undervaluing of the tumor dissemination state.
(Staging accuracy in colorectal carcinoma. Wong et al. Journal of Clinical Oncology. Vol 17. nº
9 1999pp2896-2900).
A panel sponsored by the American Joint Committee on Cancer (AJCC) and the National
Cancer Institute of the USA and presented at the World Conference on Gastroenterology of
Sydney in 1990 (J. Gastroenterol Heptol 6:325-244. 1991) has recommended that at least 12
lymph nodes be examined in patients with colon and rectal cancer in order to confirm the lack
of node involvement due to the tumor. Wong et al. recommend at least the analysis of 14 nodes
in pT2 and pT3 tumors.
There is a special situation with staging patients with rectal cancer and neoadjuvant chemother‐
apy with ypT0-2. In these cases, staging based on the surgical specimen usually shows a decrease
in size and in the involvement of the wall of the intestine of the tumor, but if this is taken into
account together with the reduction in the number of existing nodes in the specimen re‐
moved from the rectum, it could lead to an undervaluing with negative consequences for the
patient’s survival (Comparative Analisis of Limph Node Metastasis in Patients UIT ypT0-2
Rectal Cancers. Park et al. Disease of the Colon and Rectum. Volume 56: 2 (2013). Here, it is
necessary to insist on the fact that, just as the primary treatment of node metastases in CRC must
spread as much as possible (total mesorectal excision, or TME); in the case of patients who have
undergone neoadjuvant treatment with chemotherapy it is also essential to perform a TME.
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The studies that want to ensure the diagnosis of node involvement have researched the
presence of micrometastases or metastases that have been diagnosed with immunohistochem‐
ical techniques in patients in stages I and II (that is, without node involvement in microscopical
terms), and they have found that the presence of micrometastases in these patients does not
affect the prognosis and must not be taken into account when treating CRC (Are Lymph Node
Micrometastases of any Clinical Significance in Dukes Stages A and B Colorectal Cancer?
Oberg et al. Dis Colon Rectum, October 1998 ol. 41, No. 10 1244-1249).
3.2. Sentinel lymph node
In tumors with a metastasis that takes place through the lymphatic system (breast cancer and
melanoma, mainly), there has been a great success in mapping the dissemination of the
primary tumor with the so called sentinel lymph node biopsy technique. In view of this
situation, several studies have started to analyze it, because lymphadenectomy is an important
part in the primary treatment of CRC, both from the staging point of view and in order to
prevent recurrence of the tumor if there are infiltrated lymph nodes left. Having a map of
lymph dissemination similar to the one obtained with breast cancer would mean knowing the
minimum required level of lymphadenectomy, or even of visceral resection. This would allow
the medical team to apply an adequate surgical treatment from an oncological perspective but
with the minimum morbidity and mortality. Unfortunately, it does not seem that this technique
shows reliable results with colorectal cancer (“Técnica del ganglio centinela…”. Sardon Ramos
et al. CIR ESP. 2013 91(6) 366-371.1).
The identification of the sentinel lymph node shows a low sensitivity in the detection of
metastasis and micrometastasis. Approximately one half of the adenopathies are lost if a
lymphadenectomy is performed based on the results of the sentinel lymph node study.
Faerden et al: sentinel node mapping in colonic cancer Disease of the colon & rectum. Volume
51: 891–896 (2008).
3.3. Treatment of lymphatic metastasis
Treatment of lymphatic metastasis, given its close relation with the growth of the primary
tumor, is the same as for the original lesion: primary resection with exeresis of the nodes of
the lymphatic area that drain the tumor. If there is a tumor recurrence in the nodes, the patient
is classified as stage IV, which means that there will be the corresponding treatment: chemo‐
therapy and surgery and radiotherapy, which will be provisionally palliative.
4. Bone metastases
4.1. Introduction
Bone metastases from colorectal cancer are uncommon (10-23% in autopsy cases). They usually
appear late in the natural history of metastatic disease and are associated with liver or lung
metastasis. Acrometastasis is reported to be 0.3-3% of all bone metastases. Cancers of the
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rectum and cecum are accompanied by bone metastasis more frequently than cancers of other
portions of the colon. Signet ring cell carcinoma shows a high incidence of bone metastasis.
Pain is the most common symptom of bone metastasis. As a result of the loss of bone density
affected bones become prone to fracture and injury.
Testing for bone metastasis includes X-ray and bone scanning. Open biopsy is necessary to
establish the diagnosis, exclude osteomyelitis and allow treatment. Early diagnosis is impor‐
tant for improving quality of life in these patients.
Therapeutic management of this condition includes chemotherapy, radiotherapy and surgery,
but because survival after onset of bone metastasis is very poor, palliative treatment is the main
objective.
4.2. Physiopathology
Bone destruction secondary to metastasis is not caused by the tumor cells, but by the activation
of the osteoclasts. The tumor cells secrete an osteoclast activating factor, and the osteoclasts
induce the loss of cortical bone and trabecular bone. This process is divided in four stages
(Mundy & Yoneda, 1995):
1. The tumor cells adhere to the basement membrane (laminin, E-cadherin, integrins).
2. The tumor cells produce proteolytic enzymes that damage the basement membrane.
3. The tumor cells migrate via the basement membrane under the specific control of
chemotactic factors.
4. The tumor cells can stimulate the activity of the osteoclasts.
Clohisy et al. have described four mechanisms that stimulate osteoclast-mediated bone
destruction (Clohisy et al., 2000):
a. Stimulation of the union between the osteoclasts and the bone.
b. Stimulation of the osteoclast-mediated bone resorption.
c. Extension of the survival time of osteoclasts.
d. Acceleration of the production of osteoclasts by precursor cells.
4.3. Clinical presentation
a. Constitutional symptoms: Some patients report anorexia, nausea, vomiting, asthenia,
malaise, and weight loss.
b. Symptoms derived from the primary location: Colorectal carcinoma usually presents itself
accompanied by an alteration of the intestinal rhythm and by the expulsion of blood
originated in the rectum. In advanced stages of the disease, the patient presents consti‐
pation, and a transabdominal mass can be perceived on palpation. A rectal examination
needs to be performed, because tumors of the lower part of the rectum can be easily found.
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c. Symptoms derived from the metastatic disease: Regardless of the symptoms that metastases
may produce on other regions, bone metastases can lead to:
a. PAIN in the affected area, or referred pain, which may be of insidious, and either
progressive or sudden onset, and it may be slight and intermittent or continuous and
activity-related. Night pain is a typical symptom, and it does not always disappear with
oral analgesics, unlike the pain that derives from degenerative processes, such as osteo‐
arthritis, which increases with loads and articular mobility. When pain affects a long bone,
it is easily located by the patient, but when it affects the pelvis or the spinal column, the
pain makes it difficult to properly locate the lesion. When it affects the femur or the tibia
(load-bearing bones), patients report pain when walking, although the pain usually
appears when the bone destruction levels are over 50% and they indicate an imminent
fracture.
b. SWELLING: It may be a sign of lesion aggressiveness when the tumor invades the cortical
bone and affects soft tissue. This presentation is characteristic from colorectal carcinoma,
renal carcinoma and melanoma.
c. FUNCTIONAL DEFICIT: it appears as a consequence of pain. It may be a result of a
medullary or radicular involvement in the case of spinal metastases.
d. IMMINENT FRACTURE: It is a fracture that can appear as a result of a physiological load.
Anamnesis and plain X-ray are necessary for the diagnosis, and the cortical involvement,
the location and characteristics of the lesion (lytic, sclerotic or mixed) and the existence of
fracture lines must be assessed. Permeating and lytic lesions of the proximal third of the
femur are prone to fractures. Pain after radiation is also a sign of an imminent fracture. In
cases in which an imminent fracture is expected on an active patient, a prophylactic
fixation is recommended, especially in load-bearing bones.
4.4. Diagnostic assessment
In the context of colorectal carcinoma, bone metastases normally appear when the disease is
already in an advanced stage (with metastases on other areas), and when the diagnosis has
already been established. For this reason, a histological diagnosis is not usually necessary, and
a treatment can be planned in advance. However, we must also take into account the fact that
in 1-2% of the cases, the osteolytic lesion is unrelated to the primary tumor, which means that
a biopsy is advisable.
4.4.1. Complete physical examination
Including the thyroid gland, breasts, lungs and digestive system.
4.4.2. Laboratory analyses
1. COMPLETE BLOOD COUNT: Anemia, leukopenia or thrombocytopenia may be a sign
of medullary involvement.
2. ESR: High levels may indicate a myeloma or an active process.
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3. ELECTROPHORESIS OF SERUM PROTEINS: They can show a monoclonal gammopathy
and they can confirm a possible myeloma diagnosis.
4. BIOCHEMICAL ANALYSIS: It can rule out hyperparathyroidism.
5. ALKALINE PHOSPHATASE: It shows high levels in cases of advanced metastatic
disease. Very high levels show an unfavourable prognostic factor.
6. CARCINOEMBRYONIC ANTIGEN: Its levels are high in digestive or hepatocellular
carcinomas.
7. PROSTATE-SPECIFIC ANTIGEN: It can detect a prostate carcinoma.
8. HEPATIC ENZYMES AND SERUM ELECTROLYTES: They can show bone and liver
involvement.
4.4.3. Imaging tests
1. ANTEROPOSTERIOR AND LATERAL X-RAYS OF THE LESION: In order to assess an
imminent fracture and to analyse the information they provide.
2. THORACIC X-RAY: In order to see the existence of carcinoma or lung metastases.
3. THORACIC AND ABDOMINAL CT SCAN: In order to assess the existence of possible
visceral metastases.
4. Tc99m BONE SCINTIGRAPHY: In order to assess bone lesions.
Data from the clinical record, an exhaustive physical examination, blood tests and imaging
tests identify more than 85% of all the primary tumors that appear as a bone metastasis. The
following tests could also be performed, albeit only when required:
• NMR: It is seldom recommended in cases of isolated bone lesions (fig. 1), but it may be useful
in cases of a single metastasis in which a resection can be performed, in order to rule out
skip metastases or metastases inside the bone and on the vertebrae, due to its excellent
properties for the exploration of the bone marrow.
• POSITRON EMISSION TOMOGRAPHY (PET): This imaging technique is becoming more
and more important in the field of orthopaedic oncology. It uses [18F]2-fluoro-2-deoxy-
Dglucose (FDG) as a tracer. This is a glucose analog which is taken to the cells by a group
of proteins. This marker is absorbed by malignant tissue with an increased metabolic
activity. PET scans have a very high sensitivity, and it is an important technique for the
identification of primary lesions and other metastases. It can establish the difference
between a local recurrence and a scar, and it is also useful in the assessment of response to
treatment.
4.4.4. Biopsy
Puncture biopsy is an excellent way to confirm a diagnosis of bone metastasis. CT-guided fine-
needle aspiration and thick- or trephine-needle biopsies are very precise techniques, and they
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are easy to use. The orthopaedic surgeon must choose the exact location, taking into account
the location of the lesion, viable access routes and, whenever possible, the final incision line
of the operation, in case of resection surgery, excising the entire area of the biopsy, because it
might be contaminated.
When finding certain locations (usually on the pelvis), a CT scan may be necessary in order to
identify the best point and route of access that will reach the metastatic area and to avoid
regions with reactive sclerotic bone, because these parts may not have tumor cells.
If colorectal carcinoma presents itself with a bone metastasis and the lesion is biopsied, the
biopsy may not always provide a diagnosis for the primary tumor, because a tissue compatible
with adenocarcinoma does not always tell the difference between primary tumors of the
digestive system, prostate, breast and lung.
4.5. Supportive measures
4.5.1. Analgesic therapy
Around 70% of all patients with a bone metastasis report pain at some point along the course
of the disease. The physiopathological pain may be due to medullary compression, distension
of the periosteum or peripheral neurovascular involvement, as well as to pathological
fractures, whenever they are present and mediated by substances such as histamine, substance
P or other cytokines.
4.5.2. Bisphosphonates
Metastatic osteolysis is caused by the stimulation of osteoclast activity. For this reason,
bisphosphonates can play an important role in this process, because they inhibit the osteoclast
activity. They bind with the mineral bone matrix and they have a great physicochemical impact
on the hydroxyapatite crystals.
Some authors have suggested that they are not only useful in the treatment of pain and the
prevention of osteolytic complications, but that they can also modify the natural course of
evolution of cancer in some cases, due to the effect they have on some intermediate products,
such as growth factors.
Ross et al. carried out a systematic review of all randomized essays on patients with bone
metastasis. It is a meta-analysis based on 18 randomized studies in which different bisphosph‐
onates have been compared with a placebo or between themselves. Most of these studies were
performed on patients with breast carcinoma (Ross et al, 2004). The review showed a decrease
in the incidence and an increase in the time until the appearance of bone complications, with
a better evolution of pain and functional capacity, with regard to the control group who
received a placebo. Treatment with oral bisphosphonates (clodronate, etidronate) caused a
decrease in the number of spinal and non-spinal fractures, but it had no effect on the indications
of radiotherapy or in hypercalcaemia.
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4.5.3. Treatment of hypercalcaemia
Hypercalcaemia affects 10-40% of cancer patients at some point, and it causes anorexia, nausea,
vomiting, polydipsia, polyuria, dehydration, constipation, confusion and coma.
It is the result of PTHrP production, which activates bone metabolism and induces an excess
of osteoclast activity. Osteoclasts are then stimulated by local factors produced by tumor cells,
such as interleukin 6. Moreover, calcium levels are also increased due to lower levels of renal
calcium elimination, because PTHrP acts on the renal receptors of the parathyroid hormone
and it increases calcium resorption on the renal tubule. Polyuria and reduction of intravascular
volume appear as a consequence, and for this reason, the initial treatment with these patients
is rehydration with intravenous saline serum in order to balance the intravascular volume and
to improve glomerular filtration and renal secretion of calcium.
Calcitonin inhibits osteoclasts and it has a rapid effect, although for a brief period of time. For
this reason, it is mainly used in emergency treatments.
Plicamycin normalizes calcium levels in up to 50% of the cases, but its serious adverse effects
make it unadvisable to use it.
4.6. Non-surgical treatment
4.6.1. Treatment of metastatic bone disease secondary to colorectal carcinoma
The treatment of bone metastases derived from colorectal tumors is the same as the treatment
for other metastases caused by other tumors. Surgical resection of the primary tumor, together
with chemotherapy and radiotherapy for the rectal cancer is the treatment of choice, depending
on the cases.
4.6.2. Radiotherapy
Radiotherapy is the most widely used palliative treatment for bone metastasis. It is the
treatment of choice for painful lytic bone metastases without short-term risk of fracture, and
it is combined with surgery when there is an imminent fracture or when the fracture has
already taken place. It leads to the necrosis of tumor cells, which makes it possible for the bone
tissue to regenerate afterwards. The result is pain relief and, later on, a re-calcification of the
destroyed areas of the bone, which is important for the functional recovery of the patient and
the prevention of pathological fractures.
4.6.3. Surgical treatment
Surgery for bone metastases requires a previous complete general and local assessment. It
presents its own indications, objectives, techniques and means, and it is associated to a program
for postoperative radiotherapy that follows the lines that have been previously described.
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5. Brain metastases
The increasing incidence of brain metastases in patients with metastatic colorectal cancer has
been attributed to the longer survival rates seen with newer systemic therapies. Compared to
the era when 5-fluorouracil was the primary agent for metastatic disease, median survival has
increased markedly with the introduction of oxaliplatin, irinotecan, and biologic therapies
(from 6 to 7 to approximately 24 months).
However, the incidence of brain metastases in metastatic colorectal cancer is still low, 2.3
percent in one of the series. Brain metastases are usually a late-stage phenomenon, and the
vast majority of patients have metastases in other sites, particularly the lung. Outcomes are
poor, despite aggressive treatment.
The most common mechanism of metastasis to the brain is by hematogenous spread. Meta‐
stases are usually located directly at the junction of the gray matter and white matter where
blood vessels decrease in diameter and act as a trap for clumps of tumor cells. Brain metastases
also tend to be more common at the terminal "watershed areas" of arterial circulation. The
distribution of metastases roughly follows the relative weight and blood flow in each area:
• Cerebral hemispheres — approximately 80 percent
• Cerebellum — 15 percent
• Brainstem — 5 percent
Different primary tumors may have a predilection for metastasis to different areas within the
brain. Gastrointestinal tumors more commonly metastasize to the posterior fossa.
5.1. Clinical presentation
Brain metastases have highly variable clinical features and should be suspected in any cancer
patient who develops neurologic symptoms or behavioural abnormalities. However, multiple
other causes can also be responsible. In the majority of patients, a gradually expanding tumor
mass and its associated edema cause symptoms. Less commonly, intratumoral hemorrhage,
obstructive hydrocephalus, or embolization by tumor cells result in symptoms.
Headache: Headaches occur in approximately 40 to 50 percent of patients with brain metasta‐
ses. The frequency is higher when multiple lesions are present or a metastasis is located in the
posterior fossa.
Focal neurologic dysfunction: Focal neurologic dysfunction is the presenting symptom of 20
to 40 percent of patients. Hemiparesis is the most common complaint but the manifestations
depend upon the location of the metastases.
Cognitive dysfunction: Cognitive dysfunction, including memory problems and mood or
personality changes, is the presenting problem in 30 to 35 percent of patients.
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4.5.3. Treatment of hypercalcaemia
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Seizures: New onset of seizures is the presenting symptom in 10 to 20 percent of patients.
Seizures in patients with brain metastases are almost exclusively associated with supratento‐
rial disease.
Stroke: Another 5 to 10 percent present acutely due to stroke caused by hemorrhage into a
metastasis, hypercoagulability, invasion or compression of an artery by tumor, or embolization
of tumor cells.
5.2. Diagnosis
Imaging studies provide useful information but brain biopsy is necessary in some cases for a
definitive diagnosis.
Contrast-enhanced MRI is the preferred imaging study for the diagnosis of brain metastases.
Biopsy should be performed when the diagnosis of brain metastases is in doubt. This is
particularly important in patients with a single lesion.
Positron emission tomography (PET) may also be useful in these patients by finding other sites
of metastatic disease.
5.3. Treatment
Patients with BM from CRC have a poor prognosis, because they often have substantial
extracranial metastatic disease.
Traditionally, the therapeutic goal in many of these patients has been to palliate debilitating
neurologic symptoms, because most of these patients die of systemic disease. However, new
advances in metastatic CRC management—including the incorporation of monoclonal
antibody therapies bevacizumab, cetuximab, and panitumumab— are enhancing the out‐
comes of patients with systemic disease.
6. Ovarian metastases
Isolated ovarian metastases from primary CRC occur with a low frequency. The incidence of
ovarian metastases (synchronous or metachronous) in patients with CRC is 1 to 14 percent.
Bulky ovarian metastases are often symptomatic and less responsive to systemic chemother‐
apy than are other sites of disease. Resection is associated with fairly low morbidity and, in
some cases, may improve quality of life and prolong survival, even in the setting of widespread
extraovarian metastatic disease. There is a debate regarding prophylactic oophorectomy at the
time of curative resection for primary CRC.
There is a rare variety of ovarian metastasis known as Krukenberg tumor (KT), which has been
the focus of extensive research due to its poor prognosis. Although the age range of patients
is highly variable, KT usually appears in premenopausal women, and for some authors, the
diagnosis of primary tumor after KT is a factor for poor prognosis. They are usually large
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bilateral lesions, solid and bulbous, and they have a gastrointestinal origin in more than 90%
of the cases. Although the form of presentation and the treatment are not different from the
rest of metastatic ovarian lesions secondary to a primary tumor with a digestive origin, the
prognosis is worse. It has been proven that a combined therapy of radical surgery and
radiochemotherapy can achieve a slight improvement in long-term survival rates.
7. Peritoneum metastases
7.1. Definition and physiopathology
Colorectal cancer is a pathological process that spreads through the lymphatic channels
through hematogenous ways and through the invasion of the intestine wall. These mechanisms
result in metastases to the lymph nodes, liver and also peritoneal dissemination. Although the
spread to the lymph and venous systems implies the existence of a local invasive process,
peritoneal dissemination can appear in tumors with high as well as low malignancy. The
dissemination of the cancer that leads to liver and lymph node metastases takes place before
the surgical resection of the primary colorectal neoplasm. Peritoneal dissemination, as well as
dissemination in the resection area (local recurrence) can also take place as a result of the
surgical trauma associated to the resection of the primary neoplasm. The filtration of malignant
cells through the severed lymph channels can also be a mechanism in this intraoperative
phenomenon of cancer dissemination. Dissemination inside the peritoneal cavity is one of the
most severe forms of carcinomatous dissemination from the colon, because it rapidly takes
away —provisionally— all hope for a surgical resection of the lesion. Together with lymphatic
and hematogenous dissemination, transcoelomic spread is one of the routes of tumor dissem‐
ination. In the early stages of peritoneal invasion, transcoelomic spread may be limited to the
neighbouring structures just around the primary tumor, with a potential development of
isolated carcinoid plaques in the adjacent peritoneum. It is of course a possibility that some of
these nodes are not originated in a transperitoneal spread but in a dissemination of the
subperitoneal lymph nodes, as Miles proposes (1926). In a later stage, peritoneal metastases
spread until there is a diffuse peritoneal carcinomatosis in which there are tumor nodes that
spread through the entire parietal peritoneum, greater omentum and adjacent viscera, and
abundant ascites appears (Cirugía del ano, recto y colon. John Golligher 2ª edición). For Hara
(Hara et al. Comparative analysis of intraperitoneal minimal free cancer cells between color‐
ectal and gastric cancer patients using quantitative RT-PCR: possible reason for rare peritoneal
recurrence in colorectal cancer. Clin Exp Metastasis 2007;24:179–89), peritoneal metastases take
place in two stages: first of all, the tumor cells detach themselves from the serosal surface of
the primary tumor and are transported in the peritoneal cavity, and in the second stage,
malignant cells in the peritoneum adhere to places like the omentum and the mesenterium,
and they grow and spread through the peritoneal cavity afterwards.
Four characteristics have been identified as risk factors for tumor cell exfoliation in the
peritoneal cavity: 1. Depth of the invasion, 2. Involvement of lymph nodes, 3. Lymph node
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away —provisionally— all hope for a surgical resection of the lesion. Together with lymphatic
and hematogenous dissemination, transcoelomic spread is one of the routes of tumor dissem‐
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these nodes are not originated in a transperitoneal spread but in a dissemination of the
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spread until there is a diffuse peritoneal carcinomatosis in which there are tumor nodes that
spread through the entire parietal peritoneum, greater omentum and adjacent viscera, and
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ectal and gastric cancer patients using quantitative RT-PCR: possible reason for rare peritoneal
recurrence in colorectal cancer. Clin Exp Metastasis 2007;24:179–89), peritoneal metastases take
place in two stages: first of all, the tumor cells detach themselves from the serosal surface of
the primary tumor and are transported in the peritoneal cavity, and in the second stage,
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invasion, and 4. Venous invasion (Peritoneal cytology in colorectal cancer. Noura et al: Diseases
of the Colon & Rectum. volume 52: 7 2009).
The identification of these tumor cells with preoperative peritoneal washing cytology can
identify those patients at risk of presenting a peritoneal recurrence of the tumor process.
Peritoneal carcinomatosis is a common form of recurrence, and it is frequently the only one,
after surgical curative treatment in digestive and gynecological tumors. It is logical to think
that the dissemination of tumor cells by the tumor is a common previous mechanism for
peritoneal carcinomatosis of abdominal tumors.
There are studies about the mechanisms and incidence of intraperitoneal dissemination of CRC
that have contributed to a better comprehension and a different perception of the pathological
basis of peritoneal carcinomatosis. Although the incidence rates for the presence of tumor cells
during the resection of primary tumors widely vary, the presence of free tumor cells in the
peritoneal cavity (similar to the micrometastases in the blood or the bone marrow) is not an
independent prognostic factor, and it seems possible that these tumor cells can effectively
contribute to the failure of the treatment at an intraperitoneal level. In fact, two studies found
a correlation between the presence of free tumor cells in the peritoneal cavity and the recur‐
rence of the tumor in the peritoneal cavity (Peritoneal Carcinomatosis of Colorectal Origin.
M.J. Koppe. Ann Surg 2006 Febrero. 243(“): 212-222).
Approximately 50% of the patients with CRC stage IV present peritoneal carcinomatosis, and
approximately 25% of the patients present a recurrence of their tumor in the peritoneal cavity
(peritoneal carcinomatosis), without a clear involvement of the liver or the lungs (Chu DZ,
Lang NP, Thompson C, et al. Peritoneal carcinomatosis in nongynecologic malignancy: a
prospective study of prognostic factors. Cancer. 1989;63:364–367. Sugarbaker PH, Cunliffe WJ,
Belliveau J, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy
into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16:83–97).
Local or peritoneal metastases are factors that represent a poor prognosis for colorectal cancer
(Graf et al, 1991; Mahteme et al, 1996; Shepherd et al, 1997; Assersohn et al, 1999) and their
treatment is still an important challenge.
The EVOCAPE study shows an average survival of 5.2 months in patients with peritoneal
carcinomatosis of colorectal origin. (Sadeghi B, Arvieux C, Glehen O, et al. Peritoneal carci‐
nomatosis from non-gynecologic malignancies: results of the EVOCAPE Multicentric pro‐
spective study. Cancer. 2000;88:358–363.).
Patients with peritoneal metastases or locally advanced tumors without distance metastases
can benefit from cytoreductive surgery with intraperitoneal chemotherapy (Mahteme et al.
British Journal of Cancer (2004) 90 403-407).
The average survival rate for patients with carcinomatosis treated with chemotherapy is
around 6-12 months (Gramont er al.2000), although this does not factor the modern therapeutic
approaches that include immunomodulating agents, which have not yet been evaluated
enough and appeared after the year 2000.
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7.2. Peritoneal cytology
In this situation, peritoneal cytology before the resection of the primary tumor and, when
needed, cytoreduction, is a useful tool to assess the prognosis of the patients (both with and
without peritoneal carcinomatosis). And it can also be useful when deciding whether to choose
systemic or intraperitoneal chemotherapy.
In a multivariate analysis, peritoneal cytology appears as an independent predictor for survival
in patients with tumors pT3 or pT4 (Peritoneal cytology in colorectal cancer. Noura et al:
Diseases of the Colon & Rectum. volume 52: 7 2009). Patients with negative cytology results
show better five-year survival rates in cases in which at least the serosal layer is affected by
the tumor than patients with positive results (68% vs. 20.6%). These results are also reflected
in the fact that patients with positive cytology results present a higher rate of peritoneal
dissemination than patients with negative cytology results. Some patients with macroscopic
peritoneal dissemination and negative cytology have been proven to have survived for a long
time (more than 10 years, in some cases); whereas patients with peritoneal dissemination and
positive cytology results show five-year survival rates close to zero. When the peritoneal
cytology results are positive, monitoring has to be particularly careful in order to obtain an
early detection of recurrence (Peritoneal Cytology in Colorectal Cancer. Nishikawa et al.
Disease of the Colon and Rectum. Volume 52:12 (2009). All these promising results with regard
to peritoneal cytology must be included in the evaluation, prognosis and therapeutic approach,
and this requires subsequent prospective studies that homogenize the way in which the
cytology is performed (technique, staining, etc.) and its inclusion in the different studies, such
as its inclusion in the selection protocols to perform Sugarbaker technique.
7.3. Treatment
Peritoneal carcinomatosis and ascites are usually signs of advanced colorectal cancer, and
survival rates, as we have said, are low. However, a more aggressive approach for surgical
cytoreduction of the peritoneal disease has been used as in the treatment for ovarian cancer,
primary peritoneal cancer and appendicular mucinous tumors such as pseudomyxoma and
cystadenocarcinoma, and it shows better results than palliative surgery and conventional
chemotherapy by themselves. The extrapolation of these therapies to the treatment of CRC
seems inappropriate, because these tumors are biologically different, and they are mainly of
a low grade. The arrival of intraperitoneal chemotherapy combined with peritoneal debulking
seems to offer an increased survival rate in selected patients with colorectal carcinomatosis.
Sugarbaker described in 1995 the surgical techniques that lead, when this is not possible, to a
complete resection of the peritoneal neoplastic disease. As in other scenarios of resectable
metastatic disease, it is advisable to consolidate the results obtained thanks to surgery with a
complementary treatment that eradicates the residual microscopic disease. The intraperitoneal
administration of certain cytostatic drugs leads to a higher exposure of the peritoneal surface
to the drugs than with the usual systemic administration. The perioperative administration
(hypertermia-modulated intraoperative administration and/or early postoperative adminis‐
tration) avoids the difficulties that have been traditionally associated with the intraperitoneal
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a low grade. The arrival of intraperitoneal chemotherapy combined with peritoneal debulking
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administration of cytostatic drugs (difficulty of access, erratic distribution, pain…), which have
been one of the main causes of its poor reception by specialists in medical oncology.
This way, and after decades of preclinical and clinical efforts, cytoreductive surgery combined
with preoperative hyperthermic intraperitoneal chemotherapy (HIPEC) appear in this new
century as an indissoluble and feasible multimodal strategy with proven effectiveness in the
treatment of selected cases of peritoneal carcinomatosis in colorectal cancer, although, as we
have said before, it can also be useful for other tumors (González-Moreno S. Cirugía citore‐
ductora y quimioterapia intraperitoneal perioperatoria para las neoplasias con diseminación
peritoneal: ha llegado el momento. Cir Esp. 2005;78(6):341-3)(Sugarbaker PH, Mora JT,
Carmignani P, Stuart OA, Yoo D. Update on chemotherapeutic agents utilized for periopera‐
tive intraperitonealchemotherapy. Oncologist. 2005;10:112-22.)(Treatments and Outcomes of
Peritoneal Surface Tumors Through a Centralized National Service (United Kingdom) S. Rout,
Diseases Of The Colon & Rectum Volume 52: 10 (2009).
There are protocols for the selection of patients which, among other things, try to establish the
mass of the tumor and its location by mapping the abdominal cavity in order to assess the size
of the tumor and the possibility of achieving an adequate cytoreduction. Laparoscopy is a
technique that is currently included in the treatment protocols when there is suspicion or
preoperative evidence of peritoneal carcinomatosis. After obtaining a laparoscopic diagnosis
of the affected areas (including images obtained during the process, if possible), the patient is
sent to a health centre with experience in cytoreductive surgery and HIPEC in order to assess
the procedure (commonly referred to as Sugarbaker technique).
The prognosis and results depend on the level of cytoreduction. It is necessary to take into
account the fact that this cytoreduction goes through a peritonectomy and the resection of
visceral metastases that sometimes involve several days of surgery, with the corresponding
increase of morbidity and mortality. For this reason, it is essential to have specialized or
experienced centres when assessing the results.
As we have said, the level of cytoreduction is directly related to the prognosis. The success rate
of cytoreduction has been established according to different systems, although it is generally
classified as CCR 0 (Completeness of Cancer Resection) when there is no microscopic tumor,
CCR 1 when there are no nodes larger than 0.5 cm and CCR 2 when there are clearly visible
tumors (more than 0.5 cm). Average survival is 33 months for CCR 0, 12.5 months for CCR 1
and 8.5 months for CCR 2 (Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly
FN. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with
peritoneal carcinomatosis of colorectal origin. Br J Surg. 2004;91:747–754).
The most commonly used chemotherapeutic agents are mitomycin C and cisplatin combined
with 5-FU. These agents are heated to 47-59 ºC and inserted in the peritoneal cavity, which lets
the surgeon spread it to all necessary spaces. They are left in the cavity for one hour and a half
to two hours, and then they are drained. The catheters are left in place for postoperative
drainage (Royal RE, Pingpank JF Jr. Diagnosis and management of peritoneal carcinomatosis
arising from adenocarcinoma of the colon and rectum. Semin Oncol. 2008;35:183–191).
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Morbidity rates in the procedure of cytoreduction and HIPEC are around 30% and 60%, and
mortality is less than 2%. Logically, covering the logistic needs for intensive care, chemother‐
apy and trained surgeons with an established protocol allow for an adequate morbidity and
mortality. This therapy must be applied to patients in whom a complete or almost complete
cytoreduction can be achieved. With these conditions, the existing studies (although retro‐
spective) show an important improvement of survival, with some results showing a five-year
survival rate of 49% when cytoreduction is complete. (Yan TD, Black D, Savady R, Sugarbaker
PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative
intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin
Oncol. 2006;24: 4011–409).
It is possible to apply delayed and repeated intraperitoneal systemic chemotherapy after the
cytoreduction with acceptable morbidity rates. It is also possible to administer delayed
intraperitoneal chemotherapy in up to 83% of the patients who had previously undergone
cytoreduction (Delayed Repeated Intraperotoneal Chemotherapy. Fajardo et al. Diseases of
Colon and Rectum. Volumen 55.: 10 (2012)).
On the other hand, there are reasons to be optimistic about the use of immunomodulat‐
ing  treatments  (targeted  monoclonal  antibodies)  which,  when  combined  with  other
‘traditional’ chemotherapeutic approaches, are showing some really promising results. We
still need more studies that let us know what conditions lead to a successful outcome (such
as the KRAS status of the primary tumor) and also whether they have a beneficial effect in
peritoneal carcinomatosis.
Chemotherapy and targeted therapies: There are currently eight active and approved drugs
for patients with metastatic colorectal cancer which are used separately or combined with other
drugs:
5-FU, Capecitabine, Irinotecan., Oxaliplatin, Bevacizumab, Cetuximab, Aflibercept and
Panitumumab.
These chemotherapeutic agents, some of which are monoclonal antibodies, can be combined
in different ways and represent an encouraging future for patients with peritoneal metastases
who were previously called ‘terminally ill’.
7.4. Treatment of metastatic disease
Initial  management of the primary site in patients who present with stage IV disease is
controversial,  and  there  are  no  data  from  prospective  randomized  studies  to  guide
treatment. In general, the choice and sequence of treatment is guided by the presence or
absence  of  symptoms  from  the  primary  tumor  and  whether  or  not  the  metastases  are
potentially resectable.
Surgery provides a potentially curative option for selected patients who present with limited
metastatic colorectal cancer.
Management in patients with unresectable metastatic disease: systemic and hepatic arterial
infusion chemotherapy may be useful treatment options in patients with unresectable disease.
Other established treatment is radiofrequency ablation.
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1. Introduction
Colorectal cancer (CRC) is the second most common cause of cancer death worldwide [1]. The
liver is the most frequent site of metastasis in CRC, both at the time of diagnosis (15-20% of
cases) and after apparently radical surgery on the primary tumour (nearly 40% of cases). If
patients with colorectal liver metastasis (CRC-LM) are not treated, prognosis is very poor, with
a near zero five-year survival rate. At present, liver resection is the only treatment modality
that has the potential to achieve long-term survival and to offer the possibility of a cure. Patients
who undergo complete (R0) resection of liver metastases have a five-year survival rate of
approximately 40-50% [2]. Unfortunately, however, 50% to 70% of patients develop secondary
metastatic disease after R0-resection of CRC-LM [3].
In order to obtain the best results in a systemic disease such as metastatic CRC (mCRC), the
optimal integration of medical treatment and surgery is essential. The introduction of several
effective cytotoxic and targeting agents, in combination with surgical treatment, has extended
survival [4]. In addition, promising emerging therapies –cancer stem cell (CSC)-targeted
therapies, pathway inhibitors for CRC, induction of tumour cell differentiation, improving
liver regeneration, and nanoparticle (NP)-guided tumour ablation, among others– may be
found to be effective in achieving better control and even complete eradication of CRC-LM. If
confirmed, these strategies will bring significant benefits to patients, particularly in terms of
long-term survival. Further, in this era of multimodality treatment of CRC, it is critically
important to identify effective biomarkers for prognosis and prediction of individual treatment
responses, and these are expected to become useful tools for improving therapeutic ap‐
proaches.
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The present chapter aims i, to present the state of the art related to criteria for appropriate
decision making for CRC-LM treatment; ii, to review the current data on the role of biomarkers
used for the prediction of response to CRC-LM therapies; and iii, to outline emerging targeting
agents and new therapeutic techniques to improve life expectancy and quality of life in CRC-
LM patients.
2. Therapeutic approaches to colorectal liver metastases: The state of the art
More than half of patients with CRC will develop liver metastases, and nearly 80% of them
are initially unresectable. Hence, optimal management of hepatic metastases often requires a
multidisciplinary approach. The availability of new medical therapies, including neoadjuvant
chemotherapy and targeted therapies, render a considerable percentage (up to 40%) of initially
unresectable patients potentially resectable, improving the overall outcomes of patients with
mCRC.
Nowadays, to optimise the integration between surgery and medical approaches in the
treatment of mCRC it is necessary to consider different groups, based on current guidelines
for stratification of patients according to clinical goals and treatment. In this section, we
summarise the recommended therapeutic approaches for CRC-LM according to the afore‐
mentioned patient stratification.
2.1. Selection criteria for resection of colorectal liver metastases: Definition of resectability
Patients diagnosed with mCRC should undergo an upfront evaluation by a multidisciplinary
team, including medical oncologists, surgeons, radiotherapists and radiologists, in order to
assess resectability status and to achieve the best therapeutic results [5]. The target end point
for assessing resectability is the potential of surgery to cure the disease when achieving RO
resection of all evident disease. Incomplete resection (macroscopic or microscopic), so-called
debulking surgery, has not been found to help achieve this end point [6].
Classically, surgical criteria have determined resectability [7], but over recent years several
authors have questioned the relevance of many of them. Nowadays, the only surgical criteria
that continue to be widely used are complete tumour resection with the preservation of two
contiguous liver segments (with adequate vascular inflow and outflow) and an adequate liver
remnant (at least 25% of the total liver volume considering the healthy organ) [8]. If, however,
we seek a more comprehensive definition of resectability, we should also take into account
prognostic evaluation and predicted response to different treatments, by including multiple
clinical and molecular factors, which influence patient outcome. Some validated clinical scores
are already available, while molecular factors are still under investigation (discussed in more
detail below in the section entitled Predictive biomarkers for response to treatment in colorectal
cancer. In relation to this, the study conducted by Fong et al. [9]at the Memorial-Sloan Kettering
Cancer Center has been one of the most useful attempts to define prognosis after surgical
management of CRC-LM. The score proposed integrates a range of risk factors which influence
the risk of death after surgery: preoperative carcinoembryonic antigen (CEA) level > 200
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ng/ml, synchronous metastases or metachronous metastases with a disease-free interval of less
than twelve months, more than one metastasis, extrahepatic disease, a tumour > 5 cm in
diameter and lymph node involvement associated with the primary tumour.
Over recent years, several studies, well summarised in the systematic review of Quan et al. [10],
have investigated the validity of these various criteria. Notably, the value of the following
indicators have been questioned: the number of lesions, maximum lesion dimensions, timing
of metastases, absence of metastatic spread outside the liver, and margin of healthy liver tissue,
as has the definition of an adequate liver remnant after resection [11].
In summary, the criteria listed in this section can be regarded as an invaluable tool for patient
stratification before liver resection, but failure to meet them should not constitute an absolute
contraindication to surgery.
2.2. Optimal chemotherapy timing and regimes
In the case of resectable CRC-LM, current guidelines recommend the administration of a course
of an active systemic chemotherapy regimen for a total perioperative treatment time of
approximately six months [12]. The preferred regimens are combination chemotherapy based
on fluoropyrimidines XELOX (capecitabine plus oxaliplatin), FOLFOX (5-fluorouracil,
leucovorin and oxaliplatin) and FOLFIRI (5-fluorouracil, leucovorin and irinotecan), option‐
ally together with antiangiogenic biological agents (bevacizumab, cetuximab or panitumu‐
mab). In order to improve the selection of the regimen to be used, KRAS mutation status should
be determined in all patients at the time of diagnosis of metastatic disease. If no KRAS
mutations are identified, BRAF testing should be considered [13]. New targeting biological
agents are emerging and they can be expected to lead to improvements in clinical effectiveness.
Their effects, pathways and theoretical and practical applications will be discussed in more
detail below in the section entitled Emerging targeting agents for colorectal liver metastases.
In patients with few metastases that are easy to surgically resect and no poor prognostic
indicators, postoperative chemotherapy is usually preferred [14]. On the other hand, in other
clinical situations, perioperative (neoadjuvant plus postoperative) chemotherapy can be used
[15]. The optimal sequencing of chemotherapy is not clear, however, and recent studies have
assessed the pros and cons of different possible timings of administration [16-17]. Potential
advantages of administering chemotherapy preoperatively include earlier treatment of
micrometastatic disease, evaluation of responsiveness to chemotherapy (which can be
prognostic and help decision making) and avoidance of surgery in patients who progress early.
On the other hand, several disadvantages have also been highlighted: the risk of missing the
window of opportunity for resection, which may be due to disease progression or due to a
complete response making it difficult to identify areas for resection; radiological complete
response does not always mean pathological response, as viable cancer cells can remain at the
original sites of metastases [18]; hepatotoxicity develops with some regimens with serious
clinical implications both before and after surgery [19]; and finally, frequent radiological
examinations must be undertaken to determine the appropriate timing for surgery [20]. There
is now a general trend towards the use of perioperative chemotherapy for patients with
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The present chapter aims i, to present the state of the art related to criteria for appropriate
decision making for CRC-LM treatment; ii, to review the current data on the role of biomarkers
used for the prediction of response to CRC-LM therapies; and iii, to outline emerging targeting
agents and new therapeutic techniques to improve life expectancy and quality of life in CRC-
LM patients.
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unresectable patients potentially resectable, improving the overall outcomes of patients with
mCRC.
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treatment of mCRC it is necessary to consider different groups, based on current guidelines
for stratification of patients according to clinical goals and treatment. In this section, we
summarise the recommended therapeutic approaches for CRC-LM according to the afore‐
mentioned patient stratification.
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assess resectability status and to achieve the best therapeutic results [5]. The target end point
for assessing resectability is the potential of surgery to cure the disease when achieving RO
resection of all evident disease. Incomplete resection (macroscopic or microscopic), so-called
debulking surgery, has not been found to help achieve this end point [6].
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contiguous liver segments (with adequate vascular inflow and outflow) and an adequate liver
remnant (at least 25% of the total liver volume considering the healthy organ) [8]. If, however,
we seek a more comprehensive definition of resectability, we should also take into account
prognostic evaluation and predicted response to different treatments, by including multiple
clinical and molecular factors, which influence patient outcome. Some validated clinical scores
are already available, while molecular factors are still under investigation (discussed in more
detail below in the section entitled Predictive biomarkers for response to treatment in colorectal
cancer. In relation to this, the study conducted by Fong et al. [9]at the Memorial-Sloan Kettering
Cancer Center has been one of the most useful attempts to define prognosis after surgical
management of CRC-LM. The score proposed integrates a range of risk factors which influence
the risk of death after surgery: preoperative carcinoembryonic antigen (CEA) level > 200
Colorectal Cancer - Surgery, Diagnostics and Treatment220
ng/ml, synchronous metastases or metachronous metastases with a disease-free interval of less
than twelve months, more than one metastasis, extrahepatic disease, a tumour > 5 cm in
diameter and lymph node involvement associated with the primary tumour.
Over recent years, several studies, well summarised in the systematic review of Quan et al. [10],
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mutations are identified, BRAF testing should be considered [13]. New targeting biological
agents are emerging and they can be expected to lead to improvements in clinical effectiveness.
Their effects, pathways and theoretical and practical applications will be discussed in more
detail below in the section entitled Emerging targeting agents for colorectal liver metastases.
In patients with few metastases that are easy to surgically resect and no poor prognostic
indicators, postoperative chemotherapy is usually preferred [14]. On the other hand, in other
clinical situations, perioperative (neoadjuvant plus postoperative) chemotherapy can be used
[15]. The optimal sequencing of chemotherapy is not clear, however, and recent studies have
assessed the pros and cons of different possible timings of administration [16-17]. Potential
advantages of administering chemotherapy preoperatively include earlier treatment of
micrometastatic disease, evaluation of responsiveness to chemotherapy (which can be
prognostic and help decision making) and avoidance of surgery in patients who progress early.
On the other hand, several disadvantages have also been highlighted: the risk of missing the
window of opportunity for resection, which may be due to disease progression or due to a
complete response making it difficult to identify areas for resection; radiological complete
response does not always mean pathological response, as viable cancer cells can remain at the
original sites of metastases [18]; hepatotoxicity develops with some regimens with serious
clinical implications both before and after surgery [19]; and finally, frequent radiological
examinations must be undertaken to determine the appropriate timing for surgery [20]. There
is now a general trend towards the use of perioperative chemotherapy for patients with
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resectable CRC-LM, but more studies are necessary to provide stronger evidence regarding
the benefit of this approach.
It is important to note that patients diagnosed with rectal cancer and resectable synchronous
liver metastases usually need a specific approach due to the risk of locoregional failure.
Preoperative chemoradiotherapy in locally advanced rectal tumours (cT3/4, cN+) decreases
the risk of pelvic recurrence after surgery, and postoperative chemotherapy is also mandatory
[21]. Some studies suggest that pelvic radiotherapy diminishes tolerance to biological agents,
but there is not enough data to guide decisions on when this approach may be suitable. After
surgical resection of metastases and rectal lesions, pathological rectal disease determines
adjuvant therapy. Specifically, postoperative chemoradiotherapy is advised for patients who
have not received prior chemoradiation and have a higher risk of pelvic recurrence (pT3/4 or
pN1/2) [22]. Patients with pT1-2pN0 tumours should receive six months of adjuvant chemo‐
therapy without pelvic radiation.
In brief, the choices of type of chemotherapy/chemoradiotherapy regimen and its timing
depend on a number of factors, namely a patient’s disease history and pathological status,
tumour gene expression, and previous treatment (including chemotherapy and associated
drug toxicity/safety), as well as institutional preferences.
2.3. Conversion or downsizing chemotherapy
When patients present initially unresectable disease, owing to technical difficulties and/or the
presence of poor prognostic factors, treatment decisions are difficult. In this clinical situation,
preoperative chemotherapy is being considered in highly selected cases in an attempt to
downsize CRC-LM and convert them to a resectable status. In these cases, any active metastatic
chemotherapy regimen can be used, the goal being to reduce the size of the visible metastases
as much as possible. Several trials have been conducted using different combinations of
chemotherapy and biological agents, but they have not provided compelling evidence to
favour one regimen over another [23-24].
Further, there are other factors we must keep in mind when considering this kind of treatment.
Some chemotherapy regimens may cause hepatotoxicity (steatohepatitis and sinusoidal liver
injury, among others) [25]with clinical implications for liver surgery, and we must measure
responsiveness, so radiological and clinical reassessment should be scheduled approximately
every two months after the initiation of chemotherapy. If the disease becomes resectable,
surgery should be performed as soon as possible, in order to limit toxicity.
In addition, we must optimise imaging of CRC-LM choosing the most accurate methods.
Radiological imaging techniques, namely computed tomography (CT), magnetic resonance
imaging (MRI), and positron emission tomography-PET/CT in selected cases, are the essential
tools to measure patient tumour response and resectability, while intraoperative ultrasonog‐
raphy (IOUS) remains mandatory in all patients undergoing surgical resection of CRC-LM.
Indeed, several authors have demonstrated that IOUS can change the surgical management
in up to 35% of patients [26-27].
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Furthermore, it must be taken into account that sometimes a radiological complete response
can be achieved in patients with one or more metastases. However, a systematic review of the
literature suggests that between 17 and 51% of such patients will have residual microscopic
disease [28-29]. Accordingly, all liver metastases, including those with radiological complete
response after chemotherapy, should be resected when technically feasible. In addition, almost
all authors recommend postoperative chemotherapy in these cases.
Overall, recent studies have reported that resectability is achieved in 10 to 40% of selected
patients after chemotherapy. It remains difficult, however, to draw firm conclusions as the
definition of unresectable disease, patient selection criteria, drug regimens, and outcome
measures vary, and there is insufficient data from randomised controlled trials [10].
2.4. Surgical strategy
Liver resection remains the only treatment modality that can achieve long-term survival and
offers a possibility of a cure [2]. Selection criteria for resection of CRC-LM are continually being
refined (see the aforementioned Definition of resectability). In this field, advances in surgical
strategy (timing, techniques, etc.) have improved results, but patient management is complex
and tends to require a combination of different approaches (colorectal resection, liver resection,
chemotherapy, and radiotherapy, among others).
At present, when oncology committees evaluate CRC-LM for surgical treatment, several
clinical scenarios are considered: resectable synchronous metastases, resectable metachronous
metastases and unresectable disease amenable to conversion chemotherapy.
2.4.1. Resectable synchronous metastases
Close to a third (15-34%) of patients have liver metastases at the time of diagnosis (synchronous
metastases). Evidence-based protocols for the management of synchronous metastases are,
however, poor, and few prospective studies have been published recently, such results as are
available being difficult to generalise [30]. In any case, some suggestions can be made.
One of the open questions is the timing of colorectal and liver surgery (simultaneous versus
staged). The traditional approach has been to perform surgery on the primary lesions (color‐
ectal resection), followed by chemotherapy and subsequent liver surgery. Nowadays, simul‐
taneous colorectal and liver resections are preferred when feasible [31]. This combined surgery
can be safely performed whenever minor hepatectomies are planned, but there is no consensus
on the best approach in cases requiring major hepatectomies. Considering the largest series,
some show similar rates in simultaneous and staged resections [32], but a multicentre database
analysis in the USA found increased morbidity and mortality after simultaneous major
hepatectomy and colorectal resection [33]. Thus, in the absence of clear evidence, the decision
to undertake more complex procedures must be made on a case-by-case basis. Even though
surgery is the key treatment in patients with CRC-LM, chemotherapy (and sometimes
radiotherapy) must also be administered. The sequencing of chemotherapy has been discussed
above, and often influences surgical timing.
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the risk of pelvic recurrence after surgery, and postoperative chemotherapy is also mandatory
[21]. Some studies suggest that pelvic radiotherapy diminishes tolerance to biological agents,
but there is not enough data to guide decisions on when this approach may be suitable. After
surgical resection of metastases and rectal lesions, pathological rectal disease determines
adjuvant therapy. Specifically, postoperative chemoradiotherapy is advised for patients who
have not received prior chemoradiation and have a higher risk of pelvic recurrence (pT3/4 or
pN1/2) [22]. Patients with pT1-2pN0 tumours should receive six months of adjuvant chemo‐
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In brief, the choices of type of chemotherapy/chemoradiotherapy regimen and its timing
depend on a number of factors, namely a patient’s disease history and pathological status,
tumour gene expression, and previous treatment (including chemotherapy and associated
drug toxicity/safety), as well as institutional preferences.
2.3. Conversion or downsizing chemotherapy
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presence of poor prognostic factors, treatment decisions are difficult. In this clinical situation,
preoperative chemotherapy is being considered in highly selected cases in an attempt to
downsize CRC-LM and convert them to a resectable status. In these cases, any active metastatic
chemotherapy regimen can be used, the goal being to reduce the size of the visible metastases
as much as possible. Several trials have been conducted using different combinations of
chemotherapy and biological agents, but they have not provided compelling evidence to
favour one regimen over another [23-24].
Further, there are other factors we must keep in mind when considering this kind of treatment.
Some chemotherapy regimens may cause hepatotoxicity (steatohepatitis and sinusoidal liver
injury, among others) [25]with clinical implications for liver surgery, and we must measure
responsiveness, so radiological and clinical reassessment should be scheduled approximately
every two months after the initiation of chemotherapy. If the disease becomes resectable,
surgery should be performed as soon as possible, in order to limit toxicity.
In addition, we must optimise imaging of CRC-LM choosing the most accurate methods.
Radiological imaging techniques, namely computed tomography (CT), magnetic resonance
imaging (MRI), and positron emission tomography-PET/CT in selected cases, are the essential
tools to measure patient tumour response and resectability, while intraoperative ultrasonog‐
raphy (IOUS) remains mandatory in all patients undergoing surgical resection of CRC-LM.
Indeed, several authors have demonstrated that IOUS can change the surgical management
in up to 35% of patients [26-27].
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can be achieved in patients with one or more metastases. However, a systematic review of the
literature suggests that between 17 and 51% of such patients will have residual microscopic
disease [28-29]. Accordingly, all liver metastases, including those with radiological complete
response after chemotherapy, should be resected when technically feasible. In addition, almost
all authors recommend postoperative chemotherapy in these cases.
Overall, recent studies have reported that resectability is achieved in 10 to 40% of selected
patients after chemotherapy. It remains difficult, however, to draw firm conclusions as the
definition of unresectable disease, patient selection criteria, drug regimens, and outcome
measures vary, and there is insufficient data from randomised controlled trials [10].
2.4. Surgical strategy
Liver resection remains the only treatment modality that can achieve long-term survival and
offers a possibility of a cure [2]. Selection criteria for resection of CRC-LM are continually being
refined (see the aforementioned Definition of resectability). In this field, advances in surgical
strategy (timing, techniques, etc.) have improved results, but patient management is complex
and tends to require a combination of different approaches (colorectal resection, liver resection,
chemotherapy, and radiotherapy, among others).
At present, when oncology committees evaluate CRC-LM for surgical treatment, several
clinical scenarios are considered: resectable synchronous metastases, resectable metachronous
metastases and unresectable disease amenable to conversion chemotherapy.
2.4.1. Resectable synchronous metastases
Close to a third (15-34%) of patients have liver metastases at the time of diagnosis (synchronous
metastases). Evidence-based protocols for the management of synchronous metastases are,
however, poor, and few prospective studies have been published recently, such results as are
available being difficult to generalise [30]. In any case, some suggestions can be made.
One of the open questions is the timing of colorectal and liver surgery (simultaneous versus
staged). The traditional approach has been to perform surgery on the primary lesions (color‐
ectal resection), followed by chemotherapy and subsequent liver surgery. Nowadays, simul‐
taneous colorectal and liver resections are preferred when feasible [31]. This combined surgery
can be safely performed whenever minor hepatectomies are planned, but there is no consensus
on the best approach in cases requiring major hepatectomies. Considering the largest series,
some show similar rates in simultaneous and staged resections [32], but a multicentre database
analysis in the USA found increased morbidity and mortality after simultaneous major
hepatectomy and colorectal resection [33]. Thus, in the absence of clear evidence, the decision
to undertake more complex procedures must be made on a case-by-case basis. Even though
surgery is the key treatment in patients with CRC-LM, chemotherapy (and sometimes
radiotherapy) must also be administered. The sequencing of chemotherapy has been discussed
above, and often influences surgical timing.
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On the other hand, we should not forget that patients with synchronous metastases have a
poorer prognosis [34]. Various strategies have been proposed in an attempt to improve results.
One possibility, suggested by Mentha et al. [35], is a change in the treatment sequence, the so-
called reverse approach, which consists of treatment with systemic chemotherapy followed
by liver resection and subsequent primary tumour treatment (with the option of radiotherapy
of the rectal tumour prior to resection). More recently, Bruquet et al. [36], have reported their
experience at the MD Anderson Cancer Center comparing the traditional approach, combined
or simultaneous resection, and a “reverse” strategy. These authors found similar oncological
outcomes, morbidity and mortality with the three options. This lack of strong evidence makes
us cautious, but we believe that the reverse strategy can be considered a reasonable option in
patients with asymptomatic primary CRC but advanced CRC-LM.
2.4.2. Resectable metachronous metastases
Most patients with CRC-LM (2/3 of cases) develop liver metastases after initial treatment,
during the course of the disease (metachronous metastases). The management of resectable
metachronous disease is distinct from that of synchronous disease, though it should also
include diagnostic imaging of CRC-LM, as well as evaluation of the chemotherapy and surgical
history.
In this group of patients, PET/CT should be considered preoperatively to characterise the extent
of metastatic disease and to identify possible sites of extrahepatic disease that could preclude
surgery [37]. In addition, it is important to evaluate previous chemotherapy to guide the choice
of regimen. In general, six months of perioperative (pre- and/or postoperative) chemotherapy
is recommended, but in selected cases observation is also considered appropriate. In addi‐
tion, previous hepatotoxicity and other side effects should be taken into account [12].
In relation to the type of surgery to be performed, previous surgery can preclude surgical
treatment of metachronous metastases, especially if upfront liver resection was performed, it
being necessary to assess the remnant liver and technical difficulties. Finally, recent data
suggest that it is safe to adopt a surgical approach to the treatment of recurrent hepatic disease
isolated to the liver, but that survival decreases with each subsequent curative surgical
approach [38].
2.4.3. Unresectable disease amenable to conversion chemotherapy
In this clinical situation, preoperative chemotherapy is considered in highly selected cases, with
the aim of downsizing CRC-LM [39]. After disease becomes resectable, surgery should be
performed as soon as possible and all liver metastases, including those with radiographic
complete response after chemotherapy, should be resected when technically feasible [10]. The
treatment of the primary tumour can be postponed until the completion of adjuvant therapy [36].
2.4.4. New surgical techniques
A feasible approach has emerged for patients who would be left with an inadequate future
liver remnant (FLR) if complete disease clearance were to be attempted with a single hepatec‐
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tomy: this is a two-stage hepatectomy for bilobular liver metastases in combination with
selected use of portal venous embolization. It offers the best chance of achieving an adequate
degree of liver remnant hypertrophy, being more effective than portal venous embolization
before a single hepatectomy [40].
Although the standard of care for resectable liver metastases is surgical resection, in selected
patients other liver-directed therapies can be used in addition to or instead of surgical
resection. These include intrahepatic arterial chemotherapy [41], radiofrequency tumour
ablation [42], radioembolization [43]and stereotactic external beam radiation [44]. Some of
these innovative techniques will be discussed in more depth below in the section entitled New
therapeutic techniques for colorectal liver metastases.
3. Predictive biomarkers for response to treatment in colorectal cancer
Over the past decade, developments in CRC-LM therapy have improved the prognosis of
patients. Combination chemotherapy, such as FOLFOX or FOLFIRI, has become the standard
regimen for unresectable advanced or recurrent CRC, and high response rates have been
reported. On the other hand, not all patients respond well to these therapies, and it has been
suggested that differential responses are due to the specific molecular profile of each patient
and/or tumour. To facilitate the design of personalised therapeutic strategies for CRC patients,
it is therefore important to identify biomarkers which are able to accurately predict the
sensitivity of patients to the potential therapies and to estimate the likely course of the illness.
Recent advances in the fields of genomics and proteomics have contributed to our under‐
standing of CRC at the molecular level by evaluating the expression profiles of genes and
proteins in tissues and body fluids. To date, some of the candidate biomarkers have yielded
somewhat contradictory results. On the other hand, several studies have identified candidate
molecular biomarkers that may help to predict the response to cytotoxic chemotherapy and
guide treatment selection.
3.1. Molecular predictors of response to chemotherapy
5-Flurouracil (5-FU) is the main stay of all current standard CRC chemotherapy regimens,
despite the fact that it causes serious side effects (grade 3 or 4) in up to 30% of patients. Sev‐
eral enzymes involved in 5-FU metabolism have been proposed as predictors of response to
fluopyrimidine treatment: 5-FU exerts its activity by inhibiting thymidylate synthase (TS), a
key enzyme of nucleotide pyrimidine metabolism that is essential for DNA synthesis and
cellular proliferation. Thymidine phosphorylase (TP) is another enzyme involved in thymi‐
dine metabolism, which regulates the conversion of thymine to thymidine; this is why it is
thought to limit the toxicity of high levels of thymidine and prevent replication errors dur‐
ing DNA synthesis. In this role, TP degrades 5-FU, limiting the activity of this chemothera‐
peutic agent. Dihydropyridimine dehydrogenase (DPD) is a rate-limiting hepatic enzyme
involved in the catabolism of 5-FU [45]. It was found that low levels of expression of TP,
DPD and TS were independently associated with improved overall survival [46]. Specifical‐
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of regimen. In general, six months of perioperative (pre- and/or postoperative) chemotherapy
is recommended, but in selected cases observation is also considered appropriate. In addi‐
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suggest that it is safe to adopt a surgical approach to the treatment of recurrent hepatic disease
isolated to the liver, but that survival decreases with each subsequent curative surgical
approach [38].
2.4.3. Unresectable disease amenable to conversion chemotherapy
In this clinical situation, preoperative chemotherapy is considered in highly selected cases, with
the aim of downsizing CRC-LM [39]. After disease becomes resectable, surgery should be
performed as soon as possible and all liver metastases, including those with radiographic
complete response after chemotherapy, should be resected when technically feasible [10]. The
treatment of the primary tumour can be postponed until the completion of adjuvant therapy [36].
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degree of liver remnant hypertrophy, being more effective than portal venous embolization
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patients other liver-directed therapies can be used in addition to or instead of surgical
resection. These include intrahepatic arterial chemotherapy [41], radiofrequency tumour
ablation [42], radioembolization [43]and stereotactic external beam radiation [44]. Some of
these innovative techniques will be discussed in more depth below in the section entitled New
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Over the past decade, developments in CRC-LM therapy have improved the prognosis of
patients. Combination chemotherapy, such as FOLFOX or FOLFIRI, has become the standard
regimen for unresectable advanced or recurrent CRC, and high response rates have been
reported. On the other hand, not all patients respond well to these therapies, and it has been
suggested that differential responses are due to the specific molecular profile of each patient
and/or tumour. To facilitate the design of personalised therapeutic strategies for CRC patients,
it is therefore important to identify biomarkers which are able to accurately predict the
sensitivity of patients to the potential therapies and to estimate the likely course of the illness.
Recent advances in the fields of genomics and proteomics have contributed to our under‐
standing of CRC at the molecular level by evaluating the expression profiles of genes and
proteins in tissues and body fluids. To date, some of the candidate biomarkers have yielded
somewhat contradictory results. On the other hand, several studies have identified candidate
molecular biomarkers that may help to predict the response to cytotoxic chemotherapy and
guide treatment selection.
3.1. Molecular predictors of response to chemotherapy
5-Flurouracil (5-FU) is the main stay of all current standard CRC chemotherapy regimens,
despite the fact that it causes serious side effects (grade 3 or 4) in up to 30% of patients. Sev‐
eral enzymes involved in 5-FU metabolism have been proposed as predictors of response to
fluopyrimidine treatment: 5-FU exerts its activity by inhibiting thymidylate synthase (TS), a
key enzyme of nucleotide pyrimidine metabolism that is essential for DNA synthesis and
cellular proliferation. Thymidine phosphorylase (TP) is another enzyme involved in thymi‐
dine metabolism, which regulates the conversion of thymine to thymidine; this is why it is
thought to limit the toxicity of high levels of thymidine and prevent replication errors dur‐
ing DNA synthesis. In this role, TP degrades 5-FU, limiting the activity of this chemothera‐
peutic agent. Dihydropyridimine dehydrogenase (DPD) is a rate-limiting hepatic enzyme
involved in the catabolism of 5-FU [45]. It was found that low levels of expression of TP,
DPD and TS were independently associated with improved overall survival [46]. Specifical‐
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ly, deficiency in DPD activity caused by mutations in the gene encoding DPD (the DYPD
gene) can lead to severe 5-FU-related toxicities, which can be fatal. However, as mutations in
the DPYD gene are responsible for only some of the adverse reactions to 5-FU and the asso‐
ciation between genotype and phenotype is not clear [47], further assay development and
prospective trials are needed to evaluate the clinical usefulness of these enzymes in predict‐
ing which patients are likely to develop serious, life-threatening toxicity to 5-FU [48].Irinote‐
can (CPT-11), a topoisomerase inhibitor, shows efficacy in the treatment of mCRC when
used either as a single agent or in combination with radiotherapy and/or other chemothera‐
peutic drugs. Irinotecan acts as an inhibitor of DNA topoisomerase I (Topo I) and exerts a
cytotoxic effect in replicating cells by inducing DNA strand breaks [49]. The active metabo‐
lite of irinotecan is SN-38, which is metabolised in vivo through conjugation by the liver en‐
zyme uridine diphosphate glucuronosyltransferase (UGT1A1). A variant of the gene
encoding this enzyme (UGTA1*28) has come to be considered the main pharmacogenetic
marker for severe haematological toxicity (neutropaenia) of the drug. Nevertheless,
UGT1A1*28 testing as a predictive marker of adverse effects needs to be further investigated
before translation to clinical practice and the available data are not conclusive in defining a
precise genotype-based dosage [50-51]. In addition, tumour expression of Topo-I has been
explored as a biomarker of the efficacy of irinotecan-based therapies [52]. Although further
studies are needed, it has been shown that high levels of Topo-I in tumour tissue are associ‐
ated with a good response to irinotecan [53-54]; these data are consistent with the hypothe‐
sis that a larger amount of Topo I would facilitate the activity of a Topo I inhibitor
[55].Oxaliplatin is a platinum analogue that improves response rate and survival in patients
with advanced CRC. DNA kinking is the major feature of platinum-DNA adducts that block
DNA replication and lead to cancer cell death. These DNA strand breaks are recognised and
repaired by the nucleotide excision repair (NER) pathway, whose major components are ex‐
cision repair cross-complementation group (ERCC1 and ERCC2) proteins, acting as the rate-
limiting enzymes of oxaliplatin efficacy. Several studies have demonstrated that low levels
of ERCC1 and/or ERCC2 gene expression correlate well with better response rates following
oxaliplatin-based therapy in advanced CRC patients, leading to improved survival [56-58].
Despite these promising findings, most of the studies have been retrospective and differed
significantly in design, and results have not been consistent. Further prospective trials are
needed to assess the correlation between decreased expression of ERCC1 and ERCC2 and
platinum toxicities.
3.2. Molecular predictors of response to anti-EGFR therapy
We should also consider other markers which it has been suggested may be useful for
predicting patient responses to biological agents, in particular anti-epidermal growth factor
receptor (EGFR) monoclonal therapy. EGFR is a member of the transmembrane tyrosine kinase
receptor family ErbB, involved in tumour cell proliferation, inhibition of apoptosis, invasion,
migration and angiogenesis [59-60]. When a ligand binds the EGFR homo or hetero-dimers
are formed with other ErbB family members, initiating two main intracellular cascades, which
are important for cell survival, proliferation and migration. On the one hand, membrane
localization of the lipid kinase PIK3CA counteracts PTEN and promotes AKT1 phosphoryla‐
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tion and, on the other, KRAS activates BRAF, which in turn triggers the mitogen-activated
protein kinases [61]. Abnormal expression of EGFR has been demonstrated in many advanced
tumours, including in breast cancers, gliomas and lung cancer. In the case of mCRC, EGFR
overexpression has been detected in 60-80% of cases [59]and a correlation has been reported
with early tumour recurrence and extra-hepatic metastasis [62]. For these reasons, researchers
started to explore therapeutic strategies to disrupt EGFR function.
Cetuximab, a chimeric IgG1 monoclonal antibody (mAb), and panitumumab, a humanised IgG2
mAb, target the EGFR and have small, but nonetheless clinically important response rates of
around 10% in unselected patients with chemotherapy-refractory metastatic CRCs. However,
its exact role in the CRC metastatic cascade has not yet been characterised due to controver‐
sial results obtained with anti-EGFR antibody therapy. In fact, it has been shown that the
response to this therapy is independent of EGFR expression in tumour tissue [63]. In relation
to this, some studies suggest that EGFR expression in the primary tumour does not necessari‐
ly correspond with the level of expression in metastatic tissue, while other studies have reported
78-100% concordance in EGFR expression in the two tissue compartments [64]. These find‐
ings prompted an effort to identify alternative predictive molecular biomarkers that could help
to select patients more likely to benefit from anti-EGFR agents. Candidates that have been
investigated so far include not only molecular alterations affecting the EGFR, but also molecu‐
lar events downstream in the pathway, such as aberrations in the interlinked RAS-RAF-mitogen-
activated protein kinase and PI3K-AKT-mTOR intracellular signalling transducers.
KRAS encodes for a cytoplasmic GTP-binding protein with low inherent GTPase activity.
When the KRAS protein is bound to GTP, it relays signals of cellular proliferation and inhib‐
ition of apoptosis, acting as a typical oncogene. Activating mutations in KRAS lead to a gain
in function of this gene, and hence over-expression of RAS/RAF-dependent proteins. Specifi‐
cally, mutations in codons 12 and 13 of exon 2 have been demonstrated to predict low re‐
sponse rate to EGFR monoclonal antibodies-targeted therapy [65]. A lack of efficacy and also
a possible detrimental effect on anti-EGFR–based chemotherapy in KRAS-mutated patients
have been suggested by some trials using cetuximab in first-line therapy for mCRC, such as
OPUS (oxaliplatin plus cetuximab) [66] and CRYSTAL (irinotecan plus cetuximab) [67].
These data indicate that KRAS mutations can be considered a highly specific biomarker to
predict poor response to treatment with anti-EGFR mAbs. In addition, due to the fact that
anti-EGFR agents fail to achieve either objective responses or disease stabilization in a sub‐
stantial proportion of patients with wild-type KRAS tumours also, it seems necessary to in‐
vestigate mutations in other genes involved in signalling pathways downstream of EGFR,
including NRAS, BRAF, PIK3CA and PTEN.
Activating mutations in other members of the RAS family are less common than those found
in KRAS. For instance, the reported frequency of NRAS mutations is 2.2 to 2.6%. Patients with
tumours with these mutations had a significantly poorer response rate to anti-EGFR therapy
[68], although no significant differences were seen in overall survival between patients with
wild-type and mutant NRAS.
Mutations in BRAF, the major effector of KRAS, have also been associated with reduced
sensitivity to EGFR-directed therapy. In a retrospective study, Di Nicolantino et al.
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ly, deficiency in DPD activity caused by mutations in the gene encoding DPD (the DYPD
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ciation between genotype and phenotype is not clear [47], further assay development and
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encoding this enzyme (UGTA1*28) has come to be considered the main pharmacogenetic
marker for severe haematological toxicity (neutropaenia) of the drug. Nevertheless,
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[55].Oxaliplatin is a platinum analogue that improves response rate and survival in patients
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limiting enzymes of oxaliplatin efficacy. Several studies have demonstrated that low levels
of ERCC1 and/or ERCC2 gene expression correlate well with better response rates following
oxaliplatin-based therapy in advanced CRC patients, leading to improved survival [56-58].
Despite these promising findings, most of the studies have been retrospective and differed
significantly in design, and results have not been consistent. Further prospective trials are
needed to assess the correlation between decreased expression of ERCC1 and ERCC2 and
platinum toxicities.
3.2. Molecular predictors of response to anti-EGFR therapy
We should also consider other markers which it has been suggested may be useful for
predicting patient responses to biological agents, in particular anti-epidermal growth factor
receptor (EGFR) monoclonal therapy. EGFR is a member of the transmembrane tyrosine kinase
receptor family ErbB, involved in tumour cell proliferation, inhibition of apoptosis, invasion,
migration and angiogenesis [59-60]. When a ligand binds the EGFR homo or hetero-dimers
are formed with other ErbB family members, initiating two main intracellular cascades, which
are important for cell survival, proliferation and migration. On the one hand, membrane
localization of the lipid kinase PIK3CA counteracts PTEN and promotes AKT1 phosphoryla‐
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tumours, including in breast cancers, gliomas and lung cancer. In the case of mCRC, EGFR
overexpression has been detected in 60-80% of cases [59]and a correlation has been reported
with early tumour recurrence and extra-hepatic metastasis [62]. For these reasons, researchers
started to explore therapeutic strategies to disrupt EGFR function.
Cetuximab, a chimeric IgG1 monoclonal antibody (mAb), and panitumumab, a humanised IgG2
mAb, target the EGFR and have small, but nonetheless clinically important response rates of
around 10% in unselected patients with chemotherapy-refractory metastatic CRCs. However,
its exact role in the CRC metastatic cascade has not yet been characterised due to controver‐
sial results obtained with anti-EGFR antibody therapy. In fact, it has been shown that the
response to this therapy is independent of EGFR expression in tumour tissue [63]. In relation
to this, some studies suggest that EGFR expression in the primary tumour does not necessari‐
ly correspond with the level of expression in metastatic tissue, while other studies have reported
78-100% concordance in EGFR expression in the two tissue compartments [64]. These find‐
ings prompted an effort to identify alternative predictive molecular biomarkers that could help
to select patients more likely to benefit from anti-EGFR agents. Candidates that have been
investigated so far include not only molecular alterations affecting the EGFR, but also molecu‐
lar events downstream in the pathway, such as aberrations in the interlinked RAS-RAF-mitogen-
activated protein kinase and PI3K-AKT-mTOR intracellular signalling transducers.
KRAS encodes for a cytoplasmic GTP-binding protein with low inherent GTPase activity.
When the KRAS protein is bound to GTP, it relays signals of cellular proliferation and inhib‐
ition of apoptosis, acting as a typical oncogene. Activating mutations in KRAS lead to a gain
in function of this gene, and hence over-expression of RAS/RAF-dependent proteins. Specifi‐
cally, mutations in codons 12 and 13 of exon 2 have been demonstrated to predict low re‐
sponse rate to EGFR monoclonal antibodies-targeted therapy [65]. A lack of efficacy and also
a possible detrimental effect on anti-EGFR–based chemotherapy in KRAS-mutated patients
have been suggested by some trials using cetuximab in first-line therapy for mCRC, such as
OPUS (oxaliplatin plus cetuximab) [66] and CRYSTAL (irinotecan plus cetuximab) [67].
These data indicate that KRAS mutations can be considered a highly specific biomarker to
predict poor response to treatment with anti-EGFR mAbs. In addition, due to the fact that
anti-EGFR agents fail to achieve either objective responses or disease stabilization in a sub‐
stantial proportion of patients with wild-type KRAS tumours also, it seems necessary to in‐
vestigate mutations in other genes involved in signalling pathways downstream of EGFR,
including NRAS, BRAF, PIK3CA and PTEN.
Activating mutations in other members of the RAS family are less common than those found
in KRAS. For instance, the reported frequency of NRAS mutations is 2.2 to 2.6%. Patients with
tumours with these mutations had a significantly poorer response rate to anti-EGFR therapy
[68], although no significant differences were seen in overall survival between patients with
wild-type and mutant NRAS.
Mutations in BRAF, the major effector of KRAS, have also been associated with reduced
sensitivity to EGFR-directed therapy. In a retrospective study, Di Nicolantino et al.
New Strategies to Enhance the Efficacy of Surgical Treatment for Colorectal Liver Metastasis
http://dx.doi.org/10.5772/57326
227
[69]examined tumours from patients who had received anti-EGFR therapy. They found that
none of the patients carrying the BRAF V600E mutation responded and that none of the
responders had a BRAF mutation. Moreover, De Roock et al. [68]recently conducted a large
trial in which they analysed tumour specimens from CRC patients treated with the anti-EGFR
agent cetuximab. They found that KRAS and BRAF mutations were mutually exclusive; the
BRAF mutation was identified in 4.7% of cases and those carrying the mutation had a signifi‐
cantly lower response to anti-EGFR therapy, than those with BRAF wild-type tumours.
The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin, PI3K/AKT/mTOR,
pathway is another major intracellular signalling effector pathway activated by EGFR
stimulation. Mutations in this pathway are present in as many as 30-40% of CRC patients. In
particular, mutations in PI3KCA have been described in 15% of colon carcinomas, 20% of these
being found in exon 20. Patients carrying these mutations and treated with anti-EGFR therapy
have poorer clinical outcomes than wild-type PIK3CA carriers. However, because the number
of patients with these mutations is very low in most studies, there is a need for controlled trials
to assess whether the use of BRAF and PIK3CA mutation analysis as predictors of anti-EGFR
therapy efficacy improves clinical outcomes [70].
PTEN is the only tumour suppressor gene involved in the PI3K/AKT-mTOR pathway. Loss
of PTEN function, due to mutations, deletions or epigenetic silencing, leads to activation of
this pathway. On the other hand, intact PTEN expression in metastatic tissue was found to
be predictive of response to cetuximab, while this was not observed in patients with intact
PTEN expression in primary tumour tissue [71]. These data are, however, limited and the
findings need to be explored in larger confirmatory studies.
3.3. Molecular predictors of response to anti-VEGFR therapy
VEGF is overexpressed in CRC and the level of expression is directly correlated with the
development of metastasis [72]. The VEGF family is made up of six growth factors (GFs) which
exert their effects via binding to one of the three VEGFRs which belong to the tyrosine kinase
receptor (TKR) family, mostly found in endothelial cells and angioblasts [64]. Bevacizumab is
a humanised mAb which binds to VEGFA blocking the binding of this GF to VEGFR, thereby
avoiding the corresponding intracellular signal transduction. Although several groups have
focused their research efforts on finding a biomarker to accurately predict the clinical benefit
of adding bevacizumab to therapy, no predictive molecules have yet been identified.
Several candidate predictive biomarkers similar to the KRAS mutation for cetuximab, have
been proposed for bevacizumab, but they have remained elusive [73]. Specifically, it has
been shown that the efficacy of bevacizumab therapy is independent of KRAS, BRAF and
p53 status [74-75].
Another candidate is Ang-2, a regulator of angiogenesis that exerts context-dependent effects
on endothelial cells. Although this ligand binds the endothelial-specific receptor tyrosine
kinase 2 (TIE2) and acts as a negative regulator of angiogenesis, recent data from analysis of
tumours indicate that, under certain conditions, Ang-2 can stimulate endothelial cells, acting
as an anti-apoptotic agent in these cells [76]. In this context, serum Ang-2 has been proposed
as a candidate biomarker due to the fact that patients having low pre-therapeutic Ang-2 serum
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levels was significantly associated with response rate after receiving bevacizumab-containing
treatment, though results should be further validated [77].
Recently, the development of quantitative predictive biomarkers has led to the increased use
of imaging in the evaluation of tumour angiogenesis. Dynamic contrast enhanced-MRI (DCE-
MRI) is a technique that can assess tumour perfusion and microvascular vessel wall permea‐
bility. Although it is difficult to evaluate the subtle changes occurring during bevacizumab
treatment, correlations between tumour grade, microvessel density and VEGF expression in
clinical trials of angiogenesis inhibitors have led to DCE-MRI parameters being proposed as
biomarkers of drug efficacy [73]. Lastly, some authors have investigated changes in plasma
cytokines and angiogenic factors during treatment as potential markers of therapeutic
response and resistance [78].
3.4. DNA microarray-based gene expression profiling
Due to the genetic heterogeneity of CRC, many authors agree that it is likely to be necessary
to assemble a panel of biomarkers to obtain high enough sensitivity to use these types of
biomarkers as a screening test in clinical practice [48, 52]. To date, however, a limited number
of markers have been identified in CRC, and their individual use has led to conflicting results.
In this context, advances in genomic techniques, such as DNA microarrays (allowing high-
throughput analysis of genes), are very important as they provide large volumes of data which
increases the probability of uncovering potential biomarkers. Recently, a total of 66 genes
associated with benefit from adjuvant 5-FU/leucovorin treatment were identified. Six of the so-
called “chemotherapy benefit genes” were selected to create treatment score algorithms. If
validated, these signatures will quantify the likelihood of differential treatment benefit from 5-
FU-based therapy [79]. Further, DNA microarray-based gene expression profiling provides a
strategy to search systematically for molecular markers of colon cancer. Gene expression
analysis studies have already resulted in many new insights into cancer biology and mRNA
expression analysis is turning out to be a very useful tool for disease outcome prediction [80-81].
4. Emerging targeting agents for colorectal liver metastasis
The current treatment recommendations for mCRC indicate that therapeutic approach should
be multidisciplinary [82], as surgery plus perioperative treatment offers better survival than
surgery alone in patients with resectable or potentially resectable disease. Thus, whereas
primary surgery is the gold standard for individuals with a single mestatasis, it seems that for
multinodular disease, neoadyuvant chemotherapy followed by surgery may be more appro‐
priate [83]. Though in cases of unresectable aggressive disease, treatment should be decided
on a case-by-case basis (adapting the strategy to the characteristics of the patient), a multidis‐
ciplinary approach should be taken to planning treatment from the outset. In fact, in select
unresectable patients chemotherapy allows subsequent rescue surgery and achieves a
significant increase in five-year survival rates [39]. An essential aspect of the treatment strategy
for advanced CRC is the consideration of treatment as a continuum. Thus, sequential admin‐
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[69]examined tumours from patients who had received anti-EGFR therapy. They found that
none of the patients carrying the BRAF V600E mutation responded and that none of the
responders had a BRAF mutation. Moreover, De Roock et al. [68]recently conducted a large
trial in which they analysed tumour specimens from CRC patients treated with the anti-EGFR
agent cetuximab. They found that KRAS and BRAF mutations were mutually exclusive; the
BRAF mutation was identified in 4.7% of cases and those carrying the mutation had a signifi‐
cantly lower response to anti-EGFR therapy, than those with BRAF wild-type tumours.
The phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin, PI3K/AKT/mTOR,
pathway is another major intracellular signalling effector pathway activated by EGFR
stimulation. Mutations in this pathway are present in as many as 30-40% of CRC patients. In
particular, mutations in PI3KCA have been described in 15% of colon carcinomas, 20% of these
being found in exon 20. Patients carrying these mutations and treated with anti-EGFR therapy
have poorer clinical outcomes than wild-type PIK3CA carriers. However, because the number
of patients with these mutations is very low in most studies, there is a need for controlled trials
to assess whether the use of BRAF and PIK3CA mutation analysis as predictors of anti-EGFR
therapy efficacy improves clinical outcomes [70].
PTEN is the only tumour suppressor gene involved in the PI3K/AKT-mTOR pathway. Loss
of PTEN function, due to mutations, deletions or epigenetic silencing, leads to activation of
this pathway. On the other hand, intact PTEN expression in metastatic tissue was found to
be predictive of response to cetuximab, while this was not observed in patients with intact
PTEN expression in primary tumour tissue [71]. These data are, however, limited and the
findings need to be explored in larger confirmatory studies.
3.3. Molecular predictors of response to anti-VEGFR therapy
VEGF is overexpressed in CRC and the level of expression is directly correlated with the
development of metastasis [72]. The VEGF family is made up of six growth factors (GFs) which
exert their effects via binding to one of the three VEGFRs which belong to the tyrosine kinase
receptor (TKR) family, mostly found in endothelial cells and angioblasts [64]. Bevacizumab is
a humanised mAb which binds to VEGFA blocking the binding of this GF to VEGFR, thereby
avoiding the corresponding intracellular signal transduction. Although several groups have
focused their research efforts on finding a biomarker to accurately predict the clinical benefit
of adding bevacizumab to therapy, no predictive molecules have yet been identified.
Several candidate predictive biomarkers similar to the KRAS mutation for cetuximab, have
been proposed for bevacizumab, but they have remained elusive [73]. Specifically, it has
been shown that the efficacy of bevacizumab therapy is independent of KRAS, BRAF and
p53 status [74-75].
Another candidate is Ang-2, a regulator of angiogenesis that exerts context-dependent effects
on endothelial cells. Although this ligand binds the endothelial-specific receptor tyrosine
kinase 2 (TIE2) and acts as a negative regulator of angiogenesis, recent data from analysis of
tumours indicate that, under certain conditions, Ang-2 can stimulate endothelial cells, acting
as an anti-apoptotic agent in these cells [76]. In this context, serum Ang-2 has been proposed
as a candidate biomarker due to the fact that patients having low pre-therapeutic Ang-2 serum
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levels was significantly associated with response rate after receiving bevacizumab-containing
treatment, though results should be further validated [77].
Recently, the development of quantitative predictive biomarkers has led to the increased use
of imaging in the evaluation of tumour angiogenesis. Dynamic contrast enhanced-MRI (DCE-
MRI) is a technique that can assess tumour perfusion and microvascular vessel wall permea‐
bility. Although it is difficult to evaluate the subtle changes occurring during bevacizumab
treatment, correlations between tumour grade, microvessel density and VEGF expression in
clinical trials of angiogenesis inhibitors have led to DCE-MRI parameters being proposed as
biomarkers of drug efficacy [73]. Lastly, some authors have investigated changes in plasma
cytokines and angiogenic factors during treatment as potential markers of therapeutic
response and resistance [78].
3.4. DNA microarray-based gene expression profiling
Due to the genetic heterogeneity of CRC, many authors agree that it is likely to be necessary
to assemble a panel of biomarkers to obtain high enough sensitivity to use these types of
biomarkers as a screening test in clinical practice [48, 52]. To date, however, a limited number
of markers have been identified in CRC, and their individual use has led to conflicting results.
In this context, advances in genomic techniques, such as DNA microarrays (allowing high-
throughput analysis of genes), are very important as they provide large volumes of data which
increases the probability of uncovering potential biomarkers. Recently, a total of 66 genes
associated with benefit from adjuvant 5-FU/leucovorin treatment were identified. Six of the so-
called “chemotherapy benefit genes” were selected to create treatment score algorithms. If
validated, these signatures will quantify the likelihood of differential treatment benefit from 5-
FU-based therapy [79]. Further, DNA microarray-based gene expression profiling provides a
strategy to search systematically for molecular markers of colon cancer. Gene expression
analysis studies have already resulted in many new insights into cancer biology and mRNA
expression analysis is turning out to be a very useful tool for disease outcome prediction [80-81].
4. Emerging targeting agents for colorectal liver metastasis
The current treatment recommendations for mCRC indicate that therapeutic approach should
be multidisciplinary [82], as surgery plus perioperative treatment offers better survival than
surgery alone in patients with resectable or potentially resectable disease. Thus, whereas
primary surgery is the gold standard for individuals with a single mestatasis, it seems that for
multinodular disease, neoadyuvant chemotherapy followed by surgery may be more appro‐
priate [83]. Though in cases of unresectable aggressive disease, treatment should be decided
on a case-by-case basis (adapting the strategy to the characteristics of the patient), a multidis‐
ciplinary approach should be taken to planning treatment from the outset. In fact, in select
unresectable patients chemotherapy allows subsequent rescue surgery and achieves a
significant increase in five-year survival rates [39]. An essential aspect of the treatment strategy
for advanced CRC is the consideration of treatment as a continuum. Thus, sequential admin‐
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istration of conventional drug combinations based on fluoropyrimidines plus oxaliplatin or
irinotecan, results in longer survival. While XELOX, FOLFOX and FOLFIRI are the schemes
most commonly used, the trend has been for the standard of care chemotherapy for first-line
mCRC to change from FOLFIRI to FOLFOX [84]. In order to improve the poor prognosis of
patients with mCRC, treatment intensification has been also tested using the combination of
the three active agents 5-FU/leucovorin, oxaliplatin and irinotecan (FOLFOXIRI), and this has
achieved increase in R0 secondary resection rate and in overall survival [85]. Other schemes
are currently being evaluated in randomised phase II trials as first-line chemotherapy for
advanced CRC; these include TOMOX (oxaliplatin plus raltitrexed) which has been found to
have a similar efficacy to FOLFOX [86].
The development of new drugs that selectively target specific molecular pathways involved
in tumour progression (targeted therapy) has resulted in one of the most important advances
in mCRC in the last decade, with biological agents today being a commonly used weapon in
the armamentarium against mCRC, particularly in chemorefractory patients and those who
are not initially suitable liver resection candidates [87]. In recent years, intense efforts have
been focused on developing new molecules to inhibit targets that are critical for CRC, including
new anti-angiogenesis agents, novel tyrosine kinase inhibitors (TKIs), agents to act on the PI3K/
Akt signalling pathway, modulators of autophagy, and proteasome inhibitors, as well as
targeted therapies against cancer stem cells, among others.
4.1. Targeting angiogenesis
GFs have been identified as important targets [88]and the development of targeting biological
agents, directed to block effects of GFs on tumour cells, and their integration with cytotoxic
chemotherapy regimens has resulted in significant improvements in efficacy outcomes.
One of the most important effects of some GFs is the promotion of angiogenesis, an essential
mechanism for both primary tumour growth and metastasis. Due to this, novel therapeutic
approaches have focused on the role of angiogenesis-targeting inhibitors. So far, three
antiangiogenic biological agents have been approved for the treatment of patients with mCRC:
bevacizumab, cetuximab and panitumab. The first successful targeting agent was bevacizu‐
mab; today, there is clear evidence to recommend addition of this anti-VEGF antibody to
cytotoxic therapy (irrespective of the selected chemotherapy regimen) in both the first- and
second-line treatment, this significantly increasing overall survival [75]. Moreover, it has been
shown that bevacizumab, combined with FOLFOX or FOLFIRI, may also be active in chemo‐
refractory and selected mCRC patients [89]. Currently, new trials (CHARTA and PERIMAX)
are being conducted with bevacizumab plus FOLFIRI, designed to assess the benefits and
limitations of a highly active four-drug regimen in mCRC [4]. In addition, it is also important
to note that in patients with mCRC on a bevacizumab-containing regimen who show disease
progression and hence need a change in the chemotherapy regimen, maintenance therapy with
bevacizumab appears to be associated with significantly longer overall survival than the same
regimen without bevacizumab [90]; this fact highlights the importance of bevacizumab therapy
beyond disease progression in patients with mCRC, although this use is not currently recom‐
mended outside clinical trials.
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The other two antiangiogenenic biological agents, cetuximab and panitumumab target the
ligand-binding domain of EGFR. Signalling of this receptor appears to modulate angiogenesis
via the upregulation of VEGF and other angiogenic factors [60]. The use of these EGFR
inhibitors was approved for mCRC in patients with wild-type KRAS, whose tumours express
EGFR. In fact, as described previously, BRAF and codon 12 KRAS mutations are predictive of
adverse outcome in CRC patients receiving cetuximab, being associated with a shorter time to
progression and poor survival [91]. In contrast, it has been demonstrated that the combination
of chemotherapy, such as irinotecan or FOLFIRI, and cetuximab as a first line in patients with
wild-type KRAS significantly improves survival [67, 92]. Cetuximab is also indicated as a
monotherapy in such patients following failure of both irinotecan- and oxaliplatin-based
chemotherapy [93], while panitumumab is also a valid second-line option for wild-type KRAS
patients, as a monotherapy or combined with FOLFIRI [94], though the addition of this EGFR
inhibitor to oxaliplatin-based chemotherapy in first-line treatment of mCRC did not improve
survival or response rate [95]. In an attempt to increase anti-tumour activity by simultaneously
blocking both VEGF and EGFR pathways, some randomised studies have explored the
combination of cetuximab or panitumumab with bevacizumab plus chemotherapy, but no
benefits were observed, and in some cases the outcome was actually poorer with a greater
toxicity, so this type of combination is not recommended for mCRC [64].
In relation to toxicity, treatment with these biological agents is associated with a wide range
of adverse events that sometimes require discontinuation of treatment; these include severe
hypersensitivity and skin toxicities, in the case of EGFR mAbs, and hypertension, throm‐
boembolic events, bleeding and proteinuria, with bevacizumab treatment [93].
Despite the aforementioned advances, the targeted biological agents currently available are
only effective in a small subset of patients (for example, less than half of the KRAS-wild type
patient population benefits from anti-EGFR strategies) [96]and their overall impact on the
treatment of mCRC has been relatively modest (beneficial effects only lasting on the order of
weeks to a few months). These limited results, coupled with the undesirable effects, has led to
intensification of the search for novel antiangiogenic therapies to increase the anti-tumour
activity in advanced CRC. There are currently several molecules in phase II and III trials for
treatment of mCRC that target various members of the VEGF family (aflibercept), signalling
by VEGFRs (ramucirumab and IMC-18F1) or the tyrosine kinase components of these receptors
(regorafenib, brivanib alaninate, cediranib and linifanib) [93, 97].
Aflibercept is a multiple angiogenic factor trap designed to block the angiogenesis network by
binding VEGF-A, VEGF-B and placental growth factor (PLGF) [98]. The recent results of a
multinational phase III study (VELOUR trial: aflibercept/FOLFIRI vs. placebo/FOLFIRI)
demonstrated significant improvements in median overall survival, supporting the use of this
VEGF Trap as a second-line option for patients with prior oxaliplatin treatment [99]. Ramu‐
cirumab is a fully humanised mAb directed against the extracellular domain of VEGFR-2,
which binds VEGF-A and is believed to be the key VEGFR involved in tumour angiogenesis.
Like aflibercept, ramucirumab is currently being evaluated in combination with FOLFIRI in a
phase III trial for the second-line treatment of mCRC patients for whom prior oxaliplatin- and
bevacizumab-containing initial therapy has failed [100]. In addition, a phase II study of
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in mCRC in the last decade, with biological agents today being a commonly used weapon in
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new anti-angiogenesis agents, novel tyrosine kinase inhibitors (TKIs), agents to act on the PI3K/
Akt signalling pathway, modulators of autophagy, and proteasome inhibitors, as well as
targeted therapies against cancer stem cells, among others.
4.1. Targeting angiogenesis
GFs have been identified as important targets [88]and the development of targeting biological
agents, directed to block effects of GFs on tumour cells, and their integration with cytotoxic
chemotherapy regimens has resulted in significant improvements in efficacy outcomes.
One of the most important effects of some GFs is the promotion of angiogenesis, an essential
mechanism for both primary tumour growth and metastasis. Due to this, novel therapeutic
approaches have focused on the role of angiogenesis-targeting inhibitors. So far, three
antiangiogenic biological agents have been approved for the treatment of patients with mCRC:
bevacizumab, cetuximab and panitumab. The first successful targeting agent was bevacizu‐
mab; today, there is clear evidence to recommend addition of this anti-VEGF antibody to
cytotoxic therapy (irrespective of the selected chemotherapy regimen) in both the first- and
second-line treatment, this significantly increasing overall survival [75]. Moreover, it has been
shown that bevacizumab, combined with FOLFOX or FOLFIRI, may also be active in chemo‐
refractory and selected mCRC patients [89]. Currently, new trials (CHARTA and PERIMAX)
are being conducted with bevacizumab plus FOLFIRI, designed to assess the benefits and
limitations of a highly active four-drug regimen in mCRC [4]. In addition, it is also important
to note that in patients with mCRC on a bevacizumab-containing regimen who show disease
progression and hence need a change in the chemotherapy regimen, maintenance therapy with
bevacizumab appears to be associated with significantly longer overall survival than the same
regimen without bevacizumab [90]; this fact highlights the importance of bevacizumab therapy
beyond disease progression in patients with mCRC, although this use is not currently recom‐
mended outside clinical trials.
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The other two antiangiogenenic biological agents, cetuximab and panitumumab target the
ligand-binding domain of EGFR. Signalling of this receptor appears to modulate angiogenesis
via the upregulation of VEGF and other angiogenic factors [60]. The use of these EGFR
inhibitors was approved for mCRC in patients with wild-type KRAS, whose tumours express
EGFR. In fact, as described previously, BRAF and codon 12 KRAS mutations are predictive of
adverse outcome in CRC patients receiving cetuximab, being associated with a shorter time to
progression and poor survival [91]. In contrast, it has been demonstrated that the combination
of chemotherapy, such as irinotecan or FOLFIRI, and cetuximab as a first line in patients with
wild-type KRAS significantly improves survival [67, 92]. Cetuximab is also indicated as a
monotherapy in such patients following failure of both irinotecan- and oxaliplatin-based
chemotherapy [93], while panitumumab is also a valid second-line option for wild-type KRAS
patients, as a monotherapy or combined with FOLFIRI [94], though the addition of this EGFR
inhibitor to oxaliplatin-based chemotherapy in first-line treatment of mCRC did not improve
survival or response rate [95]. In an attempt to increase anti-tumour activity by simultaneously
blocking both VEGF and EGFR pathways, some randomised studies have explored the
combination of cetuximab or panitumumab with bevacizumab plus chemotherapy, but no
benefits were observed, and in some cases the outcome was actually poorer with a greater
toxicity, so this type of combination is not recommended for mCRC [64].
In relation to toxicity, treatment with these biological agents is associated with a wide range
of adverse events that sometimes require discontinuation of treatment; these include severe
hypersensitivity and skin toxicities, in the case of EGFR mAbs, and hypertension, throm‐
boembolic events, bleeding and proteinuria, with bevacizumab treatment [93].
Despite the aforementioned advances, the targeted biological agents currently available are
only effective in a small subset of patients (for example, less than half of the KRAS-wild type
patient population benefits from anti-EGFR strategies) [96]and their overall impact on the
treatment of mCRC has been relatively modest (beneficial effects only lasting on the order of
weeks to a few months). These limited results, coupled with the undesirable effects, has led to
intensification of the search for novel antiangiogenic therapies to increase the anti-tumour
activity in advanced CRC. There are currently several molecules in phase II and III trials for
treatment of mCRC that target various members of the VEGF family (aflibercept), signalling
by VEGFRs (ramucirumab and IMC-18F1) or the tyrosine kinase components of these receptors
(regorafenib, brivanib alaninate, cediranib and linifanib) [93, 97].
Aflibercept is a multiple angiogenic factor trap designed to block the angiogenesis network by
binding VEGF-A, VEGF-B and placental growth factor (PLGF) [98]. The recent results of a
multinational phase III study (VELOUR trial: aflibercept/FOLFIRI vs. placebo/FOLFIRI)
demonstrated significant improvements in median overall survival, supporting the use of this
VEGF Trap as a second-line option for patients with prior oxaliplatin treatment [99]. Ramu‐
cirumab is a fully humanised mAb directed against the extracellular domain of VEGFR-2,
which binds VEGF-A and is believed to be the key VEGFR involved in tumour angiogenesis.
Like aflibercept, ramucirumab is currently being evaluated in combination with FOLFIRI in a
phase III trial for the second-line treatment of mCRC patients for whom prior oxaliplatin- and
bevacizumab-containing initial therapy has failed [100]. In addition, a phase II study of
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ramucirumab in the first-line setting in combination with FOLFOX6 therapy is also in progress
[101]. Another anti-VEGFR mAb, IMC-18F1, which targets VEGFR-1 has been developed
recently [102], and is also being studied in a phase II trial in mCRC.
Other candidate molecules represent new approaches to intracellular signal blockade of the
VEGF and fibroblast growth factor (FGF) signalling pathways, via TKIs. In a recent phase III
study (CORRECT trial), regorafenib has been found to improve survival in mCRC patients
who progressed after all standard therapies, making it the first small-molecule multikinase
inhibitor to have demonstrated survival benefits in such patients [103]. Brivanib alaninate is
an oral TKI that specifically inhibits the VEGFR-1 and FGFR. This FGF signalling blockade
may represent an important advantage, since it has been suggested that resistance to bevaci‐
zumab is associated with increased expression of FGF [78], and hence brivanib could have
antiangiogenic activity in bevacizumab-resistant patients. In addition, a phase III trial com‐
bining brivanib and cetuximab in second/third line therapy in patients with advanced wild-
type KRAS mCRC found improved progression free survival with no impact in overall survival
[97]. Cediranib is an inhibitor of VEGFRs, platelet-derived growth factor-(PDGF) receptor beta
and FGF receptor, whose activity has been compared with that of bevacizumab as a first-line
treatment in combination with FOLFOX (HORIZON phase III trial) for mCRC patients;
although cediranib activity was comparable to that of bevacizumab, the patient-reported
outcomes were significantly less favourable [104]. Similarly, linifanib (a TKI that targets both
VEGFRs and PDGFRs), in combination with FOLFOX, did not offer any advantages (over
bevacizumab) in a randomised phase II trial as a second-line treatment for mCRC [105].
4.2. Targeting PI3K/Akt/mTOR pathway
The PI3K/Akt/mTOR pathway, an essential regulator of protein translation and cell prolifer‐
ation, is another important target being investigated for mCRC in phase II and III trials. The
PI3K/AKT/mTOR signalling cascade is constitutively active in many types of cancer and, in
particular, it plays a critical role in the growth and progression of CRC. In addition, it has been
demonstrated that this pathway may be upregulated after blockade of both VEGF- and EGFR-
mediated signalling [101].
These aforementioned data provide the rationale for targeting this pathway therapeutically in
CRC patients. Perifosine is an oral alkylphospholipid that targets both AKT and nuclear
transcription factor-kappa B (NF-ĸB) pathways. This novel molecule appears to enhance the
cytotoxic effects of 5-FU: it has produced promising results in a phase II randomised trial of
capecitabine ± perifosine in previously treated patients with mCRC and, hence, is currently in
phase III clinical development in combination with this 5-FU prodrug [106].
Activation  of  the  PI3K/AKT  cascade  promotes  mTOR,  a  serine-threonine  kinase  whose
activation results in cell cycle progression and protein synthesis, and is involved in the CRC
metastatic process. The mTOR inhibitors are analogues of rapamycin, including everolimus
and temsirolimus, which are being investigated in clinical trials in combination with irinote‐
can, cetuximab, FOLFOX, bevacizumab or panatimumab in patients with mCRC progressing
on prior chemotherapy [101]. Current expert opinion suggests that mTOR inhibitors may
represent  an attractive  anti-tumour target  in  combination with strategies  to  target  other
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pathways that may overcome resistance [107]. In relation to this, it has been demonstrated that
addition of the multikinase inhibitor, sorafenib, enhances the therapeutic effect of rapamycin
on induction of apoptosis and inhibition of cell-cycle progression, migration and invasion of
CRCs [108].  In  addition,  it  has  been suggested that  mTOR inhibition by metformin (an
antidiabetic drug), via activation of the AMP-activated protein kinase (AMPK) pathway, which
functions as a sensor for cellular nutrient and energy levels, could be a new option for CRC [109].
4.3. Autophagy modulators and proteasome inhibitors
Autophagy is a multistep process of sequestration and subsequent elimination of cytosolic
proteins, damaged organelles and protein aggregates in autophagosomes [110]. This self-
degradation, via the lysosome, is responsible for the maintenance of intracellular homeostasis
and enables cell survival under stress conditions. In the cancer cell, autophagy can be used as
a strategy of self-adaption to generate nutrients and energy during tumour progression and
in periods of hypoxia and stress, such as induced by chemotherapy, leading to development
of drug resistance. The role of autophagy after chemotherapy remains controversial, it having
been suggested that autophagy induction may increase efficacy of other anti-tumour agents,
while most evidence suggests that the inhibition of autophagy is what can increase the
effectiveness of these agents. As autophagy inhibitor, an analogue of chloroquine, hydroxy‐
chloroquine (HCQ), is currently involved in two different phase II studies for advanced CRC
in combination with FOLFOX/bevacizumab or capecitabine/oxaliplatin/bevacizumab [111].
Given that HCQ induces ocular toxicities, such as retinopathy, novel autophagy inducers, such
as Lys05, are currently being investigated in CRC [112].
In relation to autophagy inducers, since the PI3K/Akt/mTOR pathway is a key regulator of
autophagy [113], mTOR inhibitors have been also used to modulate this mechanism, proving
to be effective in many models for CRCs, but their clinical use has been less successful [114].
Proteasome inhibitors have also been described as autophagy inducers. It has been shown that
proteasome inhibition generates a stress response through alteration of the protein milieu,
which, in turn, induces endoplasmic reticulum stress; this causes an accumulation of misfolded
proteins in the endoplasmic reticulum lumen and, consequently, induction of cellular stress
responses, such as the unfolded protein response and autophagy to maintain endoplasmic
reticulum homeostasis [110]. Bortezomib, the main proteasome inhibitor, was shown to induce
autophagy in CRC cells [115]. However, in a randomised phase II study in relapsed or
refractory CRC, bortezomib alone or in combination with irinotecan was not effective [116].
There are current trials examining combinations of bortezomib with other chemotherapies,
such as oxaliplatin, 5-FU and leucovorin, in patients with advanced CRC [117]. In view of the
limited results with autophagy inducers, some authors have suggested that optimal anti-
tumour efficacy might be achieved by the combination of proteasome inhibitors and autoph‐
agy inhibitors [118].
4.4. Targeting cancer stem cells, Wnt pathway inhibitors, and tumour cell differentiation
inducers
Cancer stem cells (CSCs) are a subpopulation of tumour cells that possess the capacity to self-
renew and to give rise to the heterogeneous lineages of cancer cells that comprise the tumour,
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may represent an important advantage, since it has been suggested that resistance to bevaci‐
zumab is associated with increased expression of FGF [78], and hence brivanib could have
antiangiogenic activity in bevacizumab-resistant patients. In addition, a phase III trial com‐
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although cediranib activity was comparable to that of bevacizumab, the patient-reported
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VEGFRs and PDGFRs), in combination with FOLFOX, did not offer any advantages (over
bevacizumab) in a randomised phase II trial as a second-line treatment for mCRC [105].
4.2. Targeting PI3K/Akt/mTOR pathway
The PI3K/Akt/mTOR pathway, an essential regulator of protein translation and cell prolifer‐
ation, is another important target being investigated for mCRC in phase II and III trials. The
PI3K/AKT/mTOR signalling cascade is constitutively active in many types of cancer and, in
particular, it plays a critical role in the growth and progression of CRC. In addition, it has been
demonstrated that this pathway may be upregulated after blockade of both VEGF- and EGFR-
mediated signalling [101].
These aforementioned data provide the rationale for targeting this pathway therapeutically in
CRC patients. Perifosine is an oral alkylphospholipid that targets both AKT and nuclear
transcription factor-kappa B (NF-ĸB) pathways. This novel molecule appears to enhance the
cytotoxic effects of 5-FU: it has produced promising results in a phase II randomised trial of
capecitabine ± perifosine in previously treated patients with mCRC and, hence, is currently in
phase III clinical development in combination with this 5-FU prodrug [106].
Activation  of  the  PI3K/AKT  cascade  promotes  mTOR,  a  serine-threonine  kinase  whose
activation results in cell cycle progression and protein synthesis, and is involved in the CRC
metastatic process. The mTOR inhibitors are analogues of rapamycin, including everolimus
and temsirolimus, which are being investigated in clinical trials in combination with irinote‐
can, cetuximab, FOLFOX, bevacizumab or panatimumab in patients with mCRC progressing
on prior chemotherapy [101]. Current expert opinion suggests that mTOR inhibitors may
represent  an attractive  anti-tumour target  in  combination with strategies  to  target  other
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pathways that may overcome resistance [107]. In relation to this, it has been demonstrated that
addition of the multikinase inhibitor, sorafenib, enhances the therapeutic effect of rapamycin
on induction of apoptosis and inhibition of cell-cycle progression, migration and invasion of
CRCs [108].  In  addition,  it  has  been suggested that  mTOR inhibition by metformin (an
antidiabetic drug), via activation of the AMP-activated protein kinase (AMPK) pathway, which
functions as a sensor for cellular nutrient and energy levels, could be a new option for CRC [109].
4.3. Autophagy modulators and proteasome inhibitors
Autophagy is a multistep process of sequestration and subsequent elimination of cytosolic
proteins, damaged organelles and protein aggregates in autophagosomes [110]. This self-
degradation, via the lysosome, is responsible for the maintenance of intracellular homeostasis
and enables cell survival under stress conditions. In the cancer cell, autophagy can be used as
a strategy of self-adaption to generate nutrients and energy during tumour progression and
in periods of hypoxia and stress, such as induced by chemotherapy, leading to development
of drug resistance. The role of autophagy after chemotherapy remains controversial, it having
been suggested that autophagy induction may increase efficacy of other anti-tumour agents,
while most evidence suggests that the inhibition of autophagy is what can increase the
effectiveness of these agents. As autophagy inhibitor, an analogue of chloroquine, hydroxy‐
chloroquine (HCQ), is currently involved in two different phase II studies for advanced CRC
in combination with FOLFOX/bevacizumab or capecitabine/oxaliplatin/bevacizumab [111].
Given that HCQ induces ocular toxicities, such as retinopathy, novel autophagy inducers, such
as Lys05, are currently being investigated in CRC [112].
In relation to autophagy inducers, since the PI3K/Akt/mTOR pathway is a key regulator of
autophagy [113], mTOR inhibitors have been also used to modulate this mechanism, proving
to be effective in many models for CRCs, but their clinical use has been less successful [114].
Proteasome inhibitors have also been described as autophagy inducers. It has been shown that
proteasome inhibition generates a stress response through alteration of the protein milieu,
which, in turn, induces endoplasmic reticulum stress; this causes an accumulation of misfolded
proteins in the endoplasmic reticulum lumen and, consequently, induction of cellular stress
responses, such as the unfolded protein response and autophagy to maintain endoplasmic
reticulum homeostasis [110]. Bortezomib, the main proteasome inhibitor, was shown to induce
autophagy in CRC cells [115]. However, in a randomised phase II study in relapsed or
refractory CRC, bortezomib alone or in combination with irinotecan was not effective [116].
There are current trials examining combinations of bortezomib with other chemotherapies,
such as oxaliplatin, 5-FU and leucovorin, in patients with advanced CRC [117]. In view of the
limited results with autophagy inducers, some authors have suggested that optimal anti-
tumour efficacy might be achieved by the combination of proteasome inhibitors and autoph‐
agy inhibitors [118].
4.4. Targeting cancer stem cells, Wnt pathway inhibitors, and tumour cell differentiation
inducers
Cancer stem cells (CSCs) are a subpopulation of tumour cells that possess the capacity to self-
renew and to give rise to the heterogeneous lineages of cancer cells that comprise the tumour,
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and it is believed that they could be crucial in controlling and curing cancer [119]. Specifically,
there is increasing evidence that CSCs play an important role in the occurrence, growth, and
progression of tumours, as well as possibly in the initiation of distant metastases. In addition,
CSCs are also involved in resistance to conventional chemotherapeutic drugs, novel tumour-
targeted drugs, and radiation therapy [120].
CSCs have been identified not only in leukaemias, but also in solid tumours, including CRC.
In fact, it has been suggested that CRC stem cells are responsible for tumour relapse, because
conventional drugs fail to eliminate the CSC reservoir [121]. Due to this important clinical
feature, CRC stem cells have recently been identified as a rational therapeutic target. Several
CSC-targeted therapies have been proposed, including microbial- and plant-derived biomo‐
lecules; therapies directed at CSC-specific surface markers; some classical drugs, such as
tranilast, curcumin and thioridazine; and reversal of their resistance to anti-tumour agents; so
far, however, the toxicity of some of these approaches in normal stem cells and treatment
resistance remain important limitations [122].
Various signalling pathways, such as Wingless/Int (Wnt), Hedgehog and Notch, are involved
in maintaining the stemness of CSCs. Among these, Wnt, stands out for being particularly
active in the majority of CRCs, and hence is the first being investigated for therapeutic targeting
in CRC. A primary consequence of Wnt signalling activation is the stabilization of β-catenin
in the cytoplasm, resulting in an increased translocation of β-catenin to the nucleus and, in
turn, activation of Wnt target gene expression. Misregulation of the canonical Wnt/β-catenin
pathway and aberrant activation of Wnt signalling target genes are common in CRC and
contribute to cancer progression [123]. Despite the importance of this pathway, few com‐
pounds have progressed beyond preclinical development. Efforts have been made to investi‐
gate the inhibition of a number Wnt genes, including the matrix metalloproteinases (MMPs),
which play an important role in the degradation of extracellular matrix component, crucial for
invasion and metastasis. Some studies have shown that increased expression of various MMPs
(MMP-1, MMP-2 and MMP-9) favours CRC progression and could predict liver metastasis.
Further, several therapeutic MMP inhibitors have been developed, but so far they have failed
to produce a survival benefit and, in addition, they have been associated with adverse effects,
such as musculoskeletal syndrome. The development of more selective MMP inhibitors is seen
as a possible way forward [124].
Another novel compound is salinomycin, a polyether ionophore antibiotic that has been shown
to kill CSCs in various types of human cancer, including CRC cells, mostly by interfering with
ABC drug transporters and the Wnt/β-catenin signalling pathway. Salinomycin inhibits the
migratory and invasive capacity, and reduces the proportion of CD133 CSCs in HT29 and
SW480 CRC cells [125]. The results from preclinical trials and its ability to kill therapy-resistant
cancer cells make salinomycin a promising anticancer drug [126].
In recent years, other agents have been shown to suppress the self-renewal of CSCs in vitro
and in vivo; these include metformin, DECA-14, rapamycin, oncostatin M, some natural
compounds, oncolytic viruses, microRNAs, TNF-related apoptosis inducing ligand, telomer‐
ase inhibitors, mAbs and all-trans retinoic acid (ATRA). It has been suggested that combina‐
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tions of these agents and conventional therapy could significantly reduce tumour growth,
metastasis and recurrence [127].
CSCs are characterised by two main properties of normal stem cells, self-renewal and differ‐
entiation. Given this, the induction of differentiation using retinoids would be a plausible
therapeutic strategy. ATRA, a potent differentiating agent, has been demonstrated to induce
CSC growth inhibition, and this has been associated with down-regulation of Wnt/β-catenin
signalling [128]. In a CRC tumour model of liver metastasis, we have demonstrated the anti-
tumour effects of ATRA. This pro-differentiating agent hindered or completely abolished the
pro-tumour stimulus produced by serum obtained from hepatectomised rats, and by a wide
variety of GFs (HGF, VEGF, PDGF, EGF, and bFGF). In addition, in combination with 5-FU,
an additive effect was observed in in vitro studies [129]. In in vivo experiments, ATRA also
reduced tumour progression, though it failed to increase survival, both alone and in combi‐
nation with 5-FU (unpublished data).
5. New therapeutic techniques for colorectal liver metastasis
Although surgical excision of tumour tissue remains the only potentially curative treatment
for CRC-LM, several other techniques are now being developed to be used when surgery is
not feasible or to improve surgical results.
The list of possible new therapeutic techniques for CRC-LM seems likely to increase over the
next five years, including:
• Surgical approaches focused on increasing the size of the liver lobes (staged surgery or portal
branch ligatures), as the percentage of remnant liver after hepatectomy is a limiting factor
in many patients
• Techniques for percutaneous tumour ablation, which can reduce CRC-LM volume and
allow surgery or at least delay the progression of the illness
• Nanoparticles (NPs) to selectively deliver drugs to tumour cells or induce local hyper‐
thermia.
First, let us consider patients who could benefit from surgical excision of their liver metastases,
but in whom the FLR would be less than 25%, which is currently considered the threshold of
what can be tolerated. Initially, strategies for such cases were focused on selectively increasing
the liver mass of liver lobes free of tumour. Some clinical trials have found that portal vein
embolization (PVE) of the lobes bearing metastases induces regeneration of the other lobes,
and this has been found to result in a 20-45% increase in their relative volume in two to eight
weeks [130]. However, the clinical benefit of this procedure is not clear and, as there were also
reports of tumour progression due to hepatectomy, it has not been widely adopted.
In patients who have inadequate FLR to undergo disease clearance with a single hepatectomy,
two-stage hepatectomy for bilobar liver metastases in combination with selected use of portal
venous embolization is feasible. It offers the best chance of achieving adequate FLR hypertro‐
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feature, CRC stem cells have recently been identified as a rational therapeutic target. Several
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tranilast, curcumin and thioridazine; and reversal of their resistance to anti-tumour agents; so
far, however, the toxicity of some of these approaches in normal stem cells and treatment
resistance remain important limitations [122].
Various signalling pathways, such as Wingless/Int (Wnt), Hedgehog and Notch, are involved
in maintaining the stemness of CSCs. Among these, Wnt, stands out for being particularly
active in the majority of CRCs, and hence is the first being investigated for therapeutic targeting
in CRC. A primary consequence of Wnt signalling activation is the stabilization of β-catenin
in the cytoplasm, resulting in an increased translocation of β-catenin to the nucleus and, in
turn, activation of Wnt target gene expression. Misregulation of the canonical Wnt/β-catenin
pathway and aberrant activation of Wnt signalling target genes are common in CRC and
contribute to cancer progression [123]. Despite the importance of this pathway, few com‐
pounds have progressed beyond preclinical development. Efforts have been made to investi‐
gate the inhibition of a number Wnt genes, including the matrix metalloproteinases (MMPs),
which play an important role in the degradation of extracellular matrix component, crucial for
invasion and metastasis. Some studies have shown that increased expression of various MMPs
(MMP-1, MMP-2 and MMP-9) favours CRC progression and could predict liver metastasis.
Further, several therapeutic MMP inhibitors have been developed, but so far they have failed
to produce a survival benefit and, in addition, they have been associated with adverse effects,
such as musculoskeletal syndrome. The development of more selective MMP inhibitors is seen
as a possible way forward [124].
Another novel compound is salinomycin, a polyether ionophore antibiotic that has been shown
to kill CSCs in various types of human cancer, including CRC cells, mostly by interfering with
ABC drug transporters and the Wnt/β-catenin signalling pathway. Salinomycin inhibits the
migratory and invasive capacity, and reduces the proportion of CD133 CSCs in HT29 and
SW480 CRC cells [125]. The results from preclinical trials and its ability to kill therapy-resistant
cancer cells make salinomycin a promising anticancer drug [126].
In recent years, other agents have been shown to suppress the self-renewal of CSCs in vitro
and in vivo; these include metformin, DECA-14, rapamycin, oncostatin M, some natural
compounds, oncolytic viruses, microRNAs, TNF-related apoptosis inducing ligand, telomer‐
ase inhibitors, mAbs and all-trans retinoic acid (ATRA). It has been suggested that combina‐
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therapeutic strategy. ATRA, a potent differentiating agent, has been demonstrated to induce
CSC growth inhibition, and this has been associated with down-regulation of Wnt/β-catenin
signalling [128]. In a CRC tumour model of liver metastasis, we have demonstrated the anti-
tumour effects of ATRA. This pro-differentiating agent hindered or completely abolished the
pro-tumour stimulus produced by serum obtained from hepatectomised rats, and by a wide
variety of GFs (HGF, VEGF, PDGF, EGF, and bFGF). In addition, in combination with 5-FU,
an additive effect was observed in in vitro studies [129]. In in vivo experiments, ATRA also
reduced tumour progression, though it failed to increase survival, both alone and in combi‐
nation with 5-FU (unpublished data).
5. New therapeutic techniques for colorectal liver metastasis
Although surgical excision of tumour tissue remains the only potentially curative treatment
for CRC-LM, several other techniques are now being developed to be used when surgery is
not feasible or to improve surgical results.
The list of possible new therapeutic techniques for CRC-LM seems likely to increase over the
next five years, including:
• Surgical approaches focused on increasing the size of the liver lobes (staged surgery or portal
branch ligatures), as the percentage of remnant liver after hepatectomy is a limiting factor
in many patients
• Techniques for percutaneous tumour ablation, which can reduce CRC-LM volume and
allow surgery or at least delay the progression of the illness
• Nanoparticles (NPs) to selectively deliver drugs to tumour cells or induce local hyper‐
thermia.
First, let us consider patients who could benefit from surgical excision of their liver metastases,
but in whom the FLR would be less than 25%, which is currently considered the threshold of
what can be tolerated. Initially, strategies for such cases were focused on selectively increasing
the liver mass of liver lobes free of tumour. Some clinical trials have found that portal vein
embolization (PVE) of the lobes bearing metastases induces regeneration of the other lobes,
and this has been found to result in a 20-45% increase in their relative volume in two to eight
weeks [130]. However, the clinical benefit of this procedure is not clear and, as there were also
reports of tumour progression due to hepatectomy, it has not been widely adopted.
In patients who have inadequate FLR to undergo disease clearance with a single hepatectomy,
two-stage hepatectomy for bilobar liver metastases in combination with selected use of portal
venous embolization is feasible. It offers the best chance of achieving adequate FLR hypertro‐
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phy, better than a strategy involving PVE before a single hepatectomy. In addition, rates of
macroscopic surgical clearance greater than 65% have been reported [131].
Surgical strategies must be individualised after careful assessment of disease distribution and
its relationship to key underlying vascular and biliary structures. Thus, the majority of authors
perform the first surgical stage focused on the minor hepatectomy and concurrent procedures
as required. When necessary, ligature or embolization of the portal vein is carried out, to
enhance the hepatic regeneration response induced by hepatectomy [132]. Nowadays,
embolization is preferred to avoid surgical manipulation of the porta hepatis prior to major
hepatectomies, and to achieve segment IV total portal inflow occlusion if a right hepatectomy
is planned. Hypertrophy after PVE is maximal in the first three weeks, and tends to plateau
after this period [133]. The time interval between hepatectomies must be long enough for
adequate recovery from the first hepatectomy and liver hypertrophy, but not so long as to
enable disease progression, since tumour volume may still increase within the occluded liver
[134]. This interval is not well defined but is believed to be around eight to sixteen weeks. In
the second-stage operation, the liver surgery usually is complex, often involving other
procedures such as radiofrequency ablation. Consequently, postoperative morbidity is
significant (50-60%) after this second surgery, particularly due to transient or permanent liver
insufficiency. Nevertheless, when performed in referral centres for hepatic surgery the
mortality rate is low (2.6-5%). Further, reported three-year survival rates after two-staged
hepatectomy range from 30 to 58% [135], and in all series were significantly higher than in
those patients treated with best palliative chemotherapy. Given this survival benefit and the
feasibility of the surgery, this two-stage approach can be justified in suitably selected patients.
More recently, in situ liver transection with portal vein ligation has been proposed as a useful
alternative for patients who have some segments of the left liver free of tumour, but an FLR
that is too small [136]. In a first surgical intervention, arterial vessels and veins draining the
lobes containing metastases are dissected and marked with vessel loops; then, the portal
branches to those lobes are severed (most commonly, all right portal branches and segment I
and IV branches). Some clinical trials have found that a 40-80% increase in FLR is achieved
after three to eight days, and the patient can be re-operated on to remove the previously
prepared lobes [137]. The results so far reported (daily increases of FRL up to 22%) are
promising, but further clinical trials need to be carried out before this procedure can be
generally recommended.
A quite different approach is percutaneous tumour ablation, an old design that is continuously
being refined and improved with new technical developments. Initially, ablation of liver
metastases was achieved by alcoholisation (ethanol injection), this being used as a downstag‐
ing procedure prior to surgery, then came radiofrequency thermoablation [42], and this was
soon followed by microwave thermoablation. These procedures proved to be useful tools to
reduce tumour volume, but only provided a transient effect when applied to CRC-LM. More
recently, laser tumour ablation and cryoablation have gone through experimental trials in
animals and are now being tested in patients, but still limited to primary liver tumours. As
with previous treatments, if and when they prove to be useful in hepatocarcinomas, they will
be tried in CRC-LM [138]
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A different, perhaps more subtle, approach is embolization of the arterial vessels supplying
the tumour. Transarterial embolisation with 300- to 500-μm microspheres has been widely
used either as a downstaging procedure or as a palliative treatment. This classic technique was
improved by adding selective transarterial chemotherapy prior to embolisation, which
allowed higher doses of chemotherapy with fewer side effects [139].
One of the problems in treating CRC-LM is the low tolerance of the liver parenchyma to
radiation [140]. An elegant solution to overcome this limitation is known as selective internal
radiation therapy and consists in the administration of 90Y-resin microspheres through the
arterial branches supplying the tumour. First applied to non-resectable hepatocarcinoma
patients, achieving a reduction in tumour burden, relief of symptoms and increase in survival,
it is now being tested in CLR-LM with promising results. However, the type of radiolabelled
microspheres, indications and dosing schedules have to be better defined [141].
A novel approach has been the use of precharged particles to chemoembolise liver tumours.
Smaller (50- to 100-μm) electrically-activated microspheres are exposed to a chemotherapeutic
agent which binds to them by electrostatic forces. These spheres are delivered to the vascular
tumour bed where they are widely and uniformly seeded; then the drug is released and exerts
its effect specifically on the tumour tissue, while the spheres block further blood supply.
Preliminary reports have been quite promising, and may lead to the procedure being applied
in CRC-LM [142].
All these techniques can, however, only be applied to selected macroscopic liver metastases,
leaving untreated residual microfoci responsible for tumour recurrence. We need therapeutic
tools to attack individual cancer cells seeded throughout the whole liver parenchyma from the
primary colorectal tumour. Currently, one of the most promising avenues is radioimmuno‐
therapy, with ongoing preclinical and clinical studies in CRC. This type of therapy involves
the administration of radiolabeled mAbs that are directed specifically against tumour-
associated antigens or against the tumour microenvironment. Some phase II trials have
suggested that radioiodinated antibodies against CEA, as an adjuvant treatment after R0-
resection of CRC-LM, improve overall survival [143]. More recently, new studies are being
undertaken to assess the safety and efficacy of combining anti-CEA-RIT and kinase inhibitors,
such as imatinib, to increase antibody distribution in CRC tumours [144].
On the other hand, the new field of nanosystems for cancer diagnostics and treatment is highly
promising [145]. NPs, which easily escape detection and destruction by our immune system,
are being used to deliver drugs directly to the tumour bed and selectively destroy cancer cells.
It has been suggested that this strategy may be able to overcome tumour resistance and reduce
toxicity in healthy organs. Tumour tissue tends to retain NPs, probably due to its particular
characteristics (abnormally leaky endothelium and underdeveloped lymphatic drainage)
[146], and this could explain the tendency of NPs to accumulate in liver metastases more than
in normal liver parenchyma when administered through the hepatic artery, as we have recently
shown [147]. Further, in order to decrease the severe dose-limiting toxicity of 5-FU and to
enhance the concentration of this agent in the tumour mass, some researchers are investigating
the use of 5-FU-loaded biodegradable NPs, and have already shown a significant improvement
in the anticancer activity of the drug in an in vitro CRC model [148]. Finally, magnetic NPs are
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hepatectomy range from 30 to 58% [135], and in all series were significantly higher than in
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feasibility of the surgery, this two-stage approach can be justified in suitably selected patients.
More recently, in situ liver transection with portal vein ligation has been proposed as a useful
alternative for patients who have some segments of the left liver free of tumour, but an FLR
that is too small [136]. In a first surgical intervention, arterial vessels and veins draining the
lobes containing metastases are dissected and marked with vessel loops; then, the portal
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promising, but further clinical trials need to be carried out before this procedure can be
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metastases was achieved by alcoholisation (ethanol injection), this being used as a downstag‐
ing procedure prior to surgery, then came radiofrequency thermoablation [42], and this was
soon followed by microwave thermoablation. These procedures proved to be useful tools to
reduce tumour volume, but only provided a transient effect when applied to CRC-LM. More
recently, laser tumour ablation and cryoablation have gone through experimental trials in
animals and are now being tested in patients, but still limited to primary liver tumours. As
with previous treatments, if and when they prove to be useful in hepatocarcinomas, they will
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being investigated in combination with high-frequency magnetic fields to induce local
hyperthermia in the tumour, promising results having been obtained in experimental settings
(CRC-LM in rats) [149].
6. Conclusion
Liver metastases are a common undesirable development in CRC and represent the leading
cause of death in this high-prevalence disease. The management of CRC-LM has significantly
changed over the past two decades, with dramatic improvements in patient outcomes. This
has been made possible by the application of several key concepts when implementing
different therapeutic approaches for subsets of patients with mCRC. Firstly, there is a clear
consensus that the best management is achieved with a multimodality approach, including
surgery, perioperative chemotherapy, biological agents and/or radiotherapy. Secondly, the
therapeutic option with the best potential for cure in patients with CRC-LM remains complete
resection of the metastases. Strategies to facilitate liver resection are allowing significantly
increases in overall survival in this complex disease. In relation to this, the use of optimal first-
line chemotherapy doublet (FOLFOX, FOLFIRI, XELOX) or triplet regimens (FOLFOXIRI) in
combination with targeted therapy is now recognised as a good therapeutic approach in
potentially resectable patients. In particular, the development of new biological molecules for
targeted therapy (bevacizumab, cetuximab, and panatimumab) has been a key factor in the
most important advances in mCRC treatment.
Nevertheless, much remains to be done. The fact that these current targeted biological agents
are only effective in small subsets of patients with mCRC, and that their overall impact in the
management of the disease is still relatively modest, has encouraged researchers to search for
novel molecules that selectively target specific molecular pathways. This has resulted in a
plethora of new antiangiogenic agents (aflibercept, ramucirumab, regorafenib, etc.) and novel
molecules directed against new biological targets (such as, autophagy or CSCs) or various
different signalling pathways (Wnt and PI3K/AKT/mTOR, among others); these are currently
being tested in preclinical studies or in phase II and III trials.
Additionally, new therapeutic techniques, such as surgical approaches focused on increasing
the size of the liver lobes, SIRT, radiofrequency ablations and, more recently, NPs to selectively
deliver drugs or to induce local hyperthermia in the tumour bed, promise to increase overall
outcome in patients with advanced mCRC, in particular, in those with special characteristics
that complicate treatment of their disease (inadequate FLR and others).
Finally, it is important not to forget the need to continue the search for new biomarkers to
enable better patient stratification for each treatment option. Based on a better understanding
of the process involved in the development and progression of CRC, biomarker panels will be
developed and this will greatly facilitate the design of personalized medicine for CRC patients.
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1. Introduction
Malignant tumors of the colon and rectum represent a separate entity, due to their early
clinical  manifestation,  specific  methods  of  examination  and,  particularly,  due  to  treat‐
ment,  which  is  predominantly  based  on  the  need  for  conservation  of  the  sphincter
mechanism,  without  disturbing  the  oncological  principles  of  surgical  treatment  and the
necessary  radicalism.  In  spite  of  introduction  of  the  new  surgical  procedures,  and  the
significant improvements in radio, i.e. chemotherapy, the prognosis of these tumors remains
serious.




4. Gastrointestinal stromal tumors (GISTs),
5. Squamous cell carcinoma
6. Melanomas
7. Other (extremely rare forms of malignant tumors)
Adenocarcinomas account for 95-97% of all malignant tumors, while the remaining 3-5%
belongs  to,  so  called,  rare  tumors  of  colon  and  rectum.  The  annual  percent  change  in
incidence for each rare tumor increased significantly during the 10 years (range: 3.1–9.4%,
p<0.05), except squamous cell carcinoma (5.9%, p>0.05) [1]. With regard to the incidence,
all rare tumors of the large bowel can be divided into 2 groups:
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1. tumors with the incidence 0,1-2% and
2. rare tumors with the incidence <0,1%.
In the first group the most common ones are: carcinoids 1,8%, primary lymphomas 0,1-1%,
GISTs 0,9%, melanomas 0,5-1%, and squamous cell carcinoma 0,1% (without the anal canal).
The second group or extremely rare forms of malignant tumors consist of: teratoma, plasmo‐
cytoma, schwannomas, metastatic tumor. Literature data are limited and mostly concern series
of operated patients of some institutions or several published national studies, but there are
no randomized studies or meta-analyses which have higher degree of scientific verification
because these tumours are very rare [2].
The aims of studying the rare tumors of the colon and rectum are:
– determination of the incidence among population,
– determination of the clinical characteristics
– comparative analysis of the treatment outcome in different parts of the gastrointestinal tract
and
– overall and five-year survival of patients.
2. Carcinoids
Carcinoid tumors represents rare, slow growing tumors and they occur in 1,8% of all malignant
tumors of the large bowel. There is no clear predominance related to sex and, in the most of
cases, the patients are in their sixties or seventies. They originate from the enterochromaffin
(argentafil, Kulchitsky) cells, as a part of the diffuse endocrine system and they belong to the
group of neuroendocrine tumors, so called well-differentiated “NET’s”. They are also called
APUDomas, which is an abbreviation for “amine precursor uptake and decarboxylation”, due
to their ability to take over and decarboxylase amines, originally described by Pearse in 1969
[3]. They can occur in all parts of gastrointestinal tract as well as outside of the tract. Therefore
with regard to the place of occurrence and according to the division of the primitive intestine
during the embryological development, carcinoids are divided into:
1. foregut carcinoid tumors start in the lungs, bronchi, or stomach;
2. midgut carcinoid tumors start in the small intestine, appendix,or proximal large bowel;
3. hindgut carcinoid tumors start in the distal colon or rectum.
Data from literature indicate that the incidence of carcinoids in certain locations is different,
although it is considered to be most often localized on the appendix vermiformis, in about 40%
of cases, on ileum about 25%, on rectum 15-20% and on respiratory system around 10%. On
the other hand, the Japanese National Study has identified, in 90 057 operated patients during
the period of 15 years, 345 cases of carcinoids on the small and large bowel, out of which 0,9%
was localized on the ileum, 2,3% on the appendix, 8,2% on the colon and 88,6% on the rectum
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[1]. Their secretion is active and secrete around 30 vasoactive substances, the most important
of which are serotonin, histamine and substance P. In 1867, Langhans [1] first described a gut
carcinoid tumor, but the first detailed description of the tumor, similar to carcinoid, was given
by Lubrasch 1888, after performing the autopsy on two persons, previously treated due to
having multiple tumors of ileum. A German pathologist Oberndorfer first mentioned the term
“carcinoid” in 1907, while Siburg published the first data about the rectum carcinoid in 1929
[4-5]. The term “carcinoid” indicates that the tumor, according to some histological character‐
istics, is similar to carcinoma, but it behaves in a more benign way and less aggressive. They
have often been discovered accidently, during the colonoscopy, or by examination of the
clinical symptoms, such as rectoragia or diarrhea. During the primary diagnosing, 60-90% of
carcinoids are less than 1 cm of size.These tumors have a variable malignant potential, which
depends on: size, localization, depth of invasion and way of growth of the tumor itself.
According to the data from literature, the colon and rectum carcinoids less than 1 cm of size
have metastases in about 5,5% of cases. The bigger sized tumors, 1-1.9 cm, have metastasis
within the range of 4 to 30%, while those above 2 cm, within the range of 70-80%. With regard
to localization, the rectum carcinoids have metastasis in 18% on average, unlike the colon ones
in 60%, jejunoileal localization in 34%, stomach in 23% and lungs in 21% [2]. The depth of
invasion, particularly the tumors, which are less than 2 cm in size, represents a very important
predictive factor in the method and outcome of treatment. Invasion of muscularis propria and
lymphovascular, i.e. perineural invasion, anaplastic reaction, positive Ki-67 mutations and
frequent mitosis increase the risk of metastasis of tumors, which are less than 2 cm in size.
Macroscopically, these are small tumors in the nodular form, covered with the normal mucosa,
with intensive fibrosis of the intestine wall. Ulcerous forms with a tendency of bleeding, have
metastasis in larger percent and represent a significant risk factor. Histologically, the tumor
cells look similar, rounded or polygonal with expressed nucleus and acidophilic cytoplasmic
granules. Immunohistochemically, they show focal or diffuse existence of chromaganin A and/
or neuron-specific enolase, synaptophysina, CD 56 and pancreatic polypeptide. There is no
clear histological difference between benign and malignant large bowel carcinoids, except the
size of the tumor itself and invasion of muscularis proprie.
(a) (b) 
Figure 1. a) colon carcinoid (H&E 10x); b) colon carcinoid (chromogranin A 10x)
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2.1. Clinical presentation and diagnosis
The clinical presentation is characterized by the existence of symptoms resulting from the
secretion of different biochemical substances and growth of the tumor itself. Occasional
abdominal pains, followed by facial flushing, diarrhea, bronchospasm, arrhythmia, hyper‐
thermia, - blood pressure variations and vasomotor collapse, which, based on the intensity can
lead to a life dangerous condition, or so called “carcinoid crisis”. Various daily activities and
psychological conditions, such as alcohol drinking, emotional stress, increased body temper‐
ature and difficult defecation potentiate the intensity of symptoms.
The diagnosis of the large bowell carcinoids was usually made by detailed anamnesis and
clinical examination of the abdomen and digital rectal examination. Very often, it is an unclear
finding, due to the intact mucosa, so it is necessary to take biopsy from the part of the tumor
surface, as well as, from the deeper structures. It is also necessary to include a colonoscopy in
clinical examination, due to the possible existence of the synchronous lesion, and magnetic
resonance imaging or endoluminal ultrasound of the small pelvis, because of the pre-operative
staging. The examination of the liver metastatsis, should be completed with an ultra-sound
and CT scan. The modern diagnostics of carcinoids understands also the, so called, functional
or biochemical examinations based on taking over of the certain substances by the tumor cells,
which makes them different from the normal tissue. The biochemical properties of carcinoid
tumors reflect the presence of neurosecretory granules. They are classified as biochemically
typical or atypical based on the presence of high levels of serotonin in so-called typical tumors.
The best known metabolite of serotonin in carcinoid tumors is 5-HIAA( hydroxyl indole acetic
acid). In a 24-hour sample, the urinary level of 5-HIAA is the test most commonly used in the
endocrine work-up of carcinoid tumors. Despite its popularity, it lacks the sensitivity and
specificity for the diagnosis of carcinoid tumors because 5-HIAA may not be elevated in
atypical carcinoids and can be elevated in other conditions such as tropical sprue, celiac
disease, Whipple's disease, and small bowel obstruction, and can be caused by ingestion of
food high in serotonin, or certain medications.
Although a number of other tumor markers have been investigated for carcinoid tumor
overproduction, serum analysis of chromogranin A, a glycoprotein that is secreted with other
hormones by neuroendocrine tumors, appears to be the most promising, with specificity
approaching 95% and sensitivity for carcinoid tumors approaching 80 percent. A 40 percent
false-positive rate has been seen in patients with multiple myeloma[6].
For this purpose, the scintigraphy of the somatostin receptors on the surface of tumor cells is
applied, or SRS and PET scan, which uses a metabolic taking over of FDG Fluorin- 18 fluoro‐
deoxyglucose, by the tumor cells. The results of the research indicate that, Octreoscan is the
most optimal for identification of the primary tumor and existence of the positive lymph nodes,
while in the case of distant metastasis, it is CT or NMR. Within the frame of the biochemical
analyses, in case of doubt that there is a carcinoid present, it is necessary to determine the level
of 5 hydroxy-indole acetic acid in urine.
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2.2. Treatment
The treatment of the colon carcinoid can be divided into two groups:
a. minimally invasive procedure
b. laparatomy
c. Minimally invasive procedure includes several types of interventions:
– endoscopic mucosectomy or submucosectomy
– transanal tumor extirpation
– TEM (transanal endoscopic microsurgery)
– laparoscopic resections of colon and rectum
Endoscopic mucosectomy or submucosectomy represent one of the possible methods in the
conditions of the initial stadium of disease, without penetration into muscularis mucosae, and
up to 1 cm of size. The literature data show that endoscopic mucosetomy or submucosetomy
are performed in 54% of patients suffering from rectum carcinoid, transanal extirpation of
tumor /TEM in 27% of the operated patients, on one hand, as well as in 6% of patients treated
by the invasive procedure, on the other [7-9].
The results of the treatment indicate that, in patients treated by the endoscopic methods, in
83% of cases, it was about the positive limits (R1 status), in 16% it was the residual tumor (R2
status) with 2% of acute complications in terms of the occurrence of post-operative bleeding.
In 12 patients (14%), a sub-mucosectomy was done, with 42% of the positive margins present.
The advantage of the endoscopic approach is a minimally invasive procedure, faster recovery
of a patient and smaller operative trauma, but there are also disadvantages in terms of the high
percent of R1 or R2 procedure, (positive margins or residual tumor).
Transanal exstirpation/TEM is indicated in the conditions of rectal carcinoid invasion to the
submucose and muscularis proprie. They are mainly performed after the unsuccessful,
previously done mucosectomy i.e. sub-mucosectomy. The results of treatment indicate that in
43% of the operated patients, RO resection was done, while in 52% of cases R1, i.e. R2 resection
was done. The post-operative complications occurred in about 9% of patients. The disadvant‐
age of the procedure is still a high percentage of R1 and R2 operations.
Laparoscopic resections of colon and rectum represent a trend in the modern colorectal
surgery, with all characteristics of the minimally invasive procedure. It is indicated in tumors,
which spread to the structures deeper than lamina muscularis mucosa (T2 stadium), most often
to the upper third of rectum, but the other parts of rectum as well, where performing the
endoscopic procedure would lead to a high percent of R1 and R2 operations.
2.2.1. Laparatomy
– resection of colon (according to the type of segmental or right/left hemicolectomies)
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2.2.1. Laparatomy
– resection of colon (according to the type of segmental or right/left hemicolectomies)
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– (resections of rectum with different forms of reconstructions T-T anastomosis, L-T anasto‐
mosis, colonic J pouch, etc.)
– incontinence operations (abdominoperineal amputation of rectum, etc.)
– in case of inoperability of tumor, the performance of colostomy.
Laparotomy is indicated in carcinoids of greater median size, so-called bulky tumors, with
infiltration to the surrounding organs, as well as, with the potential risk of the colon obstruc‐
tion. In relation to the outcome of treatment, the resection procedures are loaded with a higher
percent of the local recurrence rate, which is explained by the existence of the more invasive
and bigger tumors, treated in this way [10-13].
Systemic therapy in carcinoid treatment has two aims
– to reduce intensity of the systemic effects of disease and
– treatment of metastasis.
Reducing intensity of the systemic effects means the use of various medicaments, such as: H2
blockers, Phenothiazin, corticosteroids, serotonin blockers serotonin, bronchodilators etc. The
analogues of Somatostatin have a significant effect that, by blocking the receptors reduce the
production and systemic effects, primarily the intensity of flushing and diarrhea, in 80% of
patients.
Staging system Colon carcinoids
% patien. 5-year surv.%
Rectal carcinoids
% patient. 5-year surv.%
I 13 97 83 97
II 32 69 6,5 84
III 12 21 2,8 27
IV 43 17 7,4 20
N 0 52 96
1 48 4
M 0 76 97,6
1 24 2,4
Table 1. Staging system and 5- year survival rate [14-16]
In treatment of metastasis, the effect of chemotherapy application ( 5-fluorouracil, strreptozo‐
tocin, doxorubicin,, etoposide, cisplatin, carboplatin, etc. ) is insignificant, with a clinical
response ( Response Rate- RR) from 0 to 30%. In some cases, Interferon is used, in duration of
up to 2,5 years, but due the numerous unfavorable effects, its use is limited [6].
The prognosis of the disease, depending on TNM stadium. A search of 15,983 patients with
carcinoid tumors from the National Cancer Institute's SEER (Surveillance Epidemiology and
Colorectal Cancer - Surgery, Diagnostics and Treatment258
End Results) database identified 2459 with colon tumors and 4701 patients with rectal carcinoid
tumors from 1973 to 2004. Patients were analyzed according to various clinicopathologic
factors and a tumor (T1, T2, T3), lymph node (N0, N1), and metastasis (M0, M1) staging system
was created according to these parameters. Results is shown in Table 1.
3. Primary non-Hodgkin lymphomas
Lymphomas of colon and rectum are the rare tumors that make 1,4% of human lymphomas,
10-20% of gastrointestinal lymphomas, 0,2-0,6% of all malignant tumors of colon, that is, 0,1-1%
of all tumors of the large bowel. According to the incidence in the gastrointestinal system in
adults, they take a third place, following the stomach and small intestine, unlike with the age
of up to seventeen, where the intestinal localization is predominant. In relation to the incidence
of all malignant colon and rectum diseases, they take a third place, following adenocarcinoma
and carcinoids [17,18]. The predilection places of occurrence are cecum and rectum, due to
large amount of lymph tissue in these regions of the large bowel.
Figure 2. Primary non-Hodgkin lymphoma of the cekum
It occurs more often in male patients, older than 50. With regard to the degree of spreading,
diseases can be: primary (localized) and secondary (diffuse form). The primary lymphomas of
the large bowel are characterized by the existence of the so-called Dawson’s criteria [19]:
1. no palpable, superficial lymph nodes at presentation;l
2. no enlarged mediastinal lymph nodes on chest x-ray;
3. normal range for white blood cell count including total and differential
4. at surgery, only the regional lymph nodes are involved;
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5. the liver and spleen are without disease
Primary lymphoma of the colon is a predominantly extranodal form of non-Hodgkin lym‐
phoma, while Hodgkin type is much rarer, present in less than 5% of all patients autopsied
due to this disease [20-22]. Devin and his coworkers from the Mayo Clinic, published the largest
study of patients with rectum lymphomas,which shows that, out of 61 patients treated in the
period of 27 years, 49 of them had a diffuse form and only 12 had a localized disease [23]. The
tumors usually have a form of polypoid and ulceriform mass, and sometimes, they form
excrescent on mucosa, similar to multiple adenomatous polyposis.
Etiological factors in formation of the large bowel lymphoma are unknown, as well as for the
other types of malignant diseases. However, the higher incidence was noticed in the conditions
of immunosuppression, such as the inflammatory disease – ulcerative colitis, HIV virus
infections and conditions after organ transplantations, although there are no clear scientific
proofs about the connections among these diseases.
More than two-thirds of intestinal lymphomas are supposed to be of B cell lineage, while T
cell intestinal lymphomas are rather infrequent and often multifocal and most frequently
localized in the small bowel. In relation to the histological type of B cell, non-Hodgkin
lymphomas can be: diffuse B cell type, MALT lymphoma, mantle type, Burkitt type and
follicular lymphoma. The incidence of some histopathological forms differs from study to
study, so Anderson and his associates presented the data of the, so-called, International Study
Group about Lymphomas, which included 1378 patients from 8 different cities from 4
continents. Out of the total number of the histopathological findings, in 80% of cases B-cell
lymphoma was diagnosed, where the most common form was the one with the large cells,
while the other forms, such as mantle, Burkitt and MALT types were significantly rare. In
relation to the histological grades, in 75% of tumors, a moderate and intermediately type of
diffuse lymphoma of the large cells was established [24-27].
Figure 3. Mantle type of primary non-Hodgkin lymphoma
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The degree of disease spreading to the surrounding structures was the best presented by the,
so-called, Ann-Arbor staging, modification according to Musshoffu [28,29]. The aim of the
successful treatment is the early detection of the disease in IE or IIE stage where still there is
a possibility of curative resection. The data from literature are significantly different in relation
to the stage of a disease in treated patients, which is a consequence of the various criteria
according to which the patients were included into the study, different methodologies of
performance and the level of health culture among the tested population.
Stage Characteristics
IE Limited to the colonic/rectal wall
IIE 1 Involvement of paracolic lymph nodes
IIE 2 Involvement of intermedial lymph nodes.
III
Involvement of the large bowel and lymph nodes on both
sides of diaphragm
IV
Involvement of distant organs (large bowel and one or
more extralymphatic organs or tissue)
Table 2. Ann-Arbor staging- Musshoff modifications of primary colorectal lymphoma[29].
3.1. Clinical presentation and diagnosis
The clinical presentation is characterized by the existence of rectoragia and the changed bowel
habits. By analyzing the symptoms of the disease, Cho and his associates, presented the study
data, which showed that, out of 23 patients, 56% had a non-specific symptoms, abdominal pain
and weight loss or anorexia, that is, 35% the of tested patients were operated in the advanced
stage of the disease [30]. The data from the research made by Fan and associates, showed that,
out of 37 tested patients, 59% had only abdominal pain and 75,7% were operated in the stage
of the disease where positive lymphoma nodes were present in the mesenterium of colon and
mesorectum. The specific symptoms, such as bleeding per rectum, were present in only 12,5%
of patients [17]. Non-specificity of symptoms often postpones timely visit to a doctor and
timely diagnosing, which leads to a much higher incidence of the advanced stages of the
disease. A special problem is primary colorectal lymphomas - present as surgical emergency,
caused by tumors of the IIIE and IVE stages[31]. Surgical emergencies, caused by the obstruc‐
tion of the large bowel, or perforation, initiate a need for urgent surgical intervention, which
leads to significantly higher rate of mortality of 58% and more frequent disease recurrence
[32-36]. The diagnosis can be made - by taking the anamnestic data and clinical examination
including digito rectal examination and colonoscopy with biopsy. There are data from
literature, which show that it is not always possible to establish the diagnosis by endoscopic
procedures, due to inadequately made biopsy of the tumor, as well as the need for timely
performance of an adequate immunohistochemical staining during histopathological exami‐
nation, which is done by a pathologist. It very often leads to inability to give correct interpre‐
tation of the pathologic finding [37].
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Modern treatment of the primary lymphoma of colon and rectum implies a multi-modal
approach, that is, a surgical intervention, chemotherapy and radiotherapy in selected cases.
Beside the doubtless improvements achieved in surgical technique, as well as in anesthesiology
and chemotherapy, during the last three decades, there is still a low level of the five-year
survival among the operated patients, which is 42% [29, 37]. The treatment of the large bowel
Non-Hodgkin lymphoma is characterized by the existence of different attitudes about it, from
applying only chemo and radiotherapy on one side, to the performance of surgical procedures,
on the other. Bilsel and his associates published a review of the case from 2005, which gave a
complete clinical response of the primary rectal lymphoma, after the treatment with chemo
and radiotherapy [24]. The other authors also presented similar data [ 38,39]. Pricolo and his
associates, in their analysis of the case presentation from 2002, describe the treatment of rectum
lymphoma using the resection procedures and then chemo and radio therapy, while Shimono
from Japan recommends a pre-operative radiotherapy first, and then a surgical intervention
[40,41]. Regarding the type of operation, there are recommendations that, with small dimen‐
sion primary rectal lymphoma and low malignant potential – MALT or mantle type lympho‐
ma, it is enough to perform a limited resection or transanal extirpation of tumor [42,43]. The
differences in attitude are the consequence of the results achieved based on the presentations
of cases or studies about a small number of patients and a heterogeneous groups of the treated
tumors, in various stages of the disease, with different histopathological diagnosis etc.
Nevertheless, based on the modest experience of the authors, the resection of the large bowel
is recommended whenever possible, together with neo or adjuvant therapy [44, 45].
4. GISTs
Gastrointestinal stromal tumors or, shortly GISTs, are the most common mesenchymal tumors,
which are characterized by positive c-KIT, that is, CD117, CD 34 antigens, and they make
0,1-1% of all gastrointestinal tract tumors. They occur most commonly in the stomach 60-70%
and small intestine 20-25%, while they are the least present in the large bowel, around 5%, and
0,9% of all tumors in the rectum. In relation to the incidence of occurrence only in the large
bowel, they occur in 80% of all patients in the rectum, while in 20% of cases it is in the colon.
They occur in middle-aged persons between 40-60 and between both sexes equally, with the
incidence of 6,8 / 1 000 000 [46].
At the beginning of XXth century, Theodor Bilroth provided the first descriptions of the stromal
tumors. However, the term “stromal tumor” was introduced bay Mazur and Clark only in
1983, following the development of immunohistochemistry. One year later, in 1984, Henry
Appelman introduced the term "GIST-gastrointestinal stromal tumors" for the first time, while
Kindblom and his associates proved that GISTs originate from the interstitial Cajal cells, which
represent the so called, pace maker cells of the gastrointestinal tract. Due to the similar
structural and immunohistochemical characteristics of GISTs and Cajal cells, many authors
are of the opinion that they originate from the same mesenchimal cell [45]. Invasiveness, or
Colorectal Cancer - Surgery, Diagnostics and Treatment262
the metastasis risk assessment of the GISTs on various locations, determined by the size of
tumor and mitotic index, as shown in table 4 [47].
Mitotic count Size Gastric GIST Duodenal GIST Jejunal & ileal GIST Rectal GIST
≤5/50
<2 cm 0% 0% 0% 0%
>2 ≤5 1.9% 8.3% 4.3% 8.5%
>5 ≤10 3.6% 34% 24% 57%
>10 12% 52%
>5/50
≤2 0% N/A 50% 54%
>2 ≤5 16% 50% 73% 52%
>5 ≤10 55% 86% 85% 71%
>10 86% 90%
Table 3. Metastasis risk assessment of GISTs in different parts of GI tract [48].
4.1. Clinical presentation and diagnosis
GISTs are symptomatic in about 70%, - in about 10% asymptomatic and in 20% they are
discovered during the autopsy, which shows that 1/3 of the large bowel stromal tumors are
clinically completely silent. The symptomatology is very similar to the other colon tumors, and
is characterized by hematochezia, abdominal or rectal pain, occurrence of complete rectum
prolapse etc.[49]. Depending on the tumor size, it is possible to get the clinical presentation of
the obstruction or ileus, caused by the growth of GISTs. The diagnosis - can be made by taking
the anamnestic data, clinical examination including a digital rectal exam, which should be
completed with rectoscopy, colonoscopy, endorectal ultrasound and NMR. It is necessary to
do a biopsy of tumor with immunohistochemical analysis, for definite confirmation of the GIST
existence in the large bowel. In the case of any doubt that there is metastasis in the liver, it is
also necessary to perform the ultrasound and CT scan, within the complete staging of tumor.
PET scan is indicated in the operated patients in order to follow up.
4.2. Treatment
Surgical intervention is a method of choice in treatment of large bowel GISTs, and is applied




The main aims of surgical treatment of the primary disease are the complete resection, so-called
R0 resection and preservation of the tumor pseudocapsule, without wide resection margins
and lymphadenectomy. This is very important in treatment of the rectum GISTs, due to the
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aims of sphincter saving procedure and improve the patient’s quality of life. With regard to
the size and localization of the large bowel stromal tumors, it is possible to use various surgical
procedures: segmental resection, local excision, anterior and abdominoperineal resection. The
performance of the anterior resection (high or low), means the observance of the partial or total
mesorectal excision principles, in order to prevent sacral nerves injury, bleeding or local
recurrence.
Figure 4. Rectal GIST
When GIST adheres to contiguous organs, consideration should be given to an en bloc
resection. The modern aspects of the GISTs treatment also mean the use of Imatinib, a
medicament, which revolutionary contributed to the significantly better results in treatment
in GISTs. Joensuua, Heinrick van Oosterona and Tuveson made the first reports about the use
of Imatinib in 2001. An immediate cause for the invention of this medicament was the discovery
of Hirot about the existence of the abnormal activation of KIT oncoprotein or transmembrane
receptor tyrosine kinase and the following mutation of C-kit gene, with exceptional cellular
proliferation. Imatinib selectively inhibits the receptors of the transmembrane tyrosin kinese,
thus blocking the abnormal growth of tumor. Van Oosteron and his associates published the
results from 70% of clinical responses in KIT-positive metastatic GISTs [50,51]. Primary
unresectable GISTs of the large bowel are initially treated with Imatinib, with an aim to reduce
the size of a tumor – “downsizing”. In the case of the existence of a metastatic disease, a non-
adjuvant use of Imanitib is indicated, in order to secure good clinical response, meaning a
disease without progression, with the possibility of performing R0 resection [52]. When there
is a small volume metastasis in liver, some authors recommend the simultaneous resection of
the large bowel and liver, and then the application of Imatinib[53]. Distant metastasis occur
on the liver in over 50%, and they are treated with the initial application of Imatinib, followed
by the various resection procedures.
The treatment of GISTs using chemotherapy has a minimum effect, RR<10%, and has no
significance for the overall survival, as well as the application of radiotherapy, since the tumor
is radio resistant.
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4.3. Treatment outcomes
The outcome of the large bowel GISTs treatment is troubled with a high percentage of local
and distant recurrences, so after the R0 resection, it occurs in 45-50% of cases, 20-25 months
after the surgical intervention. The average five-year survival rate is 50%, 73% after the R0 and
in 26% after R1 and R2 resections. In the case of the advanced disease with local recurrence
and metastatic disease, a five-year survival rate is 28-35% [54].
5. Squamous cell carcinoma
Squamous cell Carcinoma of the large bowel is a very rare disease, unlike its localizations on
the esophagus and the anal canal. The data from literature are based on the reviews of the
clinical cases and series with a small number of patients. Schmidtmann first described the
squamous cell carcinoma of the large bowel, actually cecum in 1919, and Reiford described the
same disease on the rectum in 1933. Currently, there are about 100 cases of the squamous cell
carcinoma of the large bowel described in literature, and the incidence of the disease is 0,1-0,25
on 1000 patients suffering from the colorectal carcinoma [55].
Due to a very rare occurrence of the tumor, there is a lack of prospective studies, or meta
analyses, which would offer data about the demographic characteristics of the patients, risk
factors, the nature of the disease behavior, as well as the optimal treatment.It mainly occurs in
patients of the average age of 60, more often among women 66% than among men 34%
[56].Etiology of the occurrence of colorectal squamous cell carcinoma is still unknown, as well
as of the other kinds of malignant diseases, although there are several theories trying to explain
the formation of this neoplasm:
– The influence of differentiation of stem cells,
– Squamous metaplasia at the place of existence of colorectal adenoma,
– Proliferation of uncommitted mucosal basal cells into squamous cells which subsequently
undergo a malignant transformation
– Oncogenic influence of the chronicle kidney insufficiency, as well as, the application of the
immunosuppressive therapy in terms of development of some cancerous viruses or oncogenic
differentiation of the stem cells,
– Special influences of irradiation, colocutaneous fistula, ulcerous colitis, Entamoeba histoli‐
tyca colitis, homosexuality, immunosuppression, schistosomiasis, and still unclear influence
of HIV (human papilloma viruses types 16, 18, 31, 33) [57- 59].
5.1. Clinical presentation and diagnosis
The symptoms of the disease are very similar to the symptoms of colon carcinoma, such as
bleeding, abdominal pain, change in bowel habits with the episodes of diarrhea and obstipa‐
tion and weight loss.The diagnosis is established by taking the anamnestic data, clinical
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aims of sphincter saving procedure and improve the patient’s quality of life. With regard to
the size and localization of the large bowel stromal tumors, it is possible to use various surgical
procedures: segmental resection, local excision, anterior and abdominoperineal resection. The
performance of the anterior resection (high or low), means the observance of the partial or total
mesorectal excision principles, in order to prevent sacral nerves injury, bleeding or local
recurrence.
Figure 4. Rectal GIST
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examination including digital rectal exam, which should be completed with rectoscopy,
colonoscopy, MSCT, endorectal ultrasound andd NMR.Williams and his associates published
the following criteria for diagnosing the squamous cell carcinoma of the large bowel, in 1979:
1. non-existence of the squamous cell carcinoma and its metastasis on the other locations
(particularly the skin),
2. careful anoscopy and rectoscopy in order to exclude the existence proximal extension of
anal squamous cell carcinoma,
3. non-existence of a fistulous tract lined by squamous cells [55, 58].
These criteria should be completed with the excision biopsy of tumor, as well as, the PH, or
immunohistochemical confirmation (presence of cytokeratin CAM 5.2, AE1/AE3 i 34B12. CAM
5.2). Sub-mucous localizations of the squamous cell carcinoma represent a separate problem,
due to difficult identification during standard examinations, so, in these cases, it is recom‐
mended to use endoluminal ultrasound guided needle biopsy of tumor. Determination of
values of the tumor markers represents one of the possible auxiliary diagnostic procedures for
determination of the disease, under the condition that the marker is specific for a particular
tumor. In the case of the squamous cell carcinoma of the colon and rectum, there are no specific
tumor markers, so those, usually used for the anal squamous cell carcinoma or for the so called
layer plate cells of carcinoma antigen ( Squamous cell carcinoma antigen "-SCC Ag)", are used.
According to the opinions of some authors, SCC Ag is not specific for the initial diagnosis, but
for the follow up of the occurance of local and distant recurrence after treatment [60].
5.2. Treatment
Surgical intervention is a method of choice in treatment of the squamous cell carcinoma of the
large bowel. The type of surgical intervention depends on the size of tumor, its localization,
depth of invasion into the colon wall, presence of local and distant metastasis, BMI (Body Mass
Index), general condition of the patient and presence of comorbidity. The types of surgical
intervention are similar to those used with the colon carcinoma: endoscopic mucosa/sub-
mucosa resection, segmental or hemi colectomy, local excision, resection procedures on the
rectum, as well as abdominoperineal amputation of the rectum. Endoscopic mucosa/sub-
mucosa resection is applied based on the experience acquired in treatment of adenocarcinoma,
and is indicated in patients with superficial tumors – T1 stage and with an expressed comor‐
bidity. Endoscopic mucosa/sub-mucosa resection, local excision (trans-anal or trans-anal
endoscopic microsurgery-TEM) is a method of choice with T1 stage of the disease, which means
a tumor spreading to mucosa/sub-mucosa. There are some dilemmas about the type of
treatment in T2 stage (spreading to muscularis proprie), because after application of the local
excision, a recurrence rate is present in 20% of the operated patients. In these cases, it is
necessary to make a good pre-operative staging of tumor in relation to the existence of the
positive lymph nodes and the range of spreading to the large bowel wall.In the cases of the
transmural spreading to the wall, up to the pericolic/rectal fat tissue – T3 stage, as well as the
infiltration into the surrounding organs T4-stage, there are dilemmas whether it is better to do
a surgical intervention first, and then the chemotherapy, or vice versa. The researches, which
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were made based on the application of the identical treatment protocol in anal squamous cell
carcinoma - (combination of the chemo and radio therapy 5-FU +mitomycin-C and radio 45
Gy), did not give the expected results in localization of the proximal parts of the rectum and
colon. There are data in literature, which recommend only application of the chemo and radio
therapy, as well as, the simultaneous chemo-radiation. However, the majority of authors agree
that, for the time being and based on the experiences acquired in treatment of a small number
of patients, the optimal therapy means surgical intervention and the adjuvant chemo radiation
[52]. Surgical treatment of the advanced disease means the application of the resection
procedures (colectomy, high and low resection of rectum) and abdominoperineal amputations
of rectum. The resections of rectum, as a sphincter preserving operation, enable better quality
of life of the patient on one hand, and compliance with the oncological principles on the other.
Regardless of the advantages of the resection procedures in relation to the amputation surgery
of rectum, the data from literature show that Miles’s operation has been performed twice as
much in treatment of the squamous cell carcinoma of rectum, which has been explained by a
large number of advanced tumors at the time of diagnosing [61].
The disease prognosis is based on determination of the TNM stage, the most important
prognostic factor, identical to the one in anal squamous cell carcinoma. The TNM stage is
shown in Table 4.
Stadium T N M
0 Tis N0 M0
I T1 N0 M0
T2 N0 M0
IIA T3 N0 M0
IIB T4 N0 M0
IIIA T1-T2 N1 M0
IIIB T3-T4 N1 M0
IIIC Any T N2 M0
IV Any T Any N M1
Table 4. TNM staging system of squamous cell carcinoma of the large bowel [56].
By comparing the disease prognosis from adenocarcinoma of the colon and rectum of the same
stage, it has been established that stages of the disease I and II have a similar prognosis, unlike
the advanced ones (stages III and IV), where squamous cell carcinoma has worse prognosis.
The average five-year survival is 32%, with variations, which are related to the certain stages:
Dukes B 50%, Dukes C 33% & Dukes D 0%. Application of the adjuvant therapy improves the
overall survival of a patient, on one hand, while the pre-operative radiotherapy increases the
percent of the sphincter preserving operation, on the other [58,59].
Rare Tumors of the Colon and Rectum
http://dx.doi.org/10.5772/56937
267
examination including digital rectal exam, which should be completed with rectoscopy,
colonoscopy, MSCT, endorectal ultrasound andd NMR.Williams and his associates published
the following criteria for diagnosing the squamous cell carcinoma of the large bowel, in 1979:
1. non-existence of the squamous cell carcinoma and its metastasis on the other locations
(particularly the skin),
2. careful anoscopy and rectoscopy in order to exclude the existence proximal extension of
anal squamous cell carcinoma,
3. non-existence of a fistulous tract lined by squamous cells [55, 58].
These criteria should be completed with the excision biopsy of tumor, as well as, the PH, or
immunohistochemical confirmation (presence of cytokeratin CAM 5.2, AE1/AE3 i 34B12. CAM
5.2). Sub-mucous localizations of the squamous cell carcinoma represent a separate problem,
due to difficult identification during standard examinations, so, in these cases, it is recom‐
mended to use endoluminal ultrasound guided needle biopsy of tumor. Determination of
values of the tumor markers represents one of the possible auxiliary diagnostic procedures for
determination of the disease, under the condition that the marker is specific for a particular
tumor. In the case of the squamous cell carcinoma of the colon and rectum, there are no specific
tumor markers, so those, usually used for the anal squamous cell carcinoma or for the so called
layer plate cells of carcinoma antigen ( Squamous cell carcinoma antigen "-SCC Ag)", are used.
According to the opinions of some authors, SCC Ag is not specific for the initial diagnosis, but
for the follow up of the occurance of local and distant recurrence after treatment [60].
5.2. Treatment
Surgical intervention is a method of choice in treatment of the squamous cell carcinoma of the
large bowel. The type of surgical intervention depends on the size of tumor, its localization,
depth of invasion into the colon wall, presence of local and distant metastasis, BMI (Body Mass
Index), general condition of the patient and presence of comorbidity. The types of surgical
intervention are similar to those used with the colon carcinoma: endoscopic mucosa/sub-
mucosa resection, segmental or hemi colectomy, local excision, resection procedures on the
rectum, as well as abdominoperineal amputation of the rectum. Endoscopic mucosa/sub-
mucosa resection is applied based on the experience acquired in treatment of adenocarcinoma,
and is indicated in patients with superficial tumors – T1 stage and with an expressed comor‐
bidity. Endoscopic mucosa/sub-mucosa resection, local excision (trans-anal or trans-anal
endoscopic microsurgery-TEM) is a method of choice with T1 stage of the disease, which means
a tumor spreading to mucosa/sub-mucosa. There are some dilemmas about the type of
treatment in T2 stage (spreading to muscularis proprie), because after application of the local
excision, a recurrence rate is present in 20% of the operated patients. In these cases, it is
necessary to make a good pre-operative staging of tumor in relation to the existence of the
positive lymph nodes and the range of spreading to the large bowel wall.In the cases of the
transmural spreading to the wall, up to the pericolic/rectal fat tissue – T3 stage, as well as the
infiltration into the surrounding organs T4-stage, there are dilemmas whether it is better to do
a surgical intervention first, and then the chemotherapy, or vice versa. The researches, which
Colorectal Cancer - Surgery, Diagnostics and Treatment266
were made based on the application of the identical treatment protocol in anal squamous cell
carcinoma - (combination of the chemo and radio therapy 5-FU +mitomycin-C and radio 45
Gy), did not give the expected results in localization of the proximal parts of the rectum and
colon. There are data in literature, which recommend only application of the chemo and radio
therapy, as well as, the simultaneous chemo-radiation. However, the majority of authors agree
that, for the time being and based on the experiences acquired in treatment of a small number
of patients, the optimal therapy means surgical intervention and the adjuvant chemo radiation
[52]. Surgical treatment of the advanced disease means the application of the resection
procedures (colectomy, high and low resection of rectum) and abdominoperineal amputations
of rectum. The resections of rectum, as a sphincter preserving operation, enable better quality
of life of the patient on one hand, and compliance with the oncological principles on the other.
Regardless of the advantages of the resection procedures in relation to the amputation surgery
of rectum, the data from literature show that Miles’s operation has been performed twice as
much in treatment of the squamous cell carcinoma of rectum, which has been explained by a
large number of advanced tumors at the time of diagnosing [61].
The disease prognosis is based on determination of the TNM stage, the most important
prognostic factor, identical to the one in anal squamous cell carcinoma. The TNM stage is
shown in Table 4.
Stadium T N M
0 Tis N0 M0
I T1 N0 M0
T2 N0 M0
IIA T3 N0 M0
IIB T4 N0 M0
IIIA T1-T2 N1 M0
IIIB T3-T4 N1 M0
IIIC Any T N2 M0
IV Any T Any N M1
Table 4. TNM staging system of squamous cell carcinoma of the large bowel [56].
By comparing the disease prognosis from adenocarcinoma of the colon and rectum of the same
stage, it has been established that stages of the disease I and II have a similar prognosis, unlike
the advanced ones (stages III and IV), where squamous cell carcinoma has worse prognosis.
The average five-year survival is 32%, with variations, which are related to the certain stages:
Dukes B 50%, Dukes C 33% & Dukes D 0%. Application of the adjuvant therapy improves the
overall survival of a patient, on one hand, while the pre-operative radiotherapy increases the
percent of the sphincter preserving operation, on the other [58,59].




Melanoma of the gastrointestinal tract is a rare mucosal melanoma with a particularly
aggressive biology compared with cutaneous one of equal stage. They most often occur as a
metastatic tumor, while the primary localization is rare and possible in esophagus, stomach,
small intestine and anorectum, that is, at the places where melanocyte normally exist. The
colon melanoma is an extremely rare tumor with regard to the fact that, embryologically,
melanocytes do not exist in this part of colon and that, up to now, only 12 cases have been
describes in the English literature. There are several theories, which describe the formation of
the colon melanoma: relation to neural crest cells, model of tumor regression and ectodermal
differentiation, but none of them has been completely proved so far. Localization in the
anorectum takes the third place regarding the incidence of localization, behind the rest of skin
and eyes surfaces and it makes 1-1,5% of all melanomas in the human body, and 3-15% of all
tumors of the colon and rectum [62,63]. Moore described it for the first time in 1857 and, until
now, the total of 500 cases was described in the literature. The most often it occurs on the skin,
under the dental line, and rarely at the level of cuboidal epithelium of the transition zone and
mucosae of the distal rectum. It is more common in women (twice as much than in men),
between 60 and 70 years of age [64]. The melanoma represents a disease of the neuroectodermal
origin, which the most often originates from melanocytes and nevus cells of the basal layer of
epidermis, and significantly less from mucosa. It has an extremely worse long-term prognosis,
because of the disease discovery in the advanced stage, mainly with metastasis in the inguinal
nodes. Beside the lymhogenous dissemination, spreading is possible by the local ingrowth and
in hematogenous way. The local spread is according to the radial (horizontal) and vertical
growth. Radial growth means circular spreading around the primary tumor, through the
epithelium of mucosa and the superficial layers of sub-mucosa, without tendency of metasta‐
sizing. Vertical growth means penetration into the deeper layers of the colon wall, with
simultaneous metastasizing. Determination of level of the vertical tumor growth, i.e. involve‐
ment of the colon and rectum wall layers, is essential for the choice of surgical intervention.
The most important roles here have the MSCT (multi-slice scanner), NMR (magnetic reso‐
nance) and endoluminal ultrasound. Hematogenous dissemination occurs by penetration of
the melanoma cells into the blood vessels, with further spreading to the whole body. About
30% of patients, at the moment of diagnosing, are considered to have a disseminated process,
while only 17% of the operated ones have a five-year survival. [65,66]. It differs from skin
melanoma in the way that 25% of tumors do not contain a pigment of the so called “coloured”
tumor, and because ultraviolet radiation is a factor of protection, not a risk. In case of existence
of the pigment tumor of the rectum, the macroscopic appearance is very similar to thrombosed
external and prolapsing internal hemorrhoids (see figure 5), which can mislead a doctor in
setting a diagnosis[67,68].
The symptoms of the disease are different, but the most common ones are the abdominal pain,
weight loss and bleeding.The diagnosis of the disease implies to detailed anamnesis, physical
examination with special reference to inspection of all parts of skin and eyes, as the most
common primary localizations, as well as, taking biochemical laboratory analyses, digito rectal
examination, colonoscopy, barium enema, multi-slice scanner (MSCT), magnetic resonance
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(NMR), endoluminal ultrasound and tumor biopsy with pathohistological and immunohis‐
tochemical processing. Special attention should be paid to the examination of certain groups
of lymph nodes, depending on the primary tumor localization. Taking into account the results
made by Kalid and his associates, the most often localization of the primary colon melanoma
is cekum ascedens and transversum, while with the metastatic melanoma these are the
ascendant and descendant parts of colon [62]. Curative treatment of the large bowel melanoma
is exclusively surgical. The main aim of the treatment is to achieve a compromise between the
necessity to apply a radical oncological treatment and a need to preserve the patient’s quality
of living. The contemporary approach to treatment of the primary colon and rectum melanoma
implies to the performance of surgical interventions, such as:
a. colectomy with wide excisional margins (partial, hemi-colectomy, subtotal and total)
b. trans-anal wide local excision with preservation of the anal sphincter (in the case of the
initial stage of the rectum tumor)
c. extensive surgeries according to the type of the rectum resection or abdominoperineal
amputation.
There are numerous dilemmas about which type of surgical intervention to be applied in
certain stages of the disease. The supporters of radical treatment recommend the resection or
rectum abdominoperineal amputation, depending on the localization, with dissection of both
inguinal regions, stating the following advantages:
– possibility of the detailed exploration of the abdomen and the eventual discovery of distant
metastasis;
– lower percent of the local recurrence rate [69].
On the other hand, some authors recommend a wide local excision of tumor with preservation
of the sphincter mechanism, for the following reasons:
– absence of definitive stoma,
– similar five-year survival [70,71].
(a) (b) 
Figure 5. a). Prolapsed melanoma recti; b). Histopathological finding of melanoma recti (H&E 40x)
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The authors from MD Anderson Cancer Center present 20-year experience with treatment of
54 patients with localized anorectal melanoma, demonstrating that combined surgical wide
local excision and adjuvant radotherapy provides good local disease control with acceptable
side effects [72].The existence of such different attitudes in literature is a consequence of,
primarily, uneven criteria of the researches made, comparison of different localizations of the
anorectal melanoma and stage of the disease. The most significant parameter, based on which
a decision about the type of surgical intervention is made, is the thickness of tumor. According
to Weynadt and his associates, indication for a wide local excision are melanomas up to 4 mm
thick, with the limits of excision up to 2 cm from the primary tumor, without involvement of
sphincter, while the extensive surgeries on the rectum are recommended for the melanomas
over 4 mm thick [73].In relation to the adjuvant therapy, melanomas are considered hemi
resistant tumors, so certain cytostatic medicaments have an effect in 10-25% of the treated ones.
The most often used are: dacarbazin, temozolamid, cisplatin, carboplatin, nitrosoureas.The
latest research showed that determination of biological markers RAS/RAF/MEK/ERK,
represent a significant indicator of the cell growth intensity degree, as well as, the invasion
and survival [62]. The adjuvant therapy of anorectum melanoma is not very much successful
because all these tumors are radio resistant and scarcely responsive to chemotherapy[74,75].
6. Extremely rare tumors
Other tumors include an extremely rare malignant diseases of the large bowel: primary
teratomas, extramedullary plasmacytomas, schwannomas and metastasis of distant tumors.
Primary teratomas of the large bowel are very rare diseases and, there are only about 50 cases
published in literature until now, mainly the ones in the rectum and in the form of clinical
presentation. It occurs more often in women at the average age of 42,5. They are considered to
originate as consequence of the ectopic development of the so-called “captured” ectodermal
tissue although, in their composition, some structures of mesodermal endodermal origin are
possible. Histologically, it is composed of the stratified squamous epithelia, fat cells, hair
follicle, cartilage and, partially glandular tissue. They are usually benign tumors, however
some malignant transformations are also possible, which create a need for the total elimination
of tumor, due to compliance with the oncological principles. Data from literature indicate that
teratomas usually occur in the ovary, testicles, mediastinum and the middle lines such as
sacrococcygeal region, while they occur less frequently in the gastrointestinal tract (rectum,
sigmoid part of colon, appendix and terminal ileum) [76]. The rectal teratomas usually have a
polypoid cystic form, with protrusion into the lumen area. The solitary cysts are mainly
present, filled in with sebaceous whitish liquid into which the sebaceous glands, hair follicles
and teeth are immersed. Beside the cystic form, the existence of the solid tumors is possible,
which indicates a mature form of the teratoma.
The clinical presentation is characterized by the presence of pain during defecation, bleeding
and change in bowel habits. The diagnosis is established by the anamnesis and digital rectal
examination, which confirms the existence of the polypoid tumor mass of mainly smooth edges
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and a pedicle. The cases of rupture of the ovarian teratoma into the rectal lumen are described,
with the similar difficulties. The additional diagnostic procedures, such as the endoluminal
ultrasound, multi-slice scanner and NMR give the additional information about the extensity
of the tumor itself, as well as, the estimation of operability. Some malignant transformations
of teratomas with a tendency of creating squamous cell carcinoma are possible, and due to
this, it is not advisable to perform the transanal punctuation because of the danger of malignant
cells spreading, on one hand, and the potential infection, on the other. The method of choice
in the treatment is the complete elimination of the cystic tumor.
The most frequent form of plasma cell neoplasm is a multiple myeloma. Out of the total
number of all multiple myeloma, only 2% are the so-called extramedullary plasmacytoma.
More the 75% of extramedullary plasmacytoma occur in the upper part of the respiratory
system, while the most common places of occurence in the gastrointestinal tract are the
stomach and small intestine. Until now, 22 cases of the occurence of extramedulllary plasma‐
cytoma in the colon, have been reported, where the average age of patients was around 52,3.
The most frequent localization on the large bowel are the cecum with 36,4% and rectum with
22,7%. It is essential to make a differential diagnosis differentiation between the primary and
secondary plasmacytoma, that is, the metastasis of the multiple myeloma. It is achieved by
determination of the Bence-Jones proteins in urine, by serum electrophoresis, as well as, the
immunohistochemical finding of the collections of monoclonal plasma cells.
The treatment involves the application of:
– surgical intervention in 81,8% of cases,
– radio-therapy in 9% of cases,
– combined application of surgical intervention and radio-therapy in 4,5% of cases [77,78].
Schwannomas originate from Schwann cells, which form neural sheath and belong to the
group of stromal tumors. In the gastrointestinal tract, they most frequently appear in the
stomach, while the primary Schwannomas of the large bowel are extremely rare and, until to
now, only 39 clinical cases have been reported. They mainly occur in older patients around 65
years of age, of both sexes equally. They grow slowly and there is a large number of patients
who do not have any symptoms at the moment of diagnosing. The symptoms occur depending
on the size and localization of tumor, but vague pain in the abdomen, bleeding and change of
bowel habitus mainly manifest them. The pre-operative diagnosing, using the standard
procedures such as anamnesis, physical examination, colonoscopy MSCT, NMR and endolu‐
minal ultrasound, is possible in determination of the tumor mass, but not the type and kind
of tumor because it resembles to the GIST tumors of the colon. The most accurate diagnosis
implies the elimination of tumor as a whole, with pathohistologic and immunohistochemical
analyisis. It is also difficult to differentiate it from GISTs in respect of immunohistochemical
analyisis and some authors classify it the sub-group of GISTs, such as GANT tumors, i.e.
gastrointestinal autonomous nerve tumors [79].
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The authors from MD Anderson Cancer Center present 20-year experience with treatment of
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7. Metastases in the colon and rectum from the distant tumors
The metastasis of distant primary tumors rarely spread to the large bowel, and it is usually
related to the carcinoma of the surrounding organs (stomach, pancreas, ovarian etc.) which,
due to their growth and size, spread to the surrounding parts of colon, or “fall” on the
intraperitoneal rectum with secondary infiltration. The degree of the tumor spreading depends
on the length of the primary tumor existence and the histologic type, although the literature
data indicate that serosa is infiltrated in 28%, muscles’ layer in 31% and mucosa in 14% of
patients. The expansion of the prostate cancer is possible, with perforation to Denonvilliers
fascia and the secondary spreading to the rectum, according to the type of circumferential, i.e.
annular stenosis, without spreading to mucosa in men, as well as the carcinoma portie vaginalis
uteri, in women [80,81]. The pouch of Douglas, as the lowest point in the abdomen and in the
close vicinity of the rectum, is a place of intraperitoneal spreading of carcinoma of any intra-
abdominal or retroperitoneal organ, with predomination of the stomach and ovarium.
Carcinoma metastasis of retroperitoneal and extra-abdominal organs, pancreas, kidneys and
breast, are described in literature [82,83]. The clinical presentation is similar to those of the
other colon tumors (bleeding, change in the bowel habitus, pain in the region of anus),
supplemented with symptomatology of the primary localization of the malignant process. The
diagnosis implicates anamnesis, digital rectal examination, colonoscopy, endoanal ultrasound,
multi-slice scanner, NMR, as well as, the biopsy with pathohisiological confirmation.
The strategy of treatment depends on:
– localization of the primary malignant process,
– advancement of the disease,
– histological type of the primary tumor
If the primary tumor localization is in the immediate vicinity of the colon and rectum (pancreas,
sigma, prostate, cervix and vagina), it is recommended to use the so called en block resections,
with an aim to achieve the oncological principle of radicalism or R0 procedure [84]. Sometimes,
it is necessary to perform a non-adjuvant therapy in order to reduce the volume of tumor, so
called “downsizing”, and the biological aggressiveness of tumor, “down-staging”, on one
hand, or to supplement the surgical intervention with the adjuvant therapy, on the other. In
the case of extra abdominal localization of the primary tumor, it is necessary to assess the effect
of successfulness of the surgical intervention in achieving a R0 resection, or the application of
the neoadjuvant therapy.
8. Conclusion
Rare tumors of the colon and rectum represent an important group of neoplasms, due to their
specific prognosis secondary to late diagnosis, and resistance to conventional cancer therapy.
Over the last 20 years, their overall incidence has increased, due to advent of novel imaging
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techniques, especially the development of more sophisticated diagnostic tools including high
resolution CT and MRI, capsule endoscopy and somatostatin scintigraphy for NETs. Although
the development of specific targeted therapies such as tyrosine kinase inhibitors for GISTs and
somatostatin analogs for NETs have improved prognosis, early detection remains the critical
variable in determining outcome. Similarly, promising therapeutic data in some subgroups
are encouraging although the majority is still diagnosed late and targeted effective therapy is
lacking. Difference in survival is the consequence of the difference in biological aggressiveness
of tumor, way of the disease spreading and tendency towards metastasis on one hand, and the
frequency of appearance and symptomatology on the other. Carcinoid was an indolent tumor
with the best prognosis, both non-Hodgkin lymphoma and squamous cell carcinoma of the
large bowel showed significantly worse overall survival rate, as compared to adenocarcinoma,
while melanoma has the shortest time of survival. The aim of this chapter is to draw our
attention to the rare tumors in everyday clinical practice.
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1. Introduction
Colorectal cancer represents the third most prevalent cancer in the United States, and the third
most common cause of cancer-related mortality [1]. Due to the widespread introduction of
screening of asymptomatic patients age 50 and above, the incidence of colorectal cancer has
been declining [2]. Unfortunately the incidence of colorectal cancer in those under the age of
50 is increasing [3]. In its earliest stages colorectal cancer is highly treatable and curable. Cures
in patients with advanced disease are uncommon, but with improved systemic therapies and
oncologic surgery, is increasing over time. However, despite modern therapeutic advances,
less than 20% of patients with distant metastatic disease will be alive and disease free for five
years following the diagnosis [4].
Management of colorectal cancer highlights the importance of oncologic multidisciplinary
care. Surgical adjuvant chemotherapy and chemoradiation therapy have led to improved
outcomes for patients with colon cancer and rectal cancer, respectively. This is one of the factors
associated with a decrease in colorectal cancer mortality over the last decade. Adherence to
treatment guidelines has been shown to be associated with improved patient outcomes
[5].Further refinements in adjuvant therapy will involve molecular risk adaption and im‐
proved selection of patients for chemotherapy and adjuvant chemoradiation therapy, incor‐
poration of molecularly targeted agents into the treatment paradigm, and studies to define
more clearly the optimal time and duration of adjuvant therapy following colorectal surgery.
2. Staging of colon cancer
The pathologic stage of colon cancer is currently based on the seventh version of the American
Joint Commission of Cancer Staging [6]; a simplified version is reproduced in Table 1.
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Pathologic stage is currently the most accurate predictor of those at greatest risk of relapse,
and those most likely to benefit from additional adjuvant therapy. As greater than 80% of
patients with stage I disease are cured with surgery alone additional adjuvant therapy has not
been shown to improve the already favorable prognosis. Patients with stage II and III are at
high risk of systemic relapse and in stage III patients the benefit of adjuvant chemotherapy has
clearly been demonstrated and the data supporting it will be reviewed in section 3. Systemic
therapy for patients with resected stage II disease remains highly controversial and will be
addressed in section 4.
Stage Description 5-year survival
I T1,2, N0 85-95%
II T3,4 N0 60-80%
III Any T, N 1,2, M0 30-60%
IV M1 < 20%
Table 1. Simplified AJCC Staging Classification and Estimated 5-year Survival
3. Treatment of stage III colon cancer
5-Flurouracil -based Adjuvant Chemotherapy
The prodrug 5-flurouracil was synthesized and patented in 1957 [7] and had shown modest
efficacy in the treatment of patients with metastatic colorectal cancer, increasing the median
survival from 6-9 months without therapy to an average of 12-14 months. Initial studies
evaluating its efficacy, combined with the immune modulatory agent levamisole, were
conducted by the North Central Cancer Treatment Group (NCCTG) in the 1980s. In a large,
randomized, prospective trial, involving multiple sites across the United States, patients
treated with 5-flurouracil and levamisole for 12 months were noted to have a 40% reduction
in the relative risk of recurrence, and a 33% reduction in the relative risk of mortality [8]. Long
term follow up data from this study confirms the increased cure rate in association with the
use of adjuvant chemotherapy, not merely the representation of a lead-time bias [9]. Thus 5-
flurouracil became, and remains, the backbone of surgical adjuvant therapy for resected stage
III colon cancer. Levamisole was associated with significant toxicity however, and subsequent
clinical trials demonstrated that 5-flurouracil, modulated by leucovorin, was also associated
with a survival benefit [10] but with less neurological toxicity.
Adjuvant 5-flurouracil -based chemotherapy for colon cancer has been refined over time.
Weekly 5-flurouracil has been administered (Roswell Park regimen) and in a randomized
clinical trial, was demonstrated to be superior to the combination of 5-FU, semustine, and
vincristine [10]. Studies comparing 5-flurouracil combined with leucovorin versus levamisole
demonstrated that 6 months treatment of 5-flurouracil + leucovorin was equivalent to 12
months 5-flurouracil levamisole; 6 months of 5-flurouracil plus levamisole was determined to
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be less effective, in terms of 5-year disease free survival. Thus, six months of therapy is
determined to be the optimal. As will be reviewed the optimal duration of chemotherapy is
currently under active investigation.
It had been noted that in the metastatic setting, meta-analysis of randomized phase II trials
suggested that infusional 5-flurouracil is more active when compared to bolus intravenous 5-
flurouracil [11]. 5-flurouracil has a different mechanism of action when given continuously,
with a greater inhibition of messenger ribonucleic acid (RNA), when compared to bolus 5-
flurouracil, where the action is more directed at targeting DNA synthesis through inhibition
of thymidylate synthetase. Reduced folate (leucovorin) increases the binding of 5-flurouracil
to thymidylate synthase, thereby increasing the efficacy of 5-flurouracil in inhibiting DNA
synthesis (see Figure 1). Although no large, randomized studies comparing bolus 5-flurouracil
compared to infusional 5-flurouracil have been performed, the superior toxicity profile of
infusional 5-flurouracil (less diarrhea, mucositis, and myelosuppression), and the potential for
additive benefit of infusional 5-flurouracil (given its different mechanism of action) have led
to infusional 5-flurouracil combined with bolus 5-flurouracil being used more commonly in
5-flurouracil adjuvant chemotherapy combined with other novel agents.
Oral Fluropyrimidines
Capecitabine is an oral pro-drug which is converted to thymidine phosphorylase into 5-
flurouracil. It has been demonstrated that tumor cells have higher levels of thymidine
phosphorylase and therefore at least theoretically there could be preferential accumulation of
5-FU in tumor cells. In a large phase III study (the X-ACT) trial was found to be non-inferior
to bolus 5-flurouracil/leucovorin (Mayo Clinic regimen) [12]. Therefore capecitabine is
currently approved for patients who are deemed to be suitable candidates for monotherapy,
and is an alternative to bolus or infusional 5- flurouracil. Other oral fluropyrimidines have
been examined for efficacy; UFT is a combination of uracil (a dihydropyrimidine dehydryo‐
genase inhibitor (DPD), the enzyme responsible for metabolizing 5-FU, and tegafur (a 5-FU
prodrug). When evaluated in a randomized phase III study of stage II and III patients, and
compared to bolus flurouracil modulated with leucovorin (Roswell Park regimen) it was found
to be equal in efficacy [13]. UFT was approved for use in much Europe and Asia but has not
been approved for use in the United States.
CapeOx is currently recommended as one of the chemotherapy regimens in the latest version
of the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in
Oncology (version 1.2011) for the adjuvant treatment of stage III colon cancer. The NO16968
(XELOXA) trial, a large randomized phase III study of CapeOx versus bolus 5-flurouracil
(Roswell Park) was performed in more than 1,800 stage III colon cancer patients. It showed a
significantly superior three-year disease free survival with CapeOx when compared to the
control arm (71% versus 67%, P = 0.0045) [14]. CapeOx was associated with less febrile
neutropenia and stomatitis than 5FU/LV, although as expected peripheral neuropathy were
more frequent; peripheral neuropathy was observed in a similar proportion of patients
receiving FOLFOX or CapeOx.
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addressed in section 4.
Stage Description 5-year survival
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IV M1 < 20%
Table 1. Simplified AJCC Staging Classification and Estimated 5-year Survival
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As a consequence of the efficacy of oxaliplatin, demonstrated in the metastatic setting, a large
randomized trial compared the efficacy of infusional 5-FU plus oxaliplatin, and infusional 5-
FU combined with bolus 5-FU (the Multi-center International Study of Oxaliplatin, 5-FU, and
Leucovorin, in the Adjuvant Treatment of Colon Cancer, or MOSAIC Study). Initial data
reported a 23% risk reduction of disease recurrence at three years [15]. Updated 6-year disease-
free survival data demonstrated a 6% improvement in disease-free survival, confirming the
initial positive results [16]. Since 2003 FOLFOX has been the standard-of-care for patients with
resected stage III disease with no contraindications to adjuvant chemotherapy.
Due to the young age of participants in the MOSIAC trial the efficacy of FOLFOX chemother‐
apy has been questioned in elderly patients, given its increased toxicity, primarily peripheral
neuropathy. Pooled analysis of four randomized trials, involving 3,742 patients (of whom 614
were greater or equal to 70 years old) demonstrated that the benefit of FOLFOX chemotherapy
did not differ by age, nor did dose intensity [17]. Thus in patients over the age of 70 who are
deemed appropriate candidates may still benefit from the addition of oxaliplatin, although
very few patients over 80 were included in these studies, thus the data for octogenarians and
nonagenarians is limited.
Oxaliplatin was also evaluated in combination with bolus 5-FU (FLOX); in the National
Surgical Adjuvant Breast Project (NSABP) randomized 2,407 patients with stage II or III colon
cancer to either the Roswell Park regiment (bolus 5-FU modulated with leucovorin) or the
Roswell Park regimen combined with fortnightly oxaliplatin. There was a superior 5-year
disease-free survival with FLOX but not a difference in 5-year overall survival [18].
Adjuvant Irinotecan
Other combination cytotoxic regimens have been subjected to randomized phase III clinical
trial evaluation in the stage III setting. Given the trend to evaluate agents with efficacy in the
metastatic setting, and assume at least the potential for benefit in the adjuvant setting,
irinotecan has been studied in combination with 5-FU. Prior metastatic studies confirmed the
superiority of combination bolus 5-FU plus irinotecan when compared to bolus 5-Flurouracil
monotherapy alone [19], as well as when combined with infusional 5-FU (FOLFIRI) (Douillard
JY, et al. 2000). Thus irinotecan was evaluated in the surgical adjuvant setting for high risk
patients, both combined with bolus 5-FU (IFL) [21] or as FOLFIRI compared to infusional and
bolus 5-flurouracil (LV5-FU2), the PETACC-3 study [22]; neither of these studies demonstrated
a benefit to the addition of irinotecan. Therefore at this time irinotecan is not indicated in the
adjuvant treatment of colon cancer.
Efficacy of Anti-Epidermal Growth Factor Monoclonal Antibodies in the Adjuvant Therapy of Colon
Cancer
Given the efficacy of the anti-epidermal growth factor antibodies cetuximab [23] and panitu‐
mumab [24] in the metastatic setting, it seemed reasonable to explore the efficacy of these
antibodies in the adjuvant setting. A large prospective randomized study evaluated the
efficacy of FOLFOX with or without cetuximab chemotherapy. During the course of the trial
studies demonstrated that the benefit to cetuximab therapy was limited to those patients with
KRAS wild type tumors [25]; thus protocol entry to limited to those patients whose tumors
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harbored a KRAS mutation (see Figure 2). Despite this selection of therapy there was no
improvement in the disease-free survival in the cetuximab treated arm [26].
Figure 1. Possible Explanation for Lack of Efficacy of Anti-Epidermal Growth Factor Antibodies in KRAS Mutant Color‐
ectal Cancer
Efficacy of Anti-Epidermal Growth Factor Monoclonal Antibodies in the Adjuvant Therapy of Colon
Cancer
Colorectal cancer is the first tumor for which anti-angiogenesis therapies have proven to be
effective. The addition of irinotecan plus 5-FU plus the fully humanized anti-vascular endo‐
thelial antibody bevacizumab was associated with a 5 month prolongation in overall survival
when compared to chemotherapy alone in patients with metastatic disease. This suggested a
potential role for this novel targeted agent in the adjuvant therapy of stage III colon cancer.
However two studies, the C08 [27] and the AVANT trial [28], both failed to demonstrate a
disease free survival benefit to the addition of bevacizumab to standard chemotherapy.
Future Cytotoxic Approaches to Adjuvant Colon Therapy
Although irinotecan did not add to the efficacy of adjuvant chemotherapy there is a suggestion
that certain patients with molecular subtypes of colon cancer may benefit from it, possibly
patients with microsatellite instable disease [29] Recent randomized phase III clinical trials
suggests superior efficacy of the three agents (5-FU, oxaliplatin, and irinotecan, or FOLFOXIRI)
when compared to two agents FOLFIRI [30-33]. The efficacy of FOLFOXIRI is under consid‐
eration for testing in a prospective randomized clinical trial compared to FOLFOX chemo‐
therapy.
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Duration of Adjuvant Therapy in Colon Cancer
As discussed previously, the standard duration of adjuvant chemotherapy was initially 12
months when adjuvant therapy was first approved for colon cancer in 1990. As noted previ‐
ously subsequent studies determined that 6 months adjuvant duration was determined to be
equally effective. A prospective randomized trial comparing 3 months of LV5-FU2 when
compared to 6 months 5-flurouracil modulated with leucovorin (Mayo regimen) did not
demonstrate a statistically significant difference in overall survival (P>0.05Given as the trial
was not powered as a non-inferiority study, there are four ongoing studies comparing 3 versus
6 months adjuvant chemotherapy (see table 2). Although there are some differences in the
study design, close to 18,000 patients will be entered on these four studies during this decade.
In order to pool the data from these studies, the International Drug Evaluation of Adjuvant
Chemotherapy (IDEA) was formed to coordinate the data analysis of the pooled results. It is
hoped that by the end of the decade the question of whether or not the shorter course (3 months)




Start Date Target Accrual Treatment Plan
SCOT* III 3/27/2008 9,500
CapeOx/FOLFOX 6 months vs. CapeOx/
FOLFOX 3 months
TOSCA II, III 6/20/2007 3,450
FOLFOX 6 vs. 3 months (plus optional
bevacizumab randomization for stage
IIIc)
GERCOR III 5/2/2009 2,500 FOLFOX 6 vs. 3 months
CALGB/SWOG
C80702
III 7/1/2010 2,500 FOLFOX 6 vs. 3 ± celecoxib/placebo
*Short Course Oncology Therapy
Table 2. Planned Randomized Phase III Studies Evaluating the Duration of Adjuvant Chemotherapy
4. Adjuvant radiation therapy for colon cancer
No prospective data to date has suggested a survival benefit with the addition of radiation
therapy as adjuvant following surgery. Retrospective data suggests that patients with high
risk features for recurrence may receive benefit from radiation, including those who had T4
disease (involving another organ), a positive margin (microscopic residual disease, not true
adjuvant), and clinical perforation had a better disease-free survival with the addition of
adjuvant chemoradiation [34]. One large prospective randomized study evaluating the efficacy
of radiation in colon cancers (non-transverse colon) was inconclusive due to the failure to meet
accrual. The study was underpowered but was not able to demonstrate a benefit of the addition
of radiation to chemotherapy [35]. Treatment decisions have to be made based upon the
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patient’s specific risk factors for local recurrence. At this time the use of radiation as adjuvant
for resected stage III colon cancer is mainly limited to those patients with microscopic residual
disease (positive pathologic margin).
5. Adjuvant treatment of stage II colon cancer
Due to the significantly better prognosis, with the majority of patients being cured with surgery
alone, it is more difficult to demonstrate a significant survival benefit with the use of adjuvant
chemotherapy. The initial adjuvant NCCTG adjuvant study of 5-flurouracil and levamisole
was unable to demonstrate a survival benefit for the chemotherapy arm; this may in part be
due to the higher number of non-cancer-related deaths in the 5-flurouracil treated group [8].
A large randomized, prospective trial of 3,239 patients with resected stage II disease demon‐
strated a 3.6% 5-year improvement in survival following 6 months adjuvant 5-fluorouracil and
leucovorin (Mayo regimen) when compared to observation alone [35]. All agree that if a benefit
exists it is relatively small and that the routine use of chemotherapy is not indicated. Of note,
in the MOSIAC trial, there was no difference in outcome between stage II patients treated with
FOLFOX when compared to infusional and bolus 5-flurouracil chemotherapy. Different
pathologic characteristics may indicate those patients at slightly higher risk of relapse [see
table 3]. Tumor microsatellite instability analysis has been associated with a more favorable
prognosis, as well as a lack of benefit from adjuvant 5-flurouracil chemotherapy in resected
stage II and stage III tumors; in stage II tumors those patients with mismatch repair tumors
had an inferior outcome with the use of 5-fluoruracil adjuvant chemotherapy when compared
to observation [39]. Tumor molecular genotyping is being utilized in order to predict those
stage II tumors most likely to relapse. To date, these genomic tests have not been sufficiently
predictive of those most likely to relapse and are of limited clinical utility [40-41].
Pathologic Feature Reference
Less than 12 Lymph Nodes Analyzed 36, 37
Poorly differentiated 38
Clinical Perforation 38
Table 3. Pathologic Features Associated with a Relatively Adverse Prognosis in Stage II Disease
6. Adjuvant and neoadjuvant approaches in rectal cancer
Rectal adenocarcinomas present a unique challenge given its anatomic location in the pelvis
and the fact that part of the rectum is intraperitoneal and part is extraperitoneal. The vast
majority of rectal malignancies are adenocarcinomas; less common pathologies are gastroin‐
testinal stromal tumor (GIST), carcinoid, squamous, adenosquamous tumors and melanoma.
For the purposes of this chapter we will limit our discussed to rectal adenocarcinomas.
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Compared the large bowel the close proximity of rectum to other local organs such as uro‐
genital system requires different surgical techniques and significantly increases the likelihood
of local relapse after surgery when compared to colon cancer [42]. For this reason, in addition
to total mesorectal excision combination therapeutic options have arisen to decrease local
recurrence. Subsequently, these multimodality therapy approaches have become standard-of-
care in locally advanced rectal cancer. In this book chapter, we aimed to summarize scientific
progression in the field of treatment of locally advanced rectal cancer.
Development of Adjuvant Therapy
The standard care of rectal cancer remains surgery with a total mesorectal excision. However
locally advanced disease were relapsing significantly higher than early stage disease after
surgery-only approach [43]. Rectal cancer transmurally invades the rectal wall directly and
can spread through the lymphatic system to regional lymph nodes. These characteristics of
locally advanced disease put the patients at higher risk of local and distant recurrence which
is associated worse overall survival. Given the high rate of the recurrent disease, combination
treatment approaches have evolved in locally advance rectal cancer over the last two decades.
First, adjuvant radiotherapy and then combined modality therapy (chemotherapy concur‐
rently with radiation therapy) was integrated in standard care to enhance survival outcomes
of locally advanced rectal cancer.
An early prospectively randomized clinical trial was conducted to assess the question of
the  adjuvant  benefit  roles  of  radiation,  chemotherapy,  or  combined  modality  therapy
(chemoradiation) in the treatment of locally advance rectal cancer by the Gastrointestinal
Tumor  Study  Group  (GTSG)  in  1985  [44].  In  this  study,  patients  after  having  curative
surgery (202 in  total),  were  enrolled and randomized into four  different  groups includ‐
ing; patients received no adjuvant treatment, patients treated with adjuvant radiotherapy
either at dose of 40 or 48 Gray, patients received adjuvant chemotherapy with semustine
and  5-fluorouracil,  and  a  final  group  treated  with  combination  of  chemotherapy  and
radiotherapy.  All  patients  were  followed  up  to  for  80  months.  Although  there  was  no
significant  difference  for  OS  in  four  groups,  authors  found  significantly  better  disease-
free survival in combination therapy arm compared to resection-alone [44]. In same study,
recurrence  rate  was  highest  in  resection-alone  with  55%,  while  the  lowest  relapse  was
observed in  combination therapy group (33%).  The follow-up results  of  this  study con‐
firmed a significantly improved overall survival reported in combination treatment group
compared to surgery alone group [45]. By the end of the 10 year follow up, 10-year survival
rates were 26% vs. 45% in control group vs. combination treatment group and was showing
the  superiority  of  combination  treatment  group.  Independently,  The  National  Surgical
Adjuvant and Breast and Bowel Project (NSABP) released the result of R-01 that compar‐
ing adjuvant radiation or chemotherapy to surgery alone and provided superior overall
and disease-free survival in chemo group respect to the surgery alone (P = 0.03, P = 0.006
respectively) [46]. No significant survival benefit observed in radiation alone group.
The North Central Cancer Treatment Group (NCCTG) reported a trial comparing the adjuvant
radiation versus the combined chemoradiation. In this study, total 209 patients randomized
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in two arms. The combined modality arm was found to have 34% reduced overall recurrence
compared to the radiation alone. (P < 0.003) [47]. Decreased recurrence incidence was observed
in both local (25% versus 13% P < 0.02) and distant relapse (43% versus 29.5% P < 0.003). After
this study National Surgical Adjuvant Breast Program (NSABP) examined the impact of the
adjuvant chemotherapy alone versus chemoradiotherapy on overall survival and disease free
survival in protocol R-02. In this study, all female patients received 5-flurouracil and leuco‐
vorin whereas male patients either received MOF regimen including 5-flurouracil, semustine,
vincristine or 5-flurouracil combined with leucovorin. Radiotherapy was given in 25 fractions
at a daily 18 Gray dose. Although there was a significant decrease in cumulative local relapse
incidence after 5-year follow-up (13% versus 8%, P = 0.02), they observed no overall or disease-
free survival differences in between these two groups.
Neoadjuvant Radiotherapy
Absence of clinical evidence to use radiotherapy in adjuvant settings urged the researchers to
test the efficacy of radiotherapy in preoperative settings. Swedish investigators conducted a
phase III clinical trial to understand the possible role of neoadjuvant radiotherapy (i.e. pre-
operative radiation therapy) [48]. They enrolled 1,168 patients and randomly assigned to
receive either conventional surgery alone or surgery with preceded neoadjuvant radiotherapy
designed as a total dose of 25 Gy in five fractions. After five years follow up, recurrence rate
was found 11% in neoadjuvant radiotherapy group, whereas it was observed as high as 27%
in patients with surgery alone (P < 0.001). Additionally, the authors reported significantly
better five year-survival in radiotherapy arm (58% compared to 48%, P = 0.004). Since con‐
ventional surgery was performed in this study, the additive role of the radiation in TME was
still not clear. In 2007, this question was addressed by Dutch Colorectal Cancer Group. They
conducted a randomized clinical trial enrolled the patients into TME alone and 5 fractions
radiotherapy with total 25 Gray dose plus total mesorectal excision [49]. After a median 6.1
years follow- up, no significant overall survival difference was demonstrated. Moreover, there
was no significant difference in distal recurrence incidence. On the other hand, they found a
significant decrease in local recurrence rate (5.6 % vs 10.9%, P < 0.001).
Currently, two different preoperative radiotherapy protocols are commonly preferred in
locally advanced rectal cancer treatment including conventional (50.4 Gray administered in 28
fractions) and short-term treatment (25 Gray in 5 fractions). Although both models have been
shown to decrease local recurrence, there are debates on prolonged side effect in short-term
radiotherapy modality [50]. While short-term neoadjuvant radiation treatment is commonly
used in European countries, conventional radiation is standard-of-care of locally advance
rectal cancer in USA.
Neoadjuvant Chemoradiation Therapy (Combined Modality Therapy)
Better outcomes observed in chemoradiation in adjuvant settings raised the question of
possible neoadjuvant chemoradiation for treatment of patients with locally advanced rectal
cancer. In 2004, German Rectal Cancer Study Group (GRCSG) examined the role preoperative
chemoradiation in rectal cancer patients with T3 or T4 stages or node positivity [51]. They
randomized 823 patients in two groups; the neoadjuvant arm received a total 50.4 Gray dose
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Compared the large bowel the close proximity of rectum to other local organs such as uro‐
genital system requires different surgical techniques and significantly increases the likelihood
of local relapse after surgery when compared to colon cancer [42]. For this reason, in addition
to total mesorectal excision combination therapeutic options have arisen to decrease local
recurrence. Subsequently, these multimodality therapy approaches have become standard-of-
care in locally advanced rectal cancer. In this book chapter, we aimed to summarize scientific
progression in the field of treatment of locally advanced rectal cancer.
Development of Adjuvant Therapy
The standard care of rectal cancer remains surgery with a total mesorectal excision. However
locally advanced disease were relapsing significantly higher than early stage disease after
surgery-only approach [43]. Rectal cancer transmurally invades the rectal wall directly and
can spread through the lymphatic system to regional lymph nodes. These characteristics of
locally advanced disease put the patients at higher risk of local and distant recurrence which
is associated worse overall survival. Given the high rate of the recurrent disease, combination
treatment approaches have evolved in locally advance rectal cancer over the last two decades.
First, adjuvant radiotherapy and then combined modality therapy (chemotherapy concur‐
rently with radiation therapy) was integrated in standard care to enhance survival outcomes
of locally advanced rectal cancer.
An early prospectively randomized clinical trial was conducted to assess the question of
the  adjuvant  benefit  roles  of  radiation,  chemotherapy,  or  combined  modality  therapy
(chemoradiation) in the treatment of locally advance rectal cancer by the Gastrointestinal
Tumor  Study  Group  (GTSG)  in  1985  [44].  In  this  study,  patients  after  having  curative
surgery (202 in  total),  were  enrolled and randomized into four  different  groups includ‐
ing; patients received no adjuvant treatment, patients treated with adjuvant radiotherapy
either at dose of 40 or 48 Gray, patients received adjuvant chemotherapy with semustine
and  5-fluorouracil,  and  a  final  group  treated  with  combination  of  chemotherapy  and
radiotherapy.  All  patients  were  followed  up  to  for  80  months.  Although  there  was  no
significant  difference  for  OS  in  four  groups,  authors  found  significantly  better  disease-
free survival in combination therapy arm compared to resection-alone [44]. In same study,
recurrence  rate  was  highest  in  resection-alone  with  55%,  while  the  lowest  relapse  was
observed in  combination therapy group (33%).  The follow-up results  of  this  study con‐
firmed a significantly improved overall survival reported in combination treatment group
compared to surgery alone group [45]. By the end of the 10 year follow up, 10-year survival
rates were 26% vs. 45% in control group vs. combination treatment group and was showing
the  superiority  of  combination  treatment  group.  Independently,  The  National  Surgical
Adjuvant and Breast and Bowel Project (NSABP) released the result of R-01 that compar‐
ing adjuvant radiation or chemotherapy to surgery alone and provided superior overall
and disease-free survival in chemo group respect to the surgery alone (P = 0.03, P = 0.006
respectively) [46]. No significant survival benefit observed in radiation alone group.
The North Central Cancer Treatment Group (NCCTG) reported a trial comparing the adjuvant
radiation versus the combined chemoradiation. In this study, total 209 patients randomized
Colorectal Cancer - Surgery, Diagnostics and Treatment290
in two arms. The combined modality arm was found to have 34% reduced overall recurrence
compared to the radiation alone. (P < 0.003) [47]. Decreased recurrence incidence was observed
in both local (25% versus 13% P < 0.02) and distant relapse (43% versus 29.5% P < 0.003). After
this study National Surgical Adjuvant Breast Program (NSABP) examined the impact of the
adjuvant chemotherapy alone versus chemoradiotherapy on overall survival and disease free
survival in protocol R-02. In this study, all female patients received 5-flurouracil and leuco‐
vorin whereas male patients either received MOF regimen including 5-flurouracil, semustine,
vincristine or 5-flurouracil combined with leucovorin. Radiotherapy was given in 25 fractions
at a daily 18 Gray dose. Although there was a significant decrease in cumulative local relapse
incidence after 5-year follow-up (13% versus 8%, P = 0.02), they observed no overall or disease-
free survival differences in between these two groups.
Neoadjuvant Radiotherapy
Absence of clinical evidence to use radiotherapy in adjuvant settings urged the researchers to
test the efficacy of radiotherapy in preoperative settings. Swedish investigators conducted a
phase III clinical trial to understand the possible role of neoadjuvant radiotherapy (i.e. pre-
operative radiation therapy) [48]. They enrolled 1,168 patients and randomly assigned to
receive either conventional surgery alone or surgery with preceded neoadjuvant radiotherapy
designed as a total dose of 25 Gy in five fractions. After five years follow up, recurrence rate
was found 11% in neoadjuvant radiotherapy group, whereas it was observed as high as 27%
in patients with surgery alone (P < 0.001). Additionally, the authors reported significantly
better five year-survival in radiotherapy arm (58% compared to 48%, P = 0.004). Since con‐
ventional surgery was performed in this study, the additive role of the radiation in TME was
still not clear. In 2007, this question was addressed by Dutch Colorectal Cancer Group. They
conducted a randomized clinical trial enrolled the patients into TME alone and 5 fractions
radiotherapy with total 25 Gray dose plus total mesorectal excision [49]. After a median 6.1
years follow- up, no significant overall survival difference was demonstrated. Moreover, there
was no significant difference in distal recurrence incidence. On the other hand, they found a
significant decrease in local recurrence rate (5.6 % vs 10.9%, P < 0.001).
Currently, two different preoperative radiotherapy protocols are commonly preferred in
locally advanced rectal cancer treatment including conventional (50.4 Gray administered in 28
fractions) and short-term treatment (25 Gray in 5 fractions). Although both models have been
shown to decrease local recurrence, there are debates on prolonged side effect in short-term
radiotherapy modality [50]. While short-term neoadjuvant radiation treatment is commonly
used in European countries, conventional radiation is standard-of-care of locally advance
rectal cancer in USA.
Neoadjuvant Chemoradiation Therapy (Combined Modality Therapy)
Better outcomes observed in chemoradiation in adjuvant settings raised the question of
possible neoadjuvant chemoradiation for treatment of patients with locally advanced rectal
cancer. In 2004, German Rectal Cancer Study Group (GRCSG) examined the role preoperative
chemoradiation in rectal cancer patients with T3 or T4 stages or node positivity [51]. They
randomized 823 patients in two groups; the neoadjuvant arm received a total 50.4 Gray dose
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radiation in 28 fractions and 5-flurouracil 120-hour continuous infusion during the first and
fifth weeks of radiation at a dose of 1,000 mg per square meter of body surface then followed
by surgery after completing the chemoradiation. Patients also received four cycles of 5-
flurouracil (500 mg per square meter body surface) which was designed as five time weekly
during the four weeks. The adjuvant group also received the same treatment except additional
a boost of 5.4 Gray radiation after total mesorectal excision. No significant difference was
reported for five year-survival in between neoadjuvant and adjuvant group (74% vs 76%
respectively, P = 0.80). Interestingly, five years cumulative incidence of local recurrence was
significantly lower in neoadjuvant group than the adjuvant. (6% versus 13% respectively, P =
0.006). Moreover they observed less acute and long term toxicity in neoadjuvant arm of the
study compared the adjuvant arm (P = 0.001 versus P = 0.01).
In another study, European Organization for Research and Treatment of Cancer (EORTC)
randomized 1,011 patients with locally advanced rectal cancer into four different groups: a)
preoperative radiotherapy designed as 45 Gy in five weeks, b) preoperative radiotherapy plus
two course of 5-flurouracil and leucovorin (350 mg/m2/day and 20 mg/m2/day), c) preoperative
radiotherapy plus postoperative four course of 5-flurouracil and leucovorin, and d) preoper‐
ative radiotherapy and two course of bolus 5-flurouracil and leucovorin, plus postoperative
four course of postoperative 5-flurouracil and leucovorin. In early preliminary results of the
study, authors reported a significant benefit towards preoperative chemoradiotherapy groups
for tumor size, lymph node involvement, pathological complete response (P < 0.0001, P = 0.046,
P < 0.001). [52]. Later in follow up results, no significant difference was observed in OS between
neoadjuvant chemoradiotherapy and neoadjuvant radiotherapy (P=0.085). On the other hand,
local recurrence was significantly lower in preoperative chemoradiation groups (P = 0.002)
[53]. Chemotherapy protocol which was given in this study was an uncommon protocol
possibly is a contributing factor for absence of survival difference in between chemoradiation
and radiation alone group in preoperative settings.
To better understand the additive role of neoadjuvant chemoradiation for patients with locally
advanced rectal cancer, NSABP R-03 trial was conducted. Two hundreds and sixty-seven
patients enrolled in two arms; patients who received neoadjuvant or adjuvant chemoradiation.
Neoadjuvant group received a bolus of 5-flurouracil with leucovorin for six weeks followed
by radiation given as a total 45 Gray dose in 25 fractions with an additional 5.4 Gray boost.
Then, patients were resected and postoperatively received 24 more weeks of weekly 5-FU and
LV. Patients in adjuvant arm also received same courses of treatment in the same order except
initial surgical resection. The most striking finding of this study was superior 5-year disease-
free survival observed in neoadjuvant arm (64.7% vs 53.4%, P=0.011). Although there was not
a significant difference in OS (P = 0.65), There was trend for observed five-year overall survival
as 74.7% vs 65.6% in the neoadjuvant and adjuvant arms respectively [54]. Overall, all these
clinical trials support the use neoadjuvuvant chemotheradiation as standart-care-of locally
advance colorectal cancer. Although there is no clear result proving as an evidence for the
superior OS compared to adjuvant chemoradiation, decreased local recurrence incidence with
neoadjuvant treatment promises better local disease control. Moreover decreased acute and
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prolonged treatment related toxicities and improved sphincter preservation observed in
preoperative treatment also favor the neoadjuvant chemoradiation modality [54].
Current Drugs for Neoadjuvant Therapy of Rectal Cancer
5-Fluorouracil
5-flurouracil has become the recommended first-line chemotherapy in locally advanced rectal
cancer patients based on the GTSG and NCCTG data [44,47].The most commonly preferred
administration mode of 5-flurouracil is continuous intravenous infusion( 225-300mg/m2 daily).
To compare the bolus administration with continuous intravenous infusion, the NCCTG
randomized 660 patients in two arms. Both arms received concurrent radiotherapy. First group
received bolus 5-flurouracil on three consecutive days as s rapid infusion of 500 mg/m2 while
the other group received as protracted infusion (225 mg/m2/day). Four-year relapse free
survival was 63% in continuous infusion group while it was 53% in the bolus arm (P = 0.01).
Significant difference for 4-year overall survival was also observed in the same study. Four-
year overall survival was 70% as compared to 60% in continuous infusion and bolus group
respectively (P = 0.005). Interestingly, no benefit was observed for local relapse in continuous
infusion group (P = 0.110). While leukopenia was more common in bolus group, diarrhea
incidence was found higher in continuous infusion group.
Capecitabine
Since superior outcomes observed in continuous intravenous administration of 5-flurouracil
in chemoradiation regimens, an equivalent fluropyrimidine, capecitabine was studied for
locally advanced rectal cancer treatment. Oral administration of capecitabine which has very
similar pharmacokinetics to continuous intravenous 5-flurouracil provided more convenient
treatment for patients if they are able to tolerate oral administration. In a phase I clinical study,
the recommended dose of the capecitabine was determined as 1800 mg/m2 daily given orally
in two divided doses combined with 50.4 Gray preoperative radiation [56]. A prospectively
randomized study of 1,987 patients was enrolled into two groups; a) patients who received
capecitabine orally, b) patients who were administered bolus 5-flurouracil modulated with
leucovorin [58]. In the results of this study, non-inferior disease-free survival was observed in
capecitabine group. The capecitabine improved relapse-free survival (P = 0.04). Moreover,
fewer adverse effects were seen with capecitabine treatment compared to bolus 5-flurouracil
plus leucovorin arm (P < 0.001) [58].
The NSABP R-04 trial compared the use of capecitabine to continuous infusion 5-flurouracil
with or without oxaliplatin during combined modality therapy in locally advance rectal cancer.
5-fluorouracil was given as a 225 mg/m2 daily protracted venous infusion during radiation and
capecitabine was given at 1650 mg/m2 orally in two divided doses daily on the days of radiation
only. There was no significant different regarding pathologic complete response, surgical
downstaging or sphincter-saving surgery. Local recurrence and overall survival have yet to
be reported [59].
More recently, in a randomized phase III study, German researchers compared the efficacy of
capecitabine with 5-flurouracil as neoadjuvant radiosensitizing agent [60]. In this study, 392
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radiation in 28 fractions and 5-flurouracil 120-hour continuous infusion during the first and
fifth weeks of radiation at a dose of 1,000 mg per square meter of body surface then followed
by surgery after completing the chemoradiation. Patients also received four cycles of 5-
flurouracil (500 mg per square meter body surface) which was designed as five time weekly
during the four weeks. The adjuvant group also received the same treatment except additional
a boost of 5.4 Gray radiation after total mesorectal excision. No significant difference was
reported for five year-survival in between neoadjuvant and adjuvant group (74% vs 76%
respectively, P = 0.80). Interestingly, five years cumulative incidence of local recurrence was
significantly lower in neoadjuvant group than the adjuvant. (6% versus 13% respectively, P =
0.006). Moreover they observed less acute and long term toxicity in neoadjuvant arm of the
study compared the adjuvant arm (P = 0.001 versus P = 0.01).
In another study, European Organization for Research and Treatment of Cancer (EORTC)
randomized 1,011 patients with locally advanced rectal cancer into four different groups: a)
preoperative radiotherapy designed as 45 Gy in five weeks, b) preoperative radiotherapy plus
two course of 5-flurouracil and leucovorin (350 mg/m2/day and 20 mg/m2/day), c) preoperative
radiotherapy plus postoperative four course of 5-flurouracil and leucovorin, and d) preoper‐
ative radiotherapy and two course of bolus 5-flurouracil and leucovorin, plus postoperative
four course of postoperative 5-flurouracil and leucovorin. In early preliminary results of the
study, authors reported a significant benefit towards preoperative chemoradiotherapy groups
for tumor size, lymph node involvement, pathological complete response (P < 0.0001, P = 0.046,
P < 0.001). [52]. Later in follow up results, no significant difference was observed in OS between
neoadjuvant chemoradiotherapy and neoadjuvant radiotherapy (P=0.085). On the other hand,
local recurrence was significantly lower in preoperative chemoradiation groups (P = 0.002)
[53]. Chemotherapy protocol which was given in this study was an uncommon protocol
possibly is a contributing factor for absence of survival difference in between chemoradiation
and radiation alone group in preoperative settings.
To better understand the additive role of neoadjuvant chemoradiation for patients with locally
advanced rectal cancer, NSABP R-03 trial was conducted. Two hundreds and sixty-seven
patients enrolled in two arms; patients who received neoadjuvant or adjuvant chemoradiation.
Neoadjuvant group received a bolus of 5-flurouracil with leucovorin for six weeks followed
by radiation given as a total 45 Gray dose in 25 fractions with an additional 5.4 Gray boost.
Then, patients were resected and postoperatively received 24 more weeks of weekly 5-FU and
LV. Patients in adjuvant arm also received same courses of treatment in the same order except
initial surgical resection. The most striking finding of this study was superior 5-year disease-
free survival observed in neoadjuvant arm (64.7% vs 53.4%, P=0.011). Although there was not
a significant difference in OS (P = 0.65), There was trend for observed five-year overall survival
as 74.7% vs 65.6% in the neoadjuvant and adjuvant arms respectively [54]. Overall, all these
clinical trials support the use neoadjuvuvant chemotheradiation as standart-care-of locally
advance colorectal cancer. Although there is no clear result proving as an evidence for the
superior OS compared to adjuvant chemoradiation, decreased local recurrence incidence with
neoadjuvant treatment promises better local disease control. Moreover decreased acute and
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prolonged treatment related toxicities and improved sphincter preservation observed in
preoperative treatment also favor the neoadjuvant chemoradiation modality [54].
Current Drugs for Neoadjuvant Therapy of Rectal Cancer
5-Fluorouracil
5-flurouracil has become the recommended first-line chemotherapy in locally advanced rectal
cancer patients based on the GTSG and NCCTG data [44,47].The most commonly preferred
administration mode of 5-flurouracil is continuous intravenous infusion( 225-300mg/m2 daily).
To compare the bolus administration with continuous intravenous infusion, the NCCTG
randomized 660 patients in two arms. Both arms received concurrent radiotherapy. First group
received bolus 5-flurouracil on three consecutive days as s rapid infusion of 500 mg/m2 while
the other group received as protracted infusion (225 mg/m2/day). Four-year relapse free
survival was 63% in continuous infusion group while it was 53% in the bolus arm (P = 0.01).
Significant difference for 4-year overall survival was also observed in the same study. Four-
year overall survival was 70% as compared to 60% in continuous infusion and bolus group
respectively (P = 0.005). Interestingly, no benefit was observed for local relapse in continuous
infusion group (P = 0.110). While leukopenia was more common in bolus group, diarrhea
incidence was found higher in continuous infusion group.
Capecitabine
Since superior outcomes observed in continuous intravenous administration of 5-flurouracil
in chemoradiation regimens, an equivalent fluropyrimidine, capecitabine was studied for
locally advanced rectal cancer treatment. Oral administration of capecitabine which has very
similar pharmacokinetics to continuous intravenous 5-flurouracil provided more convenient
treatment for patients if they are able to tolerate oral administration. In a phase I clinical study,
the recommended dose of the capecitabine was determined as 1800 mg/m2 daily given orally
in two divided doses combined with 50.4 Gray preoperative radiation [56]. A prospectively
randomized study of 1,987 patients was enrolled into two groups; a) patients who received
capecitabine orally, b) patients who were administered bolus 5-flurouracil modulated with
leucovorin [58]. In the results of this study, non-inferior disease-free survival was observed in
capecitabine group. The capecitabine improved relapse-free survival (P = 0.04). Moreover,
fewer adverse effects were seen with capecitabine treatment compared to bolus 5-flurouracil
plus leucovorin arm (P < 0.001) [58].
The NSABP R-04 trial compared the use of capecitabine to continuous infusion 5-flurouracil
with or without oxaliplatin during combined modality therapy in locally advance rectal cancer.
5-fluorouracil was given as a 225 mg/m2 daily protracted venous infusion during radiation and
capecitabine was given at 1650 mg/m2 orally in two divided doses daily on the days of radiation
only. There was no significant different regarding pathologic complete response, surgical
downstaging or sphincter-saving surgery. Local recurrence and overall survival have yet to
be reported [59].
More recently, in a randomized phase III study, German researchers compared the efficacy of
capecitabine with 5-flurouracil as neoadjuvant radiosensitizing agent [60]. In this study, 392
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patients were randomized into two groups. Patients in capecitabine arm were enrolled to
receive two cycles of capecitabine (2,500 mg/m2 days 1-14, repeated day 22), then followed by
chemoradiotherapy (50 4 Gray plus capecitabine 1650 mg/m2 days 1-38 and additionally three
cycles of capecitabine). Two cycles of bolus 5-flurouracil (500 mg/m2 days 1-5, repeated day
29), followed by chemoradiotherapy (50 4 Gray plus infusional 5-flurouracil 225 mg/m2 daily),
finally two cycles of bolus 5-FU were administered patients in 5-flurouracil arm. Results were
promising for non-inferiority with significantly better 5-year OS in capecitabine group (76%
as compared to 67%, P = 0.05). Similarly disease-free survival was also higher in capecitabine
group (75% versus 67%, P = 0.07).
Oxaliplatin
Given the promising results of oxaliplatin treatment of colon cancer in adjuvant setting [15]
and metastatic disease [61] its possible additive effect to the neoadjuvant treatment of rectal
cancer has been investigated. In a phase II clinical trial, oxaliplatin (at 50 mg/m2 on days 1, 8,
22, and 29) plus capecitabine (1,650 mg/m2 on days 1 to 14 and 22 to 35) with radiotherapy (50.4
Gray in 28 fraction) was tested both for activity and safety [62]. Pathologic complete response
was achieved in 17% patients whereas 53/103 patients showed more than 50% tumor regres‐
sion. Although results were not superior to standard 5-FU treatment phase III trials were
warranted. The randomized phase III Studio Terapia Adiuvante Retto ( STAR)-01 trial has
tested to outcomes of addition of oxaliplatin (60 mg/m2) to chemoradiation (225 mg/m2/day
plus 50.4 Gray in 28 daily fractions) comparing with standard chemoradiation [62]. Addition
of oxaliplation did not increase pathologic complete response rate (16% versus 16% ) but rather
increased grade 3 to 4 adverse events in oxaliplatin arms (P < 0.001).
Recently published German CAO/ARO/AIO-04 randomised phase III trial also investigated
the role of oxaliplatin in neoadjuvant chemoradiation [63]. In the study control group was
treated with standard 5-flurouracil-based combined modality treatment, consisting of
preoperative radiotherapy of 50.4 Gray plus infusional 5-flurouracil (1000 mg/m2 days 1-5 and
29-33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m2 days 1-5 and 29).
Oxaliplatin arm received preoperative radiotherapy of 50.4 Gray plus infusional 5-flurouracil
(250 mg/m2 days 1-14 and 22-35) and oxaliplatin (50 mg/m2 days 1, 8, 22, and 29), followed by
surgery and eight cycles of adjuvant chemotherapy with oxaliplatin (100 mg/m2 days 1 and
15), leucovorin (400 mg/m2 days 1 and 15), and again infusional 5-flurouracil. Authors reported
better pathologic complete response outcomes in oxaliplatin treatment arm compared to
standard group (17% vs 13% respectively, P = 0.038). Controversially, ACCORD 12/0405-
PRODIGE 2 trial reported no benefit with additional oxaliplatin [64]. In this study control
patients were assigned to receive 5 weeks of treatment with radiotherapy 45 Gy/25 fractions
with concurrent capecitabine 800 mg/m2 twice daily (5 days per week). The experimental arm
of the study received 50 Gray in 25 fractions radiation with capecitabine 800 mg/m2 twice daily
(5 days per week) and oxaliplatin 50 mg/m2 (once weekly). Although there was trend toward
oxaliplatin plus group for pCR it was not significant (19.2% s 13.9% P=0.09). Preoperative grade
3 and 4 toxicities were observed significantly higher in oxalipatin plus arm (P < 0.001). Since
there is no consensus in clinical trials for benefit with additional oxaliplatin it is not currently
standard-of-care of locally advanced rectal cancer.
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Targeted Therapies
Monoclonal antibodies targeting the critical survival signaling pathways such as epidermal
growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are
currently under the investigation to determine their role in neoadjuvant chemoradiaton
treatment in rectal cancers. The potential role of cetuximab and bevacizumab in the treatment
of locally advanced rectal cancer has been tested in phase I and phase II clinical trials.
In a phase I/II clinical study the safety and potential benefit of cetuximab in neoadjuvant
chemoradiation investigated in locally advanced rectal cancer patients. Forty patients enrolled
to receive initial intravenous dose of 400 mg/m2 cetuximab which was given 1 week before the
initiation of radiation followed by 250 mg/m2/week for 5 weeks and capecitabine during the
radiotherapy 650 mg/m2 orally twice daily and 825 mg/m2 twice daily, as a second dose level
[65]. Observed pathologic complete response was only in two patients (5%), while diarrhea
was seen in 65% of the patients. Grade 3 diarrhea was detected in 15% of cases. In one patient
three grade 4 toxic effect was reported by authors; one myocardial infarction, one pulmonary
embolism, and one pulmonary infection with sepsis.
In the EXPERT-C trial, combination of cetuximab and capecitabine plus oxaliplatin was studied
in neoadjuvant settings. One hundred sixty-five patients enrolled in two arms to receive four
cycles of capecitabine/oxaliplatin and then capecitabine chemoradiotherapy, surgery, and
adjuvant CAPOX (four cycles) or the same regimen plus weekly cetuximab [66]. In this study
the most striking finding was significantly improved OS in cetuximab plus group (P = 0.034).
Additionally, a better radiologic response was determined in cetuximab group. On the other
hand there was no difference either in pathologic complete response rate or progression-free
survival (P = 1.0, P = 0.363 respectively)
Another fully humanized monoclonal antibody, that binds circulating anti-vascular epithelial
growth factor, bevacizumab, has also been investigated in combination neoadjuvant treatment
of rectal cancer. In a phase I/II study, bevacizumab combined with preoperative 5-FU and
radiotherapy in 32 locally advanced rectal cancer patients [67]. Patients were administered
four cycles of bevacizumab infusion (5 or 10 mg/kg) on day 1 of each cycle; 5-FU (225 mg/m2/24
hours) during cycles 2 to 4; radiotherapy in 28 fractions with a total dose of 50.4 Gy over 5.5
weeks. Surgery was performed 7 to 10 weeks after completion of all therapies. No grade4
toxicity was detected and the most frequent toxicity was diarrhea. Pathologic complete
response was achieved in 5 out of 32 patients. In another phase II study, bevacizumab was
explored in a combination treatment of capecitabine and radiotherapy [68]. Twenty-five rectal
cancer patients received neoadjuvant therapy with radiotherapy (50.4 Gy in 28 fractions over
5.5 weeks), bevacizumab every 2 weeks (3 doses of 5 mg/kg), and capecitabine (900 mg/m2
orally twice daily during the radiation). Surgical resection was performed a median of 7.3
weeks later initial treatment. An encouraging pathologic complete response rate was reported
in 8 of 25 patients (32%). Six of 24 patients showed less than 10% viable tumor cells in final
pathological specimens. No patient was reported with grade 3 gastrointestinal toxicity or
significant hematologic toxicity.
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patients were randomized into two groups. Patients in capecitabine arm were enrolled to
receive two cycles of capecitabine (2,500 mg/m2 days 1-14, repeated day 22), then followed by
chemoradiotherapy (50 4 Gray plus capecitabine 1650 mg/m2 days 1-38 and additionally three
cycles of capecitabine). Two cycles of bolus 5-flurouracil (500 mg/m2 days 1-5, repeated day
29), followed by chemoradiotherapy (50 4 Gray plus infusional 5-flurouracil 225 mg/m2 daily),
finally two cycles of bolus 5-FU were administered patients in 5-flurouracil arm. Results were
promising for non-inferiority with significantly better 5-year OS in capecitabine group (76%
as compared to 67%, P = 0.05). Similarly disease-free survival was also higher in capecitabine
group (75% versus 67%, P = 0.07).
Oxaliplatin
Given the promising results of oxaliplatin treatment of colon cancer in adjuvant setting [15]
and metastatic disease [61] its possible additive effect to the neoadjuvant treatment of rectal
cancer has been investigated. In a phase II clinical trial, oxaliplatin (at 50 mg/m2 on days 1, 8,
22, and 29) plus capecitabine (1,650 mg/m2 on days 1 to 14 and 22 to 35) with radiotherapy (50.4
Gray in 28 fraction) was tested both for activity and safety [62]. Pathologic complete response
was achieved in 17% patients whereas 53/103 patients showed more than 50% tumor regres‐
sion. Although results were not superior to standard 5-FU treatment phase III trials were
warranted. The randomized phase III Studio Terapia Adiuvante Retto ( STAR)-01 trial has
tested to outcomes of addition of oxaliplatin (60 mg/m2) to chemoradiation (225 mg/m2/day
plus 50.4 Gray in 28 daily fractions) comparing with standard chemoradiation [62]. Addition
of oxaliplation did not increase pathologic complete response rate (16% versus 16% ) but rather
increased grade 3 to 4 adverse events in oxaliplatin arms (P < 0.001).
Recently published German CAO/ARO/AIO-04 randomised phase III trial also investigated
the role of oxaliplatin in neoadjuvant chemoradiation [63]. In the study control group was
treated with standard 5-flurouracil-based combined modality treatment, consisting of
preoperative radiotherapy of 50.4 Gray plus infusional 5-flurouracil (1000 mg/m2 days 1-5 and
29-33), followed by surgery and four cycles of bolus fluorouracil (500 mg/m2 days 1-5 and 29).
Oxaliplatin arm received preoperative radiotherapy of 50.4 Gray plus infusional 5-flurouracil
(250 mg/m2 days 1-14 and 22-35) and oxaliplatin (50 mg/m2 days 1, 8, 22, and 29), followed by
surgery and eight cycles of adjuvant chemotherapy with oxaliplatin (100 mg/m2 days 1 and
15), leucovorin (400 mg/m2 days 1 and 15), and again infusional 5-flurouracil. Authors reported
better pathologic complete response outcomes in oxaliplatin treatment arm compared to
standard group (17% vs 13% respectively, P = 0.038). Controversially, ACCORD 12/0405-
PRODIGE 2 trial reported no benefit with additional oxaliplatin [64]. In this study control
patients were assigned to receive 5 weeks of treatment with radiotherapy 45 Gy/25 fractions
with concurrent capecitabine 800 mg/m2 twice daily (5 days per week). The experimental arm
of the study received 50 Gray in 25 fractions radiation with capecitabine 800 mg/m2 twice daily
(5 days per week) and oxaliplatin 50 mg/m2 (once weekly). Although there was trend toward
oxaliplatin plus group for pCR it was not significant (19.2% s 13.9% P=0.09). Preoperative grade
3 and 4 toxicities were observed significantly higher in oxalipatin plus arm (P < 0.001). Since
there is no consensus in clinical trials for benefit with additional oxaliplatin it is not currently
standard-of-care of locally advanced rectal cancer.
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Targeted Therapies
Monoclonal antibodies targeting the critical survival signaling pathways such as epidermal
growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) are
currently under the investigation to determine their role in neoadjuvant chemoradiaton
treatment in rectal cancers. The potential role of cetuximab and bevacizumab in the treatment
of locally advanced rectal cancer has been tested in phase I and phase II clinical trials.
In a phase I/II clinical study the safety and potential benefit of cetuximab in neoadjuvant
chemoradiation investigated in locally advanced rectal cancer patients. Forty patients enrolled
to receive initial intravenous dose of 400 mg/m2 cetuximab which was given 1 week before the
initiation of radiation followed by 250 mg/m2/week for 5 weeks and capecitabine during the
radiotherapy 650 mg/m2 orally twice daily and 825 mg/m2 twice daily, as a second dose level
[65]. Observed pathologic complete response was only in two patients (5%), while diarrhea
was seen in 65% of the patients. Grade 3 diarrhea was detected in 15% of cases. In one patient
three grade 4 toxic effect was reported by authors; one myocardial infarction, one pulmonary
embolism, and one pulmonary infection with sepsis.
In the EXPERT-C trial, combination of cetuximab and capecitabine plus oxaliplatin was studied
in neoadjuvant settings. One hundred sixty-five patients enrolled in two arms to receive four
cycles of capecitabine/oxaliplatin and then capecitabine chemoradiotherapy, surgery, and
adjuvant CAPOX (four cycles) or the same regimen plus weekly cetuximab [66]. In this study
the most striking finding was significantly improved OS in cetuximab plus group (P = 0.034).
Additionally, a better radiologic response was determined in cetuximab group. On the other
hand there was no difference either in pathologic complete response rate or progression-free
survival (P = 1.0, P = 0.363 respectively)
Another fully humanized monoclonal antibody, that binds circulating anti-vascular epithelial
growth factor, bevacizumab, has also been investigated in combination neoadjuvant treatment
of rectal cancer. In a phase I/II study, bevacizumab combined with preoperative 5-FU and
radiotherapy in 32 locally advanced rectal cancer patients [67]. Patients were administered
four cycles of bevacizumab infusion (5 or 10 mg/kg) on day 1 of each cycle; 5-FU (225 mg/m2/24
hours) during cycles 2 to 4; radiotherapy in 28 fractions with a total dose of 50.4 Gy over 5.5
weeks. Surgery was performed 7 to 10 weeks after completion of all therapies. No grade4
toxicity was detected and the most frequent toxicity was diarrhea. Pathologic complete
response was achieved in 5 out of 32 patients. In another phase II study, bevacizumab was
explored in a combination treatment of capecitabine and radiotherapy [68]. Twenty-five rectal
cancer patients received neoadjuvant therapy with radiotherapy (50.4 Gy in 28 fractions over
5.5 weeks), bevacizumab every 2 weeks (3 doses of 5 mg/kg), and capecitabine (900 mg/m2
orally twice daily during the radiation). Surgical resection was performed a median of 7.3
weeks later initial treatment. An encouraging pathologic complete response rate was reported
in 8 of 25 patients (32%). Six of 24 patients showed less than 10% viable tumor cells in final
pathological specimens. No patient was reported with grade 3 gastrointestinal toxicity or
significant hematologic toxicity.
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In a recent study, bevacizumab was tested in a combined treatment including the oxaliplatin,
5-FU, and radiotherapy in 26 patients [69]. Patients were initially treated with 1 month of
induction bevacizumab and FOLFOX6, then received 50.4 Gy of radiation and concurrent
bevacizumab (5 mg/kg on Days 1, 15, and 29), oxaliplatin (50 mg/m2/week for 6 weeks), and
continuous infusion 5-FU (200 mg/m(2)/day). This trial was terminated early because of high
incidence of significant grade 3 toxicity. Authors reported 19 (75%) of 25 patients experienced
grade 3 toxicities. Five (20%) out of 25 patients had pathologic response. The effect of bevacu‐
zimab was also studied with erlotinib, a small molecule epidermal growth factor receptor
tyrosine kinase inhibitor in a combination treatment of 5-flurouracil and external beam
radiation in 21 patients [70]. Seven (47%) of 15 patients who completed the therapy and had
surgery achieved pathologic complete response. Reported toxicities were including lympho‐
penia 6 (40%), diarrhea 4 (24%), rash 2 (12%), cardiac ischemia 1(6%), transaminitis (6%) and
mucositis (6%).
Obtained promising pathologic response and observed safety results by the addition of
monoclonal antibodies in neoadjuvant chemoradiation encourages to further explore the role
of these drugs in treatment of locally advanced rectal cancer. On the other hand these targeting
agents are yet to be standard-care-of rectal cancer in neoadjuvant settings.
7. Conclusions
The clinical advances over the last two decades have led to demonstrable improvements in the
outcomes of patients with colorectal cancer and are a testament to the success of multidisci‐
plinary cancer care. Continued development of novel therapeutics in the metastatic setting
will undoubtedly lead to changes in our surgical adjuvant treatments. Refinement in predictive
and prognostic studies will allow us greater ability to tailor the appropriate therapy for
patients, and allow for greater patient’s participation in the shared decision process.
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1. Introduction
Worldwide, more than 1 million people develop colorectal cancer (CRC) annually [1]. CRC
is a major health problem in the Western world and the second most common cause of
cancer  mortality  [2].  To  improve  performance,  the  role  of  chemotherapy  for  CRC  has
increased dramatically over the last decade. Of course surgery remains the cornerstone of
treatment,  the  vast  majority  of  CRC  patients  now  receive  chemotherapy  with  multiple
agents that are currently approved for the treatment in the appropriate setting. However,
it  is a complex process to select the optimal chemotherapy for each patient and practice
evidence gap is still a problem. We found large differences in patterns of institution, region
and country.  The results  suggest  that  the lack of  evidence for CRC chemotherapy prac‐
tice still exists around the world. [3] Recently, standardization of cancer treatment, including
chemotherapy, has become of particular importance for the quality of cancer therapy. It is
important  to  know whether  the overhaul  performed normalization of  CRC chemothera‐
py. Measures and quality indicators are needed and several studies on indicators of quality
of  cancer  care  have  been reported.  However,  measures  to  assess  the  standardization of
cancer therapy are not well established. In this study, we evaluated the usefulness of the
oncology market research to assess the evidence gap in practice CRC chemotherapy. We
also discuss the role of the method to measure the effect of normalization of CRC chemo‐
therapy. [4, 5]
Although  surgery  remains  the  cornerstone  of  treatment,  the  vast  majority  of  CRC  pa‐
tients  now receive  chemotherapy to  reduce the  risk  of  metastatic  spread by eradicating
microscopic  tumor  foci  that  are  distant  from  the  primary  tumor  and  undetectable  in
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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perioperative assessment of tumor extension. [5] Five-year survival of patients are mainly
determined  by  the  histological  stage  of  the  tumor  at  the  time  of  resection.  The  most
important prognostic factor for survival in patients without visceral metastases is the stage
of the tumor determined by the depth of penetration of the tumor in the bowel wall and
the number of lymph nodes [4] (lymph nodes >12 examined). Result of the meta - analy‐
sis  of  over  10  studies  showed  that  each  -  two-month  delay  of  adjuvant  chemotherapy
resulted  in  a  14%  decrease  in  overall  survival,  suggesting  that  adjuvant  chemotherapy
should be administered as soon as possible [5].
The introduction of new cytotoxic agents such as oral fluoropyrimidines, oxaliplatin and
irinotecan in chemotherapy (CT) regimens have improved the response rate, disease-free
survival (DFS) and overall survival (OS) in patients with metastatic colorectal cancer. [6, 7]
This has encouraged the trials in the adjuvant treatment of non-metastatic disease, especially
in patients with stage III tumors. Table 1 shows the most common regimens used for the
CT adjuvant. Surgery alone is usually curative for colon cancer stage II, but about 20% to
30% of  these  patients  develop recurrence  and die  of  metastatic  disease.  [8]  This  under‐
pins  the  need  for  prognostic  factors  such  as  microsatellite  instability  (MSI),  which  are
potentially  predictive  of  tumor  response  to  cytotoxic  agents.  [7]  Prognostic  factors  are
particularly useful in the context of stage II colorectal cancer, where the benefits of cytotoxic
adjuvant  therapy  are  more  controversial  than  in  stage  III  disease.  The  identification  of
accurate  and  validated  predictive  and  prognostic  markers  help  clinicians  in  choosing
appropriate use of adjuvant chemotherapy in patients with stage II CRC.
MSI is  a  change in the length of  microsatellite  DNA due to the insertion or deletion of
repeating units  –  from 1to 5 nucleotides caused by defects  in mismatch repair  genes or
methylation  of  their  promoters.  [9]  Tumors  with  MSI  are  more  often  proximal,  poorly
differentiated, mucinous, and show a significant lymphocytic infiltration. [9] Colon cancers
with high-frequency MSI have clinical and pathological features that distinguish them from
microsatellite stable tumors and MSI is a marker of favorable outcome and a predictor for
the benefit  decreased from fluorouracil  -  based adjuvant  chemotherapy in patients  with
stage II  or  colon cancer  stage III  with  microsatellite  stable  tumors  or  tumors  with  low-
frequency  microsatellite  instability.  [10]  Silence  or  mutation  of  mismatch  repair  (MMR)
genes can lead to protein deficiency MMR and MSI 10. This is observed in patients with
Lynch syndrome, and it is a rare cause of hereditary colon cancer 2 to 4% of the 11 cases.
Somatic mutation is reported in 19% of CRC [12], while silencing of MMR genes can be
observed in up to 52% of sporadic colon cancers [13].
In sporadic CRC, three tumor phenotypes were defined: microsatellite stable (MSS), low-
frequency MSI (MSI-L) and high frequency MSI (MSI-H). It has been reported that MSI-H are
more frequently found in stage II disease than in stage III disease 14. This may partly explain
the benefit decreased from 5 - fluorouracil adjuvant chemotherapy (5FU) in patients with stage
II. Tente identify patients who might benefit from adjuvant chemotherapy led to the devel‐
opment of multigene tests as several Oncotype DX etc. Unfortunately, there is no evidence that
any of them can predict the potential benefit of adjuvant chemotherapy. [13]
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2. Treatment guidelines for CRC
Some guidelines for the treatment of CRC have been developed to promote the standardization
of CRC treatment. Only two drugs, panitumumab and cetuximab first line were still causing
discord. Bevacizumab or capecitabine combined with oxaliplatin is used for the treatment of
advanced and recurrent CRC, while the FOLFOX regimen is used in patients with a high risk
of recurrence in the adjuvant chemotherapy. In this major revision, current controversies are
treated as clinical issues with many references.
Adjuvant  5-FU chemotherapy  is  the  standard  treatment  used  in  patients  with  stage  III
(Dukes C) and high-risk stage II (Dukes B) tumors. Capecitabine and bolus 5FU regimes
have proven efficacy and are associated with a low risk of severe toxicity. The addition of
oxaliplatin to 5FU improves patient outcomes in the adjuvant setting. Mosaic of random‐
ized trials in 2246 patients with stage 2 or 3 of the CRC to receive LV5FU2 or FOLFOX-4
chemotherapy. The operating system after 6 years of follow-up for all patients was 78.5%
for FOLFOX-4 against 76% for LV5FU2. Subgroup analysis showed stage-specific 6-year OS
rate of 72.9% against 68.7% in patients with stage 3 of the CRC and 86.9% compared with
86.8% in patients with stage 2 CRC for FOLFOX-4 and LV5FU2, respectively. The NSABP
C-07 trial  had a similar design, the addition of oxaliplatin to 5FU adjuvant chemothera‐
py, but used a different calendar 5FU and oxaliplatin doses delivered also less than in the
MOSAIC study (nine against twelve). The first results showed a similar improvement in
disease-free survival (DFS) than that observed in the MOSAIC trial. A recently presented
the  final  results  confirm  improved  DFS,  but  showed  shorter  survival  time  after  recur‐
rence in the oxaliplatin arm and an improvement in overall survival has not been seen. A
significant  interaction  between  age  and  survival  of  certain  parameters  were  observed.
Patients less than 70 years appeared to benefit from the addition of oxaliplatin while patients
over 70 years,  no benefit  was observed consistently.  The analysis  of  the ACCENT data‐
base, including 10, 449 patients less than 70 years and 2170 patients over 70 years from six
randomized trials have demonstrated a significant interaction between age and treatment
effect. No differences in results were noted between experimental (combination) chemother‐
apy and chemotherapy in patients with fluoropyrimidine control  over 70 years.  Adding
oxaliplatin to 5FU increases the overall incidence of grade 3 toxicity and is associated with
the occurrence of peripheral sensory neuropathy. Over 90% of patients experience tempora‐
ry  symptoms typically  induced cold,  with  a  minority  of  patients  with  persistent  symp‐
toms affecting activities of daily living (grade 2 and 3 toxicity). In the MOSAIC study, grade
3 peripheral sensory neuropathy was noted in 12.5% of patients treated with oxaliplatin for
the treatment. After 48 months of follow-up, rates of toxicity were grade 11.9% 1, % [22] 8
degree and 0.7% grade 3, respectively. Similar data were presented for the NSABP C-07
study.
Decisions regarding the use of  adjuvant  chemotherapy combinations are  more complex.
The incidence of approximately 3% of significant long-term peripheral neuropathy and MS
MT  Seymour  Braun  could  interfere  with  the  activities  of  the  daily  life  of  the  patient
influences decision-making in relation to the small additional benefit accrued to receive the
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oxaliplatin.  MOSAIC  and  NSABP  the  C-07  trials  delivered  a  total  dose  of  oxaliplatin
different, but both studies noted similar improvements in DFS. International trials evaluat‐
ing shorter periods of oxaliplatin-based chemotherapy in the adjuvant setting (12 versus 24
weeks  of  chemotherapy  oxaliplatin/5FU  ISRCTN  59757862)  in  order  to  assess  the  non-
inferiority of short periods of treatment, as well as consideration of the evaluation criteria
of quality of life. The relative benefit of chemotherapy is also a key factor in the choice of
treatment for patients in the adjuvant setting.  Patients with stage 3 are a heterogeneous
group and decisions based on age, the relative risk of recurrence (N1 N2 against disease),
and the additional benefit that can be achieved by adding oxaliplatin need to be carefully
considered. Given the new data in patients over 70 years, it seems likely that chemothera‐
py oxaliplatin are used less frequently in this group. Patients with disease stage 2 have an
excellent  prognosis  with  or  without  chemotherapy  5FU-based  and  high-risk  patients
functions are selected for processing. Both C-07 and MOSAIC are powered to assess the
benefit of adding oxaliplatin to 5-FU in patients with stage 2 disease, but a trend towards
improved DFS was noted. However, no OS benefit is probably very low in absolute terms
(<2%) and difficult to justify given the excellent overall performance (> 80% at 5 years of
operation) and the risk of neurotoxicity. [23]
3. 5FU
In  1990,  Moertel  and  colleagues  first  reported  the  value  of  adjuvant  chemotherapy  in
patients  with  stage  III  colon cancer  (Dukes  C,  Tx  N +  M0).  [15]  This  study showed an
increase  in  overall  survival  and  progression-free  survival  in  patients  receiving  5FU/
Levamisole - based chemotherapy for 1 year against levamisole alone or without chemother‐
apy. With a median follow - up of 6.5 years, patients treated with 5-FU / levamisole showed
a 40% reduction in recidivism and an estimated reduction of 33% of overall mortality [16].
5-FU is a pyrimidine analogue, which inhibits thymidylate synthase (TS) (involved in the
de novo synthesis of thymidine) and is involved in incorporation into RNA and DNA with
the  inhibition  of  DNA synthesis  and function  [17].  With  5FU bolus  injection  maximum
concentration is reached in the plasma and bone marrow 100-1000 times higher than with
continuous infusion. More than 85% of the administered drug is inactivated by dihydropyr‐
imidine dehydrogenase (DPD), expressed mainly in the liver.  Some mutation in DPD in
about  2%  in  the  general  population  can  lead  to  serious  life-threatening  toxicity  [17].
Leucovorin (LV) or folinic acid enhance the antitumor activity of 5FU. Today, there is a
lack  of  LV  in  the  United  States,  despite  the  absence  of  specific  data  confirming  this
statement. The QUASAR study investigators demonstrated that patients treated with 175
mg of LV similar survival and 3 - year recurrence rate of LV 25 mg when administered as
a  bolus  5-FU as  adjuvant  therapy for  CRC 7.  Similar  results  have been reported in  the
parameters in metastatic CRC patients -  there was no difference in survival or response
rate in patients receiving 5FU bolus high - dose or low-dose LV [18]. Therefore, when LV
is not available without LV treatment is reasonable. Comparison of monthly bolus FU / LV
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regimen (5FU bolus followed by LV 15 minutes) with double - monthly infusion LV5FU2
(LV for 2 hours, followed by bolus 5-FU, followed by a continuous infusion of 5-FU over
2 days) in 905 patients with stage II (43%) or III (57%) colon cancer showed that the regime
was less toxic LV5FU2, especially regarding hematological and gastrointestinal events (P
<0.001) [19]. No significant difference in DFS and OS was observed in one of two regi mens
median follow-up 6 years. Two other studies have shown that the two ways of 5FU bolus
administration combined with LV with or without levamisole and a continuous infusion of
5-FU  are  equivalent.  Saini  and  colleagues  conducted  a  multicenter  randomized  trial
comparing the efficacy and toxicity of 12 weeks of 5FU delivered by continuous intrave‐
nous  infusion against  the  standard bolus  5-FU and LV for  6  months  as  adjuvant  treat‐
ment in colorectal cancer. The two schemes are equivalent, but the plan 12 weeks was less
toxic [20]. The analysis of data from several trials in which patients were randomly resection
of the tumor or tumor resection followed by adjuvant 5-FU/LV showed that the benefit of
adjuvant chemotherapy was observed in patients with stage III [21, 22], which suggests that
because of nodal status of these patients are at higher risk. Both studies showed that the
addition  of  oxaliplatin  to  5-FU/LV as  adjuvant  therapy  in  stage  II  and  elderly  patients
showed no significant DFS or OS [23, 24] benefits even in patients with characteristics high
risk - T4 tumors, intestinal obstruction, venous invasion, etc. This suggests that, despite the
failure  of  our  definition  of  high-risk  patients  with  stage  II,  5-FU/LV  regimen  may  be
preferable. QUASAR investigators reported their analysis of 3238 patients, the majority of
them  were  in  stage  II  colon  cancer.  Patients  were  randomized  to  receive  5-FU/LV  or
observation. The relative risk of death from all causes in the 5-FU/LV arm versus observa‐
tion was 0.82 (95% CI, 0.70 to 0.95, p = 0.008). The relative risk of recurrence was 0.78 (95%
CI, 0.67-0,  91,  p = 0.001) [7].  The investigators did not separate patients into individuals
high or low risk. Risk factors are obstruction or bowel perforation, elevated preoperative
CEA,  poorly  differentiated tumors,  removal  of  CDC patients  and MSI-S.  The  impact  of
adjuvant chemotherapy and the potential benefit of this new could not be clearly demon‐
strated in this study of patients with stage II.
4. Oral fluoropyrimidines
Two oral  prodrugs of  5FU -  capecetabine and uracil  /  tegafur  (UFT),  has  demonstrated
efficacy in metastatic disease, which is comparable with bolus 5-FU/LV regimens [25, 26].
After  oral  administration,  capecitabine  is  rapidly  absorbed  with  plasma  concentrations
peaking after 1.5 hours [27]. Pharmacokinetics is largely dose - dependent. The pharmacol‐
ogy of capecitabine is not significantly influenced by gender, race, performance status, body
surface area, albumin or hepatic dysfunction [28]. The half-life of capecitabine is between
0.49 and 0.89 hours, whereas the half-life of the metabolite (5-FU) extends from 0.67 to 1.15
hours [29]. Regarding renal excretion primarily (more than 70% of metabolites), capecita‐
bine is against - in patients with severe renal impairment (creatinine clearance less than 30
mL / min).
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adjuvant chemotherapy and the potential benefit of this new could not be clearly demon‐
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Two oral  prodrugs of  5FU -  capecetabine and uracil  /  tegafur  (UFT),  has  demonstrated
efficacy in metastatic disease, which is comparable with bolus 5-FU/LV regimens [25, 26].
After  oral  administration,  capecitabine  is  rapidly  absorbed  with  plasma  concentrations
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ogy of capecitabine is not significantly influenced by gender, race, performance status, body
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mL / min).
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VEGF, vascular endothelial growth factor; EGFR, epidermal growth factor receptor.
Table 1. Types of therapeutical agents and their mechanism of action
The X-ACT (Xeloda (capecitabine) in adjuvant therapy of colon cancer) Phase III trial in
patients (N = 1.987) compared capecitabine (2500 mg / m 2 / day, 14 to 21 days) for bolus 5-FU/
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LV. After a median follow-up of 6.9 years, both treatments showed similar efficacy in terms
of DFS and OS [30]. The HR for DFS of capecitabine compared 5-FU/LV was 0.88 (95% CI, 0.77
to 1.01), the upper limit of the 95% is well below the predefined non-inferiority margin of 1.20
(p <0.0001) [30]. The 5-year DFS rate for capecitabine and 5-FU/LV were 60.8% and 56.7%,
respectively. These monitoring data confirm that, as adjunctive therapy for patients with colon
cancer resected stage III oral capecitabine is at least equivalent to iv bolus treatment of 5-
FU/LV in terms of 5 - year DFS, the primary endpoint of X-ACT study. Infusional 5-FU
regimens are now often favored because they offer similar efficacy or improved slightly bolus
5-FU/LV regimes and are generally better tolerated [31]. However, the plasma concentration
profile of capecitabine is administered twice daily for 14 days, closer to that of a continuous
infusion of 5-FU bolus injections as daily or weekly 5FU.La capecitabine Profile improved
safety compared to bolus 5-FU/LV in terms of significantly lower rates of diarrhea, stomatitis,
neutropenia, nausea, alopecia, febrile neutropenia [30].
UFT and oral LV was evaluated in the adjuvant setting in the NSABP C-06 trial. More than
1000 patients with colon cancer were randomized to receive either oral or intravenous UFT
with LV 5FU with LV. 47% of patients had colon cancer stage II, and 53% had colon cancer
stage III. Median follow-up was 62.3 months time. There was no significant difference in
disease-free survival - or overall showing that the UFT is an acceptable alternative to parenteral
5-FU/LV [32]. No difference in toxicity profiles of the two regimens has been reported.
5. Adjuvant therapy combination
The hypothesis  that  the antitumor activity of  the combination agent,  including oxalipla‐
tin, irinotecan, bevacizumab, cetuximab in metastatic cure rates would result in increased
adjuvant  proved  to  be  often  wrong.  Oxaliplatin  is  a  platinum  compound  and  third
generation of the safe administration of evidence of clinical activity has been reported 33.
Platinum compounds exert their effect through the development of covalent adducts with
cellular DNA, which is not portable - specific cycle [34]. Platinum derivative oxaliplatin is
described as having a "tri-exponential" reason for removing the half - life being successive‐
ly 0.28 hours, 16.3 hours and 273 hours [35]. The fact that the third half-life of oxaliplatin
hundreds of hours, the accumulation of the drug in the tissues can reasonably be expect‐
ed. In this regard, one study examined the long - term retention of platinum 8-75 months
after treatment with cisplatin and oxaliplatin [36].  Narrow therapeutic index of oxalipla‐
tin  and  adverse  reactions  are  mainly  reported  in  the  hematopoietic  system,  peripheral
nerves, and gastrointestinal tract [35]. The addition of oxaliplatin to 5FU improves patient
outcomes in the adjuvant setting. Mosaic of randomized 2246 patients with stage II or III
CRC will LV5FU2 or FOLFOX-4 (which is LV5FU2 chemotherapy plus oxaliplatin on day
1].  The 5-year  DFS rate  of  Phase II  and III  patients  were 73.3% and 67.4% in the FOL‐
FOX-4  groups  and  LV5FU2,  respectively  (RR  0.80,  95%  CI,  0.68-0,  93,  p  =  0.003)  [37].
Subgroup analysis showed stage - specific 6 years OS rate of 72.9% against 68.7% in patients
with stage III  CRC (HR 0.80,  95% CI,  0.65-0,  97,  P  =  0.023)  and 85.0% against  83.3% in
patients with stage II CRC (P = 0.65] in the FOLFOX-4 and LV5FU2, respectively [38]. As
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profile of capecitabine is administered twice daily for 14 days, closer to that of a continuous
infusion of 5-FU bolus injections as daily or weekly 5FU.La capecitabine Profile improved
safety compared to bolus 5-FU/LV in terms of significantly lower rates of diarrhea, stomatitis,
neutropenia, nausea, alopecia, febrile neutropenia [30].
UFT and oral LV was evaluated in the adjuvant setting in the NSABP C-06 trial. More than
1000 patients with colon cancer were randomized to receive either oral or intravenous UFT
with LV 5FU with LV. 47% of patients had colon cancer stage II, and 53% had colon cancer
stage III. Median follow-up was 62.3 months time. There was no significant difference in
disease-free survival - or overall showing that the UFT is an acceptable alternative to parenteral
5-FU/LV [32]. No difference in toxicity profiles of the two regimens has been reported.
5. Adjuvant therapy combination
The hypothesis  that  the antitumor activity of  the combination agent,  including oxalipla‐
tin, irinotecan, bevacizumab, cetuximab in metastatic cure rates would result in increased
adjuvant  proved  to  be  often  wrong.  Oxaliplatin  is  a  platinum  compound  and  third
generation of the safe administration of evidence of clinical activity has been reported 33.
Platinum compounds exert their effect through the development of covalent adducts with
cellular DNA, which is not portable - specific cycle [34]. Platinum derivative oxaliplatin is
described as having a "tri-exponential" reason for removing the half - life being successive‐
ly 0.28 hours, 16.3 hours and 273 hours [35]. The fact that the third half-life of oxaliplatin
hundreds of hours, the accumulation of the drug in the tissues can reasonably be expect‐
ed. In this regard, one study examined the long - term retention of platinum 8-75 months
after treatment with cisplatin and oxaliplatin [36].  Narrow therapeutic index of oxalipla‐
tin  and  adverse  reactions  are  mainly  reported  in  the  hematopoietic  system,  peripheral
nerves, and gastrointestinal tract [35]. The addition of oxaliplatin to 5FU improves patient
outcomes in the adjuvant setting. Mosaic of randomized 2246 patients with stage II or III
CRC will LV5FU2 or FOLFOX-4 (which is LV5FU2 chemotherapy plus oxaliplatin on day
1].  The 5-year  DFS rate  of  Phase II  and III  patients  were 73.3% and 67.4% in the FOL‐
FOX-4  groups  and  LV5FU2,  respectively  (RR  0.80,  95%  CI,  0.68-0,  93,  p  =  0.003)  [37].
Subgroup analysis showed stage - specific 6 years OS rate of 72.9% against 68.7% in patients
with stage III  CRC (HR 0.80,  95% CI,  0.65-0,  97,  P  =  0.023)  and 85.0% against  83.3% in
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expected,  the  toxicity  of  the  regimen  FOLFOX-4  was  higher  than  that  observed  in  the
LV5FU2 arm.  All  -  cause mortality  in  the  first  60  days was the same in  both arms.The
NSABP  C-07  trial  had  a  similar  design,  the  addition  of  oxaliplatin  to  5-FU  adjuvant
chemotherapy,  but  using  a  different  calendar  5FU  and  also  provide  fewer  doses  of
oxaliplatin in  the MOSAIC study (nine against  twelve).  FLOX regimen in this  trial  was
studied - oxaliplatin was given on weeks 1, 3, and 5 more per week 5-FU/LV bolus of 1-6
weeks, repeated at 8 week cycle, depending on the standard weekly 5-FU/LV treatment.
Over  2000  patients  were  randomized to  receive  5-FU/LV and FLOX treatment.  Stage  II
patients were 29% and stage III patients was 71%. The median duration of follow up was
34 months. The hazard ratio of FLOX against 5-FU/LV was 0.79 (95% CI, 0.67 to 0.93], with
a risk reduction of 21% in favor of FLOX [39]. As expected, treatment toxicity FLOX was
higher than that observed in the 5-FU/LV arm. 15 deaths were recorded in the treatment
with FLOX and 14 deaths 5-FU/LV. Update this study showed that the benefit of FLOX in
DFS was observed in 7 - year median follow - but there was no significant difference in
overall survival when the two arms were compared 24 (HR, 0.88, 95% CI, 0.74 to 1.05, P =
0.1428).  A  significant  interaction  between  age  and  survival  of  certain  parameters  were
observed. Patients less than 70 years appeared to benefit from the addition of oxaliplatin
while in patients over 70 years, no benefit was observed consistently. MOSAIC and NSABP
the C-07 trials delivered a total dose of oxaliplatin different, but both studies noted similar
improvements in DFS. International trials evaluating shorter periods of oxaliplatin - based
chemotherapy in the adjuvant setting (12 versus 24 weeks of chemotherapy oxaliplatin/5FU
ISRCTN 59757862)  in  order  to  assess  the non-inferiority  of  short  periods treatment.Both
NSABP C-07 and MOSAIC are powered to assess the benefit  of adding oxaliplatin to 5-
FU in patients with stage II disease, but a trend towards improved DFS was noted.Howev‐
er, no OS benefit is probably very low in absolute terms (<2%) and difficult to justify given
the excellent overall performance (> 80% at 5 years of operation) and the risk of neurotox‐
icity.  Analysis of a phase III  trial  comparing capecitabine plus oxaliplatin (XELOX) with
bolus 5-FU/LV as adjuvant treatment for colon cancer stage III showed that XELOX was an
improvement of 3 years compared to 5-FU/LV DFS rate [40, 41]. Patients receiving XELOX
had  less  adverse  reactions  such  as  diarrhea,  alopecia,  and  more  neurosensory  toxicity,
vomiting and hand-foot syndrome than patients receiving FU / LV. All these studies suggest
that  FOLFOX,  XELOX  FLOX  and  can  be  used  interchangeably  in  contexts  adjuvant.
Irinotecan is a semisynthetic analogue of camptothecin, originally isolated from the China /
Tibet  ornamental  tree  Camptotheca  acuminata.It  is  a  chemotherapy  agent  that  causes
destruction of cells in S phase-specific topoisomerase I poison in the cell [42]. CALGB 89803
trial by Saltz and colleagues randomized 1264 patients to receive standard weekly bolus 5-
FU / LV bolus regimen or weekly irinotecan and 5-FU bolus / LV. The primary endpoints
of the study were overall survival and disease-free survival. Surprisingly, they found no
difference in either DFS (0.84] or OS (P = 0.74] between the two treatment arms with lethal
and non-lethal toxicity increased by the addition of irinotecan to standard 5FU / LV pattern
43.This trial showed the need for randomized controlled trials adjuvant because advances
in  the  treatment  of  metastatic  disease  does  not  necessarily  translate  into  advances  in
adjuvant  therapy.  Phase  III  trial  was  conducted by large  investigators  PETACC-3.  They
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investigated  whether  the  addition  of  irinotecan  to  LV5FU2 would  improve  disease-free
survival in patients with colon cancer. After surgery, patients with stage II and III colon
cancer were randomized to receive surgery LV5FU2 (LV 200 mg / m 2 infused over 2 hours,
followed by 5-FU as a 400 mg / m 2 bolus and then one of 600 mg / m 2 by continuous
infusion  over  22  hours  on  days  1  and  2  every  2  weeks  for  12  cycles)  with  or  without
irinotecan (180 mg / m 2 infused over 30 to 90 minutes, day 1, every 2 weeks) [44]. After
a median follow-up of  66.3 months,  the rate at  5  years was 56.7% with DFS irinotecan/
LV5FU2  and  54.3%  for  LV5FU2  alone  (p  =  0.106).  They  observed  that  the  addition  of
irinotecan to LV5FU2 was associated with an increased incidence of adverse reactions and
neutropenia. They concluded that irinotecan added to LV5FU2 as adjuvant therapy does
not confer a statistically significant improvement in overall survival or DFS in patients with
colon cancer stage III versus LV5FU2 alone. For the moment, there are no data support‐
ing the use of irinotecan-containing regimens in adjuvant stage II and III patients. Analy‐
sis PETACC-3 trial could not confirm the expected benefit of adding irinotecan in MSI-H
patients. Bevacizumab is a recombinant humanized monoclonal antibody directed against
the vascular endothelial growth factor (VEGF) which is used to inhibit the function of VEGF
in vascular endothelial cells and thereby inhibit tumor angiogenesis-dependent solid tumors
for  growth  and  metastasis  [45].  Bevacizumab  has  demonstrated  clinical  activity  to  in‐
crease in the standard CT metastatic settings.This led to the consideration of this agent in
the adjuvant chemotherapy in the NSABP C-08 trial. More than 2500 patients, most of whom
had stage  III  were  randomized to  receive  FOLFOX6 modified  6  months,  alone  or  with
bevacizumab [46]. In the bevacizumab arm, bevacizumab was administered for more than
6 months, for a total of 1 year of bevacizumab.The primary endpoint of the study was 3
years DFS. The relative risk of FOLFOX plus bevacizumab versus FOLFOX alone was 0.89
(95% CI, 0.76 to 1.04, p = 0.15). This study did not demonstrate the benefits of the use of
bevacizumab in the adjuvant treatment of stage II and III CRC and for this reason the use
of bevacizumab cannot be recommended for use in the adjuvant treatment of patients with
colon cancer.  Cetuximab is a monoclonal antibody capable of inhibiting the degradation
and transmembrane receptor EGFR epidermal growth factor  47.Inhibition of  EGFR is  of
major importance because EGFR control many important activities of tumor cells, includ‐
ing tumor growth and neo - angiogenesis, inhibition of the apoptotic response to chemother‐
apy and radiotherapy.  In a Phase III,  randomized, Alberts  and colleagues evaluated the
potential benefit of cetuximab added to the sixth amended plan FOLFOX.Ils randomized
over  2500  patients  to  receive  12  cycles  of  FOLFOX  every  two  weeks  with  or  without
cetuximab. The mutational status of the KRAS gene was decided at the central level. The
median follow-up of 28 months. Three-year disease-free survival for FOLFOX alone was
74.6% against 71.5% with the addition of cetuximab (HR, 1.21, 95% CI, 0.98 to 1.49, P = 0
08) in patients with wild-type KRAS, and 67.1% against 65.0% (HR 1.12, 95% CI, 0.86 to
1.46, p = 0.38) in patients with mutated KRAS 48.The trial did not demonstrate any benefit
when adding cetuximab to FOLFOX regimen. More patients with grade 3 or higher adverse
events (72.5% versus 52.3%, odds ratio (OR) 2.4, 95% CI, 2.1 to 2.8, p <.001) and failure to
carry Good 12 cycles (33% versus 23%, OR 1.6, 95% CI, 1.4 to 1.9, p <0, 001) were significant‐
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investigated  whether  the  addition  of  irinotecan  to  LV5FU2 would  improve  disease-free
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cetuximab. The mutational status of the KRAS gene was decided at the central level. The
median follow-up of 28 months. Three-year disease-free survival for FOLFOX alone was
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08) in patients with wild-type KRAS, and 67.1% against 65.0% (HR 1.12, 95% CI, 0.86 to
1.46, p = 0.38) in patients with mutated KRAS 48.The trial did not demonstrate any benefit
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ly higher with cetuximab.Increased toxicity was observed in patients aged 70 years or older.
Therefore, the role of cetuximab in the adjuvant treatment is insignificant for the moment.
6. Chemotherapy in elderly
Colon cancer usually occurs in the elderly with a median age at diagnosis> 70 years in the USA.
Given the increasing life expectancy, patients aged >75 years will be an important component
of oncology practice in the future. Despite this fact, very few patients >75 years participate in
clinical trials. There is disagreement in the administration of standard adjuvant therapy
between young and elderly patients, despite a significant survival benefit for most patients
[49]. The pooled analyzes of safety and efficacy of adjuvant chemotherapy in the elderly
showed comparable rates of toxicity and similar survival benefits compared to younger
patients [50].The majority of data for adjuvant therapy in elderly patients is not the incorpo‐
ration of new therapeutic agents such as oxaliplatin. Subsequent population-based studies
have suggested that older people (eg the elderly category <75 years versus> 75 years [51] were
less likely to have received adjuvant therapy, but experienced similar survival rates compared
younger patients [52]. Finally, although the majority of recommendations to reduce colorectal
cancer screening for persons aged <75 years, the study results indicate that [53] patients aged
>75 years account for almost 20% of cases of colon cancer lymph nodes.In this large population-
based study, investigators found that age was associated with significantly lower rates of
adjuvant chemotherapy administration, whereas the survival benefits of such treatment are
comparable to those of younger patients with stage III in [53] colon cancer.Although chrono‐
logical age alone should not be an exclusion criterion, more work is needed to establish an
optimal strategy and effective way to understand who would benefit most from adjuvant
therapy after surgical resection.
7. Efectivness
Patients with metastatic CRC being treated with chemotherapy are followed closely to monitor
efficacy. There are standardized efficacy measures, such as the RECIST (response evaluation
criteria in solid tumors) criteria, used as endpoints for large clinical trials. A partial response
is defined as a 30% decrease in the longest dimension of each measurable tumor deposit, using
unidimentional, or RECIST criteria [54-56]. A complete response is complete disappearance of
all clinically detectable disease. The response rate (RR) is the percentage of patients who meet
either a partial or complete response. Measures used to determine the duration of treatment
benefit include:
1. progression-free survival (PFS), which is the time from the start of treatment to the date
the disease, worsens;
2. disease-free survival (DFS), which is the length of time patients are free of disease after
completion of curative treatment; and
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3. overall survival (OS), which is the length of time patients are alive after diagnosis or
initiation of treatment for metastatic disease.
8. Postoperative management
Postoperative, or “adjuvant” systemic therapy has become standard for stage III colon cancer.
Adjuvant therapy should also be strongly considered in stage II patients. It is generally
recommended for any medically fit patient with stage II cancer with unfavorable factors,
including colonic perforation, poorly differentiated histology, colonic obstruction, lympho
vascular invasion, or inadequately sampled lymph nodes [61]. The optimal choice of adjuvant
chemotherapy has recently changed from a 6-month course of 5FU-based chemotherapy alone
to a 6-month course of infusional 5FU plus LV and oxaliplatin (FOLFOX) based on a large trial
of adjuvant systemic therapy for resected stage II or III colon cancer [62].This trial demon‐
strated an increase in disease-free survival at 3 years from 72.9 to 78.2% (p = 0.002) with addition
of oxaliplatin to FU/LV. Five-year disease-free survival remained significant (HR: 0.80; p =
0.003) and at 6 years there was an overall survival benefit for stage III patients (68.3% versus
72.9%) [64].Toxicities were comparable between the two groups, with the exception that
oxaliplatin is associated with a much higher rate of paresthesia: 12.4% versus 0.2% grade 3
(serious) toxicity. This neurotoxicity persisted at a grade 3 level in 1.1% of treated patients at
one-year of follow-up.
Many advances have occurred recently in the treatment of metastatic CRC. Active agents, in
addition to the original 5FU, that have been approved by the Food & Drug Administration
(FDA) for mCRC include irinotecan, capecitabine, oxaliplatin, bevacizumab, cetuximab, and
panitumumab. The goals of systemic therapy of mCRC include palliation of symptoms,
prolongation of life, and in selected cases of liver-only metastases, tumor regression to facilitate
surgical resection of these metastases. The median survival of a patient with mCRC has
improved during the last decade from less than 1 year, with only 5FU-based therapy, to ~2
years, with multiagent systemic therapy.
5FU, often modified by LV, has been clinically used for half a century as a standard agent for
mCRC [64]. This was the only available agent until 1996, when irinotecan was approved. Over
the last decade, chemotherapies such as oxaliplatin and capecitabine and targeted agents such
as bevacizumab, cetuximab, and panitumumab have been approved. 5FU blocks the enzyme
thymidylate synthase (TS), which is essential for DNA synthesis. Leucovorin (LV), also known
as folinic acid, enhances the antineoplastic effects of 5FU. Both LV (FOL = folinic acid) and 5FU
(F = fluorouracil) can be combined with irinotecan (IRI) or oxaliplatin (OX) with the treatment
acronyms FOLFIRI or FOLFOX, respectively. These alternative treatments consist of admin‐
istration of a bolus of 5FU, LV, and either oxaliplatin or irinotecan. The patient is then sent
home with a 2-day infusion of low-dose 5FU, administered by a small, lightweight, portable
pump, usually worn on a belt or shoulder strap, infused through a centrally placed catheter.
The patient or health care provider can simply disconnect the catheter after the 2-day infusion.
Capecitabine is an oral fluoropyrimidine with a similar mechanism of action and similar
efficacy as 5FU.
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Irinotecan is a derivative of camptothecin, found in Camptotheca acuminata, a plant native to
China. It potently inhibits topoisomerase I, an enzyme that facilitates the uncoiling and
recoiling of DNA during replication by cleaving one strand and subsequently reattaching that
strand. Oxaliplatin is a platinum chemotherapy that inhibits DNA replication and transcrip‐
tion by forming inter- and intrastrand DNA adducts/cross-links.
In patients with mCRC, optimal chemotherapy consists of initial administration of a fluoro‐
pyrimidine and oxaliplatin or irinotecan (e.g., FOLFOX or FOLFIRI). Tournigand et al [65] and
Colucci et al [66] performed randomized trials where patients received either FOLFIRI
followed by FOLFOX, or vice versa. In the Tournigand et al study, FOLIRI was found to have
a response rate (RR) of 56% and a 8.5-month median progression free survival (mPFS), whereas
FOLFOX had a RR of 54% and a mPFS of 8 months. Colucci et al found that FOLFIRI had a RR
of 31% and FOLFOX had a RR of 34%. Both regimens had a mPFS of 7 months. Both investi‐
gators concluded that both regimens had similar efficacy when used as first-line therapy.
Therefore, either FOLFOX or FOLFIRI can be considered standard options for first-line
treatment of mCRC. These regimens are typically given with bevacizumab.
Bevacizumab is a monoclonal antibody that binds to vascular endothelial growth factor
(VEGF) ligand to inhibit angiogenesis. Its antineoplastic effect is ascribed to regression of
microvascular density, inhibition of neovascularization, and “normalization” of grossly
abnormal tumor vasculature that permits more effective chemotherapy delivery to the tumor.
The FDA recently approved bevacizumab in combination with 5FU-based chemotherapy for
mCRC based on findings that addition of bevacizumab to irinotecan, 5FU, and LV for mCRC
improved PFS from 6.2 months to 10.6 months, improved the response rate from 35 to 45 [67]
and improved overall survival from 15.6 to 20.3 months. Saltz et al found that the addition of
bevacizumab to oxaliplatin-based chemotherapy significantly improved PFS from 8.0 to 9.3
months without an improvement in response rate [68]. The finding of improved PFS without
improved RR is common in trials of targeted therapy because the metastatic lesions can cavitate
or has necrosis rather than regress. Recently, XELOX chemotherapy with or without bevacu‐
zimab was found to be noninferior to FOLFOX with or without bevacuzimab [69]. XELOX
chemotherapy includes a combination of oral 5FU known as capecitabine or xeloda (XEL) plus
oxaliplatin (OX). XELOX can be used as an alternative in patients who cannot tolerate FOLFOX
side effects.
In 2004, the FDA approved cetuximab, the chimeric (human/mouse) monoclonal antibody
targeting epidermal growth factor receptor (EGFR), for treatment of mCRC with irinotecan,
and as a single agent for patients intolerant of irinotecan-based therapy. Early randomized
trials showed benefit of cetuximab in previously treated mCRC patients. When cetuximab was
combined with irinotecan in patients refractory to irinotecan-based chemotherapy, the
response rate was 22.9% versus 10.8% for irinotecan alone [70]. Among patients who failed
previous lines of treatment, monotherapy with cetuximab was found to improve overall
survival, PFS, and quality of life compared with best support care alone [71]. Cetuximab causes
an acneform rash on the face and upper body in more than 80% of patients. The rash is
associated with improved survival.
Colorectal Cancer - Surgery, Diagnostics and Treatment316
Although the FDA approved cetuximab for use in epidermal growth factor receptor (EGFR)
expressing mCRC, there is no evidence that the presence or absence of EGFR expression
influences RR, and routine testing for this is unnecessary. K-ras mutations have been shown
to predict response to cetuximab. The K-ras gene encodes a GTPase protein that is involved in
cell signal transduction pathways [72]. Wild-type (nonmutated) K-ras is found in normal cells.
Approximately 40% of colorectal tumor cells have a mutated K-ras gene resulting in constitu‐
tively active protein and abnormal cell growth, proliferation, and differentiation. Evidence
suggests there is no benefit in using cetuximab monotherapy in previously treated and
untreated mCRC patients who have mutated K-ras tumors. Previously treated metastatic
colorectal patients with mutated K-ras tumors did not benefit from cetuximab monotherapy,
in contrast to patients with wild-type K-ras who had significantly improved overall survival
and PFS [74]. FOLIFIRI and cetuximab as first-line therapy in mCRC was found to reduce the
risk of disease progression; however, the benefit was limited to patients with K-ras wild-type
tumors (HR 0.68, CI 0.50–0.94) [73].
In 2006, the FDA approved panitumumab, a monoclonal antibody to EGFR, which unlike
cetuximab, is fully humanized (not chimeric). It is indicated for patients with mCRC who have
progressed on or are following 5FU, oxaliplatin, and irinotecan-containing regimens. In a large
randomized trial of panitumumab versus best supportive care for mCRC, a response rate of
10% was found [74]. Like cetuximab, panitumumab causes an acneform skin rash. As a fully
human monoclonal antibody, panitumumab has a lower risk of serious infusion reactions than
the 3% rate observed with cetuximab. Similar to cetuximab, panitumumab monotherapy is
more efficacious in patients with wild- rather than mutant-type K-ras tumors. In a randomized
clinical trial of previously treated mCRC patients, median PFS and OS was significantly
improved in the wild-type K-ras group compared with the mutant group [75]. 17% of patients
with wild-type K-ras responded to treatment versus 0% of patients with mutant K-ras. The
relative activity of cetuximab versus panitumumab, as well as the relative activity of panitu‐
mumab when given with chemotherapy, is currently unknown.
9. Rectal cancer
Given the higher local recurrence rates and poorer overall survival of patients with rectal
cancer, multimodality management is important. In the early 1990s, the standard of care
following surgical resection for full thickness (T3–4) or lymph node positive rectal cancer
was postoperative chemoradiotherapy as it was found to improve both local control and
OS compared with surgery alone [77, 78].  Recently, preoperative chemoradiotherapy has
become the treatment of choice for full  thickness rectal  cancers prior to total  mesorectal
excision based on a randomized clinical trial conducted by Sauer et al. Although this trial
showed no difference in OS, improved local recurrence rates (6% versus 13%) were found
for  patients  receiving  preoperative  5FU-based  chemoradiotherapy  as  compared  with
postoperative chemoradiotherapy [79]. Preoperative 5FU chemoradiotherapy as compared
with preoperative radiation alone also has been shown to improve local recurrence rates
(2.7% versus 14.6%) [80].
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The standard of care for patients with resectable liver metastases as their only site of cancer
spread is changing from previous surgical resection alone to a combination of perioperative
chemotherapy and surgery based on a trial conducted by Nordlinger et al [76]. This trial
randomized patients with one to four potentially resectable liver metastases to either perio‐
perative chemotherapy (six cycles of FOLFOX chemotherapy both pre- and postresection) or
surgery alone. The authors concluded that perioperative chemotherapy reduced the risk of
events such as progressive or recurrent disease and death by 25% in eligible and resected
patients without increased severe, life-threatening toxicity. The results of this trial are contro‐
versial because when all randomized patients were included in the analysis only a trend and
not significance in PFS favoring the chemotherapy arm was found.
11. Targeted therapy
Although new drug development takes years, targeted drug use can occur more quickly with
advanced tests and will be a focus of future work. In addition, efforts will focus on identifying
biomarkers that predict response to systemic therapy so that tailored therapy can be initiated.
With  regards  to  the  future  of  adjuvant  systemic  chemotherapy,  microsatellite-instability
(MSI)  testing  of  tumor  DNA may be  used  to  identify  which  patients  will  benefit  from
additional therapy (i.e., predictive biomarker) [81, 82]. Approximately 15% of colon cancers
exhibit MSI commonly caused by loss of DNA mismatch-repair pathways. Tumors display
short repeated nucleotide sequences called microsatellites secondary to frame-shift muta‐
tions  and base-pair  substitutions.  Recent  retrospective  evidence demonstrated that  adju‐
vant  5FU-based  chemotherapy  improved  OS  among  patients  with  microsatellite-stable
tumors. However, there was no benefit to those patients with high MSI [83-90]. Ongoing
trials are attempting to replicate these findings in a prospective manner. The clinical benefit
of  cetuximab,  a  monoclonal  antibody against  EGFR,  varies  greatly  depending on tumor
biology:  the  greatest  benefit  is  among  patients  with  wild-type  (nonmutated)  K-ras  tu‐
mors.  In the metastatic setting,  potential  predictive biomarkers of interest  include K-ras,
epiregulin, B-raf, PTEN, and Pi3K. Jonker et al found that mCRC patients with both high
epiregulin (ligand for EGFR) gene expression and K-ras wild-type status had greater benefit
from cetuximab therapy (HR for overall survival 0.43, p = 0.001) [94]. In addition, loss of
the  tumor-suppressor  gene  PTEN  [95]  and  having  mutated  protein  kinase  B-raf  may
[96]predict for resistance to EGFR therapy such as cetuximab.
12. Discussion
Over the past decade, the prevention and treatment of colorectal cancer has rapidly evolved.
To implement evidence-based care a multidisciplinary team is required including surgeons,
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radiation and medical oncologists, as well as gastroenterologists, radiologists, pathologists,
and primary care physicians. Unfortunately, despite improvements in surgical techniques and
systemic therapy CRC still remains the number two cause of cancer mortality in North
America. This study evaluated the usefulness of oncology assess the standardization of CRC
chemotherapy and the results at the rate of recurrence and survival. The methodology has
enabled the understanding of patterns used for CRC chemotherapy around the world. The
results showed significant differences in patterns between countries, regions and institutions.
In addition, the actual use of CRC chemotherapy may depend on the health policies of the
respective governments. Schemes used are in line with the recommendations of the new
guidelines, with the exception of hospital characteristics depended specialization. In first-line
chemotherapy for stage IV CRC, general hospitals still favored the use of oral fluoropyrimi‐
dines, such as UFT / LV and S-1. However, the differences between general hospitals, cancer
centers and university hospitals has decreased after the revision of the guidelines. In adjuvant
chemotherapy for stage III CRC, cancer centers and general hospitals used similar patterns,
but those that are used in different hospitals. Measures and indicators are greatly needed to
evaluate and improve the quality of cancer treatment. Using market research to develop
indicators for the standardization of care against cancer is a new methodology. Data not only
showed evidence practice gap, but also the growing standardization of CRC affected by
chemotherapy treatment guidelines. Methodology indicates a lack of standardization in the
care of CRC. Oncology market research also has the potential for cost-effectiveness analyzes,
such as sales data for each agent can be evaluated using the analysis system of oncology. Efforts
to improve screening utilization by the general population are required to improve mortality
and morbidity from CRC. Research advances in medical oncology will result in better
understanding of tumor genetics and biology of the host. This will allow systemic therapy to
be tailored to specific tumor molecular targets, while sparing toxicity to normal tissue. With
these improvements in CRC care, the disease will be treatable with tailored medical treatments
that are effective with low toxicity.
13. Recommendations
13.1. Stage II colorectal cancer
• The routine use of adjuvant chemotherapy for all patients with stage II colon cancer is not
recommended. However, the subset of patients with high-risk stage II disease who should
be considered for adjuvant therapy includes patients with inadequately sampled nodes, T4
lesions, perforation, or poorly differentiated histology.
• The ultimate clinical decision should be based on discussions with the patient about the
nature of the evidence supporting treatment, the anticipated morbidity of treatment, the
presence of high-risk prognostic features on individual prognosis, and patient preferences.
• When treated with adjuvant therapy, high-risk stage II patients should receive similar
regimens to those recommended for stage III patients. The enrolment of resected high-risk




The standard of care for patients with resectable liver metastases as their only site of cancer
spread is changing from previous surgical resection alone to a combination of perioperative
chemotherapy and surgery based on a trial conducted by Nordlinger et al [76]. This trial
randomized patients with one to four potentially resectable liver metastases to either perio‐
perative chemotherapy (six cycles of FOLFOX chemotherapy both pre- and postresection) or
surgery alone. The authors concluded that perioperative chemotherapy reduced the risk of
events such as progressive or recurrent disease and death by 25% in eligible and resected
patients without increased severe, life-threatening toxicity. The results of this trial are contro‐
versial because when all randomized patients were included in the analysis only a trend and
not significance in PFS favoring the chemotherapy arm was found.
11. Targeted therapy
Although new drug development takes years, targeted drug use can occur more quickly with
advanced tests and will be a focus of future work. In addition, efforts will focus on identifying
biomarkers that predict response to systemic therapy so that tailored therapy can be initiated.
With  regards  to  the  future  of  adjuvant  systemic  chemotherapy,  microsatellite-instability
(MSI)  testing  of  tumor  DNA may be  used  to  identify  which  patients  will  benefit  from
additional therapy (i.e., predictive biomarker) [81, 82]. Approximately 15% of colon cancers
exhibit MSI commonly caused by loss of DNA mismatch-repair pathways. Tumors display
short repeated nucleotide sequences called microsatellites secondary to frame-shift muta‐
tions  and base-pair  substitutions.  Recent  retrospective  evidence demonstrated that  adju‐
vant  5FU-based  chemotherapy  improved  OS  among  patients  with  microsatellite-stable
tumors. However, there was no benefit to those patients with high MSI [83-90]. Ongoing
trials are attempting to replicate these findings in a prospective manner. The clinical benefit
of  cetuximab,  a  monoclonal  antibody against  EGFR,  varies  greatly  depending on tumor
biology:  the  greatest  benefit  is  among  patients  with  wild-type  (nonmutated)  K-ras  tu‐
mors.  In the metastatic setting,  potential  predictive biomarkers of interest  include K-ras,
epiregulin, B-raf, PTEN, and Pi3K. Jonker et al found that mCRC patients with both high
epiregulin (ligand for EGFR) gene expression and K-ras wild-type status had greater benefit
from cetuximab therapy (HR for overall survival 0.43, p = 0.001) [94]. In addition, loss of
the  tumor-suppressor  gene  PTEN  [95]  and  having  mutated  protein  kinase  B-raf  may
[96]predict for resistance to EGFR therapy such as cetuximab.
12. Discussion
Over the past decade, the prevention and treatment of colorectal cancer has rapidly evolved.
To implement evidence-based care a multidisciplinary team is required including surgeons,
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radiation and medical oncologists, as well as gastroenterologists, radiologists, pathologists,
and primary care physicians. Unfortunately, despite improvements in surgical techniques and
systemic therapy CRC still remains the number two cause of cancer mortality in North
America. This study evaluated the usefulness of oncology assess the standardization of CRC
chemotherapy and the results at the rate of recurrence and survival. The methodology has
enabled the understanding of patterns used for CRC chemotherapy around the world. The
results showed significant differences in patterns between countries, regions and institutions.
In addition, the actual use of CRC chemotherapy may depend on the health policies of the
respective governments. Schemes used are in line with the recommendations of the new
guidelines, with the exception of hospital characteristics depended specialization. In first-line
chemotherapy for stage IV CRC, general hospitals still favored the use of oral fluoropyrimi‐
dines, such as UFT / LV and S-1. However, the differences between general hospitals, cancer
centers and university hospitals has decreased after the revision of the guidelines. In adjuvant
chemotherapy for stage III CRC, cancer centers and general hospitals used similar patterns,
but those that are used in different hospitals. Measures and indicators are greatly needed to
evaluate and improve the quality of cancer treatment. Using market research to develop
indicators for the standardization of care against cancer is a new methodology. Data not only
showed evidence practice gap, but also the growing standardization of CRC affected by
chemotherapy treatment guidelines. Methodology indicates a lack of standardization in the
care of CRC. Oncology market research also has the potential for cost-effectiveness analyzes,
such as sales data for each agent can be evaluated using the analysis system of oncology. Efforts
to improve screening utilization by the general population are required to improve mortality
and morbidity from CRC. Research advances in medical oncology will result in better
understanding of tumor genetics and biology of the host. This will allow systemic therapy to
be tailored to specific tumor molecular targets, while sparing toxicity to normal tissue. With
these improvements in CRC care, the disease will be treatable with tailored medical treatments
that are effective with low toxicity.
13. Recommendations
13.1. Stage II colorectal cancer
• The routine use of adjuvant chemotherapy for all patients with stage II colon cancer is not
recommended. However, the subset of patients with high-risk stage II disease who should
be considered for adjuvant therapy includes patients with inadequately sampled nodes, T4
lesions, perforation, or poorly differentiated histology.
• The ultimate clinical decision should be based on discussions with the patient about the
nature of the evidence supporting treatment, the anticipated morbidity of treatment, the
presence of high-risk prognostic features on individual prognosis, and patient preferences.
• When treated with adjuvant therapy, high-risk stage II patients should receive similar
regimens to those recommended for stage III patients. The enrolment of resected high-risk
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stage II patients in clinical trials is encouraged. Additional trials comparing adjuvant
therapy with observation are needed and are ethically acceptable in stage II colon cancer.
13.2. Stage III colorectal cancer
It could be recommended that patients with completely resected stage III colon cancer should
be offered adjuvant chemotherapy and that this treatment should start within eight weeks of
surgery. Treatment should depend on factors such as patient suitability and preference, and
patients and clinicians must work together to determine the optimal course of treatment. The
recommended treatment option is:
• 5-FU given intravenously in combination with leucovorin (LV) and oxaliplatin in the
regimens known as FOLFOX or FLOX. These 5-FU/LV/oxaliplatin regimens have demon‐
strated superior DFS when compared with 5-FU plus LV and are the recommended
regimens. Oxaliplatin administration is associated with a 1% risk of persistent grade 3
neuropathy that needs to be considered in conjunction with expected benefits of therapy.
• Some patients would not be considered appropriate for oxaliplatin regimens. Examples
include patients with underlying neurologic conditions or at increased risk of neuropathy,
patients at increased risk for infections, and patients likely to poorly tolerate infections as a
result of chemotherapy. For these patients, the treatment options are:
• Oral capecitabine administered for six months, which has equivalent efficacy to intravenous
5-FU/LV. Capecitabine results in significantly less diarrhea, stomatitis, neutropenia, nausea/
vomiting, and alopecia but significantly more hand-foot syndrome when compared with 5-
FU/LV.
• 5-FU in combination with LV administered for six months using either the weekly or
monthly schedule.
Suitable patients should be offered entry into clinical trials testing new adjuvant treatments
for resected stage III colon cancer.
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1. Introduction
Cancer is not just one disease, but a generic term used to encompass a group of more than two
hundred diseases sharing common characteristics. From a clinical point of view, cancer is a
large group of diseases, that vary in their age of onset, rate of growth, state of cellular differ‐
entiation, diagnostic detectability, invasiveness, metastatic potential, response to treatment,
and prognosis. From a molecular and cell biological point of view, however, cancer may be a
relatively small number of diseases caused by similar molecular defects in cell function
resulting from common types of alterations to a cell’s genes. Ultimately, cancer is a disease of
abnormal gene expression. There are a number of mechanisms by which this altered gene
expression occurs. These mechanisms may occur via a direct insult to DNA, such as a gene
mutation, translocation, amplification, deletion, loss of heterozygosity, or via a mechanism
resulting from abnormal gene transcription or translation. The overall result is an imbalance
of cell replication and cell death in a tumor cell population that leads to an expansion of tumor
tissue. Cancers (carcinomas) are characterized by their unregulated growth and spread of cells
to other parts of the body [1,2]. Treatment of an individual diagnosed with cancer is not only
dependent upon which type of malignancy (cancer) they have, but also on the extent of its
spread, together with its sensitivity to treatment [3].The total care of the patient will involve
assessment of their physical, psychological and social needs, so that a complete care package
can be developed to support them and their carer(s) throughout the whole of their patient.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
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© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.1. Colorectal cancer
Colorectal cancer (CRC), less formally known as bowel cancer, is a cancer characterized by
neoplasia in the colon, rectum, or vermiform appendix. CRC is a leading cause of cancer
mortality in the Western World. In the United States, CRC is the third most commonly
diagnosed cancer in men and women and the second leading cause of cancer-related mortality
[4]. Because 5% of persons (1 in 20 persons) will develop colorectal cancer, this disease is an
important public health issue.
1.2. Incidence of colorectal cancer
Globally, cancer of the colon and rectum is the third mostcommon cancer in males and in
females with mortality paralleling incidence [5]. An estimated 141,210 cases (71,850 male and
69360 female) of CRC were expected to occur in 2011.An estimated 49, 380 deaths (25,250 male
and 24,130 female)of CRC were expected to occur in 2011, accounting for about 9% of all cancer
deaths (Table 1). The5-year survival is 90% when CRC is diagnosed at an early stage however,
less than 40% cases are diagnosed when the cancer is still localized [6]. The frequency of CRC
varies remarkably among different populations. The incidence of colorectal cancer is increas‐
ing in certain countries where risk was historically low (Japan, Puerto Rico). In high-risk
countries, trends are gradually increasing (England), stabilizing (New Zealand), or declining
(United States) with time. The greatest increases in the incidence of colorectal cancer are in
Asia (Japan, Hong Kong, Singapore), Eastern Europe (Hungary, Poland), Israel, and Puerto
Rico. In contrast to the recent decrease in rates seen in some western and northern European
countries, relatively large increases have been observed in Spain. The decrease in incidence in
the United States partially reflects the increase in detection and removal of precancerous
lesions; the increase in several Asian and Eastern European countries may reflect changes in
the prevalence of obesity and dietary patterns. Age standardized incidence of colorectal cancer
around the world is depicted in graph 1.
In India, CRC does not figure amongst the 10 most common malignancies. The age-standar‐
dized rates of CRC in India have been estimated to be 4.2 and 3.2/100,000 for males and females,
respectively.
Inter-regional differences in the incidence of CRC, including difference among population
groups living in geographic proximity but with different life styles, suggest that environment
plays a role in the development of the disease [7]. Change in the location of these tumours is
seen with increasing age. The proportion of tumours beyond the reach of sigmoidoscopy
increases with age [8]. Sub site distribution also may differ according to ethnicity [9]
1.3. Risk factors
Epidemiologic studies have revealed a number of risk factors for colorectal cancer including
age, family history of colon cancer or inflammatory bowel disease, smoking, alcohol con‐
sumption, obesity, and diet.
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Age
Colorectal cancer is most commonly found in those aged 50 years and over.
Sex
Men are more likely than women to develop colorectal cancer. The incidence rate of colorectal
cancer between 2000 and 2004 was 69.2 per 100,000 population among men and 45.8per 100,000
populations among women [10]
Estimated New cases Estimated Deaths
Male Female Male Female
Prostate Breast Lung & bronchus Lung & bronchus
240,890 (29%) 230,480 (30%) 85,600 (28%) 71,340 (26%)
Lung & bronchus Lung & bronchus Prostate Breast
115,060 (14%) 106,070 (14%) 33,720 (11%) 39,520 (15%)
Colon & rectum Colon & rectum Colon & rectum Colon & rectum
71,850 (9%) 69,360 (9%) 25,250 (8%) 24,130 (9%)
Urinary bladder Uterine corpus Pancreas Pancreas
52,020 (6%) 46,470 (6%) 19,360 (6%) 18,300 (7%)
Melanoma of the skin Thyroid
Liver & intrahepatic bile
duct
Ovary
40,010 (5%) 36,550 (5%) 13,260 (4%) 15,460 (6%)
Kidney & renal pelvis Non-Hodgkin lymphoma Leukemia Non-Hodgkin lymphoma
37,120 (5%) 30,300 (4%) 12,740 (4%) 9,570 (4%)
Non-Hodgkin lymphoma Melanoma of the skin Esophagus Leukemia
30,220 (4%) 11,910 (4%) 9,040 (3%)36,060 (4%)
Oral cavity & pharynx Kidney & renal pelvis Urinary bladder Uterine corpus
27,710 (3%) 10,670 (4%) 8,120 (3%)23,800 (3%)
Leukemia Ovary Non-Hodgkin lymphoma Liver & intrahepatic bile duct
25,320 (3%) 21,990 (3%) 9,750 (3%) 6,330 (2%)
Pancreas Pancreas Kidney & renal pelvis Brain & other nervous
22,050 (3%) 21,980 (3%) 8,270 (3%) system
5,670 (2%)
All sites All sites All sites All sites
822,300 (100%) 774,370 (100%) 300,430 (100%) 271,520 (100%)
Table 1. Leading Sites of New Cancer Cases and Deaths (2011, American Cancer Society, Inc., Surveillance) 2011.
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Graph 1: Age standardized incidence of colorectal cancer/100,000populations around the
world (Arshad et al., 2011)
According to the CDC (Centre for Disease Control and Prevention), those who have a family
history of colorectal cancer are at higher risk for developing colorectal cancer themselves. In
addition to particular genetic pathways that are activated in the development of colon cancer,
there are also known genetic mutations that can be inherited and make up approximately10%
of all colorectal cancer cases [11]
Smoking
Tobacco use does not only put persons at risk for higher rates of lung, mouth, and esophageal
cancers, it has also been associated with higher risk for developing colon cancer [11,12]
Diet
There have been a number of different dietary factors that have been linked to a higher risk of
colorectal cancer including higher levels of red meat consumption, low levels of fruit and
vegetable consumption, and diets that are low in fiber.
Obesity
Obesity is an important risk factor to consider based on the recent trends in the U.S. A number
of studies have shown that being overweight is associated with increased risk of colorectal
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cancer. A case-control study conducted by Caan et al [13] found that men who had a BMI in
the highest quintile were almost 2 times as likely to develop colon cancer as men with a BMI
in the lowest quintile.
1.4. Classification and grade of CRC
Staging describes the extent or spread of the disease at the time of diagnosis. It is essential in
determining the choice of therapy and in assessing prognosis. Stage is based on the primary
tumour’s size and location and whether it has spread to other areas of the body. A number of
different staging systems are used to classify tumours. For CRC patients´ pathologic stage
represents one of the most important prognostic factors. The Dukes´ system was the classic
staging method for CRC, however the tumour, node, metastasis (TNM) staging system is more
detailed and is most commonly used today. On occasion, Roman numerals I through IV are
used in CRC staging (Table 2). These numerals correspond with Dukes´ classes.TNM staging
system is useful for descriptive and statistical analysis of tumour registry data. If cancer cells
are present only in the layer of cells where they originated and have not penetrated the
basement membrane of the tissue, the stage is in situ; otherwise it is invasive. Stage is catego‐
rized as local if cancer cells are confined to the organ of origin, regional if the cells have spread
beyond their original (primary) site to nearby lymph nodes or tissues, and distant if they have
spread from the primary site to distant organs or distant lymph nodes.
AJCC stage TNM stage TNM stage criteria for colorectal cancer
Stage 0 Tis N0 M0 Tis: Tumour confined to mucosa; cancer-in-situ
Stage I T1 N0 M0 T1: Tumour invades submucosa
Stage I T2 N0 M0 T2: Tumour invades muscularispropria
Stage II-A T3 N0 M0
T3: Tumour invades subserosa or beyond (without other
organs involved)
Stage II-B T4 N0 M0
T4: Tumour invades adjacent organs or perforates the
visceral peritoneum
Stage III-A T1-2 N1 M0 N1: Metastasis to 1 to 3 regional lymph nodes. T1 or T2.
Stage III-B T3-4 N1 M0 N1: Metastasis to 1 to 3 regional lymph nodes. T3 or T4.
Stage III-C any T, N2 M0 N2: Metastasis to 4 or more regional lymph nodes. Any T.
Stage IV any T, any N, M1 M1: Distant metastases present. Any T, any N.
Table 2. TNM staging for colorectal cancer
1.5. Genetics of CRC
Fifteen years ago, Fearon and Vogelstein [14] proposed a genetic model to explain the stepwise
formation of CRC from normal colonic tissues. This model states that 1) CRC is the result of
changes (mutations) of genes with important functions in regulating cell proliferation or repair
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of DNA damages, 2) mutations in more than one gene are required, and 3) the sequence of
mutations is important in determining the eventual formation of CRC. The model is illustrated
in (Figure 1), which also incorporated information from more recent studies.
The genes involved in the genetic paradigm leading to CRC can be broadly divided into two
classes: tumour suppressor genes (TSGs) and oncogenes. TSGs encode proteins that either
inhibit cell proliferation or promote apoptosis.
Figure 1. Correlation between CRC Progression and the accumulation of genetic alterations according to Fearon &
Vogelstein (1990). The genetic alterations frequently found in CIN tumours are depicted in black; genetic alterations
more common in MIN tumours are depicted in red.
TSGs are often inactivated in CRC. In contrast, oncogenes are activated versions of proto-
oncogenes, which are often involved promoting cell proliferation or development. Once
activated, oncogenes can lead to accelerated cell growth and contribute to tumour formation
[15]. It is widely accepted that the molecular genetics of human cancers can be used to
categorize colorectal carcinomas into two major types of genomic instabilities, chromosomal
instability (CIN) and microsatellite instability (MSI) [16].The majority of colorectal carcinomas
are categorized into the CIN pathway, which is characterized by a high frequency of allelic
losses, deletions, and/or mutations of tumour suppressor genes such as APC and p53, and
abnormal tumour DNA (Figure 2) [16]. Aneuploidy in CIN phenotype tumours had been
demonstrated in colorectal cancer cell lines and tumour tissues. Although CIN is a common
finding in colorectal carcinomas, the mechanism of CIN has not been clearly elucidated.
Defects in DNA replication check point genes and many other genes increase the rate of
genome rearrangement and it is suggested to be associated with CIN [17].
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The other pathway, namely the MSI pathway, begins with the inactivation of one of a group
of genes responsible for DNA nucleotide mismatch repair, which leads to extensive mutations
in both repetitive and non-repetitive DNA sequences with low frequencies of allelic losses and
rare alterations of tumour DNA content [18]. The mechanism of tumorigenesis in high-
microsatellite instability (MSI-H) tumours is thought to involve frame shift mutations of
microsatellite repeats within coding regions of the affected target genes, and the inactivation
of these target genes is believed to directly contribute to tumour development and progression.
Although these two distinct major genetic pathways of genetic instabilities are widely
accepted, some tumours reveal different genetic pathways i.e., some tumours show both types
of genomic instabilities and some tumours do not show any of these two instabilities. Further
evidence for alternative pathways come from studies which show that mutations in APC,
KRAS as well as p53 do not occur in all tumours and some tumours may only contain a mutation
in one of these genes. Another novel pathway has been described termed the CpG island
methylator phenotype (CIMP) [17]. Two groups of tumours were identified. CIMP-positive
tumours show a high degree of CpG island methylation in genes such as p16 and hMLH1 and
are accompanied by mutations in KRAS and TGF RII. CIMP-negative tumours, which by
definition do not contain a high degree of methylation, are characterized by p53 mutations.
CIMP-positive tumours may show a degree of correlation with the MSI pathway. Finally,
colorectal cancers, arising from ulcerative colitis, do not develop from adenomas suggesting
that they follow yet another different pathway 9 (Figure 2) [19]
Figure 2. Characteristics of the two major pathways in CRC.
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Axin1 (also simply called Axin), which encodes isoformaand b, and Axin2 (also called Axil or
Conductin) have 45%identity at the nucleotide level and the proteins they encode appear to
be functionally similar. However, whereas Axin1 is expressed ubiquitously during mouse
embryogenesis, Axin2 is expressed in a restricted pattern [20]. Axin1 is the constitutively
expressed component of the degradation complex and is essential for the maintenance of low
Wnt signalling activity in the basal state. In contrast, Axin2 is upregulated in response to
increased β-catenin concentrations and thus serves to limit the duration and intensity of the
Wnt signal [21]. Axin is downregulated in a Wnt dependent manner and is dephosphorylated
after Wnt stimulation, which leads to Axin1 destabilisation over time. Cells that receive Wnt
ligand signals have low concentrations of Axin. Biochemical studies show that the intracellular
concentrations of Axin are approximately 1000 times lower than other destruction complex
components, suggesting that Axin is the limiting factor in this pathway [22]
1.6.1. Role of Axin in signaling pathways
Axin has emerged as a major scaffold protein for regulating a variety of signaling pathways
and biological functions (Figure 3). In Wnt signalling, Axin binds to many components in the
pathway, including the Wnt co-receptor LRP (low-density lipoprotein-related protein recep‐
tor) [23] Dishevelled or Dvl [24], tumour suppressor adenomatous polyposis coli (APC),
GSK-3β, β-catenin [25], Casein kinases [26], protein phosphatase 2A (PP2A) [27], Diversin [28]
Ccd1 [29], and Axam [30].Interestingly, Axin itself is regulated with its stability being modu‐
lated by Wnt receptors, Dvl [31], and phosphorylation by GSK-3β. Inaddition, Axin also
interacts with proteins that have no close relevance to Wnt signalling, including MAP kinase
kinase (MEKK) [32, 33], I-MFA [34], DCAP [35], SH2/3 adaptor protein Grb4 [36], and Smad3.
Interaction of Axin with MEKK leads to JNK activation, proceeding through a cascade from
Axin, MEKK, and MKK to JNK[37].The most intriguing aspect of JNK activation by Axin is
that multiple seemingly concrete structural elements of Axin are required [38]. Axin interacts
with Smad3 and affects TGF-β signalling pathway.
1.6.2. Mutation of Axin in colorectal cancers
Alterations in both Axin1 and Axin2 have been detected in several different tumours. Muta‐
tions are found in most Axin domains including the APC (RGS) and β-catenin-binding
domains. Axin sequence variants have also been found in colon, ovarian, endometrioid,
adenocarcinoma, and HCC cell lines. Biochemical and functional studies have shown that these
mutations interfere with the binding of GSK3 and that they also alter the interaction between
Axin and two upstream activators of TCF-dependent transcription, Frat1, and DVL. Many
components of the Wnt signalling system are mutated in colorectal cancer. Germ line loss of
function mutations in the APC gene are associated with an inherited form of colorectal cancer
—familial adenomatous polyposis— with 90–95% penetrance. Somatic APC mutations are also
found in most sporadic colorectal cancers [39]. Alterations in other components of Wnt
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signalling, including β-catenin, TCF, Axin1, and Axin2, found in colorectal cancer indicate the
important role that this pathway plays in the etiology of this disease [40]. Most Axin1 mutations
in colorectal cancer occur between exon 1 and 5, where the APC, GSK3, and β-catenin-binding
domains are located. Mutations in Axin2 have been found in approximately 20% of mismatch
repair deficient colorectal tumours [41]. In most cases, one base deletion or insertion occurs in
the mononucleotide repeat sequences located in exon 7, leading to a frame shift and premature
protein truncation [42]. These mutations lead to elimination of the DIX domain, where DVL
binds and negatively regulates Axin activity. This domain is also essential for homo-oligome‐
rization of Axin. The mutant form of Axin2 appears to be more stable than the wild-type
Figure 3. Regulation of three signalling pathways by Axin (1) Axin in the absence of Wnt ligand stimulates β-catenin
degradation by proteosome complex and halts its transcriptional activity (2) The presence of transforming growth fac‐
tor receptor signals Axin and stimulates Smad phosphorylation by TGF-β receptor I & II. The activated Smads then
translocate into nucleus and stimulates transcription of downstream target gene. (3) Cells subjected to stress Axin
bind to mitogenactivated protein and stimulate stress-activated protein kinase (SAPK/Jun) mediated apoptosis. (cour‐
tesy. S Salahshor et al. 2004)




Axin1 (also simply called Axin), which encodes isoformaand b, and Axin2 (also called Axil or
Conductin) have 45%identity at the nucleotide level and the proteins they encode appear to
be functionally similar. However, whereas Axin1 is expressed ubiquitously during mouse
embryogenesis, Axin2 is expressed in a restricted pattern [20]. Axin1 is the constitutively
expressed component of the degradation complex and is essential for the maintenance of low
Wnt signalling activity in the basal state. In contrast, Axin2 is upregulated in response to
increased β-catenin concentrations and thus serves to limit the duration and intensity of the
Wnt signal [21]. Axin is downregulated in a Wnt dependent manner and is dephosphorylated
after Wnt stimulation, which leads to Axin1 destabilisation over time. Cells that receive Wnt
ligand signals have low concentrations of Axin. Biochemical studies show that the intracellular
concentrations of Axin are approximately 1000 times lower than other destruction complex
components, suggesting that Axin is the limiting factor in this pathway [22]
1.6.1. Role of Axin in signaling pathways
Axin has emerged as a major scaffold protein for regulating a variety of signaling pathways
and biological functions (Figure 3). In Wnt signalling, Axin binds to many components in the
pathway, including the Wnt co-receptor LRP (low-density lipoprotein-related protein recep‐
tor) [23] Dishevelled or Dvl [24], tumour suppressor adenomatous polyposis coli (APC),
GSK-3β, β-catenin [25], Casein kinases [26], protein phosphatase 2A (PP2A) [27], Diversin [28]
Ccd1 [29], and Axam [30].Interestingly, Axin itself is regulated with its stability being modu‐
lated by Wnt receptors, Dvl [31], and phosphorylation by GSK-3β. Inaddition, Axin also
interacts with proteins that have no close relevance to Wnt signalling, including MAP kinase
kinase (MEKK) [32, 33], I-MFA [34], DCAP [35], SH2/3 adaptor protein Grb4 [36], and Smad3.
Interaction of Axin with MEKK leads to JNK activation, proceeding through a cascade from
Axin, MEKK, and MKK to JNK[37].The most intriguing aspect of JNK activation by Axin is
that multiple seemingly concrete structural elements of Axin are required [38]. Axin interacts
with Smad3 and affects TGF-β signalling pathway.
1.6.2. Mutation of Axin in colorectal cancers
Alterations in both Axin1 and Axin2 have been detected in several different tumours. Muta‐
tions are found in most Axin domains including the APC (RGS) and β-catenin-binding
domains. Axin sequence variants have also been found in colon, ovarian, endometrioid,
adenocarcinoma, and HCC cell lines. Biochemical and functional studies have shown that these
mutations interfere with the binding of GSK3 and that they also alter the interaction between
Axin and two upstream activators of TCF-dependent transcription, Frat1, and DVL. Many
components of the Wnt signalling system are mutated in colorectal cancer. Germ line loss of
function mutations in the APC gene are associated with an inherited form of colorectal cancer
—familial adenomatous polyposis— with 90–95% penetrance. Somatic APC mutations are also
found in most sporadic colorectal cancers [39]. Alterations in other components of Wnt
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signalling, including β-catenin, TCF, Axin1, and Axin2, found in colorectal cancer indicate the
important role that this pathway plays in the etiology of this disease [40]. Most Axin1 mutations
in colorectal cancer occur between exon 1 and 5, where the APC, GSK3, and β-catenin-binding
domains are located. Mutations in Axin2 have been found in approximately 20% of mismatch
repair deficient colorectal tumours [41]. In most cases, one base deletion or insertion occurs in
the mononucleotide repeat sequences located in exon 7, leading to a frame shift and premature
protein truncation [42]. These mutations lead to elimination of the DIX domain, where DVL
binds and negatively regulates Axin activity. This domain is also essential for homo-oligome‐
rization of Axin. The mutant form of Axin2 appears to be more stable than the wild-type
Figure 3. Regulation of three signalling pathways by Axin (1) Axin in the absence of Wnt ligand stimulates β-catenin
degradation by proteosome complex and halts its transcriptional activity (2) The presence of transforming growth fac‐
tor receptor signals Axin and stimulates Smad phosphorylation by TGF-β receptor I & II. The activated Smads then
translocate into nucleus and stimulates transcription of downstream target gene. (3) Cells subjected to stress Axin
bind to mitogenactivated protein and stimulate stress-activated protein kinase (SAPK/Jun) mediated apoptosis. (cour‐
tesy. S Salahshor et al. 2004)
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protein. Transfection of normal fibroblasts with Axin2 mutants led to the accumulation of β-
catenin in the nuclei. Li-Hua Jin et al.2003analysed 54 colorectal tumour tissues for Axin1
mutation and reported 11% missense mutation suggesting Axin mutation may contribute to
the onset of colorectal tumourigenesis. Webster et al [43] screened Axin gene in a range of
human tumour cell lines including colon cancer cell lines. They identified two sequence
variants carrying a substitution in four colon cancer cell lines. Biochemical and functional
studies carried out by them showed that the L 396M change interfered with Axin’sability to
bind GSK-3. Interestingly, this mutation and a neighboring L392M change differentially
altered Axin’sability to interfere with two upstream activators of TCF dependent transcription
factor Frat-1 and Dishevelled. Suraweera et al [44] reported heterozygous frame shift mutation
and an in frame deletion in exon 7 of Axin2. They also reported 8% mutation of Axin in colon
cancer cell lines. These studies indicates role of Axin gene in colorectal carcinogenesis.
1.7. Deleted in colorectal cancers (DCC) gene
The development of human cancer has been proposed to be a multistep process [45]. Vogelstein
et al., 1988 showed that colonic tumorigenesis provides the systematic course to the multistep
hypothesis at the molecular level. Several genes have been identified that alter during tumour
progression. Frequent and consistent loss of heterozygosity (LOH) of specific chromosomes
in human cancers has been associated with the presence of tumour suppressor genes [46]. In
particular, the long arm of chromosome 18 has been shown to be lost in about 75% of colonic
cancers [47].The tumour-suppressor gene DCC (deleted in colorectal carcinoma),located on
the long arm of chromosome 18 (Figure 2) encodes a cell surface protein containing homology
with N-CAM [14].DCC a putative tumour suppressor gene has been mapped on the long arm
of 18th chromosome (18q). In normal conditions, DCC induced apoptosis limits cellular
lifespan in the intestinal crypt and thereby inhibits the initiation of malignant transformation.
Transfection of DCC cDNA into a human cell line lacking DCC expression suppresses tumour
growth and results in apoptosis and cell cycle arrest [48].
1.7.1. Loss of heterozygosity of DCC gene
Human cancers arise by a combination of discrete mutations and chromosomal alterations.
Loss of heterozygosity (LOH) of chromosomal regions bearing mutated tumour suppressor
genes is a key event in the evolution of epithelial and mesenchymal tumours. The term Loss
of heterozygosityv (LOH), refers to a technique widely used in cancer research.LOH relies
upon an individual processing two non-identical alleles for specific genetic marker, which can
be distinguished from each other. These individuals are referred to as heterozygote with
respect to this allele. Distinguishing between alleles can be done by the presence of a restriction
site on one allele or through polymorphic microsatellite repeats (also referred to as microsa‐
tellite markers).In the latter the alleles differ from one another based on their size. Using LOH,
a comparison is made between the DNA extracted from normal and tumour tissue. If an allele
is present in the normal DNA but missing in the tumour than we can suggest that this region
of DNA has been lost or deleted through mutation. Therefore the tumour cells have lost an
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allele as only one is detected, hence loss of heterozygosity. Most commonly the deletion of
DNA will not be isolated to just this marker but will more than likely also involve the loss of
gene surrounding that region. This is important if the surrounding region contains one or more
tumour suppressor genes. In fact LOH studies are often used to examine neoplasms to locate
frequent chromosomal regions that are lost and hence may harbor putative tumour suppressor
genes pivotal in the development of cancer. The greater the degree of LOH, the more geneti‐
cally unstable the tumour type and more aggressive it is likely to be.
Global patterns of LOH can be understood through allele typing of tumours with polymorphic
genetic markers. Simple sequence length polymorphisms (SSLPs or microsatellites) are reliable
genetic markers for studying LOH. Microsatellites are short repetitive sequences of DNA that
are scattered throughout the genome and are stably inherited, unique to each individual and
have low inherent mutation rate [49]. Several studies have shown that alterations due to
mutations in the simple repeat sequences or microsatellites are a feature in a number of cancers
[50].Researchers working on colon cancers found the length of microsatellite DNA in tumour
tissue vary from matching normal tissue. This variation in length of microsatellite represents
a mutational process of insertion or deletion within tumour DNA [51].Loss of heterozygosity
(LOH) i.e., loss of one allele at a constitutional heterozygous locus indicates the probability of
loss of a tumour suppressor gene, which might promote neoplastic progression [52].
2. Aim and objectives
India is heavily burdened with CRC. Most of the genes implicated in CRC (like APC, KRAS,
SMAD etc) have been studied in CRC patients of this population. Results therein have depicted
either some semblance or little discrepancies in CRC in comparison to other studies conducted
in other ethnic groups. The important genes like Axin 1, Axin 2 and DCC have been reported
to be involved in etio-pathology of CRC, but their role is yet to be elucidated in CRC patients
of North India. Keeping in view of this, we carried out this study with following objectives
• To analyse the mutations, if any, in the coding exons (1a,1b,1c,2,4,6 and 10) of Axin1 gene
• To analyse the mutations, if any, in exon 7 of Axin2 gene.
• To establish the correlation of Axin1 and Axin2 gene mutation with clinicopathological
variables of CRC patients
• To analyse expression of Axin in CRC patients using western blotting technique andto
correlate the altered expression of Axin with clinico -pathological characteristics of CRC
patients.
• To analyse Loss of Heterozygosity of DCC gene at VNTR and D18S8-M2 markers in CRC
patients and to correlate LOH of DCC gene with clinicopathological variables.
• Polymorphic studies of SNPs at codon 399 of XRCC1 genes.
The main goals of this work are based on the hypothesis to understand
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protein. Transfection of normal fibroblasts with Axin2 mutants led to the accumulation of β-
catenin in the nuclei. Li-Hua Jin et al.2003analysed 54 colorectal tumour tissues for Axin1
mutation and reported 11% missense mutation suggesting Axin mutation may contribute to
the onset of colorectal tumourigenesis. Webster et al [43] screened Axin gene in a range of
human tumour cell lines including colon cancer cell lines. They identified two sequence
variants carrying a substitution in four colon cancer cell lines. Biochemical and functional
studies carried out by them showed that the L 396M change interfered with Axin’sability to
bind GSK-3. Interestingly, this mutation and a neighboring L392M change differentially
altered Axin’sability to interfere with two upstream activators of TCF dependent transcription
factor Frat-1 and Dishevelled. Suraweera et al [44] reported heterozygous frame shift mutation
and an in frame deletion in exon 7 of Axin2. They also reported 8% mutation of Axin in colon
cancer cell lines. These studies indicates role of Axin gene in colorectal carcinogenesis.
1.7. Deleted in colorectal cancers (DCC) gene
The development of human cancer has been proposed to be a multistep process [45]. Vogelstein
et al., 1988 showed that colonic tumorigenesis provides the systematic course to the multistep
hypothesis at the molecular level. Several genes have been identified that alter during tumour
progression. Frequent and consistent loss of heterozygosity (LOH) of specific chromosomes
in human cancers has been associated with the presence of tumour suppressor genes [46]. In
particular, the long arm of chromosome 18 has been shown to be lost in about 75% of colonic
cancers [47].The tumour-suppressor gene DCC (deleted in colorectal carcinoma),located on
the long arm of chromosome 18 (Figure 2) encodes a cell surface protein containing homology
with N-CAM [14].DCC a putative tumour suppressor gene has been mapped on the long arm
of 18th chromosome (18q). In normal conditions, DCC induced apoptosis limits cellular
lifespan in the intestinal crypt and thereby inhibits the initiation of malignant transformation.
Transfection of DCC cDNA into a human cell line lacking DCC expression suppresses tumour
growth and results in apoptosis and cell cycle arrest [48].
1.7.1. Loss of heterozygosity of DCC gene
Human cancers arise by a combination of discrete mutations and chromosomal alterations.
Loss of heterozygosity (LOH) of chromosomal regions bearing mutated tumour suppressor
genes is a key event in the evolution of epithelial and mesenchymal tumours. The term Loss
of heterozygosityv (LOH), refers to a technique widely used in cancer research.LOH relies
upon an individual processing two non-identical alleles for specific genetic marker, which can
be distinguished from each other. These individuals are referred to as heterozygote with
respect to this allele. Distinguishing between alleles can be done by the presence of a restriction
site on one allele or through polymorphic microsatellite repeats (also referred to as microsa‐
tellite markers).In the latter the alleles differ from one another based on their size. Using LOH,
a comparison is made between the DNA extracted from normal and tumour tissue. If an allele
is present in the normal DNA but missing in the tumour than we can suggest that this region
of DNA has been lost or deleted through mutation. Therefore the tumour cells have lost an
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allele as only one is detected, hence loss of heterozygosity. Most commonly the deletion of
DNA will not be isolated to just this marker but will more than likely also involve the loss of
gene surrounding that region. This is important if the surrounding region contains one or more
tumour suppressor genes. In fact LOH studies are often used to examine neoplasms to locate
frequent chromosomal regions that are lost and hence may harbor putative tumour suppressor
genes pivotal in the development of cancer. The greater the degree of LOH, the more geneti‐
cally unstable the tumour type and more aggressive it is likely to be.
Global patterns of LOH can be understood through allele typing of tumours with polymorphic
genetic markers. Simple sequence length polymorphisms (SSLPs or microsatellites) are reliable
genetic markers for studying LOH. Microsatellites are short repetitive sequences of DNA that
are scattered throughout the genome and are stably inherited, unique to each individual and
have low inherent mutation rate [49]. Several studies have shown that alterations due to
mutations in the simple repeat sequences or microsatellites are a feature in a number of cancers
[50].Researchers working on colon cancers found the length of microsatellite DNA in tumour
tissue vary from matching normal tissue. This variation in length of microsatellite represents
a mutational process of insertion or deletion within tumour DNA [51].Loss of heterozygosity
(LOH) i.e., loss of one allele at a constitutional heterozygous locus indicates the probability of
loss of a tumour suppressor gene, which might promote neoplastic progression [52].
2. Aim and objectives
India is heavily burdened with CRC. Most of the genes implicated in CRC (like APC, KRAS,
SMAD etc) have been studied in CRC patients of this population. Results therein have depicted
either some semblance or little discrepancies in CRC in comparison to other studies conducted
in other ethnic groups. The important genes like Axin 1, Axin 2 and DCC have been reported
to be involved in etio-pathology of CRC, but their role is yet to be elucidated in CRC patients
of North India. Keeping in view of this, we carried out this study with following objectives
• To analyse the mutations, if any, in the coding exons (1a,1b,1c,2,4,6 and 10) of Axin1 gene
• To analyse the mutations, if any, in exon 7 of Axin2 gene.
• To establish the correlation of Axin1 and Axin2 gene mutation with clinicopathological
variables of CRC patients
• To analyse expression of Axin in CRC patients using western blotting technique andto
correlate the altered expression of Axin with clinico -pathological characteristics of CRC
patients.
• To analyse Loss of Heterozygosity of DCC gene at VNTR and D18S8-M2 markers in CRC
patients and to correlate LOH of DCC gene with clinicopathological variables.
• Polymorphic studies of SNPs at codon 399 of XRCC1 genes.
The main goals of this work are based on the hypothesis to understand
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• What is the role of Axin 1 and Axin 2 gene aberrations in CRC?
• To understand the pattern of Axin expression in CRC tumours with respect to normal
samples?
• What is the role of DCC gene aberrations in CRC?
• What is the role of Arg399Gln SNP of XRCC1 gene in CRC?
3. Methodology and results
3.1. Mutational analysis of Axin 1 and Axin 2 gene
Characteristics of the study subjects
A total of fifty (n=50) tissue samples of colorectal carcinoma and their adjacent normal samples
were used for mutational analysis of Axin1 and Axin2 gene. Same samples were used for
analysis of Axin protein expression. Tumour and adjacent normal tissue samples were
collected in the General Surgery Department (SKIMS) after surgical resection. All the resected
tissue specimens were histologically confirmed to be colorectal carcinomas by a panel of 2
expert pathologists. Median age at the time of diagnosis was 52 years (range 30-75); and male:
female ratio was 1:1. Clinico-pathological characteristics of patients are given in table 3.On the
basis of age, the patients were grouped into two categories, less than 50 years (<50) and greater
than or equal to 50 years of age (≥50). The number of cases in the age group of ≥50 were 62 %
(31/50) and less than <50 years were 38 % (19/50).In this study 29(58%) patients had cancer in
the colon while as cancer of rectum accounted for 21(42%) of CRC cases. 33(61%) cases of CRC
were well differentiated and 17(34%) were poorly/moderately differentiated. 31(62%) of CRC
patients belonged to rural area and 19 (38%) to urban area. Based on the smoking status,
21(42%) patients were non-smokers and 29 (58%) were smokers. Almost all the patients with
left colon carcinoma had attended the hospital with a clinical presentation of bleeding per
rectum.
3.2. Molecular analysis of Axin 1 and Axin 2 gene
High molecular weight genomic DNA isolated from the samples (tumour tissues and corre‐
sponding normal tissues) (Figure 4) were subjected to PCR to amplify the exon 1a, 1b, 1c, 2, 4,
6 and 10 of Axin1 and exon 7 of Axin2.The representative gel pictures of each amplified exon
of Axin1 and Axin2 genes are given in figure 5. PCR products were purified manually and then
purified samples were subjected to DNA sequence analysis. To identify the sequence varia‐
tions, the electrophoregram obtained after sequencing of the PCR products were compared
manually with the reference sequence of the Axin1 and Axin2 gene deposited in the NCBI Gene
Bank database (Accession No.NC 000016 & NC 000017).

























WD: well differentiated; MD: moderately differentiated, PD: poorly differentiated
Table 3. Clinico-epidemiological characteristics of the CRC patients
Lane M: 100bp DNA ladder; Lane 1: DNA derived from blood of CRC patients; Lane 2: DNA derived from blood of a
normal healthy control; Lane 3 and 4: DNA derived from Tumour Tissue; Lane 5, 6 and 7: DNA derived from adjacent
Normal Tissue
Figure 4. Agarose gel electrophoresis of DNA isolated from blood, tumour tissue, and adjacent normal tissue of CRC
patients.
Possible Role of Proto-Oncogenes in Colorectal Cancer — A Population Based Study
http://dx.doi.org/10.5772/57380
343
• What is the role of Axin 1 and Axin 2 gene aberrations in CRC?
• To understand the pattern of Axin expression in CRC tumours with respect to normal
samples?
• What is the role of DCC gene aberrations in CRC?
• What is the role of Arg399Gln SNP of XRCC1 gene in CRC?
3. Methodology and results
3.1. Mutational analysis of Axin 1 and Axin 2 gene
Characteristics of the study subjects
A total of fifty (n=50) tissue samples of colorectal carcinoma and their adjacent normal samples
were used for mutational analysis of Axin1 and Axin2 gene. Same samples were used for
analysis of Axin protein expression. Tumour and adjacent normal tissue samples were
collected in the General Surgery Department (SKIMS) after surgical resection. All the resected
tissue specimens were histologically confirmed to be colorectal carcinomas by a panel of 2
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(31/50) and less than <50 years were 38 % (19/50).In this study 29(58%) patients had cancer in
the colon while as cancer of rectum accounted for 21(42%) of CRC cases. 33(61%) cases of CRC
were well differentiated and 17(34%) were poorly/moderately differentiated. 31(62%) of CRC
patients belonged to rural area and 19 (38%) to urban area. Based on the smoking status,
21(42%) patients were non-smokers and 29 (58%) were smokers. Almost all the patients with
left colon carcinoma had attended the hospital with a clinical presentation of bleeding per
rectum.
3.2. Molecular analysis of Axin 1 and Axin 2 gene
High molecular weight genomic DNA isolated from the samples (tumour tissues and corre‐
sponding normal tissues) (Figure 4) were subjected to PCR to amplify the exon 1a, 1b, 1c, 2, 4,
6 and 10 of Axin1 and exon 7 of Axin2.The representative gel pictures of each amplified exon
of Axin1 and Axin2 genes are given in figure 5. PCR products were purified manually and then
purified samples were subjected to DNA sequence analysis. To identify the sequence varia‐
tions, the electrophoregram obtained after sequencing of the PCR products were compared
manually with the reference sequence of the Axin1 and Axin2 gene deposited in the NCBI Gene
Bank database (Accession No.NC 000016 & NC 000017).

























WD: well differentiated; MD: moderately differentiated, PD: poorly differentiated
Table 3. Clinico-epidemiological characteristics of the CRC patients
Lane M: 100bp DNA ladder; Lane 1: DNA derived from blood of CRC patients; Lane 2: DNA derived from blood of a
normal healthy control; Lane 3 and 4: DNA derived from Tumour Tissue; Lane 5, 6 and 7: DNA derived from adjacent
Normal Tissue
Figure 4. Agarose gel electrophoresis of DNA isolated from blood, tumour tissue, and adjacent normal tissue of CRC
patients.
Possible Role of Proto-Oncogenes in Colorectal Cancer — A Population Based Study
http://dx.doi.org/10.5772/57380
343
                M          1         2         3         4          5          6             M          1         2         3          4          5                                   
           
                  A: Axin 1; Exon 1a (311bp)                                       B: Axin 1; Exon 1b (387 bp) 
                  M          1         2         3         4          5         6          M      1        2       3       4        5        6      7                            
            
                               C: Axin 1; Exon 1c (405bp)                                        D: Axin 1; Exon 2 ( 224bp) 
                  M        1         2         3         4         5         6            M        1         2         3        4         5         6        
            
                             E: Axin1; Exon 4 (253 bp)                                             F: Axin1; Exon 6 (256 bp)
                          M       1         2        3       4        5        6           M       1        2         3        4         5         6      
               
                             G: Axin 1;Exon 10 (260 bp)                                    H: Axin 2; Exon 7  (320bp) 
  Figure 5:   PCR amplification of different exons of Axin1 and Axin2 genes 
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3.3 Mutational spectrum of Axin 1 and Axin 2 gene 
In this study DNA sequencing was used to analyze the exon 1a, 1b, 1c, 2, 4, 6 and 10 of Axin1 and 
exon 7 of Axin2 in a series of 50 CRC patients. No previously reported mutations were detected in any of the 
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3.3. Mutational spectrum of Axin 1 and Axin 2 gene
In this study DNA sequencing was used to analyze the exon 1a, 1b, 1c, 2, 4, 6 and 10 of Axin1
and exon 7 of Axin2 in a series of 50 CRC patients. No previously reported mutations were
detected in any of the analysed exons of Axin1 and Axin2 genes in CRC patients except two
SNPs mentioned below. However, an interesting finding of this study was that we detected a
novel mutation of G>T (GCT>TCT) transversion in exon 7 of Axin2 gene at codon G695T
(p.alanine>serine) which has not been reported before this study [53] This G695T novel
mutation was further confirmed by reverse sequence of the same samples. This novel mutation
was found at a frequency of 6% (3/50). Among these three patients two were chronic smokers
with mean age of fifty seven years. All the three patients had well differentiated adenocarci‐
noma. Clinico-pathological characteristics of patients having novel mutation are given in Table
4. In the same exon of Axin2 gene a single nucleotide polymorphism (SNP) (rs 35415678) of
C>T transition was detected in codon L688L (CCT>CTT) at a frequency of 18/50(36%). In exon1c
of Axin1 we detected a SNP of T>C transition at codon D726D (GAT>GAC) at a frequency of
31/50 (62.5%) (Table 5.). This SNP is synonymous and does not lead to any change of amino
acid (Figures 6, 7 & 8 ). Table 4.3 shows the changes in nucleotides of Axin1 and Axin2 genes
observed in our study. No significant association of these SNPs was found in this report with
any clinico-epidemiological characteristics (Table 6 & 7).
3.4. Analysis of protein expression of Axin
In the present study, 50 colorectal cancer tissues and their adjacent normal samples previously
studied for mutation spectrum were analysed for the protein expression of the Axin. The
clinicopathological characteristics of the studied subjects are given in Table 3. The represen‐
tative picture of the proteins extracted that were run on SDS page is shown in the figure 9. Out
of 50 cases of CRC, 26% (13/50) showed reduced expression of Axin (Figure 10) and the rest
74% (37/50) of the cases showed normal protein (Axin) expression. Among 13 cases of CRC
with reduced expression,27% (9/33) were of well differentiated grade and 24% (4/17) of
moderately/poorly differentiated grade. Reduced expression of Axin was found to be 25%
(7/28) and 27% (6/22) of cases of stage I/II and III/IV respectively. Reduced expression of Axin
was found to be in 4/21 (19%) of never smokers and 9/29 (31%) of ever smokers. Reduced
expression of Axin in males was observed as 5/24 (21%) and in females as 8/26 (31%). 24%
(7/29) of the CRC cases with colon carcinoma and 29% (6/21) cases of rectal carcinoma showed
reduced expression of Axin. Association of reduced expression of Axin with clinicopatholog‐
ical characteristics is shown in Graph 2. No significant association of reduced expression of
Axin with any of the clinicopathological characteristic was found (p>0.05) (Table 8).
3.5. Loss of heterozygosity (LOH) of DCC gene
Loss of heterozygosity of DCC gene was determined by PCR-LOH assay in eighty samples of
colorectal carcinoma and corresponding adjacent normal tissue. Mean age at the time of
diagnosis was 52 years (range 30-80) with male: female ratio of 1:1.All the tumour samples
included in this study were histopathologically confirmed cases of CRC. Histopathological
findings of the CRC cases revealed 51 of 80 (64%) as well differentiated grade and 29 of 80
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3.3. Mutational spectrum of Axin 1 and Axin 2 gene
In this study DNA sequencing was used to analyze the exon 1a, 1b, 1c, 2, 4, 6 and 10 of Axin1
and exon 7 of Axin2 in a series of 50 CRC patients. No previously reported mutations were
detected in any of the analysed exons of Axin1 and Axin2 genes in CRC patients except two
SNPs mentioned below. However, an interesting finding of this study was that we detected a
novel mutation of G>T (GCT>TCT) transversion in exon 7 of Axin2 gene at codon G695T
(p.alanine>serine) which has not been reported before this study [53] This G695T novel
mutation was further confirmed by reverse sequence of the same samples. This novel mutation
was found at a frequency of 6% (3/50). Among these three patients two were chronic smokers
with mean age of fifty seven years. All the three patients had well differentiated adenocarci‐
noma. Clinico-pathological characteristics of patients having novel mutation are given in Table
4. In the same exon of Axin2 gene a single nucleotide polymorphism (SNP) (rs 35415678) of
C>T transition was detected in codon L688L (CCT>CTT) at a frequency of 18/50(36%). In exon1c
of Axin1 we detected a SNP of T>C transition at codon D726D (GAT>GAC) at a frequency of
31/50 (62.5%) (Table 5.). This SNP is synonymous and does not lead to any change of amino
acid (Figures 6, 7 & 8 ). Table 4.3 shows the changes in nucleotides of Axin1 and Axin2 genes
observed in our study. No significant association of these SNPs was found in this report with
any clinico-epidemiological characteristics (Table 6 & 7).
3.4. Analysis of protein expression of Axin
In the present study, 50 colorectal cancer tissues and their adjacent normal samples previously
studied for mutation spectrum were analysed for the protein expression of the Axin. The
clinicopathological characteristics of the studied subjects are given in Table 3. The represen‐
tative picture of the proteins extracted that were run on SDS page is shown in the figure 9. Out
of 50 cases of CRC, 26% (13/50) showed reduced expression of Axin (Figure 10) and the rest
74% (37/50) of the cases showed normal protein (Axin) expression. Among 13 cases of CRC
with reduced expression,27% (9/33) were of well differentiated grade and 24% (4/17) of
moderately/poorly differentiated grade. Reduced expression of Axin was found to be 25%
(7/28) and 27% (6/22) of cases of stage I/II and III/IV respectively. Reduced expression of Axin
was found to be in 4/21 (19%) of never smokers and 9/29 (31%) of ever smokers. Reduced
expression of Axin in males was observed as 5/24 (21%) and in females as 8/26 (31%). 24%
(7/29) of the CRC cases with colon carcinoma and 29% (6/21) cases of rectal carcinoma showed
reduced expression of Axin. Association of reduced expression of Axin with clinicopatholog‐
ical characteristics is shown in Graph 2. No significant association of reduced expression of
Axin with any of the clinicopathological characteristic was found (p>0.05) (Table 8).
3.5. Loss of heterozygosity (LOH) of DCC gene
Loss of heterozygosity of DCC gene was determined by PCR-LOH assay in eighty samples of
colorectal carcinoma and corresponding adjacent normal tissue. Mean age at the time of
diagnosis was 52 years (range 30-80) with male: female ratio of 1:1.All the tumour samples
included in this study were histopathologically confirmed cases of CRC. Histopathological
findings of the CRC cases revealed 51 of 80 (64%) as well differentiated grade and 29 of 80
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(36%) as moderately/poorly differentiated grade. In order to analyse LOH of DCC gene at two
markers both the markers were amplified the amplified PCR products for D18S8-M2 (396bp)
was digested by MspI restriction enzyme and analyzed on 8% polyacrylamide gel whereas
amplified product of VNTR region was directly run on 8% PAGE (Figure 12) and photograph‐
ed under ultraviolet light.
S. code Age Gender
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Status
Dwelling Location HPG C.change A.Achange
N.
change















Abbrevations: S.code=sample code;S.Status=Smaoking status; C.smoker=chronic smoker;
N.smoker=non-smoker HP G = Histopathological grade;WD=well differentiated; A.A change=Amino acid change;
N.N change =nucleotide change C.Change=codon change; A. Colon= ascending colon.
Table 4. Clinico-epidemiological characteristics of the patients with novel mutation in Axin 2 gene
Gene/Exon Nucleotide change Codon change Amino Acid change Frequency
Axin1
GAT→GAC
Exon 1c 1134 T→C Asp→ Asp 31/50(62.5%)
Axin2
CCT→CTT
Exon 7 2376 C→T Leu→ Leu 18/50(36%)
(Transcript ID of Axin1 gene ENSG00000103126, NCBI Reference Sequence NC_000016.9) (Transcript ID of Axin2 gene
ENSG00000168646, NCBI Reference Sequence: NC_000017.10)
Table 5. Single nucleotide changes in Axin1 & Axin2 genes in CRC patients.
In this study only informative cases were included (cases in which normal samples were
heterozygous at M2-D18S8 marker), whereas uninformative cases (cases in which normal
sample showed no heterozygosity) (Figure 11) were excluded from the study. Digested
product of D18S8-M2 region yielded products of size 396, 257 and 139bp. LOH was considered
positive for samples with absence of 396 bp bands and presence of 257 and139 bp (Figure 11).
PCR product of VNTR when run directly on 8% PAGE generated a spectrum of alleles ranging
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in size from 150 to 210bp (Figure 12) depending on insertion or deletion. LOH at both D18S8-
M2 and VNTR markers was observed as 39% (20/51) in samples with well differentiated grade
and 86% (25/29) in moderately/poorly differentiated samples. 47 of 80 (59%) cases of CRC were
of stage I-II and 33 of 80 (41%) of stage III-IV. LOH was found 47% (22/47) and 70% (23/33) at
both the markers in stage I-II and III-IV respectively. The overall combined frequency of LOH
at two markers (D18S8-M2 and VNTR) in CRC cases was reported to be 56.25 % (45/80) (Table
10; see Graph 3 also). LOH of DCC was found to be highly frequent in patients with higher
stage/grade of CRC and this association was found to be significant (p<0.05). However no










WD 33(66%) 13(39%) 20(61%) Reference
0.77
MD/PD 17(34%) 06(35%) 11(65%) 1.2(0.3-4.7)
Age Group
<50 19(38%) 08(42%) 11(58%) Reference
0.63
≥50 31(62%) 11(35%) 20(65%) 1.3(0.4-4.1)
Gender
Male 24(48%) 10(42%) 14(58%) Reference
0.63
Female 26(52%) 09(35%) 17(65%) 1.3(0.4-4.1)
Smoking
Never 21(42%) 09(43%) 12(57%) Reference
0.62
Ever 29(58%) 10(34%) 19(66%) 1.4(0.4-4.0)
Residence
Rural 31(62%) 12(39%) 19(61%) Reference
0.33
Urban 19 (38%) 10(53%) 09(47%) 0.5(0.09-2.9)
Tumor site
Colon 29(58%) 10(34%) 19(66%) Reference
0.54
Rectum 21 (42%) 09(43%) 12(57%) 0.7(0.2-2.2)
WD=Well Differentiated; MD= Moderately differentiated
Table 6. Single nucleotide changes in Axin1 & Axin2 genes in CRC patients.
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Table 6. Single nucleotide changes in Axin1 & Axin2 genes in CRC patients.










WD 33(66%) 19(58%) 14(42%) Reference
0.19
MD/PD 17(34%) 13(76%) 04(24%) 0.4(0.2-1.5)
AgeGroup
<50 19(38%) 13(68%) 06(32%) Reference
0.10
≥50 31 (62%) 19(61%) 12(39%) 1.3(0.4-4.8)
Gender
Male 24(48%) 16(67%) 08(33%) Reference
0.7
Female 26 (52%) 16(62%) 10(38%) 1.3(0.3-4.2 )
Smoking
Never 21(42%) 13(62%) 08(38%) Reference
0.79
Ever 29(58%) 19(66%) 10(34%) 0.8(0.24-2.6)
Residence
Rural 31(62%) 20(65%) 11(35%) Reference
0.9
Urban 19 (38%) 12(63%) 07(37%) 1(0.3-3.2)
Tumorsite
Colon 29(58%) 18(62%) 11(38%) Reference
0.7
Rectum 21 (42%) 14(67%) 07(33%) 0.8(0.24-3.0)
Table 7. Clinico-epidemiological Characteristics of the CRC Patients with single nucleotide polymorphism at codon
688 CCT>CTT Axin2 gene.
Figure 6. Partial nucleotide sequences in Exon 7 of normal (left) and of the mutants in (right) of the Axin 2 gene co‐
don (GCT>TCT) Partial reverse sequence of the same mutation (below). Arrow points toward base change in mutants
with respect to normal sequence.
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Figure 7. Partial nucleotide sequences in Exon 7 of the normal (left) and mutants in exon 7 of the Axin2 gene codon











37(74%) 13(26%) - -
Age Reference 0.3
<50 19(38%) 15(79%) 4(21%)
1.9(0.57-7)
>50 31(62%) 22(71%) 9(29%)
Sex Reference 0.4
Male 24(48%) 19(79%) 5(21%)
1.68(1.0-2.3)
Female 26(52%) 18(69%) 8(31%)
Dwelling Reference 0.2
Rural 31(62%) 21(68%) 10(32%)
0.39(0.09-1.6)
Urban 19(38%) 16(84%) 03(16%)
Smoking Reference 0.3
Never 21(42%) 17(81%) 4(19%)
1.9(0.57-7.2)
Ever 29(58%) 20(69%) 9(31%)
Grade Reference 0.77
WD 33(66%) 24(73%) 9(27%)
0.8(0.2-3.0)
MD/PD 17(34%) 13(76%) 4(24%)
Stage Reference 0.8
I/II 28(56%) 21(75%) 7(25%)
1.1(0.3-3.8)
III/IV 22(44%) 16(73%) 6(27%)
Location Reference 0.7
Colon 29(58%) 22(76%) 7(24%)
1.25(0.35-4.3)
Rectum 21(42%) 15(71%) 6(29%)
χ2 was used to calculate the p-value of the variables. *P-Value <0.05 was considered statistically significant
Table 8. Association of Clinic pathological characteristics with reduced expression of Axin
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Figure 8. Partial nucleotide sequences in Exon1c of the normal (left) and mutants in exon 1c of the Axin1 gene codon
(GAT →GAC).Arrow points toward base change in mutants with respect to normal sequence.
Figure 9. Representative gel picture of 10% SDS-PAGE. In each case 25 µl of the crude protein extract from tumor as
well as normal tissue was loaded.
Lanes N: Protein extracted from Normal tissues; Lanes T: Protein extracted from Tumour tissue; Membrane was pro‐
bed with a polyclonal antibody specific for Axin
Figure 10. Western blot analysis of Axin protein in colorectal tumour and adjacent normal tissues. Figure A-D Repre‐
sentative immunoblot showing the expression of Axin in Colorectal carcinoma as compared to their adjacent normals.
Extract from samples was separately run for β-actin protein expression as loading control.
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Variables Cases n=80 LOH–ve [%] LOH+ve [%] P-value
Grade(differentiation)
Well differentiated 51(64%) 31(61%) 20 (39%)
0.00019*
Mod/Poorly differentiated 29(36%) 4(14%) 25 (86%)
Clinical staging
Stages I-II 47(59%) 25(53%) 22(47%)
0.044*
Stages III-IV 33(41%) 10(30%) 23(70%)
Location
Colon 42(52.5%) 15 (36%) 27 (64%)
0.12
Rectum 38(47.5%) 20 (53%) 18 (47%)
Dwelling
Rural 46(57.5%) 22 (48%) 24 (52%)
0.393
Urban 34(42.5%) 13 (38%) 21 (62%)
Age
<50 33(41.25%) 14 (42%) 19 (58%)
0.8412
≥50 47(58.75%) 21 (45%) 26 (55%)
Sex
Male 43(53.75%) 21(49%) 22(51%)
0.323
Female 37(46.25%) 14(38%) 23(62%)
χ2 was used to calculate the p-value of the variables. *p-Value<0.05 was considered statistically significant
Table 9. Relation of clinico-pathological variables with LOH of DCC gene




χ2 was used to calculate the P-value of the variables
Table 10. Percentage of Cases with and without Loss of Heterozygosity at two different markers
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Graph 2. Association of reduced expression of Axin with clinic-pathological characteristics
Lane M: 100bp DNA ladder,N=Normal; T=tumour. Normal samples showed three bands (band size 396,257 &139).
LOH+ve Informative cases. LOH -ve samples showed no loss of heterozygosity.
Figure 11. (a): LOH of DCC gene at D18S8-M2 region, (b): Uninformative cases (UI) were excluded from the study.
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Figure 12. LOH of DCC gene at VNTR region. Lane M: 100bp DNA ladder, N: normal DNA, T: tumor DNA. Strong allelic
imbalance is seen in tumor showing range of bands (150-200bp) not in adjacent normal tissues, with dominance of
the larger 200-base pair allele.
Graph 3. Frequency of distribution of LOH at two markers D18S8-M2 & VNTR of DCC gene
4. Summary and conclusion
Colorectal cancer (CRC) is a leading cause of death in the western world. [54]. The frequency
of CRC varies remarkably among different populations. In India, CRC does not figure amongst
the 10 most common malignancies [55]. In Kashmir incidence of cancer is showing an increas‐
ing trend and sites among the top ten common cancers [56]
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Multiple factors contribute to the development of CRC, dietary and life style factors on one
hand and genetic factors on the other [57]. Colon cancer is a common disease in both men and
women. Because 5% of persons (1 in 20 persons) will develop colorectal cancer, this disease is
an important public health issue. Colon cancer is usually observed in one of three specific
patterns: sporadic, inherited or familial. Sporadic disease, with no familial or inherited
predisposition, accounts for approximately 70% of colorectal cancer in the population.
Sporadic colon cancer is common in persons older than 50 years of age, probably as a result of
dietary and environmental factors as well as normal aging. Fewer than 10% of patients have
an inherited predisposition to colon cancer. The inherited syndromes include those in which
colonic polyps are a major manifestation of disease and those in which they are not. The
polyposis syndromes are subdivided into familial adenomatous polyposis and the hamar‐
tomatous polyposis syndromes. The non-polyposis predominant syndromes include heredi‐
tary non-polyposis colorectal cancer (HNPCC) (Lynch syndrome I) and the cancer family
syndrome (Lynch syndrome II). Although uncommon, these syndromes provide insight into
the biology of all types of colorectal cancer. The third and least understood pattern of colon
cancer development is known as familial colon cancer. In affected families, colon cancer
develops too frequently to be considered sporadic colon cancer but not in a pattern consistent
with an inherited syndrome. Up to 25% of all cases of colon cancer may fall into this category.
CRC is more common in North America, parts of Europe, Australia, New Zeeland and Japan
than in eastern Asia and Africa [58] This together with the fact that populations migrating from
a low-incidence to a high-incidence geographical area show a similar incidence as those living
in the high-incidence area, points towards life style and dietary habits being causative [59] The
exact causes are still controversial but epidemiological studies indicate that diets that include
low fruit, vegetable or fiber intake, high red meat or saturated fat consumption increase the
risk of developing CRC. Exposure to caffeine, cigarette smoke and alcohol has also been
suggested to increase risk. Diets high in calcium, folate and regular physical activity are
associated with a reduced risk of developing CRC [60]
According to the model developed by Vogelstein and coworkers, colorectal neoplasia evolves
through a series of genetic alterations that includes the activation of oncogenes by mutation
and the inactivation of tumor suppressor genes by mutation, loss of gene, or methylation [61].
As per their multistage model of colorectal carcinogenesis alteration of genes like Axin, APC,
β-Catenin, Smads, TGF-β, B-Raf are early events whereas alteration of p53,DCC are late events
in the development of CRC. In our population genes like APC, β-catenin and Smads have been
previously studied in relation to the development of colorectal cancer. As per one of the study
carried out on Kashmiri population by Sameer et al., 2010 the mutational aberrations of APC
and β-catenin were reported to be low in CRC cases in Kashmiri populations however,
frequency of the epigenetic silencing of the APC gene was reported to be high. SMAD4 gene
aberrations were reported to be the common event in CRC development [62].
We studied genetic alterations of Axin 1, Axin 2 and DCC genes in CRC patients of Kashmiri
population. Following are the major findings of our study
• In the present study we studied fifty CRC and adjacent normal samples, we found a novel
mutation in exon 7 of Axin2 gene at codon 695.This G>T transversion leads to the change of
codon GCT>TCT.
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• The frequency of this novel mutation was found to be 6 % (3/50).
• This novel mutation leads to the change of amino acid alanine to serine.
• A SNP (rs 35415678) of C>T was found in exon 7 of Axin2 gene at a frequency of 32%
(18/50).This SNP was found at codon L688L resulting in the change of codon CCT>CTT.
However this SNP was synonymous and hence does not lead to the change of amino acid.
• A SNP (rs 1805105) of T>C was found in exon 1c of Axin1 gene at a frequency of 62.5%
(31/50).This SNP was found at codon D726D leading to the change of codon GAT>GAC.
This SNP was also found to be synonymous and hence does not lead to the change of amino
acid
• No other sequence variation in any other analysed exons of Axin gene was found
• We did not find any significant association of any of the clinical epidemiological character‐
istic with the development of CRC.
• Protein expression of Axin gene in fifty tumour specimens with respect to their adjacent
normal samples was studied. The samples which were studied for protein expression were
same studied for mutational analysis.
• 26% (13/50) CRC patients showed reduced expression of Axin.
• No association was found with any of the clinico-pathological characteristic of CRC with
the reduced expression of Axin.
• LOH of DCC gene at D18S8-M2 and VNTR marker was studied in eighty CRC tumour
samples with respect to adjacent normal samples.
• LOH of DCC gene at D18S8M2 marker was found to be 23.75 % (19/80).
• LOH of DCC gene at VNTR marker was found to be 32.50 % (26/80).
• Aggregate percentage of loss of heterozygosity of DCC gene was found to be 55.25%.
• We found a significant association of LOH of DCC gene with higher stage and grade (P<0.05)
• No significant association of any other clinical pathological parameter was found with the
development of CRC.
• Arg/Arg (GG) and Arg/Gln (GA) were found to be significantly associated with higher risk
of CRC.
• The frequency of the XRCC1 allele Gln/Gln was found to be 6(5%) for cases & 34(23.3%) for
controls with P<0.05
• The frequency of the XRCC1 allele Arg/Gln was found to be 80(66.7%) for cases & 62(42.5%)
for controls.
• No significant association of Arg399Gln SNP with any clinico-pathological parameters was
found.
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Multiple factors contribute to the development of CRC, dietary and life style factors on one
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the biology of all types of colorectal cancer. The third and least understood pattern of colon
cancer development is known as familial colon cancer. In affected families, colon cancer
develops too frequently to be considered sporadic colon cancer but not in a pattern consistent
with an inherited syndrome. Up to 25% of all cases of colon cancer may fall into this category.
CRC is more common in North America, parts of Europe, Australia, New Zeeland and Japan
than in eastern Asia and Africa [58] This together with the fact that populations migrating from
a low-incidence to a high-incidence geographical area show a similar incidence as those living
in the high-incidence area, points towards life style and dietary habits being causative [59] The
exact causes are still controversial but epidemiological studies indicate that diets that include
low fruit, vegetable or fiber intake, high red meat or saturated fat consumption increase the
risk of developing CRC. Exposure to caffeine, cigarette smoke and alcohol has also been
suggested to increase risk. Diets high in calcium, folate and regular physical activity are
associated with a reduced risk of developing CRC [60]
According to the model developed by Vogelstein and coworkers, colorectal neoplasia evolves
through a series of genetic alterations that includes the activation of oncogenes by mutation
and the inactivation of tumor suppressor genes by mutation, loss of gene, or methylation [61].
As per their multistage model of colorectal carcinogenesis alteration of genes like Axin, APC,
β-Catenin, Smads, TGF-β, B-Raf are early events whereas alteration of p53,DCC are late events
in the development of CRC. In our population genes like APC, β-catenin and Smads have been
previously studied in relation to the development of colorectal cancer. As per one of the study
carried out on Kashmiri population by Sameer et al., 2010 the mutational aberrations of APC
and β-catenin were reported to be low in CRC cases in Kashmiri populations however,
frequency of the epigenetic silencing of the APC gene was reported to be high. SMAD4 gene
aberrations were reported to be the common event in CRC development [62].
We studied genetic alterations of Axin 1, Axin 2 and DCC genes in CRC patients of Kashmiri
population. Following are the major findings of our study
• In the present study we studied fifty CRC and adjacent normal samples, we found a novel
mutation in exon 7 of Axin2 gene at codon 695.This G>T transversion leads to the change of
codon GCT>TCT.
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• The frequency of this novel mutation was found to be 6 % (3/50).
• This novel mutation leads to the change of amino acid alanine to serine.
• A SNP (rs 35415678) of C>T was found in exon 7 of Axin2 gene at a frequency of 32%
(18/50).This SNP was found at codon L688L resulting in the change of codon CCT>CTT.
However this SNP was synonymous and hence does not lead to the change of amino acid.
• A SNP (rs 1805105) of T>C was found in exon 1c of Axin1 gene at a frequency of 62.5%
(31/50).This SNP was found at codon D726D leading to the change of codon GAT>GAC.
This SNP was also found to be synonymous and hence does not lead to the change of amino
acid
• No other sequence variation in any other analysed exons of Axin gene was found
• We did not find any significant association of any of the clinical epidemiological character‐
istic with the development of CRC.
• Protein expression of Axin gene in fifty tumour specimens with respect to their adjacent
normal samples was studied. The samples which were studied for protein expression were
same studied for mutational analysis.
• 26% (13/50) CRC patients showed reduced expression of Axin.
• No association was found with any of the clinico-pathological characteristic of CRC with
the reduced expression of Axin.
• LOH of DCC gene at D18S8-M2 and VNTR marker was studied in eighty CRC tumour
samples with respect to adjacent normal samples.
• LOH of DCC gene at D18S8M2 marker was found to be 23.75 % (19/80).
• LOH of DCC gene at VNTR marker was found to be 32.50 % (26/80).
• Aggregate percentage of loss of heterozygosity of DCC gene was found to be 55.25%.
• We found a significant association of LOH of DCC gene with higher stage and grade (P<0.05)
• No significant association of any other clinical pathological parameter was found with the
development of CRC.
• Arg/Arg (GG) and Arg/Gln (GA) were found to be significantly associated with higher risk
of CRC.
• The frequency of the XRCC1 allele Gln/Gln was found to be 6(5%) for cases & 34(23.3%) for
controls with P<0.05
• The frequency of the XRCC1 allele Arg/Gln was found to be 80(66.7%) for cases & 62(42.5%)
for controls.
• No significant association of Arg399Gln SNP with any clinico-pathological parameters was
found.
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• We found a protective role of Gln/Gln allele against the risk of development of CRC in
Kashmiri population.
In conclusion, our study demonstrates significant role of Axin in the development of colorectal
cancer. Eventhough we did not find any of the reported mutation in Axin1 gene but we found
reduced expression of Axin1 in majority of CRC cases which clearly suggests its possible role
in the development of CRC. Thus, our study points to the fact those other possible genetic
alterations other than mutation could be responsible for malfunctioning of Axin1 gene which
may be responsible for the development of CRC. In Axin2 gene the novel mutation was found
at low frequency of 6% leading to the change of amino acid from alanine to serine. The codon
at which this novel mutation was found lies in the region capable of binding to various proteins
and thus may somehow render Axin incapable of binding various other proteins involved in
different pathways. This may lead to the derangement of Wnt, TGF-β, and Jun/SAPK path‐
ways. Aberration in specific binding of these signaling molecules to Axin due to the mutation
G695T found in our study perhaps may aid in the deregulation of pathways and hence may
lead to colorectal carcinogenesis.
Our study also supports the multistep model of colorectal carcinogenesis in which alteration
of DCC gene has been reported to be the late event in the development of CRC as observed in
our report. In this study we found that LOH has a frequency of 56% in patients with CRC and
is highly frequent in patients with higher stage/grade in CRC suggesting that LOH of DCC
gene may be one of the genetic events involved in the development of colorectal cancer in
Kashmiri population.
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1. Introduction
The emergence of the field of genomics, proteomics and more recently lipidomics in science
has advanced diagnostic and therapeutic medicine in no small measure. These fields typically
deal with the documentation of the identity, abundance and localization of DNA, RNA, protein
and lipid biomolecules in a given cell, tissue or organism. An in-depth knowledge of the
biologic and physiologic localization, chemistry, and methodology for isolation of these
essential biomolecules is key to a successful analysis and interpretation of information
retrieved in the ‘omics field.
The recent rapid development of these fields can be accounted for by the concurrent develop‐
ment of new state of the art, high throughput technologies such as real time qualitative
polymerase chain reaction (RTqPCR), microarrays, flow cytometry, mass spectrometry and
sequencing. These high throughput technologies have found extensive utility in diverse areas
of human biology, particularly following the completion of the human genome project (HGP)
in 2003. This project, which successfully documented the full complement of genes present
physiologically within the human cell, gave a scientific platform to newer experimental
initiatives thereafter.
Clinical application of ‘Omics based approaches have gained popularity and are believed to
be the future of medicine because of its inherent ability to determine disease-associated
changes in the human genome, transcriptome, proteome, lipidome and metabolome. Docu‐
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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mentation of these changes in principle enables the identification of disease-associated
biomarkers for use in diagnostic tests, as well as with identifying molecular mechanisms of
disease.
Establishment of the HGP was then followed by the initiation of the Cancer Genome Atlas
project to create a repertoire of genomic profiles for 20 different types of cancers. This project
is designed to evaluate, across-the-board, the molecular and genomic depiction of different
cancer types and to delineate the networks and maps for disease pathogenesis; the first results
to be published from this project were for human glioblastomas [1], followed by ovarian
carcinomas. [2]
Most recently, human colon and rectal cancers have been added to the Cancer Genome Atlas
Project [3], the aim being to evaluate somatic modifications in such carcinomas using genome
level methodologies to assess variation in DNA copy number, methylation patterns, micro‐
RNA expression, exon utilization; and acquired mutations: To date, genetic mutations have
been found in 29 genes and amplifications of ERBB2 and IGF2 have also been observed. This
large scale identification of novel genetic changes in human colorectal cancer (CRC) may in
due course enable the identification of underlying molecular mechanisms of cancer develop‐
ment and new therapeutic targets, as well as the development of diagnostic and/or predictive
tests for CRC.
Current knowledge of cancer cell biology shows that the complex carcinogenesis process is
made up of several intricate molecular pathways and that different cancer cells express a
heterogeneous array of signals. Hence individualized administration of beneficial treatment
regimens to patients, rather than a ‘one-size-fits-all’ approach, is becoming more acceptable as
a generic principle to strive towards, not least since it would be similar to the use of specific
antibiotics based on microscopic culture and drug sensitivity testing instead of using a broad
spectrum/empirical antibiotic approach.
According to the GLOBOCAN cancer fact sheet of the International Agency for Research on
Cancer (IARC), over 12 new cancer cases and 7 million cancer deaths are reported worldwide
annually. Colorectal cancer is the third most common cancer in males (663,000 new cases
representing 10.0% of the total cancer cases) and the second most common cancer in females
(571,000 new cases representing 9.4% of the total cancer cases). [4] Roughly 600,000 cases of
colorectal cancer deaths are expected annually, accounting for almost a tenth of all cancer
deaths, making it the fourth leading cause of cancer death worldwide. In trend, mortality rates
are higher in males than in females except in the Caribbean regions.
Over half of the global CRC burden is occurs in developed countries and its incidence is known
to be lowest in third world countries. The lowest incidence is reported in Africa; however in
South Africa the incidence of CRC more closely resembles that of developed countries. Even
though the mortality and incidence figures are poorly reported and cannot be harmonized
reliably, reports from the currently defunct National Cancer Registry of South Africa revealed
that in 1999 CRC was the sixth commonest cancer in the general population, accounting for
about 2,367 cases of the total 26,606 new cancer cases reported. [5]
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Whilst research and health institutions in the developed world are replete with ongoing studies
and discoveries of candidate disease biomarkers, significant attendant challenges are associ‐
ated with ‘omics based studies in a developing world setting, inter alia: infrastructure, human
capacity and funding. Here we provide a synoptic overview of the prospects, challenges and
benefits of ‘omics based approaches in the diagnosis and treatment of CRC in a developing
world, using our Cape Town experience as a case example.
2. Diagnostic inaccuracies in colorectal cancer
The intricacies of CRC are due in part to its multiple implicated aetiologies and the heteroge‐
neity of the tumour. Important aetiologic considerations include; location (right sided or left
sided, surface or cryptic, colonic or rectal), whether sporadic or hereditary, de novo or sequel
to adenomatous polyp; intra-tumour heterogeneity (ITH) also plays an important role in the
accuracy of histopathologic and molecular diagnosis. The classical theory of ‘field cancerisa‐
tion’ [6] presupposes that cancer develops from multifocal areas of precancerous changes; this
concept is supported by latter studies which demonstrated that true cancer boundaries often
exceed the physically discernible margin taken out at surgery, with histological analyses
showing that these multiple abnormal tissues constituting premalignant cancer cell field
changes persist and surround the tumor and may form multiple independent lesions that
sometimes coalesce. The implications of such findings are profound when differentiating the
cancer field recurrence from second primary tumours [6-8]. Subsequently, others have
considered the concept of ‘sequential carcinogenesis’ which suggests that cancers develop as
a progression from patchy premalignant lesions which later show evidence of mild, then
moderate and then severe epithelial dysplasia. [7] These dysplastic lesions eventually progress
to carcinoma-in-situ (high grade intraepithelial neoplasm), then to microinvasive carcinoma
and advanced invasive carcinoma.
The literature is replete with the extensive application of the field concept of Slaughter in
surgical management of head and neck cancers and is gradually becoming a major consider‐
ation in the management of cancer of other organs such as the stomach, skin, cervix, lungs,
vulva, bladder, colon, breast, and ovaries. [9, 10] In addition, molecular investigations have
been used to assess correlation between phenotypic stages of cancer progression and expres‐
sion of cancer specific genes and mutations; these studies have demonstrated significant
correlations between both [7, [11], implying that molecular markers have the potential to
significantly enhance the precise diagnosis, staging and treatment monitoring of cancers.
The possibility of a physically normal tissue adjacent to the tumour area and expressing cancer
specific genetic profiles has spurred interest in the origin of molecular level heterogeneity and
histologic variability in the immediate field surrounding the cancer area. Some researchers
have suggested that the heterogeneity in cancer growth follows a Darwinian evolutionary
theory of natural selection [12], whilst others have concluded that there are two plausible
origins of diversity in tumour cells expansion, described by the ‘clonal evolution’ theory and
the ‘cancer stem cell’ theory. [13-15] The clonal evolution theory (cancer monoclonality)
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presupposes that tumour cells result from a solitary clone of mitotically unstable cell that
differentiate into different offspring lineage clones that have developed additional unique
genetic damage down the lineage. [13] By contrast, the cancer stem cell theory (cancer
polyclonality) is premised on the possibility of cancer developing from multiple cancer stem
cells that proliferate concurrently and drive the expansion of the tumour. Both theories have
therapeutic implications in that only a fraction of the tumour bulk drives its expansion, hence
targeted molecular therapies at these ‘driver cells’ could in principle be established for cancer
treatment.
Phylogenetic evidence suggests that well-characterized subpopulations of tumour cells,
including annotations of genetic mutations, have been derived from sequential genetic events
[16] and mathematical models have been described to account for this, but to date have mostly
provided a one-dimensional insight into the complexities of ITH. [17, 18] The mechanistic
development of cancer is a multi- dimensional event and multiple factors have been estab‐
lished to govern its progression such as: the shape of the organ in which it occurs; blood supply;
surgical interference; the consistency of the surface on which it occurs; tumour microenviron‐
ment; and the genetic nature of the cell. Clearly ITH is a reality that affects tumour diagnosis,
classification, prognosis, and treatment; and requires further understanding.
2.1. Reliability of histopathology reports
Introduction: Histopathology is the science of utilising classical histological techniques to assess
micro- and macroscopic evidence of potential disease. Classical histology routinely utilises
microscopic observation of micrometer cross-sections of tissue, differential staining techni‐
ques, as well as immunohistochemical assays, to assess the tissue specimen in question. The
visual evidence provided by each technique, or combination thereof, allows a pathologist to
identify potential evidence of pathology, thereby providing a pathological diagnosis for a
given specimen.
Classical histological techniques are inherently limited in their scope for the detection of
pathology as they rely on a microscopically visible presentation of clear or strong evidence of
pathology, e.g. in the case of advanced disease. Furthermore, any aberrant change at the sub-
microscopic level, i.e. the molecular level, needs to have translated into morphological change
at the subcellular and/or overall cellular morphological level, or to have produced a variation
in the abundance of a particular protein, or set of proteins, that is detectable through immu‐
nohistochemistry.
Evidence of molecular changes that are not yet detectable at the histological level: In molecular studies
of tumour biopsies and adjacent “paired” normal samples, researchers often seek to identify
molecular signatures that can distinguish tumour samples compared to histologically normal
samples obtained from anatomical sites distal to the primary lesion. However, recent studies
have investigated the possibility of significant molecular differences between histologically
normal colorectal tissue from patients with polyps, or colorectal carcinoma, versus the same
tissue from healthy individuals [19], suggesting that significant aberrant molecular changes
occur in apparently normal colorectal tissue, despite being apparently distinctly located from
the original lesion. In turn, this suggests that classic histopathological techniques are limited
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in their scope to identify such clinically relevant aberrant changes in tissue that appears
morphologically normal; interestingly, these molecular observations are entirely consistent
with Slaughter’s ‘field cancerisation’ theory. [6] However, whether or not such a field has a
gradually tapering aberrant effect as function of distance from the tumour remains incom‐
pletely answered. For instance, it has been found that there was no significant correlation
between the degree of aberrant gene expression perturbation and distance from a polyp or
tumour. [20] Irrespective, of the specific characteristics of any field effect, it is interesting to
note that supporting evidence of aberrant perturbations in histologically normal colorectal
mucosa appeared five decades after Slaughter’s original hypothesis as a direct result of modern
genomic, epigenomic, and proteomic research.
In a study of normal colonic mucosa from individuals with a family history of sporadic cancer
conducted by Hao et al [21], it was found that there was a significant difference in the expres‐
sion of several genes in these individuals’ normal mucosa relative to the same tissue from
healthy controls. In particular, the gene expression levels of PPAR-gamma, SAA1, and IL-8
were found to be significantly different in the morphologically normal rectosigmoid tissue
samples in the individuals with a family history of CRC. Furthermore, a follow-up study in
individuals with adenomatous polyps with or without familial history of colorectal carcinoma
again found that there was a difference between gene expression in normal rectosigmoid
mucosa from these individuals and healthy controls, regardless of the presence of a familial
history of cancer. [22]
Polley et al [19] observed significantly different proteomic signatures in morphologically
normal mucosa from patients with colorectal neoplasia compared to the same tissue from
healthy subjects. It therefore appears that a larger than anticipated field of tissue in the
colorectum may be affected by the presence of a neoplastic lesion, implying in turn that the
method used to determine clear margins estimated during surgical resection may need the
support of molecular assays in the future. However, whether or not the molecularly perturbed
normal mucosa will progress to disease remains to be determined.
In addition to genomic and proteomic perturbations, epigenetic changes have also been
reported in CRC tissues, one example being the hypomethylation of L1 promoter sequences
in colorectal tumours and in adjacent normal tissue of 6 out of 19 cancer patients, but not in
colonic mucosa of 14 healthy individuals. Furthermore, genomic CpG methylation appeared
to be lower in normal colorectal tissue from diseased patients, compared to healthy subjects,
and significantly lower in patients with hypomethylation of the L1 promoter sequences. [23]
The above examples at the genomic, proteomic and epigenetic level provide substantial
evidence of molecular aberrations in morphologically normal tissue sample adjacent to a
tumour. These changes might be subtle and may not effect a microscopically visible phenotype,
but could well represent significant perturbations that impart normal tissue samples with pre-
cancerous characteristics. It is therefore important that such findings are considered when
assessing individual biopsies by histopathology since these samples may in fact have under‐
lying molecular signals of disease that, if interpreted correctly, could provide insight into the
disease.
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Molecular Intratumour heterogeneity due to branched evolutionary clonal expansion: Intratumour
heterogeneity in terms of cellular morphology and types of cells, is a well-established obser‐
vation in anatomical pathology. However, it is only recently that a further layer of complexity
has been introduced through the discovery of an added layer of heterogeneity at the genomic
and epigenomic level. This molecular heterogeneity further complicates biopsy selection and
subsequent histopathological assessment because a specific lineage of clones, with a distinct
genomic profile, may occur in physical clusters on a given tumour and thus be physically
separated from other clonal populations. Therefore, each biopsy taken may present a uniform
or slightly variable morphological appearance but might be distinct at the molecular level with
unique functional potential and characteristics. This has fundamental ramifications when it
comes to assessing the severity of disease and the prognosis, as well as deciding the appropriate
course of treatment. Furthermore, intra-tumour heterogeneity governs how each unique
tumour lineage evolves and adapts to therapeutic interventions and should therefore ideally
be understood when developing new chemo- and biological treatments.
In a landmark study by Gerlinger et al [14], multiple spatially separated biopsy samples
obtained from primary renal carcinomas and associated metastatic sites showed evidence of
branched evolutionally growth by unique clonal population lineages. Furthermore, the
majority of all somatic mutations (63 – 69%) were not found to be present across all tumour
biopsies. One clinically relevant consequence of these findings was the identification of both
good and poor prognostic signatures in different biopsies of the same tumour. This study
highlights the inherent complexity of utilising a single biopsy for biomarker development,
prognostic or predictive measures based on molecular markers to guide treatment regimen. It
is clear that future biopsy collection - for the purpose of treatment planning or for biomarker
research - should ensure collection and molecular assessment of multiple biopsies from
physically separate sites on the same tumour.
A recent study by Kreso et al [24] has provided supporting evidence, in the context of colorectal
carcinoma, that the distinct genetic profile of each intratumoural clonal subpopulation has
implications in growth potential and chemotherapy tolerance and therefore has an impact on
treatment outcomes. This appears to be due to Darwinian style natural selection, with certain
subpopulations becoming more dominant by leveraging their intrinsic tolerance to selective
pressure such as chemotherapeutic intervention. These findings highlight the fact that different
tumour subpopulations have distinct proliferative potentials and chemotherapy tolerance
mechanisms; as such, treatment regimens in the future my need to target each type of cellular
population individually in order to prevent disease recurrence.
Future directions for modern pathological assessments of cancer tissue samples: Given the recent
developments in the field of intratumour heterogeneity, and the evidence of significant
molecular aberrations in histologically normal mucosa, it is clear that classical histopatholog‐
ical techniques are limited in their ability to assess the underlying clinically relevant hetero‐
geneity in tumour and normal tissue samples, suggesting that modern, validated, cost-effective
molecular assays should be integrated into histopathological assessments. Amongst others,
this would ensure that clinically relevant phenotypic or functional characteristics - whether
dormant or active - which may directly govern a tumours response to therapeutic intervention
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can be identified. This enhanced approach should facilitate the development of novel treatment
regimens that efficaciously target all heterogeneous subpopulations for a given tumour and,
in doing so, potentially also thwart aberrant histologically normal tissue from progressing to
a malignant lesion.
The possibility that distinct subpopulation of cells and/ or genetic signals exist in different
areas of a particular biopsy specimen poses a major challenge in implementing personalized
therapy. [25] ‘Omics based research can in principle generate a more robust predictor of
therapeutic benefits, but this often involve an extensive sample collection for discovery and
validation, adequate funding and availability of appropriate manpower: an example of one
such initiative is the ‘Personalized RNA Interference to Enhance the Delivery of Individualized
Cytotoxic and Targeted Therapeutics’ (PREDICT) consortium [26] that aims to identify reliable
biomarkers of different cancer types.
2.2. Tumour classification and staging
The earliest classification system for CRC by Dukes [27], modified by Astler [28], considered
the staging of CRC severity to be based on its depth of invasion. More recently, a standardized
widely accepted staging system of the American Joint Committee on Cancer (AJCC) also
known as the TNM system which incorporated the tumour size, nodal involvement and
presence of distant metastasis was introduced [29]: These three classifications are largely based
on morphologic evidence and can be subject to inaccuracies. To minimize errors in diagnosis,
these phenotypically driven systems of staging colorectal tumour could now in principle be
usefully complemented with a validated molecular diagnostic method.
Newer and often more reliable molecular based assessment of tumour staging and prognosis
are beginning to emerge for CRC based on new molecular cancer knowledge and ‘omics based
techniques and complement existing orthodox morphology based methods. One of such
molecular classification is based on CpG island methylator phenotype (CIMP), as well as
microsatellite instability (MSI), and is scored as type 1-5 based on different combinations of
these molecular features. [11] Chromosomal instability (CIN) has also been identified as an
important global molecular classifiers of CRC. [30] In addition, KRAS mutations have emerged
as the most common prognostic biomarker of CRC for anti-EGFR therapy patients and many
more candidate markers for prediction of therapeutic outcomes in colorectal cancer are being
discovered now using ‘omics based techniques, including loss of PTEN signals, PI3KCA
mutation and BRAF gene mutation. [31]
Identification of cancer specific genes, proteins, lipids and metabolites is increasingly regarded
as a promising route to early diagnosis, treatment and monitoring of disease progress. For
instance, the following genes have been recognized as associated with the risk of developing
colorectal cancer; TP53, MLH1, MSH2, MSH6, MYH, EPCAM, KIT, BLM, SMAD4, PGDFRA,
BMPR1A, APC, AXIN2, and STK11. Vogelstein et al [32] In a recent meta-analysis of 25 different
genetic expression studies of colorectal cancer, a statistically significant down-regulation of
carbonic anhydrase II (CAII) and CEACAM1 was observed, while there was up-regulation of
TGFβ1, IFITM1, SPARC, GDF15 and MYC genes. [33] Based on these molecular patterns, a
novel staging and classification system that is devoid of errors can now potentially be evolved.
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ical techniques are limited in their ability to assess the underlying clinically relevant hetero‐
geneity in tumour and normal tissue samples, suggesting that modern, validated, cost-effective
molecular assays should be integrated into histopathological assessments. Amongst others,
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widely accepted staging system of the American Joint Committee on Cancer (AJCC) also
known as the TNM system which incorporated the tumour size, nodal involvement and
presence of distant metastasis was introduced [29]: These three classifications are largely based
on morphologic evidence and can be subject to inaccuracies. To minimize errors in diagnosis,
these phenotypically driven systems of staging colorectal tumour could now in principle be
usefully complemented with a validated molecular diagnostic method.
Newer and often more reliable molecular based assessment of tumour staging and prognosis
are beginning to emerge for CRC based on new molecular cancer knowledge and ‘omics based
techniques and complement existing orthodox morphology based methods. One of such
molecular classification is based on CpG island methylator phenotype (CIMP), as well as
microsatellite instability (MSI), and is scored as type 1-5 based on different combinations of
these molecular features. [11] Chromosomal instability (CIN) has also been identified as an
important global molecular classifiers of CRC. [30] In addition, KRAS mutations have emerged
as the most common prognostic biomarker of CRC for anti-EGFR therapy patients and many
more candidate markers for prediction of therapeutic outcomes in colorectal cancer are being
discovered now using ‘omics based techniques, including loss of PTEN signals, PI3KCA
mutation and BRAF gene mutation. [31]
Identification of cancer specific genes, proteins, lipids and metabolites is increasingly regarded
as a promising route to early diagnosis, treatment and monitoring of disease progress. For
instance, the following genes have been recognized as associated with the risk of developing
colorectal cancer; TP53, MLH1, MSH2, MSH6, MYH, EPCAM, KIT, BLM, SMAD4, PGDFRA,
BMPR1A, APC, AXIN2, and STK11. Vogelstein et al [32] In a recent meta-analysis of 25 different
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carbonic anhydrase II (CAII) and CEACAM1 was observed, while there was up-regulation of
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2.3. Role of surgical pathology
The rationale behind the histopathologic use of slide sections from biopsy samples has been
to evaluate for diagnostic purposes a representative microcosm of disease from a routine‐
ly processed, waxed, and miniaturized specimen blocks. However this has sometimes led
to mis- or under- diagnosis of tumour depending on the exact site from which the biopsy
was taken from. In principle,  the goal of surgical resection is to take adequate ‘tumour-
free’  margin;  however achievement of  this goal  in practice is  at  best  an estimated blind
procedure, since cancer specific molecular alterations in the ‘apparently’ tumour free regions
are  largely  unknown.  This  makes  it  difficult  to  readily  determine  the  adequacy  of  a
surgically resected margin. Not least, pathologists have had to take multiple biopsies from
different sites in a resected tumour mass, trying to maximize the chances of locating the
accurate  tumour  areas.  This  blind  sampling  procedure  is  a  major  potential  source  of
diagnostic inaccuracies in practice and it is therefore important to detect colorectal cancer
early to improve the chances of getting an adequate ‘tumour free’ surgical margin. Prompt
surgical  intervention,  coupled  with  accurate  determination  of  the  most  beneficial  adju‐
vant therapy for the specific patient, appears to hold the key. Surgical pathology - which
is the interface between surgery and pathologic specimen processing - is thus a vital control
point for the eradication of diagnostic inaccuracies.  Given the current molecular eviden‐
ces on intratumour and interbiopsy heterogeneity, an exclusive morphology based sampling
technique is a potential minefield for diagnostic errors, even with the best mastery.
A delicate  balance  needs  to  be  achieved during sampling of  surgical  specimens for  the
assessment of tumour heterogeneity. The most prominent, average pattern of expression is
most  likely to  be identified during sampling of  a  large tumour biopsy sample,  but  this
approach risks masking the less prominent but potentially equally important information
about sub-populations of  tumour cells  in the biopsy sample.  By contrast,  signal-to-noise
ratios  have  to  be  carefully  balanced  when  analysing  smaller  biopsy  samples  since  this
approach presents a smaller sampling frame within which it may be impractical to identify
all possible biomarker signals a tumour could express. [34] Surgeons and pathologists also
need  to  bear  in  mind  the  downstream  requirements  and  applications  of  ‘omics  based
research when surgical  biopsy samples are taken,  especially  since mining the molecular
archives  of  formalin  fixed  paraffin  embedded  (FFPE)  specimens  through  genomics,
proteomics and lipidomics research is  beginning to gain traction now. However,  factors
such as age of tissue, condition of storage, tissue sample size, fixation time, pH influen‐
ces and buffers are known to influence the outcome of ‘omics based analyses on surgical
specimens. [35] In particular, RNA degrades rapidly at room temperature, whilst formal‐
in damages nucleic acids within the specimen by forming sclerotic crosslinks of DNA and
RNA via methylol adducts and methylene bridges. [35] Thus, immediate snap freezing of
fresh sections in liquid nitrogen or dry ice is good practice, whilst use of newer alcohol-
based kits [36], or of phosphate buffered formalin [37, 38], provide useful alternatives to
standard formalin for rapid fixation of surgical specimens prior transport to the lab.
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2.4. Patient evaluation and therapeutic loopholes
Biomarker discovery research will in principle enable accurate stratification of patients into
appropriate risk categories. The orthodox clinical approach of prescribing a common thera‐
peutic cancer regimen to all colorectal cancer patients is fast becoming a subject of evidence-
based debates. Certain differences exist between patients who come from demographically,
geographically and genetically divergent backgrounds. Such inter-patient variability may also
present significant differences in tumour phenotype, behavior and natural histories across a
population, an important observation that is referred to as single nucleotide polymorphism
(SNP) noise. [39] Patient stratification based on these natural clusters can enable meaningful
biomarker discovery using ‘omics based techniques. For instance, in a culturally heterogene‐
ous South African population composed of Caucasians, Indigenous African, Indian, and Mixed
Ancestries, the a priori expectation is that different racial groups may express different
biomarkers of disease. In the same light, candidate biomarkers discovered from studies on
developed world patient cohorts may not necessarily be effective for the management of
colorectal cancer in a developing world situation due to differing ethnicities, which has clear
implications for the planning and execution of ‘omics based discovery and validation of
biomarkers.
In principle, it is possible to predict response to specific targeted therapies (e.g. Herceptin)
using ‘omics based approaches, with patients who would not respond to specific targeted
therapies being identified at the outset and given alternative therapies. Patient dependent
source of variation for biomarker discovery includes individual genetic make-up, metabolism,
stage of disease, health, immunocompetence, nutritional factors, and environmental factors.
Careful patient selection to eliminate confounders must be carried out prior to experiments
and biomarkers must be validated in a standardized acceptable manner.
Genetic profiling of patients for KRAS mutation, BRAF genes, Microsatellite instability (MSI)
and CpG island methylator phenotypes (CIMP) is now being increasingly carried out for
colorectal cancer patients in the developed world and this has contributed significantly to
treatment planning. Patients that exhibit MSI have been found to possess better overall survival
than those with chromosomal instability and are less affected by p53 mutations [40], whilst
CRC with p53 +, MSI + profiles are usually more aggressive than those with p53-, MSI + profiles.
[41] Biomarkers such as telomerase and survivin have been used to assess the long term risk
of CRC development [42] whilst morphologic biomarkers in patients include neoplastic
colorectal polyposis and the presence of aberrant cryptic foci (AFC); the presence of adenomas
with Intraepithelial Neoplasm in the colorectal region can also be used in surveillance as
surrogate endpoint biomarkers. [43] Paradoxically, most anti-cancer agents do not have well-
established single predictors of individualized response, however with the advances in ‘omics
based approaches it should be possible to provide such molecular predictors. For example,
MSI has been documented to be an effective predictor of response to fluoropyrimidine therapy,
whilst ERCC1 was found to be beneficial in patients using platinum containing anticancer
regimen. [31]
‘Omics based techniques relevant to colorectal cancer management
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Ancestries, the a priori expectation is that different racial groups may express different
biomarkers of disease. In the same light, candidate biomarkers discovered from studies on
developed world patient cohorts may not necessarily be effective for the management of
colorectal cancer in a developing world situation due to differing ethnicities, which has clear
implications for the planning and execution of ‘omics based discovery and validation of
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In principle, it is possible to predict response to specific targeted therapies (e.g. Herceptin)
using ‘omics based approaches, with patients who would not respond to specific targeted
therapies being identified at the outset and given alternative therapies. Patient dependent
source of variation for biomarker discovery includes individual genetic make-up, metabolism,
stage of disease, health, immunocompetence, nutritional factors, and environmental factors.
Careful patient selection to eliminate confounders must be carried out prior to experiments
and biomarkers must be validated in a standardized acceptable manner.
Genetic profiling of patients for KRAS mutation, BRAF genes, Microsatellite instability (MSI)
and CpG island methylator phenotypes (CIMP) is now being increasingly carried out for
colorectal cancer patients in the developed world and this has contributed significantly to
treatment planning. Patients that exhibit MSI have been found to possess better overall survival
than those with chromosomal instability and are less affected by p53 mutations [40], whilst
CRC with p53 +, MSI + profiles are usually more aggressive than those with p53-, MSI + profiles.
[41] Biomarkers such as telomerase and survivin have been used to assess the long term risk
of CRC development [42] whilst morphologic biomarkers in patients include neoplastic
colorectal polyposis and the presence of aberrant cryptic foci (AFC); the presence of adenomas
with Intraepithelial Neoplasm in the colorectal region can also be used in surveillance as
surrogate endpoint biomarkers. [43] Paradoxically, most anti-cancer agents do not have well-
established single predictors of individualized response, however with the advances in ‘omics
based approaches it should be possible to provide such molecular predictors. For example,
MSI has been documented to be an effective predictor of response to fluoropyrimidine therapy,
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The management of CRC has to date been based on fairly invasive techniques for diagnosis
and treatment. In contrast, ‘omics based techniques in most instances are non- or minimally
invasive, thereby improving patient compliance, eliminating surgical morbidities and
ultimately reducing the burden of disease through early diagnosis and effective treatment
monitoring. The potential utility of increasingly common-place ‘omics based techniques in the
diagnosis, surveillance, treatment, and prevention of colorectal cancer is thus discussed below.
2.5. Genomics and epigenomics
Introduction: In genomic investigations, high-throughput technologies such as microarray
platforms or DNA/ RNA sequencing are now commonplace. These technologies are now
routinely applied to large sample collections, with complete clinical annotations, and aim to
produce profound insights into disease at the resolution of single nucleotide polymorphisms,
gene expression, and the status of epigenetic regulatory mechanisms such as hypo- and
hypermethylation.
Extensive bioinformatic analysis of these high-throughput, multi-level, datasets has provided
in-depth insights into the mechanisms of disease and treatment resistance. These findings have
been translated into biomedical research aimed at addressing the significant challenge in
treating cancer of the colorectum. While it is well established that cure rate for treating TNM
stage I colorectal cancer is over 90%, the clinical management of stage II CRC is more compli‐
cated. [44, 45] Furthermore, improved chemo- or biological treatment regimens are needed to
address the high rates of recurrent disease observed with stage II and III CRC disease, as well
as for TNM stage IV disease which is generally considered incurable at present. [46, 47]
The overall disease-free survival statistics for TNM stage II disease, treated with surgery alone,
are as high as 75%. [44] However, certain sub-populations of patients experience a worse
prognosis and have clinical outcomes more similar to TNM stage III disease. Therefore, much
focus has been on finding genetic markers to guide treatment regimen selection in stage II and
III disease, the goal being to improve overall efficacy, decrease treatment failures, reduce the
incidence of recurrent disease, whilst at the same time lowering the cost of treatment by
limiting costly chemotherapeutics to those patients with predicted benefit.
High-throughput genomic studies today provide a comprehensive means to analyse amongst
others the expression level of every individual gene, as well as to assess chromosomal segment
copy number- and DNA methylation pattern variations and to determine single nucleotide
polymorphism and mutation frequencies, all in a genome-wide manner. Biomarker research
can thereafter be carried out to identify and validate distinct signatures derived from inte‐
grated value measurements associated with each gene, as a prelude to translating such findings
into a clinical setting, as either biomarkers or novel therapeutic targets.
3. Transcriptomics
The field of transcriptomic research, within the context of prognosis and treatment outcome
prediction, has seen much attention in recent years. High-volume real-time gene expression
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assays, gene expression microarrays and, more recently, ‘next generation sequencing’ based
methods have provided the necessary platforms to investigate putative prognostic and
predictive genetic markers. These platforms, combined with known clinical outcomes, enable
panels of genes to be significantly correlated with prognosis, or the outcome of treatment with
various chemotherapeutic agents. However, genetic association studies require large datasets
in order to identify putative prognostic and predictive markers with significance worthy of
clinical utility. As such, there are to date a limited number of landmark publications that
present such multi-gene panel lists associated with prognosis and treatment outcome predic‐
tion in TNM stage II and III colon and rectal cancers.
A study by O’Connell et al [48] involved the combined analyses of four independent studies
of colorectal cancer patients. Samples were obtained from 1851 CRC patients in the United
States, with stage II or III disease, who participated in the National Surgical Adjuvant Breast
and Bowel Project (C-01/C-02 and Cleveland Clinic (CC); C04; C-06) and 1136 candidate genes
(761 genes assessed in C-01/C-02; 375 genes in CC/C-06) were evaluated. The aim of the study
was to establish a panel of markers that could be associated with the risk of disease recurrence
and that could determine the likelihood of patients benefitting from adjuvant 5-fluorouracil/
leucovorin adjuvant therapy. The analyses resulted in the identification of 48 genes signifi‐
cantly associated with the risk of disease recurrence and 66 genes significantly associated with
5-FU/LV benefit (with four genes in common between the two sets). For practical reasons a
gene panel of 7 genes predictive of disease recurrence, 6 predicted of 5-FU/LV benefit, and 5
reference genes were selected. The clinical utility of this predictive panel was then independ‐
ently evaluated in the Quick and Simple and Reliable (QUASAR) study. [49] The aforemen‐
tioned study validated the use of this gene panel, and it’s consequent recurrence score, as an
independent predictor of the risk of recurrent disease in stage II colon cancer patients who had
undergone surgery. This gene panel was then commercialized by Genomic Health by the
production of a multi-gene panel called the Oncotype DX® Colon Cancer Assay.
In separate work, Salazar et al [50] described a gene expression signature - named ColoPrint -
in early 2011 that allowed for improved prediction of prognosis in TNM stage II and III
colorectal cancer. The gene signature consists of 18 genes that were identified from analysis of
188 frozen tumour samples (TNM stage I-IV; 78.7% not treated with adjuvant chemotherapy),
and a cross-validated on 206 independent tumour samples (TNM stage I-III; 60.7% not treated
with adjuvant chemotherapy) originating from three sites in the Netherlands. This panel
showed better predictive accuracy, in comparison to the American Society of Clinical Oncology
criteria for assessing the risk of cancer recurrence without prescreening for microsatellite
instability (MSI), with a hazard ratio of 2.69 (95% CI, 1.41 to 5.13; P = 0.003) for patients with
stage II disease. Results such as these are encouraging, and provide strong supporting evidence
for the utility of molecular approaches over purely clinical markers.
In a related study, a panel of 13 genes - referred to as ColoGuideEx - was reported by Ågesen
et al [51] to be significantly associated with predicting prognosis for stage II colorectal cancer
patients. This study was conducted on an initial dataset obtained from 207 colorectal samples
originating from three independent Norwegian patient series, and validated on a 108-sample
gene expression dataset originating from the USA and Australia. The independent prognostic
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prognosis and have clinical outcomes more similar to TNM stage III disease. Therefore, much
focus has been on finding genetic markers to guide treatment regimen selection in stage II and
III disease, the goal being to improve overall efficacy, decrease treatment failures, reduce the
incidence of recurrent disease, whilst at the same time lowering the cost of treatment by
limiting costly chemotherapeutics to those patients with predicted benefit.
High-throughput genomic studies today provide a comprehensive means to analyse amongst
others the expression level of every individual gene, as well as to assess chromosomal segment
copy number- and DNA methylation pattern variations and to determine single nucleotide
polymorphism and mutation frequencies, all in a genome-wide manner. Biomarker research
can thereafter be carried out to identify and validate distinct signatures derived from inte‐
grated value measurements associated with each gene, as a prelude to translating such findings
into a clinical setting, as either biomarkers or novel therapeutic targets.
3. Transcriptomics
The field of transcriptomic research, within the context of prognosis and treatment outcome
prediction, has seen much attention in recent years. High-volume real-time gene expression
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assays, gene expression microarrays and, more recently, ‘next generation sequencing’ based
methods have provided the necessary platforms to investigate putative prognostic and
predictive genetic markers. These platforms, combined with known clinical outcomes, enable
panels of genes to be significantly correlated with prognosis, or the outcome of treatment with
various chemotherapeutic agents. However, genetic association studies require large datasets
in order to identify putative prognostic and predictive markers with significance worthy of
clinical utility. As such, there are to date a limited number of landmark publications that
present such multi-gene panel lists associated with prognosis and treatment outcome predic‐
tion in TNM stage II and III colon and rectal cancers.
A study by O’Connell et al [48] involved the combined analyses of four independent studies
of colorectal cancer patients. Samples were obtained from 1851 CRC patients in the United
States, with stage II or III disease, who participated in the National Surgical Adjuvant Breast
and Bowel Project (C-01/C-02 and Cleveland Clinic (CC); C04; C-06) and 1136 candidate genes
(761 genes assessed in C-01/C-02; 375 genes in CC/C-06) were evaluated. The aim of the study
was to establish a panel of markers that could be associated with the risk of disease recurrence
and that could determine the likelihood of patients benefitting from adjuvant 5-fluorouracil/
leucovorin adjuvant therapy. The analyses resulted in the identification of 48 genes signifi‐
cantly associated with the risk of disease recurrence and 66 genes significantly associated with
5-FU/LV benefit (with four genes in common between the two sets). For practical reasons a
gene panel of 7 genes predictive of disease recurrence, 6 predicted of 5-FU/LV benefit, and 5
reference genes were selected. The clinical utility of this predictive panel was then independ‐
ently evaluated in the Quick and Simple and Reliable (QUASAR) study. [49] The aforemen‐
tioned study validated the use of this gene panel, and it’s consequent recurrence score, as an
independent predictor of the risk of recurrent disease in stage II colon cancer patients who had
undergone surgery. This gene panel was then commercialized by Genomic Health by the
production of a multi-gene panel called the Oncotype DX® Colon Cancer Assay.
In separate work, Salazar et al [50] described a gene expression signature - named ColoPrint -
in early 2011 that allowed for improved prediction of prognosis in TNM stage II and III
colorectal cancer. The gene signature consists of 18 genes that were identified from analysis of
188 frozen tumour samples (TNM stage I-IV; 78.7% not treated with adjuvant chemotherapy),
and a cross-validated on 206 independent tumour samples (TNM stage I-III; 60.7% not treated
with adjuvant chemotherapy) originating from three sites in the Netherlands. This panel
showed better predictive accuracy, in comparison to the American Society of Clinical Oncology
criteria for assessing the risk of cancer recurrence without prescreening for microsatellite
instability (MSI), with a hazard ratio of 2.69 (95% CI, 1.41 to 5.13; P = 0.003) for patients with
stage II disease. Results such as these are encouraging, and provide strong supporting evidence
for the utility of molecular approaches over purely clinical markers.
In a related study, a panel of 13 genes - referred to as ColoGuideEx - was reported by Ågesen
et al [51] to be significantly associated with predicting prognosis for stage II colorectal cancer
patients. This study was conducted on an initial dataset obtained from 207 colorectal samples
originating from three independent Norwegian patient series, and validated on a 108-sample
gene expression dataset originating from the USA and Australia. The independent prognostic
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value of the panel of genes was confirmed by multivariate Cox regression analyses (p≤0.004),
which included various clinicopathological variables and all three-sample series.
O’Connell et al (2010)
O’Connell et al (2010)
Oncotype DX® Colon Assay
Salazar et al (2011)
ColoPrint®
Ågesen et al (2012)
ColoGuideEx
5FU benefit Disease recurrence Disease recurrence Disease recurrence
ATP5E ATP5E CA4388O2 AZGP1
AXIN2 BGN CTSC BNIP3
BIK C-MYC CYFIP2 CXCL10
EFNB2 FAP EDEM1 CXCL13
GPX1 GADD45B HSD3B1 DSC3
HSPE1 GPX1 IL2RA ENPP3
MAD2L1 INHBA IL2RB EPHA7
PGK1 Ki-67 LAMA3 KLK6
RUNX1 MYBL2 LIF MMP3
UBB PGK1 MCTP1 PIGR








Table 1. A list of multi-gene panels that are significantly associated with disease recurrence, or benefit from adjuvant
5-fluorouracil (5-FU) and leucovorin (LV) chemotherapy, as published in three independent studies.
Table 1 illustrates the various gene panels from the four studies described above and it is
noteworthy that there are no genes in common between these gene panels. Furthermore, the
biological relevance the genes utilised in each panel has yet to be fully explained and may
represent an opportunity to identify pathologically associated genes and pathways when
molecular enrichment analyses are applied across multiple gene panel studies in the context
of prognostic and predictive biomarkers used in recurrent colorectal cancer. For example, there
are genes across the lists in Table 1 that share a relationship by virtue of their KEGG pathway
associations: (1) Cytokine-cytokine receptor interaction (n=6 genes; CXCL10 and CXCL13 [Che‐
mokines; CXC subfamily] from Ågesen et al (2012), LIF [gpl30 shared] from Salazar et al (2011),
IL2RA and IL2RB [IL2RG shared] from the Hematopoietins from Salazar et al (2011), and
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INHBA [TGF-ß family] O’Connell et al (2010); (2) Axon guidance (n=3 genes; EPHA7 from
Ågesen et al (2012), EFNB2 from O’Connell et al (2010), and SEMA3A from Ågesen et al (2012);
(3) Pathways in Cancer (n=3 genes; LAMA3 from Salazar et al (2011), AXIN2 from O’Connell et
al (2010), RUNX1 from O’Connell et al (2010)); (4) p53 signaling pathway – target genes (n=2 genes;
SESN1 from Ågesen et al (2012), and GADD45B from O’Connell et al (2010)). These KEGG
pathway association mappings were adapted from outputs generated by GeneCodis. [52-54]
In a novel study that utilised eight published prognostic and predictive gene expression
signatures, Shi et al [55] combined the datasets and integrated them with publically available
protein-protein interaction network data in order to identify candidate molecular markers
associated directly with the recurrent colorectal cancer phenotype. As a result, they were able
to not only infer pathophysiological mechanisms underpinning the recurrent disease pheno‐
type, but also used the augmented and cross-study integrated signature to identify both a
prognostic signature and a multi-gene signature to predict treatment outcome. The resultant
gene signature consists of 487 genes and is referred to as the NEM signature (as it integrates
information from Network, Expression, and Mutation datasets).
It is clear therefore that gene expression panels are developing to the point where they are
close to translation into a clinical setting and adoption into routine clinical practice. It remains
to be seen though how many of the published gene panels will make it into the clinic after
appropriate validation studies have been carried out to assess performance across larger and
more ethnically diverse patient populations. In this context, it is important to note that such
signatures might yet be inherently compromised by the likely existence of multiple, possibly
opposing, signatures in the same tissue sample (vide supra). Therefore, testing of multiple
biopsies from the same tumour may be necessary in order to generate a holistic prognosis and
to provide guidance on treatment strategy. Furthermore, in developing nations where the
incidence of colorectal cancer is not yet decreasing and cases consistently present at more
advanced stages of disease, it remains to be seen whether the cost of such diagnostic or
prognostic panels will be affordable in the public sector where there is the most need and where
the greatest diversity exists.
Single nucleotide polymorphisms: Colorectal cancer has classically been treated by 5-fluorouracil
(Capecitabine; Xeloda®; Hoffmann-La Roche Inc.), combined with either Oxaliplatin (Eloxa‐
tin®; Sanofi-Synthélabo Inc.) or Irinotecan (Camptosar® or CPT-11; Pfizer Pharmaceuticals
Inc.). Over the past decade these regimens have been augmented by the addition of biological
therapeutic agents, such as the monoclonal antibodies Cetuximab (Erbitux®; ImClone Systems
Inc.), Panitumumab (Vectibix®; Amgen Inc.), and Bevacizumab (Avastin®; Genentech Inc).
Each drug has a different mechanism of action and a unique set of molecular targets, as well
as distinct sets of enzymes responsible for its metabolism; furthermore, particularly in the case
of biological agents, specific enzymes that are functionally important to the pathways targeted
by the biologic are major determinants of response. It is well-established that polymorphic
variations in enzymes involved in drug metabolism can alter drug availability, thereby causing
a variation in clinical response, by altering the rate and specificity of drug metabolism. Such
variant drug metabolizing enzymes are generally encoded by single nucleotide polymor‐
phisms (SNPs) that result in changes in the amino acid composition of the relevant gene
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value of the panel of genes was confirmed by multivariate Cox regression analyses (p≤0.004),
which included various clinicopathological variables and all three-sample series.
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Table 1. A list of multi-gene panels that are significantly associated with disease recurrence, or benefit from adjuvant
5-fluorouracil (5-FU) and leucovorin (LV) chemotherapy, as published in three independent studies.
Table 1 illustrates the various gene panels from the four studies described above and it is
noteworthy that there are no genes in common between these gene panels. Furthermore, the
biological relevance the genes utilised in each panel has yet to be fully explained and may
represent an opportunity to identify pathologically associated genes and pathways when
molecular enrichment analyses are applied across multiple gene panel studies in the context
of prognostic and predictive biomarkers used in recurrent colorectal cancer. For example, there
are genes across the lists in Table 1 that share a relationship by virtue of their KEGG pathway
associations: (1) Cytokine-cytokine receptor interaction (n=6 genes; CXCL10 and CXCL13 [Che‐
mokines; CXC subfamily] from Ågesen et al (2012), LIF [gpl30 shared] from Salazar et al (2011),
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INHBA [TGF-ß family] O’Connell et al (2010); (2) Axon guidance (n=3 genes; EPHA7 from
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(3) Pathways in Cancer (n=3 genes; LAMA3 from Salazar et al (2011), AXIN2 from O’Connell et
al (2010), RUNX1 from O’Connell et al (2010)); (4) p53 signaling pathway – target genes (n=2 genes;
SESN1 from Ågesen et al (2012), and GADD45B from O’Connell et al (2010)). These KEGG
pathway association mappings were adapted from outputs generated by GeneCodis. [52-54]
In a novel study that utilised eight published prognostic and predictive gene expression
signatures, Shi et al [55] combined the datasets and integrated them with publically available
protein-protein interaction network data in order to identify candidate molecular markers
associated directly with the recurrent colorectal cancer phenotype. As a result, they were able
to not only infer pathophysiological mechanisms underpinning the recurrent disease pheno‐
type, but also used the augmented and cross-study integrated signature to identify both a
prognostic signature and a multi-gene signature to predict treatment outcome. The resultant
gene signature consists of 487 genes and is referred to as the NEM signature (as it integrates
information from Network, Expression, and Mutation datasets).
It is clear therefore that gene expression panels are developing to the point where they are
close to translation into a clinical setting and adoption into routine clinical practice. It remains
to be seen though how many of the published gene panels will make it into the clinic after
appropriate validation studies have been carried out to assess performance across larger and
more ethnically diverse patient populations. In this context, it is important to note that such
signatures might yet be inherently compromised by the likely existence of multiple, possibly
opposing, signatures in the same tissue sample (vide supra). Therefore, testing of multiple
biopsies from the same tumour may be necessary in order to generate a holistic prognosis and
to provide guidance on treatment strategy. Furthermore, in developing nations where the
incidence of colorectal cancer is not yet decreasing and cases consistently present at more
advanced stages of disease, it remains to be seen whether the cost of such diagnostic or
prognostic panels will be affordable in the public sector where there is the most need and where
the greatest diversity exists.
Single nucleotide polymorphisms: Colorectal cancer has classically been treated by 5-fluorouracil
(Capecitabine; Xeloda®; Hoffmann-La Roche Inc.), combined with either Oxaliplatin (Eloxa‐
tin®; Sanofi-Synthélabo Inc.) or Irinotecan (Camptosar® or CPT-11; Pfizer Pharmaceuticals
Inc.). Over the past decade these regimens have been augmented by the addition of biological
therapeutic agents, such as the monoclonal antibodies Cetuximab (Erbitux®; ImClone Systems
Inc.), Panitumumab (Vectibix®; Amgen Inc.), and Bevacizumab (Avastin®; Genentech Inc).
Each drug has a different mechanism of action and a unique set of molecular targets, as well
as distinct sets of enzymes responsible for its metabolism; furthermore, particularly in the case
of biological agents, specific enzymes that are functionally important to the pathways targeted
by the biologic are major determinants of response. It is well-established that polymorphic
variations in enzymes involved in drug metabolism can alter drug availability, thereby causing
a variation in clinical response, by altering the rate and specificity of drug metabolism. Such
variant drug metabolizing enzymes are generally encoded by single nucleotide polymor‐
phisms (SNPs) that result in changes in the amino acid composition of the relevant gene
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product (i.e. protein), resulting in altered enzymatic activity. As such, the biomedical com‐
munity has utilised an arsenal of molecular techniques, including high-throughput genomic
platforms, to identify such SNPs and to quantify their frequency in populations in order to
correlate with treatment outcomes and thereby to identify biomarkers that are predictive of
therapeutic response.
This area of research has been comprehensively reviewed recently by Asghar et al [56], Bandrés
et al [57], Benheim et al [58], Coate et al [59], De Roock et al [60], and Ross et al [61] and forms
the basis of the rich pharmacogenetic resource, PharmGKB® (http://www.pharmgkb.org)
which documents each therapeutic agent together with an aggregated list of SNPs reported in
the literature to be associated with treatment outcome.
4. Pharmacogenomics
4.1. Markers of treatment outcomes when treated with classical chemotherapeutics
5-Fluorouracil: 5-Fluorouracil (5-FU) was introduced more than 50 years ago by Heidelberger
et al [62] and is the foundational cytotoxic agent used in the treatment of colorectal neoplasia.
5-FU can be administered in three different physical forms: either through an intravenous
solution, or as an oral compound (Capecitabine, and Tegafur). The metabolism of either of
these compounds results in the formation of fluoronucleotides. A subset of these molecules,
fluorouridine triphosphate (FUTP) and fluorodeoxyuridine monophosphate (FdUMP) are
misincorporation into DNA and RNA during their in vivo biosynthesis. In addition, FdUMP
inhibits thymidylate, synthase thereby resulting in a nucleotide imbalance due to a depleted
intracellular reserve of thymidine for DNA synthesis. The enzymes responsible for producing
the active metabolites have been studied for polymorphic variation and analysed for their
correlation to treatment response (as seen in Table 2).




TP Increased expression Increased response Bandrés et al (2007)
TS TSER2R Decreased expression Increased response Bandrés et al (2007)
DPD DYPD*2A Decreased activity
Increased response
Increased toxicity




Increased response Bandrés et al (2007)
Table 2. A list of single nucleotide polymorphism (SNP) markers associated with treatment outcome, as reported by
Bandrés et al (2007), when using a 5-fluorouracil-based regimen.
Oxaliplatin: Oxaliplatin is a platinum analog that results in inter- and intra-molecular DNA
cross-links, resulting in the inhibition of DNA synthesis, transcription and repair processes.
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This compound has been extensively utilised in combination with 5-FU and Leucovorin, a
regimen referred to as FOLFOX and commonly prescribed for treatment of advanced colorectal
cancer.
There are two groups of genes that are primarily responsible for altered response to Oxalipla‐
tin, namely genes involved in DNA repair and in glutathione conjugation reactions. In the
former group, a polymorphism in the X-ray repair cross-complementing group 1 enzyme
(XRCC1) - which is part of the base excision repair system - has been associated with variable
initiation of DNA repair. [57] In addition, a polymorphism in a component of the ubiquitous
nucleotide excision repair pathway - the excision repair cross complementing group 2 (ERCC2)
gene - has been significantly associated with a clinical response to platinum-based chemo‐
therapy. [57] However, there are no known polymorphisms in the DNA mismatch repair
pathway associated with variation in treatment response with Oxaliplatin. In the second
group, it has been reported that platinum compounds are inactivated by glutathione conju‐
gation and therefore the enzymes responsible for catalyzing this reaction have been investi‐
gated. In particular, SNPs in several glutathione-S-transferase (GST) genes have been
implicated in conferring resistance to Oxaliplatin. [57]




GSTP1 613G Decreased activity Increased response Bandrés et al (2007)
GSTT1 Deletion Decreased activity Increased response Bandrés et al (2007)
GSTM1 Deletion Decreased activity Increased response Bandrés et al (2007)
XRCC1 388Gln Decreased activity Increased response Bandrés et al (2007)
ERCC2 751Gln Decreased activity Increased response Bandrés et al (2007)
Table 3. A list of single nucleotide polymorphism (SNP) markers associated with treatment outcome, as reported by
Bandrés et al (2007), when using a chemotherapeutic regimen that includes Oxaliplatin.
It is noteworthy that in a recent study by Fernandez-Rozadilla et al [63], seven SNPs
(rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568, rs4243761) were found
to be significantly associated with adverse drug reactions in the context of singular 5-FU or
FOLFOX treatment. Given the relatively large sample size of 221 CRC patients and a validation
set of 791 patients, these results hold strong statistical significance and provide potential
predictive capacity for toxicity response on an individual patient basis if validated through a
larger cohort.
Irinotecan (CPT-11): Irinotecan is a camptothecin analogue with well-established anti-neoplasia
activity exerted though stabilization of the ordinarily transient DNA topoisomerase I-DNA
complex, thus preventing the repair of temporary single stranded breaks during DNA
replication and leading to cell death. [64] There are two primary pathways that have been
implicated in variable response to Irinotecan treatment: drug transport into the extracellular
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product (i.e. protein), resulting in altered enzymatic activity. As such, the biomedical com‐
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platforms, to identify such SNPs and to quantify their frequency in populations in order to
correlate with treatment outcomes and thereby to identify biomarkers that are predictive of
therapeutic response.
This area of research has been comprehensively reviewed recently by Asghar et al [56], Bandrés
et al [57], Benheim et al [58], Coate et al [59], De Roock et al [60], and Ross et al [61] and forms
the basis of the rich pharmacogenetic resource, PharmGKB® (http://www.pharmgkb.org)
which documents each therapeutic agent together with an aggregated list of SNPs reported in
the literature to be associated with treatment outcome.
4. Pharmacogenomics
4.1. Markers of treatment outcomes when treated with classical chemotherapeutics
5-Fluorouracil: 5-Fluorouracil (5-FU) was introduced more than 50 years ago by Heidelberger
et al [62] and is the foundational cytotoxic agent used in the treatment of colorectal neoplasia.
5-FU can be administered in three different physical forms: either through an intravenous
solution, or as an oral compound (Capecitabine, and Tegafur). The metabolism of either of
these compounds results in the formation of fluoronucleotides. A subset of these molecules,
fluorouridine triphosphate (FUTP) and fluorodeoxyuridine monophosphate (FdUMP) are
misincorporation into DNA and RNA during their in vivo biosynthesis. In addition, FdUMP
inhibits thymidylate, synthase thereby resulting in a nucleotide imbalance due to a depleted
intracellular reserve of thymidine for DNA synthesis. The enzymes responsible for producing
the active metabolites have been studied for polymorphic variation and analysed for their
correlation to treatment response (as seen in Table 2).
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Increased response Bandrés et al (2007)
Table 2. A list of single nucleotide polymorphism (SNP) markers associated with treatment outcome, as reported by
Bandrés et al (2007), when using a 5-fluorouracil-based regimen.
Oxaliplatin: Oxaliplatin is a platinum analog that results in inter- and intra-molecular DNA
cross-links, resulting in the inhibition of DNA synthesis, transcription and repair processes.
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This compound has been extensively utilised in combination with 5-FU and Leucovorin, a
regimen referred to as FOLFOX and commonly prescribed for treatment of advanced colorectal
cancer.
There are two groups of genes that are primarily responsible for altered response to Oxalipla‐
tin, namely genes involved in DNA repair and in glutathione conjugation reactions. In the
former group, a polymorphism in the X-ray repair cross-complementing group 1 enzyme
(XRCC1) - which is part of the base excision repair system - has been associated with variable
initiation of DNA repair. [57] In addition, a polymorphism in a component of the ubiquitous
nucleotide excision repair pathway - the excision repair cross complementing group 2 (ERCC2)
gene - has been significantly associated with a clinical response to platinum-based chemo‐
therapy. [57] However, there are no known polymorphisms in the DNA mismatch repair
pathway associated with variation in treatment response with Oxaliplatin. In the second
group, it has been reported that platinum compounds are inactivated by glutathione conju‐
gation and therefore the enzymes responsible for catalyzing this reaction have been investi‐
gated. In particular, SNPs in several glutathione-S-transferase (GST) genes have been
implicated in conferring resistance to Oxaliplatin. [57]
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GSTT1 Deletion Decreased activity Increased response Bandrés et al (2007)
GSTM1 Deletion Decreased activity Increased response Bandrés et al (2007)
XRCC1 388Gln Decreased activity Increased response Bandrés et al (2007)
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Table 3. A list of single nucleotide polymorphism (SNP) markers associated with treatment outcome, as reported by
Bandrés et al (2007), when using a chemotherapeutic regimen that includes Oxaliplatin.
It is noteworthy that in a recent study by Fernandez-Rozadilla et al [63], seven SNPs
(rs16857540, rs2465403, rs10876844, rs10784749, rs17626122, rs7325568, rs4243761) were found
to be significantly associated with adverse drug reactions in the context of singular 5-FU or
FOLFOX treatment. Given the relatively large sample size of 221 CRC patients and a validation
set of 791 patients, these results hold strong statistical significance and provide potential
predictive capacity for toxicity response on an individual patient basis if validated through a
larger cohort.
Irinotecan (CPT-11): Irinotecan is a camptothecin analogue with well-established anti-neoplasia
activity exerted though stabilization of the ordinarily transient DNA topoisomerase I-DNA
complex, thus preventing the repair of temporary single stranded breaks during DNA
replication and leading to cell death. [64] There are two primary pathways that have been
implicated in variable response to Irinotecan treatment: drug transport into the extracellular
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environment, and metabolism of Irinotecan into its active (SN-38 and SN-38G) and inactive
metabolites.
Hydrolysis of Irinotecan by carboxylesterases: CES1 and CES2 results in the production of its
active metabolite, SN-38. This metabolite then undergoes detoxification via the process of
glucuronidation, catalyzed by uridine diphosphate-glucurono-syltransferase 1A (UGT1A), to
produce a metabolite called SN-38G which then interacts directly with the DNA topoisomerase
I enzyme. However, Irinotecan can also be oxidized by members of the Cytochrome P450 3A
subfamily (CYP3A) to produce inactivate metabolites. Each of these metabolites is transported
out of the cell by the adenosine-triphosphate (ATP) binding cassette (ABC) transporter
transmembrane proteins. As such, polymorphic variation in these enzymes has been associ‐
ated with altered metabolism, transport and therapeutic efficacy of this drug and its metabo‐
lites. A selection of these SNPs is detailed in the Table 4.




CES2 IVS10-88 Decreased expression Decreased response Bandrés et al (2007)
CYP3A ? Decreased activity Decreased response Bandrés et al (2007)
UGT1A1 UGT1A1*28 Decreased activity
Increased response
Increased toxicity
Bandrés et al (2007)
ABCB1 1236C"/>T Decreased activity
Increased response
Increased toxicity
Bandrés et al (2007)
ABCB1 3435C"/>T Decreased activity
Increased response
Increased toxicity
Bandrés et al (2007)
ABCC2 3792T Increased response Bandrés et al (2007)
ABCG2 421A Decreased activity Increased response Bandrés et al (2007)
Table 4. A list of the single nucleotide polymorphism (SNP) markers associated with treatment outcome, as reported
by Bandrés et al (2007), when using a chemotherapeutic regimen that includes Irinotecan (CPT-11).
Markers of treatment outcomes when treated with biological agents: In recent years there has been
an emergence of a new class of antibody-based therapeutics that directly and specifically target
molecules belonging to processes fundamental to cancer pathophysiology. Comprehensive
reviews of the hallmarks of the cancer phenotype have been updated recently by Hanahan and
Weinberg [65, 66]; in addition, comprehensive reviews of biomarkers associated with mono‐
clonal antibody therapies that are currently in being used in the treatment of this disease have
also been published recently. [56, 60]
Vascular endothelial growth factor as a target: It is well understood that tumours have angiogenic
potential, i.e. they possess the ability to induce the production of new blood vessels, and
thereby increase their supply of oxygen and nutrients; this characteristic provides an oppor‐
tunity for therapeutic intervention, targeting the vascular endothelial growth factor (VEGF)
and associated VEGF receptors (VEGFR-1, -2, and -3). In particular, overexpression of VEGF
has been associated with vascularity, endothelial cell migration and invasion, poor prognosis
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and aggressiveness in most malignancies [67]; mAbs have thus been designed to target VEGF,
thereby reducing the amount of free VEGF, reducing VEGF receptor activation, and ultimately
reducing angiogenesis. [68] A recombinant humanized IgG1 monoclonal antibody, Bevacizu‐
mab, that specifically targets VEGF is currently indicated as part of combination therapy in
metastatic colorectal cancer; however, a biomarker that is predictive of response to anti-VEGF
therapy is yet to be discovered.
Epidermal growth factor receptor as a target: Another fundamental hallmark of the cancer
phenotype is the ability for tumours to alter their response to growth factors through differ‐
ential gene expression of growth factor receptors. This too presents the opportunity interrupt
aberrant growth mechanisms. In colorectal cancer, it has been shown that there is an abnormal
activation of epidermal growth factor receptor (EGFR). [69] As such, a humanized monoclonal
antibody, Cetuximab, targeted at the extracellular domain of EGFR has been evaluated in
clinical trials. This mAb blocks specific EGF-mediated signal transduction events [70], thereby
inhibiting cellular proliferation and inducing apoptosis. [71] Treatment with Cetuximab also
leads to increased responses to classic chemotherapeutic agents and radiotherapy, as well as
inhibiting cellular proliferation, angiogenesis and metastasis. [72] Another recombinant
human IgG2 monoclonal antibody, Panitumumab, which also targets EGFR is currently
indicated in metastatic colorectal carcinoma where there has been resistance to fluoropyrimi‐
dine, Oxaliplatin, and Irinotecan containing regimens.
To date there have been a small but useful number of genes harboring mutations that provide
insight into the outcome of anti-EGFR therapy. For example, the mutational status of the
Kirsten-ras (KRAS) gene is currently being used in predicting treatment benefit in the context
of anti-EGFR therapy for patients with metastatic disease. Other common genes with muta‐
tions relevant to anti-EGFR mAb therapy include BRAF and PIK3CA, as well as loss of
expression of PTEN.
Conclusion: It is clear that SNP biomarkers associated with treatment outcome are generally
found in genes with specific characteristics of cancer pathophysiology, or with drug metabo‐
lism and transport, and numerous low-throughput, focused, yet fruitful studies have resulted
in clinically translatable SNP biomarkers being identified. This contrasts with the high-
throughput transcriptomic approach to identification of biomarker gene panels that is typically
initially blind to the functional significance of each individual gene. As such, these simple SNP
markers present a cost-effective option to predicting the efficacy of a specific therapeutic agent,
or combination thereof, prior to prescription, enabling design of individualized therapy that
will result in increased efficacy and improved treatment outcomes.
5. Epigenomics and epigenetics
Molecular studies of cancer have revealed the presence of not only of genetic mutations, copy
number alterations, altered gene expression, but also of aberrant epigenetic changes. Intense
investigation in recent years has shown that epigenetic regulation of gene expression plays a
crucial role in embryonic development, imprinting, and tissue differentiation. [73] Therefore,
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environment, and metabolism of Irinotecan into its active (SN-38 and SN-38G) and inactive
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glucuronidation, catalyzed by uridine diphosphate-glucurono-syltransferase 1A (UGT1A), to
produce a metabolite called SN-38G which then interacts directly with the DNA topoisomerase
I enzyme. However, Irinotecan can also be oxidized by members of the Cytochrome P450 3A
subfamily (CYP3A) to produce inactivate metabolites. Each of these metabolites is transported
out of the cell by the adenosine-triphosphate (ATP) binding cassette (ABC) transporter
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ated with altered metabolism, transport and therapeutic efficacy of this drug and its metabo‐
lites. A selection of these SNPs is detailed in the Table 4.




CES2 IVS10-88 Decreased expression Decreased response Bandrés et al (2007)
CYP3A ? Decreased activity Decreased response Bandrés et al (2007)
UGT1A1 UGT1A1*28 Decreased activity
Increased response
Increased toxicity
Bandrés et al (2007)
ABCB1 1236C"/>T Decreased activity
Increased response
Increased toxicity
Bandrés et al (2007)
ABCB1 3435C"/>T Decreased activity
Increased response
Increased toxicity
Bandrés et al (2007)
ABCC2 3792T Increased response Bandrés et al (2007)
ABCG2 421A Decreased activity Increased response Bandrés et al (2007)
Table 4. A list of the single nucleotide polymorphism (SNP) markers associated with treatment outcome, as reported
by Bandrés et al (2007), when using a chemotherapeutic regimen that includes Irinotecan (CPT-11).
Markers of treatment outcomes when treated with biological agents: In recent years there has been
an emergence of a new class of antibody-based therapeutics that directly and specifically target
molecules belonging to processes fundamental to cancer pathophysiology. Comprehensive
reviews of the hallmarks of the cancer phenotype have been updated recently by Hanahan and
Weinberg [65, 66]; in addition, comprehensive reviews of biomarkers associated with mono‐
clonal antibody therapies that are currently in being used in the treatment of this disease have
also been published recently. [56, 60]
Vascular endothelial growth factor as a target: It is well understood that tumours have angiogenic
potential, i.e. they possess the ability to induce the production of new blood vessels, and
thereby increase their supply of oxygen and nutrients; this characteristic provides an oppor‐
tunity for therapeutic intervention, targeting the vascular endothelial growth factor (VEGF)
and associated VEGF receptors (VEGFR-1, -2, and -3). In particular, overexpression of VEGF
has been associated with vascularity, endothelial cell migration and invasion, poor prognosis
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and aggressiveness in most malignancies [67]; mAbs have thus been designed to target VEGF,
thereby reducing the amount of free VEGF, reducing VEGF receptor activation, and ultimately
reducing angiogenesis. [68] A recombinant humanized IgG1 monoclonal antibody, Bevacizu‐
mab, that specifically targets VEGF is currently indicated as part of combination therapy in
metastatic colorectal cancer; however, a biomarker that is predictive of response to anti-VEGF
therapy is yet to be discovered.
Epidermal growth factor receptor as a target: Another fundamental hallmark of the cancer
phenotype is the ability for tumours to alter their response to growth factors through differ‐
ential gene expression of growth factor receptors. This too presents the opportunity interrupt
aberrant growth mechanisms. In colorectal cancer, it has been shown that there is an abnormal
activation of epidermal growth factor receptor (EGFR). [69] As such, a humanized monoclonal
antibody, Cetuximab, targeted at the extracellular domain of EGFR has been evaluated in
clinical trials. This mAb blocks specific EGF-mediated signal transduction events [70], thereby
inhibiting cellular proliferation and inducing apoptosis. [71] Treatment with Cetuximab also
leads to increased responses to classic chemotherapeutic agents and radiotherapy, as well as
inhibiting cellular proliferation, angiogenesis and metastasis. [72] Another recombinant
human IgG2 monoclonal antibody, Panitumumab, which also targets EGFR is currently
indicated in metastatic colorectal carcinoma where there has been resistance to fluoropyrimi‐
dine, Oxaliplatin, and Irinotecan containing regimens.
To date there have been a small but useful number of genes harboring mutations that provide
insight into the outcome of anti-EGFR therapy. For example, the mutational status of the
Kirsten-ras (KRAS) gene is currently being used in predicting treatment benefit in the context
of anti-EGFR therapy for patients with metastatic disease. Other common genes with muta‐
tions relevant to anti-EGFR mAb therapy include BRAF and PIK3CA, as well as loss of
expression of PTEN.
Conclusion: It is clear that SNP biomarkers associated with treatment outcome are generally
found in genes with specific characteristics of cancer pathophysiology, or with drug metabo‐
lism and transport, and numerous low-throughput, focused, yet fruitful studies have resulted
in clinically translatable SNP biomarkers being identified. This contrasts with the high-
throughput transcriptomic approach to identification of biomarker gene panels that is typically
initially blind to the functional significance of each individual gene. As such, these simple SNP
markers present a cost-effective option to predicting the efficacy of a specific therapeutic agent,
or combination thereof, prior to prescription, enabling design of individualized therapy that
will result in increased efficacy and improved treatment outcomes.
5. Epigenomics and epigenetics
Molecular studies of cancer have revealed the presence of not only of genetic mutations, copy
number alterations, altered gene expression, but also of aberrant epigenetic changes. Intense
investigation in recent years has shown that epigenetic regulation of gene expression plays a
crucial role in embryonic development, imprinting, and tissue differentiation. [73] Therefore,
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deregulation of such a fundamental mechanism might offer insight into the driving molecular
mechanisms associated with the development, and regulation, of a carcinoma phenotype,
particularly in cases where other genomic perspectives have not yet provided an answer.
In cancer studies, the field of epigenomics has encompassed investigations into aberrant DNA
methylation, post-translational modification of histones that affects chromatin structure,
altered expression of microRNAs and non-coding RNAs, and nucleosome positioning. [73-75]
For complete reviews of this specific topic see Ballestar et al [76], Hatziapostolou et al [77],
Khare et al [74], Lao et al [75], Liu et al [78], Sawan et al [79], Sharma et al [73], Ting et al [80],
and van Engeland et al [81].
DNA methylation studies have focused particularly on the methylation patterns of cytosine
and guanine (CpG)-rich DNA sequences. In particular, regions of the genome that have a
higher than expected number of CpG nucleotides compared to the rest of the genome – so-
called “CpG islands” – are of particular interest because they have been shown to overlap the
promoter regions of 60-70% of genes. [75] An extension of this concept has been the discovery
of CpG sites outside of promoter regions, referred to as “CpG Island shores”, that are within
two kilobases of the 5’ end of a CpG island. [75] Methylation of CpG islands is largely associated
with transcriptional repression [75, 82] and, in general, CpG islands are protected from
aberrant methylation but in cancer this does not appear to be the case. Since methylation
changes can significantly alter gene expression profiles and thereby deregulate important
biological pathways, a sound understanding of which genes and which associated pathways
are affected in which individual patients might in the future be applied in the clinic to guide
the selection of appropriate treatment regimens.
The first report of epigenetic alterations in tumours of the colon revealed an extensive loss of
5’-methylcytosine when compared to normal colon tissue. [83] However, it is only recently
that this area of research has gained increased attention. Today, high-throughput methylation-
specific microarray and sequencing technologies, together with a well-established array of
commercially available methylation assay kits, have facilitated large-scale epigenomic
investigations and contributed to an increased understanding of the methylome on a multi-
gene scale.
Arguably the most important epigenetic finding to date, in the context of colorectal cancer, has
been the identification of a unique molecular subtype characterized by a high frequency of
gene methylation. Colorectal tumours of this variety are now referred to as having the CpG
island Methylator Phenotype (CIMP). The exact panel for diagnosing CIMP varies from study
to study, but the panel of genes proposed by Weisenberger et al [84] has been commonly used,
i.e. NEUROG1, SOCS1, RUNX3, IGF2, and CACNA1G. In general, if a panel has more than 60%
of its genes methylated, then is considered to be CIMP positive. Despite, the lack of a stand‐
ardized CIMP diagnostic panel, this type of tumour is reported to be predominantly associated
with right-sided colon cancer, and tends to be more common in woman. [84, 85]
Diagnosing CIMP tumours is clinically relevant because approximately 20% of colorectal
tumours have this phenotype and generally share a high frequency of the BRAF c.1799T>A (p.
V600E) mutation [75] that has been reported to negatively impact treatment outcomes in anti-
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EGFR mAb-mediated therapy in patients with KRAS wild-type tumours and metastatic
disease. [60, 86, 87] As such, classifying a patient’s tumour as having the CIMP phenotype
could be used in the future to guide the selection of biological therapeutics to ensure that the
most efficacious treatment regimen is utilised.
The current lack of a standardized panel of genes from which to assess the status of genomic
methylation highlights the fact that this is an emerging field of study. As such, the translation
of these panels into the clinic as diagnostic or prognostic biomarkers is still premature.
However, as the field progresses and more literature-based evidence is published in support
and validation of a particular panel, the full potential of such epigenomic biomarkers may
ultimately be translated into patient benefit.
While the field is currently in its infancy, there are a number of encouraging studies that
represent good examples of novel discoveries of methylation markers that have highly
significant associations. For example, Wang et al [88] examined the methylation status of five
tumour suppressor genes in eighty-five paired colorectal tumours and normal mucosa samples
from Chinese patients and showed that the methylation status of two genes, CDH13 and
FLBN3, were significantly associated with stage of disease and prognosis. In particular, CDH13
was significantly associated with poor differentiation (p=0.019) and had a relatively strong
association with advanced stage of disease (p=0.084). In a similar fashion, FLBN3 was signif‐
icantly associated with advanced disease (p=0.027) and with the presence of lymph node
metastasis (p=0.029). Furthermore, CDH13 and/or FLBN3 methylation status was found to be
predictive of a poor overall survival (p=0.001) and conversely the presence of methylated
hMHL1 indicated a better chance of survival (p=0.046).
In a clinical setting, samples that are obtained in a non- or minimally invasive manner are
preferred and there have been a number of studies based on stool and blood plasma samples
to assess aberrant methylation patterns. One example is the clinically validated methylation
status of the Vimentin gene (VIM) - which has been found in the majority of colorectal tumours
(53 – 84%; Lao et al 2011) – with assays conducted on stool samples, thus providing a non-
invasive mechanism for early detection of colorectal cancer. This assay is currently commer‐
cially available in the United States as the ColoGuard assay (LabCorp), and reports a sensitivity
of 83% and a specificity of 82%. [89, 90] Outside of the United States, in Europe and the Middle
East there is now an additional non-invasive test for early detection of colorectal cancer by
assessing the methylation status of SEPT9. This assay is currently commercially available as
Epi proColon (Epigenomics AG).
The field of epigenomics, and epigenetics, applied to colorectal cancer is providing valuable
insights into underlying mechanisms of this disease and seems to be a promising avenue of
research. It is clear that assessing the status of DNA methylation alone holds prognostic and
predictive value, and as such we would expect this field to gain much momentum towards
translating these findings into a routine clinical setting. As this field of study can be conducted
on a broad spectrum of sample types, along with commercially available kits to assess
methylation, this field is likely to see an increased number of significant findings in the near
future. However, as in the case of gene expression-based biomarkers, each epigenetic finding
will need to be assessed in patients of diverse ethnicities. A recent study by Nieminen et al [91]
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two kilobases of the 5’ end of a CpG island. [75] Methylation of CpG islands is largely associated
with transcriptional repression [75, 82] and, in general, CpG islands are protected from
aberrant methylation but in cancer this does not appear to be the case. Since methylation
changes can significantly alter gene expression profiles and thereby deregulate important
biological pathways, a sound understanding of which genes and which associated pathways
are affected in which individual patients might in the future be applied in the clinic to guide
the selection of appropriate treatment regimens.
The first report of epigenetic alterations in tumours of the colon revealed an extensive loss of
5’-methylcytosine when compared to normal colon tissue. [83] However, it is only recently
that this area of research has gained increased attention. Today, high-throughput methylation-
specific microarray and sequencing technologies, together with a well-established array of
commercially available methylation assay kits, have facilitated large-scale epigenomic
investigations and contributed to an increased understanding of the methylome on a multi-
gene scale.
Arguably the most important epigenetic finding to date, in the context of colorectal cancer, has
been the identification of a unique molecular subtype characterized by a high frequency of
gene methylation. Colorectal tumours of this variety are now referred to as having the CpG
island Methylator Phenotype (CIMP). The exact panel for diagnosing CIMP varies from study
to study, but the panel of genes proposed by Weisenberger et al [84] has been commonly used,
i.e. NEUROG1, SOCS1, RUNX3, IGF2, and CACNA1G. In general, if a panel has more than 60%
of its genes methylated, then is considered to be CIMP positive. Despite, the lack of a stand‐
ardized CIMP diagnostic panel, this type of tumour is reported to be predominantly associated
with right-sided colon cancer, and tends to be more common in woman. [84, 85]
Diagnosing CIMP tumours is clinically relevant because approximately 20% of colorectal
tumours have this phenotype and generally share a high frequency of the BRAF c.1799T>A (p.
V600E) mutation [75] that has been reported to negatively impact treatment outcomes in anti-
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EGFR mAb-mediated therapy in patients with KRAS wild-type tumours and metastatic
disease. [60, 86, 87] As such, classifying a patient’s tumour as having the CIMP phenotype
could be used in the future to guide the selection of biological therapeutics to ensure that the
most efficacious treatment regimen is utilised.
The current lack of a standardized panel of genes from which to assess the status of genomic
methylation highlights the fact that this is an emerging field of study. As such, the translation
of these panels into the clinic as diagnostic or prognostic biomarkers is still premature.
However, as the field progresses and more literature-based evidence is published in support
and validation of a particular panel, the full potential of such epigenomic biomarkers may
ultimately be translated into patient benefit.
While the field is currently in its infancy, there are a number of encouraging studies that
represent good examples of novel discoveries of methylation markers that have highly
significant associations. For example, Wang et al [88] examined the methylation status of five
tumour suppressor genes in eighty-five paired colorectal tumours and normal mucosa samples
from Chinese patients and showed that the methylation status of two genes, CDH13 and
FLBN3, were significantly associated with stage of disease and prognosis. In particular, CDH13
was significantly associated with poor differentiation (p=0.019) and had a relatively strong
association with advanced stage of disease (p=0.084). In a similar fashion, FLBN3 was signif‐
icantly associated with advanced disease (p=0.027) and with the presence of lymph node
metastasis (p=0.029). Furthermore, CDH13 and/or FLBN3 methylation status was found to be
predictive of a poor overall survival (p=0.001) and conversely the presence of methylated
hMHL1 indicated a better chance of survival (p=0.046).
In a clinical setting, samples that are obtained in a non- or minimally invasive manner are
preferred and there have been a number of studies based on stool and blood plasma samples
to assess aberrant methylation patterns. One example is the clinically validated methylation
status of the Vimentin gene (VIM) - which has been found in the majority of colorectal tumours
(53 – 84%; Lao et al 2011) – with assays conducted on stool samples, thus providing a non-
invasive mechanism for early detection of colorectal cancer. This assay is currently commer‐
cially available in the United States as the ColoGuard assay (LabCorp), and reports a sensitivity
of 83% and a specificity of 82%. [89, 90] Outside of the United States, in Europe and the Middle
East there is now an additional non-invasive test for early detection of colorectal cancer by
assessing the methylation status of SEPT9. This assay is currently commercially available as
Epi proColon (Epigenomics AG).
The field of epigenomics, and epigenetics, applied to colorectal cancer is providing valuable
insights into underlying mechanisms of this disease and seems to be a promising avenue of
research. It is clear that assessing the status of DNA methylation alone holds prognostic and
predictive value, and as such we would expect this field to gain much momentum towards
translating these findings into a routine clinical setting. As this field of study can be conducted
on a broad spectrum of sample types, along with commercially available kits to assess
methylation, this field is likely to see an increased number of significant findings in the near
future. However, as in the case of gene expression-based biomarkers, each epigenetic finding
will need to be assessed in patients of diverse ethnicities. A recent study by Nieminen et al [91]
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highlighted this in observing that colorectal carcinomas in an Egyptian cohort had a signifi‐
cantly higher state of methylation, in microsatellite stable tumours, compared with sporadic
colorectal cancers in a Finnish cohort.
5.1. Proteomics
The field of proteomics deals with identification of the total complement of peptides and
proteins expressed in a cell, tissue or an organism and is in principle more directly related to
phenotypic changes associated with disease pathogenesis. Proteomic studies are able to define:
the functional state of protein activities; protein-ligand interactions; protein-protein interac‐
tions; and a host of dynamic post-translational modifications such as glycosylation, phos‐
phorylation, ubiquitinylation, SUMOylation, proteolytic cleavage, lipoylation and acetylation
of proteins. The proteome of a cell may vary from one time point to another and in different
states of health and disease so proteomics techniques have been employed to identify cancer
specific proteomes as a means to identify candidate biomarkers of early disease. A huge
amount of data is generated from single proteomic experiments and these are typically
analyzed to understand the mechanistic pathways of pathologic events in protein networks
using various databases, workflows and algorithms. For proteomics analysis, complex
mixtures of proteins derived from a given biological sample are typically rendered into a set
of peptides via proteolysis, most commonly using the enzyme trypsin; direct liquid chroma‐
tography-tandem mass spectrometry (LC-MS/MS) based methods are then typically employed
to separate, quantify and identify thousands of individual tryptic peptides in a sample [92-94],
from which the identity and quantity of the parent proteins in the original biological sample
can be inferred. For example, one notable recent study identified and quantified >7,000 unique
proteins from FFPE tissue blocks from individual colorectal cancer patients [95], amply
demonstrating the potential of the technology.
Common sources of current proteomics biomarkers for CRC include stool, blood, biopsy and
urine samples. A common fecal proteomics biomarker in use today is hemoglobin [96], while
carcinoembryonic antigen (CEA) is a common blood-based biomarker currently in use. [97]
Tissue inhibitor of metalloproteinase 1 (TIMP-1) has also been used and has been found useful
in the early detection of cancer although, paradoxically, other studies using multivariate
analysis have described TIMP-1 as independent of the stage of cancer. [98] Proteasome
activator complex subunit-3 (PSME-3), nicotinamide N-methyltransferase (NNMT), collapsin
response mediator protein-2 (CRMP-2), MIF, M2-PK, M-CSF, HNP 1-3, CCSA-2, CCSA-3,
CCSA-4, laminin, MMP-9, MMP-7, and a host of other serum proteomics biomarkers are being
developed and optimized for clinical use. For example, surface enhanced laser desorption-
ionisation (SELDI) mass spectrometry was used to analyze the serum of 62 CRC patients
compared to 31 controls, and four proteomic markers were found in detectable levels in the
serum of CRC patients: apolipoprotein C1, alpha-1-antitrypsin, C3a-desArg and transferrin.
[99] A separate study carried out at the Mayo Clinic revealed elevated levels of 5 serum
biomarkers in CRC: DcR3, TRAIL-2, spondin-1, MIC 1 and Reg IV [100]; usefully, this ‘5-
biomarker panel’ has been reported to exceed the performance of CEA both in specificity and
sensitivity. Immunoproteomics - involving techniques such as immunoblotting, ELISA and
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immunocapture-mass spectrometry - has also yielded candidate biomarkers in CRC, including
antibodies against inosine monophosphate dehydrogenase II [101], MUC-5A, MUC-1,
MAPKAPK3, AVCR2B, HlpA, RpL7/L12, and nucleobindin- 1. [102-106]
5.2. Lipidomics
Lipidomics is a novel ‘omics field which deals with complex large scale analysis of the full
complement of various classes of lipids and lipid networks expressed by a cell, tissue or
organism (the ‘lipidome’) and involves the high throughput systems-level identification and
quantification of lipid metabolic pathways that may be involved in disease using chromato‐
graphic methods coupled to mass spectrometry. Generally, lipids are hydrophobic molecules
that are involved in energy storage, structural components of a cell, cell signaling, endocrine
actions, signal transduction, membrane trafficking, and morphogenesis. Structurally, lipids
can be classified as: fatty acids; glycerolipids; glycerophospholipids; sphingolipids; sterol
lipids; prenol lipids; saccharolipids; and polyketides. These 8 classes of lipids can also be
further subdivided into several subclasses.
Whilst there is currently a paucity of clinically validated lipidomics biomarkers for colorectal
cancer, the prospects of this field to complement proteomics and genomics in a combined
‘systems biology’ approach for disease detection, monitoring and treatment is worth consid‐
eration since over the past two decades, numerous publications have described the perturba‐
tion of lipid metabolism and signaling in colorectal carcinogenesis. [107-110] Lipidomics
analysis of primary and metastatic colorectal cancer cell lines (SW480 and SW620) identified
600 and 694 lipids respectively in ‘shotgun’ study [111]; increased level of triglyceride lipid
and plasmacholine were observed, while a decrease in the level of C-16 containing sphingo‐
myelin, ceramide lipid and plasmenylethanolamine were observed in the metastatic CRC cell
line compared to the primary isogenic CRC cell line, implying that lipidomic biomarkers of
metastatic CRC disease might be plausible.
Empirically, polyunsaturated fatty acids have been known to be more beneficial in the
prevention of colorectal diseases compared to saturated long-chain types, but the pathways
related to this were largely unclear. The emergence of lipidomics techniques however has
revealed that metabolic control of long chain fatty acids is an important factor in development
of CRC, with short chain fatty acids from the gut microflora/ microbiome being described as
onco-preventive. [112]
Elevated level of lysophosphatidic acid - a phosphoglyceride - has been described as a
prospective cancer biomarker of ovarian tumours [113-115] but, paradoxically, a marked
decrease in the serum level of lysophosphatidylcholine has been reported in CRC. [116]
Similarly, elevated profiles of phosphatidylcholine and choline kinase activity have been
demonstrated it colon cancers [117] and a high ratio of phosphatidylcholine to phosphatidy‐
lethanolamine has been used to differential metastatic colon cancers from localized ones. [118]
Elevated levels of sphingomyelin have also been reported to characterize human colon cancer,
based on nuclear magnetic resonance (NMR) studies [119], whilst cancer cell motility was
shown to be down-regulated by the interaction between CD9 and sialoglycosphingolipid GM3
using CRC cell lines [120] and ceramides have been found to induce apoptosis in CRC cell lines
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Empirically, polyunsaturated fatty acids have been known to be more beneficial in the
prevention of colorectal diseases compared to saturated long-chain types, but the pathways
related to this were largely unclear. The emergence of lipidomics techniques however has
revealed that metabolic control of long chain fatty acids is an important factor in development
of CRC, with short chain fatty acids from the gut microflora/ microbiome being described as
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Elevated level of lysophosphatidic acid - a phosphoglyceride - has been described as a
prospective cancer biomarker of ovarian tumours [113-115] but, paradoxically, a marked
decrease in the serum level of lysophosphatidylcholine has been reported in CRC. [116]
Similarly, elevated profiles of phosphatidylcholine and choline kinase activity have been
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lethanolamine has been used to differential metastatic colon cancers from localized ones. [118]
Elevated levels of sphingomyelin have also been reported to characterize human colon cancer,
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(HT-29, LOVO, and HCT-116). [121-123] Urinary phospholipids analysis using nanoflow LC-
ESI MS/MS has been previously used for the analysis of breast [124, 125]) and prostate cancer
[124], but there is a dearth of literature on the application of this method to colorectal cancer.
Interestingly though, urinary levels of metabolites of prostaglandin E2 have been used as a
biomarker for colorectal cancer risk evaluation. [126, 127] Overall, these observations of
disease-associated variation in colorectal cancer lipid profiles provide a sound precedent for
the future development of reliable lipidomics biomarkers.
5.3. Metabolomics
The relatively new field of ‘omics techniques that investigates the presence and abundance of
low molecular weight metabolites in cells and body fluids is known as ‘metabolomics’. This
new branch in the ‘omics world has emerged to address molecular biologic problems that have
hitherto not been amenable to genomics or proteomics approaches. Common specimens
compatible with metabolomics experiments include urine, serum and tissue. As is the case for
genomics, proteomics and lipidomics, the ‘metabolome’ changes depending on physiologic
and pathologic states of an individual and identification of unique metabolites provides
potentially useful insight into pathogenetic mechanism of disease.
A number of analytical techniques have been used for metabolomics research, including: gas
chromatography mass spectrometry (GC-MS); liquid chromatography mass spectrometry
(LC-MS); capillary electrophoresis mass spectrometry (CE-MS); matrix assisted laser desorp‐
tion-ionization mass spectrometry (MALDI-MS); and nuclear magnetic resonance (NMR).
[128] By way of example, metabolomics studies on CRC patient serum samples, using a
combination of proton-NMR and GC-MS techniques, was used to differentiate locoregional
CRC from metastatic types as well as to identify CRC that metastasized to the liver. [129]
Separately, in a review of eight metabolomics studies on CRC for diagnostic accuracy and
distinguishing metabolites, twelve metabolites were found to be elevated. [130] In a further
study using GC-MS, 34 endogenous metabolites were found significantly elevated in CRC
compared with health individual, whilst the serum 3-hydroxybutyric acid level was noted to
be reduced. [131] A predictive model developed in yet another study comprised of 2-hydrox‐
ybutyrate, kynurenine, cystamine and aspartic acid and was found to have specificity,
sensitivity and accuracy as high as 85%, 85%, and 85% respectively. [128] Finally, Cheng et al
[132] found evidence of dysregulation of several metabolic pathways through urine analysis
of colorectal cancer patients, whilst Qui et al [133] also observed evidence of similar pertur‐
bations in tricarboxylic acid (TCA) and tryptophan metabolic pathways. With a solid founda‐
tion, a panel of metabolite markers may ultimately be developed for metabolomic profiling of
colorectal patients as a means to improve diagnosis.
5.4. Molecular Imaging
Visualisation of precursor lesions and of malignant tissue is a major aspect of diagnosis and
monitoring of therapeutic interventions in oncology. Classically this has been carried out using
anatomical and functional technologies, such as Ultrasound (US), Computerised Tomography
(CT), and Magnetic Resonance Imaging (MRI). While these approaches have been the mainstay
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of medical imaging, they are limited to information at the gross anatomical and physiological
levels respectively. Recent years have however seen the emergence of molecular imaging and
its addition to the repertoire of techniques to visualise disease.
In previous sections we have discussed how a range of different ‘omics technologies have
facilitated an in-depth view of the pathophysiology and molecular pathology of cancer. These
insights provide candidate biomarkers based on the identification of differentially expressed
genes and proteins between tumours and normal tissue. These biomarkers have either been
associated with prognosis, stage of disease, molecular subtypes, predictors of treatment
outcome, and markers of discriminating carcinoma from benign lesions at the molecular level.
In this light, molecular imaging is then the science of utilising the ever-increasing knowledge
of cancer molecular pathology to: identify the appropriate molecular targets; design molecular
constructs to selectively and specifically interact with them; and produce a visual signal that
is measurable through an imaging technology. In order for this methodology to succeed at the
molecular level, the target should be available for interaction and should be unique enough to
ensure selective and specific interactions. Furthermore, once a signal has been generated from
the appropriate interaction, it is important that a suitably sensitive imagining technology exists
in order to visualise, and quantify, signal emission.
In the context of colorectal cancer, plasma-membrane associated proteins are generally
considered good candidate targets since they are reasonably accessible and a subset of them
play vital roles in signal transduction. In a similar fashion, aberrantly expressed or deregulated
intracellular and secreted enzymes represent potentially useful targets for molecular imaging,
based on their ability to catalyse formation of spectroscopically-measurable products. Both of
these types of targets are accessible through the extensive vascularisation of the colorectum,
but more importantly these targets can be accessed via the luminal surface through topical
application of an appropriately designed molecular construct.
Molecular imaging provides tremendous opportunities to enhance the early detection of CRC,
as well as potentially aiding the demarcation of clear margins during surgical resection, as
reviewed recently by Abdullah [134], Seaman et al [135] and Akin et al [136].
By way of illustration of the potential of molecular imaging methods, colorectal cancers have
been found to naturally emit a red fluorescent signal due to the accumulation of protopor‐
phyrin IX (PpIX) in primary colorectal tumours and associated metastases located in lymph
nodes. [137] These authors postulated that endogenous PpIX accumulates as a result of
aberrant metabolic changes in the CRC cells; Kemmner et al [138] subsequently provided
supporting evidence for this hypothesis by showing that there is a significant down-regulation
of ferrochelatase (FECH) mRNA expression in gastric, colon, and rectal carcinomas, leading
to accumulation of PpIX. In an effort to utilise this information Moesta et al [137] found that
metastatically involved lymph nodes could be identified compared to all other palpable nodes;
in the context of previously untreated patients (n=24), this observation had a sensitivity of 62%
and a specificity of 78% (p < 0.0001). However, in a neoadjuvant setting there was a reduction
in PpIX fluorescence in primary tumours, and a drastic reduction of fluorescent signal in
metastases that resulted in not being able to discriminate between lymph nodes containing
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[124], but there is a dearth of literature on the application of this method to colorectal cancer.
Interestingly though, urinary levels of metabolites of prostaglandin E2 have been used as a
biomarker for colorectal cancer risk evaluation. [126, 127] Overall, these observations of
disease-associated variation in colorectal cancer lipid profiles provide a sound precedent for
the future development of reliable lipidomics biomarkers.
5.3. Metabolomics
The relatively new field of ‘omics techniques that investigates the presence and abundance of
low molecular weight metabolites in cells and body fluids is known as ‘metabolomics’. This
new branch in the ‘omics world has emerged to address molecular biologic problems that have
hitherto not been amenable to genomics or proteomics approaches. Common specimens
compatible with metabolomics experiments include urine, serum and tissue. As is the case for
genomics, proteomics and lipidomics, the ‘metabolome’ changes depending on physiologic
and pathologic states of an individual and identification of unique metabolites provides
potentially useful insight into pathogenetic mechanism of disease.
A number of analytical techniques have been used for metabolomics research, including: gas
chromatography mass spectrometry (GC-MS); liquid chromatography mass spectrometry
(LC-MS); capillary electrophoresis mass spectrometry (CE-MS); matrix assisted laser desorp‐
tion-ionization mass spectrometry (MALDI-MS); and nuclear magnetic resonance (NMR).
[128] By way of example, metabolomics studies on CRC patient serum samples, using a
combination of proton-NMR and GC-MS techniques, was used to differentiate locoregional
CRC from metastatic types as well as to identify CRC that metastasized to the liver. [129]
Separately, in a review of eight metabolomics studies on CRC for diagnostic accuracy and
distinguishing metabolites, twelve metabolites were found to be elevated. [130] In a further
study using GC-MS, 34 endogenous metabolites were found significantly elevated in CRC
compared with health individual, whilst the serum 3-hydroxybutyric acid level was noted to
be reduced. [131] A predictive model developed in yet another study comprised of 2-hydrox‐
ybutyrate, kynurenine, cystamine and aspartic acid and was found to have specificity,
sensitivity and accuracy as high as 85%, 85%, and 85% respectively. [128] Finally, Cheng et al
[132] found evidence of dysregulation of several metabolic pathways through urine analysis
of colorectal cancer patients, whilst Qui et al [133] also observed evidence of similar pertur‐
bations in tricarboxylic acid (TCA) and tryptophan metabolic pathways. With a solid founda‐
tion, a panel of metabolite markers may ultimately be developed for metabolomic profiling of
colorectal patients as a means to improve diagnosis.
5.4. Molecular Imaging
Visualisation of precursor lesions and of malignant tissue is a major aspect of diagnosis and
monitoring of therapeutic interventions in oncology. Classically this has been carried out using
anatomical and functional technologies, such as Ultrasound (US), Computerised Tomography
(CT), and Magnetic Resonance Imaging (MRI). While these approaches have been the mainstay
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of medical imaging, they are limited to information at the gross anatomical and physiological
levels respectively. Recent years have however seen the emergence of molecular imaging and
its addition to the repertoire of techniques to visualise disease.
In previous sections we have discussed how a range of different ‘omics technologies have
facilitated an in-depth view of the pathophysiology and molecular pathology of cancer. These
insights provide candidate biomarkers based on the identification of differentially expressed
genes and proteins between tumours and normal tissue. These biomarkers have either been
associated with prognosis, stage of disease, molecular subtypes, predictors of treatment
outcome, and markers of discriminating carcinoma from benign lesions at the molecular level.
In this light, molecular imaging is then the science of utilising the ever-increasing knowledge
of cancer molecular pathology to: identify the appropriate molecular targets; design molecular
constructs to selectively and specifically interact with them; and produce a visual signal that
is measurable through an imaging technology. In order for this methodology to succeed at the
molecular level, the target should be available for interaction and should be unique enough to
ensure selective and specific interactions. Furthermore, once a signal has been generated from
the appropriate interaction, it is important that a suitably sensitive imagining technology exists
in order to visualise, and quantify, signal emission.
In the context of colorectal cancer, plasma-membrane associated proteins are generally
considered good candidate targets since they are reasonably accessible and a subset of them
play vital roles in signal transduction. In a similar fashion, aberrantly expressed or deregulated
intracellular and secreted enzymes represent potentially useful targets for molecular imaging,
based on their ability to catalyse formation of spectroscopically-measurable products. Both of
these types of targets are accessible through the extensive vascularisation of the colorectum,
but more importantly these targets can be accessed via the luminal surface through topical
application of an appropriately designed molecular construct.
Molecular imaging provides tremendous opportunities to enhance the early detection of CRC,
as well as potentially aiding the demarcation of clear margins during surgical resection, as
reviewed recently by Abdullah [134], Seaman et al [135] and Akin et al [136].
By way of illustration of the potential of molecular imaging methods, colorectal cancers have
been found to naturally emit a red fluorescent signal due to the accumulation of protopor‐
phyrin IX (PpIX) in primary colorectal tumours and associated metastases located in lymph
nodes. [137] These authors postulated that endogenous PpIX accumulates as a result of
aberrant metabolic changes in the CRC cells; Kemmner et al [138] subsequently provided
supporting evidence for this hypothesis by showing that there is a significant down-regulation
of ferrochelatase (FECH) mRNA expression in gastric, colon, and rectal carcinomas, leading
to accumulation of PpIX. In an effort to utilise this information Moesta et al [137] found that
metastatically involved lymph nodes could be identified compared to all other palpable nodes;
in the context of previously untreated patients (n=24), this observation had a sensitivity of 62%
and a specificity of 78% (p < 0.0001). However, in a neoadjuvant setting there was a reduction
in PpIX fluorescence in primary tumours, and a drastic reduction of fluorescent signal in
metastases that resulted in not being able to discriminate between lymph nodes containing
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metastatic cells. In a follow-up study by Wan et al [139], conducted in xenografted nude mice,
a novel siRNA-mediated knockdown of FECH was used to enhance the accumulation of PpIX,
thereby increasing the endogenous fluorescence in tumour cells. While these results still need
to be developed further, and tested in a clinical trial, they do hold promise for increasing the
accuracy of early detection of primary and metastatic lesions and monitoring therapeutic
response based on the size of the visualised tumour.
In different work, differential gene expression profiling, confirmed by immunohistochemistry,
demonstrated that matrix-metalloproteases (MMPs) are differentially expressed in the context
of colorectal adenocarcinoma by macrophage subpopulations and, at times, by the tumours
themselves. MMPs are a family of zinc-dependent endopeptidases with multiple human
peptidase members. For example, MMP-9 is able to degrade specific components of the
extracellular matrix, including type IV collagen, after activation of the secreted zymogen [140]
and as a direct consequence, malignant cells are thereby able to become mobile and achieve
metastatic potential.
Of particular interest to surgical resection was the finding that colorectal adenocarcinomas
express MMP-9 via a distinct macrophage subpopulation found at the edge of primary tumours
and local lymph node metastases. [140] Fudala et al [141] have subsequently designed a dual
fluorophore beacon molecule that is specifically cleaved by MMP-9, resulting in the emission
of a specific fluorescent signal, suggesting that if a suitably non-invasive and anti-immuno‐
genic method is developed to administer the beacon molecule to an anatomical structure under
investigation, then accurate measurement of the tumour edge may be possible during surgical
resection procedures.
As can be seen from the above examples, molecular imaging holds considerable promise for
application in CRC. As this field becomes more developed and is validated through clinical
trials, it should provide improved visualisation ability coupled with the ability to quantify
specific molecules, enabling novel insights into diagnosis, prognosis, treatment response
monitoring, and underlying tumour physiology and molecular pathology in CRC.
5.5. Cancer nanotechnology
Nanotechnology as a division of engineering concerned with the manipulation of atomic and
subatomic molecules has recently found its place in the detection, staging, imaging, and
management of human cancers. Various physical, chemical and biologic principles have been
applied to improve the diagnosis and treatment using elements and molecules in the Nano-
range (~10-9). [142]
For diagnosis of CRC, nanoparticles have been used to enhance the precision and reliability
of colonoscopy and other conventional diagnostic methods, largely resulting in earlier
detection and obviating variables such as operator skills and speed of examination. Quantum
dots (QD) and surface-enhanced Raman scattering (SERS) are two important nano- method‐
ologies used to improve tissue based diagnosis of cancer, avoiding the cumbersome protocols
and lower reliability of multiplexed tissue staining. Both methods have the ability to detect
multiple biomolecular signals in a single cancer cell. Gold and silver particles have been
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derivatized and stabilized with Raman active particles and silica respectively for used in
generating composite organic and inorganic nanoparticles (COINs) for potential improvement
of biopsy diagnosis. [143] Simultaneous Multiple Aptamers and RGD Targeting (SMART)
cancer probes have also been used to detect multiple cancer biomarker signals using currently
available imaging techniques. [144] Superconducting quantum interference device (SQUID)
sensors and magnetic relaxometry - which are both nanotechnology based techniques - have
been reported to be more accurate in the diagnosis of breast cancer than mammography and
MRI respectively. KRAS mutant alleles have been detected in gastrointestinal malignancies,
including colorectal carcinoma, using nanofluidic digital PCR which showed a better per‐
formance in detection of mutation KRAS in colorectal adenomas compared to conventional
PCR. [145] Nanoparticles have been coupled with short cancer specific oligonucleotides
(aptamers) for targeted binding to prostate specific membrane antigen positive cells in prostate
cancer cell lines. [146] Finally, serum detection of colorectal cancer has been achieved with
gold nanoparticles using SERS spectroscopy in a study which exemplified the use of this
approach as a viable, minimally invasive screening method for colorectal cancer. [147]
Nanotechnology also has significant potential in the development of targeted therapeutics for
cancer, with many studies currently at experimental- and a few at clinical validation stages.
Different types of nanostructures, including mesoporous silica nanoshells, dendrimers,
supramagnetic iron cores, nanosuspensions, gold nanoparticles, nanolipogels, nanoemul‐
sions, carbon nanotubes, titanium oxide nanoparticles, liposomes, polymeric miscelles, and
other lipid based nanoparticles have been used as drug delivery vehicles and facilitators of
targeted cancer therapies. [148-155] Although most of the cancer nanodiagnostic and nano‐
therapy studies are still in their infancy, it seems clear that nanotechnology will play an
important role in colorectal cancer diagnostics and therapeutics in the future.
6. Prospects of ‘Omics based molecular approaches in colorectal cancer
diagnosis and treatment in a developing country: A case study in Cape
Town
Groote Schuur Hospital, situated in Cape Town, South Africa, is a quaternary hospital where
the many colorectal cancer patients from the Western Province region are treated by combi‐
nations of radiotherapy, colonic resection and standard chemotherapeutic regimens. However,
there are two complicating factors involved in treating these patients with the greatest efficacy:
(1) the relatively high cost of utilising platinum- or modern monoclonal antibody-based
regimens; and (2) the fact that the majority of patients present with advanced stages of disease,
typically between TNM stage II and III. As mentioned earlier, these stages of disease have
relatively high recurrence rates and as such timely diagnosis and efficacious treatment
schedules are needed to reduce disease recurrence and improve patient prognoses.
To illustrate this point, consider the cost of the standard chemotherapeutic regimen of 5-
fluorouracil (5-FU) alone versus Oxaliplatin: One cycle of Oxaliplatin costs approximately ZAR
5,000.00 (~USD 560), while one cycle of 5-FU is drastically less at a cost of ZAR 200 (~USD 22).
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metastatic cells. In a follow-up study by Wan et al [139], conducted in xenografted nude mice,
a novel siRNA-mediated knockdown of FECH was used to enhance the accumulation of PpIX,
thereby increasing the endogenous fluorescence in tumour cells. While these results still need
to be developed further, and tested in a clinical trial, they do hold promise for increasing the
accuracy of early detection of primary and metastatic lesions and monitoring therapeutic
response based on the size of the visualised tumour.
In different work, differential gene expression profiling, confirmed by immunohistochemistry,
demonstrated that matrix-metalloproteases (MMPs) are differentially expressed in the context
of colorectal adenocarcinoma by macrophage subpopulations and, at times, by the tumours
themselves. MMPs are a family of zinc-dependent endopeptidases with multiple human
peptidase members. For example, MMP-9 is able to degrade specific components of the
extracellular matrix, including type IV collagen, after activation of the secreted zymogen [140]
and as a direct consequence, malignant cells are thereby able to become mobile and achieve
metastatic potential.
Of particular interest to surgical resection was the finding that colorectal adenocarcinomas
express MMP-9 via a distinct macrophage subpopulation found at the edge of primary tumours
and local lymph node metastases. [140] Fudala et al [141] have subsequently designed a dual
fluorophore beacon molecule that is specifically cleaved by MMP-9, resulting in the emission
of a specific fluorescent signal, suggesting that if a suitably non-invasive and anti-immuno‐
genic method is developed to administer the beacon molecule to an anatomical structure under
investigation, then accurate measurement of the tumour edge may be possible during surgical
resection procedures.
As can be seen from the above examples, molecular imaging holds considerable promise for
application in CRC. As this field becomes more developed and is validated through clinical
trials, it should provide improved visualisation ability coupled with the ability to quantify
specific molecules, enabling novel insights into diagnosis, prognosis, treatment response
monitoring, and underlying tumour physiology and molecular pathology in CRC.
5.5. Cancer nanotechnology
Nanotechnology as a division of engineering concerned with the manipulation of atomic and
subatomic molecules has recently found its place in the detection, staging, imaging, and
management of human cancers. Various physical, chemical and biologic principles have been
applied to improve the diagnosis and treatment using elements and molecules in the Nano-
range (~10-9). [142]
For diagnosis of CRC, nanoparticles have been used to enhance the precision and reliability
of colonoscopy and other conventional diagnostic methods, largely resulting in earlier
detection and obviating variables such as operator skills and speed of examination. Quantum
dots (QD) and surface-enhanced Raman scattering (SERS) are two important nano- method‐
ologies used to improve tissue based diagnosis of cancer, avoiding the cumbersome protocols
and lower reliability of multiplexed tissue staining. Both methods have the ability to detect
multiple biomolecular signals in a single cancer cell. Gold and silver particles have been
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derivatized and stabilized with Raman active particles and silica respectively for used in
generating composite organic and inorganic nanoparticles (COINs) for potential improvement
of biopsy diagnosis. [143] Simultaneous Multiple Aptamers and RGD Targeting (SMART)
cancer probes have also been used to detect multiple cancer biomarker signals using currently
available imaging techniques. [144] Superconducting quantum interference device (SQUID)
sensors and magnetic relaxometry - which are both nanotechnology based techniques - have
been reported to be more accurate in the diagnosis of breast cancer than mammography and
MRI respectively. KRAS mutant alleles have been detected in gastrointestinal malignancies,
including colorectal carcinoma, using nanofluidic digital PCR which showed a better per‐
formance in detection of mutation KRAS in colorectal adenomas compared to conventional
PCR. [145] Nanoparticles have been coupled with short cancer specific oligonucleotides
(aptamers) for targeted binding to prostate specific membrane antigen positive cells in prostate
cancer cell lines. [146] Finally, serum detection of colorectal cancer has been achieved with
gold nanoparticles using SERS spectroscopy in a study which exemplified the use of this
approach as a viable, minimally invasive screening method for colorectal cancer. [147]
Nanotechnology also has significant potential in the development of targeted therapeutics for
cancer, with many studies currently at experimental- and a few at clinical validation stages.
Different types of nanostructures, including mesoporous silica nanoshells, dendrimers,
supramagnetic iron cores, nanosuspensions, gold nanoparticles, nanolipogels, nanoemul‐
sions, carbon nanotubes, titanium oxide nanoparticles, liposomes, polymeric miscelles, and
other lipid based nanoparticles have been used as drug delivery vehicles and facilitators of
targeted cancer therapies. [148-155] Although most of the cancer nanodiagnostic and nano‐
therapy studies are still in their infancy, it seems clear that nanotechnology will play an
important role in colorectal cancer diagnostics and therapeutics in the future.
6. Prospects of ‘Omics based molecular approaches in colorectal cancer
diagnosis and treatment in a developing country: A case study in Cape
Town
Groote Schuur Hospital, situated in Cape Town, South Africa, is a quaternary hospital where
the many colorectal cancer patients from the Western Province region are treated by combi‐
nations of radiotherapy, colonic resection and standard chemotherapeutic regimens. However,
there are two complicating factors involved in treating these patients with the greatest efficacy:
(1) the relatively high cost of utilising platinum- or modern monoclonal antibody-based
regimens; and (2) the fact that the majority of patients present with advanced stages of disease,
typically between TNM stage II and III. As mentioned earlier, these stages of disease have
relatively high recurrence rates and as such timely diagnosis and efficacious treatment
schedules are needed to reduce disease recurrence and improve patient prognoses.
To illustrate this point, consider the cost of the standard chemotherapeutic regimen of 5-
fluorouracil (5-FU) alone versus Oxaliplatin: One cycle of Oxaliplatin costs approximately ZAR
5,000.00 (~USD 560), while one cycle of 5-FU is drastically less at a cost of ZAR 200 (~USD 22).
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The response rate obtained with 5-FU alone can be improved by utilising Leucovorin (LV) in
a combination therapy approach. However, it has been observed that the further addition of
Oxaliplatin or Irinotecan can improve the stage II/III CRC response rates drastically to around
40 – 50%. [156, 157] The relatively recent appearance of monoclonal antibody based therapies
has also offered significant gains in treatment response rates.
South Africa is a developing nation with a limited budget for treating non-communicable
diseases such as cancer, not least because a large proportion of the country’s healthcare budget
is understandably spent on addressing the concurrent HIV/AIDS and TB epidemics (see for
example the Lancet series on “Health in South Africa” published in 2009, with particular
emphasis on the following publications: Abdool et al [158]; Chopra et al [159]; Coovadia et al
[160]; and Mayosi et al [161]). Considering these financial constraints, two possible situations
can be envisaged in which a patient treated in the public sector (i.e. subject to government
healthcare budgets) could access platinum-based regimens and/or modern biological thera‐
peutic agents:
The first opportunity for a patient to access medication with greater efficacy would be through
participation in clinical trials conducted by pharmaceutical companies either wanting to assess
their treatment in ethnically diverse cohorts (which could be required by local regulatory
authorities) or to explore a new disease indication for an existing therapeutic agent. The second
opportunity might be one afforded by the use of ‘omics approaches, leveraging biomarker
panels to provide predictive indications of whether or not a patient might benefit from a
particular chemo- or biological therapeutic agent. Furthermore, given the heterogeneity of
tumours and the unique molecular subtypes of colorectal cancer, it would be instructive to
assess the relative likelihood of recurrent disease. Such a measurement could be used to
motivate the aggressiveness of the treatment regimen prescribed.
In terms of possible cost effective benefits from the addition of platinum-based drugs to the
standard regimen of 5-FU and LV, a trial conducted in the United Kingdom found that the
relative levels of topoisomerase-1 (Topo1), assessed by routine immunohistochemistry, could
be used to identify patient subpopulations who could potentially benefit from the addition of
Oxaliplatin to their 5-FU/LV regimen [162]. Furthermore, Paré and colleagues [163] reported
that a particular polymorphism in the excision repair cross-complementing 1 ERCC1 gene
(codon 118) can predict response and overall survival in patients treated with an Oxaliplatin/
5-FU/LV regimen. Provided that these markers are further validated in a clinical setting, it then
stands to reason that a simple immunohistochemical or real-time polymerase chain reaction
assay could therefore be routinely requested to determine likely response to Oxaliplatin and
therefore to motivate additional expenditure on an Oxaliplatin-supplemented regimen. This
type of personalised approach has the obvious advantage of improving treatment efficacy, and
reducing the risk of disease recurrence with a concomitant cost saving for the hospital authority
from not having to conduct lengthy additional treatments, after possible first round treatment
failure.
Similarly, assessment of the common SNPs that are predictive of benefit from the limited array
of biological agents (e.g. the mutational status of the KRAS and BRAF genes) could provide
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an indication of whether or not the comparatively expensive anti-epidermal growth factor
receptor mAb therapy should be prescribed.
As discussed above, a number of gene expression panels could also be used to predict patient
prognosis and the associated likelihood of disease recurrence, with results being used to design
a personalised treatment regimen in which the aggressiveness of the treatment schedule
correlates with the severity of disease, the most likely prognosis and the likelihood of recur‐
rence. In this context, Genomic Health’s Oncotype DX® Colon Cancer Assay costs ~USD 3,200
[45], which translates to approximately ZAR 28,560 in South Africa; this assay could provide
a very useful clinical metric of the likelihood of recurrence, particularly in complicated TNM
stage II cases and stage III cases where recurrence rates are still unfavorably high, but in reality
such a test is beyond the financial means available for treatment of CRC disease at a public
facility in South Africa today, not least since its cost dwarfs even that of Oxaliplatin-based
treatments. The prospects for wide uptake of the Oncotype DX® Colon Cancer Assay in South
Africa therefore seem remote.
As the complexities of biopsy heterogeneity are addressed by the biomedical community, it is
thus clear that local validation studies of simple and cost-effective, assays will be necessary to
ensure that the prognostic and treatment outcome biomarkers reported in the literature apply
to the diverse ethnicities in South Africa. Given the financial constraints imposed by the
government funded healthcare system, it appears that relatively inexpensive techniques such
as PCR based SNP assays would be well-suited to the public sector since, despite being a
simple, low cost assay, the results could have a profound impact on treatment outcomes for
the patients afflicted with this disease. Importantly, if utilised correctly such a molecular
diagnostics strategy could actually result in significant cost savings mid-term for the hospitals
administering care by avoiding the complexities of treatment failures.
7. Conclusion
‘Omics based techniques represent novel, scientifically sound approaches to the diagnostic
and therapeutic aspects of managing colorectal cancer patients, but there remain very signif‐
icant challenges regarding their uptake and wide utilisation in developing world healthcare
settings, primarily due to financial considerations. None-the-less, surgeons, clinicians, basic
medical researchers and all other healthcare workers at the cutting edge of colorectal cancer
management need to remain abreast of the prospects and potential effectiveness of integrating
molecular approaches in to colorectal cancer management. The old paradigm where patients
had no active choice or participation in their disease management, with treatment choices
being exclusively the decision of the clinician, is under threat today since many patients now
have access to information about emerging therapeutic options via the internet. It is therefore
important that surgeons and clinicians, in spite of their invariably tight schedules, consider
some form of participation in basic medical research in order to contribute clinical perspectives
as well as to improve their understanding of molecular approaches to diagnosis and treatment.
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The response rate obtained with 5-FU alone can be improved by utilising Leucovorin (LV) in
a combination therapy approach. However, it has been observed that the further addition of
Oxaliplatin or Irinotecan can improve the stage II/III CRC response rates drastically to around
40 – 50%. [156, 157] The relatively recent appearance of monoclonal antibody based therapies
has also offered significant gains in treatment response rates.
South Africa is a developing nation with a limited budget for treating non-communicable
diseases such as cancer, not least because a large proportion of the country’s healthcare budget
is understandably spent on addressing the concurrent HIV/AIDS and TB epidemics (see for
example the Lancet series on “Health in South Africa” published in 2009, with particular
emphasis on the following publications: Abdool et al [158]; Chopra et al [159]; Coovadia et al
[160]; and Mayosi et al [161]). Considering these financial constraints, two possible situations
can be envisaged in which a patient treated in the public sector (i.e. subject to government
healthcare budgets) could access platinum-based regimens and/or modern biological thera‐
peutic agents:
The first opportunity for a patient to access medication with greater efficacy would be through
participation in clinical trials conducted by pharmaceutical companies either wanting to assess
their treatment in ethnically diverse cohorts (which could be required by local regulatory
authorities) or to explore a new disease indication for an existing therapeutic agent. The second
opportunity might be one afforded by the use of ‘omics approaches, leveraging biomarker
panels to provide predictive indications of whether or not a patient might benefit from a
particular chemo- or biological therapeutic agent. Furthermore, given the heterogeneity of
tumours and the unique molecular subtypes of colorectal cancer, it would be instructive to
assess the relative likelihood of recurrent disease. Such a measurement could be used to
motivate the aggressiveness of the treatment regimen prescribed.
In terms of possible cost effective benefits from the addition of platinum-based drugs to the
standard regimen of 5-FU and LV, a trial conducted in the United Kingdom found that the
relative levels of topoisomerase-1 (Topo1), assessed by routine immunohistochemistry, could
be used to identify patient subpopulations who could potentially benefit from the addition of
Oxaliplatin to their 5-FU/LV regimen [162]. Furthermore, Paré and colleagues [163] reported
that a particular polymorphism in the excision repair cross-complementing 1 ERCC1 gene
(codon 118) can predict response and overall survival in patients treated with an Oxaliplatin/
5-FU/LV regimen. Provided that these markers are further validated in a clinical setting, it then
stands to reason that a simple immunohistochemical or real-time polymerase chain reaction
assay could therefore be routinely requested to determine likely response to Oxaliplatin and
therefore to motivate additional expenditure on an Oxaliplatin-supplemented regimen. This
type of personalised approach has the obvious advantage of improving treatment efficacy, and
reducing the risk of disease recurrence with a concomitant cost saving for the hospital authority
from not having to conduct lengthy additional treatments, after possible first round treatment
failure.
Similarly, assessment of the common SNPs that are predictive of benefit from the limited array
of biological agents (e.g. the mutational status of the KRAS and BRAF genes) could provide
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an indication of whether or not the comparatively expensive anti-epidermal growth factor
receptor mAb therapy should be prescribed.
As discussed above, a number of gene expression panels could also be used to predict patient
prognosis and the associated likelihood of disease recurrence, with results being used to design
a personalised treatment regimen in which the aggressiveness of the treatment schedule
correlates with the severity of disease, the most likely prognosis and the likelihood of recur‐
rence. In this context, Genomic Health’s Oncotype DX® Colon Cancer Assay costs ~USD 3,200
[45], which translates to approximately ZAR 28,560 in South Africa; this assay could provide
a very useful clinical metric of the likelihood of recurrence, particularly in complicated TNM
stage II cases and stage III cases where recurrence rates are still unfavorably high, but in reality
such a test is beyond the financial means available for treatment of CRC disease at a public
facility in South Africa today, not least since its cost dwarfs even that of Oxaliplatin-based
treatments. The prospects for wide uptake of the Oncotype DX® Colon Cancer Assay in South
Africa therefore seem remote.
As the complexities of biopsy heterogeneity are addressed by the biomedical community, it is
thus clear that local validation studies of simple and cost-effective, assays will be necessary to
ensure that the prognostic and treatment outcome biomarkers reported in the literature apply
to the diverse ethnicities in South Africa. Given the financial constraints imposed by the
government funded healthcare system, it appears that relatively inexpensive techniques such
as PCR based SNP assays would be well-suited to the public sector since, despite being a
simple, low cost assay, the results could have a profound impact on treatment outcomes for
the patients afflicted with this disease. Importantly, if utilised correctly such a molecular
diagnostics strategy could actually result in significant cost savings mid-term for the hospitals
administering care by avoiding the complexities of treatment failures.
7. Conclusion
‘Omics based techniques represent novel, scientifically sound approaches to the diagnostic
and therapeutic aspects of managing colorectal cancer patients, but there remain very signif‐
icant challenges regarding their uptake and wide utilisation in developing world healthcare
settings, primarily due to financial considerations. None-the-less, surgeons, clinicians, basic
medical researchers and all other healthcare workers at the cutting edge of colorectal cancer
management need to remain abreast of the prospects and potential effectiveness of integrating
molecular approaches in to colorectal cancer management. The old paradigm where patients
had no active choice or participation in their disease management, with treatment choices
being exclusively the decision of the clinician, is under threat today since many patients now
have access to information about emerging therapeutic options via the internet. It is therefore
important that surgeons and clinicians, in spite of their invariably tight schedules, consider
some form of participation in basic medical research in order to contribute clinical perspectives
as well as to improve their understanding of molecular approaches to diagnosis and treatment.
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1. Introduction
Colorectal cancer (CRC) is the third most frequently diagnosed cancer in both men and women
and the second leading cause of cancer death after lung cancer. Even though CRC is considered
to be 90% curable if detected in early stage, the majority of patients are diagnosed with
advanced stages, III or IV [1].
Screening tests applied according to well known strategies make the early diagnosis of CRC
possible and there is is strong evidence evidence that screening lowers mortality and incidence
rates of cancer, if recommended at proper time in people at risk [2]. Still, the existing tests
practiced on a large scale in CRC screening do not fully accomplish the goal of best specificity
and sensitivity or either an optimal cost/efficiency ratio. A more effective screening test may
significantly decrease disease burden.
Extensive research over the past two decades provided large information about genetic
aberrations underlying CRC and revealed complex and heterogeneous mechanisms in the
occurrence of the disease [3, 4]. Genetic changes occurred in normal colonic epithelium cells
promoting the neoplastic transformation into benign adenomas and subsequently malignant
adenocarcinomas were the essence for understanding the disease behavior and related clinical
outcome, and created a perspective for future improvements in diagnosis, treatment and
survival rates.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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2. Colorectal cancer genesis — Gene mutations and underlying stool testing
A cancer cell develops through a collection of gene mutations. Mutations left uncorrected by
cell cycle regulation before division are fixed in that cell and in its future progenitors. A cell
undergoes full carcinogenic transformation once a sufficient number of genes are mutated and
the cell can no longer respond to the external signals that act as brakes on cell growth.
Comparing with breast cancer, in which a single gene is required for disease initiation, in CRC
there are 7 to 10 genes responsible for neoplastic transformation and thereforee, the genetic-
based screening for CRC is a more laborious task than screening breast cancer [5].
Although a smaller subgroup can arise as a result of inherited mutations or previous inflam‐
matory bowel disease (Crohn’s disease or ulcerative colitis), the great majority of CRC arise
sporadically. This means that mutated genes are present only in precancerous and cancerous
lesions in the colon and rectum, and are not present in all cells of the body. Therefore, CRC
cannot be detected by a blood test, as breast cancer does [6].
Over the time, mutations of three different classes of genes have been described in colon cancer
etiology: oncogenes, suppressor genes, and mismatch repair genes [7]. Knowledge of many of
the specific mutations responsible for colon carcinogenesis allowed understanding the
phenotypic manifestations and provided a large field for genetic testing from stool cell’s DNA
[8]. Although genetic testing is possible and available, it is not yet clear what battery of genetic
tests are more accurate to use as an alternative diagnostic tool instead present widely accepted
stool test.
Until now, the genetic changes targeted in the stool cell’s DNA involved in the development
of some colorectal cancers included: activating mutations of the K-RAS oncogene, inactivating
mutations of the adenomatous polyposis cancer (APC) and TP53 tumor suppressor genes [9]
and germline or somatic mutations of mismatch repair genes (MMR) [10, 11].
A much less studied biomarker targeted in stool samples for early diagnosis of CRC in patients
at risk is COL11A1 gene, mutations of which have been first described in Marshall’s syndrome
and Stickler’s syndrome [12]. The normal function of this gene is the production of collagen
type XI, which participate to build the structure and the resistance of conjunctive tissues. Beside
its main role in the assembly, organization and development of cartilage, COL11A1 was found
to be expressed at low level in a wide variety of normal adult human tissues, including lung,
parotid gland and colorectal cells.
Few studies have found overexpression of the COL11A1 gene in various types of cancers, such
as non-small cell lung cancer (NSCLC), ovarian, oral cavity and colorectal cancers. In partic‐
ular, overexpression of the COL11A1 gene was found to be correlated with invasive and
metastatic potential of these cancers [13-16].
This gene is located on chromosome 1, arm p, site 21, between the 103.055.015 and 103.286.072
pair of bases, and is composed of 231 kbase. It contains 68 exons, not yet wholly sequenced [17].
A major contribution to the COL11A1 gene sequencing knowleddgee, especially with the
purpose of detecting mutations, is Annune S research and results [18]. Recent extented studies
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demonstrated that some polymorphysms of COL11A1 are associated with different types of
adenocarcinoma [19].
3. AIM
This study was designed to analyze COL11A1 gene mutations identified in the DNA of
exfoliated epithelial cells of the colon in the stool of the patients diagnosed with CRC through
screening and to demonstrate the perfect similarity between the detected mutations in tumor
samples and in exfoliated stool cells, in order to prove the reliability of the method as a
diagnostic tool for early CRC diagnosis.
4. Patients and method
We selected 250 patients diagnosed in the Endoscopy Department of Emergency Hospital of
Constanta with adenomatous polyps and CRC using colonoscopy and biopsy and confirmed
by histopathological exam, during screening programme or admitted and investigated for
intestinal disturbances such as chronic diarrhea or recent exacerbated constipation, stool
bleeding or association of the above symptoms in their recent history.
We collected samples biopsied from tumors during colonoscopy and stool sample from each
patient.
Colonoscopy and biopsies were performed with Olympus Exera equipment.
The bowel preparation was done according to guidelines and its quality was noted.
The colonoscopist documented the presence, size, location and extension of colonic tumors.
Biopsy or surgical resection samples were examined histopathologically and genetically.
Subjects were instructed prior stool collection. No dietary or medication modifications were
required. Until shipping samples to genetic lab, these were disposed in a coded container into
a refrigerator, between 0 and 4°C. Specimens were required to arrive within 3 days after
collection.
The minimum quantity of stool sample required was 30 g. Samples were stored at –80°C until
genetic analysis.
DNA was extracted from biopsy and feaces samples for mutation analysis:
• from stool, with QIAmp stool extraction kit (QIGene, Germany);
• from biopsy sample, with IQ-DNA Extraction Kit (Promega USA).
Primers for PCR amplification were provided by TIB MOLBIOL, Germany.
The COL11A1 gene, examined in the present study, produces a component of the colagen type
XI, named pro-alpha1 chain, an important factor for connective tissue structure and resistance.
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The method used for COL11A1 mutations was polyacrylamide gel electrophoresis method for
the heteroduplex analysis (HA).
Investigation of COL11A1 gene is made sequentially by setting fragments to be analyzed. To
do this, fragments that usually carry most mutations are identified. Each fragment of COL11A1
gene that is proposed for investigation is amplified by PCR. For this, primers flanking each
particular fragment are used.
PCR conditions are dependent on the characteristics of each pair of primers. Each program
contains a PCR initial denaturing step, lasting for 3 minutes at 94°C, followed by 30-35 reaction
cycles (depending on the length of the fragment of interest and the size and composition of
the primers), each cycle comprising: denaturation, alignment, elongation (conditions are
established for each pair of primers used), and the final elongation step, lasting for 5 minutes
at 72°C. Obtained amplicons are subjected to additional steps of forced denaturation-renatu‐
ration (to encourage heteroduplex formation), and then migrated in a 6% polyacrylamide gel.
The heteroduplex is represented by a fragment of double-stranded DNA in which the two
strands do not express perfect complementarity. When DNA is denatured, the two strands are
separated. Through renaturation, complementary chains come together to form a homodu‐
plex. If there is a mutation in one of the two strands, heteroduplex is formed (figure 1).
Heteroduplex analysis was imagined by Ziemmermann et al in 1993 [20] and has been used to
enhance the sensitivity of denaturing gradient gel electrophoresis (DGGE) in the detection of
point mutation [21-23]. DNA fragments for HA can be visualized via a variety of methods
including bromide staining, labelling with radioisotopes and silver staining. The mutations
detection rate of HA under ideal conditions is near 90%.
Heteroduplex differ from homoduplex by electrophoretic migration speed in polyacrylamide
gel. Mutational alteration of a single base pair is sufficient to produce changes in mobility.
Electrophoretic mobility of heteroduplex is lower than that of homoduplex, and it can be
detected as a slower migrating band. This method can detect insertions, deletions and
substitutions of even a single base pair in fragment lengths smaller than 200 bp.
The working protocol for this technique is very simple and quick and consists of a denatura‐
tion-renaturation step for which we set the following conditions: 94°C – 1 minute, 72°C – 1
minute, 65°C – 1 minute, 40°C – 1 minute and thermal shock at 4°C. Each stage is covered by
one cycle. The existence of deletion mutations will result in the formation of four bands, two
heteroduplex and two homoduplex (heterozygous condition) (Figure 1).
Migration occurs differently based on molecular weight. Samples from patients and healthy
individuals (control samples) are migrated in the same gel, in order to analyze the difference
in migration. If the investigated individual is a normal homozygous or a homozygous for
analyzed mutation, a single band will be displayed in each case. The difference between these
conditions is based on different migration and reported to the molecular weight marker used.
If there is a substitution mutation, two bands are visualized on polyacrylamide gel: a band
representing heteroduplex and a band representing homoduplex. In this case, the difference
in migration is explained on the basis of different chemical composition of the four DNA
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strands. For optimal view of amplification products, we used 6% polyacrylamide gel, con‐
taining 0.5 μg ethidium bromide, migrated 6 V/cm. The gel is observed and photographed on
UV transilluminator.
In the latter stages of a PCR amplification the polymerase is limiting, so that during the final
annealing and synthesis steps, a proportion of the single stranded products spontaneously
reanneals without primer extension. When amplifying from individuals heterozygous for any
sequence difference, the single strands do not necessarily rehybridize exactly with the
complementary strand. They can alternatively form a DNA hybrid (heteroduplex) consisting
of a sense strand with one sequence variant and an antisense strand with another variant.
As a consequence, the heteroduplex DNA has a region of at least one base pair mismatch. The
region of mismatch can elicit a mobility shift by altering the conformation adopted by the
heteroduplex DNA, probably by causing it to bend at the location of the mismatch. The
mobility shifts are usually small but can be visualized after prolonged electrophoresis on native
polyacrylamide gels.
Figure 1. Denaturation and renaturation of normal and mutated DNA fragments in order to generate four types of
fragments: two heteroduplex and two homoduplex. Fragments were migrated parallel on denaturating gradient gel.
“Melting” heteroduplex are modified in the sense that they denaturate at a lower concentration of denaturant, allow‐
ing their visualization.
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1. Detection of COL11A1 gene mutations included the following steps:
2. Genomic DNA extraction from the analyzed samples: tumor tissue obtained through
biopsy and exfoliated cells from feces;
3. Amplification of the interested gene amplicons through PCR reaction;
4. Amplification check up through electrophoresis in agarosis gel and bromide ethidium
staining;
5. Mutations identification through DGGE technique and silver or ethidium bromide
staining.
5. DNA extraction from proposed samples
DNA extraction from stool has been made by a specific kit for stool extraction [24, 25]. DNA
tissue extraction from the colorectal biopsy has been performed using DNA IQ (TM) System
kit [26]. DNA IQ (TM) System kit uses the principle of DNA extraction based on a paramagnetic
resine. In addition, the kit contains a series of denaturating agents (“lysis buffer”), having the
role of disintegrating the biologic product that is the DNA source.
An important advantage of this kit is that it provides extraction of an optimal DNA quantity
for PCR reaction (100 ng/μl).
6. DNA extraction from stool
DNA extraction from stool was performed with a kit designed for extraction from faeces
(QIAGEN GmbH, Hilden Germany). The technique included the following steps:
1. 200 mg of faeces were suspended in 2 ml of ASL buffer by vortexing for 1 minute.
2. 1.6 ml of this lysate was transferred to a new tube.
3. Suspension was boiled for 5 minutes.
4. Centrifuged at maximum speed for 1 minute.
5. Transfered 1.2 ml of supernatant into a new tube containing an InhibitEX tablet.
6. Vortexed the tube for 1 minute and incubated for 1 minute at room temperature.
7. Centrifuged the tube for 3 minutes.
8. Transfered 200 μl of supernatant into a new tube containing 15 μl of proteinase K.
9. Added 200 μl of Buffer AL and vortex.
10. Incubated at 70°C for 10 minutes.
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11. Added 200 μl of ethanol to lysate and vortex.
12. Content was applyed in a column of centrifugation and centrifuged at 10,000 x g for 1
minute.
13. The column was washed once with 500 μl of Buffer AW1 at 10,000 x g for 1 minute and
then with 500 μl of Buffer AW2 at 10,000 x g for 1 minute.
14. DNA was eluted from the column at 10,000 x g, 1 minute, with 100 μl heated buffer AE.
7. DNA tissue extraction from colorectal biopsy
DNA extraction from biological product was performed with DNA kit IQTM System, manu‐
factured by Promega, USA. DNA IQTM System is a kit that uses a new DNA extraction
principle based on the use of paramagnetic resin. In addition, the kit contains a number of
denaturating agents (“lysis buffer”) which are designed to disintegrate biological product that
is the source of DNA.
For some biological products (hair, tissue) which are resistant to this type of disintegration, an
additional pretreatment with proteinase K is used, an enzyme that produces sample lysis.
A considerable advantage of this kit is that it provides an optimal quantity of DNA extraction
for PCR reaction, respectively 100 ng/μl, regardless of used biological product.
Used magnetic resin binds only a limited amount of DNA even if it is in excess. Finally, DNA
is eluted from the resin with 100 μl of eluent solution yielding a final concentration of 1 ng/μl.
Thus, it is no longer necessary to quantify the amount of extracted DNA.
In principle extraction kit use the following steps:
• Extraction of the sample and its lysis;
• Resin-capture DNA;
• Magnetic resin-washing;
• Elution of DNA from the resin.
8. Purification of DNA from a tissue sample
1. We place about 1 mg of tissue in a 1.5 ml tube.
2. We added 50-100 μl of incubation buffer solution/freshly prepared proteinase K and
incubated at 56°C for 2 hours. Usually all tissue is digested after 2 hours, and if it doesn’t
occur, incubation is extended.
3. We removed the source sample incubation and added 2 volumes of lysis buffer.
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4. We added 7 μl of magnetic resin. The sample was vortex 3 seconds and left at room
temperature for 5 minutes.
5. Then the simple was vortex for 2 seconds and left the tube on the magnetic stand.
Separation occured instantly.
6. Carefully we aspirated all the solution without disturbing the resin at the bottom of the
tube.
7. We add 100 μl of prepared lysis buffer. We removed the tube from the magnetic stand
and vortex 2 seconds.
8. Placed the tube again on the magnetic stand and vacuum lysis buffer.
9. Added 100 μl of Wash Buffer preparation. We removed the tube from the magnetic stand
and vortex 2 seconds.
10. We replaced the tube in the magnetic stand and aspirated the solution.
11. We repeated steps 9 and 10, 2 times to make a total of three washes.
12. Tubes were allowed in the magnetic stand with the lid open for 5 minutes to dry.
13. We added 25-100 μl of elution buffer, depending on the amount of biological material
used.
14. Then we closed the lid and vortexed 2 seconds. We incubated at 65°C for 5 minutes.
15. Removed the tube from the heating device, vortexed 2 seconds and immediately puted
the tube on the magnetic stand.
16. Finally, we aspirated DNA containing solution and left the tube in conservation.
9. Validation of human origin of DNA extracted from stool by STR loci
typing
The analysis of the nuclear DNA extracted from stools is a recent new method for CRC
diagnostics.
In the preliminary phase of our study, we comparatively analyzed the DNA extracted from
the biopsy samples of the patients with the DNA extracted from the stool samples of the same
patients. This comparative analysis was performed by investigating a number of 9 human STR
loci, frequently used in the DNA typing techniques of forensic medicine.
The STR type loci (“short tandem repeat” or “microsatellite repeats”) contain 4 bases of
segments that repeat 5-50 folds, depending on the loci. These STR are of a very small size
(100-400 bases) and are very useful for the degraded DNA analysis. These repetitive sequences
are largely spread in the human genome, being a rich source of polymorphic markers that may
be detected through PCR.
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For the DNA typing in our cases, we used a number of 9 STR loci. Determination of the 9 loci
can be made by using kits of molecular biology, forming GenePrintSTR Systems of Multiplex
type.
10. Amplification of the interested gene amplicons through PCR reaction
Primers the analysis of all the 68 exons of COL11A1 gene are not yet available. We managed
to obtain sequence for primers of two groups of amplicons containing amplified segments in











PCR reactions were done simultaneously for each of the two groups above. We used PCR
amplification kit manufactured by Promega (USA) called “PCR Core System”. It was designed
to enhance any type of amplicon, by usind standard type Taq polymerase.
Materials required:
• Thermal cicler for 0.2 ml tubes;
• microcentrifuge;
• Taq DNA polymerase;
• Nucleases-free water;
• Mineral Oil;
• 0.2 ml Amplification tubes;
• 1.5 ml microcentrifuge tubes;
• Anti-aerosol pipette tips;
• Ice.
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11. Thermal cycling protocol
Manufacturing company recommends several types of thermal cycling protocols and the
choice depends on the thermo-cicler and optimized version that has been established. We have
optimized the following protocol – protocol COL11A1:
• Step 1: 94°C, 1 minute;
• Step 2: 52°C, 1 minute;
• Step 3: 72°C, 1 minute;
Repeated successive steps 1, 2 and 3, in 5 cycles.
• Step 4: 94°C, 1 minute;
• Step 5: 50°C, 1 minute;
• Step 6: 72°C, 1 minute;
Repeated successive steps 4, 5 and 6, in 5 cycles.
• Step 7: 94°C, 1 minute;
• Step 8: 48°C, 1 minute;
• Step 9: 72°C, 1 minute;
• Step 10: 72°C, 3 minutes;
• Step 11 (rest): 4°C.
12. Amplification setting
To prevent contamination it is strongly recommended the use of gloves and anti-aerosol
pipette tips. Maneuvers that must be cosidered are as follows:
1. Defrost kit components and pairs of primers and then put them on ice.
2. Mark each 0.2 ml amplification tube and place it in the stand.
3. Determine the number of reactions to be performed. This number must include the
positive and negative control reaction, respectively. Add to this number another 1-2
reactions in addition, to compensate for pipetting errors.
4. Prepare the amplification (PCR Master Mix) solution, according to the table below (table
1). Multiply the volume per sample (μl) with the total number of reactions, to obtain the
final volume.
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PCR Master Mix Component Volume per sample (μl)
MgCl2 25 mM sol. 1.5
10X Buffer Taq DNA Polymerase 2.5
PCR Nucleotide mix, 10 mM 0.5
“Primer Upstream”, 15 μM 1.65
“Primer "Downstream”, 15 μM 1.65
Taq DNA Polymerase (at 5 u/μl) 0.12
Distilled water without nucleases 17.08
Total volume 22.5
Table 1. Preparation of PCR Master Mix.
1. In order from above table lay the final volume of each reagent in a sterile tube. Shake
gently (not vortex) and place the tube on ice.
2. Add 22.5 μl of PCR Master Mix to each reaction tube and place tubes on ice.
3. Pipette 2.5 μl of each DNA sample to respective tubes containing 22.5 μl of PCR Master
Mix.
4. Pipette 2.5 μl (5 ng) of K562 DNA (diluted to 2 ng/μl) in a reaction tube containing 22.5
μl of PCR Master Mix, which is a positive control.
5. Pipette 2.5 μl of sterile distilled water (instead of DNA) in a reaction tube containing 22.5
μl of PCR Master Mix, which is a negative control.
6. Add 1 drop of mineral oil to each tube. Close the tubes.
7. Centrifuge tubes to bring the contents to the bottom of the tube.
8. Assemble the tubes in thermal triggers cicler and start amplification.
9. After amplification, the tubes must be kept at –20°C.
12.1. Electrophoresis of amplified samples for evidence heteroduplex
For this complex electrophoresis technique, we used a device type “DCode Universal Mutation
Detection System” manufactured by Bio-Rad (Germany).
12.2. Formation reaction of heteroduplex
Protocol consists of a denaturation-renaturation step of PCR sample obtained from normal
witness mixed with PCR sample from analyzed patient was established under the following
conditions:
• 94°C – 1 minute;
• 72°C – 1 minute;
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• 65°C – 1 minute;
• 40°C – 1 minute;
• heat shock at 4°C.
Heteroduplex are generated by adding to the same PCR reaction the mold of mutant and
normal DNA, or by PCR product mixing, denaturation and ultimately their renaturation. A
heteroduplex contains a mismatch base in the double chain, causing a distortion in its confor‐
mation; bands containing heteroduplex always migrates more slowly compared to bands
containing homoduplex.
12.3. Preparation of reagents
Acrylamide concentration used generally depends on the sample to be analyzed, and we used
a 40% stock solution containing acrylamide and bis-acrylamide.
• Acrylamide/Bis – 40% (37.5:1);
• Acrylamide – 38.9 g;
• Bis-acrylamide – 1.07 g;
• Water dist. – ad. 100 ml.
In the table below (table 2) we present the concentration of acrylamide/bis used to separate
different DNA molecules:




Table 2. Concentration of acrylamide/bis used to separate DNA molecules.
We worked with a solution of acrylamide/bis 6%, given the length of amplified fragments.
• Acrylamide/Bis solutions, 6% (1.25 x TAE, 6M urea);
• Acrylamide/Bis 40% 6.0 ml;
• 50X TAE buffer 1 ml;
• Urea 14.4 g;
• TEMED 40 μl;
• Ammonium persulfate 10% 400.0 μl;
• Total volume 40 ml.
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We added water to 40 ml. Pour gel immediately after adding TEMED and ammonium
persulphate.
• 50X TAE buffer:
◦ Tris base 242.0 g;
◦ glacial acetic acid 57.1 ml;
◦ 0.5M EDTA, pH 8.0, 100 ml;
◦ water dist. ad. 1000 ml.
• Ammonium persulfate 10%:
◦ ammonium persulfate 0.1 g;
◦ water dist. 1 ml;
• Staining solution DCode;
◦ bromophenol blue 0.05 g;
◦ xylene cyanol 0,05 g;
◦ 1X TAE buffer 10 ml;
• Solution for implementing samples:
◦ bromophenol blue 0.25 ml 2%;
◦ xylene cyanol 0.25ml 2%;
◦ glycerol 7.0 ml;
◦ water dist. 2.5 ml;
• 1.25 X TAE buffer migration:
◦ 50X TAE buffer 175 ml;
◦ water dist. 6825 ml.
13. Sample preparation
1. It is important that PCR is optimized to decrease the formation of artifact products that
may interfere with test itself. PCR products should be assessed for purity by agarose gel
electrophoresis before being used for electrophoresis.
2. On gel we applied 180-300 ng of amplified DNA per well. On each gel and for each
amplicon there were joined migration of the sample and normal DNA.
3. At each sample, we added a volume of 2X sample application solution.
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may interfere with test itself. PCR products should be assessed for purity by agarose gel
electrophoresis before being used for electrophoresis.
2. On gel we applied 180-300 ng of amplified DNA per well. On each gel and for each
amplicon there were joined migration of the sample and normal DNA.
3. At each sample, we added a volume of 2X sample application solution.
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13.1. Preheating migration buffer
1. Electrophoresis tank was filled with a quantity of 7 L of 1X TAE buffer.
2. We placed the temperature control module above the electrophoresis tank.
3. Then we adjusted the temperature to 60°C. To achieve this temperature 1-1.5 hours
wereneeded. If the buffer is preheated in the oven, this time can be reduced.
13.2. Assemble gel sandwich
Casting procedure is extremely laborious and is was done by strict electrophoresis guidelines
provided by equipment manufacturer. A system of 16x16cm plates was used and the prepared
gel was “sandwich” type.
1. “Sandwich” gel is mounted on a clean surface. We have placed large plate first, then we
have set the spacers on the short edges of this plate.
2. Lower plate was disposed over the large plate so the bottom was flush with large plate
edge.
3. We loosen the black screw of the two sandwich cutters. We placed plates in these pliers
so that the arrows were facing upwards.
4. We tightened the clamps so that the glass plates were well fixed.
5. Sandwich assembly was inserted into the alignment (without clips into place) so short
board was facing forward. We loosen the clips and clamps easily inserted between the
plates alignment plate which serves to align the spacers.
6. We aligned the plates and spacers by moving laterally and obliquely claws. We must
ensure that the spacers are perfectly parallel and the lower edge of the two plates was
perfectly aligned. We tightened the screw clamps for immobilizing overall assembly.
7. We removed the plate alignment between glass plates. Then we removed the sandwich
from the stand and check the lower edges of the plates and spacers are aligned perfectly.
13.3. Casting the gel
1. We placed the gray foam in the space provided for pouring the gel. Pins of the base were
completely relaxed. Placed plates mounted on the lower plate to the front pad. After it
was placed correctly by turning the cam, pressing the lower edge of the foam boards was
performed.
2. In a 50 ml tube we puted the required amount of gel solution. Ammonium persulfate and
TEMED were added to a final concentration of 0.09% (v/v). Stopped the tube and mixed
by inversion.
3. We inserted the comb into sandwich and positioned it so that it was slightly bent (angle)
to the edge boards. This prevented the formation of air bubbles between the gel and the
comb teeth.
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4. Poured the gel solution into the sandwich until comb teeth were covered. Then pressed
the comb in its correct position. Solution was added to the filling.
5. We allowed the gel to polymerize for 60 minutes. After polymerization we carefully
removed the comb.
13.4. Migrating samples
1. Electrophoresis tank must contain 7 liters of buffer migration.
2. After the temperature was reached by the migration buffer (60°C) we disconnected
temperature maintenance system.
3. Removed the temperature module from the electrophoresis tank. Gel fitting with gel
electrophoresis was introduced into the tank and the temperature module was placed
again into position.
4. Filled the volume of migration buffer until the level mark on the camera, and added also
into the anode upper chamber.
5. Before applying the samples we left the machine running again to reach a migration
temperature of 60°C.
6. Applied the samples after each well was previously rinsed with buffer. Sample application
was made through a specially designed device that is provided.
7. Samples prepared as described above were applyed by automated pipetting carefully so
that they do not spread outside the wells.
8. Closed the device and connected to the source. Migration was 5 hours at a voltage of 5 V/
cm.
13.5. Gel staining
Electrophoresis was performed after the gel is removed from the tank, and glass plates
carefully unfold. The gel sticks to the glass plate. Staining can be done by two procedures:
simple procedure with Ethidium Bromide and fluorescence examination or staining procedure
Argent. We opted for the second.
Protocol described below is an adaptation of that offered by the company with the Promega
kit “DNA Silver Staining System”.
A kit contains the following ingredients required for 10 stains:
• 500μl Bind silane;
• 20 G Silver Nitrate (10 x 2g);
• 60 Ml Formaldehyde, 37% (20 x 3 ml);
• 10 Ml Sodium thiosulfate, 10 mg/ml (10 x 1 ml);
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4. Poured the gel solution into the sandwich until comb teeth were covered. Then pressed
the comb in its correct position. Solution was added to the filling.
5. We allowed the gel to polymerize for 60 minutes. After polymerization we carefully
removed the comb.
13.4. Migrating samples
1. Electrophoresis tank must contain 7 liters of buffer migration.
2. After the temperature was reached by the migration buffer (60°C) we disconnected
temperature maintenance system.
3. Removed the temperature module from the electrophoresis tank. Gel fitting with gel
electrophoresis was introduced into the tank and the temperature module was placed
again into position.
4. Filled the volume of migration buffer until the level mark on the camera, and added also
into the anode upper chamber.
5. Before applying the samples we left the machine running again to reach a migration
temperature of 60°C.
6. Applied the samples after each well was previously rinsed with buffer. Sample application
was made through a specially designed device that is provided.
7. Samples prepared as described above were applyed by automated pipetting carefully so
that they do not spread outside the wells.
8. Closed the device and connected to the source. Migration was 5 hours at a voltage of 5 V/
cm.
13.5. Gel staining
Electrophoresis was performed after the gel is removed from the tank, and glass plates
carefully unfold. The gel sticks to the glass plate. Staining can be done by two procedures:
simple procedure with Ethidium Bromide and fluorescence examination or staining procedure
Argent. We opted for the second.
Protocol described below is an adaptation of that offered by the company with the Promega
kit “DNA Silver Staining System”.
A kit contains the following ingredients required for 10 stains:
• 500μl Bind silane;
• 20 G Silver Nitrate (10 x 2g);
• 60 Ml Formaldehyde, 37% (20 x 3 ml);
• 10 Ml Sodium thiosulfate, 10 mg/ml (10 x 1 ml);
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• 600 G Sodium Carbonate (10 x 60g).
13.6. Materials required
• Fixing solution/stop:
◦ 200 ml glacial acetic acid;
◦ 1800 ml distilled water;
• Coloring solution:
◦ silver nitrate (AgNO3) 2 g;
◦ 3 ml 37% formaldehyde;
◦ 2000 ml distilled water;
• Developing solution:
◦ 3 ml 37% formaldehyde;
◦ Sodium thiosulfate 10 mg/ml, (Na2S2O3 x 5H2O) 400 μl ;
◦ 2000 ml distilled water;
◦ sodium carbonate (Na2CO3) 60 g.
We prepared the solution just in time to use it, cooled at 4-10°C before use.
14. Technique used
1. Gel plates were placed on a flat surface. With a plastic “feather” glass was removed. The
gel was caught on the short board.
2. The gel attached on short plate was placed in a plastic tray.
3. Argent coloring followed few steps:
a. fixing /stop solution – 20 minutes;
b. distilled water – 2 minutes;
c. Repeat step “b” 2 times 2 x 2 minutes;
d. staining solution – 30 minutes;
e. distilled water – 10 seconds;
f. developing solution (4-10°C) up to 5 minutes (to become visible Ladder allele);
g. fixing/stop solution* – 5 minutes;
h. distilled water – 2 minutes;
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*Solution was added directly above solution developer to stop the developer reaction.
4. We placed the gel upright and dry overnight.
15. Mutations identification through DGGE technique and silver or
ethidium bromide staining
After amplification the samples were checked to confirm successful amplification by agarose
gel electrophoresis. For migration were applied two tests, one that was considered the normal
type (same in all cases) and the other representing the analyzed case.
To see if amplifyed amplicons in the studied cases presented mutations, we used samples
examined by agarose gel electrophoresis, for electrophoresis on polyacrylamide 6%.
16. Statistical analysis
Statistical analysis was performed using Graph Pad InState and Graph Pad State Mate.
17. Results
Demographic and clinical characteristics of patients examined during study period were as
follows (table 3).
Histopathological classification and localization of tumors in patients investigated through
colonoscopy and biopsy referred to genetic analysis of COL11A1 mutations can be seen in
table 4.
From the total of 250 patients genetically explored, 178 (71.20%) were diagnosed with adeno‐
carcinoma and TNM staged after hiistopathological and imagistic examinations. Most of the
patients were staged as stage II or III (18.80%, respectively 23.60%).
We analyzed 51 patients diagnosed with advanced adenomatous polyps. Polyps were
classified according to hiistopathological features in: 26 polyps with high-grade dysplasia
(10.40%), 17 villous adenoma (6.80%), and 8 tubular adenoma bigger than 1 cm (3.20%).
Among the 250 patients studied, 178 had adenocarcinomas, 51 had advanced adenomas, and
the rest 21 had minor polypspolyps.
All samples analyzed for fecal COL11A1 mutations were processed in a single laboratory.
The plan for COL11A1 analyses in feces or biopsy has been described previously and is shown
in figure 2.
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(10.40%), 17 villous adenoma (6.80%), and 8 tubular adenoma bigger than 1 cm (3.20%).
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APC (adenomatous polyposis coli) 16 6.40
CRC 49 19.60
Other cancer 37 14.80
Without family history of cancer/polyps 148 59.20
























































































































Table 4. Hiistopathological classification and tumor localization.
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I. Genomic DNA extraction from the analyzed samples 
Tumor tissue obtained through biopsy 
Purification of DNA from a tissue sample 
Exfoliated cells from feces 
Validation of human origin of DNA extracted from 
stool by STR loci typing 
II.  Amplification of the interested gene amplicons 
through PCR reaction 
III . Electrophoresis of amplified samples for 
heteroduplex evidence 
IV . DGGE analysis of COL11A1 gene mutations 
through DNA heteroduplexes 
Figure 2. Approach to Extraction and Analysis of Fecal and Tumor DNA analysis.
Also laboratory handling of all samples was fully described above.
Each exon of gene COL11A1 studied was assessed independently.
We considered a positive result any modified component of the study gene, and we noted any
mutation as a positive fecal DNA test.
18. DGGE analysis of COL11A1 gene mutations through DNA
heteroduplexes
COL11A1 is located on chromosome 1p21 and consists of 232,030 bases. It contains 68 exons,
yet not wholly sequenced, of which exons 38, 41, 16, 54, 55, 56 and 57 were until now studied.
HE analysis for exons 38, 41 and 16
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Exfoliated cells from feces 
Validation of human origin of DNA extracted from 
stool by STR loci typing 
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through PCR reaction 
III . Electrophoresis of amplified samples for 
heteroduplex evidence 
IV . DGGE analysis of COL11A1 gene mutations 
through DNA heteroduplexes 
Figure 2. Approach to Extraction and Analysis of Fecal and Tumor DNA analysis.
Also laboratory handling of all samples was fully described above.
Each exon of gene COL11A1 studied was assessed independently.
We considered a positive result any modified component of the study gene, and we noted any
mutation as a positive fecal DNA test.
18. DGGE analysis of COL11A1 gene mutations through DNA
heteroduplexes
COL11A1 is located on chromosome 1p21 and consists of 232,030 bases. It contains 68 exons,
yet not wholly sequenced, of which exons 38, 41, 16, 54, 55, 56 and 57 were until now studied.
HE analysis for exons 38, 41 and 16
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For all 3 analyzed amplicons in all 250 studied cases, the migration speed was identical for
both control and samples.
HE analysis for exons 54, 55, 56 and 57
HE analysis of exons 54 clearly demonstrated in 52 cases (20.80%) the presence of the same
displaced bands pattern in the biopsy and stool extracted cells samples compared with the
control. This pattern of mutation was correlated positively with male gender, TNM stage
II/III tumors, vegetative pattern, descendent and sigmoid localization – table 5.
No. Pacient no. DNA sample
Mutations/amplicons
38 41 16 54 55 56 57
1 1
Biopsy - - - + - - -
Faeces - - - + - - -
2 4
Biopsy - - - - - + -
Faeces - - - - - + -
3 7
Biopsy - - - + - - -
Faeces - - - + - - +
4 8
Biopsy - - - + - - -
Faeces - - - + - - +
5 11
Biopsy - - - + - - +
Faeces - - - + - - +
6 13
Biopsy - - - + - - +
Faeces - - - + - - -
7 14
Biopsy - - - - - + -
Faeces - - - - - + -
8 16
Biopsy - - - + - - -
Faeces - - - + - - -
9 17
Biopsy - - - - - + -
Faeces - - - + - + -
10 20
Biopsy - - - - - + -
Faeces - - - - - + -
11 21
Biopsy - - - + - - -
Faeces - - - + - - +
12 26
Biopsy - - - + - + -
Biopsy - - - + - + -
13 29
Faeces - - - + - + -
Biopsy - - - + - + -
14 34
Biopsy - - - + - + -
Faeces - - - + + -
15 38 Biopsy - - - + - - -
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No. Pacient no. DNA sample
Mutations/amplicons
38 41 16 54 55 56 57
Biopsy - - - + - - -
16 46
Faeces - - - + -
Biopsy - - - + - + -
17 48
Biopsy - - - + - - -
Faeces - - - + -
18 56
Biopsy - - - - - + -
Faeces - - - + -
19 59
Biopsy - - - + - + -
Faeces - - - - - + -
20 74
Biopsy - - - - - + +
Faeces - - - - - + -
21 78
Biopsy - - - + - - -
Faeces - - - + -
22 84
Biopsy - - - + - - -
Biopsy - - - + - - -
23 89
Faeces - - - + -
Biopsy - - - + - - -
24 93
Biopsy - - - + - - -
Faeces - - - + -
25 96
Biopsy - - - + - + -
Biopsy - - - + - - -
26 104
Faeces - - - + +
Biopsy - - - + - - +
27 107
Biopsy - - - + - - -
Faeces - - - + - - -
28 109
Biopsy - - - - - + -
Faeces - - - - - +
29 116
Biopsy - - - + - - -
Biopsy - - - + - - -
30 119
Faeces - - - + - - -
Biopsy - - - + - - -
31 121
Biopsy - - - + - + -
Faeces + - - -
32 129
Biopsy - - - + - - +
Faeces - - - + - - +
33 132
Biopsy - - - + - - -
Faeces - - - + - - -
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No. Pacient no. DNA sample
Mutations/amplicons
38 41 16 54 55 56 57
34 134
Biopsy - - - + - + -
Faeces - - - + - - -
35 138
Biopsy - - - + - - -
Faeces - - - + - - -
36 143
Biopsy - - - + - + -
Biopsy - - - + - + -
37 146
Faeces - - - - - + -
Biopsy - - - - - + -
38 147
Biopsy - - - + - - -
Faeces - - - + - - -
39 159
Biopsy - - - - - + -
Biopsy - - - - - + -
40 166
Faeces - - - + - + -
Biopsy - - - + - + +
41 168
Biopsy - - - + - + -
Faeces - - - + - + -
42 171
Biopsy - - - - - + -
Faeces - - - - - + -
43 177
Biopsy - - - + - - -
Biopsy - - - + - - -
44 179
Faeces - - - + - - -
Biopsy - - - + - - -
45 182
Biopsy - - - + - - +
Faeces - - - + - - +
46 189
Biopsy - - - + - - -
Faeces - - - + - - -
47 201
Biopsy - - - + - - -
Faeces - - - + - - -
48 203
Biopsy - - - + - - -
Faeces + - - -
49 208
Biopsy - - - + - - -
Faeces - - - + - - -
50 211
Biopsy - - - + - - -
Biopsy - - - + - - -
51 220
Faeces - - - - - + +
Biopsy - - - - - + +
52 224 Biopsy - - - + - - -
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No. Pacient no. DNA sample
Mutations/amplicons
38 41 16 54 55 56 57
Faeces - - - + - - -
53 228
Biopsy - - - - - - -
Biopsy - - - - - - -
54 230
Faeces - - - +
Biopsy - - - + - - -
55 236
Biopsy - - - + - - -
Faeces - - - + - - -
56 237
Biopsy - - - + - - +
Faeces - - - + - - -
57 211
Biopsy - - - - - - +
Biopsy - - - - - - +
58 220
Faeces + -
Biopsy - - - + - - -
59 224
Biopsy - - - + - - +
Faeces + +
60 228
Biopsy - - - + - - -
Faeces - - - + - - -
61 230
Faeces - - - - - - +
Biopsy - - - - - - +
62 236
Biopsy - - - + - - -
Faeces - - - + - - -
63 237
Biopsy - - - + - - -
Faeces - - - + - - -
64 238
Biopsy - - - + - - -
Faeces - - - + - - -
65 241
Biopsy - - - - - - +
Biopsy - - - - - - +
66 244
Faeces - - - + - - +
Biopsy - - - + - - +
67 248
Biopsy - - - + - - -
Faeces - - - - - - -
68 249
Biopsy - - - + - - -
Faeces - - - + - - -
69 250
Faeces - - - + - - -
Biopsy - - - + - - -
Table 5. Patients with COL11A1 gene mutations
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Biopsy - - - + - - -
51 220
Faeces - - - - - + +
Biopsy - - - - - + +
52 224 Biopsy - - - + - - -
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No. Pacient no. DNA sample
Mutations/amplicons
38 41 16 54 55 56 57
Faeces - - - + - - -
53 228
Biopsy - - - - - - -
Biopsy - - - - - - -
54 230
Faeces - - - +
Biopsy - - - + - - -
55 236
Biopsy - - - + - - -
Faeces - - - + - - -
56 237
Biopsy - - - + - - +
Faeces - - - + - - -
57 211
Biopsy - - - - - - +
Biopsy - - - - - - +
58 220
Faeces + -
Biopsy - - - + - - -
59 224
Biopsy - - - + - - +
Faeces + +
60 228
Biopsy - - - + - - -
Faeces - - - + - - -
61 230
Faeces - - - - - - +
Biopsy - - - - - - +
62 236
Biopsy - - - + - - -
Faeces - - - + - - -
63 237
Biopsy - - - + - - -
Faeces - - - + - - -
64 238
Biopsy - - - + - - -
Faeces - - - + - - -
65 241
Biopsy - - - - - - +
Biopsy - - - - - - +
66 244
Faeces - - - + - - +
Biopsy - - - + - - +
67 248
Biopsy - - - + - - -
Faeces - - - - - - -
68 249
Biopsy - - - + - - -
Faeces - - - + - - -
69 250
Faeces - - - + - - -
Biopsy - - - + - - -
Table 5. Patients with COL11A1 gene mutations
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We also noticed the same pattern of different speed migration in case of HE analysis of exon
56 in 18 patients (7.20%) and exon 57 in 11 patients (4.40%).
Statistic analysis revealed that the last two kind of mutations were correlated with tumor stage
IV, male gender and advanced age (> 70 yrs old) – table 6.








































Table 6. Correlation between hiistopathological examination and genetic analysis.
The migrating front presented two bands, out of which the slowest part generates the hetero‐
duplexes obtained through denaturation-renaturation, and the faster one, the homoduplexes
(figure 3).
The samples were different from the wild type due to the fact that they contain amplified
mutant type DNA, which through electrophoresis leads to speed migration modification.
The mutation detected by us is a substitutive type one as a series of 2 bands was evident on
the migration front.
There were no seen mutations for the rest of the analyzed cases for the exon 55.
All detected mutations can be observed in table no. 5
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Among 229 patients with advanced neoplasia (tubular adenoma 1 cm in diameter or larger,
villous polyp, polyps with high-grade dysplasia, or cancer), 69 patients (27.60%) presented
mutations in COL11A1 gene in at least 1 exon (table no. 5 and 6).
Regarding benign polyps, none of patients presented COL11A1 mutations.
19. Disscusions and conclusions
COL11A1 gene overexpression has been implicated as a candidate marker of various types of
cancers [26]. Previous studies have found overexpression of the COL11A1 gene in different
types of cancers, such as non-small cell lung (NSCLC), ovarian, oral cavity and colorectal
cancers [13-16]. In particular, overexpression of the COL11A1 gene was found to be correlated
with invasion and metastasis of these cancers [13-16].
As we previously detected in a pilot study regarding genetic mutations related to COL11A1
gene in exfoliated epithelial cells in the stool, we found mutations involving exon 54 [27].
L – molecular weight ladder. M – healthy individual allele (control). P – unprocessed allele for exon 54. M+P – dena‐
tured-renatured sample.
Figure 3. Electrophoresis in 6% polyacrylamid gel of the processed samples in order to point out heteroduplexes for
exon 54, using silver staining.
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Our present study confirmed the presence of COL11A1 mutations in patients with colorectal
adenomas or cancer. Polyacrylamide gel electrophoresis method for the heteroduplex analysis
(HA) was a sensitive genetic method to diagnose mutations of COL11A1.
Mutations detected in biopsy cells were present in exfoliated cells from feaces, proving the
usefulness of this genetic approach for noninvasive early diagnosis. Genetic alterations were
detected at the level of exons 54, 56 and 57.
Our results are similar with the results of other studies which have previously shown that
COL11A1 is upregulated in the majority of sporadic colorectal cancer [28], emphasizing the
fact that the expression of COL11A1 could be the primary change giving rise to a tumorigenic
response in epithelial cells [28].
1. Another study found a statistically significant overexpression of COL11A1 in polyps from
a patient with FAP [29]. The results from this study suggested that the expression of
COL11A1 could directly contribute to tumorigenesis in fibroblasts in FAP and explain
osteomas and desmoids, or indirectly to polyp-formation and tumor progression in
sporadic CRC [29].
2. The study of Croner R et al [30] also showed up-regulation of COL11A1 in CRC versus
normal colonic mucosa (p<0.001). The same result was shown by Lascorz et al study, in
which extracellular matrix receptor interaction and focal adhesion shared nine genes
(COL1A1, COL1A2, COL3A1, COL4A1, COL11A1, FN1, ITGA2, SPP1, and THBS2) were
upregulated in colorectal cancer [31].
Joined by other well known genetic tools already examined in the stool cell’s DNA involved
in the development of some colorectal cancers, COL11A1 could be a feasible genetic biomarker
targeted in stool samples for early diagnosis of colorectal cancer at risk patients.
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1. Introduction
Boveri's hypothesis about the genetic basis of cancer, a century ago, subsequently confirmed
by Loeb et al. in 1974, opened the gate for genetic studies that became essential for cancer
management. [1, 2]
Cancer is a disease that arises from altered cell due to multiple genetic and epigenetic altera‐
tions that confer them the properties of apoptosis evasion and growth advantage. These
properties represent a competitive advantage over normal cells, leading to the expansion and
colonization of other tissues by these cells, which cause patient´s death by interfering with the
normal function of its organs. [3]
Introduction of chemotherapy in cancer treatments has supposed an important improvement
in progression-free survival but, it is also associated to life threatening secondary effects, in
the worst scenario, and an important quality life reduction in the best one. Furthermore, due
to the difficulty to stratify patients in low and high risk, there are a substantial number of them
that will receive the therapy but will not experience any benefit from it. These consequences,
underline the importance of personalized treatment in cancer management. [4, 5]
The first chemotherapy treatments were based on a frequently observed characteristic of cancer
cells, this is, a high proliferation index. Their effectiveness rates vary among cancers, but all of
them are characterized by important secondary effects as consequence of their low specificity,
since these chemotherapeutics also affects normal cells.
The use of this traditional chemotherapy effectively shrinks tumor mass but, observation of
tumor metastases and recurrences led to the idea of the existence of cell populations unaffected
by the treatment, either because they are a type of cells with different characteristics from the
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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cells that the drug was designed to, because they have undergone genetic changes that confer
them resistance or because the microenvironment protects them. Identification of the resist‐
ance cause is one of the cornerstones of cancer treatment and in this attempt, identification of
cells that have tumorigenic potential to sustain cancer is fundamental. [6]
Based on this, studies of tumor organization were performed. As indicated by Shackleton et
al, research on tumor organization intends to determine which cells have tumorigenic potential
to sustain cancer, this is, all cells in a cancer or only a specific population of them. There are
two principal models of tumor organization, not mutually exclusive, the clonal evolution
model [stochastic] and the stem cell model [hierarchical], that have been subjected to deep
examination owing to their implications in cancer management. [6]
The clonal evolution model was described by Nowell in 1976, and it is quite verified that it
seems to be ubiquitous in all cancers. It describes cancer development by the successive
acquisition of differential features in the derived cells giving rise to the formation of cell clones,
this is, group of cells with common features because they originate from the same progenitor
cell that can be a stem cell or not. Some of these features can be positive and provide a selective
advantage to these cells over the others, with the consequent establishment of these clones.
This model supports the idea that all cells in a tumor are important since the cancer can be
sustained due to the possible acquisition of resistance or advantage features in the derived
cells. On the other hand, this process is not random, tumors share similarities, but these
similarities will be modulated by the tumor environment turning each tumor into unique
entities. [3, 7]
To establish a model of tumor organization is fundamental since it should drastically change
treatment cancer approach. Identification of cells that drive tumor progression will allow us
to design target drugs against this cells instead of nonspecific drugs that treat all cancer cells,
even normal cells. Tumors that have a hierarchical organization from stem cells to more
differentiated cells are said to follow the stem cell model that have been recently proved in a
few cancers, among them, the colorectal cancer. [3, 6-13] Stem cells are a very specific type of
cells that possess differential capabilities such as being pluripotent, remain in a quiescent state,
have a long life as well as self-renewal capacity which allows them to perpetuate themselves
and repopulate different cells linages.
Nonetheless, both models are not incompatible, mutation causing clonal expansion may
happen in the stem cell compartment and manifests its effects on the progenitors cells or may
happen in the progenitors cells that can re-activate the auto-renewal machinery to generate
stem cells. [14] As long as the disease progresses, these changes can induce alterations in the
normal patterns of development of these cells, reducing their ability to differentiate and
increasing their auto-renewal capacity, causing the uncontrolled increase of undifferentiated
cells, as it happens in leukemia. [15] As Nowell denoted the observation of non-differentiation
of tumor cells is explained by focus the cell resources in increasing cell proliferation and
invasiveness. [3]
Both models describe a scenario of intratumor genetic heterogeneity that reproduces the tumor
tissue heterogeneity observed in patients, and also describes the heterogeneity observed in the
different stages of cancer as consequence of selection in different environments. [3, 7]
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Nonetheless, cells in this tissue are not independent units, there is a communication between
them and even collaboration has been proved in leukemogenic cells. [16] This communication
is performed through the extracellular matrix by different signals to which cells respond and
its behavior is modulated by these signals as them change over time. Hence, during cancer
development, cells in a tumor, experiment different genetic alterations selected by their fitness
which is determined by the tumor microenvironment and tissue characteristics where the
tumor is being developed. All these characteristics explain the observed intra-tumor hetero‐
geneity in cancer and the different subtypes identify in a specific type of cancer, which added
to the modification performed by the individual genetic background makes each cancer a
unique entity. [7]
To add more complexity to the system, not all the mutations within a tumor are important for
its progression or survival. Due to alterations in DNA repair systems, numerous mutations
are produced that do not provide any advantage nor disadvantage to cells at a given moment
but, its presence and proportion in the tumor mass will depend on if they are produced in
clones which have driver mutations, this is mutations that will lead tumor development and
response to the environment. Differentiate which mutations are drivers from passengers it is
another important and confounding factor for both, identification of tumor and pharmacoge‐
netic markers. [7, 17, 18]
Equally importantly is to determine the global effects that mutations cause, since understand‐
ing the aims of the tumor through the modulation of the pathways that performs will help us
to predict the compensatory mechanism that executes. [3] Knudson´s two hits hypothesis
postulates that more than one mutation is needed in cells to become malignant. [19, 20] The
fine regulation that tumor cells exert, and the importance of the molecular pathways implied
is exemplified by the °Just-right hypothesis° that postulates that the second mutation in the
adenomatous polyposis coli [APC] gene [which is a gene where germline mutations are found
to be associated to an hereditary form of colorectal cancer] produces in a tumor is dependent
on the type and localization of the germline mutation in a patient in order to maintain some
basal APC activity, which it is needed for cell functioning. [21]
Apart from all these convolutions, each tumor has an inherent progression; there is a pattern
of genetic alterations typical of each tumor, whose establishment is a priority when designing
cancer treatments. The goal is to increase drug efficiency along with its specificity in order to
diminish the secondary effects. In this road, there have been two important events that have
helped us to achieve this ultimate goal.
Firstly, advances in knowledge of genetics have allowed us to discover the hereditary compo‐
nent of cancer as well as the steps that follow in cancer development, the more important
pathways trigger in them and have pointed out the key deregulated molecules against to specific
drugs can be designed. The studies realized to determine the cancer characteristics have also
contributed to the discovery of specific and differential patterns of each cancer. [22-25]
Secondly, drug development research has focused their efforts in the development of target
drugs that act specifically on those molecules in order to avoid the important secondary effects
of classical chemotherapy.
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cells that the drug was designed to, because they have undergone genetic changes that confer
them resistance or because the microenvironment protects them. Identification of the resist‐
ance cause is one of the cornerstones of cancer treatment and in this attempt, identification of
cells that have tumorigenic potential to sustain cancer is fundamental. [6]
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al, research on tumor organization intends to determine which cells have tumorigenic potential
to sustain cancer, this is, all cells in a cancer or only a specific population of them. There are
two principal models of tumor organization, not mutually exclusive, the clonal evolution
model [stochastic] and the stem cell model [hierarchical], that have been subjected to deep
examination owing to their implications in cancer management. [6]
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this is, group of cells with common features because they originate from the same progenitor
cell that can be a stem cell or not. Some of these features can be positive and provide a selective
advantage to these cells over the others, with the consequent establishment of these clones.
This model supports the idea that all cells in a tumor are important since the cancer can be
sustained due to the possible acquisition of resistance or advantage features in the derived
cells. On the other hand, this process is not random, tumors share similarities, but these
similarities will be modulated by the tumor environment turning each tumor into unique
entities. [3, 7]
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treatment cancer approach. Identification of cells that drive tumor progression will allow us
to design target drugs against this cells instead of nonspecific drugs that treat all cancer cells,
even normal cells. Tumors that have a hierarchical organization from stem cells to more
differentiated cells are said to follow the stem cell model that have been recently proved in a
few cancers, among them, the colorectal cancer. [3, 6-13] Stem cells are a very specific type of
cells that possess differential capabilities such as being pluripotent, remain in a quiescent state,
have a long life as well as self-renewal capacity which allows them to perpetuate themselves
and repopulate different cells linages.
Nonetheless, both models are not incompatible, mutation causing clonal expansion may
happen in the stem cell compartment and manifests its effects on the progenitors cells or may
happen in the progenitors cells that can re-activate the auto-renewal machinery to generate
stem cells. [14] As long as the disease progresses, these changes can induce alterations in the
normal patterns of development of these cells, reducing their ability to differentiate and
increasing their auto-renewal capacity, causing the uncontrolled increase of undifferentiated
cells, as it happens in leukemia. [15] As Nowell denoted the observation of non-differentiation
of tumor cells is explained by focus the cell resources in increasing cell proliferation and
invasiveness. [3]
Both models describe a scenario of intratumor genetic heterogeneity that reproduces the tumor
tissue heterogeneity observed in patients, and also describes the heterogeneity observed in the
different stages of cancer as consequence of selection in different environments. [3, 7]
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Nonetheless, cells in this tissue are not independent units, there is a communication between
them and even collaboration has been proved in leukemogenic cells. [16] This communication
is performed through the extracellular matrix by different signals to which cells respond and
its behavior is modulated by these signals as them change over time. Hence, during cancer
development, cells in a tumor, experiment different genetic alterations selected by their fitness
which is determined by the tumor microenvironment and tissue characteristics where the
tumor is being developed. All these characteristics explain the observed intra-tumor hetero‐
geneity in cancer and the different subtypes identify in a specific type of cancer, which added
to the modification performed by the individual genetic background makes each cancer a
unique entity. [7]
To add more complexity to the system, not all the mutations within a tumor are important for
its progression or survival. Due to alterations in DNA repair systems, numerous mutations
are produced that do not provide any advantage nor disadvantage to cells at a given moment
but, its presence and proportion in the tumor mass will depend on if they are produced in
clones which have driver mutations, this is mutations that will lead tumor development and
response to the environment. Differentiate which mutations are drivers from passengers it is
another important and confounding factor for both, identification of tumor and pharmacoge‐
netic markers. [7, 17, 18]
Equally importantly is to determine the global effects that mutations cause, since understand‐
ing the aims of the tumor through the modulation of the pathways that performs will help us
to predict the compensatory mechanism that executes. [3] Knudson´s two hits hypothesis
postulates that more than one mutation is needed in cells to become malignant. [19, 20] The
fine regulation that tumor cells exert, and the importance of the molecular pathways implied
is exemplified by the °Just-right hypothesis° that postulates that the second mutation in the
adenomatous polyposis coli [APC] gene [which is a gene where germline mutations are found
to be associated to an hereditary form of colorectal cancer] produces in a tumor is dependent
on the type and localization of the germline mutation in a patient in order to maintain some
basal APC activity, which it is needed for cell functioning. [21]
Apart from all these convolutions, each tumor has an inherent progression; there is a pattern
of genetic alterations typical of each tumor, whose establishment is a priority when designing
cancer treatments. The goal is to increase drug efficiency along with its specificity in order to
diminish the secondary effects. In this road, there have been two important events that have
helped us to achieve this ultimate goal.
Firstly, advances in knowledge of genetics have allowed us to discover the hereditary compo‐
nent of cancer as well as the steps that follow in cancer development, the more important
pathways trigger in them and have pointed out the key deregulated molecules against to specific
drugs can be designed. The studies realized to determine the cancer characteristics have also
contributed to the discovery of specific and differential patterns of each cancer. [22-25]
Secondly, drug development research has focused their efforts in the development of target
drugs that act specifically on those molecules in order to avoid the important secondary effects
of classical chemotherapy.
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Molecular specific drugs, like tyrosine kinase inhibitors or antibody-based therapies are the
next-generation cancer treatment. [4] As result of this molecular specificity, effectiveness of
these selective treatments is more dependent on the biology of the target cell. Consequently,
the pace of the improvements in cancer treatments is highly dependent on the knowledge of
cancer cells biology.
But, as stated above, cancer cells are not islands, its behavior is modulated by the signals that
its surroundings emit, as well as its surroundings control the quantity of nutrients, oxygen and
chemicals that reach the tumor. Therefore, treatment efficiency is influenced by drug phar‐
macokinetics, that is dependent of the biology of the normal cells, as well as the secondary
effects are determined by drug pharmacodynamics, that is subject to drug specificity and the
inherited sensibility of normal cells to chemotherapeutic agents determined by different
mechanisms, for example, detoxifying mechanisms. [3] Subsequently, when trying to person‐
alize treatments it is important to identify both, the genetic of the tumor and the genetic of
normal cells. This is one of the causes that explain the variability in response to chemotherapy
observed in patients with similar tumor characteristics. [4]
Despite the efforts realized, the only pharmacogenetics markers used today in clinic are KRAS
and BRAF mutations. Some of the causes of this delay in markers discovery are then. No
intention of this chapter is to provide a deep review of the different subtypes but offer an
outline of the principal characteristics of the diverse subtypes according to the literature, in
order to expose the cause of the delay in markers discovery that was previously mentioned,
and reflect that problems in pharmacogenetic studies obtained are due, in part, to the high
heterogeneity in colorectal cancer which makes difficult to establish clearly differentiated
groups of study and at the same time, to reflect that intense research has a positive point of
view, since important advances in tumor characterization and target molecules discovery have
also been done.
2. Colorectal cancer biology — Heterogeneity of colorectal cancer
Colon tissue is organized in a repetition of structural subunits called crypts. Cells in each crypt
have an ordered configuration, being the stem cells at the base of the crypt and the subsequent
differentiated cells upwards along the crypt. The main conductor in the colonic cell differen‐
tiation is the Wnt/β-catenin signaling pathway. [26] β-Catenin is a transcriptional co-activator
of genes implicated in cell growth and differentiation. Activation of the Wnt pathway disrupts
the cytoplasmatic complex that marks β-catenin for degradation allowing it to enter the
nucleus were exerts its activity. [27-29] APC protein forms part of the degradation complex.
Concordant to their function in the differentiation and growing pattern, there is an inverse
gradient of APC/β-catenin expression along the crypt axle, being APC mostly expressed in the
upper part of the crypt and β-catenin in the lower part on the crypt. [30]
Colorectal cancer is a highly heterogeneous malignancy caused by genetic and epigenetic
alterations in the stem cells of the crypt of the bowel which give rise to precancerous lesion,
aberrant crypt foci, that overgrow usually forming polyps that after a successful accumulation
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of genomic alterations become tumor cells. [11-13, 31, 32] It can arise in a sporadic form or it
can have a hereditary component.
Identification of the cause that predisposes to cancer in the hereditary syndromes have given
us clues, due to the similarities of the mechanisms identified, to understand what happen in
the sporadic tumors, that involves the majority of the colorectal cancer cases. Germline
mutations in known oncogenes or DNA repair genes have been identify as causative of a
predisposition to endure colorectal cancer but the origin of the sporadic form is still unclear
and it is attributed to genetic alterations caused by the environmental as chemical carcinogens,
age related factors which increase DNA errors rate and nutritious factors. All these conditions
will probably determine the activated cancer mechanism depending on which factor has
triggered the cancer. But, environment is also an important factor that modulates colorectal
cancer appearance in patients with a hereditary component since germline mutations cause a
predisposition to cancer, but another mutation is needed in the cells for them to become
malignant, as it is postulated in Knudson´s two hits hypothesis. [19, 20]
In recent times it has become evident the need of establish subtypes in colorectal cancer due
to the differential characteristics of the proximal and distal segments of the colon as well as
diverse features, at both histological and molecular level, observed in colorectal cancer.
Proximal and distal colon, proceed from a different embryological origin, midgut and hindgut
respectively. Besides the embryological origin, its distinctions span from innervation and
blood supply to functional differences and differential gene expression. [33, 34]
At histological level, most the polyps are adenomatous [95%], but only a small percentage of
them progress to cancer and not all the colorectal cancer cases are presented with polyps.
[35-37] Actually, prevalence of each type of polyp is only rough since it is population depend‐
ent, due to its genetic background and environmental dependence apart from the expertise of
the pathologist to identify the polyp, which sometimes is difficult. [37, 38] Histological features
of the tumors are associated to the underlying molecular pathway. So far, two main types of
carcinoma have been identified, traditional and serrated carcinomas, that have several
subtypes and whose development is driven by three main molecular mechanisms, chromo‐
somal instability (CIN), microsatellite instability (MSI) and CpG island methylator phenotype
(CIMP). Combinations of these mechanism and some additional genetic and epigenetics
changes according to the tumor environment give raise to the large varieties of histological
forms observed. [38]
On molecular basis, colorectal cancer development is mainly, but not exclusively, driven by
the deregulation of one of these mechanisms (CIN, MSI or CIMP), CIN being the most
prevalent. [23, 39-44] But it not clear if these mechanisms are the cause or the major alterations
trigger in cancer. [2]
The predominance, of one of these mechanisms over the others, since they are not mutually
exclusive, provides the tumor their differential features, which includes morphological
characteristics, cancer prognosis and treatment efficiency. This heterogeneity observed in
colorectal cancer is due to the diverse scenarios in which colorectal cancer develops so,
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Molecular specific drugs, like tyrosine kinase inhibitors or antibody-based therapies are the
next-generation cancer treatment. [4] As result of this molecular specificity, effectiveness of
these selective treatments is more dependent on the biology of the target cell. Consequently,
the pace of the improvements in cancer treatments is highly dependent on the knowledge of
cancer cells biology.
But, as stated above, cancer cells are not islands, its behavior is modulated by the signals that
its surroundings emit, as well as its surroundings control the quantity of nutrients, oxygen and
chemicals that reach the tumor. Therefore, treatment efficiency is influenced by drug phar‐
macokinetics, that is dependent of the biology of the normal cells, as well as the secondary
effects are determined by drug pharmacodynamics, that is subject to drug specificity and the
inherited sensibility of normal cells to chemotherapeutic agents determined by different
mechanisms, for example, detoxifying mechanisms. [3] Subsequently, when trying to person‐
alize treatments it is important to identify both, the genetic of the tumor and the genetic of
normal cells. This is one of the causes that explain the variability in response to chemotherapy
observed in patients with similar tumor characteristics. [4]
Despite the efforts realized, the only pharmacogenetics markers used today in clinic are KRAS
and BRAF mutations. Some of the causes of this delay in markers discovery are then. No
intention of this chapter is to provide a deep review of the different subtypes but offer an
outline of the principal characteristics of the diverse subtypes according to the literature, in
order to expose the cause of the delay in markers discovery that was previously mentioned,
and reflect that problems in pharmacogenetic studies obtained are due, in part, to the high
heterogeneity in colorectal cancer which makes difficult to establish clearly differentiated
groups of study and at the same time, to reflect that intense research has a positive point of
view, since important advances in tumor characterization and target molecules discovery have
also been done.
2. Colorectal cancer biology — Heterogeneity of colorectal cancer
Colon tissue is organized in a repetition of structural subunits called crypts. Cells in each crypt
have an ordered configuration, being the stem cells at the base of the crypt and the subsequent
differentiated cells upwards along the crypt. The main conductor in the colonic cell differen‐
tiation is the Wnt/β-catenin signaling pathway. [26] β-Catenin is a transcriptional co-activator
of genes implicated in cell growth and differentiation. Activation of the Wnt pathway disrupts
the cytoplasmatic complex that marks β-catenin for degradation allowing it to enter the
nucleus were exerts its activity. [27-29] APC protein forms part of the degradation complex.
Concordant to their function in the differentiation and growing pattern, there is an inverse
gradient of APC/β-catenin expression along the crypt axle, being APC mostly expressed in the
upper part of the crypt and β-catenin in the lower part on the crypt. [30]
Colorectal cancer is a highly heterogeneous malignancy caused by genetic and epigenetic
alterations in the stem cells of the crypt of the bowel which give rise to precancerous lesion,
aberrant crypt foci, that overgrow usually forming polyps that after a successful accumulation
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of genomic alterations become tumor cells. [11-13, 31, 32] It can arise in a sporadic form or it
can have a hereditary component.
Identification of the cause that predisposes to cancer in the hereditary syndromes have given
us clues, due to the similarities of the mechanisms identified, to understand what happen in
the sporadic tumors, that involves the majority of the colorectal cancer cases. Germline
mutations in known oncogenes or DNA repair genes have been identify as causative of a
predisposition to endure colorectal cancer but the origin of the sporadic form is still unclear
and it is attributed to genetic alterations caused by the environmental as chemical carcinogens,
age related factors which increase DNA errors rate and nutritious factors. All these conditions
will probably determine the activated cancer mechanism depending on which factor has
triggered the cancer. But, environment is also an important factor that modulates colorectal
cancer appearance in patients with a hereditary component since germline mutations cause a
predisposition to cancer, but another mutation is needed in the cells for them to become
malignant, as it is postulated in Knudson´s two hits hypothesis. [19, 20]
In recent times it has become evident the need of establish subtypes in colorectal cancer due
to the differential characteristics of the proximal and distal segments of the colon as well as
diverse features, at both histological and molecular level, observed in colorectal cancer.
Proximal and distal colon, proceed from a different embryological origin, midgut and hindgut
respectively. Besides the embryological origin, its distinctions span from innervation and
blood supply to functional differences and differential gene expression. [33, 34]
At histological level, most the polyps are adenomatous [95%], but only a small percentage of
them progress to cancer and not all the colorectal cancer cases are presented with polyps.
[35-37] Actually, prevalence of each type of polyp is only rough since it is population depend‐
ent, due to its genetic background and environmental dependence apart from the expertise of
the pathologist to identify the polyp, which sometimes is difficult. [37, 38] Histological features
of the tumors are associated to the underlying molecular pathway. So far, two main types of
carcinoma have been identified, traditional and serrated carcinomas, that have several
subtypes and whose development is driven by three main molecular mechanisms, chromo‐
somal instability (CIN), microsatellite instability (MSI) and CpG island methylator phenotype
(CIMP). Combinations of these mechanism and some additional genetic and epigenetics
changes according to the tumor environment give raise to the large varieties of histological
forms observed. [38]
On molecular basis, colorectal cancer development is mainly, but not exclusively, driven by
the deregulation of one of these mechanisms (CIN, MSI or CIMP), CIN being the most
prevalent. [23, 39-44] But it not clear if these mechanisms are the cause or the major alterations
trigger in cancer. [2]
The predominance, of one of these mechanisms over the others, since they are not mutually
exclusive, provides the tumor their differential features, which includes morphological
characteristics, cancer prognosis and treatment efficiency. This heterogeneity observed in
colorectal cancer is due to the diverse scenarios in which colorectal cancer develops so,
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characterization of the colorectal cancer in different subtypes, according to its distinctive
signatures, will help us to stratify cancer progression risk and personalize treatments. [45-47]
But these subtypes are not mutually exclusive, the intra-heterogeneity observed in a patient´s
polyps reflects the heterogeneity of the molecular pathways and mechanisms that can be
implicated. [37]
Despite this overlap, predominant characteristics can be distinguished into the subtypes and
even alterations that are, in principal, mutually exclusive have been identified, that reflect the
unique signature of each tumor. [48, 49]
2.1. Molecular mechanism
2.1.1. Chromosomal instability mechanism – CIN
Chromosomal instability mechanism (CIN) is detected in the 65-70% of the colorectal cancers.
It is defined by the identification of changes at chromosomal level in tumor cells that cause
gene dose variations. [2] This mechanism is associated to the major hereditary syndrome, the
polyposis adenomatous familiar (FAP) as well as its attenuated variant (AFAP), that accounts
for 1% of the colorectal cases and it is the most frequently detected in the sporadic form [38,
50-52]. Less commonly, CIN is categorized in subtypes as CIN-high and low. [47, 52, 62]
The molecular steps that describe this mechanism were proposed by Fear and Vogelstein in
the °adenoma-carcinoma sequence°, where mutations in the APC gene (chr.5q) is the first step
identified in a sequence of genetic alterations on oncogenes and tumor suppressor genes that
leads to its keys characteristics, the aneuploidy and loss of heterozigosity. [22, 52-54]
Germline mutations in the APC gene are associated with these hereditary syndromes, as well
as mutations in this gene are detected in the 72%-85 of sporadic colorectal cancer cases and
hypermethylation of its promoter in the 18%. According to the importance of the Wnt pathway
in the colorectal cancer, in half of the patients where genetic alterations in APC are not detected,
gain of function mutations in the β-catenin gene have been found that account for 10% of
colorectal cases. [52, 55-57]
Besides its function in the repression complex of the β-catenin, APC has numerous functions,
among which highlights its implication in chromosomal segregation and, according to its
parallel increasing expression with cell differentiation, plays a role in different features of cell
differentiation. [52, 55, 56]
Mutations in APC are followed by genetic alterations with a different frequency, in KRAS,
DCC, SMAD4 and p53 that are detected in the progression of a tumor from adenoma to
carcinoma. [22, 58] All these genes are key points of regulation of important pathways that
control cell behavior thus, KRAS [chr.12p] is member of the Ras and PI3K pathway, which are
usually dysregulated in cancer and is implicated in cell proliferation, differentiation, survival,
metabolism and apoptosis. Its activation triggers both pathways. [58, 59]
SMAD4 belongs to the transforming growth factor β pathway signaling which is a tumor
suppressor pathway. Its inactivation is related to tumor progression and invasion, being
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associated to the transition from adenoma to carcinoma. This pathway has also a function on
the microenvironment regulation of cell by autocrine and paracrine factors. [58, 60]
Because of its important and numerous functions in cells, like cell cycle regulation or mainte‐
nance of genomic integrity, p53 (chr.17p) is called the guardian of the genome. Being one of
the most frequently mutated genes in cancer, its inactivation is associated to metastasis. [58, 61]
Nonetheless, the establishment of the adenoma-carcinoma sequence does not implied that all
mutations described are needed for the progression of cancer nor the uniques but the more
frequently ones detected, with different prevalence across the stages. [22]
2.1.2. Microsatellite instability (MSI)
Microsatellite instability (MSI) is defined by the detection of alterations in the length of short
repeated sequences known as microsatellite, which is indicative of defects in the DNA
mismatch repair system (MMR). These alterations influence expression of the affected genes.
[63] The genes that have been found associated to this altered mechanism are MLH1, PMS2,
PMS1 and MSH6. This mechanism is detected in 15-20% of colorectal cancers in both sporadic
and hereditary tumors. It is the main feature of another hereditary syndrome, Lynch syndrome
that accounts for 2-3% of colorectal cases. [38, 64] The number of altered microsatellites, is also
important, defining two subtypes as this number is high, MSI-H, or low, MSI-L. [65]
Mutations in MUTYH are associated to another hereditary syndrome, rarely found in sporadic
cases, called adenomatous polyposis associated to Mutyh (MAP). This protein belongs to the
DNA base-excision repair system, which is important in DNA oxidative damage repair that
causes guanosine (G) to thymidine (T) transversions. [66] Molecular mechanisms are not yet
totally clarified and polyps from MAP have some of the features but not all of both, CIN and
MSI mechanism. [67, 68]
2.1.3. Methylator Phenotype (CIMP)
CpG island methylator phenotype (CIMP) is defined by the detection of high degree of
methylation. [69] Hypermethylation of the promoter region causes silencing expression of
affected genes. It is generally age-related and it is related to cell response to inflammation. [65]
This mechanism is frequent in sporadic tumor and has also been detected associated to
hereditary mechanisms with a non-Darwinian patter of inheritance. [58, 70-75] There are two
panels of genes studied to identify the CIMP state, which define two subtypes, CIMP-high and
CIMP-low. CIMP-H is associated to neoplastic methylation meanwhile CIMP-L are age related.
2.2. Molecular pathways
2.2.1. Traditional pathway (Chromosomal instability mechanism – CIN)
The traditional pathway of colorectal cancer is the most prevalent, 60% of CCR arise by this
pathway. [76] Histologically, tumors that follow the traditional pathway are tubular polyps
that can be subdivided into tubular, tubulovillous and villous, being the former the most
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characterization of the colorectal cancer in different subtypes, according to its distinctive
signatures, will help us to stratify cancer progression risk and personalize treatments. [45-47]
But these subtypes are not mutually exclusive, the intra-heterogeneity observed in a patient´s
polyps reflects the heterogeneity of the molecular pathways and mechanisms that can be
implicated. [37]
Despite this overlap, predominant characteristics can be distinguished into the subtypes and
even alterations that are, in principal, mutually exclusive have been identified, that reflect the
unique signature of each tumor. [48, 49]
2.1. Molecular mechanism
2.1.1. Chromosomal instability mechanism – CIN
Chromosomal instability mechanism (CIN) is detected in the 65-70% of the colorectal cancers.
It is defined by the identification of changes at chromosomal level in tumor cells that cause
gene dose variations. [2] This mechanism is associated to the major hereditary syndrome, the
polyposis adenomatous familiar (FAP) as well as its attenuated variant (AFAP), that accounts
for 1% of the colorectal cases and it is the most frequently detected in the sporadic form [38,
50-52]. Less commonly, CIN is categorized in subtypes as CIN-high and low. [47, 52, 62]
The molecular steps that describe this mechanism were proposed by Fear and Vogelstein in
the °adenoma-carcinoma sequence°, where mutations in the APC gene (chr.5q) is the first step
identified in a sequence of genetic alterations on oncogenes and tumor suppressor genes that
leads to its keys characteristics, the aneuploidy and loss of heterozigosity. [22, 52-54]
Germline mutations in the APC gene are associated with these hereditary syndromes, as well
as mutations in this gene are detected in the 72%-85 of sporadic colorectal cancer cases and
hypermethylation of its promoter in the 18%. According to the importance of the Wnt pathway
in the colorectal cancer, in half of the patients where genetic alterations in APC are not detected,
gain of function mutations in the β-catenin gene have been found that account for 10% of
colorectal cases. [52, 55-57]
Besides its function in the repression complex of the β-catenin, APC has numerous functions,
among which highlights its implication in chromosomal segregation and, according to its
parallel increasing expression with cell differentiation, plays a role in different features of cell
differentiation. [52, 55, 56]
Mutations in APC are followed by genetic alterations with a different frequency, in KRAS,
DCC, SMAD4 and p53 that are detected in the progression of a tumor from adenoma to
carcinoma. [22, 58] All these genes are key points of regulation of important pathways that
control cell behavior thus, KRAS [chr.12p] is member of the Ras and PI3K pathway, which are
usually dysregulated in cancer and is implicated in cell proliferation, differentiation, survival,
metabolism and apoptosis. Its activation triggers both pathways. [58, 59]
SMAD4 belongs to the transforming growth factor β pathway signaling which is a tumor
suppressor pathway. Its inactivation is related to tumor progression and invasion, being
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associated to the transition from adenoma to carcinoma. This pathway has also a function on
the microenvironment regulation of cell by autocrine and paracrine factors. [58, 60]
Because of its important and numerous functions in cells, like cell cycle regulation or mainte‐
nance of genomic integrity, p53 (chr.17p) is called the guardian of the genome. Being one of
the most frequently mutated genes in cancer, its inactivation is associated to metastasis. [58, 61]
Nonetheless, the establishment of the adenoma-carcinoma sequence does not implied that all
mutations described are needed for the progression of cancer nor the uniques but the more
frequently ones detected, with different prevalence across the stages. [22]
2.1.2. Microsatellite instability (MSI)
Microsatellite instability (MSI) is defined by the detection of alterations in the length of short
repeated sequences known as microsatellite, which is indicative of defects in the DNA
mismatch repair system (MMR). These alterations influence expression of the affected genes.
[63] The genes that have been found associated to this altered mechanism are MLH1, PMS2,
PMS1 and MSH6. This mechanism is detected in 15-20% of colorectal cancers in both sporadic
and hereditary tumors. It is the main feature of another hereditary syndrome, Lynch syndrome
that accounts for 2-3% of colorectal cases. [38, 64] The number of altered microsatellites, is also
important, defining two subtypes as this number is high, MSI-H, or low, MSI-L. [65]
Mutations in MUTYH are associated to another hereditary syndrome, rarely found in sporadic
cases, called adenomatous polyposis associated to Mutyh (MAP). This protein belongs to the
DNA base-excision repair system, which is important in DNA oxidative damage repair that
causes guanosine (G) to thymidine (T) transversions. [66] Molecular mechanisms are not yet
totally clarified and polyps from MAP have some of the features but not all of both, CIN and
MSI mechanism. [67, 68]
2.1.3. Methylator Phenotype (CIMP)
CpG island methylator phenotype (CIMP) is defined by the detection of high degree of
methylation. [69] Hypermethylation of the promoter region causes silencing expression of
affected genes. It is generally age-related and it is related to cell response to inflammation. [65]
This mechanism is frequent in sporadic tumor and has also been detected associated to
hereditary mechanisms with a non-Darwinian patter of inheritance. [58, 70-75] There are two
panels of genes studied to identify the CIMP state, which define two subtypes, CIMP-high and
CIMP-low. CIMP-H is associated to neoplastic methylation meanwhile CIMP-L are age related.
2.2. Molecular pathways
2.2.1. Traditional pathway (Chromosomal instability mechanism – CIN)
The traditional pathway of colorectal cancer is the most prevalent, 60% of CCR arise by this
pathway. [76] Histologically, tumors that follow the traditional pathway are tubular polyps
that can be subdivided into tubular, tubulovillous and villous, being the former the most
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prevalent. Colorectal cancer from FAP and AFAP patients, are the canonical tumors develop
by these pathway. This type of adenomas affects the epithelial layer and are originated from
dysplastic aberrant crypt foci. [77]
CIN is the most prevalent molecular mechanism in the traditional pathway of colorectal cancer,
which is also characterized for being microsatellite stable (MSS) and CIMP-. Tumors driven
by this mechanism are more frequently detected in distal localization and have a worse
prognosis than MSI tumors. They recently have showed the use of CIN as useful marker for
predicting survival, being patients that harbors CIN high tumors associated with a poor
survival. [62]
Adenoma – carcinoma sequence also lies beneath Lynch syndrome polyps but develops at a
faster tempo. [78, 79] Lynch syndrome polyps are more frequently associated to the proximal
colon, and even though it can be tubular, are more frequently associated with a mucinous or
signet ring histology and villous structures. These polyps show a high grade dysplasia, poorly
differentiated cells and Crohn’s-like infiltration of lymphocytes which has been found
associated to an increased survival. These polyps have higher risk of cancer but are less
invasive, have a better prognosis and a different response to chemotherapeutics. Less fre‐
quently these polyps have KRAS or p53 mutations. [64, 65, 78-80]
Although, presence of this mechanism in tumors has been reported to be inversely related to
CIMP, either CIMP-L or CIMP-H, [81, 82] there is a subgroup of CIN/MSS tumors characterized
by the presence of BRAF mutation that seems to be correlated with CIMP and poor survival.
[83] BRAF is implicated in MERK-ERK activation pathway by its recruitment by KRAS.
Confirming previous reports of KRAS and BRAF mutations as mutually exclusive, these
tumors are wild type KRAS. [84]
2.2.2. Alternative pathway (KRAS)
The alternative pathway is still not very well characterized. Some studies indicate the presence
of KRAS as its hallmark. [85] Histologically, the presence of KRAS, p53 mutation and recently
GNAS, has been associated to villous histology and a high grade dysplasia [86-88] and the
presence of CIMP+ to tubule villous size, right side localization and amount of villous, [89,
90] as well as to a differential pattern of the Wnt pathway genes. [91] Villous polyps are also
characterized for being microsatellite stable [MSS] and CIMP-L.
2.2.3. Serrated pathway CpG Island [methylator phenotype (CIMP)
The serrated pathway underlines the 20-35% of colorectal cancer cases. [37, 76] Histologically,
it is characterized by hyperplastic polyps, sessile serrated polyps or traditional serrated
adenomas, originated from non-dysplastic aberrant crypt foci that can either be mucinous or
not mucinous. [77, 85, 92] This type of tumor is mostly localized in the proximal colon and has
bad prognosis. [37]
Serrated polyps can be hyperplastic (HP) (20-30%), sessile serrated adenomas (SSA) (2-9%)
and traditional serrated adenomas (TSA) (0.3%) that are subsequently divided into subtypes.
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HP can distinguish polyps of microvesicular type (MVHP), Goblet cell–rich type (GCHP) or
Mucin poor type (MPHP), according to their content in mucin. SSA can be with/without
cytological dysplasia as well as TSA can be with/without conventional dysplasia. [37, 76]
The molecular characteristic of the majority of serrated polyps is the BRAF mutation and CIMP
+ mechanism. [93]
The CpG island methylator phenotype (CIMP) is detected in 15%-40% of the colorectal tu‐
mors. [94, 95] This kind of tumor is mostly related to ageing and environmental factors. One of
these genes identified as susceptible of hypermethylation is MLH1, which belongs to the DNA
mismatch repair system (MMR), being the causal mechanism of MSI in the serrated pathway.
[37, 65, 69]
The sequential steps described in this pathway from normal mucosa to carcinoma goes from
the presence of BRAF mutation in microvesicular hyperplastic polyps and posterior acquisi‐
tion of CIMP phenotype in sessile serrated polyps to a co-occurrence of both genetics alteration
leading to sessile serrated polyps. The acquisition of MLH1 promoter methylation is related
to the carcinoma stage. [76]
Goblet cell-rich hyperplastic polyps (GCHP) and traditional serrated adenomas (TSA) are
associated to KRAS mutations and while it has not been demonstrated a progression of GCHP
to carcinoma, it was proved in TSA. It has also been suggested MSI-L after MGMT methylation
or partial MLH1 methylation. [76]
Tumors associated to MUTYH can be since hyperplastic and sessile serrated polyps to no
polyps at CRC presentation. A higher association of KRAS mutations (70%) has been found in
MAP tumors that follow the serrated pathway compared to sporadic (17%), as well as an
increased on G:C to T:A transversions (94% vs. 29%). The findings of mutations on APC in
adenomas indicate two pathways of development of MAP tumors. [67, 96]
These data seem to confirm that are, at least, as many cancers as patients.
3. State of the art of pharmacogenetics
Personalized medicine is based on the clinical use of molecular biomarkers. A biomarker is
any specific physical trait or measurable biological change in the organism related to disease
or health conditions, being a very broad concept that includes many different measurements
of a biologic status.
Besides being diagnostic [used for the establishment of a particular disease present in the
patient sample [97]] or prognostic [used for the establishment of an association with clinical
outcomes, such as overall survival or recurrence-free survival independently of the treatment
[98] biomarkers can be predictive, by the assessment of the likely benefit of a specific treatment
to a specific patient, [99] or pharmacodynamic, by the measurement of the drug effect in a
disease [100].
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[83] BRAF is implicated in MERK-ERK activation pathway by its recruitment by KRAS.
Confirming previous reports of KRAS and BRAF mutations as mutually exclusive, these
tumors are wild type KRAS. [84]
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90] as well as to a differential pattern of the Wnt pathway genes. [91] Villous polyps are also
characterized for being microsatellite stable [MSS] and CIMP-L.
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The serrated pathway underlines the 20-35% of colorectal cancer cases. [37, 76] Histologically,
it is characterized by hyperplastic polyps, sessile serrated polyps or traditional serrated
adenomas, originated from non-dysplastic aberrant crypt foci that can either be mucinous or
not mucinous. [77, 85, 92] This type of tumor is mostly localized in the proximal colon and has
bad prognosis. [37]
Serrated polyps can be hyperplastic (HP) (20-30%), sessile serrated adenomas (SSA) (2-9%)
and traditional serrated adenomas (TSA) (0.3%) that are subsequently divided into subtypes.
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cytological dysplasia as well as TSA can be with/without conventional dysplasia. [37, 76]
The molecular characteristic of the majority of serrated polyps is the BRAF mutation and CIMP
+ mechanism. [93]
The CpG island methylator phenotype (CIMP) is detected in 15%-40% of the colorectal tu‐
mors. [94, 95] This kind of tumor is mostly related to ageing and environmental factors. One of
these genes identified as susceptible of hypermethylation is MLH1, which belongs to the DNA
mismatch repair system (MMR), being the causal mechanism of MSI in the serrated pathway.
[37, 65, 69]
The sequential steps described in this pathway from normal mucosa to carcinoma goes from
the presence of BRAF mutation in microvesicular hyperplastic polyps and posterior acquisi‐
tion of CIMP phenotype in sessile serrated polyps to a co-occurrence of both genetics alteration
leading to sessile serrated polyps. The acquisition of MLH1 promoter methylation is related
to the carcinoma stage. [76]
Goblet cell-rich hyperplastic polyps (GCHP) and traditional serrated adenomas (TSA) are
associated to KRAS mutations and while it has not been demonstrated a progression of GCHP
to carcinoma, it was proved in TSA. It has also been suggested MSI-L after MGMT methylation
or partial MLH1 methylation. [76]
Tumors associated to MUTYH can be since hyperplastic and sessile serrated polyps to no
polyps at CRC presentation. A higher association of KRAS mutations (70%) has been found in
MAP tumors that follow the serrated pathway compared to sporadic (17%), as well as an
increased on G:C to T:A transversions (94% vs. 29%). The findings of mutations on APC in
adenomas indicate two pathways of development of MAP tumors. [67, 96]
These data seem to confirm that are, at least, as many cancers as patients.
3. State of the art of pharmacogenetics
Personalized medicine is based on the clinical use of molecular biomarkers. A biomarker is
any specific physical trait or measurable biological change in the organism related to disease
or health conditions, being a very broad concept that includes many different measurements
of a biologic status.
Besides being diagnostic [used for the establishment of a particular disease present in the
patient sample [97]] or prognostic [used for the establishment of an association with clinical
outcomes, such as overall survival or recurrence-free survival independently of the treatment
[98] biomarkers can be predictive, by the assessment of the likely benefit of a specific treatment
to a specific patient, [99] or pharmacodynamic, by the measurement of the drug effect in a
disease [100].
The Complexity of Colorectal Cancer Biology — Putting Bricks on the Path to Personalized Medicine
http://dx.doi.org/10.5772/57172
441
The term, Pharmacogenetics, was first used by Vogel in 1959 as the science about the effects
of heritability on drug response [101]. According to the definitions approved by the US Food
and Drug Administration (FDA), pharmacogenetics is ‘the study of variations in DNA
sequence as related to drug response’ [102] while the more comprehensive term Pharmaco‐
genomics is defined as ‘the study of variations of DNA and RNA characteristics as related to
drug response’ [103]. Sometimes used indistinctly, Pharmacogenomics is related to the study
of whole genome, the gene transcripts and population variability, with the aim of predicting
the right treatment in individual patients and designing new drugs.
In last years work in the field has grown almost exponentially [104], at the same pace as the
expectations about the increasing of clinical benefit and reduction of the risk of adverse drug
reactions (ADR), at least in outliers, i.e. people whose drug responses are not “average” [105].
Nonetheless, adoption of validated pharmacogenetic markers into routine clinical practice has
been slow, mainly in the oncological field. Pharmacogenetics has mainly focused on the
association between monogenic polymorphisms and in variations in drug metabolism. [102]
But, limitations exist on the role of pharmacogenetics in cancer therapy, mainly because of the
non-concordance at genetic level between germinal and somatic line of patients [106]. Herit‐
ability can be used to assess toxicity, but there are major concerns in their use to assess
effectivity.
Today, more than a 100 drugs have pharmacogenomic biomarkers in drug labels approved by
the U.S. Food and Drug Administration (FDA), being 35 oncology drugs [107]. In the opposite
sense, the European Medicines Agency (EMA) has been more conservative in the implemen‐
tation of pharmacogenetic markers in drug labels.
In the oncology field, hematology has been the more rewarding, due in part to the lack of some
of the architectural barriers found in solid tumors. As result of the pharmacogenetic manage‐
ment, survival rates of some leukemias have improved drastically. Albeit the efforts realized
to infer drug efficiency from germline markers, the only ones that have been consistently
replicated across the studies for efficiency, are tumor markers, leaving germline markers for
the identification of patients with toxicity risk and posterior evaluation of risk/benefit of the
drug.
3.1. Colorectal cancer treatment efficiency
In colorectal cancer, 75% of patients with stage I to III can be treated with surgery alone or in
combination with chemotherapy, with a 5-year survival rate of 93.2%, 82.5%, and 59.5%,
respectively, in contrast with only 8.1% survival rate of patients harbouring stage IV disease. [108]
For patients management, the probability of distant metastasis and response to chemotherapy,
are the most important clinical variables. With or without surgery, adjuvant chemotherapy is
routinely employed to treat those colorectal cancer patients at high risk of developing recur‐
rence or, those who already have metastatic disease at the time of diagnosis (up to 20 %).
The initial standard treatment with 5-fluorouracil (5-FU), with a median overall survival of 12
months or less and an overall response rate of 10%, has evolved to combinations with oxali‐
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platin or irinotecan that have dramatically improved survival. [109-111]. The preoperative
application of radiotherapy with infusional 5-FU have significantly decreased, the rate of local
recurrence [112-114]. In advanced colorectal cancer fluoropyrimidine chemotherapies are
basics for treatment in combination with oxaliplatin or irinotecan [115]. The integration of
biological agents with conventional cytotoxic drugs has expanded the treatment of metastatic
disease, resulting in an increased response rate and survival and achieving downstaging for
surgical resection and potential cure. The currently approved and widely used targeted
treatments are the monoclonal antibodies bevacizumab that recognizes the vasculature
endothelial growth factor (VEGF) and cetuximab and panitumumab, targeting the epidermal
growth factor receptor [EGFR]. These combinations reach response rates of up to 50% with a
median time of progression free survival of 10–12 months for patients with advanced CRC.
Biomarker development is now essential to aid selection of patients likely to respond to
therapy, rationalizing treatments and improving outcomes. But the different approaches used
in order to establish biomarkers of the response to treatments in patients with CRC are not
lacking in controversial. Even though numerous biomarkers have been postulated to be used
as pharmacogenetic markers, only a few of them are actually being used to manage cancer
treatment [116].
3.2. Biomarkers of 5-FU response
Thymidylate synthase (TS) is the primary intracellular target of 5-FU. 5-FU acts by preventing
the methylation of the deoxyuridine monophosphate to deoxythymidine monophosphate by
forming a stable complex, 5-FU–TYMS, causing a thymine deficiency. [117] In CRC, the
overexpression of TS has been associated with 5-FU resistance. [118] Several studies analysed
genetic polymorphisms as potential predictive factors to 5-FU response [119] but the associa‐
tion between TS expression or TS polymorphisms and response after 5-FU adjuvant treatment
is still largely unclear. Thus, although most studies report a TS expression decrease with a
better response, [120] there are studies that contradict this association, regarding both the
genotype and level of expression, and that link genotypes of high expression of TS with a better
response [121] and even a lack of association. [116, 122] Among the several factors that can
explain the variability of results, a relevant role might be played by the use of germline genetic
data despite the target of 5-FU is the tumor cell. In fact, the TS genotypes from germline and
tumor cells from a single patient can differ widely in rectal cancer, distorting the influence of
TS on the response to 5-FU. [116]
Although MSI CRCs have a prognostic advantage, [123] mainly due to the minor metastatic
potential of MSI CRCs, [124] the predictive value of MSI is still controversial. [125-127] MSI is
a strong and well validated prognostic marker to be used in the decision making process in an
appropriate clinical setting, for example in stage II, the favourable outcome of patients with
MSI CRC suggests that adjuvant chemotherapy could be avoided. [128]
Loss of heterozygosity (LOH) or allelic imbalance (AI) is common in chromosomal instability
(CIN) CRC. LOH of chromosome 18q leads to the loss of the tumor suppressor gene Deleted
in Colon Cancer (DCC) and had been associated with a poor prognosis of stage II and III CRC
patients in several studies [129], but these data were not confirmed. [130] In addition, their role
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tion between TS expression or TS polymorphisms and response after 5-FU adjuvant treatment
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Although MSI CRCs have a prognostic advantage, [123] mainly due to the minor metastatic
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a strong and well validated prognostic marker to be used in the decision making process in an
appropriate clinical setting, for example in stage II, the favourable outcome of patients with
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(CIN) CRC. LOH of chromosome 18q leads to the loss of the tumor suppressor gene Deleted
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as predictor of outcome in CCR patients following 5-FU based adjuvant therapy, is contro‐
versial too.
Near 30–50% of colorectal tumors harbour mutations in the KRAS oncogene, 90% of the
mutations occurring either in codon 12 or 13. [131] However, there is no consensus about the
role of KRAS as a prognostic marker [132] and KRAS mutation can hardly be expected to be
a predictive marker of response to standard chemotherapy. [132, 133]
Global hypomethylation and hypermethylation of tumor, characterize epigenomic instability.
Due to this context of genomic instability is difficult to know how the hypermethylated
phenotype “CpG island methylator phenotype” (CIMP) affect survival rate. Despite initial
results, [134] CIMP positivity in CRC seems not to be a significant independent predictor of
survival benefit from 5-FU chemotherapy. [135]
3.3. Biomarkers of platinum response
Glutathione, a ubiquitous tripeptide thiol, is a vital antioxidant and has a protective role against
a range of toxins including metal compounds such as cisplatin. Glutathione S-transferase P1
(GSTP1) acts directly in the detoxification of platinum compounds so it is an important factor
related to resistance to platinum [136]. However, and despite initial studies [137] reporting the
association between GSTP1 Ile105Val and oxaliplatin efficacy and toxicity, results of subse‐
quent studies were inconclusive. [138, 139]
High levels of excision repair cross-complementing 1 (ERCC1), an endonuclease of the
nucleotide excision repair (NER) system, are associated with an increased platinum resistance.
[140, 141] The x-ray repair cross complementing group 1 (XRCC1), a member of the base
excision repair (BER) pathway, links to other proteins related to the BER pathways and repair
specific base damage, caused by oxaliplatin. [142] XRCC1 polymorphisms increase the risk of
oxaliplatin resistance, via inadequate repair or increased damage tolerance. [143] XPD
(ERCC2) has an important role in DNA repair by removing bulky DNA adducts produced by
environmental toxins and xenobiotics. The XPD Lys751Gln polymorphism has been associated
to clinical outcome following platinum-based chemotherapy. [136, 139, 144]
3.4. Biomarkers of monoclonal antibodies response
There is a wide consensus on the predictive value of KRAS mutations in response to treatment
with anti-EGFR drugs. Interestingly, a single first study, in barely 30 patients with metastatic
CRC treated with cetuximab, demonstrated the relation between KRAS mutation and non-
response: KRAS mutations were found in 68% of non-responding patients but in none of the
responders. [145] [145]. The fact is that KRAS is downstream in the EGFR signalling pathway
and that pathway is activated by KRAS mutations irrespective of the receptor status, overrid‐
ing the efficacy of anti-EGFR therapy. The Food and Drug Administration (FDA) approved,
in a record time, label changes to cetuximab and panitumumab to advise against their use in
patients with KRAS positive metastatic CCR [146, 147]
BRAF mutations also affects the EGFR signalling pathway and are found in CRC at lower
frequency than KRAS (≤10%), in fact BRAF and KRAS mutations are mutually exclusive events
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in tumors. [148] The most frequent BRAF mutation (V600E) represents 50% of BRAF mutations
in CCR, being more common in MSI CRC, than in microsatellite stable tumors. [128] BRAF
mutation is involved in MEK-ERK pathway activation and CRC carcinogenesis. BRAF V600E
is also associated with the CIMP phenotype, 70% of CIMP CRC can harbour BRAF mutations.
[93] BRAF mutations have been associated with poor prognosis in patients with stage IV CRC.
In agreement with the role of BRAF mutations in enhancing stimulation of downstream MEK-
ERK signalling, in patients with metastatic CRC, BRAF mutations are predictive of non-
response to EGFR-targeted agents. [149]
3.5. Biomarkers of toxicity
As stated previously, more than a 100 drugs have pharmacogenomic biomarkers in drug labels
approved by the FDA. It is paradoxical that, while germline genetical markers should be better
for the identification of patients with toxicity risk, the efforts in pharmacogenetic studies were
realized to infer drug efficiency. Only six of the FDA approved oncology biomarkers are
associated with toxicity. DPYD*2A for capecitabine and UGT1A1*28 irinotecan are the
biomarker associated to CRC chemotherapy. [107]
With this data, the problem related to discovering biomarkers of ADRs is clear. Most studied
biomarkers related to ADRs are reflected in Table 1, but they are not extensively used in clinical
practice.
Gene Treatment Toxicity Review
DPYD fluoropyrimidine myelotoxicity
Amstutz U et al. Pharmacogenomics. 2011, 12 [9]:1321-36






Marques SC, Hum Genomics. 2010, 4 [4]:238-49
FDA Camptosar® Label [http://www.accessdata.fda.gov/
drugsatfda_docs/label/2006/020571s030lbl.pdf]
EGFR EGFR inhibitors Skin rash Galvani E, Future Oncol. 2012, 8 [8]: 1015-29
VEGF VEGF inhibitors hypertension
Schneider BP, J. Clin. Oncol. 2008,
26 [28]: 4672–4678
ABCB1 capecitabine neutropenia















Cortejoso L, López-Fernández LA. Pharmacogenomics.
2012, 12 [10]:1173-1191
Table 1. Association of genes to toxicity in colorectal treatments.
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as predictor of outcome in CCR patients following 5-FU based adjuvant therapy, is contro‐
versial too.
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mutations occurring either in codon 12 or 13. [131] However, there is no consensus about the
role of KRAS as a prognostic marker [132] and KRAS mutation can hardly be expected to be
a predictive marker of response to standard chemotherapy. [132, 133]
Global hypomethylation and hypermethylation of tumor, characterize epigenomic instability.
Due to this context of genomic instability is difficult to know how the hypermethylated
phenotype “CpG island methylator phenotype” (CIMP) affect survival rate. Despite initial
results, [134] CIMP positivity in CRC seems not to be a significant independent predictor of
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related to resistance to platinum [136]. However, and despite initial studies [137] reporting the
association between GSTP1 Ile105Val and oxaliplatin efficacy and toxicity, results of subse‐
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in tumors. [148] The most frequent BRAF mutation (V600E) represents 50% of BRAF mutations
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practice.
Gene Treatment Toxicity Review
DPYD fluoropyrimidine myelotoxicity
Amstutz U et al. Pharmacogenomics. 2011, 12 [9]:1321-36






Marques SC, Hum Genomics. 2010, 4 [4]:238-49
FDA Camptosar® Label [http://www.accessdata.fda.gov/
drugsatfda_docs/label/2006/020571s030lbl.pdf]
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VEGF VEGF inhibitors hypertension
Schneider BP, J. Clin. Oncol. 2008,
26 [28]: 4672–4678
ABCB1 capecitabine neutropenia















Cortejoso L, López-Fernández LA. Pharmacogenomics.
2012, 12 [10]:1173-1191
Table 1. Association of genes to toxicity in colorectal treatments.
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3.6. Biomarkers used in clinical practice
In conclusion, currently the UICC/AJCC Tumor Node Metastasis (TNM) stage system remains
the only valid prognostic marker for predicting the outcome of CRC patients. [150-155] Besides
different histomorphological, immunohistochemical and molecular biomarkers have been
proposed [156, 157] to improve stratification of CRC patients into prognostic subgroups. But,
if no additional prognostic and predictive factors were included in the pre- and postoperative
management of non-metastatic CRC until now, for metastatic CRC patients gene mutations
are arising as predictive biomarker, mainly the KRAS mutational status, with the implemen‐
tation of anti-EGFR therapy.
4. Establishment issue of genotype-phenotype correlations in cancer
In the last years, numerous candidate prognostic and predictive markers have been reported
in hundreds of studies and failed to demonstrate clinical utility. It is difficult to review, even
monthly, all described molecular markers of prognosis. Clearly a validation is necessary to
establish an association between any of these markers with prognosis or with the response to
therapy but the validation itself is not an explanation of why so many potential markers fail
to be validated. Inconsistencies can arise between initial reports and subsequent studies
because differences in assays, study design, genetic substructure of human populations,
statistical power or methodologies. But the establishment of clear genotype-phenotypes
correlations, mostly in solid tumors, is still a wide and difficult field of study due to several
reasons:
4.1. Architecture of solid tumor
Hematologic cancers treatments have turned them, in some cases, in chronic diseases with the
appropriate treatment. Even though they share a common problem with solid tumor, this is,
localization and properties of the cancer stem cells, majority of leukemia cells are located in
the bloodstream so once drugs reach the bloodstream do not have additional barriers to
trespass but the cellular membrane. This more easily access by the drug allows reduce cancer
cells load.
But in solid tumors, drugs have to overcome several barriers to access the cells. To get access
to tumor drugs first have to extravasate and diffuse across the extracellular matrix to reach all
the cells in a tumor, included not well irrigated zones where transportation into the cells is
even more difficult due to the extracellular acidic pH. [158, 159]
Tumor mass is a not equally organized mass of cells with an equally distributed blood capillary
network that supplies all cells in a tumor but a disorganized mass of different cells with
unequally blood supply subject to a different interstitial fluid pressure that produce differential
gradient of molecules distribution, among them, drugs. Thus, obstruction of an adequate
intratumoral drug delivery in one the cause is one of the causes for cancer recurrence. [158, 159]
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Indeed, modification of tumor microenvironment is one of the novel mechanisms to overcome
drug resistance. [160, 161]
4.2. Tumor microenvironment
It is already established that tumor microenvironment has an important role in tumor behavior
as well as physical impediment of drug delivery but its function in promoting cancer devel‐
opment and drug resistance by segregating molecules by stromal cells have been recently
proved. [161-164]
In colorectal cancer, presence of tumor-infiltrating lymphocytes, as part of the immune system
response, has been associated positively to both survival and chemotherapy response. [165, 166]
Straussman et al. showed that resistance to RAF inhibitors are not only due to gene activated
mutations but mediated by the segregation of hepatocyte growth factor (HGF) by the stromal
cells. Their work confirmed the microenvironment as a frequent cause of chemotherapy
resistance, principally to targeted drugs [164].
4.3. Intertumor heterogeneity
Similar to other natural ecosystems, tumor growth and development is dependent on the niche
conditions. In the case of a tumor, these conditions are primarily determined by the genetic
background and physiological state of the patient and lately, determined by the genetic of the
tumor itself. And as it happens in all ecosystems, tumor is not in a static state, as the environ‐
ment changes, the tumor will be adapted to the changed conditions. The different conditions
in which a tumor will be developed [a unique mixture of genomic and epigenomic features]
determine its specific features, which are improbable to be parallel in another organism. [167]
Albeit colorectal cancer is governed by the general mechanisms described above, the existence
of a different mutational spectrum between patients with the same type of cancer has been
broadly reported. [168] The experimental confirmation of the ‘just right hypothesis’ [169]
provided new insights into the importance of the genetic background of the patient in
determining tumourigenesis and tumor progression.
Even the triggered mechanisms into the tumor cells contribute to such divergence: Bielas et al.
determined the mutational rate in tumors and found that was, on average, 200 times greater
than in normal cells. This finding uncovered a novel cancer mechanism called point mutation
instability (PIN) [170, 171], and can have consequences over pharmacogenomic assays.
4.4. Intratumor heterogeneity
As stated before [116], intratumor heterogeneity may explain the difficulties encountered in
the validation of oncology biomarkers owing to sampling bias. As consequence of the different
conditions that tumor cells undergone, tumor cells have to adjust their behavior. The adapta‐
tion process to these variable circumstances is accompanied by a differential mutational
process that results in a genetic heterogeneous blend of cells.
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Gerlinger et al [172] demonstrated performing exome sequencing in primary renal carcinomas
that 63 to 69% of all somatic mutations were not detectable in all the samples from different
tumor sections. They also found biomarkers of good and poor prognosis in the analysis of
different regions of the same tumor and high intratumor heterogeneity when ploidy was
measured. [172] These findings indicate that intratumor heterogeneity is one of the most
important obstacles in the establishment of biomarkers of both prognosis and response to
treatment, what implies that the approaches that, so far, have been realized have to change.
4.5. Stem cells
Other possible pitfall can be the contribution of cancer stem cells to drug resistance. As
explained before, identification of the appropriate cell to direct therapy is essential to eradicate
cancer. Even though treatments can decrease tumor burden, if drugs do not target the
appropriate cell, chemotherapy can, as much, become a disease in chronic but not eliminate it
from the organism, as it has proved in leukemias. Stem cells are the only tumor-initiating cells
within a malignancy and therefore have been shown to maintain colorectal cells population,
[173] in fact, they account for about 2.5%% of cancer cells in CRC. [13] But the current chemo‐
therapy is not specific for these cells, and possibly cancer stem cells are naturally resistant to
chemotherapy through quiescence, capacity for DNA repair or expression of genes affecting
transport and effective drug release into the cells as ABC-transporter. [174]
Even more, stem cells itself are related to genetic background of the tumor. Mutations in APC
gene can increase the number of stem cells via Wnt signaling, promoting tumorigenesis [169].
4.6. Response to chemotherapy
Introduction of chemotherapy is a determinant selection factor of cell survival. The appearance
of resistance cells to treatments due to mutations that prevent treatment efficiency either by
selection of pre-existent resistant clones, either by the emergence of mutants clones induced
by the drug, either by inducing the segregation of protective molecules by autocrine or
paracrine mechanism or molecules that bypass the activity of the drug, adds new difficulties
to both, discovery of clear biomarkers and development of drugs that cure cancer.
4.7. Difficulty of identification or characterization of specific histologic subtypes
Histological identification of different colorectal cancer subtypes can be tough due to its
heterogeneity which makes it hardly dependent on the pathologist to identify the polyp. [37]
This fact introduces an error in the genotype-phenotype correlations that obscures biomarkers
identification.
4.8. Techniques limitations
The existence of high intratumor heterogeneity reveals the scarcity in the information that can
be obtained from a tumor and the impossibility, so far, of study bigger regions of the tumor
either because of the limited laboratory resources and high cost disclose high intratumor
heterogeneity is a difficult obstacle to overcome.
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Detection of genetic abnormalities is subject to the proper target identification and design of
the methodologies used. For example, one of the difficulties to categorized CIMP is the choice
of the appropriate panel of loci to study methylation. [175, 176]
4.9. Studies design
The classification of the groups is often different among studies. To analyse the statistical
association of a biomarker, some studies group patients in I-II stage and III-IV of cancer, having
each group a different association [positive, negative or not association with respect to the
analysed trait] meanwhile others does that with II-III stages. The different criteria used to
group patients, is obviously a source of contradictions, since studies compare results obtained
from patients with different characteristics. The different methodologies used between studies
is another source of confuse. [62, 83]
Some limitations in studies design are an obviously consequence of the resources restraints,
either economic or by shortage of the sample but extrapolation of results from these studies
are more hazardous.
The reality of high tumor heterogeneity and dynamic change of tumor behaviour makes easy
to understand the very little information we can acquire when study only one, two or three
markers in one slice of the tumor and this is even worse when study not targeted drugs since
cell have more options to overcome their effect like compensatory mechanisms.
As Greaves and Maley expose °genome profiles under-estimate complexity° and continue ° It
may be that only a modest number of phenotypic traits are required to negotiate all constraints
and evolve to full malignant or metastatic status but the inference is that this can be achieved
by an almost infinite variety of evolutionary trajectories and with multiple, different combi‐
nations of driver mutations° [7]
The limited capacity to detect low- prevalence clones are another source of a possible future
selection of resistance. [7]
Another reason for inconsistencies is small study sample sizes. Typically biomarker studies
are done in a subset of patients enrolled in a main study and, therefore, often not statistically
adequate to answer clinical questions. Analysis is hampered further by multiple comparisons
in correlative studies. Although this approach is crucial to sound statistical methodology,
correction for multiple comparisons [or the failure to do so] has probably led to heterogeneity.
A major statistical flaw is the potential for false-positive associations because of assessment of
multiple SNPs. The opposite is a concern too; biologically important associations frequently
cannot be detected after stringent correction because the selection of SNPs is too broad. Study
power might also be inadequate if SNPs with excessively rare minor allele frequency are
selected. Finally, racial heterogeneity within the trial is important to take into account, and
proper correction or analysis of patients in subgroups by ethnic origin must be done.
Due to the need of major research projects, both in number of samples as in appropriate
resources for their study, consolidate research consortia has become imperative.
The establishment of clear genotype-phenotypes correlations is still a wide and difficult field
of study due to the previously exposed heterogeneity and overlapping characteristics observed
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in colorectal cancer in both histological and molecular level, exacerbated by the confusion in
identifying some histologic subtypes of polyps and the designing problem of the studies,
which often compare only a few markers and patients in different stages, and with different
treatments, that as previously show have an impact in the molecular mechanism trigger. As
consequence, some of the published associations are not lately replicated
5. Conclusion
The clinical application of pharmacogenetic tests is still limited to a few drugs. But, the fact
that a significant number of patients obtain no advantage receiving chemotherapy encourage
us to increase the efforts to get more and better biomarkers. Knowledge of the problems
outlined above gives us a better understanding of the challenges of pharmacogenetics and
allow us to reach a better understanding of the biological basis of cancer treatments. While
that work continues, new genomic technologies now in development are enabling to bring
useful biomarkers from the bench to bedside in a more rapid and effective way.
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1. Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer-related mortalities in the Western
world, with over 1.2 million new cases and over 0.6 million deaths being recorded in 2008 [1].
Major risk factors of CRC are personal history of precursor lesion, inflammatory bowel disease,
age (about 90% of cases occur after age 50) and family history of CRC or a genetic susceptibility
to the development of CRC resulting from DNA mutations. It is estimated that approximately
15% of CRC cases develop as a result of inherited factors and 5-10% of them result from known
genetic syndroms, e.g., familial adenomatous polyposis (FAP) and hereditary non-polyposis
colorectal carcinoma (HNPCC), while most cases of CRC occurs sporadically (70-80%) [2]. In
patiens with inherited genetic factors CRC occurs early in life, usualy before 40 years of their
age, while in sporadic cases cancer develops after 40 years of age with the highest incidence
between 60 and 70 years of age. CRC remains asymptomatic for years. Symptoms develop
insidiously and are frequently present for months, sometimes years, before being diagnosed.
If colon tumors are not identified and removed at the precancerous or adenoma stage, the
disease gradually progresses into carcinoma stage where cancer cells invade the wall of the
intestine and distant organs [1].
There are different approaches and strategies concerning how to reduce the mortality due to
CRC. The surgical and chemotherapeutic treatment of CRC is usually costly, painful and the
prognosis is not promisig. Therefore, in clinical practice efforts have been directed toward
identification and removal of precancerous lesions. Screening programs, which are based upon
detection and removal of visible polypoid adenomas, have been implemented in a number of
countries on nationwide scale.
Global cancer statistics shows that CRC-related mortality has been decreasing in Western
countries due to improved treatment and early detection, which indicates that screening
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program is one of the important steps in reducing the mortality due to CRC [1]. However,
although screening programs are promising and represent one of the important steps in
reducing the mortality due to CRC, reports demonstrate that there is still 25% of false-negative
results due to flat or depressed precancerous lesions, which are commonly missed during
conventional colonoscopy [3].
Recently, another promising approach has been demonstrated. It is directed toward identifi‐
cation of aberrant crypt foci (ACF), intermediate biomarkers predictive for CRC. The associa‐
tion of ACF with CRC is supported by shared histological and molecular features of ACF with
colonic polyps and adenomas [4-7].
The aim of the present chapter is to summarize experimental and clinical results regarding
morphological, histological and molecular characteristics of ACF with emphasis on current
progress in the knowledge of CRC development. The role, significance and applicability of
ACF in clinical practice is also presented and discussed.
2. Aberrant crypt foci (ACF)
ACF are the first lesions in multistep development of CRC, which can be seen on the colon
surface with aid of magnification and/or dye.
ACF were first identified in 1987 by Bird on whole unembedded colon of carcinogen treated
mouse [8]. Colon was fixed, stained with methylene blue and observed under low-magnifi‐
cation (10-40x M) stereomicroscope [9; 10]. This simple and rapid methodological approach
enabled visualization of all crypts on the surface of the colon mucosa. Since their first identi‐
fication numerous studies investigating morphology, distribution, histology and molecular
characteristics of ACF have been performed. In 1991 reports on identification of ACF in the
human colon were published. ACF were identified under a dissecting microscope after
methylene blue staining on the mucosal surface of both formalin-fixed human colon resections
and fresh (unfixed) colon resections [11-13].
Based on morphological appearance of crypts on the colon surface crypts can be regarded as
normal or aberrant. Aberrant crypts can be observed as single altered crypt or as a cluster of
altered crypts that form a focus termed ACF [8; 14; 15].
It is important to keep in mind that ACF is a term that denotes topographic or endoscopic
observation. ACF can be identified as clusters of altered crypts in unembedded colon mucosa
(fixed or fresh) under magnification after visualization by different dyes. In studies using
animal models ACF are usually observed under stereomicroscope on whole colon mucosa that
is fixed flat (to prevent excessive unevenness while viewing) and stained with methylene blue
[9; 10]. In clinical practice ACF can be observed in vivo endoscopically with aid of dye spray
(methylene blue or indigo carmine) using high magnification colonoscopy [6; 7; 16].
ACF is not a histological diagnosis. Structural and cytological features of ACF can be recog‐
nized or confirmed only after histological examination. However, at the same time it is
noteworthy to mention that lesions seen in histologic sections of colon without prior topo‐
graphic identification on colon surface can not be termed ACF.
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To better understand the histological background of ACF as well as molecular alterations
recognized and described at this stage of colon carcinogenesis, the next section is brief
overview of histological criteria and classification of ACF, histologically denoted as colorectal
intraepithelial lesions [17; 18].
3. Histological characteristics of ACF
Histologically, ACF are heterogeneous group of intraepithelial lesions that exhibit variable
features, ranging from almost normal or mild atypia to severe dysplasia. Based on their
histological characteristics they can be divided into three main categories [7; 14]:
1. ACF that are almost histologically normal,
2. ACF with hyperplastic crypts and
3. ACF with dysplastic crypts.
According to World Health Organization ACF are histologically classified into two groups,
i.e. ACF with hyperplastic crypts and ACF with dysplastic crypts [19].
It has been demonstrated that the majority of observed ACF, including ACF identified in
patients with sporadic CRC, are classified as almost histologically normal (Figure 1). These
ACF are composed of crypts with almost normal histological appearance. The major histologic
difference that distinguishes this type of ACF from normal crypts is slightly enlarged crypt
diameter. The crypt diameter in this type of ACF measures up to 1.5 times the diameter of a
normal crypt. They show no other histological or molecular alterations and they even spon‐
taneously regress. Accordingly, it was found that this type of ACF has no clinical diagnostic
value [7; 14].
Figure 1. A normal human (left) and rat (right) colorectal mucosa. Crypts are parallel. The mucin is stained blue (Krey‐
berg trichrom stain).
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On the other hand, other two groups of ACF have been found to have potential clinical value
as biomarker predictive for CRC risk [7; 14].
4. ACF with hyperplastic crypts (hyperplastic intraepithelial lesions)
Hyperplastic epithelial lesions are composed of mixture of goblet and absorptive cells with
enlarged or sometimes crowded nuclei without stratification (Figure 2).
Figure 2. Hyperplastic aberrant crypts of human (left) colorectal mucosa accompanying resected sporadic colorectal
adenoma. The focus is composed of 3 hyperplastic crypts that are much wider then surrounding normal crypts. The
epithelial cells of the hyperplastic crypts are higher and composed of one layer. On the right there are hyperplastic
aberrant crypts of rat colorectal mucosa, induced by carcinogen. The focus is composed of 3 crypts with slight mucin
depletion. The level of focus is higher then of the surrounding mucosa. The epithelial cells of the hyperplastic crypts
are higher and composed of one layer (Kreyberg trichrom stain).
Mitotic figures are limited to the lower two-thirds of the crypts and are never observed on the
surface of crypts. Nuclei are basally located, ovoid or round, with occasional visible nucleoli
and usually uniformly dark. The luminal opening of crypts is slightly elevated from the
surrounding normal mucosa and the crypts are elongated and occasionally branching with
partial mucin depletion [17]. The role of hyperplastic aberrant crypts in the process of colon
carcinogenesis is not clear and is a matter of debate and further investigations [15].
5. ACF with dysplastic crypts (intraepithelial neoplasia/dysplasia)
Presence of dysplasia is regarded as early histopathological changes in the precursor lesions
of colon cancer. The word dysplasia is histological term that describes structural and cytolog‐
ical alterations in the epithelium that predispose an organ to cancer development. Inraepithe‐
lial neoplasia (IEN) is a histological term for dysplastic lesions in the epithelial layer of colon
mucosa that can be identified only after careful histological examination (Figure 3). IEN is
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synonymous with terms atypical hyperplasia, microadenoma, carcinoma in situ and dysplasia.
Depending on cytological and architectural features IEN is classified as low-grade or high
grade. The differential histological criteria involve hypercellularity with enlarged, hyperchro‐
matic nuclei, varying degrees of nuclear stratification, loss of polarity, high nuclear/cytoplas‐
mic ratio, nuclear crowding, increased mitotic index and decreased mucin excretion [17; 20].
Figure 3. Dysplastic aberrant crypts of human colorectal mucosa accompanying FAP (left). The focus is composed of 4
crypts. The level of focus is higher then that of the surrounding mucosa. The epithelial cells covering the aberrant
crypts are classified as mild dysplasia. On the right there are dysplastic aberrant crypts of rat colorectal mucosa in‐
duced by carcinogen. The focus is composed of 3 crypts that show severe mucin depletion. Numerous mitoses, stratifi‐
cation of nuclei, atypical epithelial cells, and architectural atypia are the components of dysplasia (Kreyberg trichrom
stain).
6. Molecular characteristics of ACF
Evidence from experimental and clinical studies demonstrates that ACF share similar histo‐
logical and molecular features as colonic tumors (i.e. adenomas and adenocarcinomas) [15; 21;
22]. Today, high-magnification chromoscopic colonoscopy allows detection and biopsy of ACF
in vivo in man. It also provides opportunity to investigate and characterize the earliest genetic
and molecular alterations in CRC development in man. ACF exhibit many of the molecular
and genetic abnormalities that form the basis for the adenoma-carcinoma sequence in CRC.
It has been found that ACF exhibit many of the molecular and genetic abnormalities that form
the basis for the adenoma-carcinoma sequence in CRC. Genetic alterations found in human
ACF include mutations in tumor suppressor genes, microsatellite instability, aberrant meth‐
ylation as well as aberrant expression of proteins (summarized in Figure 4). Up to date, three
molecular pathways of CRC development have been identified and described, i.e. chromoso‐
mal instability, microsatellite instability and CpG island methylator phenotype. All three types
of molecular alterations have also been found in ACF [22; 23].
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matic nuclei, varying degrees of nuclear stratification, loss of polarity, high nuclear/cytoplas‐
mic ratio, nuclear crowding, increased mitotic index and decreased mucin excretion [17; 20].
Figure 3. Dysplastic aberrant crypts of human colorectal mucosa accompanying FAP (left). The focus is composed of 4
crypts. The level of focus is higher then that of the surrounding mucosa. The epithelial cells covering the aberrant
crypts are classified as mild dysplasia. On the right there are dysplastic aberrant crypts of rat colorectal mucosa in‐
duced by carcinogen. The focus is composed of 3 crypts that show severe mucin depletion. Numerous mitoses, stratifi‐
cation of nuclei, atypical epithelial cells, and architectural atypia are the components of dysplasia (Kreyberg trichrom
stain).
6. Molecular characteristics of ACF
Evidence from experimental and clinical studies demonstrates that ACF share similar histo‐
logical and molecular features as colonic tumors (i.e. adenomas and adenocarcinomas) [15; 21;
22]. Today, high-magnification chromoscopic colonoscopy allows detection and biopsy of ACF
in vivo in man. It also provides opportunity to investigate and characterize the earliest genetic
and molecular alterations in CRC development in man. ACF exhibit many of the molecular
and genetic abnormalities that form the basis for the adenoma-carcinoma sequence in CRC.
It has been found that ACF exhibit many of the molecular and genetic abnormalities that form
the basis for the adenoma-carcinoma sequence in CRC. Genetic alterations found in human
ACF include mutations in tumor suppressor genes, microsatellite instability, aberrant meth‐
ylation as well as aberrant expression of proteins (summarized in Figure 4). Up to date, three
molecular pathways of CRC development have been identified and described, i.e. chromoso‐
mal instability, microsatellite instability and CpG island methylator phenotype. All three types
of molecular alterations have also been found in ACF [22; 23].
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Figure 4. Phenotypic, genetic and epigenetic alteration involved in multistep development of colon carcinogenesis.
7. The chromosomal instability (CIN)
CIN is the most common in sporadic CRC and shows chromosomal abnormalities such as
chromosome breaks, duplication, rearrangements, loss of heterozygosity (LOH) and sequen‐
tial inactivation of tumor suppressor genes such as APC (5q), P53 (17p) and SMAD4 (18q),
which are frequently found in sporadic carcinomas. It is known that germ line mutations in
APC lead to the hereditary syndrome of FAP [22; 23].
Loss of heterozygosity (LOH) was observed in ACF at 18q (locus that maps close to the DCC
and DPC4 genes) [24], in 67% LOH was found at locus 11p11, the location of the gene for protein
tyrosine phosphatase receptor type J (PTPRJ; tumor suppressor gene), at locus 5q21 and 18q21
[25]. LOH was identified near the APC tumor suppressor gene (at the D5S346 marker) [26].
APC mutation was found in ACF with dysplastic crypts but not in ACF with hyperplastic
crypts. This was frequently observed in ACF obtained from patients with FAP, while in ACF
obtained from patients with sporadic CRC APC mutation was rarely observed [7; 27; 28].
β-catenin mutation, which is found in 12% of adenomas and 16% of carcinomas, was not found
in ACF, regardless of the histologic type of ACF [5; 29]. Only increased expression of β-catenin
was found in the cytosol of ACF with dysplastic crypts (54%) [30; 31].
K-RAS mutation was found in 13%-95% of ACF and was much more frequent in ACF with
hyperplastic crypts (80%-100%) that in ACF with dysplastic crypts (0%-57%) [7; 27; 28; 32-35].
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8. The microsatellite instability (MSI)
MSI is a hallmark of defective DNA mismatch repair (MMR) genes such as hMLH1 or hMSH2
and leads to the accumulation of a high frequency of somatic mutations [24]. It is frequent in
patients with HNPCC (90%) but also found in sporadic CRC (15%).
MSI was identified in 30% ACF from patients of elevated risk (family or personal history) and
13% lesions from average risk patients (subjects without family or personal history) [24-26].
9. The CpG island methylator phenotype (CIMP)
CIMP is epigenetic mechanism characterized by hypermethylation of cytosine residue within
CpG islands in the promoter regions of certain genes (which are particularly rich in CpG
nucleotides such as tumor suppressor and MMR genes) and results in their inactivation (loss
of gene expression). Genes that have been shown to be silenced by promoter hypermethylation
in human CRC are p16, hMLH1, MGMT, MINT1,2,12, and 31 [22; 23].
Methylation of CpG islands was found in 34% ACF obtained from patients with both FAP and
sporadic CRC, but was more frequent in sporadic ACF (53%), especially dysplastic ACF (75%)
and less hyperplastic ACF (7%) [32].
In ACF hypermethylation of the MMR genes such as hHLM1 and MGMT (in hyperplastic ACF)
[26] and tumor suppressor genes such as p16, MINT31 [32], RASSF1A were found [26].
10. ACF revealing new insight into CRC development
As high-magnification chromoscopic colonoscopy now allow detection and biopsy of ACF in
the mucosa of large bowel, ACF might serve as a research tool for revealing new insights and
knowledge into first alterations and risk factors in CRC development.
Evidence shows that ACF in FAP patients differ from ACF in subjects with sporadic CRC.
Differences can be observed regarding endoscopic, histological and molecular characteristics.
Patients with FAP have significantly increased number of ACF than patients with sporadic
CRC. Most of the ACF in FAP patients is histologically diagnosed as dysplastic (89%), while
patients with sporadic CRC have mostly ACF with hyperplastic crypts (82%). K-RAS mutation
was found very rarely in dysplastic ACF of FAP patients, but frequently in ACF obtained from
patients with sporadic CRC (82%) [7].
Conversely, APC mutations were very rarely found in dysplastic ACF from patients with
sporadic CRC, while in ACF from FAP patients were almost always present. Methylation of
CpG islands was found in sporadic ACF but not in ACF from FAP patients [32].
Differences in the endoscopic appearance and genetic features were observed also in ACF
obtained from patients with ulcerative colitis (UC). In ACF from patients with UC K-RAS
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mutation was rarely observed and APC mutation was not found. However, in dysplastic ACF
frequent methylation of promoter region of p16 (73%) and P53 mutation (60%) was found [36].
All these data show that ACF provide opportunity to get closer insight into first molecular
events that are responsible for initiation and formation of CRC.
11. Endoscopic characteristics of ACF
As already mentioned ACF are the first lesions that can be found on the surface of the fixed or
fresh colorectal mucosa. ACF are invisible to standard endoscopic instruments but can now
be visualized in vivo endoscopically by using specialized magnifying colonoscopes in con‐
junction with dye sprays (methylene blue, indigo carmine), the technique termed high-
magnification chromoscopic colonoscopy [6].
Staining of the colonic mucosa at colonoscopy improves the visibility of the morphological
characteristics of the crypts in the mucosa, such as shape, size or luminal openings of the crypts.
Most prominent feature of aberrant crypts is that they stain more darkly than do normal
surrounding crypts. However, there are also other morphological features important for
identification of ACF. By definition, ACF are colon crypts that are larger than normal sur‐
rounding crypts, have increased pericryptal space that separates them from the normal crypts,
they have a thicker layer of epithelial cells that often stains darker, their luminal openings are
not circular but rather oval or even compressed. They are usually not in the same level as the
surrounding normal crypts but they are either slightly elevated above the mucosa or may be
even depressed. ACF may be composed of one to few hundreds of aberrant crypts per focus
(1 to 412) [10; 14; 15].
As explained, ACF are heterogeneous group of lesions that exhibit variability in histological
and molecular characteristics as well as variability in morphological characteristics.
Based on the surface morphologic features of ACF, researchers are able to distinguish three
types of ACF and predict histologic characteristics of ACF [6].
Aberrant crypts that stain more darkly and are larger, have a thicker epithelial lining and a
larger pericryptal zone than normal crypts and exhibit large oval (smooth, dilated) lumens
have been histologically diagnosed as almost normal. Such ACF have slight enlargement,
irregularity, and elongation of the ducts but show no signs of hyperplasia or dysplasia [6].
Aberrant crypts that have all above-mentioned characteristics and exhibit asteroid or slit shape
of lumens have been histologically diagnosed as hyperplastic with serrated luminal pattern.
Aberrant crypts that have ticker epithelial lining than both above mentioned types and exhibit
compressed or undistinguishable lumen are classified in the third group of ACF, histologically
diagnosed as dysplastic. Such ACF show loss of polarity, hyperchromatism and stratification
of the nuclei in the crypt epithelium [6; 12; 14].
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12. Prevalence and density of ACF
First data about density (average number of ACF per cm2 of mucosa) and anatomical location
of ACF in colonic mucosa are based on investigations of colorectal resections. Results have
shown that patients with increased risk (personal or family history) have higher average
number of ACF per cm2 than persons with average risk (subjects without personal or family
history). It was found that FAP patients have significantly higher density of ACF in colon
mucosa than patients with sporadic CRC or benign bowel disease. Higher frequencies of ACF
were observed in left than in right colon. Results have shown that density of ACF increases
from proximal to distal part of the colon, being the highest in the rectosigmoidal region, which
corresponds to anatomical location of CRC development [11-14; 34].
13. Endoscopic detection of ACF
Similar findings regarding prevalence and distribution of ACF in colorectal mucosa have been
observed in humans in vivo by using magnifying (40x) endoscopy after endoscopic staining of
colon mucosa (methylene blue). Takayama et al. [6] examined 370 subjects (147 normal
subjects, 130 patients with adenoma, and 48 patients with carcinoma) and found that ACF were
present in almost all patients with adenoma or carcinoma. ACF were most frequently observed
in the left colon, where polyps are often found. Additionally, it was found that patients with
adenoma or carcinoma had significantly higher estimated relative risks for ACF with dys‐
plastic crypts than normal subjects [6].
In normal subjects, both the prevalence and the number of ACF in subjects under 40 years of
age were very low (10%) but increased with age, particularly after the age of 40 (54% - 66%).
Conversely, patients with cancer had a consistently high prevalence (100%) and large number
of ACF regardless of age. In patients with adenoma, the age-associated increment in the
prevalence and number of ACF was intermediate [6].
Takayama et al. [6] investigated number, density, and dysplastic features of distal colorectal
ACF in patients with exophytic adenomas and carcinomas, while Hurlstone et al. [16] assessed
the prevalence and features of ACF in patients with flat and depressed colorectal neoplastic
lesions, which account for around one third of all colorectal lesions. High magnification
chromoscopic colonoscopy was performed on 574 healthy subjects, 281 patients with flat
adenomas and 14 patients with flat carcinomas in which 602 (3% of them dysplastic), 2796 (18%
dysplastic) and 594 (61 % dysplastic) ACF were identified, respectively. Similarly as in patients
with exophytic colorectal lesions, the number of ACF increased in a stepwise fashion from
normal subjects to patients with flat or depressed adenoma and then to patients with flat or
depressed carcinoma [16].
In another study 103 patients with average age of 61 (range of 28-87) were examined by using
magnification (60x) chromoscopic colonoscopy. 788 ACF were found in the distal 20 cm of
colon/rectum. Patients with a family history of CRC had a significantly higher mean number
of ACF than the average risk subjects (7.6% dysplastic and 46% hyperplastic) [5].
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Rudolph et al. [37] have demonstrated that the number of ACF is significantly increased in
patients with personal history of adenoma in comparison to subjects without personal or
family history. They also observed that number of ACF is higher in older persons than in
younger subjects [37].
14. Clinical application
Clinical application of ACF as an intermediate biomarker for CRC in humans is under
development and is thus less conclusive [4; 38].
Recently, few studies investigated relationship of human colorectal ACF and formation of
colorectal polyps on repeat colonoscopy. It was found that the number of ACF in the colorec‐
tum was associated with substantial risk for future advanced neoplasia [39-42].
Ohkubo et al. [39] investigated natural history of human ACF and correlation with risk factors
for CRC. They examined 82 subjects who underwent total colonoscopy and whose ACF
number was examined at least 2 times. They retrospectively evaluated the changes in the ACF
number at four different surveillance periods (6 months, 1 year, 2 years, 3 years) and in groups
with and without colorectal neoplasms. The subjects were classified into an increased ACF
group and a no change/decreased ACF group, and investigated the relationship between the
changes in the ACF number and known risk factors for CRC. No significant differences were
observed in the ACF number between the first and second observations in any surveillance
period groups, and in the groups classified according to the presence or absence of colorectal
neoplasms. There were no significant differences between the increased and no change/
decreased ACF groups in terms of gender, smoking habit, current alcohol consumption, age,
BMI, HbA1c or serum triglyceride level, whereas a significant difference between the groups
was observed in the serum total cholesterol level [39].
All these data strongly implicate that detection and quantification of ACF in the distal colon
may be useful in predicting CRC risk and may be considered as a useful marker in chemo‐
preventive trials. Furthermore, it is expected that one of the most important clinical applica‐
tions of ACF observation with magnifying endoscopy will be its use as a target lesion for
chemoprevention. Because ACF are small lesions, they are suggested to be eradicated during
a short time by administration of chemopreventive agents [43]. Takayama et al. [43] performed
an open chemopreventive trial of sulindac and found that the number of ACF was reduced
markedly in 2 months. Patients receiving sulindac for more than one year had no ACF in colon
mucosa. After 8 to 12 months of follow-up, the number of ACF in colorectal mucosa signifi‐
cantly decreased or even completely disappeared. In the untreated control subjects the number
of ACF was either unchanged or slightly increased [6]. Another short-term chemoprevention
trial of metformin for colorectal ACF showed suppressive effect of the drug on the formation
of ACF [44]. Other chemopreventive a double blind randomized controlled trial targeting ACF
are under investigations [43-45].
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15. Difficulties or pitfalls in detection of ACF
All these data strongly suggest that ACF in the distal colon may be useful and reliable surrogate
marker in predicting CRC risk. However, there are also limitations and difficulties. The main
limitation is the fact that chromoendoscopy and magnifying endoscopes are largely research
tools and not the equipment in gastrointestinal practice. Difficulties were reported in some
studies in which endoscopic criteria failed to predict histologic confirmation of ACF or
correlation between the number of ACF and CRC risk [46; 47]. It was also found that there was
considerable variability among endoscopists regarding accuracy to correctly identify ACF. It
was found that in spite of training, accuracy to correctly identify ACF did not improve [46].
Current knowledge about rodents ACF, which share many similarities with human pathology,
might be helpful to understand tricks and traps when using ACF. In rodents, ACF are widely
accepted as intermediate biomarkers of CRC risk assessment. They have been used as an
endpoint in identifying and assessing preventive or promotional role of natural and pharma‐
cological compounds, as well as dietary and environmental factors in the process of colon
carcinogenesis [48; 49]. However, limitations to the use of ACF as a biomarker to identify cancer
preventive agents exist. Increasing number of studies has demonstrated that ACF in both
animals and humans are heterogeneous group of lesions that contain multiple genetic,
epigenetic and phenotypic alterations [15; 22; 50]. In rodents, total number of ACF may be
considered as a valid biomarker only at very early stage of carcinogenesis, while in subsequent
weeks ACF with higher crypt multiplicities (more than 4 crypts) are considered more specific
biomarker than total number of ACF. In more advanced stages of colon carcinogenesis ACF
may not be reliable intermediate biomarker of colon carcinogenesis (explained in detail in [9]
and [51]). It is also important to mention that ACF are not equally distributed among the
proximal, middle or distal colon. The majority of ACF develop in the middle and distal colon
[52-54], which need to be taken into consideration when using ACF as biomarkers (compre‐
hensively discussed in [9; 10] and [51]. Nevertheless, when considering all above mentioned
facts ACF are useful biomarkers for the screening of compounds for their chemopreventive
activities [49; 51].
16. Conclusion
Based on experimental and clinical studies evidence demonstrates that ACF share similar
histological and molecular features as colonic tumors (i.e. adenomas and adenocarcinomas).
ACF exhibit many of the molecular and genetic abnormalities that form the basis for the
adenoma-carcinoma sequence in CRC. Today, high-magnification chromoscopic colonoscopy
allows detection and biopsy of ACF in vivo in man. It also provides opportunity to investigate
and characterize the earliest genetic and molecular alterations in CRC development in man.
However, it has been shown that ACF are heterogeneous group of lesions that exhibit variable
endoscopic, histological and molecular features. This fact has been shown to cause some
difficulties in accuracy of detection and quantification of ACF among endoscopists. However,
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considered as a valid biomarker only at very early stage of carcinogenesis, while in subsequent
weeks ACF with higher crypt multiplicities (more than 4 crypts) are considered more specific
biomarker than total number of ACF. In more advanced stages of colon carcinogenesis ACF
may not be reliable intermediate biomarker of colon carcinogenesis (explained in detail in [9]
and [51]). It is also important to mention that ACF are not equally distributed among the
proximal, middle or distal colon. The majority of ACF develop in the middle and distal colon
[52-54], which need to be taken into consideration when using ACF as biomarkers (compre‐
hensively discussed in [9; 10] and [51]. Nevertheless, when considering all above mentioned
facts ACF are useful biomarkers for the screening of compounds for their chemopreventive
activities [49; 51].
16. Conclusion
Based on experimental and clinical studies evidence demonstrates that ACF share similar
histological and molecular features as colonic tumors (i.e. adenomas and adenocarcinomas).
ACF exhibit many of the molecular and genetic abnormalities that form the basis for the
adenoma-carcinoma sequence in CRC. Today, high-magnification chromoscopic colonoscopy
allows detection and biopsy of ACF in vivo in man. It also provides opportunity to investigate
and characterize the earliest genetic and molecular alterations in CRC development in man.
However, it has been shown that ACF are heterogeneous group of lesions that exhibit variable
endoscopic, histological and molecular features. This fact has been shown to cause some
difficulties in accuracy of detection and quantification of ACF among endoscopists. However,
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chromoendoscopy and magnifying endoscopes are largely research tools and future research
on that field will bring new information about reliability and applicability of ACF as biomarker
of CRC risk in clinical practice.
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1. Introduction
Evidence-based medicine has led to an extensive investigation and development of new
therapies and programs to improve the care of the surgical patient, both in the postoperative
and in the pre-operative period, known as enhanced recovery after surgery (ERAS) programs,
“fast-track” programs or multimodal rehabilitation programs.
1.1. Definition
ERAS programs are evidenced-based protocols designed to standardize and optimize
perioperative medical care in order to reduce surgical trauma, perioperative physiological
stress and organ dysfunction related to elective procedures [1]. In addition, improved out‐
comes, decreased hospital length of stay and faster patient recovery to normal life are expected
to be obtained. Other advantages of this philosophy are the reduction of clinical complications
and the health costs together with and increase of patient satisfaction. A diagram with all the
core principles of an ERAS program can be seen on Figure 1.
This approach could not be understood and implemented without the participation and
commitment of a multidisciplinary team including surgeons, anesthesiologists, nursing staff
and hospital administration. Moreover, it is important to make the patient and their families
a partner in their care and give them join responsibility for the recovery.
These kinds of programs are not exclusive of a type of surgery or surgical procedure since they
can be applied to different specialties (digestive, vascular, thoracic, etc.), different procedures
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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(colon resection, pancreatic procedures, etc.) or different approaches (laparoscopic or open
procedures).
In this chapter we will focus on ERAS protocols applied to colorectal surgery.
1.3. Background
Patients undergoing major open colorectal surgery traditionally undergo prolonged rehabili‐
tation and complication rates even as high as 30% have been reported after this procedure [2].
Figure 1. Core principles of an ERAS program applied to digestive tract surgery.
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Surgeons learned over the years that surgery was an aggression and that the bigger the
procedure was, the bigger the aggression emerged. For example, surgeons understood that
patients undergoing major open colorectal surgery suffered prolonged rehabilitation with
profound changes in endocrine, metabolic, neural and pulmonary function during the
postoperative period. However, the scientific interest was not focused on how to control these
changes.
In digestive surgery there were some inviolable principles that were transferred between
generation of surgeons over a long period of time. Senior clinicians had strong principles and
they were assumed as a dogma. We will highlight some of them:
• Preoperative prolonged fasting is necessary to empty the bowel, prevent intraoperative
contamination and the early passage of bowel content through an anastomosis.
• Mechanical bowel preparation is imperative in colorectal surgery to prevent intraoperative
contamination and the passage of faeces through a suture line while it is healing. This
passage could increase leaking and dehiscence risk or infections.
• Systematic use of nasogastric tubes is imperative to empty stomach and prevent its content
to come into the bowel protecting sutures.
• Drains usage is essential in all kind of digestive procedures.
• Extended periods of bed rest are recommended to facilitate abdominal wall healing.
• Postoperative period is a “resting time” in which surgeons are expecting spontaneous
patient recovery.
The majority of these paradigms were only based on clinical experience instead of the scientific
evidence and, subsequently, they were passed down from masters to disciples, who preserved
them as a non-questionable tradition. However, stepwise, published studies have dispelled
these and other “truths” and the evidence has taught us that some of them may be unnecessary
and maybe they can contribute to postoperative functional deterioration. For example, the
return of bowel function is essential for postoperative recovery and this is influenced nega‐
tively by several perioperative factors such as preoperative fasting and bowel mechanical
preparation, opioid analgesic, fluid overload, immobilization and postoperative prolonged
fasting. Thus, several reviews and meta-analyses have focused in the absence of benefits in
routinely mechanical bowel preparation, routine nasogastric decompression or prolonged
postoperative fasting [3].
In 1990’s, several revolutionary changes were seen: in the field of anesthesia the development
of regional anesthetic techniques and new drugs to control pain and sedation; and in the field
of surgery the widespread use of minimally invasive (laparoscopic) techniques. As a result, a
great improvement in postoperative recovery and earlier return of patients to normal function
were achieved. Moreover, it was thought that a minimally invasive approach, with reduced
operative trauma, conducted to an earlier return of bowel function and allowed for early oral
tolerance. The next step was the thinking that some of the improvements seen were simply
due to overall changes in perioperative care attitudes.
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In the late 1990´s, based on those findings, the “fast track” concept to major abdominal surgery
was pioneered by Professor Henrik Kehlet and a solid doctrine concerning perioperative care
was born. He was a researcher surgeon interested in perioperative medicine, from the
Hvidovre University Hospital in Denmark. Kehlet and colleages were investigating in
combined pain relief, early feeding and mobilization since 1995 [4], observing that no more
complications were seen and that patients even could be discharged earlier [3]. The concept
of a “multimodal” approach was first published in 1997 [4] and subsequently prospective
studies appeared [5]. The aims of Kehlet´s study were to reduce postoperative morbidity and
mortality and to promote a faster recovery through a multimodal approach, thus minimizing
the impact of the factors that lead to surgical stress. On the other hand, in the study of Basse
et al the multimodal rehabilitation program significantly reduced the postoperative hospital
stay in high-risk patients undergoing colonic resection (two days compared to more than 10
days in some historical series) and it might also reduce postoperative ileus and cardiopulmo‐
nary complications [5].
During the following decade published studies in this issue grew exponentially. Subsequently,
cohort studies, controlled trials and several reviews and meta-analyses were published. It is
important to highlight those from Wind [6], Goubas [7], and the meta-analyses directed by
Cochrane Collaborative Group in 2011 that will be analyzed in the following chapter´s sections
[8]. Moreover, an ERAS Society was officially founded in 2010 as a natural evolution of the
ERAS Study Group. This group started its works in 2001 trying to change from tradition to
best-practice because there was a great discrepancy between the existing practices and those
which were already known to be best practice based on the existing literature. More informa‐
tion is provided in the official website http://www.erassociety.org/.
To summarize, we can conclude that published results and their meta-analyses have shown
the benefits of this package of measures, so that evidence-based medicine supports the ERAS
concept. Nevertheless, recent surveys have demonstrated slow adaptation and implementa‐
tion of the fast-track methodology. In this setting, it has been shown by Kehlet et al in an
international multicenter study based on 1,082 patients who had undergone elective colonic
operations that strategies that could contribute to improved recovery and reduce complica‐
tions were not been applied and that major improvements in outcomes and reduction of costs
could be obtained applying ERAS methodology [9].
Little by little, ERAS implementation and application in the clinical setting continued growing
in the following years until the present. Nowadays ERAS protocols, with little modifications
to adapt them to each center´s functioning, are been applied in a great number of colorectal
units worldwide. The information communicated in different conventions and published
makes us think that ERAS has changed from a promising “published” issue to a real application
in the clinical practice.
1.4. The stress response to surgery
Surgeons have shown interest in metabolic and endocrine response to the surgical trauma long
time ago. Such interest has increased by the recognition that to modulate this response to the
surgical aggression might reduce the postoperative morbidity and mortality.
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The overall metabolic changes in the stress response involve protein and fat catabolism to
provide energy. Protein from skeletal muscle and glycerol from fat breakdown are utilised in
glucogenogenesis in the liver. In addition surgery induces hormonal, haematological and
inmunological changes and activate the sympathetic nervous system (stimulated by hypoten‐
sion, hypoxaemia or metabolic acidosis, pain, anxiety and distress, autonomic and afferent
nerves and directly hypothalamus) [10]. The initial stimulus for this response comes from
cytokines, especially IL-6 and TNF, release by leucocytes and endotelial cells present at the site
of injury and they are the principal mediators of the response in the acute-phase. Postoperative
levels of these cytokines are correlated with the magnitude of the surgery and the presence of
complications. On the other hand, leucocytes are key effector cells in the response to surgery,
they mobilize quickly to devitalizated or injured tissue to begin repair and prevent secondary
microbial invasion. A few minutes after the start of surgery an ACTH, vasopresine, cortisol,
catecholamines, aldosterone and glucagon release occur pretending to provide to the disabled
organism energy, to retain liquid and salt, and supporting the cardiovascular homeostasis [11].
A randomized controlled trial has shown that Multimodal Rehabilitation programs attenuate
the response to the surgical stress as it demonstrates a significant descent of IL-1, IL-6, TNF-
α and INF-gamma levels in the postoperative period.
Summarizing, the stress response to surgery increase the levels of ACTH, cortisol, GH, IGF1,
ADH and glucagon, reduce the insulin, mobilizes glycogen (by glycogenolysis and skeletal
muscle breakdown) and promotes formation of acute phase proteins and lipolysis.
This response also generates adverse effects; some of the most important are:
• Increased myocardial oxygen demand.
• Hypoxaemia.
• Splanchnic vasoconstriction wich may impact intestinal anastomoses healing.
• Exhaustion of energy supplies and loss of lean muscle mass, leading to weakness of both
peripheral and respiratory muscle if it is severe.
• Impaired wound healing and increased risk of infections.
• Hypercoagulability (risk of Deep Vein Thrombosis).
• Sodium and water retention.
The response to the surgical trauma is protective since his final target is the survival of the
disabled organism. It depends on a delicate balance between pro-inflammatory and anti-
inflammatory mechanisms; nevertheless, it is known that it can be harmful when this balance
is altered. Thus, if the pro-inflammatory component predominates, a Systemic Inflammatory
Response Syndrome (SIRS) could be induced; on the other hand patients can suffer the effects
derived from the inmunosupresion as infections or tumor progression if predominates anti-
inflammatory components.
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2. Aim and concerns
The aims of ERAS programs are:
• To standardize and optimize perioperative medical care.
• To atenuate the stress response to surgery: metabolic, endocrine and inflamatory response
as well as reduce protein cathabolism.
• To decrease hospital length stay and a faster patient recovery to normal life.
• Regarding hospital discharge, factors such as pain, lack of gastrointestinal function and
immobility complications are the main delaying patient discharge after colorectal surgery.
So ERAS objectives will be to promote pain control, to improve gastrointestinal function
and to avoid immobility.
• Despite the discharge criteria with ERAS programs are similar than in traditional care,
patients usually reach these criteria sooner.
3. ERAS protocol components
ERAS programs are composed of preoperative, intra-operative and postoperative strategies
combined to form a multimodal pathway:
3.1. Preoperative
3.1.1. Pre-admission
Pre-operative optimization: it is focused on targeting areas to optimize patient comorbidities
(previous or related to the presenting complaint) such as anemia, diabetic and blood pressure
control, optimizing cardiovascular disease treatments, respiratory functioning,…. It is also
imperative avoid smoking and alcohol consumption. Patient´s individualized Risk stratifica‐
tion is also important to make good patient information and treatment decision.
Information: It is shown that this information reduces the patient’s anxiety and facilitates the
compliance of the program [12].
Patients and their families should be very knowledgeable about the process. It is very impor‐
tant to make them a partner in the process and give them the responsibility for their recovery
and they should be clearly informated about the perioperative care, normal course of the
protocol, discharge criteria, possible complications and the outpatient follow-up after dis‐
charge. Targets like postoperative oral intake or early mobilization are given in this stage to
the patient.
Patient education: including ostomy management and its appropiate localization for it.
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Pre-operative nutritional management: drinks and any new medication and nutritional
supplements should be given at this time.
3.1.2. Pre-operative care
Admission on the day of surgery: because the patient has been prepared for surgery in the pre-
admission period.
Pre-operative fasting and carbohydrate loading:
• Fasting is required to reduce the risk of aspiration during a general anesthesia The duration
of preoperative fasting should be two hours for liquids and six hours for solids (grade A
recommendation) [13].
• Major surgery is associated with postoperative insulin-resistance. Non-diabetic patients
should receive carbohydrate (CHO) loading pre-operatively because they increase glycerol
deposits, reduce thirst, hunger and postoperative insulin resistance [14], reducing protein
catabolism, postoperative ileus and loss of lean muscle mass. CHO has to be taken in the
evening before surgery and 2 hours before anaesthetic induction [15].
Avoid mechanical bowel preparation:
Mechanical bowel preparation can cause dehydration and fluid and electrolyte abnormalities,
particularly in elderly patients, increasing morbidity and post-operative ileus [16].
Medication:
• Medication causing long-term sedation from midnight prior to surgery must not been used,
in order to conserve the sleep pattern (grade A recommendation).
• Prophylaxis against thromboembolism with low-dose unfraccionated heparin or low-
molecular-weight heparin (grade A recommendation) and the use of elastic stockings or
pneumatic compression are recommended.
• Antibiotic prophylaxis with single-dose antibiotic prophylaxis against both anaerobes and
aerobes about one hour before surgery is recommended (grade A recommendation).
3.2. Intraoperative
Normothermia:
Changes in body temperature can lead to coagulopathy, adverse cardiac events, and decreased
resistance to surgical wound infections. An upper-body forced-air heating cover should be
used routinely (grade A recommendation).
Prevention of post-operative ileus:
Mid-thoracic epidural analgesia and avoidance of fluid overload are recommended to prevent
post-operative ileus (grade A recommendation) [16], [17].
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The use of minimally invasive techniques, where possible is advisable. Laparoscopic approach
is recommended if locally validated (grade A recommendation) [18]. It has been shown to
reduce the length of hospital stay, initial wound complications and time to return of gastro‐
intestinal tract function in colorectal surgery. If an open procedure is required, transverse
incisions should be made preferentially to reduce postoperative pain.
Peri-operative fluid management:
Perioperative fluid management for fast-track protocols must be balanced between avoiding
hypovolemia and excessive fluid administration. Overhydration has previously been common
in the perioperative period, and comparisons of liberal and restrictive fluid regimes suggest
that this may be detrimental.
Perioperative fluid overload can cause fluid retention and increase body weight; this is related
with generalized edema (which can cause a descense in tissue oxygenation [19]), visceral
edema (related with postoperative ileus), can impaire wound and anastomosis healing, can
increase cardiorespiratory complications [20,21] and also thrombotic risk.
Intra-operative and post-operative fluid restriction in major colonic surgery with avoidance
of hypovolaemia is safe (grade A recommendation) and reduce the time for return of gastro‐
intestinal tract function, improves healing, reduce length of hospital admission and avoid
pulmonary dysfunction [21] and reduce overall postoperative complications by up to two
thirds [22]. Early commencement of oral intake also allows reducing intravenous fluids sooner.
Postoperative serious hypotension may best treated with vasopressors rather than large
quantities of intravenous fluids.
No clear consensus exists regarding the optimal fluid (crystalloid or colloid), the fluid amount
(liberal, restricted or supplemental) and the fluid administration (goal-directed fluid therapy
by oesophageal Doppler-derived variables –such as stroke volume, the blood volume pumped
with each beat- versus conventional haemodynamic variables) for fluid management after and
during colectomy.
Fluid management can be then optimized using transesophageal monitoring of the cardiac
stroke volume with goal-directed administration of fluid boluses. This methodology can
improve outcome (patients recovered gut function significantly faster and suffered signifi‐
cantly less gastrointestinal and overall morbidity) in patients with significant medical comor‐
bidities allowing an earlier hospital discharge [23]. These results have been confirmed with
posterior literature review that showed a reduced hospital stay, fewer complications and ICU
admissions, less requirement for inotropes and faster return of normal gastro-intestinal
function [24].
In the last years literature reviews and metaanalyses have been published trying to give light
to these doubts: which fluid, how many and how to control the administration. We want to
highlight the one from Rahbari et al [25]. Authors included nine randomized controlled trials,
finding that restrictive fluid amount (OR 0.41 with 95% CI 0.22 to 0.77; P = 0.005) and goal-
directed fluid therapy by means of oesophageal Doppler-derived variables (OR 0.43 with 955
Colorectal Cancer - Surgery, Diagnostics and Treatment494
CI 0.26 to 0.71; P = 0.001) significantly reduced overall morbidity after colorectal resection
compared with standard fluid amount and fluid therapy guided by conventional haemody‐
namic variables respectively. No significant differences were founded in mortality, cardio‐
pulmonary morbidity, wound infection, anastomotic failure, recovery of bowel function and
hospital stay.
Nasogastric tubes:
They should be inserted only if ileus develops. They are associated with discomfort and a delay
in oral intake. Nasogastric tubes should not be used routinely in the elective situations in
postoperative period (grade A recommendation) [26],[27].
Surgical drains:
Drains are avoided, as there is no evidence of beneficial effect in reducing postoperative
morbidity, mortality, or reduce the effect of anastomotic leakage [28],[29]. Short-term (24-hour)
use of drains after low anterior resections may be advisable. They are not indicated following
routine colonic resection above the peritoneal reflection.
Epidural analgesia:
The aim of their use is to reduce the dose of general anesthetic needed and the stress response
to surgery. In order to reduce the release of stress hormones and post-operative insuline




Maintenance of hydration, avoiding overcharge and encouraging the discontinuation of
intravenous fluid therapy as soon as possible and early commencement of oral intake,
including carbohydrate drinks.
Analgesia:
Patients should receive continuous epidural mid-thoracic low-dose local anesthetic and opioid
combinations (grade A recommendation) for approximately 48 hours following elective
colonic surgery and approximately 96 hours following pelvic surgery. This provides post-
operative analgesia and reduces postoperative ileus by blockade of the sympathetic nervous
system. Low concentration local anesthetic mixtures reduce motor block and improve early
mobilization. Intravenous analgesia is used with paracetamol and non-esteroid anti-inflam‐
matory drugs [30]. Intravenous opioids are avoided because of increase sedation, ileus and
respiratory complications.
Nausea and vomiting:
It is very important a risk stratification of patients during surgery using the Apfel scoring
system with prophylaxis given for moderate or high risk patients. Risk factors are: female sex,
non-smokers, administration of opioids postoperatively, motion sickness or previous postop‐
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erative nause and vomitig [31]. Patients with two ore more risk factors should be treated.
Dexamethasone or 5HT3 receptor antagonist, droperidol or metoclopramide near the end of
surgery are recomended. It is preferred those medication that have a minimal post-operative
hang-over and effects on gastrointesinal motility. Also short-acting anesthetic and analgesic
agents should be used, avoiding long-lasting opiates where possible [32].
Nutrition support:
Early commencement of an oral intake (frequently in theater recovery) after surgery should
be encouraged (grade A recommendation). Oral nutritional supplements should be prescribed
(approximately 200 mL, energy dense, 2-3 times daily) from the day of surgery until normal
food intake is achieved. These supplements can be continued beyond the return of normal
intake if pre-operative nutritional status is poor. Early resumption of oral intake is associated
with fewer wound infections and shorter hospital admissions as well.
Early mobilization:
Early mobilization should occur in accordance with pre-operative plan and is a key element
of ERAS in colorectal surgery [10]. For patients to be out of bed for two hours on the day of
surgery and six hours thereafter is recommended. The aim is to reduce muscle loss and
improve respiratory function, reducing the risk of pneumonia, and maximizing oxygen
delivery to tissues. This is also essential to reducing the risk of venous thromboembolism. The
breathing exercises should be done, especially in patients with previous lung pathology and
these exercises must be trained before surgery.
Urinary catheter and drains:
Urinary catheters and peritoneal drains should bre removed as soon as possible in order to
reduce the incidence of urinary tract infection and because of early mobilization respectively
Early discharge:
At the end, early discharge, when the discharge criteria have been reached, is the goal of fast-
track along with the early recovery and return to normal activity.
A summary of all of these commented components of the perioperative management can be
seen on Figure 2.
4. From theory to practice — How to organize an ERAS program
• A well-educated multidisciplinary team will be needed composed by: surgeons, anesthesi‐
ologists and pain care specialists, nursing staff, physiotherapysts and occupational thera‐
pists and social workers
• ERAS programs involve a selected number of individual interventions. It is necessary to
implement all together, because only in this way they demonstrate a greater impact on
outcomes than when we implement them as individual interventions [1],[33].
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• It is necessary a review of the literature and a carefully study of the hospital resources where
the ERAS program will be implemented.
• The program should be designed in agreement with consensus documents.
• A systematic audit should be performed including length of stay, morbidity, mortality and
hospital readmissions to allow direct comparison with other institutions and provide
motivation for staff and patients.
An example of an ERAS protocol in colorectal surgery can be seen on Table 1.
PREOPERATIVE
Pre-admission Indication for surgery, information and signed consent
Optimization of the patient and education (including stoma)
Preoperative studies (anesthetist and other if is required)
Hyperproteic supplement 3 times every day during the week before surgery
Pre-operative Day before surgery
Figure 2. Components of the ERAS protocols
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Enemas (10 am- 10 pm) if laparoscopic approach is validated
No mecanical bowel preparation, except if ileostomy or intraoperative colonoscopy is
expected
Neomycin and Erythromycin 1g po at 1 pm- 2 pm- 9 pm
Liquids on demand and carbohydrate loading during the evening (800 mL)
Prophylaxis for DVT at 6 pm (dose depends on the risk)
Gabapentin 300 mg and ranitidine 150 mg at 10 pm
Day of surgery
Carbohydrate loading 2 hours before surgery (400 mL)
Antiseptic shower, shaved and elastic stockings
Preoperative medication
- Dexamethasone 4 mg and ranitidine 150 mg 30 minutes before surgery
- Augmentin 2 g immediately before anesthesia
INTRAOPERATIVE
Anesthetist Normothermia: upper-body forced-air heating cover and liquid heater (37ºC)
Mid-thoracic (T10) epidural analgesia with levobupivacaine
Maintenance Oxygen/air FiO2 0.6 – 0.8
Avoid fluids overload maintaining 5cc/kg/h (Hartmann). Hb > 8.0 g/dL
Vasoconstrictive drugs if hypotension
Ondansetron 4 mg or droperidol 1.25 mg 30 minutes before the end
Adittional dose of Augmentine 2 g if surgery takes more than 4h
Remove nasogastric tube at the end of surgery
Surgeons Laparoscopy or transverse incisions
Avoid surgical drains except short-term (24-hour) drains after low anterior resection




Mask with 4 l/m oxygen flow for 2h independent of saturation, after that nasal cannulae for
SpO2 > 95%
Epidural analgesia according with protocol of anesthesia
Day of surgery In seat for at least 2h in the evening
Fluids: 1.5 L Ringer lactate solution + 0.5 expander fluids x 24 hours
Paracetamol 1 g/6h+/- metamizol 2g/8h
Epidural analgesia according to protocol of anesthesia
Metroclopramide 10 mg/8h and ondansetron 4 mg/8h
Nasal cannulae for SpO2 > 95%
Liquid diet 2 hours after surgery including 400 mL of Hyperproteic supplement
Postoperative day 1 Mobilization 6 h a day
Suspend fluid e.v. if tolerated diet, maintaining heparine injection
Paracetamol 1g/6h +/- metamizol 2g/8h
Epidural analgesia according to protocol of anesthesia
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Liquid diet at least 2 L, including 600 mL of high protein/high calories
Laxative /12h with MgO (2g / 24h)
Heparine in order to protocol
Ranitidine t.d.s
Postoperative day 2 See day 1 recommendations
Mobilisation on demand
Remove epidural catheter
Bland/normal diet including 600 mL of high protein/high calorie
Verify if Discharge criteria have been reached by the patient
Postoperative day 3 See day 2 recommendations
Normal diet including 600 mL of high protein/high calorie
Verify if Discharge criteria have been reached by the patiente
Follow-up Telephone monitoring for 48 h
Out-patient visit after 10-14 daysRanitidine v.o. /8 h
Table 1. An ERAS protocol example in colorectal resections.
5. Discharge criteria
The goal of ERAS programs is an accelerated recovery and return to normal activity but it is
not the only focus of the protocol [34]. Discharge criteria and time-based discharge depends
on the community support and possibility to follow-up.
Patients and their families should feel comfortable with the discharge. In this setting they
should know that they will be followed as outpatient and they could return to hospital if
required.
Discharge criteria must be previously established (see Table 2):
Discharge criteria
Good mobilization
Adequate oral intake for liquids and solids





Patient know about possible complications and their detection
Patient feel comfortable with discharge
Table 2. Discharge criteria most usually used in colorectal surgery ERAS programs.
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The expanding evidence-based medicine shows that ERAS program benefits not only all
patients  (including the  elderly  or  potentially  malnourished patients)  but  also  the  health
service [35].
Patients accomplish surgery in the best condition. They have better management during and
after operation and the best post-operative recovery.
Randomized trials and meta-analysis identified a significantly shorter length of stay and lower
in-hospital postoperative complications (maybe secondary to the shorter length of hospital
stay) [6].These advantages are mainly attributed to fluid restriction and epidural analgesia.
Other outcome improvements attributed to ERAS programs are shorter duration of postop‐
erative ileus [6], better oral intake, better pain control, less cardiopulmonary morbidity, better
preservation of body mass and exercise performance [36], an improvement in grip strength
(all of them suggesting an overall improvement in muscular function), earlier resumption of
normal activities and a reduced need for daytime sleep [37].
Early discharge is the goal of Fast-Track protocols, and should not be offset by a higher rate
of hospital readmission. However, the overall rate of readmission for patients managed with
early discharge is comparable to patients with a longer median length of hospital stay
[34].Regarding the economical issues, it must be pointed out that the increased cost in
laparoscopic approach must be balanced with savings from a shorter length of hospital stay,
lower morbidity and no differences in readmission rates.
7. The research initiatives
The confirmation of the initial results should prompt the ERAS methodology embracing in
other kind of major surgical procedures as gastric or pancreatic procedures.
The possibility of applying some components of fast-track programs in patients undergoing
emergency colorectal surgery must be also evaluated, especially in order to reduce preopera‐
tive stress.
New drugs like Ketamina, Lidocaina, Alvimopan could have an important role in the future
because of their properties in analgesia and in gastrointestinal resumption.
8. Summary and recommendations
ERAS programs for colorectal surgery were developed to reduce inpatient hospital costs
through improvements in preoperative, intra-operative and postoperative strategies.
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The success of this program depends on pre-operative setting of expectations including the
concept of patients being partners in their care and taking part-ownership of post-operative
rehabilitation.
Best results are achieved when the whole multidisciplinary team believe and take part in the
program and individual interventions are implemented all together.
The keys of ERAS are: patient information, preservation of gastrointestinal function, minimize
organ dysfunction, active pain control and to promote the patient´s autonomy.
Early discharge is the goal of ERAS protocols and patients usually reach the discharge criteria
sooner than in traditional care.
Although most of the studies tend to find a lower morbidity, there are no clear advantage in
mortality and we think that more studies are needed to confirm the results and focalized in
mortality and long-term results of ERAs methodology. We can conclude that at least there are
no significant differences in mortality and morbidity with traditional care (ERAs methodology
is not dangerous for patients and probably represents a big benefice) and ERAS are more cost-
effectiveness than traditional care.
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1. Introduction
As  medical  care  based  on  information  disclosure  has  been  promoted,  the  concept  of
informed consent has also come to be understood in cancer care, and its faithful practice
is now required. However, reactions ranging from ordinary psychological reactions (such
as  discouragement  and  feelings  of  isolation,  alienation,  despair,  etc.)  to  psychological
changes requiring the attention of a specialist (i.e., depression) are sometimes seen when
information is  disclosed,  especially  after  conveying bad news,  and healthcare  providers
must constantly keep the psychological states of their patients in mind. In this chapter, I
will  first  describe the usual  psychological  reactions that  cancer patients exhibit  after  the
disclosure of cancer-related information. Additionally, I will discuss general matters to keep
in mind when delivering bad news to cancer patients. Then, I will summarize the diagno‐
sis and management of psychological distress requiring psychiatric attention that health‐
care providers in cancer care settings should know.
In addition, healthcare providers are expected to strive for good communication with the
patient and the patient’s family during the process of conveying bad news about a patient’s
condition and obtaining informed consent. In reality, however, training in communication
skills and support skills is only rarely available, and as a result, many healthcare provid‐
ers experience stress as a result of having been unable to acquire such skills adequately.
With this background in mind, I will describe the need for communication skills in cancer
care and review recent literature regarding the effectiveness of training designed to improve
such skills.
© 2014 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
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2. Typical psychological reactions to information disclosure (especially bad
news) (Table 1)
Bad news must be conveyed more often than good news when disclosing information during
the clinical course of cancer. Here, the typical psychological reactions displayed by patients
after being informed of such bad news will be explained by providing examples of reactions
after having been informed of a diagnosis of cancer. First, the initial few days are characterized
by not being ready to believe or by temporarily denying what they have been told, saying,:
“That can’t be…,” or by a sense of despair, saying,: “Oh, I’ve got cancer….” Later, a time is
reached when they sometimes say,: “My mind went blank, and it was as though it hadn’t
happened to me,” or “I don’t clearly remember what happened after I was told I had cancer.
I don’t remember how I got home.” Thus, it is important for attending physicians to recognize
that patients may not clearly remember any subsequent explanations after they have been told
that they have cancer, and that even if they describe tests and treatment in great detail, the
patients may not understand the explanations adequately.
A. First phase: period of early reaction / within a few days
Patients do not believe the information or temporarily deny the facts. Some patients retrospectively describe this
period as, ‘My mind ceased to function as if these things were not happening to me’. Others experience despair, i.e. ‘I
was told what I feared’.
B. Second phase: period of distress / after 1–2 weeks
Patients repeatedly develop symptoms such as anxiety, depression, insomnia, appetite loss or decreased
concentration. Owing to marked anxiety and decreased concentration, patients repeatedly ask the same questions.
C. Third phase: period of adaptation / after 2 weeks–1 month, sometimes 3 months
Patients face reality and begin to or try to adapt to the new situation.
Table 1. Psychological reactions to being given a bad news
Then, after a little while, a time comes when symptoms such as a sinking feeling, anxiety,
feelings of isolation from their surroundings, difficulty sleeping, or a loss of appetite might
occur repeatedly. Symptoms in the form of getting excited or upset over petty matters are
also sometimes seen. There are also times when the patient’s behavior may take the form of
repeatedly asking the same question because patients are very anxious and their ability to
concentrate has declined. As a result of these conditions, patients sometimes experience a
certain degree of interference with their daily lives, because the things that they were usual‐
ly able to do have become troublesome or take longer to complete.
After 2 weeks have gone by, however, patients gradually begin to face their real problems and
become able to adapt to their new reality. More specifically, they begin to gather information,
saying, “There’s nothing I can do about having been diagnosed with cancer. From here on, I’m
going to think about how best to make things better,” or they become capable of an optimistic
outlook, saying, “My cancer may get better.” Moreover, because they always have the feeling
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that, “I have to go about my daily life living with my cancer,” although it may be difficult to
go about their lives with the same feeling as when they were completely healthy, it does not
create a very severe obstacle to their everyday lives, and they are able to return to a living
pattern that is almost the same as before.
It is important to have a good understanding of the “typical” psychological reactions described
above that cancer patients exhibit.
3. General matters to keep in mind when delivering bad news to cancer
patients
1. Basic principles
a. The bad news should first be discussed with the patients themselves whenever possible.
b. The same physician should take charge of the patient from the initial contact until the
definitive treatment whenever possible. This allows for true informed consent, during
which the patient can calmly decide among several choices of treatment modalities. If a
situation arises where a change in the physician-in-charge is necessary, care should be
taken not to destroy patient rapport.
c. The location for discussing the bad news must be carefully chosen, providing an envi‐
ronment of privacy where the patients can fully express their feelings, as necessary. On
no account should the bad news be communicated via the telephone or while passing in
a corridor or in any public place. It was reported that 55% of patients who were told the
news by telephone expressed negative feelings [2]. Patients and their families who are
given bad news in an inconsiderate manner may never forget the thoughtlessness of the
physician.
d. From the initial interview, physicians should try to tell the truth consistently and should
provide as much information as they have available at the time. Bad news based on
unconfirmed information should not be delivered.
e. Although an accurate explanation is necessary, the patient should not be bombarded with
facts with no consideration given to the patient's state. Physicians should be prepared to
explain facts as clearly and as simply as necessary. Patients should not be expected to cope
with everything by themselves.
f. Patients are sometimes told, “You have advanced cancer and there is nothing I can do.
There is no effective treatment in your case.” Such cruel attitudes presented by the
physician causes a loss of hope, anger, resignation and a sense of alienation in patients.
Physicians should recognize that they can generate either hope or despair in patients by
their verbal expressions or attitude. Physicians should present other positive features,
including supportive care, instead of abandoning a patient with such a statement.
g. Breaking bad news is commonly performed in an outpatient clinic. An adequate amount
of time to provide an explanation and subsequent consideration is necessary. When
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explain facts as clearly and as simply as necessary. Patients should not be expected to cope
with everything by themselves.
f. Patients are sometimes told, “You have advanced cancer and there is nothing I can do.
There is no effective treatment in your case.” Such cruel attitudes presented by the
physician causes a loss of hope, anger, resignation and a sense of alienation in patients.
Physicians should recognize that they can generate either hope or despair in patients by
their verbal expressions or attitude. Physicians should present other positive features,
including supportive care, instead of abandoning a patient with such a statement.
g. Breaking bad news is commonly performed in an outpatient clinic. An adequate amount
of time to provide an explanation and subsequent consideration is necessary. When
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patients are very anxious, the physician-in-charge should provide a consultation with a
psychiatrist. Options such as talking to patients on another occasion after completing all
their duties at the outpatient clinic or offering encouragement by talking again on the
telephone on the day that the bad news has been divulged can sometimes be very effective.
h. Patients may show reservation towards physicians and sometimes fear them. Therefore,
some patients cannot express their feelings when they are given bad news or cannot ask
physicians questions, believing that they should do what the physician has told them.
However, some patients are able to be more frank when talking to nurses and may ask
them questions about the news. Therefore, it is important for physicians to hear the
patient’s true feelings and complaints through nurses. Cooperation between physicians
and nurses is very important in this situation.
i. The physician should not hurry to explain all the details on one occasion. Several inter‐
views with each patient are recommended to discuss the bad news in a step-by-step
manner.
j. The physician should put himself or herself in the patient's place and should not judge
the patient's reactions prematurely.
2. Approaches to speaking with family members
a. In principle, family members should not be told the bad news before the patient has been
told. Families who want the patient to be ignorant of the news may be worried that “…
the patient may commit suicide because of fears or shock.” However, such a risk is much
lower than generally believed [3], though this risk should always be taken into consider‐
ation.
b. When a patient is referred to our hospital and only the family has been told the bad news
at another hospital and the family strongly opposes telling the patient the truth, the family
should be repeatedly encouraged to change their minds, taking as much time as necessary.
In such cases, it is important not to blame the initial physicians for their old-fashioned
approach, since the rapport between the patient and the physicians may be impaired.
c. Families play a very important role in cancer treatment. When the bad news is told
definitively, the explanation should ideally be given to the patient and family together.
Although the patient takes priority over the family, it is very important to inform the
family of the patient's state as accurately as possible.
d. Families sometimes become more agitated than patients and cannot remember or
understand the explanation accurately Therefore, physicians should not take it for granted
that “…families will be alright when receiving bad news, because they are not patients.”
When necessary, families should also be supported. It is often helpful for the physician-
in-charge to ask a psychiatrist for advice.
3. Psychological distress requiring psychiatric attention
Derogatis et al. [4] conducted interviews with 215 inpatients and outpatients at three leading
cancer centers in the eastern United States, and investigated the prevalence of psychological
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problems based on the DSM-III (The DSM-III is a set of comprehensive diagnostic criteria for
all mental disorders that was drawn up by the American Psychiatric Association in 1980 and
is widely used throughout the world in prevalence surveys, etc. The revised DSM-III-R was
published in 1987, the DSM-IV in 1994, and the DSM-IV-TR in 2000). They reported that 32%
of the 215 subjects met the diagnostic criteria for adjustment disorders, 6% for depression, and
4% for delirium. These 3 psychological manifestations appear to be characteristic of the
psychological distress experienced by cancer patients who require psychiatric attention.
Moreover, because all these psychological manifestations reduce patients’ quality of life
(QOL), their proper diagnosis and treatment is needed.
The incidence of adjustment disorders, depression, or delirium has not been previously
assessed in colorectal cancer patients. However, some reports have described the prevalence
of psychological distress using various symptom rating scales. These reports are summarized
in Table 2 [5-13]. The reports suggest that the prevalence of psychological distress in colorectal
cancer patients is 7% - 44%. Zabora et al. [14] assessed the prevalence of psychological distress
among a large sample of cancer patients and variations in distress among 14 cancer diagnoses;
the overall prevalence of distress in this sample was 35.1% (colorectal cancer: 31.6%), and a
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Descriptive diagnosis: DSM III-R criteria
before initiating treatment
According to the clinical interview,
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disorders, 3 (3%) for phobia, and 3
(3%) for generalized anxiety
disorder.
Table 2. A summary of psychological distress in colorectal cancer patients
Below, the special features of each of these psychological manifestations are summarized.
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1. Adjustment disorders
Adjustment disorders are the most common psychological manifestation exhibited by cancer
patients, but few studies or reports have examined adjustment disorders alone. Problems with
the diagnostic criteria for adjustment disorders themselves are likely to be one of the reasons
for the lack of studies on this topic. The diagnostic criteria in the DSM-IV-TR state that
adjustment disorders are “reactions such as anxiety and depression or behavior disorders that
occur in association with psychosocial stress.” The diagnosis of adjustment disorders is made
when the degree of the reaction is stronger than expected or when symptoms interfere with
social functions from everyday life to social activities, and such disorders are said to be a
continuous condition, without any strict division from normal reactions. Thus, the criteria are
vague, and the term “adjustment disorders” is used as a “wastebasket diagnosis” when there
is a mood disorder but other diagnoses, including depression, do not apply. Nevertheless, the
term has the advantage of being able to include a variety of psychological manifestations that
would be difficult to accept as specific mental disorders.
Inadequate pain control can be listed as a primary cause of adjustment disorders. According
to a study by Derogatis et al. [1], a higher percentage of cancer patients who met the diagnostic
criteria for adjustment disorders had severe pain, compared with cancer patients who did not
meet the criteria. Anxiety, depression, and agitation are known to readily develop when pain
of unknown cause persists [15]. Clearly, understanding patients’ pain, which is a typical
symptom that requires symptomatic relief, and adequately controlling such pain seems to be
also useful for relieving psychological distress. Moreover, feelings of difficulty breathing [16]
or malaise [17], which (similar to pain) often occur in colorectal cancer patients, can have an
impact on patient QOL and can be difficult to treat, and their presence appears to be a cause
of anxiety or depression.
These adjustment disorders should be evaluated and properly managed, but few patients are
actually diagnosed correctly and treated properly [18]. One reason for this situation appears
to be that healthcare providers often miss psychological manifestations. Although the issue of
physicians and nurses who are not specialists in psychiatric care overlooking mild depression
and anxiety symptoms occurring during the course of cancer is, to some extent, unavoidable,
there seems to be a need for education regarding the diagnosis and treatment of adjustment
disorders, which are the most common psychological manifestations of cancer patients.
Psychotropic drugs, such as anxiolytic agents, hypnotics, and, depending on the circumstan‐
ces, antidepressants, are often used for treatment, but it is important to make an effort to
identify the cause of the adjustment disorders described above by sufficiently listening to what
the patient has to say, and then eliminating the cause. To accomplish this task, supportive
psychiatric care in which caregivers encourage patients to express how they are really feeling
at the present time (especially feelings of fear and anxiety), that supports and empathizes with
the patients, and that does not provide unrealistic information but provides assurance within
the realm of reality is said to be effective. In other words, supportive psychiatric care can
become a valid treatment only when the patients feel that their present suffering is understood
by the healthcare provider.













International Diagnostic Interview (CIDI)
Psychological distress: Distress
Thermometer (DT)
Anxiety and depression: Hospital
Anxiety and Depression Scale (HADS)
within 9 weeks of receiving diagnosis
Seventeen patients (17%) were
diagnosed with a current mood or
anxiety disorder, 11 (11%) met
criteria for a depressive disorder and
7 (7%) with a primary anxiety
disorder, and one patient had a








Anxiety and depression: Questionnaires
of Depression and Anxiety
After surgical resection; at the
beginning and at the end of the
treatment in the chemotherapy group
(CHG) and at the first and after 6
months of follow-up in the control
group (CG)
Mild or moderate depression was
diagnosed in 31.6% of the CHG
patients in the first evaluation and in
38.6% at the second one. There was
a higher number of patients with
moderate state or trait anxiety in the










Depression: Beck Depression Inventory
(BDI)
Anxiety: State-Trait Anxiety Inventory
(STAI)
during chemotherapy
The mean Beck depression scores
were
11.2±9.0 (range 0–44) and the mean
STAI scores were 41.9±8.8 (range







Psychological distress: Brief Symptom
Inventory-18 (BSI-18)
at baseline (after diagnosis),
approximately 6 (Time 1) and 12 months
(Time 2) postdiagnosis
The prevalence of global
psychological distress was low: 8.3%
and 6.7%
at 6 and 12 months postdiagnosis,
respectively. Of the143 participants
who met caseness for distress at
Time 1, 38% remained highly









Descriptive diagnosis: DSM III-R criteria
before initiating treatment
According to the clinical interview,
20 (20%) met criteria for adjustment
disorders, 3 (3%) for phobia, and 3
(3%) for generalized anxiety
disorder.
Table 2. A summary of psychological distress in colorectal cancer patients
Below, the special features of each of these psychological manifestations are summarized.
Colorectal Cancer - Surgery, Diagnostics and Treatment510
1. Adjustment disorders
Adjustment disorders are the most common psychological manifestation exhibited by cancer
patients, but few studies or reports have examined adjustment disorders alone. Problems with
the diagnostic criteria for adjustment disorders themselves are likely to be one of the reasons
for the lack of studies on this topic. The diagnostic criteria in the DSM-IV-TR state that
adjustment disorders are “reactions such as anxiety and depression or behavior disorders that
occur in association with psychosocial stress.” The diagnosis of adjustment disorders is made
when the degree of the reaction is stronger than expected or when symptoms interfere with
social functions from everyday life to social activities, and such disorders are said to be a
continuous condition, without any strict division from normal reactions. Thus, the criteria are
vague, and the term “adjustment disorders” is used as a “wastebasket diagnosis” when there
is a mood disorder but other diagnoses, including depression, do not apply. Nevertheless, the
term has the advantage of being able to include a variety of psychological manifestations that
would be difficult to accept as specific mental disorders.
Inadequate pain control can be listed as a primary cause of adjustment disorders. According
to a study by Derogatis et al. [1], a higher percentage of cancer patients who met the diagnostic
criteria for adjustment disorders had severe pain, compared with cancer patients who did not
meet the criteria. Anxiety, depression, and agitation are known to readily develop when pain
of unknown cause persists [15]. Clearly, understanding patients’ pain, which is a typical
symptom that requires symptomatic relief, and adequately controlling such pain seems to be
also useful for relieving psychological distress. Moreover, feelings of difficulty breathing [16]
or malaise [17], which (similar to pain) often occur in colorectal cancer patients, can have an
impact on patient QOL and can be difficult to treat, and their presence appears to be a cause
of anxiety or depression.
These adjustment disorders should be evaluated and properly managed, but few patients are
actually diagnosed correctly and treated properly [18]. One reason for this situation appears
to be that healthcare providers often miss psychological manifestations. Although the issue of
physicians and nurses who are not specialists in psychiatric care overlooking mild depression
and anxiety symptoms occurring during the course of cancer is, to some extent, unavoidable,
there seems to be a need for education regarding the diagnosis and treatment of adjustment
disorders, which are the most common psychological manifestations of cancer patients.
Psychotropic drugs, such as anxiolytic agents, hypnotics, and, depending on the circumstan‐
ces, antidepressants, are often used for treatment, but it is important to make an effort to
identify the cause of the adjustment disorders described above by sufficiently listening to what
the patient has to say, and then eliminating the cause. To accomplish this task, supportive
psychiatric care in which caregivers encourage patients to express how they are really feeling
at the present time (especially feelings of fear and anxiety), that supports and empathizes with
the patients, and that does not provide unrealistic information but provides assurance within
the realm of reality is said to be effective. In other words, supportive psychiatric care can
become a valid treatment only when the patients feel that their present suffering is understood
by the healthcare provider.




Table 3 shows the diagnostic criteria for depression based on the DSM-IV-TR. A diagnosis of
depression is made when either a depressed mood or a loss of interest or pleasure or both
occurs, and a total of 5 or more other symptoms are present for at least 2 weeks. However,
because some of the physical symptoms included among the listed symptoms of depression,
such as sleep disturbance, anorexia and weight loss, a decreased ability to concentrate, and
malaise, are common symptoms, especially in palliative care settings, these symptoms are
often not regarded as unusual even when present, and there is a strong tendency for depression
to be underestimated among cancer patients. Why is the accurate evaluation and treatment of
depression important? To answer this question, a specific case is presented below.
1. Depressed mood most of the day.
2. Diminished interest or pleasure in all or most activities.
3. Significant unintentional weight loss or gain.
4. Insomnia or sleeping too much.
5. Agitation or psychomotor retardation noticed by others.
6. Fatigue or loss of energy.
7. Feelings of worthlessness or excessive guilt.
8. Diminished ability to think or concentrate, or indecisiveness.
9. Recurrent thoughts of death.
Depressed mood and/or loss of interest or pleasure in life activities for at least 2 weeks and at least five of the above
symptoms that cause clinically significant impairment in social, work, or other important areas of functioning almost
every day.
Table 3. Diagnostic criteria of depression
[Case]
The patient was a 65-year-old man who was being followed up for advanced colorectal cancer
and had entered the terminal stage. Predominantly palliative care was being performed, and
symptom control was fairly good. However, he gradually began to experience insomnia, and
this symptom persisted. A short while later he was heard to say, “There’s no point in living
anymore. I want to die,” and he exhibited minimal facial expressions. A hypnotic was
prescribed, but the treatment was ineffective. Because the condition described above persisted,
he was referred to a psychiatrist. Based on an examination, the psychiatrist concluded that the
cause was depression, and when the patient was treated with a low dose of an antidepressant,
he no longer made the above complaints, and his facial expression became peaceful.
It is not rare for cancer patients, particularly terminal patients, to speak of suicidal ideation (a
feeling that they want to die or that there is no point in living), similar to the case described
above, and more than half of such patients are reportedly in a depressed state [19]. However,
since depression can be alleviated suicidal ideation can be stopped with proper treatment,
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whenever a patient desires an early death, it is essential to always keep depression in mind
and to evaluate the patient’s decision-making ability.
A younger age, a past history of mood disorder, a history of alcohol dependence, low social
support, a poor physical condition, and inadequate pain control have been implicated as risk
factors for depression in cancer patients [20].
In addition, caution is also necessary with regard to the fact that depression is sometimes
induced as a side effect of drugs that are used to treat physical illnesses [21]. Associations with
depression have also been pointed out for some β-adrenergic antagonists and benzodiazepines
as well as some anticancer drugs, including vincristine and asparaginase. Steroids are widely
used to treat brain edema caused by brain metastasis and for malaise and nausea, but they are
known to be possible causes of depression.
A variety of questionnaires and rating scales have become available as ways to convenient‐
ly  screen  for  depression,  and  these  tools  have  a  high  utility  value  as  indicators  of  the
presence of depression in cancer patients. However, prior to the use of these tools, healthcare
providers must first take an interest in their patients’ psychological distress and discuss the
matter with their patients. When Chochinov et al. [22] used a 13-item short version of the
depression screening scale and inquired about only a depressed mood in a study of 197
terminal-stage cancer patients, they reported that asking, “How are you feeling? Aren’t you
feeling depressed?” was the most useful  way of screening for depression.  When health‐
care  providers  are  standing  in  front  of  a  patient,  after  inquiring  “How  are  you?”  the
healthcare provider can easily ask an additional question, “How are you feeling?” with‐
out imposing any great burden on everyday clinical practice, and this additional question
seems to be a convenient and effective way of not overlooking depression that healthcare
providers can implement immediately.
As a general rule, depression is treated with drug therapy, primarily with antidepressants,
and although it takes 1-2 weeks for them to take effect, these drugs are very effective in many
cases. In the past, thirst and constipation were frequent side effects, but antidepressants with
fewer side effects have been recently developed, and it seems possible to utilize them effec‐
tively. Nevertheless, the fact that some antidepressants inhibit the metabolism of anticancer
drugs and affect their blood concentrations needs to be kept in mind when using them
concomitantly. However, as stated above, the most important point is to evaluate accurately
whether the patient is in a depressed state.
3. Delirium
Delirium is an organic mental disorder that is often seen during the early stage of cancer
therapy or from an advanced to terminal stage, and it is a “consciousness” disorder that is
accompanied by cognitive disorders such as psychomotor excitation manifesting as a mild
clouding of consciousness, delusions, and hallucinations. Because cognition is impaired, a
wide variety of accompanying psychological symptoms may develop. Classical cases of
delirium are characterized by an abrupt onset of symptoms and diurnal fluctuations in
symptoms (especially symptoms becoming worse during the night), as well as difficulty in
focusing and maintaining attention. Sometimes, psychiatric departments are frequently
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consulted, and the nature of the requests is a failure to cooperate with treatment, negativity,
and suspicion of dementia. The prevalence of delirium increases as the patients’ physical
conditions deteriorate and they reach a stage [23], and an overall prevalence of 4%-27% has
been reported for all stages.
Several hypotheses, including impaired neurotransmitter metabolism in the brain and an
impaired sleep-wakefulness mechanism, have been proposed with regard to the pathogenetic
mechanism of delirium, but nothing definite is known. The causes of delirium in cancer
patients consist of direct causes, such as cancer metastasis to the brain, and indirect causes
caused by electrolyte abnormalities (caution is particularly necessary in regard to hypercalce‐
mia secondary to bone metastasis), the side effects of drugs (drug-induced delirium is
relatively common and is seen with narcotic analgesics, such as morphine, and drugs that have
an anticholinergic action) or irradiation, and in association with multi-organ failure, infection,
changes in nutritional status, etc., the incidences of which increase as a terminal stage is
reached;, however, indirect causes are by far more common. Drug-induced delirium is
relatively frequent and is seen with narcotic analgesics, such as morphine, and drugs that have
an anticholinergic action.
An examination of the causes of delirium according to disease stage showed that single factors
based on treatment (surgery, chemotherapy, etc.) are more common during stages when the
patients’ conditions are relatively good and that multiple factors tend to be involved in the
terminal stage. Bruera et al. [23] conducted a study of the causes of delirium in terminal-stage
cancer patients using peripheral blood biochemistry tests, CT examinations of the brain, and
arterial blood gas analyses and reported that the cause was unknown in 56% of the cases. The
factors identified were, listed in order starting with the most frequent,: drugs, sepsis, brain
metastasis, hepatic or renal failure, hypercalcemia, and hyponatremia. They reported that the
results showed that two thirds of the patients with a cognitive disorder died later without
recovering and that the other third recovered before they died. A variety of factors in the
etiology of delirium have often accumulated in terminal patients, making it difficult to identify
a cause and to treat the condition.
The basic approach to treatment is to determine the cause of the delirium, and then to eliminate
the cause. However, it is important to distinguish between whether recovery in response to
treatment is possible or would be difficult and to decide upon an appropriate care goal (Table
4). A variety of factors in the etiology of delirium have often accumulated in terminal patients,
and the identification of a cause and subsequent treatment are often difficult. When intense
excitement is present or when the delirium interferes with everyday living as a result of
hallucinations, delusions, etc., symptomatic drug therapy, including treatment with antipsy‐
chotic drugs, is often performed. In principle, drug therapy is the same as for the usual
treatment of delirium: (1) benzodiazepine monotherapy is not used, (2) antiparkinsonian drugs
are not used in combination, and (3) multiple drug combinations are not used. Table 5 contains
points that should be kept in mind with regard to adverse events when using psychotropic
drugs to treat cancer patients. Moreover, modifications of the patient’s environment, family
support, and the support and education of the staff of the hospital unit are also needed, in
addition to the above.
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Benzodiazepine is used at a minimum.
Recovery from delirium




Relief of delirium symptoms
Antipsychotic drug,
Benzodiazepine is used in combination, as
appropriate.
Relief of restlessness or agitation
Maintenance of sleep
Care of families
Table 4. Delirium causes for which recovery in response to treatment is possible or difficult





Antiemetic with dopamine receptor antagonistic action (e.g., metoclopramide) is
often administered antecedently.
Adverse effects of morphine (dry mouth, constipation, dysuria, sleepiness) are
aggravated.
In case of under administration of anticancer agents or liver metastasis.
In case of the poor general conditions.
Table 5. Points regarding adverse events during the use of psychotropic drugs to treat cancer patients
4. Communication skills
Nothing is more important to the process of conveying bad news and obtaining informed
consent than that healthcare providers strive for good communication with the patient and
the patient’s family. Good communication is said to have a favorable impact on physical and
mental health, such as helping patients to cope with their disease, improving compliance, and
bringing about the control of blood pressure and blood glucose levels, as well as pain control,
and as a result of achieving a strong trusting relationship with their healthcare provider,
patients are willing to engage actively in their treatment, increasing its therapeutic effect. [24].
Moreover, forging good relationships with patients also reportedly decreases the risk of burn
out by healthcare providers [25]. However, in reality, training in communication skills and
support skills is seldom provided, and as a result, many healthcare providers are thought to
experience stress because they have not acquired adequate skills.
Against this background, a training program designed to improve communication skills was
conducted in the United Kingdom with 178 highly experienced oncologists as the subjects [26].
When the physicians were the subjects of the evaluation, the results reportedly showed that
the physicians were able to gain self-confidence with regard to communication, and had
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become able to engage in patient-centered communication, including directing their attention
to patients’ psychosocial aspects. This study was the first of its kind, and it was followed by
the start of a succession of studies regarding the effectiveness of communication skills training
(CST). The effects of CST interventions for health care professionals have been compiled and
analyzed in several systematic reviews across recent decades [27-30]. These reviews have
consistently concluded that CST leads to better communication behaviors among clinicians
[28, 30]. A recent meta-analysis of 13 studies reported a moderate effect size of 0.54 (Cohen's
d) for the impact of CST on the communication behaviors of oncology clinicians [30]. However,
on the other hand, Kissane et al. [31] pointed out in the most recent review article that outcomes
impacting patient satisfaction, improved adaptation, and enhanced quality of life are still
lacking, and that patient benefits, such as increased treatment adherence and enhanced
adaption, need to be demonstrated from CST.
Thus, evaluations of training in communication skills have not yet led to any definite conclu‐
sions, but an education system and a curriculum designed to improve communication skills
is definitely needed in the near future. Bad news must often be conveyed, particularly in cancer
care settings, and the acquisition of such skills by healthcare providers seems to be absolutely
essential.
5. Conclusion
Based on the characteristics of colorectal cancer patients, the forms of psychological distress
that are said to often be encountered in cancer care settings and to require evaluation and
management from the standpoint of a psychiatrist have been summarized. The necessary
communication skills, which are one of the skill sets that must be acquired to engage in cancer
care, have also been described. However, the people who are closely involved with such
psychosocial aspects and need such skills to deal with patients in actual clinical settings are
typically the attending physicians, who are oncologists, and allied healthcare professionals,
rather than psychiatrists. Thus, it is paramount that all healthcare providers involved in the
care of cancer patients become proficient in communication skills so that they may interact
with patients and their families and so that they may always aim to provide medical care with
patients’ psychological aspects in mind.
Author details
Hitoshi  Okamura*
Address all correspondence to: hokamura@hiroshima-u.ac.jp
Institute of Biomedical & Health Sciences, Hiroshima University, Japan
Colorectal Cancer - Surgery, Diagnostics and Treatment516
References
[1] Holland JC, Rowland JH. Handbook of Psychooncology. New York: Oxford Univ
Press; 1990, p273-282
[2] Lind SE, Good MD, Seidel S, Csordas T, Good BJ. Telling the diagnosis of cancer. J
Clin Oncol 1989; 7: 583-9.
[3] Oken D. What to tell cancer patients. A study of medical attitudes. JAMA 1961; 175:
1120-8.
[4] Derogatis LR. The prevalence of psychiatric disorders among cancer patients. JAMA
1983; 249: 751-7.
[5] Dunn J, Ng SK, Holland J, Aitken J, Youl P, Baade PD, Chambers SK. Trajectories of
psychological distress after colorectal cancer. Psychooncology. 2012; doi: 10.1002/
pon.3210.
[6] Graҫa Pereira M, Figueiredo AP, Fincham FD. Anxiety, depression, traumatic stress
and quality of life in colorectal cancer after different treatments: A study with Portu‐
guese patients and their partners. Eur J Oncol Nurs 2012; 16: 227-32.
[7] Daudt HM, Cosby C, Dennis DL, Payeur N, Nurullah R. Nutritional and psychoso‐
cial status of colorectal cancer patients referred to an outpatient oncology clinic. Sup‐
port Care Cancer 2012; 20: 1417-23.
[8] Hyphantis T, Paika V, Almyroudi A, Kampletsas EO, Pavlidis N. Personality varia‐
bles as predictors of early non-metastatic colorectal cancer patients' psychological
distress and health-related quality of life: a one-year prospective study. J Psychosom
Res 2011; 70: 411-21.
[9] Patel D, Sharpe L, Thewes B, Bell ML, Clarke S. Using the Distress Thermometer and
Hospital Anxiety and Depression Scale to screen for psychosocial morbidity in pa‐
tients diagnosed with colorectal cancer. J Affect Disord 2011; 131: 412-6.
[10] Medeiros M, Oshima CT, Forones NM. Depression and anxiety in colorectal cancer
patients. J Gastrointest Cancer 2010; 41: 179-84.
[11] Alacacioglu A, Binicier O, Gungor O, Oztop I, Dirioz M, Yilmaz U. Quality of life,
anxiety, and depression in Turkish colorectal cancer patients. Support Care Cancer
2010; 18: 417-21.
[12] Lynch BM, Steginga SK, Hawkes AL, Pakenham KI, Dunn J. Describing and predict‐
ing psychological distress after colorectal cancer. Cancer 2008; 112: 1363-70.
[13] Pugliese P, Perrone M, Nisi E, Garufi C, Giannarelli D, Bottomley A, Terzoli E. An
integrated psychological strategy for advanced colorectal cancer patients Health
Qual Life Outcomes 2006; 4: 9.
Psychosocial Care for Patients with Colorectal Cancer
http://dx.doi.org/10.5772/57140
517
become able to engage in patient-centered communication, including directing their attention
to patients’ psychosocial aspects. This study was the first of its kind, and it was followed by
the start of a succession of studies regarding the effectiveness of communication skills training
(CST). The effects of CST interventions for health care professionals have been compiled and
analyzed in several systematic reviews across recent decades [27-30]. These reviews have
consistently concluded that CST leads to better communication behaviors among clinicians
[28, 30]. A recent meta-analysis of 13 studies reported a moderate effect size of 0.54 (Cohen's
d) for the impact of CST on the communication behaviors of oncology clinicians [30]. However,
on the other hand, Kissane et al. [31] pointed out in the most recent review article that outcomes
impacting patient satisfaction, improved adaptation, and enhanced quality of life are still
lacking, and that patient benefits, such as increased treatment adherence and enhanced
adaption, need to be demonstrated from CST.
Thus, evaluations of training in communication skills have not yet led to any definite conclu‐
sions, but an education system and a curriculum designed to improve communication skills
is definitely needed in the near future. Bad news must often be conveyed, particularly in cancer
care settings, and the acquisition of such skills by healthcare providers seems to be absolutely
essential.
5. Conclusion
Based on the characteristics of colorectal cancer patients, the forms of psychological distress
that are said to often be encountered in cancer care settings and to require evaluation and
management from the standpoint of a psychiatrist have been summarized. The necessary
communication skills, which are one of the skill sets that must be acquired to engage in cancer
care, have also been described. However, the people who are closely involved with such
psychosocial aspects and need such skills to deal with patients in actual clinical settings are
typically the attending physicians, who are oncologists, and allied healthcare professionals,
rather than psychiatrists. Thus, it is paramount that all healthcare providers involved in the
care of cancer patients become proficient in communication skills so that they may interact
with patients and their families and so that they may always aim to provide medical care with
patients’ psychological aspects in mind.
Author details
Hitoshi  Okamura*
Address all correspondence to: hokamura@hiroshima-u.ac.jp
Institute of Biomedical & Health Sciences, Hiroshima University, Japan
Colorectal Cancer - Surgery, Diagnostics and Treatment516
References
[1] Holland JC, Rowland JH. Handbook of Psychooncology. New York: Oxford Univ
Press; 1990, p273-282
[2] Lind SE, Good MD, Seidel S, Csordas T, Good BJ. Telling the diagnosis of cancer. J
Clin Oncol 1989; 7: 583-9.
[3] Oken D. What to tell cancer patients. A study of medical attitudes. JAMA 1961; 175:
1120-8.
[4] Derogatis LR. The prevalence of psychiatric disorders among cancer patients. JAMA
1983; 249: 751-7.
[5] Dunn J, Ng SK, Holland J, Aitken J, Youl P, Baade PD, Chambers SK. Trajectories of
psychological distress after colorectal cancer. Psychooncology. 2012; doi: 10.1002/
pon.3210.
[6] Graҫa Pereira M, Figueiredo AP, Fincham FD. Anxiety, depression, traumatic stress
and quality of life in colorectal cancer after different treatments: A study with Portu‐
guese patients and their partners. Eur J Oncol Nurs 2012; 16: 227-32.
[7] Daudt HM, Cosby C, Dennis DL, Payeur N, Nurullah R. Nutritional and psychoso‐
cial status of colorectal cancer patients referred to an outpatient oncology clinic. Sup‐
port Care Cancer 2012; 20: 1417-23.
[8] Hyphantis T, Paika V, Almyroudi A, Kampletsas EO, Pavlidis N. Personality varia‐
bles as predictors of early non-metastatic colorectal cancer patients' psychological
distress and health-related quality of life: a one-year prospective study. J Psychosom
Res 2011; 70: 411-21.
[9] Patel D, Sharpe L, Thewes B, Bell ML, Clarke S. Using the Distress Thermometer and
Hospital Anxiety and Depression Scale to screen for psychosocial morbidity in pa‐
tients diagnosed with colorectal cancer. J Affect Disord 2011; 131: 412-6.
[10] Medeiros M, Oshima CT, Forones NM. Depression and anxiety in colorectal cancer
patients. J Gastrointest Cancer 2010; 41: 179-84.
[11] Alacacioglu A, Binicier O, Gungor O, Oztop I, Dirioz M, Yilmaz U. Quality of life,
anxiety, and depression in Turkish colorectal cancer patients. Support Care Cancer
2010; 18: 417-21.
[12] Lynch BM, Steginga SK, Hawkes AL, Pakenham KI, Dunn J. Describing and predict‐
ing psychological distress after colorectal cancer. Cancer 2008; 112: 1363-70.
[13] Pugliese P, Perrone M, Nisi E, Garufi C, Giannarelli D, Bottomley A, Terzoli E. An
integrated psychological strategy for advanced colorectal cancer patients Health
Qual Life Outcomes 2006; 4: 9.
Psychosocial Care for Patients with Colorectal Cancer
http://dx.doi.org/10.5772/57140
517
[14] Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of
psychological distress by cancer site. Psychooncology 2001; 10: 19-28.
[15] Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313: 84-95.
[16] Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Factors correlated with
dyspnea in advanced lung cancer patients: organic causes and what else? J Pain
Symptom Manage 2002; 23: 490-500.
[17] Okuyama T, Tanaka K, Akechi T, Kugaya A, Okamura H, Nishiwaki Y, Hosaka T,
Uchitomi Y. Fatigue in ambulatory patients with advanced lung cancer: prevalence,
correlated factors, and screening. J Pain Symptom Manage 2001; 22: 554-64.
[18] Minagawa H, Uchitomi Y, Yamawaki S, Ishitani K. Psychiatric morbidity in terminal‐
ly ill cancer patients. A prospective study. Cancer 1996; 78: 1131-7.
[19] Chochinov HM, Wilson KG, Enns M, Mowchun N, Lander S, Levitt M, Clinch JJ. De‐
sire for death in the terminally ill. Am J Psychiatry 1995; 152: 1185-91.
[20] Harrison J, Maguire P: Predictors of psychiatric morbidity in cancer patients. Br J
Psychiatry 165: 593-598, 1994
[21] Massie MJ, Popkin MK. Depressive disorders. In: Holland JC. (ed.) Psycho-Oncology.
New York: Oxford University Press; 1998, p518-540.
[22] Chochinov HM, Wilson KG, Enns M, Lander S. “Are you depressed?” Screening for
depression in the terminally ill. Am J Psychiatry 1997; 154: 674-6.
[23] Bruera E, Miller L, McCallion J, Macmillan K, Krefting L, Hanson J. Cognitive failure
in patients with terminal cancer: a prospective study. J Pain Symptom Manage 1992;
7: 192-5.
[24] Epstein R, Street RL Jr. Patient-Centered Communication in Cancer Care: Promoting
Healing and Reducing Suffering. http://outcomes.cancer.gov/areas/pcc/communica‐
tion/pcc_monograph.pdf. (accessed 1 December 2012).
[25] Ramirez AJ, Graham J, Richards MA, Cull A, Gregory WM, Leaning MS, Snashall
DC, Timothy AR. Burnout and psychiatric disorder among cancer clinicians. Br J
Cancer 1995; 71: 1263-9.
[26] Fallowfield L, Lipkin M, Hall A. Teaching senior oncologists communication skills:
results from phase I of a comprehensive longitudinal program in the United King‐
dom. J Clin Oncol 1998; 16: 1961-8.
[27] Cegala DJ, Lenzmeier Broz S. Physician communication skills training: a review of
theoretical backgrounds, objectives and skills. Med Educ 2002; 36: 1004-16.
[28] Rao JK, Anderson LA, Inui TS, Frankel RM. Communication interventions make a
difference in conversations between physicians and patients: a systematic review of
the evidence. Med Care 2007; 45: 340-9.
Colorectal Cancer - Surgery, Diagnostics and Treatment518
[29] Uitterhoeve RJ, Bensing JM, Grol RP, Demulder PH, VAN Achterberg T. The effect of
communication skills training on patient outcomes in cancer care: a systematic re‐
view of the literature. Eur J Cancer Care (Engl) 2010; 19: 442-57.
[30] Barth J, Lannen P. Efficacy of communication skills training courses in oncology: a
systematic review and meta-analysis. Ann Oncol 2011; 22: 1030-40.
[31] Kissane DW, Bylund CL, Banerjee SC, Bialer PA, Levin TT, Maloney EK, D'Agostino
TA. Communication skills training for oncology professionals. J Clin Oncol 2012; 30:
1242-7
Psychosocial Care for Patients with Colorectal Cancer
http://dx.doi.org/10.5772/57140
519
[14] Zabora J, BrintzenhofeSzoc K, Curbow B, Hooker C, Piantadosi S. The prevalence of
psychological distress by cancer site. Psychooncology 2001; 10: 19-28.
[15] Foley KM. The treatment of cancer pain. N Engl J Med 1985; 313: 84-95.
[16] Tanaka K, Akechi T, Okuyama T, Nishiwaki Y, Uchitomi Y. Factors correlated with
dyspnea in advanced lung cancer patients: organic causes and what else? J Pain
Symptom Manage 2002; 23: 490-500.
[17] Okuyama T, Tanaka K, Akechi T, Kugaya A, Okamura H, Nishiwaki Y, Hosaka T,
Uchitomi Y. Fatigue in ambulatory patients with advanced lung cancer: prevalence,
correlated factors, and screening. J Pain Symptom Manage 2001; 22: 554-64.
[18] Minagawa H, Uchitomi Y, Yamawaki S, Ishitani K. Psychiatric morbidity in terminal‐
ly ill cancer patients. A prospective study. Cancer 1996; 78: 1131-7.
[19] Chochinov HM, Wilson KG, Enns M, Mowchun N, Lander S, Levitt M, Clinch JJ. De‐
sire for death in the terminally ill. Am J Psychiatry 1995; 152: 1185-91.
[20] Harrison J, Maguire P: Predictors of psychiatric morbidity in cancer patients. Br J
Psychiatry 165: 593-598, 1994
[21] Massie MJ, Popkin MK. Depressive disorders. In: Holland JC. (ed.) Psycho-Oncology.
New York: Oxford University Press; 1998, p518-540.
[22] Chochinov HM, Wilson KG, Enns M, Lander S. “Are you depressed?” Screening for
depression in the terminally ill. Am J Psychiatry 1997; 154: 674-6.
[23] Bruera E, Miller L, McCallion J, Macmillan K, Krefting L, Hanson J. Cognitive failure
in patients with terminal cancer: a prospective study. J Pain Symptom Manage 1992;
7: 192-5.
[24] Epstein R, Street RL Jr. Patient-Centered Communication in Cancer Care: Promoting
Healing and Reducing Suffering. http://outcomes.cancer.gov/areas/pcc/communica‐
tion/pcc_monograph.pdf. (accessed 1 December 2012).
[25] Ramirez AJ, Graham J, Richards MA, Cull A, Gregory WM, Leaning MS, Snashall
DC, Timothy AR. Burnout and psychiatric disorder among cancer clinicians. Br J
Cancer 1995; 71: 1263-9.
[26] Fallowfield L, Lipkin M, Hall A. Teaching senior oncologists communication skills:
results from phase I of a comprehensive longitudinal program in the United King‐
dom. J Clin Oncol 1998; 16: 1961-8.
[27] Cegala DJ, Lenzmeier Broz S. Physician communication skills training: a review of
theoretical backgrounds, objectives and skills. Med Educ 2002; 36: 1004-16.
[28] Rao JK, Anderson LA, Inui TS, Frankel RM. Communication interventions make a
difference in conversations between physicians and patients: a systematic review of
the evidence. Med Care 2007; 45: 340-9.
Colorectal Cancer - Surgery, Diagnostics and Treatment518
[29] Uitterhoeve RJ, Bensing JM, Grol RP, Demulder PH, VAN Achterberg T. The effect of
communication skills training on patient outcomes in cancer care: a systematic re‐
view of the literature. Eur J Cancer Care (Engl) 2010; 19: 442-57.
[30] Barth J, Lannen P. Efficacy of communication skills training courses in oncology: a
systematic review and meta-analysis. Ann Oncol 2011; 22: 1030-40.
[31] Kissane DW, Bylund CL, Banerjee SC, Bialer PA, Levin TT, Maloney EK, D'Agostino
TA. Communication skills training for oncology professionals. J Clin Oncol 2012; 30:
1242-7






Surgery, Diagnostics and Treatment
Edited by Jim S Khan
Edited by Jim S Khan
Colorectal cancer is one of the commonest cancers affecting individuals across 
the world. An improvement in survival has been attributed to multidisciplinary 
management, better diagnostics, improved surgical options for the primary and 
metastatic disease and advances in adjuvant therapy. In this book, international 
experts share their experience and knowledge on these different aspects in the 
management of colorectal cancer. An in depth analysis of screening for colorectal 
cancer, detailed evaluation of diagnostic modalities in staging colorectal cancer, recent 
advances in adjuvant therapy and principles and trends in the surgical management 
of colorectal cancer is provided. This will certainly prove to be an interesting and 
informative read for any clinician involved in the management of patients with 
colorectal cancer.




ancer - Surgery, D
iagnostics and Treatm
ent
 7195 9
